%% This BibTeX bibliography file was created using BibDesk.
%% https://bibdesk.sourceforge.io/

%% Created for mjuetz at 2023-05-26 00:10:10 +0200 


%% Saved with string encoding Unicode (UTF-8) 

@bibdesk_info{document_info,
	Key = {}
}


@webpage{EntfernteURL,
	date-added = {2023-05-26 00:02:28 +0200},
	date-modified = {2023-05-26 00:09:13 +0200}}

@url{cite-key,
	crossref = {Linge_2016},
	date-added = {2023-05-25 23:58:26 +0200},
	date-modified = {2023-05-25 23:58:26 +0200}}

@url{cite-key,
	crossref = {w},
	date-added = {2023-05-25 23:52:19 +0200},
	date-modified = {2023-05-25 23:52:37 +0200}}

@article{w,
	date-added = {2023-05-25 21:25:54 +0200},
	date-modified = {2023-05-25 23:05:06 +0200},
	read = {1}}

@article{Becker:2023aa,
	author = {Becker, Christoph},
	date-added = {2023-05-25 21:21:59 +0200},
	date-modified = {2023-05-25 21:21:59 +0200},
	day = {01},
	doi = {10.1007/s00120-023-02043-2},
	issn = {2731-7072},
	journal = {Die Urologie},
	month = {Sep},
	number = {1},
	pages = {1--3},
	title = {Wissenstransfer von der Forschung {\"u}ber die Translation in die Klinik},
	url = {https://link.springer.com/content/pdf/10.1007/s00120-023-02043-2.pdf},
	volume = {62},
	year = {2023},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007/s00120-023-02043-2.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/s00120-023-02043-2}}

@article{ref1,
	date-added = {2023-05-25 21:21:58 +0200},
	date-modified = {2023-05-25 21:21:58 +0200},
	day = {01},
	doi = {10.1007/s00120-023-02044-1},
	issn = {2731-7072},
	journal = {Die Urologie},
	month = {Sep},
	number = {1},
	pages = {4--20},
	title = {Abstracts zum 13. AuF-$\null$Symposium},
	url = {https://link.springer.com/content/pdf/10.1007/s00120-023-02044-1.pdf},
	volume = {62},
	year = {2023},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007/s00120-023-02044-1.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/s00120-023-02044-1}}

@article{Ramasamy:2019aa,
	author = {Pathma Ramasamy and Anne-Marie Larkin and Annett Linge and Damien Tiernan and Fionnuala McAree and Noel Horgan and Paul Moriarty and Stephen Beatty and Conor C Murphy and Martin Clynes and Susan Kennedy and Paula Meleady},
	date-added = {2023-05-25 21:21:30 +0200},
	date-modified = {2023-05-25 21:21:30 +0200},
	doi = {10.1136/jclinpath-2019-206173},
	journal = {Journal of Clinical Pathology},
	month = {nov},
	number = {7},
	pages = {408--412},
	publisher = {{BMJ}},
	title = {{PRDX}3 is associated with metastasis and poor survival in uveal melanoma},
	url = {https://doi.org/10.1136%2Fjclinpath-2019-206173},
	volume = {73},
	year = 2019,
	bdsk-url-1 = {https://doi.org/10.1136%2Fjclinpath-2019-206173},
	bdsk-url-2 = {https://doi.org/10.1136/jclinpath-2019-206173}}

@article{RN45,
	doi = {10.1007/s00066-015-0847-x},
	issn = {1439-099X (Electronic) 0179-7158 (Linking)},
	journal = {Strahlenther Onkol},
	note = {ger Germany Strahlenther Onkol. 2015 Jun;191 Suppl 1:1-184. doi: 10.1007/s00066-015-0847-x.},
	pages = {1-184},
	title = {[Not Available]},
	type = {Journal Article},
	url = {https://link.springer.com/article/10.1007%2Fs00066-015-0847-x},
	volume = {191 Suppl 1},
	year = {2015},
	bdsk-url-1 = {https://link.springer.com/article/10.1007%2Fs00066-015-0847-x},
	bdsk-url-2 = {https://doi.org/10.1007/s00066-015-0847-x}}

@article{RN239,
	abstract = {PURPOSE: The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck cancer. PATIENTS AND METHODS: Eligible patients were randomly assigned between arm A (the control), single daily fractionated radiation (70 Gy at 2 Gy/d); arm B, identical radiation therapy with concurrent bolus cisplatin, given on days 1, 22, and 43; and arm C, a split course of single daily fractionated radiation and three cycles of concurrent infusional fluorouracil and bolus cisplatin chemotherapy, 30 Gy given with the first cycle and 30 to 40 Gy given with the third cycle. Surgical resection was encouraged if possible after the second chemotherapy cycle on arm C and, if necessary, as salvage therapy on all three treatment arms. Survival data were compared between each experimental arm and the control arm using a one-sided log-rank test. RESULTS: Between 1992 and 1999, 295 patients were entered on this trial. This did not meet the accrual goal of 362 patients and resulted in premature study closure. Grade 3 or worse toxicity occurred in 52% of patients enrolled in arm A, compared with 89% enrolled in arm B (P <.0001) and 77% enrolled in arm C (P <.001). With a median follow-up of 41 months, the 3-year projected overall survival for patients enrolled in arm A is 23%, compared with 37% for arm B (P =.014) and 27% for arm C (P = not significant). CONCLUSION: The addition of concurrent high-dose, single-agent cisplatin to conventional single daily fractionated radiation significantly improves survival, although it also increases toxicity. The loss of efficacy resulting from split-course radiation was not offset by either multiagent chemotherapy or the possibility of midcourse surgery.},
	author = {Adelstein, D. J. and Li, Y. and Adams, G. L. and Wagner, H., Jr. and Kish, J. A. and Ensley, J. F. and Schuller, D. E. and Forastiere, A. A.},
	doi = {10.1200/jco.2003.01.008},
	issn = {0732-183X (Print) 0732-183x},
	journal = {J Clin Oncol},
	keywords = {Adult Aged Aged, 80 and over Antineoplastic Agents/*therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Cisplatin/administration & dosage Combined Modality Therapy Disease-Free Survival Dose Fractionation, Radiation Female Fluorouracil/administration & dosage Head and Neck Neoplasms/*drug therapy/mortality/*radiotherapy Humans Male Middle Aged Neoplasms, Squamous Cell/*drug therapy/mortality/*radiotherapy Statistics, Nonparametric Survival Rate United States/epidemiology},
	note = {Adelstein, David J Li, Yi Adams, George L Wagner, Henry Jr Kish, Julie A Ensley, John F Schuller, David E Forastiere, Arlene A CA04919/CA/NCI NIH HHS/United States CA04920/CA/NCI NIH HHS/United States CA16116/CA/NCI NIH HHS/United States CA21115/CA/NCI NIH HHS/United States CA23318/CA/NCI NIH HHS/United States CA58416/CA/NCI NIH HHS/United States CA66636/CA/NCI NIH HHS/United States CA73590/CA/NCI NIH HHS/United States VA14028/VA/VA/United States Clinical Trial Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. United States 2002/12/31 J Clin Oncol. 2003 Jan 1;21(1):92-8. doi: 10.1200/JCO.2003.01.008.},
	number = {1},
	pages = {92-8},
	title = {An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer},
	type = {Journal Article},
	volume = {21},
	year = {2003},
	bdsk-url-1 = {https://doi.org/10.1200/jco.2003.01.008}}

@article{RN143,
	abstract = {PURPOSE: Oral human papillomavirus (HPV) infection is a risk factor for head and neck squamous cell carcinoma (HNSCC), and is a concern for patients with HPV-positive HNSCC and their partners. The prevalence of oral HPV infection before and after cancer therapy was investigated among patients with HPV16-positive and HPV16-negative HNSCC. EXPERIMENTAL DESIGN: Serial oral rinse samples (ORS) were collected from a cohort of 135 HNSCC cases as frequently as every 3 months for up to 3 years. Tumor HPV status was determined by HPV16 in situ hybridization. HPV was detected in ORS by consensus PCR and line blot hybridization. The HPV16 variants in positive oral rinse-tumor pairs were determined by sequencing. The odds of oral HPV infection among HPV16-positive and HPV16-negative cases were compared by use of generalized estimating equations. RESULTS: Patients were followed for a median of 21 months and provided a median of 4 samples. Forty-four of 135 patients had HPV16-positive tumors. HPV16-positive cases were more likely than HPV16-negative cases to have an oral HPV infection detected before (odds ratio, 8.6; 95% confidence interval, 3.5-21) and after therapy (OR, 2.9; 95% confidence interval, 1.1-7.4). Oral infections by HPV16 and other high-risk, but not low-risk, types were more common among HPV16-positive cases both before and after therapy. Most HPV16 variants in ORS were European, unique, and identical to that in the tumor. Persistence of a type-specific oral infection was demonstrable for as long as 5 years. CONCLUSION: Oral high-risk HPV infections are more frequent among patients with HPV16-positive than HPV16-negative HNSCC, consistent with a behavioral and/or biological disposition to infection.},
	author = {Agrawal, Y. and Koch, W. M. and Xiao, W. and Westra, W. H. and Trivett, A. L. and Symer, D. E. and Gillison, M. L.},
	doi = {10.1158/1078-0432.Ccr-08-0498},
	issn = {1078-0432 (Print) 1078-0432},
	journal = {Clin Cancer Res},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/*virology Cohort Studies DNA, Viral/analysis Female Head and Neck Neoplasms/*virology *Human papillomavirus 16/genetics Humans Longitudinal Studies Male Middle Aged Mouth Diseases/complications/epidemiology/*virology Papillomavirus Infections/*complications/epidemiology Risk},
	note = {Agrawal, Yuri Koch, Wayne M Xiao, Weihong Westra, William H Trivett, Anna L Symer, David E Gillison, Maura L R01 DE016631-03/DE/NIDCR NIH HHS/United States R01 DE016631/DE/NIDCR NIH HHS/United States DE016631/DE/NIDCR NIH HHS/United States R01 DE016631-01/DE/NIDCR NIH HHS/United States P50 CA096784-010001/CA/NCI NIH HHS/United States Z01 BC010628-04/Intramural NIH HHS/United States NIH0011255384/Intramural NIH HHS/United States 1 P50 CA96784-01/CA/NCI NIH HHS/United States R01 DE016631-02/DE/NIDCR NIH HHS/United States R01 DE016631-04/DE/NIDCR NIH HHS/United States P50 CA096784/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural 2008/11/05 Clin Cancer Res. 2008 Nov 1;14(21):7143-50. doi: 10.1158/1078-0432.CCR-08-0498.},
	number = {21},
	pages = {7143-50},
	title = {Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma},
	type = {Journal Article},
	url = {https://clincancerres.aacrjournals.org/content/clincanres/14/21/7143.full.pdf},
	volume = {14},
	year = {2008},
	bdsk-url-1 = {https://clincancerres.aacrjournals.org/content/clincanres/14/21/7143.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.Ccr-08-0498}}

@article{RN420,
	author = {Ailles, L. and Prince, M.},
	doi = {10.1007/978-1-59745-280-9_11},
	issn = {1064-3745 (Print) 1064-3745 (Linking)},
	journal = {Methods Mol Biol},
	keywords = {Animals Carcinoma, Squamous Cell/genetics/*pathology Cell Culture Techniques/*methods Flow Cytometry Fluorescent Antibody Technique Gene Expression Regulation, Neoplastic Head and Neck Neoplasms/genetics/*pathology Humans Hyaluronan Receptors/metabolism Mice Neoplasm Transplantation Neoplastic Stem Cells/metabolism/*pathology Reverse Transcriptase Polymerase Chain Reaction Tissue and Organ Harvesting Transportation},
	pages = {175-93},
	title = {Cancer stem cells in head and neck squamous cell carcinoma},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/19582427},
	volume = {568},
	year = {2009},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/19582427},
	bdsk-url-2 = {https://doi.org/10.1007/978-1-59745-280-9_11}}

@article{RN73,
	abstract = {The cancer stem cell hypothesis states that within a tumor only a subset of cells, the "cancer stem cells" (CSC), are capable of initiating and propagating the disease. In various cancers such cells have been identified and prospectively isolated based on the presence of specific cell surface antigens. In head and neck squamous cell carcinomas, we have shown that the CSCs are contained within the CD44+ subset of tumor cells. This subset contains cells capable of initiating tumor growth in mice that recapitulates the original tumor heterogeneity. Furthermore, they have a primitive cellular morphology, express high levels of nuclear BMI1, and are arrayed in characteristic tumor microdomains. The methods used to purify this subset of tumorigenic cells, to characterize their gene expression profiles, and to identify their physical location within the context of the whole tumor are described here.},
	author = {Ailles, L. and Prince, M.},
	doi = {10.1007/978-1-59745-280-9_11},
	issn = {1064-3745 (Print) 1064-3745 (Linking)},
	journal = {Methods Mol Biol},
	keywords = {Animals Carcinoma, Squamous Cell/genetics/*pathology Cell Culture Techniques/*methods Flow Cytometry Fluorescent Antibody Technique Gene Expression Regulation, Neoplastic Head and Neck Neoplasms/genetics/*pathology Humans Hyaluronan Receptors/metabolism Mice Neoplasm Transplantation Neoplastic Stem Cells/metabolism/*pathology Reverse Transcriptase Polymerase Chain Reaction Tissue and Organ Harvesting Transportation},
	note = {Ailles, Laurie Prince, Mark eng 2009/07/08 Methods Mol Biol. 2009;568:175-93. doi: 10.1007/978-1-59745-280-9_11.},
	pages = {175-93},
	title = {Cancer stem cells in head and neck squamous cell carcinoma},
	type = {Journal Article},
	url = {https://link.springer.com/protocol/10.1007%2F978-1-59745-280-9_11},
	volume = {568},
	year = {2009},
	bdsk-url-1 = {https://link.springer.com/protocol/10.1007%2F978-1-59745-280-9_11},
	bdsk-url-2 = {https://doi.org/10.1007/978-1-59745-280-9_11}}

@article{RN423,
	author = {Al-Hajj, M. and Wicha, M. S. and Benito-Hernandez, A. and Morrison, S. J. and Clarke, M. F.},
	doi = {10.1073/pnas.0530291100},
	issn = {0027-8424 (Print) 0027-8424 (Linking)},
	journal = {Proc Natl Acad Sci U S A},
	keywords = {Animals Antigens, CD/analysis Breast Neoplasms/*pathology Female Flow Cytometry Humans Mice Mice, Inbred NOD Mice, SCID Neoplasm Metastasis/*pathology Pleural Effusion/physiopathology Transplantation, Heterologous/physiology},
	number = {7},
	pages = {3983-8},
	title = {Prospective identification of tumorigenic breast cancer cells},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/12629218},
	volume = {100},
	year = {2003},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/12629218},
	bdsk-url-2 = {https://doi.org/10.1073/pnas.0530291100}}

@article{RN76,
	abstract = {Breast cancer is the most common malignancy in United States women, accounting for >40,000 deaths each year. These breast tumors are comprised of phenotypically diverse populations of breast cancer cells. Using a model in which human breast cancer cells were grown in immunocompromised mice, we found that only a minority of breast cancer cells had the ability to form new tumors. We were able to distinguish the tumorigenic (tumor initiating) from the nontumorigenic cancer cells based on cell surface marker expression. We prospectively identified and isolated the tumorigenic cells as CD44(+)CD24(-/low)Lineage(-) in eight of nine patients. As few as 100 cells with this phenotype were able to form tumors in mice, whereas tens of thousands of cells with alternate phenotypes failed to form tumors. The tumorigenic subpopulation could be serially passaged: each time cells within this population generated new tumors containing additional CD44(+)CD24(-/low)Lineage(-) tumorigenic cells as well as the phenotypically diverse mixed populations of nontumorigenic cells present in the initial tumor. The ability to prospectively identify tumorigenic cancer cells will facilitate the elucidation of pathways that regulate their growth and survival. Furthermore, because these cells drive tumor development, strategies designed to target this population may lead to more effective therapies.},
	author = {Al-Hajj, M. and Wicha, M. S. and Benito-Hernandez, A. and Morrison, S. J. and Clarke, M. F.},
	doi = {10.1073/pnas.0530291100},
	issn = {0027-8424 (Print) 0027-8424 (Linking)},
	journal = {Proc Natl Acad Sci U S A},
	keywords = {Animals Antigens, CD/analysis Breast Neoplasms/*pathology Female Flow Cytometry Humans Mice Mice, Inbred NOD Mice, SCID Neoplasm Metastasis/*pathology Pleural Effusion/physiopathology Transplantation, Heterologous/physiology},
	note = {Al-Hajj, Muhammad Wicha, Max S Benito-Hernandez, Adalberto Morrison, Sean J Clarke, Michael F eng P01 CA075136/CA/NCI NIH HHS/ P30 CA046592/CA/NCI NIH HHS/ CA-075136/CA/NCI NIH HHS/ CA-46592/CA/NCI NIH HHS/ Research Support, U.S. Gov't, P.H.S. 2003/03/12 Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8. doi: 10.1073/pnas.0530291100. Epub 2003 Mar 10.},
	number = {7},
	pages = {3983-8},
	title = {Prospective identification of tumorigenic breast cancer cells},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153034/pdf/pq0703003983.pdf},
	volume = {100},
	year = {2003},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153034/pdf/pq0703003983.pdf},
	bdsk-url-2 = {https://doi.org/10.1073/pnas.0530291100}}

@article{RN277,
	abstract = {OBJECTIVE: To evaluate the prevalence of human papillomavirus (HPV) and the prognostic significance of epidermal growth factor receptor (EGFR), p53, and p16 among patients with oropharyngeal carcinoma. DESIGN: Retrospective study. SETTING: Academic Institute of Otolaryngology, Kaohsiung, Taiwan. PATIENTS: Two hundred seventy-four patients who were diagnosed as having oropharyngeal carcinoma underwent testing for the presence of the HPV genome in the nuclei of their tumor cells from January 1, 1992, through March 31, 2008. INTERVENTIONS: The HPV genome was detected by performing polymerase chain reaction-based assays and in situ hybridization on tumor tissue from paraffin blocks. Immunohistochemistry staining for p16, p53, and EGFR was also performed. MAIN OUTCOME MEASURES: We used the Fisher exact test to evaluate the correlation between the clinicopathological variables and the presence of HPV in tumor cells. Survival analysis was based on the Kaplan-Meier method. RESULTS: We detected HPV in 45 of the 274 patients (16.4%); of these, HPV-16 and -18 were identified in 42 (93.3%) of the HPV-positive tumors. The HPV-positive oropharyngeal cancers were more likely to occur in females, nonsmoking individuals, and those who did not chew betel quid. The HPV-positive tumors significantly expressed p16 and were inversely associated with EGFR and p53 expression (all, P < .001). In addition, patients with tumor tissue that was positive for HPV (P = .008) and had negative expression of EGFR (P = .01), low expression of p53 (P = .01), and high expression of p16 (P = .04) had a better prognosis. CONCLUSION: Our results suggest that HPV, EGFR, p53, and p16 are useful biomarkers in predicting the clinical outcomes of oropharyngeal cancer.},
	author = {Al-Swiahb, J. N. and Huang, C. C. and Fang, F. M. and Chuang, H. C. and Huang, H. Y. and Luo, S. D. and Chen, C. H. and Chen, C. M. and Chien, C. Y.},
	doi = {10.1001/archoto.2010.47},
	issn = {0886-4470},
	journal = {Arch Otolaryngol Head Neck Surg},
	keywords = {Adult Aged Aged, 80 and over *Areca Biomarkers, Tumor/metabolism Cyclin-Dependent Kinase Inhibitor p16 Female Human papillomavirus 16/metabolism Human papillomavirus 18/metabolism Humans In Situ Hybridization Male Middle Aged Neoplasm Proteins/*metabolism Neoplasm Staging Oropharyngeal Neoplasms/epidemiology/metabolism/pathology/*virology Papillomavirus Infections/*epidemiology Polymerase Chain Reaction Prevalence Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Survival Rate Taiwan Tumor Suppressor Protein p53/*metabolism},
	note = {1538-361x Al-Swiahb, Jamil N Huang, Chao-Cheng Fang, Fu-Min Chuang, Hui-Ching Huang, Hsuan-Ying Luo, Sheng-Dean Chen, Chang-Han Chen, Ching-Mei Chien, Chih-Yen Journal Article Research Support, Non-U.S. Gov't United States 2010/05/19 Arch Otolaryngol Head Neck Surg. 2010 May;136(5):502-8. doi: 10.1001/archoto.2010.47.},
	number = {5},
	pages = {502-8},
	title = {Prognostic impact of p16, p53, epidermal growth factor receptor, and human papillomavirus in oropharyngeal cancer in a betel nut-chewing area},
	type = {Journal Article},
	url = {https://jamanetwork.com/journals/jamaotolaryngology/articlepdf/496289/ooa05008_502_508.pdf},
	volume = {136},
	year = {2010},
	bdsk-url-1 = {https://jamanetwork.com/journals/jamaotolaryngology/articlepdf/496289/ooa05008_502_508.pdf},
	bdsk-url-2 = {https://doi.org/10.1001/archoto.2010.47}}

@book{RN379,
	author = {Amin, M.B. and Edge, S.B. and Greene, F.L. and Byrd, D.R. and Brookland, R.K. and Washington, M.K. and Gershenwald, J.E. and Compton, C.C. and Hess, K.R. and Sullivan, D.C.},
	isbn = {9783319406176},
	publisher = {Springer International Publishing},
	title = {AJCC Cancer Staging Manual},
	type = {Book},
	url = {https://books.google.de/books?id=O2PyjwEACAAJ},
	year = {2018},
	bdsk-url-1 = {https://books.google.de/books?id=O2PyjwEACAAJ}}

@book{RN109,
	author = {Amin, M.B. and Edge, S.B. and Greene, F.L. and Byrd, D.R. and Brookland, R.K. and Washington, M.K. and Gershenwald, J.E. and Compton, C.C. and Hess, K.R. and Sullivan, D.C.},
	isbn = {9783319406176},
	publisher = {Springer International Publishing},
	title = {AJCC Cancer Staging Manual},
	type = {Book},
	url = {https://books.google.de/books?id=O2PyjwEACAAJ},
	year = {2018},
	bdsk-url-1 = {https://books.google.de/books?id=O2PyjwEACAAJ}}

@article{RN338,
	author = {Andl, T. and Kahn, T. and Pfuhl, A. and Nicola, T. and Erber, R. and Conradt, C. and Klein, W. and Helbig, M. and Dietz, A. and Weidauer, H. and Bosch, F. X.},
	issn = {0008-5472 (Print) 0008-5472 (Linking)},
	journal = {Cancer Res},
	keywords = {Carcinoma, Squamous Cell/genetics/metabolism/pathology/therapy/*virology Chromosome Aberrations Cyclin D1/metabolism Cyclin-Dependent Kinase Inhibitor p16/metabolism DNA, Viral/*isolation & purification Disease-Free Survival Follow-Up Studies Gene Deletion Gene Expression Genes, Retinoblastoma/*genetics Head and Neck Neoplasms/genetics/metabolism/pathology/therapy/virology Humans Neoplasm Proteins/metabolism Papillomaviridae/*genetics RNA, Messenger/metabolism Retinoblastoma Protein/genetics/*metabolism Tonsillar Neoplasms/genetics/metabolism/pathology/therapy/*virology Tumor Suppressor Protein p53/metabolism},
	number = {1},
	pages = {5-13},
	title = {Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9426048},
	volume = {58},
	year = {1998},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/9426048}}

@article{RN341,
	author = {Andl, T. and Kahn, T. and Pfuhl, A. and Nicola, T. and Erber, R. and Conradt, C. and Klein, W. and Helbig, M. and Dietz, A. and Weidauer, H. and Bosch, F. X.},
	issn = {0008-5472 (Print) 0008-5472 (Linking)},
	journal = {Cancer Res},
	keywords = {Carcinoma, Squamous Cell/genetics/metabolism/pathology/therapy/*virology Chromosome Aberrations Cyclin D1/metabolism Cyclin-Dependent Kinase Inhibitor p16/metabolism DNA, Viral/*isolation & purification Disease-Free Survival Follow-Up Studies Gene Deletion Gene Expression Genes, Retinoblastoma/*genetics Head and Neck Neoplasms/genetics/metabolism/pathology/therapy/virology Humans Neoplasm Proteins/metabolism Papillomaviridae/*genetics RNA, Messenger/metabolism Retinoblastoma Protein/genetics/*metabolism Tonsillar Neoplasms/genetics/metabolism/pathology/therapy/*virology Tumor Suppressor Protein p53/metabolism},
	number = {1},
	pages = {5-13},
	title = {Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9426048},
	volume = {58},
	year = {1998},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/9426048}}

@article{RN358,
	author = {Andl, T. and Kahn, T. and Pfuhl, A. and Nicola, T. and Erber, R. and Conradt, C. and Klein, W. and Helbig, M. and Dietz, A. and Weidauer, H. and Bosch, F. X.},
	issn = {0008-5472 (Print) 0008-5472 (Linking)},
	journal = {Cancer Res},
	keywords = {Carcinoma, Squamous Cell/genetics/metabolism/pathology/therapy/*virology Chromosome Aberrations Cyclin D1/metabolism Cyclin-Dependent Kinase Inhibitor p16/metabolism DNA, Viral/*isolation & purification Disease-Free Survival Follow-Up Studies Gene Deletion Gene Expression Genes, Retinoblastoma/*genetics Head and Neck Neoplasms/genetics/metabolism/pathology/therapy/virology Humans Neoplasm Proteins/metabolism Papillomaviridae/*genetics RNA, Messenger/metabolism Retinoblastoma Protein/genetics/*metabolism Tonsillar Neoplasms/genetics/metabolism/pathology/therapy/*virology Tumor Suppressor Protein p53/metabolism},
	number = {1},
	pages = {5-13},
	title = {Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9426048},
	volume = {58},
	year = {1998},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/9426048}}

@article{RN81,
	abstract = {Two hundred eight primary squamous cell carcinomas of the head and neck have been analyzed with respect to the presence of the retinoblastoma tumor suppressor protein, pRb. Of these, 23 tumors (11%) that preferentially localized to the tonsils revealed complete absence or dramatic reduction in the amount of pRb. Other cell cycle components, cyclin D1 and p16INK4A, which are intimately related to pRb through an autoregulatory loop, were also dramatically decreased or overexpressed, respectively, in these pRb-defective tumors. On the other hand, the majority of the pRb-defective tumors contained the wild-type p53 gene. No evidence was found for genetic defects at the Rb locus in these tumors. Very significantly, in 11 of 12 pRb-defective tonsillar tumors, but in none of 9 pRb-positive tonsillar tumors (P < 10[-7]), DNA of oncogenic human papillomavirus types was identified, providing a strong indication for a human papillomavirus-associated etiology of these tumors and suggesting the functional inactivation of the pRb protein by the viral E7 gene product. In comparison to all head and neck squamous cell carcinomas studied, the pRb-defective tonsillar tumors were in general more poorly differentiated (P = 0.0059), and they were all metastatic at the time of resection. Of particular clinical interest, despite these adverse histopathological factors, the clinical outcome for these patients was relatively favorable, strongly implying that the pRb-defective tumors responded uniformly well toward postoperative radiation therapy.},
	author = {Andl, T. and Kahn, T. and Pfuhl, A. and Nicola, T. and Erber, R. and Conradt, C. and Klein, W. and Helbig, M. and Dietz, A. and Weidauer, H. and Bosch, F. X.},
	issn = {0008-5472 (Print) 0008-5472 (Linking)},
	journal = {Cancer Res},
	keywords = {Carcinoma, Squamous Cell/genetics/metabolism/pathology/therapy/*virology Chromosome Aberrations Cyclin D1/metabolism Cyclin-Dependent Kinase Inhibitor p16/metabolism DNA, Viral/*isolation & purification Disease-Free Survival Follow-Up Studies Gene Deletion Gene Expression Genes, Retinoblastoma/*genetics Head and Neck Neoplasms/genetics/metabolism/pathology/therapy/virology Humans Neoplasm Proteins/metabolism Papillomaviridae/*genetics RNA, Messenger/metabolism Retinoblastoma Protein/genetics/*metabolism Tonsillar Neoplasms/genetics/metabolism/pathology/therapy/*virology Tumor Suppressor Protein p53/metabolism},
	note = {Andl, T Kahn, T Pfuhl, A Nicola, T Erber, R Conradt, C Klein, W Helbig, M Dietz, A Weidauer, H Bosch, F X eng Research Support, Non-U.S. Gov't 1998/01/13 Cancer Res. 1998 Jan 1;58(1):5-13.},
	number = {1},
	pages = {5-13},
	title = {Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control},
	type = {Journal Article},
	url = {https://cancerres.aacrjournals.org/content/canres/58/1/5.full.pdf},
	volume = {58},
	year = {1998},
	bdsk-url-1 = {https://cancerres.aacrjournals.org/content/canres/58/1/5.full.pdf}}

@article{RN188,
	abstract = {OBJECTIVES: The presence of distant metastases affects the therapeutic regime in patients with head and neck squamous cell carcinoma. This study evaluated the necessity to undertake bone scanning, chest computed tomography and abdominal ultrasonography in patients presenting with primary advanced head and neck squamous cell carcinoma. STUDY DESIGN: Retrospective analysis, university setting. METHODS: One hundred and sixty-three patients with head and neck squamous cell carcinoma who were scheduled for major surgery underwent screening for distant metastases. Chest, head and neck computed tomography, abdominal ultrasonography and bone scanning were performed in all patients. RESULTS: Distant metastases were detected in 5.52 per cent of the 163 patients. All of these patients had locoregional advanced (stage IV) tumours. Computed tomography scanning of the lungs revealed metastases in six patients. Bone metastases were found in three patients. Only one patient with primary liver metastases was detected by abdominal ultrasonography; this patient also had pulmonary metastases. CONCLUSIONS: Computed tomography of the thorax is the most important technique for screening patients with head and neck squamous cell carcinoma.},
	author = {Andrle, J. and Schartinger, V. H. and Schwentner, I. and Deibl, M. and Sprinzl, G. M.},
	doi = {10.1017/s0022215109005258},
	issn = {0022-2151},
	journal = {J Laryngol Otol},
	keywords = {Adult Aged Aged, 80 and over Bone Neoplasms/diagnosis/*secondary Bone and Bones/diagnostic imaging Carcinoma, Squamous Cell/diagnosis/*secondary Female *Head and Neck Neoplasms Humans Lung Neoplasms/diagnosis/*secondary Male Middle Aged Neoplasm Staging/methods Neoplasms, Second Primary/*diagnosis Radionuclide Imaging Retrospective Studies Tomography, X-Ray Computed/methods},
	note = {1748-5460 Andrle, J Schartinger, V H Schwentner, I Deibl, M Sprinzl, Georg M Journal Article England 2009/04/18 J Laryngol Otol. 2009 Aug;123(8):885-8. doi: 10.1017/S0022215109005258. Epub 2009 Apr 17.},
	number = {8},
	pages = {885-8},
	title = {Initial staging examinations for head and neck squamous cell carcinoma: are they appropriate?},
	type = {Journal Article},
	url = {https://www.cambridge.org/core/journals/journal-of-laryngology-and-otology/article/abs/initial-staging-examinations-for-head-and-neck-squamous-cell-carcinoma-are-they-appropriate/4CF0513F6685EDCEA8C056551FEA2FE4},
	volume = {123},
	year = {2009},
	bdsk-url-1 = {https://www.cambridge.org/core/journals/journal-of-laryngology-and-otology/article/abs/initial-staging-examinations-for-head-and-neck-squamous-cell-carcinoma-are-they-appropriate/4CF0513F6685EDCEA8C056551FEA2FE4},
	bdsk-url-2 = {https://doi.org/10.1017/s0022215109005258}}

@article{RN342,
	author = {Ang, K. K. and Harris, J. and Wheeler, R. and Weber, R. and Rosenthal, D. I. and Nguyen-Tan, P. F. and Westra, W. H. and Chung, C. H. and Jordan, R. C. and Lu, C. and Kim, H. and Axelrod, R. and Silverman, C. C. and Redmond, K. P. and Gillison, M. L.},
	doi = {10.1056/NEJMoa0912217},
	issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
	journal = {N Engl J Med},
	keywords = {Adult Aged Aged, 80 and over *Alphapapillomavirus/isolation & purification Carcinoma, Squamous Cell/mortality/*virology Female Humans Kaplan-Meier Estimate Male Middle Aged Oropharyngeal Neoplasms/mortality/*virology Papillomavirus Infections/*complications Prognosis Proportional Hazards Models Retrospective Studies Smoking/*adverse effects},
	number = {1},
	pages = {24-35},
	title = {Human papillomavirus and survival of patients with oropharyngeal cancer},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20530316},
	volume = {363},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/20530316},
	bdsk-url-2 = {https://doi.org/10.1056/NEJMoa0912217}}

@article{RN438,
	author = {Ang, K. K. and Harris, J. and Wheeler, R. and Weber, R. and Rosenthal, D. I. and Nguyen-Tan, P. F. and Westra, W. H. and Chung, C. H. and Jordan, R. C. and Lu, C. and Kim, H. and Axelrod, R. and Silverman, C. C. and Redmond, K. P. and Gillison, M. L.},
	doi = {10.1056/NEJMoa0912217},
	issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
	journal = {N Engl J Med},
	keywords = {Adult Aged Aged, 80 and over *Alphapapillomavirus/isolation & purification Carcinoma, Squamous Cell/mortality/*virology Female Humans Kaplan-Meier Estimate Male Middle Aged Oropharyngeal Neoplasms/mortality/*virology Papillomavirus Infections/*complications Prognosis Proportional Hazards Models Retrospective Studies Smoking/*adverse effects},
	number = {1},
	pages = {24-35},
	title = {Human papillomavirus and survival of patients with oropharyngeal cancer},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20530316},
	volume = {363},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/20530316},
	bdsk-url-2 = {https://doi.org/10.1056/NEJMoa0912217}}

@article{RN51,
	abstract = {BACKGROUND: Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown. METHODS: We performed a retrospective analysis of the association between tumor HPV status and survival among patients with stage III or IV oropharyngeal squamous-cell carcinoma who were enrolled in a randomized trial comparing accelerated-fractionation radiotherapy (with acceleration by means of concomitant boost radiotherapy) with standard-fractionation radiotherapy, each combined with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck. Proportional-hazards models were used to compare the risk of death among patients with HPV-positive cancer and those with HPV-negative cancer. RESULTS: The median follow-up period was 4.8 years. The 3-year rate of overall survival was similar in the group receiving accelerated-fractionation radiotherapy and the group receiving standard-fractionation radiotherapy (70.3% vs. 64.3%; P=0.18; hazard ratio for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval [CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1% among patients with HPV-negative tumors; P<0.001 by the log-rank test) and, after adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI, 0.27 to 0.66). The risk of death significantly increased with each additional pack-year of tobacco smoking. Using recursive-partitioning analysis, we classified our patients as having a low, intermediate, or high risk of death on the basis of four factors: HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage. CONCLUSIONS: Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.)},
	author = {Ang, K. K. and Harris, J. and Wheeler, R. and Weber, R. and Rosenthal, D. I. and Nguyen-Tan, P. F. and Westra, W. H. and Chung, C. H. and Jordan, R. C. and Lu, C. and Kim, H. and Axelrod, R. and Silverman, C. C. and Redmond, K. P. and Gillison, M. L.},
	doi = {10.1056/NEJMoa0912217},
	issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
	journal = {N Engl J Med},
	keywords = {Adult Aged Aged, 80 and over *Alphapapillomavirus/isolation & purification Carcinoma, Squamous Cell/mortality/*virology Female Humans Kaplan-Meier Estimate Male Middle Aged Oropharyngeal Neoplasms/mortality/*virology Papillomavirus Infections/*complications Prognosis Proportional Hazards Models Retrospective Studies Smoking/*adverse effects},
	note = {Ang, K Kian Harris, Jonathan Wheeler, Richard Weber, Randal Rosenthal, David I Nguyen-Tan, Phuc Felix Westra, William H Chung, Christine H Jordan, Richard C Lu, Charles Kim, Harold Axelrod, Rita Silverman, C Craig Redmond, Kevin P Gillison, Maura L eng P01 CA006294/CA/NCI NIH HHS/ U10 CA037422-22/CA/NCI NIH HHS/ U10 CA21661/CA/NCI NIH HHS/ R01 DE016631-05/DE/NIDCR NIH HHS/ U10 CA37422/CA/NCI NIH HHS/ DE016631/DE/NIDCR NIH HHS/ U10 CA037422/CA/NCI NIH HHS/ U10 CA021661/CA/NCI NIH HHS/ U10 CA021661-30/CA/NCI NIH HHS/ P01 CA06294/CA/NCI NIH HHS/ P01 CA006294-44/CA/NCI NIH HHS/ R01 DE016631/DE/NIDCR NIH HHS/ Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2010/06/10 N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.},
	number = {1},
	pages = {24-35},
	title = {Human papillomavirus and survival of patients with oropharyngeal cancer},
	type = {Journal Article},
	url = {https://www.nejm.org/doi/pdf/10.1056/NEJMoa0912217?articleTools=true},
	volume = {363},
	year = {2010},
	bdsk-url-1 = {https://www.nejm.org/doi/pdf/10.1056/NEJMoa0912217?articleTools=true},
	bdsk-url-2 = {https://doi.org/10.1056/NEJMoa0912217}}

@article{RN84,
	abstract = {BACKGROUND: Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown. METHODS: We performed a retrospective analysis of the association between tumor HPV status and survival among patients with stage III or IV oropharyngeal squamous-cell carcinoma who were enrolled in a randomized trial comparing accelerated-fractionation radiotherapy (with acceleration by means of concomitant boost radiotherapy) with standard-fractionation radiotherapy, each combined with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck. Proportional-hazards models were used to compare the risk of death among patients with HPV-positive cancer and those with HPV-negative cancer. RESULTS: The median follow-up period was 4.8 years. The 3-year rate of overall survival was similar in the group receiving accelerated-fractionation radiotherapy and the group receiving standard-fractionation radiotherapy (70.3% vs. 64.3%; P=0.18; hazard ratio for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval [CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1% among patients with HPV-negative tumors; P<0.001 by the log-rank test) and, after adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI, 0.27 to 0.66). The risk of death significantly increased with each additional pack-year of tobacco smoking. Using recursive-partitioning analysis, we classified our patients as having a low, intermediate, or high risk of death on the basis of four factors: HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage. CONCLUSIONS: Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.)},
	author = {Ang, K. K. and Harris, J. and Wheeler, R. and Weber, R. and Rosenthal, D. I. and Nguyen-Tan, P. F. and Westra, W. H. and Chung, C. H. and Jordan, R. C. and Lu, C. and Kim, H. and Axelrod, R. and Silverman, C. C. and Redmond, K. P. and Gillison, M. L.},
	doi = {10.1056/NEJMoa0912217},
	issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
	journal = {N Engl J Med},
	keywords = {Adult Aged Aged, 80 and over *Alphapapillomavirus/isolation & purification Carcinoma, Squamous Cell/mortality/*virology Female Humans Kaplan-Meier Estimate Male Middle Aged Oropharyngeal Neoplasms/mortality/*virology Papillomavirus Infections/*complications Prognosis Proportional Hazards Models Retrospective Studies Smoking/*adverse effects},
	note = {Ang, K Kian Harris, Jonathan Wheeler, Richard Weber, Randal Rosenthal, David I Nguyen-Tan, Phuc Felix Westra, William H Chung, Christine H Jordan, Richard C Lu, Charles Kim, Harold Axelrod, Rita Silverman, C Craig Redmond, Kevin P Gillison, Maura L eng P01 CA006294/CA/NCI NIH HHS/ U10 CA037422-22/CA/NCI NIH HHS/ U10 CA21661/CA/NCI NIH HHS/ R01 DE016631-05/DE/NIDCR NIH HHS/ U10 CA37422/CA/NCI NIH HHS/ DE016631/DE/NIDCR NIH HHS/ U10 CA037422/CA/NCI NIH HHS/ U10 CA021661/CA/NCI NIH HHS/ U10 CA021661-30/CA/NCI NIH HHS/ P01 CA06294/CA/NCI NIH HHS/ P01 CA006294-44/CA/NCI NIH HHS/ R01 DE016631/DE/NIDCR NIH HHS/ Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2010/06/10 N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.},
	number = {1},
	pages = {24-35},
	title = {Human papillomavirus and survival of patients with oropharyngeal cancer},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20530316},
	volume = {363},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/20530316},
	bdsk-url-2 = {https://doi.org/10.1056/NEJMoa0912217}}

@article{RN363,
	author = {Ang, K. K. and Harris, J. and Wheeler, R. and Weber, R. and Rosenthal, D. I. and Nguyen-T{\^a}n, P. F. and Westra, W. H. and Chung, C. H. and Jordan, R. C. and Lu, C. and Kim, H. and Axelrod, R. and Silverman, C. C. and Redmond, K. P. and Gillison, M. L.},
	doi = {10.1056/NEJMoa0912217},
	issn = {0028-4793 (Print) 0028-4793},
	journal = {N Engl J Med},
	keywords = {Adult Aged Aged, 80 and over *Alphapapillomavirus/isolation & purification Carcinoma, Squamous Cell/mortality/*virology Female Humans Kaplan-Meier Estimate Male Middle Aged Oropharyngeal Neoplasms/mortality/*virology Papillomavirus Infections/*complications Prognosis Proportional Hazards Models Retrospective Studies Smoking/*adverse effects},
	number = {1},
	pages = {24-35},
	title = {Human papillomavirus and survival of patients with oropharyngeal cancer},
	type = {Journal Article},
	volume = {363},
	year = {2010},
	bdsk-url-1 = {https://doi.org/10.1056/NEJMoa0912217}}

@article{RN99,
	abstract = {BACKGROUND: Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown. METHODS: We performed a retrospective analysis of the association between tumor HPV status and survival among patients with stage III or IV oropharyngeal squamous-cell carcinoma who were enrolled in a randomized trial comparing accelerated-fractionation radiotherapy (with acceleration by means of concomitant boost radiotherapy) with standard-fractionation radiotherapy, each combined with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck. Proportional-hazards models were used to compare the risk of death among patients with HPV-positive cancer and those with HPV-negative cancer. RESULTS: The median follow-up period was 4.8 years. The 3-year rate of overall survival was similar in the group receiving accelerated-fractionation radiotherapy and the group receiving standard-fractionation radiotherapy (70.3% vs. 64.3%; P=0.18; hazard ratio for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval [CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1% among patients with HPV-negative tumors; P<0.001 by the log-rank test) and, after adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI, 0.27 to 0.66). The risk of death significantly increased with each additional pack-year of tobacco smoking. Using recursive-partitioning analysis, we classified our patients as having a low, intermediate, or high risk of death on the basis of four factors: HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage. CONCLUSIONS: Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.)},
	author = {Ang, K. K. and Harris, J. and Wheeler, R. and Weber, R. and Rosenthal, D. I. and Nguyen-T{\^a}n, P. F. and Westra, W. H. and Chung, C. H. and Jordan, R. C. and Lu, C. and Kim, H. and Axelrod, R. and Silverman, C. C. and Redmond, K. P. and Gillison, M. L.},
	doi = {10.1056/NEJMoa0912217},
	issn = {0028-4793 (Print) 0028-4793},
	journal = {N Engl J Med},
	keywords = {Adult Aged Aged, 80 and over *Alphapapillomavirus/isolation & purification Carcinoma, Squamous Cell/mortality/*virology Female Humans Kaplan-Meier Estimate Male Middle Aged Oropharyngeal Neoplasms/mortality/*virology Papillomavirus Infections/*complications Prognosis Proportional Hazards Models Retrospective Studies Smoking/*adverse effects},
	note = {1533-4406 Ang, K Kian Harris, Jonathan Wheeler, Richard Weber, Randal Rosenthal, David I Nguyen-T{\^a}n, Phuc Felix Westra, William H Chung, Christine H Jordan, Richard C Lu, Charles Kim, Harold Axelrod, Rita Silverman, C Craig Redmond, Kevin P Gillison, Maura L P01 CA006294/CA/NCI NIH HHS/United States U10 CA037422-22/CA/NCI NIH HHS/United States U10 CA21661/CA/NCI NIH HHS/United States R01 DE016631-05/DE/NIDCR NIH HHS/United States U10 CA37422/CA/NCI NIH HHS/United States DE016631/DE/NIDCR NIH HHS/United States U10 CA037422/CA/NCI NIH HHS/United States U10 CA021661/CA/NCI NIH HHS/United States U10 CA021661-30/CA/NCI NIH HHS/United States P01 CA06294/CA/NCI NIH HHS/United States P01 CA006294-44/CA/NCI NIH HHS/United States R01 DE016631/DE/NIDCR NIH HHS/United States Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2010/06/10 N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.},
	number = {1},
	pages = {24-35},
	title = {Human papillomavirus and survival of patients with oropharyngeal cancer},
	type = {Journal Article},
	volume = {363},
	year = {2010},
	bdsk-url-1 = {https://doi.org/10.1056/NEJMoa0912217}}

@article{RN233,
	abstract = {PURPOSE: A multi-institutional, prospective, randomized trial was undertaken in patients with advanced head-and-neck squamous cell carcinoma to address (1) the validity of using pathologic risk features, established from a previous study, to determine the need for, and dose of, postoperative radiotherapy (PORT); (2) the impact of accelerating PORT using a concomitant boost schedule; and (3) the importance of the overall combined treatment duration on the treatment outcome. METHODS AND MATERIALS: Of 288 consecutive patients with advanced disease registered preoperatively, 213 fulfilled the trial criteria and went on to receive therapy predicated on a set of pathologic risk features: no PORT for the low-risk group (n = 31); 57.6 Gy during 6.5 weeks for the intermediate-risk group (n = 31); and, by random assignment, 63 Gy during 5 weeks (n = 76) or 7 weeks (n = 75) for the high-risk group. Patients were irradiated with standard techniques appropriate to the site of disease and likely areas of spread. The study end points were locoregional control (LRC), survival, and morbidity. RESULTS: Patients with low or intermediate risks had significantly higher LRC and survival rates than those with high-risk features (p = 0.003 and p = 0.0001, respectively), despite receiving no PORT or lower dose PORT, respectively. For high-risk patients, a trend toward higher LRC and survival rates was noted when PORT was delivered in 5 rather than 7 weeks. A prolonged interval between surgery and PORT in the 7-week schedule was associated with significantly lower LRC (p = 0.03) and survival (p = 0.01) rates. Consequently, the cumulative duration of combined therapy had a significant impact on the LRC (p = 0.005) and survival (p = 0.03) rates. A 2-week reduction in the PORT duration by using the concomitant boost technique did not increase the late treatment toxicity. CONCLUSIONS: This Phase III trial established the power of risk assessment using pathologic features in determining the need for, and dose of, PORT in patients with advanced head-and-neck squamous cell cancer in a prospective, multi-institutional setting. It also revealed the impact of the overall treatment time in the combination of surgery and PORT on the outcome in high-risk patients and showed that PORT acceleration without a reduction in dose by a concomitant boost regimen did not increase the late complication rate. These findings emphasize the importance of coordinated interdisciplinary care in the delivery of combined surgery and RT.},
	author = {Ang, K. K. and Trotti, A. and Brown, B. W. and Garden, A. S. and Foote, R. L. and Morrison, W. H. and Geara, F. B. and Klotch, D. W. and Goepfert, H. and Peters, L. J.},
	doi = {10.1016/s0360-3016(01)01690-x},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/pathology/*radiotherapy/*surgery Combined Modality Therapy Female Head and Neck Neoplasms/pathology/*radiotherapy/*surgery Humans Male Middle Aged Mouth Mucosa/radiation effects Neoplasm, Residual Postoperative Period Prospective Studies Radiation Injuries/etiology Risk Survival Rate Time Factors},
	note = {Ang, K K Trotti, A Brown, B W Garden, A S Foote, R L Morrison, W H Geara, F B Klotch, D W Goepfert, H Peters, L J CA-06294/CA/NCI NIH HHS/United States CA-16672/CA/NCI NIH HHS/United States Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. United States 2001/10/13 Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):571-8. doi: 10.1016/s0360-3016(01)01690-x.},
	number = {3},
	pages = {571-8},
	title = {Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer},
	type = {Journal Article},
	url = {https://www.redjournal.org/article/S0360-3016(01)01690-X/pdf},
	volume = {51},
	year = {2001},
	bdsk-url-1 = {https://www.redjournal.org/article/S0360-3016(01)01690-X/pdf},
	bdsk-url-2 = {https://doi.org/10.1016/s0360-3016(01)01690-x}}

@article{RN134,
	author = {Argiris, A. and Eng, C.},
	doi = {10.1007/0-306-48060-3_2},
	issn = {0927-3042 (Print) 0927-3042},
	journal = {Cancer Treat Res},
	keywords = {Disease Susceptibility Head and Neck Neoplasms/classification/*epidemiology/*pathology Humans *Mass Screening Neoplasm Staging Risk Factors SEER Program},
	note = {Argiris, Athanassios Eng, Cathy Journal Article Review United States 2003/03/07 Cancer Treat Res. 2003;114:15-60. doi: 10.1007/0-306-48060-3_2.},
	pages = {15-60},
	title = {Epidemiology, staging, and screening of head and neck cancer},
	type = {Journal Article},
	url = {https://link.springer.com/chapter/10.1007%2F0-306-48060-3_2},
	volume = {114},
	year = {2003},
	bdsk-url-1 = {https://link.springer.com/chapter/10.1007%2F0-306-48060-3_2},
	bdsk-url-2 = {https://doi.org/10.1007/0-306-48060-3_2}}

@article{RN372,
	author = {Argiris, A. and Karamouzis, M. V. and Raben, D. and Ferris, R. L.},
	doi = {10.1016/s0140-6736(08)60728-x},
	issn = {0140-6736 (Print) 0140-6736},
	journal = {Lancet},
	keywords = {Antineoplastic Combined Chemotherapy Protocols/*therapeutic use *Carcinoma, Squamous Cell/etiology/pathology/therapy Combined Modality Therapy Female *Head and Neck Neoplasms/etiology/pathology/therapy Humans Male Middle Aged Prognosis Randomized Controlled Trials as Topic Risk Factors Signal Transduction/drug effects/physiology},
	number = {9625},
	pages = {1695-709},
	title = {Head and neck cancer},
	type = {Journal Article},
	volume = {371},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1016/s0140-6736(08)60728-x}}

@article{RN120,
	abstract = {Most head and neck cancers are squamous cell carcinomas that develop in the upper aerodigestive epithelium after exposure to carcinogens such as tobacco and alcohol. Human papillomavirus has also been strongly implicated as a causative agent in a subset of these cancers. The complex anatomy and vital physiological role of the tumour-involved structures dictate that the goals of treatment are not only to improve survival outcomes but also to preserve organ function. Major improvements have been accomplished in surgical techniques and radiotherapy delivery. Moreover, systemic therapy including chemotherapy and molecularly targeted agents--namely, the epidermal growth factor receptor inhibitors--has been successfully integrated into potentially curative treatment of locally advanced squamous-cell carcinoma of the head and neck. In deciding which treatment strategy would be suitable for an individual patient, important considerations include expected functional outcomes, ability to tolerate treatment, and comorbid illnesses. The collaboration of many specialties is the key for optimum assessment and decision making. We review the epidemiology, molecular pathogenesis, diagnosis and staging, and the latest multimodal management of squamous cell carcinoma of the head and neck.},
	author = {Argiris, A. and Karamouzis, M. V. and Raben, D. and Ferris, R. L.},
	doi = {10.1016/s0140-6736(08)60728-x},
	issn = {0140-6736 (Print) 0140-6736},
	journal = {Lancet},
	keywords = {Antineoplastic Combined Chemotherapy Protocols/*therapeutic use *Carcinoma, Squamous Cell/etiology/pathology/therapy Combined Modality Therapy Female *Head and Neck Neoplasms/etiology/pathology/therapy Humans Male Middle Aged Prognosis Randomized Controlled Trials as Topic Risk Factors Signal Transduction/drug effects/physiology},
	note = {1474-547x Argiris, Athanassios Karamouzis, Michalis V Raben, David Ferris, Robert L P50 CA097190/CA/NCI NIH HHS/United States P50CA097190/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Review 2008/05/20 Lancet. 2008 May 17;371(9625):1695-709. doi: 10.1016/S0140-6736(08)60728-X.},
	number = {9625},
	pages = {1695-709},
	title = {Head and neck cancer},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720415/pdf/nihms-1649887.pdf},
	volume = {371},
	year = {2008},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720415/pdf/nihms-1649887.pdf},
	bdsk-url-2 = {https://doi.org/10.1016/s0140-6736(08)60728-x}}

@article{RN209,
	abstract = {Most head and neck cancers are squamous cell carcinomas that develop in the upper aerodigestive epithelium after exposure to carcinogens such as tobacco and alcohol. Human papillomavirus has also been strongly implicated as a causative agent in a subset of these cancers. The complex anatomy and vital physiological role of the tumour-involved structures dictate that the goals of treatment are not only to improve survival outcomes but also to preserve organ function. Major improvements have been accomplished in surgical techniques and radiotherapy delivery. Moreover, systemic therapy including chemotherapy and molecularly targeted agents--namely, the epidermal growth factor receptor inhibitors--has been successfully integrated into potentially curative treatment of locally advanced squamous-cell carcinoma of the head and neck. In deciding which treatment strategy would be suitable for an individual patient, important considerations include expected functional outcomes, ability to tolerate treatment, and comorbid illnesses. The collaboration of many specialties is the key for optimum assessment and decision making. We review the epidemiology, molecular pathogenesis, diagnosis and staging, and the latest multimodal management of squamous cell carcinoma of the head and neck.},
	author = {Argiris, A. and Karamouzis, M. V. and Raben, D. and Ferris, R. L.},
	doi = {10.1016/s0140-6736(08)60728-x},
	issn = {0140-6736 (Print) 0140-6736},
	journal = {Lancet},
	keywords = {Antineoplastic Combined Chemotherapy Protocols/*therapeutic use *Carcinoma, Squamous Cell/etiology/pathology/therapy Combined Modality Therapy Female *Head and Neck Neoplasms/etiology/pathology/therapy Humans Male Middle Aged Prognosis Randomized Controlled Trials as Topic Risk Factors Signal Transduction/drug effects/physiology},
	note = {1474-547x Argiris, Athanassios Karamouzis, Michalis V Raben, David Ferris, Robert L P50 CA097190/CA/NCI NIH HHS/United States P50CA097190/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Review 2008/05/20 Lancet. 2008 May 17;371(9625):1695-709. doi: 10.1016/S0140-6736(08)60728-X.},
	number = {9625},
	pages = {1695-709},
	title = {Head and neck cancer},
	type = {Journal Article},
	volume = {371},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1016/s0140-6736(08)60728-x}}

@article{RN223,
	abstract = {Most head and neck cancers are squamous cell carcinomas that develop in the upper aerodigestive epithelium after exposure to carcinogens such as tobacco and alcohol. Human papillomavirus has also been strongly implicated as a causative agent in a subset of these cancers. The complex anatomy and vital physiological role of the tumour-involved structures dictate that the goals of treatment are not only to improve survival outcomes but also to preserve organ function. Major improvements have been accomplished in surgical techniques and radiotherapy delivery. Moreover, systemic therapy including chemotherapy and molecularly targeted agents--namely, the epidermal growth factor receptor inhibitors--has been successfully integrated into potentially curative treatment of locally advanced squamous-cell carcinoma of the head and neck. In deciding which treatment strategy would be suitable for an individual patient, important considerations include expected functional outcomes, ability to tolerate treatment, and comorbid illnesses. The collaboration of many specialties is the key for optimum assessment and decision making. We review the epidemiology, molecular pathogenesis, diagnosis and staging, and the latest multimodal management of squamous cell carcinoma of the head and neck.},
	author = {Argiris, A. and Karamouzis, M. V. and Raben, D. and Ferris, R. L.},
	doi = {10.1016/s0140-6736(08)60728-x},
	issn = {0140-6736 (Print) 0140-6736},
	journal = {Lancet},
	keywords = {Antineoplastic Combined Chemotherapy Protocols/*therapeutic use *Carcinoma, Squamous Cell/etiology/pathology/therapy Combined Modality Therapy Female *Head and Neck Neoplasms/etiology/pathology/therapy Humans Male Middle Aged Prognosis Randomized Controlled Trials as Topic Risk Factors Signal Transduction/drug effects/physiology},
	note = {1474-547x Argiris, Athanassios Karamouzis, Michalis V Raben, David Ferris, Robert L P50 CA097190/CA/NCI NIH HHS/United States P50CA097190/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Review 2008/05/20 Lancet. 2008 May 17;371(9625):1695-709. doi: 10.1016/S0140-6736(08)60728-X.},
	number = {9625},
	pages = {1695-709},
	title = {Head and neck cancer},
	type = {Journal Article},
	volume = {371},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1016/s0140-6736(08)60728-x}}

@article{RN166,
	abstract = {Hypersensitivity reactions of the oral mucosa comprise an array of clinical manifestations. Some of the reactions are difficult to differentiate from toxic reactions. Hypersensitivity reactions of type I, type III, and type IV are well known, although, especially for types I and III, they are rarely encountered. Type-I reactions are most frequently seen related to application of polymers in the oral cavity, such as orthodontic bonding and fissure sealant materials. There may also be systemic manifestations such as urticaria. Type-IV reactions may be seen related to most dental materials used, from amalgam and gold to polymers. These reactions appear as chronic reddening and/or ulceration of the oral mucosa. Lichenoid reactions have histopathological characteristics compatible with type-IV hypersensitivity reactions and are the most prevalent material-adverse reactions seen in the oral cavity. A special variety inside the lips with multiple papules and/or diffuse redness has recently been identified. This lesion comprises a serious treatment challenge. Skin patch tests, applying a series of dental materials in non-toxic concentrations on the skin, have been used to identify sensitization. However, the value of those tests can be questioned. Exacerbation of geographic stomatitis may be another form of hypersensitivity to dental materials.},
	author = {Ax{\'e}ll, T.},
	doi = {10.1080/000163501750541192},
	issn = {0001-6357 (Print) 0001-6357},
	journal = {Acta Odontol Scand},
	keywords = {Dental Materials/*adverse effects Erythema Multiforme/etiology/immunology/pathology Glossitis, Benign Migratory/etiology/immunology/pathology Humans Hypersensitivity/*complications/etiology/immunology/*pathology Lichen Planus, Oral/etiology/immunology/pathology Mouth Mucosa/*immunology Stomatitis, Aphthous/etiology/immunology/pathology},
	note = {Ax{\'e}ll, T Journal Article Review England 2001/10/30 Acta Odontol Scand. 2001 Oct;59(5):315-9. doi: 10.1080/000163501750541192.},
	number = {5},
	pages = {315-9},
	title = {Hypersensitivity of the oral mucosa: clinics and pathology},
	type = {Journal Article},
	url = {https://www.tandfonline.com/doi/abs/10.1080/000163501750541192},
	volume = {59},
	year = {2001},
	bdsk-url-1 = {https://www.tandfonline.com/doi/abs/10.1080/000163501750541192},
	bdsk-url-2 = {https://doi.org/10.1080/000163501750541192}}

@article{RN211,
	abstract = {OBJECTIVES: This study evaluates the outcome of pharyngoesophageal reconstruction using radial forearm free flaps with regard to primary wound healing, speech, and swallowing in patients requiring laryngopharyngectomy. STUDY DESIGN: Retrospective review in the setting of a tertiary, referral, and academic center. PATIENTS AND METHODS: Twenty patients underwent reconstruction of the pharyngoesophageal segment using fasciocutaneous radial forearm free flaps. RESULTS: All free flap transfers were successful. An oral diet was resumed in 85% of the patients after surgery. Postoperative pharyngocutaneous fistulas occurred in 4 patients (20%) with 3 resolving spontaneously. Distal strictures also occurred in 20% of the patients. Five patients who underwent tracheoesophageal puncture achieved useful speech. CONCLUSIONS: Advantages of radial forearm free flaps for microvascular pharyngoesophageal function include high flap reliability, limited donor site morbidity, larger vascular pedicle caliber, and the ability to achieve good quality tracheoesophageal speech. The swallowing outcome is similar to that achieved after jejunal flap pharyngoesophageal reconstruction. The main disadvantage of this technique relates to a moderately high incidence of pharyngocutaneous fistulas, which contributes to delayed oral intake in affected patients.},
	author = {Azizzadeh, B. and Yafai, S. and Rawnsley, J. D. and Abemayor, E. and Sercarz, J. A. and Calcaterra, T. C. and Berke, G. S. and Blackwell, K. E.},
	doi = {10.1097/00005537-200105000-00010},
	issn = {0023-852X (Print) 0023-852x},
	journal = {Laryngoscope},
	keywords = {Carcinoma, Squamous Cell/surgery Esophagoplasty/*methods Female Forearm Humans Hypopharynx/surgery Male Middle Aged Pharyngeal Neoplasms/surgery Pharynx/*surgery Postoperative Complications Reconstructive Surgical Procedures/*methods Speech, Esophageal *Surgical Flaps},
	note = {Azizzadeh, B Yafai, S Rawnsley, J D Abemayor, E Sercarz, J A Calcaterra, T C Berke, G S Blackwell, K E Journal Article United States 2001/05/19 Laryngoscope. 2001 May;111(5):807-10. doi: 10.1097/00005537-200105000-00010.},
	number = {5},
	pages = {807-10},
	title = {Radial forearm free flap pharyngoesophageal reconstruction},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1097/00005537-200105000-00010},
	volume = {111},
	year = {2001},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/abs/10.1097/00005537-200105000-00010},
	bdsk-url-2 = {https://doi.org/10.1097/00005537-200105000-00010}}

@article{RN260,
	abstract = {PURPOSE: To report the final results of a prospective randomized trial that aimed to evaluate efficacy and toxicity of concomitant postoperative radiotherapy and Cisplatin infusion in patients with Stage III or IV squamous cell carcinoma of the head and neck and histological evidence of extracapsular spread of tumor in lymph node metastase(s). METHODS AND MATERIALS: Radiotherapy was delivered using a daily dose of 1.7 Gy for the first 54 Gy and 1.8 to 2 Gy until the completion of the treatment. Cisplatin 50 mg i.v. with forced hydratation was given or not every week (i.e., seven to nine cycles) concurrently with radiotherapy. A total of 44 patients were treated by irradiation only (RT group) and 39 by irradiation with chemotherapy (CM group). RESULTS: The RT group displayed a higher rate of loco-regional failures as compared to CM group (41 vs. 23%; p = 0.08). The overall survival, the survival corrected for deaths by intercurrent disease, and the disease-free survival were better in CM group as compared to RT group with statistically significant differences. Survival without loco-regional treatment failure was better in the CM group, the difference being close to the level of significance (p = 0.05). Survival without distant metastases were comparable in the two therapeutic groups. Ten severe late complications were observed, four in the RT group (17%) and six in the CM group (22%). Cox univariate analysis confirmed the importance of the therapeutic modality in predicting the overall survival, the survival corrected for deaths by intercurrent disease, and the disease-free survival. CONCLUSIONS: The present final report of this phase III study confirms preliminary results. The concomitant use of 50 mg weekly Cisplatin infusion and postoperative radiation improved loco-regional control and survival. No significant increase of late radiation complications was observed in the CM group.},
	author = {Bachaud, J. M. and Cohen-Jonathan, E. and Alzieu, C. and David, J. M. and Serrano, E. and Daly-Schveitzer, N.},
	doi = {10.1016/s0360-3016(96)00430-0},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Antineoplastic Agents/*therapeutic use Carcinoma, Squamous Cell/mortality/*therapy Cisplatin/*therapeutic use Combined Modality Therapy Head and Neck Neoplasms/mortality/*therapy Humans Neoplasm Recurrence, Local Prospective Studies Regression Analysis},
	note = {Bachaud, J M Cohen-Jonathan, E Alzieu, C David, J M Serrano, E Daly-Schveitzer, N Clinical Trial Clinical Trial, Phase III Journal Article Randomized Controlled Trial United States 1996/12/01 Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):999-1004. doi: 10.1016/s0360-3016(96)00430-0.},
	number = {5},
	pages = {999-1004},
	title = {Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial},
	type = {Journal Article},
	url = {https://www.redjournal.org/article/S0360-3016(96)00430-0/pdf},
	volume = {36},
	year = {1996},
	bdsk-url-1 = {https://www.redjournal.org/article/S0360-3016(96)00430-0/pdf},
	bdsk-url-2 = {https://doi.org/10.1016/s0360-3016(96)00430-0}}

@article{RN140,
	abstract = {Alcohol consumption has been linked to an increased risk for various types of cancer. A combined analysis of more than 200 studies assessing the link between alcohol and various types of cancer (i.e., a meta-analysis) sought to investigate this association in more detail. This meta-analysis found that alcohol most strongly increased the risks for cancers of the oral cavity, pharynx, esophagus, and larynx. Statistically significant increases in risk also existed for cancers of the stomach, colon, rectum, liver, female breast, and ovaries. Several mechanisms have been postulated through which alcohol may contribute to an increased risk of cancer. Concurrent tobacco use, which is common among drinkers, enhances alcohol's effects on the risk for cancers of the upper digestive and respiratory tract. The analysis did not identify a threshold level of alcohol consumption below which no increased risk for cancer was evident.},
	author = {Bagnardi, V. and Blangiardo, M. and La Vecchia, C. and Corrao, G.},
	issn = {1535-7414 (Print) 1535-7414},
	journal = {Alcohol Res Health},
	keywords = {Alcohol Drinking/*adverse effects/epidemiology Beer/adverse effects Female Humans Male Neoplasms/epidemiology/*etiology Odds Ratio Risk Assessment Smoking/adverse effects/epidemiology Wine/adverse effects},
	note = {1930-0573 Bagnardi, V Blangiardo, M La Vecchia, C Corrao, G Journal Article Meta-Analysis Research Support, Non-U.S. Gov't 2002/03/26 Alcohol Res Health. 2001;25(4):263-70.},
	number = {4},
	pages = {263-70},
	title = {Alcohol consumption and the risk of cancer: a meta-analysis},
	type = {Journal Article},
	url = {https://air.unimi.it/retrieve/handle/2434/727671/1451980/Alcohol%20consumption%20BAGNARDI%2001-8570.pdf},
	volume = {25},
	year = {2001},
	bdsk-url-1 = {https://air.unimi.it/retrieve/handle/2434/727671/1451980/Alcohol%20consumption%20BAGNARDI%2001-8570.pdf}}

@article{RN34,
	abstract = {We examined the prognostic value of tumour-infiltrating lymphocytes (TILs) in patients with squamous cell carcinoma of the head and neck (SCCHN) after surgery and postoperative cisplatin-based chemoradiotherapy. FFPE-tissue originating from the surgery of 161 patients treated in 8 DKTK partner sites was immunohistochemically stained for CD3 and CD8. Their expression was correlated with clinicopathological characteristics as well as overall survival (OS), local progression-free survival (LPFS) and distant metastases free-survival (DMFS), also in the context of the HPV16-DNA/p16 status. After a median follow-up of 48 months (range: 4100 months), OS at 4 years was 46.5% for the entire cohort. In multivariate analysis, high CD8 expression was confirmed as an independent prognostic parameter for OS (p = 0.002), LPFS (p = 0.004) and DMFS (p = 0.006), while CD3 expression lacked significance. In multivariate analysis HPV16 DNA positivity was associated with improved OS (p = 0.025) and LPFS (p = 0.013) and p16-positive patients showed improved DMFS (p = 0.008). Interestingly, high CD8 expression was a prognostic parameter for the clinical outcome in both HPV16 DNA-positive and HPV16 DNA-negative patients. Similar findings were observed in the multivariate analysis for the combined HPV16 DNA/p16 status. Altogether, CD8+ TILs constitute an independent prognostic marker in SCCHN patients treated with adjuvant chemoradiotherapy. These data indicate that CD8-positive TILs have antitumour activity and could be used for treatment stratification. Further validation of the prognostic value of CD8+ TILs as a biomarker and its role in the immune response in SCCHN patients after adjuvant chemoradiotherapy is warranted and will be performed in the prospective DKTK-ROG study.},
	author = {Balermpas, P. and Rodel, F. and Rodel, C. and Krause, M. and Linge, A. and Lohaus, F. and Baumann, M. and Tinhofer, I. and Budach, V. and Gkika, E. and Stuschke, M. and Avlar, M. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Bayer, C. and Stangl, S. and Belka, C. and Pigorsch, S. and Multhoff, G. and Combs, S. E. and Monnich, D. and Zips, D. and Fokas, E.},
	doi = {10.1002/ijc.29683},
	issn = {1097-0215 (Electronic) 0020-7136 (Linking)},
	journal = {Int J Cancer},
	keywords = {Adult Aged Antineoplastic Combined Chemotherapy Protocols/therapeutic use Biomarkers, Tumor/genetics/metabolism CD8-Positive T-Lymphocytes/*immunology/metabolism Carcinoma, Squamous Cell/*etiology/mortality/pathology/therapy DNA, Viral Female Head and Neck Neoplasms/*etiology/mortality/pathology/therapy Humans Immunophenotyping Lymphocytes, Tumor-Infiltrating/*immunology/metabolism Male Middle Aged Neoplasm Grading Neoplasm Staging *Papillomaviridae/genetics Papillomavirus Infections/complications/*virology Phenotype Postoperative Care Prognosis Squamous Cell Carcinoma of Head and Neck Treatment Outcome Tumor Virus Infections/complications/*virology Cd8 Dktk-rog Hpv Scchn postoperative chemoradiotherapy prognostic},
	note = {Balermpas, Panagiotis Rodel, Franz Rodel, Claus Krause, Mechthild Linge, Annett Lohaus, Fabian Baumann, Michael Tinhofer, Inge Budach, Volker Gkika, Eleni Stuschke, Martin Avlar, Melanie Grosu, Anca-Lidia Abdollahi, Amir Debus, Jurgen Bayer, Christine Stangl, Stefan Belka, Claus Pigorsch, Steffi Multhoff, Gabriele Combs, Stephanie E Monnich, David Zips, Daniel Fokas, Emmanouil eng Multicenter Study Int J Cancer. 2016 Jan 1;138(1):171-81. doi: 10.1002/ijc.29683. Epub 2015 Jul 30.},
	number = {1},
	pages = {171-81},
	title = {CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.29683?download=true},
	volume = {138},
	year = {2016},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.29683?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.29683}}

@book{RN401,
	author = {Barnes, L. and Pathologie, Universit{\"a}ts-Spital Zurich. Dept. and Eveson, J.W. and Pathology, International Academy of and Sidransky, D. and Organization, World Health and Cancer, International Agency for Research on and Reichart, P.},
	isbn = {9789283224174},
	publisher = {IARC Press},
	title = {Pathology and Genetics of Head and Neck Tumours},
	type = {Book},
	url = {https://books.google.de/books?id=mrm8hxiJ4XIC},
	year = {2005},
	bdsk-url-1 = {https://books.google.de/books?id=mrm8hxiJ4XIC}}

@book{RN402,
	author = {Barnes, L. and Pathologie, Universit{\"a}ts-Spital Zurich. Dept. and Eveson, J.W. and Pathology, International Academy of and Sidransky, D. and Organization, World Health and Cancer, International Agency for Research on and Reichart, P.},
	isbn = {9789283224174},
	publisher = {IARC Press},
	title = {Pathology and Genetics of Head and Neck Tumours},
	type = {Book},
	url = {https://books.google.de/books?id=mrm8hxiJ4XIC},
	year = {2005},
	bdsk-url-1 = {https://books.google.de/books?id=mrm8hxiJ4XIC}}

@book{RN116,
	author = {Barnes, L. and Pathologie, Universit{\"a}ts-Spital Zurich. Dept. and Eveson, J.W. and Pathology, International Academy of and Sidransky, D. and Organization, World Health and Cancer, International Agency for Research on and Reichart, P.},
	isbn = {9789283224174},
	publisher = {IARC Press},
	title = {Pathology and Genetics of Head and Neck Tumours},
	type = {Book},
	url = {https://books.google.de/books?id=mrm8hxiJ4XIC},
	year = {2005},
	bdsk-url-1 = {https://books.google.de/books?id=mrm8hxiJ4XIC}}

@article{RN244,
	abstract = {In this study the results of combined radiotherapy and surgery are compared with the results of surgery alone in patients with neck node metastases from squamous cell carcinomas of the head and neck region. Postoperative radiotherapy decreases the recurrence rate in the neck, especially in cases with histologically established extranodal spread. Results of preoperative radiotherapy were similar to those of irradiation after surgery. Postoperative radiotherapy is favored, because it allows a selection of patients for extra treatment on the base of prognostic information, provided by the histologic characteristics of the neck dissection specimen.},
	author = {Bartelink, H. and Breur, K. and Hart, G. and Annyas, B. and van Slooten, E. and Snow, G.},
	doi = {10.1002/1097-0142(19830915)52:6<1008::aid-cncr2820520613>3.0.co;2-b},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Carcinoma, Squamous Cell/pathology/*radiotherapy/surgery Head and Neck Neoplasms/pathology/*radiotherapy/surgery Humans Lymphatic Metastasis *Neck Dissection Neoplasm Recurrence, Local Prognosis Radiotherapy Dosage Time Factors},
	note = {Bartelink, H Breur, K Hart, G Annyas, B van Slooten, E Snow, G Journal Article United States 1983/09/15 Cancer. 1983 Sep 15;52(6):1008-13. doi: 10.1002/1097-0142(19830915)52:6<1008::aid-cncr2820520613>3.0.co;2-b.},
	number = {6},
	pages = {1008-13},
	title = {The value of postoperative radiotherapy as an adjuvant to radical neck dissection},
	type = {Journal Article},
	url = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819830915%2952%3A6%3C1008%3A%3AAID-CNCR2820520613%3E3.0.CO%3B2-B?download=true},
	volume = {52},
	year = {1983},
	bdsk-url-1 = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819830915%2952%3A6%3C1008%3A%3AAID-CNCR2820520613%3E3.0.CO%3B2-B?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/1097-0142(19830915)52:6%3C1008::aid-cncr2820520613%3E3.0.co;2-b}}

@article{RN324,
	abstract = {PURPOSE/OBJECTIVE(S): To examine the association between CD44 and c-MET expression in relation to p16 and EGFR in patients with head and neck squamous cell carcinoma (HNSCC). MATERIALS/METHODS: Immunohistochemical staining of CD44, p16, EGFR, and c-MET was performed on 105 locally advanced HNSCC patients treated with chemoradiation. CD44 expression was correlated with c-MET, EGFR, and p16, locoregional control (LRC), distant metastases (DM), disease-free survival (DFS) and overall survival (OS). RESULTS: High CD44 expression was present in 33% of patients and was associated with non-oropharynx primaries (P < 0.001), high c-MET expression (P < 0.001), p16-negative (P < 0.001) and EGFR-positive tumors (P < 0.001). Fifty-seven percent of CD44 high expressing tumors had high c-MET expression compared to 21% of CD44 low expressing tumors (P < 0.001). High CD44 expression predicted for worse LRC (HR: 2.44; 95% CI: 1.16-5.13; P = 0.018), DFS (HR: 2.61; 95% CI: 1.46-4.67; P = 0.001), and OS (HR: 2.52; 95% CI: 1.30-4.92; P = 0.007) but not DM (P = 0.57) on univariate analysis. Patients with both high CD44 and c-MET expression had a poor prognosis with a 2-year DFS of 30% compared to 70% in the rest of the cohort (P = 0.003). On multivariable analysis, after adjusting for site, T-stage, smoking history, and EGFR status, high c-MET (P = 0.039) and negative p16 status (P = 0.034) predicted for worse DFS, while high CD44 expression did not (P = 0.43). CONCLUSIONS: High CD44 expression is associated with high c-MET expression, p16-negative tumors, and EGFR-positive tumors. The combination of these markers predicts for poor prognosis in HNSCC patients treated with chemoradiation.},
	author = {Baschnagel, A. M. and Tonlaar, N. and Eskandari, M. and Kumar, T. and Williams, L. and Hanna, A. and Pruetz, B. L. and Wilson, G. D.},
	doi = {10.1111/jop.12478},
	issn = {1600-0714 (Electronic) 0904-2512 (Linking)},
	journal = {J Oral Pathol Med},
	keywords = {Carcinoma, Squamous Cell/*metabolism/pathology/virology ErbB Receptors/*metabolism Head and Neck Neoplasms/*metabolism/pathology/virology Human papillomavirus 16/isolation & purification Humans Hyaluronan Receptors/*metabolism Kaplan-Meier Estimate Multivariate Analysis Papillomavirus Infections/complications Prognosis Proto-Oncogene Proteins c-met/*metabolism Squamous Cell Carcinoma of Head and Neck Egfr Cd44 Hnscc Hpv biomarkers c-MET},
	note = {Baschnagel, Andrew M Tonlaar, Nathan Eskandari, Mohammad Kumar, Tripti Williams, Lindsay Hanna, Alaa Pruetz, Barbara L Wilson, George D eng Denmark 2016/07/22 J Oral Pathol Med. 2017 Mar;46(3):208-213. doi: 10.1111/jop.12478. Epub 2016 Jul 21.},
	number = {3},
	pages = {208-213},
	title = {Combined CD44, c-MET, and EGFR expression in p16-positive and p16-negative head and neck squamous cell carcinomas},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/10.1111/jop.12478},
	volume = {46},
	year = {2017},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/10.1111/jop.12478},
	bdsk-url-2 = {https://doi.org/10.1111/jop.12478}}

@article{RN331,
	author = {Baumann, M. and Krause, M.},
	doi = {10.1158/1078-0432.CCR-10-2244},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Biomarkers, Tumor/genetics/metabolism/physiology Carcinoma, Squamous Cell/*diagnosis/genetics/metabolism/*radiotherapy Gene Expression Regulation, Neoplastic/radiation effects Head and Neck Neoplasms/*diagnosis/genetics/metabolism/*radiotherapy Humans Hyaluronan Receptors/genetics/metabolism/*physiology Models, Biological Neoplastic Stem Cells/*metabolism/radiation effects Prognosis},
	number = {21},
	pages = {5091-3},
	title = {CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20861165},
	volume = {16},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/20861165},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-10-2244}}

@article{RN411,
	author = {Baumann, M. and Krause, M.},
	doi = {10.1158/1078-0432.CCR-10-2244},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Biomarkers, Tumor/genetics/metabolism/physiology Carcinoma, Squamous Cell/*diagnosis/genetics/metabolism/*radiotherapy Gene Expression Regulation, Neoplastic/radiation effects Head and Neck Neoplasms/*diagnosis/genetics/metabolism/*radiotherapy Humans Hyaluronan Receptors/genetics/metabolism/*physiology Models, Biological Neoplastic Stem Cells/*metabolism/radiation effects Prognosis},
	number = {21},
	pages = {5091-3},
	title = {CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20861165},
	volume = {16},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/20861165},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-10-2244}}

@article{RN21,
	abstract = {CD44, a cancer stem cell (CSC)-related surface marker, correlates with local control after radiotherapy of early laryngeal cancer. For the first time, a CSC-related marker has been functionally validated for radiotherapy in patients. CD44 expression bears the potential to predict the outcome of radiotherapy by assessment of CSC density.},
	author = {Baumann, M. and Krause, M.},
	doi = {10.1158/1078-0432.CCR-10-2244},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Biomarkers, Tumor/genetics/metabolism/physiology Carcinoma, Squamous Cell/*diagnosis/genetics/metabolism/*radiotherapy Gene Expression Regulation, Neoplastic/radiation effects Head and Neck Neoplasms/*diagnosis/genetics/metabolism/*radiotherapy Humans Hyaluronan Receptors/genetics/metabolism/*physiology Models, Biological Neoplastic Stem Cells/*metabolism/radiation effects Prognosis},
	note = {Baumann, Michael Krause, Mechthild eng Comment Clin Cancer Res. 2010 Nov 1;16(21):5091-3. doi: 10.1158/1078-0432.CCR-10-2244. Epub 2010 Sep 22.},
	number = {21},
	pages = {5091-3},
	title = {CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy},
	type = {Journal Article},
	url = {https://clincancerres.aacrjournals.org/content/clincanres/16/21/5091.full.pdf},
	volume = {16},
	year = {2010},
	bdsk-url-1 = {https://clincancerres.aacrjournals.org/content/clincanres/16/21/5091.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-10-2244}}

@article{RN39,
	abstract = {CD44, a cancer stem cell (CSC)-related surface marker, correlates with local control after radiotherapy of early laryngeal cancer. For the first time, a CSC-related marker has been functionally validated for radiotherapy in patients. CD44 expression bears the potential to predict the outcome of radiotherapy by assessment of CSC density.},
	author = {Baumann, M. and Krause, M.},
	doi = {10.1158/1078-0432.CCR-10-2244},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Biomarkers, Tumor/genetics/metabolism/physiology Carcinoma, Squamous Cell/*diagnosis/genetics/metabolism/*radiotherapy Gene Expression Regulation, Neoplastic/radiation effects Head and Neck Neoplasms/*diagnosis/genetics/metabolism/*radiotherapy Humans Hyaluronan Receptors/genetics/metabolism/*physiology Models, Biological Neoplastic Stem Cells/*metabolism/radiation effects Prognosis},
	note = {Baumann, Michael Krause, Mechthild eng Comment Clin Cancer Res. 2010 Nov 1;16(21):5091-3. doi: 10.1158/1078-0432.CCR-10-2244. Epub 2010 Sep 22.},
	number = {21},
	pages = {5091-3},
	title = {CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20861165},
	volume = {16},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/20861165},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-10-2244}}

@article{RN317,
	abstract = {Radiobiological research over the past decades has provided evidence that cancer stem cell content and the intrinsic radiosensitivity of cancer stem cells varies between tumours, thereby affecting their radiocurability. Translation of this knowledge into predictive tests for the clinic has so far been hampered by the lack of methods to discriminate between stem cells and non-stem cells. New technologies allow isolation of cells expressing specific surface markers that are differentially expressed in tumour cell subpopulations that are enriched for cancer stem cells. Combining these techniques with functional radiobiological assays holds the potential to elucidate the role of cancer stem cells in radioresistance in individual tumours, and to use this knowledge for the development of predictive markers for optimization of radiotherapy.},
	author = {Baumann, M. and Krause, M. and Hill, R.},
	doi = {10.1038/nrc2419},
	issn = {1474-175x},
	journal = {Nat Rev Cancer},
	keywords = {Animals Humans Neoplasms/pathology/*radiotherapy Neoplastic Stem Cells/*cytology *Radiation Tolerance},
	note = {1474-1768 Baumann, Michael Krause, Mechthild Hill, Richard Journal Article Research Support, Non-U.S. Gov't Review England 2008/05/31 Nat Rev Cancer. 2008 Jul;8(7):545-54. doi: 10.1038/nrc2419. Epub 2008 May 30.},
	number = {7},
	pages = {545-54},
	title = {Exploring the role of cancer stem cells in radioresistance},
	type = {Journal Article},
	volume = {8},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1038/nrc2419}}

@article{RN319,
	abstract = {PURPOSE: The present work summarises the history and current status of research into the importance of cancer stem cells for radiobiological research and for clinical radiation oncology. An effort is made to differentiate clonogenicity from stemness of cancer cells. CONCLUSION: In radiooncology, cancer stem cells have been an important research field for five decades. Quantitative transplantation assays with evaluation of the take dose 50% (TD50) remain the gold standard to verify the stemness of the selected cells. New technologies allow sorting of tumour cells according to their surface marker expression and thereby selecting subpopulations that are enriched in cancer stem cells (e.g., CD133, CD44, CD29). While development of surface-marker-based assays is a highly important step in cancer-stem-cell research, to date there are still problems to be solved, e.g., the specifity of markers, adequate animal models, and optimised in vitro assays. Of special concern for radiobiology is that clonogenic in vitro assays do not necessarily measure stemness of cancer cells. This hampers investigations into the important question of whether cancer stem cells are more radioresistant than non-stem cells. The most extensive of the limited data on this topic relate to glioma stem cells identified by the surface marker CD133. These do not provide firm evidence for difference of radiosensitivity between stem and non stem cells. In spite of many problems to be solved, the combination of stem cell markers with radiobiological assays bears considerable promise for advancing translational research in radiation oncology.},
	author = {Baumann, M. and Krause, M. and Thames, H. and Trott, K. and Zips, D.},
	doi = {10.1080/09553000902836404},
	issn = {0955-3002 (Print) 0955-3002},
	journal = {Int J Radiat Biol},
	keywords = {Animals Humans Models, Biological Neoplasm Transplantation Neoplasms/*pathology/*radiotherapy Neoplastic Stem Cells/*radiation effects/transplantation},
	note = {Baumann, Michael Krause, Mechthild Thames, Howard Trott, Klaus Zips, Daniel Journal Article Research Support, Non-U.S. Gov't Review England 2009/04/22 Int J Radiat Biol. 2009 May;85(5):391-402. doi: 10.1080/09553000902836404.},
	number = {5},
	pages = {391-402},
	title = {Cancer stem cells and radiotherapy},
	type = {Journal Article},
	volume = {85},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1080/09553000902836404}}

@article{RN318,
	abstract = {PURPOSE: The present work summarises the history and current status of research into the importance of cancer stem cells for radiobiological research and for clinical radiation oncology. An effort is made to differentiate clonogenicity from stemness of cancer cells. CONCLUSION: In radiooncology, cancer stem cells have been an important research field for five decades. Quantitative transplantation assays with evaluation of the take dose 50% (TD50) remain the gold standard to verify the stemness of the selected cells. New technologies allow sorting of tumour cells according to their surface marker expression and thereby selecting subpopulations that are enriched in cancer stem cells (e.g., CD133, CD44, CD29). While development of surface-marker-based assays is a highly important step in cancer-stem-cell research, to date there are still problems to be solved, e.g., the specifity of markers, adequate animal models, and optimised in vitro assays. Of special concern for radiobiology is that clonogenic in vitro assays do not necessarily measure stemness of cancer cells. This hampers investigations into the important question of whether cancer stem cells are more radioresistant than non-stem cells. The most extensive of the limited data on this topic relate to glioma stem cells identified by the surface marker CD133. These do not provide firm evidence for difference of radiosensitivity between stem and non stem cells. In spite of many problems to be solved, the combination of stem cell markers with radiobiological assays bears considerable promise for advancing translational research in radiation oncology.},
	author = {Baumann, M. and Krause, M. and Thames, H. and Trott, K. and Zips, D.},
	doi = {10.1080/09553000902836404},
	issn = {0955-3002 (Print) 0955-3002},
	journal = {Int J Radiat Biol},
	keywords = {Animals Humans Models, Biological Neoplasm Transplantation Neoplasms/*pathology/*radiotherapy Neoplastic Stem Cells/*radiation effects/transplantation},
	note = {Baumann, Michael Krause, Mechthild Thames, Howard Trott, Klaus Zips, Daniel Journal Article Research Support, Non-U.S. Gov't Review England 2009/04/22 Int J Radiat Biol. 2009 May;85(5):391-402. doi: 10.1080/09553000902836404.},
	number = {5},
	pages = {391-402},
	title = {Cancer stem cells and radiotherapy},
	type = {Journal Article},
	volume = {85},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1080/09553000902836404}}

@article{RN163,
	abstract = {PURPOSE: Patients with head and neck squamous cell carcinoma (HNSCC) often come to clinical attention with a neck mass due to metastatic spread to lymph nodes. Treatment is dictated by the subsequent determination of primary tumor site and stage. However, the primary site remains elusive in some patients even after an exhaustive examination. Human papillomavirus type 16 (HPV-16) is an important etiologic agent for HNSCCs that arise within the oropharynx but less so for tumors from nonoropharyngeal sites. Detection of HPV-16 or a surrogate marker may be useful in localizing tumor origin in patients who present with metastatic HNSCC. EXPERIMENTAL DESIGN: We performed in situ hybridization (ISH) for HPV-16 on lymph node metastases from 68 patients with HNSCC. P16 immunohistochemistry was also performed because HPV-16 integration disrupts the retinoblastoma pathway and induces an overexpression of p16. RESULTS: HPV-16 was detected in 22 of the 68 (32%) cases by ISH. When stratified by site of origin, HPV-16 was detected in 22 of 31 (71%) metastases from the oropharynx, but in none of the 37 (0%) metastases from other sites (P < 0.001; Fisher's exact). P16 expression was associated with the presence of HPV-16 by ISH: 21 of 22 HPV-16 positive tumors exhibited p16 expression, whereas only 4 of the 46 HPV-16-negative tumors were p16 positive (95% versus 9%; P < 0.001; Fisher's exact). P16 expression in the node metastases also correlated with site of tumor origin: 24 of 31 oropharyngeal tumors were p16 positive, whereas only 1 of 37 nonoropharyngeal tumors was p16 positive (77% versus 3%; P < 0.001; Fisher's exact). CONCLUSIONS: For patients with metastatic HNSCC, detection of HPV-16 is a reliable way to establish origin from the oropharynx, either directly by ISH or indirectly by immunohistochemistry for p16 overexpression.},
	author = {Begum, S. and Gillison, M. L. and Ansari-Lari, M. A. and Shah, K. and Westra, W. H.},
	issn = {1078-0432 (Print) 1078-0432},
	journal = {Clin Cancer Res},
	keywords = {Carcinoma, Squamous Cell/metabolism Cervix Uteri/*metabolism/virology Female Head and Neck Neoplasms/metabolism Humans Immunohistochemistry In Situ Hybridization Lymph Nodes/*metabolism/virology Lymphatic Metastasis Neoplasm Metastasis Papillomaviridae/*metabolism},
	note = {Begum, Shahnaz Gillison, Maura L Ansari-Lari, M Ali Shah, Keerti Westra, William H 1R01 DE13121-01A1/DE/NIDCR NIH HHS/United States Journal Article Research Support, U.S. Gov't, P.H.S. United States 2003/12/26 Clin Cancer Res. 2003 Dec 15;9(17):6469-75.},
	number = {17},
	pages = {6469-75},
	title = {Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin},
	type = {Journal Article},
	url = {https://clincancerres.aacrjournals.org/content/clincanres/9/17/6469.full.pdf},
	volume = {9},
	year = {2003},
	bdsk-url-1 = {https://clincancerres.aacrjournals.org/content/clincanres/9/17/6469.full.pdf}}

@article{RN414,
	author = {Bernier, J. and Cooper, J. S. and Pajak, T. F. and van Glabbeke, M. and Bourhis, J. and Forastiere, A. and Ozsahin, E. M. and Jacobs, J. R. and Jassem, J. and Ang, K. K. and Lefebvre, J. L.},
	doi = {10.1002/hed.20279},
	issn = {1043-3074 (Print) 1043-3074 (Linking)},
	journal = {Head Neck},
	keywords = {Antineoplastic Agents/therapeutic use Cisplatin/therapeutic use Combined Modality Therapy Head and Neck Neoplasms/*drug therapy/*radiotherapy/surgery Humans Neoplasm Recurrence, Local Neoplasm Staging Prognosis *Randomized Controlled Trials as Topic Risk Survival Analysis},
	number = {10},
	pages = {843-50},
	title = {Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16161069},
	volume = {27},
	year = {2005},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/16161069},
	bdsk-url-2 = {https://doi.org/10.1002/hed.20279}}

@article{RN47,
	abstract = {BACKGROUND: In 2004, level I evidence was established for the postoperative adjuvant treatment of patients with selected high-risk locally advanced head and neck cancers, with the publication of the results of two trials conducted in Europe (European Organization Research and Treatment of Cancer; EORTC) and the United States (Radiation Therapy Oncology Group; RTOG). Adjuvant chemotherapy-enhanced radiation therapy (CERT) was shown to be more efficacious than postoperative radiotherapy for these tumors in terms of locoregional control and disease-free survival. However, additional studies were needed to identify precisely which patients were most suitable for such intense treatment. METHODS: Both studies compared the addition of concomitant relatively high doses of cisplatin (on days 1, 22, and 43) to radiotherapy vs radiotherapy alone given after surgery in patients with high-risk cancers of the oral cavity, oropharynx, larynx, or hypopharynx. A comparative analysis of the selection criteria, clinical and pathologic risk factors, and treatment outcomes was carried out using data pooled from these two trials. RESULTS: Extracapsular extension (ECE) and/or microscopically involved surgical margins were the only risk factors for which the impact of CERT was significant in both trials. There was also a trend in favor of CERT in the group of patients who had stage III-IV disease, perineural infiltration, vascular embolisms, and/or clinically enlarged level IV-V lymph nodes secondary to tumors arising in the oral cavity or oropharynx. Patients who had two or more histopathologically involved lymph nodes without ECE as their only risk factor did not seem to benefit from the addition of chemotherapy in this analysis. CONCLUSIONS: Subject to the usual caveats of retrospective subgroup analysis, our data suggest that in locally advanced head and neck cancer, microscopically involved resection margins and extracapsular spread of tumor from neck nodes are the most significant prognostic factors for poor outcome. The addition of concomitant cisplatin to postoperative radiotherapy improves outcome in patients with one or both of these risk factors who are medically fit to receive chemotherapy.},
	author = {Bernier, J. and Cooper, J. S. and Pajak, T. F. and van Glabbeke, M. and Bourhis, J. and Forastiere, A. and Ozsahin, E. M. and Jacobs, J. R. and Jassem, J. and Ang, K. K. and Lefebvre, J. L.},
	doi = {10.1002/hed.20279},
	issn = {1043-3074 (Print) 1043-3074 (Linking)},
	journal = {Head Neck},
	keywords = {Antineoplastic Agents/therapeutic use Cisplatin/therapeutic use Combined Modality Therapy Head and Neck Neoplasms/*drug therapy/*radiotherapy/surgery Humans Neoplasm Recurrence, Local Neoplasm Staging Prognosis *Randomized Controlled Trials as Topic Risk Survival Analysis},
	note = {Bernier, Jacques Cooper, Jay S Pajak, T F van Glabbeke, M Bourhis, J Forastiere, Arlene Ozsahin, Esat Mahmut Jacobs, John R Jassem, J Ang, Kie-Kian Lefebvre, J L eng 5U10 CA11488/CA/NCI NIH HHS/ 5U10 CA11488-33/CA/NCI NIH HHS/ Comparative Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Head Neck. 2005 Oct;27(10):843-50. doi: 10.1002/hed.20279.},
	number = {10},
	pages = {843-50},
	title = {Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/10.1002/hed.20279},
	volume = {27},
	year = {2005},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/10.1002/hed.20279},
	bdsk-url-2 = {https://doi.org/10.1002/hed.20279}}

@article{RN270,
	abstract = {BACKGROUND: In 2004, level I evidence was established for the postoperative adjuvant treatment of patients with selected high-risk locally advanced head and neck cancers, with the publication of the results of two trials conducted in Europe (European Organization Research and Treatment of Cancer; EORTC) and the United States (Radiation Therapy Oncology Group; RTOG). Adjuvant chemotherapy-enhanced radiation therapy (CERT) was shown to be more efficacious than postoperative radiotherapy for these tumors in terms of locoregional control and disease-free survival. However, additional studies were needed to identify precisely which patients were most suitable for such intense treatment. METHODS: Both studies compared the addition of concomitant relatively high doses of cisplatin (on days 1, 22, and 43) to radiotherapy vs radiotherapy alone given after surgery in patients with high-risk cancers of the oral cavity, oropharynx, larynx, or hypopharynx. A comparative analysis of the selection criteria, clinical and pathologic risk factors, and treatment outcomes was carried out using data pooled from these two trials. RESULTS: Extracapsular extension (ECE) and/or microscopically involved surgical margins were the only risk factors for which the impact of CERT was significant in both trials. There was also a trend in favor of CERT in the group of patients who had stage III-IV disease, perineural infiltration, vascular embolisms, and/or clinically enlarged level IV-V lymph nodes secondary to tumors arising in the oral cavity or oropharynx. Patients who had two or more histopathologically involved lymph nodes without ECE as their only risk factor did not seem to benefit from the addition of chemotherapy in this analysis. CONCLUSIONS: Subject to the usual caveats of retrospective subgroup analysis, our data suggest that in locally advanced head and neck cancer, microscopically involved resection margins and extracapsular spread of tumor from neck nodes are the most significant prognostic factors for poor outcome. The addition of concomitant cisplatin to postoperative radiotherapy improves outcome in patients with one or both of these risk factors who are medically fit to receive chemotherapy.},
	author = {Bernier, J. and Cooper, J. S. and Pajak, T. F. and van Glabbeke, M. and Bourhis, J. and Forastiere, A. and Ozsahin, E. M. and Jacobs, J. R. and Jassem, J. and Ang, K. K. and Lef{\`e}bvre, J. L.},
	doi = {10.1002/hed.20279},
	issn = {1043-3074 (Print) 1043-3074},
	journal = {Head Neck},
	keywords = {Antineoplastic Agents/therapeutic use Cisplatin/therapeutic use Combined Modality Therapy Head and Neck Neoplasms/*drug therapy/*radiotherapy/surgery Humans Neoplasm Recurrence, Local Neoplasm Staging Prognosis *Randomized Controlled Trials as Topic Risk Survival Analysis},
	note = {Bernier, Jacques Cooper, Jay S Pajak, T F van Glabbeke, M Bourhis, J Forastiere, Arlene Ozsahin, Esat Mahmut Jacobs, John R Jassem, J Ang, Kie-Kian Lef{\`e}bvre, J L 5U10 CA11488/CA/NCI NIH HHS/United States 5U10 CA11488-33/CA/NCI NIH HHS/United States Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. United States 2005/09/15 Head Neck. 2005 Oct;27(10):843-50. doi: 10.1002/hed.20279.},
	number = {10},
	pages = {843-50},
	title = {Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)},
	type = {Journal Article},
	volume = {27},
	year = {2005},
	bdsk-url-1 = {https://doi.org/10.1002/hed.20279}}

@article{RN262,
	abstract = {BACKGROUND: We compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage III or IV head and neck cancer. METHODS: After undergoing surgery with curative intent, 167 patients were randomly assigned to receive radiotherapy alone (66 Gy over a period of 6 1/2 weeks) and 167 to receive the same radiotherapy regimen combined with 100 mg of cisplatin per square meter of body-surface area on days 1, 22, and 43 of the radiotherapy regimen. RESULTS: After a median follow-up of 60 months, the rate of progression-free survival was significantly higher in the combined-therapy group than in the group given radiotherapy alone (P=0.04 by the log-rank test; hazard ratio for disease progression, 0.75; 95 percent confidence interval, 0.56 to 0.99), with 5-year Kaplan-Meier estimates of progression-free survival of 47 percent and 36 percent, respectively. The overall survival rate was also significantly higher in the combined-therapy group than in the radiotherapy group (P=0.02 by the log-rank test; hazard ratio for death, 0.70; 95 percent confidence interval, 0.52 to 0.95), with five-year Kaplan-Meier estimates of overall survival of 53 percent and 40 percent, respectively. The cumulative incidence of local or regional relapses was significantly lower in the combined-therapy group (P=0.007). The estimated five-year cumulative incidence of local or regional relapses (considering death from other causes as a competing risk) was 31 percent after radiotherapy and 18 percent after combined therapy. Severe (grade 3 or higher) adverse effects were more frequent after combined therapy (41 percent) than after radiotherapy (21 percent, P=0.001); the types of severe mucosal adverse effects were similar in the two groups, as was the incidence of late adverse effects. CONCLUSIONS: Postoperative concurrent administration of high-dose cisplatin with radiotherapy is more efficacious than radiotherapy alone in patients with locally advanced head and neck cancer and does not cause an undue number of late complications.},
	author = {Bernier, J. and Domenge, C. and Ozsahin, M. and Matuszewska, K. and Lef{\`e}bvre, J. L. and Greiner, R. H. and Giralt, J. and Maingon, P. and Rolland, F. and Bolla, M. and Cognetti, F. and Bourhis, J. and Kirkpatrick, A. and van Glabbeke, M.},
	doi = {10.1056/NEJMoa032641},
	issn = {0028-4793},
	journal = {N Engl J Med},
	keywords = {Adolescent Adult Aged Antineoplastic Agents/adverse effects/*therapeutic use Carcinoma, Squamous Cell/*drug therapy/mortality/*radiotherapy/surgery Cisplatin/adverse effects/*therapeutic use Combined Modality Therapy/adverse effects Disease-Free Survival Female Follow-Up Studies Head and Neck Neoplasms/*drug therapy/mortality/*radiotherapy/surgery Humans Male Middle Aged Radiotherapy/adverse effects Risk Survival Rate},
	note = {1533-4406 Bernier, Jacques Domenge, Christian Ozsahin, Mahmut Matuszewska, Katarzyna Lef{\`e}bvre, Jean-Louis Greiner, Richard H Giralt, Jordi Maingon, Philippe Rolland, Fr{\'e}d{\'e}ric Bolla, Michel Cognetti, Francesco Bourhis, Jean Kirkpatrick, Anne van Glabbeke, Martine European Organization for Research and Treatment of Cancer Trial 22931 5U10 CA11488/CA/NCI NIH HHS/United States 5U10 CA11488-1/CA/NCI NIH HHS/United States 5U10 CA11488-10/CA/NCI NIH HHS/United States 5U10 CA11488-11/CA/NCI NIH HHS/United States 5U10 CA11488-12/CA/NCI NIH HHS/United States 5U10 CA11488-13/CA/NCI NIH HHS/United States 5U10 CA11488-14/CA/NCI NIH HHS/United States 5U10 CA11488-15/CA/NCI NIH HHS/United States 5U10 CA11488-16/CA/NCI NIH HHS/United States 5U10 CA11488-17/CA/NCI NIH HHS/United States 5U10 CA11488-18/CA/NCI NIH HHS/United States 5U10 CA11488-19/CA/NCI NIH HHS/United States 5U10 CA11488-2/CA/NCI NIH HHS/United States 5U10 CA11488-20/CA/NCI NIH HHS/United States 5U10 CA11488-21/CA/NCI NIH HHS/United States 5U10 CA11488-22/CA/NCI NIH HHS/United States 5U10 CA11488-23/CA/NCI NIH HHS/United States 5U10 CA11488-24/CA/NCI NIH HHS/United States 5U10 CA11488-25/CA/NCI NIH HHS/United States 5U10 CA11488-26/CA/NCI NIH HHS/United States 5U10 CA11488-27/CA/NCI NIH HHS/United States 5U10 CA11488-28/CA/NCI NIH HHS/United States 5U10 CA11488-29/CA/NCI NIH HHS/United States 5U10 CA11488-3/CA/NCI NIH HHS/United States 5U10 CA11488-30/CA/NCI NIH HHS/United States 5U10 CA11488-31/CA/NCI NIH HHS/United States 5U10 CA11488-32/CA/NCI NIH HHS/United States 5U10 CA11488-33/CA/NCI NIH HHS/United States 5U10 CA11488-4/CA/NCI NIH HHS/United States 5U10 CA11488-5/CA/NCI NIH HHS/United States 5U10 CA11488-6/CA/NCI NIH HHS/United States 5U10 CA11488-7/CA/NCI NIH HHS/United States 5U10 CA11488-8/CA/NCI NIH HHS/United States 5U10 CA11488-9/CA/NCI NIH HHS/United States Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S. United States 2004/05/07 N Engl J Med. 2004 May 6;350(19):1945-52. doi: 10.1056/NEJMoa032641.},
	number = {19},
	pages = {1945-52},
	title = {Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer},
	type = {Journal Article},
	url = {https://www.nejm.org/doi/pdf/10.1056/NEJMoa032641?articleTools=true},
	volume = {350},
	year = {2004},
	bdsk-url-1 = {https://www.nejm.org/doi/pdf/10.1056/NEJMoa032641?articleTools=true},
	bdsk-url-2 = {https://doi.org/10.1056/NEJMoa032641}}

@article{RN432,
	author = {Biomarkers Definitions Working, Group},
	doi = {10.1067/mcp.2001.113989},
	issn = {0009-9236 (Print) 0009-9236 (Linking)},
	journal = {Clin Pharmacol Ther},
	keywords = {Animals *Biomarkers *Clinical Trials as Topic Endpoint Determination/*methods Humans Research},
	number = {3},
	pages = {89-95},
	title = {Biomarkers and surrogate endpoints: preferred definitions and conceptual framework},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11240971},
	volume = {69},
	year = {2001},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/11240971},
	bdsk-url-2 = {https://doi.org/10.1067/mcp.2001.113989}}

@article{RN42,
	author = {Biomarkers Definitions Working, Group},
	doi = {10.1067/mcp.2001.113989},
	issn = {0009-9236 (Print) 0009-9236 (Linking)},
	journal = {Clin Pharmacol Ther},
	keywords = {Animals *Biomarkers *Clinical Trials as Topic Endpoint Determination/*methods Humans Research},
	note = {eng Review Clin Pharmacol Ther. 2001 Mar;69(3):89-95. doi: 10.1067/mcp.2001.113989.},
	number = {3},
	pages = {89-95},
	title = {Biomarkers and surrogate endpoints: preferred definitions and conceptual framework},
	type = {Journal Article},
	url = {https://ascpt.onlinelibrary.wiley.com/doi/pdfdirect/10.1067/mcp.2001.113989?download=true},
	volume = {69},
	year = {2001},
	bdsk-url-1 = {https://ascpt.onlinelibrary.wiley.com/doi/pdfdirect/10.1067/mcp.2001.113989?download=true},
	bdsk-url-2 = {https://doi.org/10.1067/mcp.2001.113989}}

@article{RN136,
	abstract = {A case-control study of oral and pharyngeal cancer conducted in four areas of the United States provided information on the tobacco and alcohol use of 1114 patients and 1268 population-based controls. Because of the large study size, it could be shown that the risks of these cancers among nondrinkers increased with amount smoked, and conversely that the risks among nonsmokers increased with the level of alcohol intake. Among consumers of both products, risks of oropharyngeal cancer tended to combine more in a multiplicative than additive fashion and were increased more than 35-fold among those who consumed two or more packs of cigarettes and more than four alcoholic drinks/day. Cigarette, cigar, and pipe smoking were separately implicated, although it was shown for the first time that risk was not as high among male lifelong filter cigarette smokers. Cessation of smoking was associated with a sharply reduced risk of this cancer, with no excess detected among those having quit for 10 or more years, suggesting that smoking affects primarily a late stage in the process of oropharyngeal carcinogenesis. The risks varied by type of alcoholic beverage, being higher among those consuming hard liquor or beer than wine. The relative risk patterns were generally similar among whites and blacks, and among males and females, and showed little difference when oral and pharyngeal cancers were analyzed separately. From calculations of attributable risk, we estimate that tobacco smoking and alcohol drinking combine to account for approximately three-fourths of all oral and pharyngeal cancers in the United States.},
	author = {Blot, W. J. and McLaughlin, J. K. and Winn, D. M. and Austin, D. F. and Greenberg, R. S. and Preston-Martin, S. and Bernstein, L. and Schoenberg, J. B. and Stemhagen, A. and Fraumeni, J. F., Jr.},
	issn = {0008-5472 (Print) 0008-5472},
	journal = {Cancer Res},
	keywords = {African Americans Age Factors Aged *Alcohol Drinking Female Humans Male Middle Aged Mouth Neoplasms/*epidemiology/etiology Pharyngeal Neoplasms/*epidemiology/etiology Sex Factors Smoking/*adverse effects United States Whites},
	note = {Blot, W J McLaughlin, J K Winn, D M Austin, D F Greenberg, R S Preston-Martin, S Bernstein, L Schoenberg, J B Stemhagen, A Fraumeni, J F Jr Comparative Study Journal Article United States 1988/06/01 Cancer Res. 1988 Jun 1;48(11):3282-7.},
	number = {11},
	pages = {3282-7},
	title = {Smoking and drinking in relation to oral and pharyngeal cancer},
	type = {Journal Article},
	url = {https://cancerres.aacrjournals.org/content/canres/48/11/3282.full.pdf},
	volume = {48},
	year = {1988},
	bdsk-url-1 = {https://cancerres.aacrjournals.org/content/canres/48/11/3282.full.pdf}}

@article{RN296,
	abstract = {The last 15 years has seen an explosion of interest in the cancer stem cell (CSC). Although it was initially believed that only a rare population of stem cells are able to undergo self-renewing divisions and differentiate to form all populations within a malignancy, a recent work has shown that these cells may not be as rare as thought first, at least in some malignancies. Improved experimental models are beginning to uncover a less rigid structure to CSC biology, in which the concepts of functional plasticity and clonal evolution must be incorporated into the traditional models. Slowly the genetic programmes and biological processes underlying stem cell biology are being elucidated, opening the door to the development of drugs targeting the CSC. The aim of ongoing research to understand CSCs is to develop novel stem cell-directed treatments, which will reduce therapy resistance, relapse and the toxicity associated with current, non-selective agents.},
	author = {Bomken, S. and Fi{\v s}er, K. and Heidenreich, O. and Vormoor, J.},
	doi = {10.1038/sj.bjc.6605821},
	issn = {1532-1827},
	journal = {British Journal of Cancer},
	number = {4},
	pages = {439-445},
	title = {Understanding the cancer stem cell},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939794/pdf/6605821a.pdf},
	volume = {103},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939794/pdf/6605821a.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/sj.bjc.6605821}}

@article{RN286,
	abstract = {BACKGROUND: Previous results from our phase 3 randomised trial showed that adding cetuximab to primary radiotherapy increased overall survival in patients with locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN) at 3 years. Here we report the 5-year survival data, and investigate the relation between cetuximab-induced rash and survival. METHODS: Patients with LASCCHN of the oropharynx, hypopharynx, or larynx with measurable disease were randomly allocated in a 1:1 ratio to receive either comprehensive head and neck radiotherapy alone for 6-7 weeks or radiotherapy plus weekly doses of cetuximab: 400 mg/m(2) initial dose, followed by seven weekly doses at 250 mg/m(2). Randomisation was done with an adaptive minimisation technique to balance assignments across stratification factors of Karnofsky performance score, T stage, N stage, and radiation fractionation. The trial was un-blinded. The primary endpoint was locoregional control, with a secondary endpoint of survival. Following discussions with the US Food and Drug Administration, the dataset was locked, except for queries to the sites about overall survival, before our previous report in 2006, so that an independent review could be done. Analyses were done on an intention-to-treat basis. Following completion of treatment, patients underwent physical examination and radiographic imaging every 4 months for 2 years, and then every 6 months thereafter. The trial is registered at www.ClinicalTrials.gov, number NCT00004227. FINDINGS: Patients were randomly assigned to receive radiotherapy with (n=211) or without (n=213) cetuximab, and all patients were followed for survival. Updated median overall survival for patients treated with cetuximab and radiotherapy was 49.0 months (95% CI 32.8-69.5) versus 29.3 months (20.6-41.4) in the radiotherapy-alone group (hazard ratio [HR] 0.73, 95% CI 0.56-0.95; p=0.018). 5-year overall survival was 45.6% in the cetuximab-plus-radiotherapy group and 36.4% in the radiotherapy-alone group. Additionally, for the patients treated with cetuximab, overall survival was significantly improved in those who experienced an acneiform rash of at least grade 2 severity compared with patients with no rash or grade 1 rash (HR 0.49, 0.34-0.72; p=0.002). INTERPRETATION: For patients with LASCCHN, cetuximab plus radiotherapy significantly improves overall survival at 5 years compared with radiotherapy alone, confirming cetuximab plus radiotherapy as an important treatment option in this group of patients. Cetuximab-treated patients with prominent cetuximab-induced rash (grade 2 or above) have better survival than patients with no or grade 1 rash. FUNDING: ImClone Systems, Merck KGaA, and Bristol-Myers Squibb.},
	author = {Bonner, J. A. and Harari, P. M. and Giralt, J. and Cohen, R. B. and Jones, C. U. and Sur, R. K. and Raben, D. and Baselga, J. and Spencer, S. A. and Zhu, J. and Youssoufian, H. and Rowinsky, E. K. and Ang, K. K.},
	doi = {10.1016/s1470-2045(09)70311-0},
	issn = {1470-2045},
	journal = {Lancet Oncol},
	keywords = {Adult Aged Aged, 80 and over Antibodies, Monoclonal/adverse effects/*therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents/adverse effects/*therapeutic use Carcinoma, Squamous Cell/*drug therapy/mortality/pathology/*radiotherapy Cetuximab Chemotherapy, Adjuvant Dose Fractionation, Radiation Exanthema/*chemically induced Female Head and Neck Neoplasms/*drug therapy/mortality/pathology/*radiotherapy Humans Male Middle Aged Neoplasm Staging Proportional Hazards Models Risk Assessment Severity of Illness Index Survival Analysis Time Factors Treatment Outcome},
	note = {1474-5488 Bonner, James A Harari, Paul M Giralt, Jordi Cohen, Roger B Jones, Christopher U Sur, Ranjan K Raben, David Baselga, Jose Spencer, Sharon A Zhu, Junming Youssoufian, Hagop Rowinsky, Eric K Ang, K Kian Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't England 2009/11/10 Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10.},
	number = {1},
	pages = {21-8},
	title = {Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival},
	type = {Journal Article},
	url = {https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70311-0/fulltext},
	volume = {11},
	year = {2010},
	bdsk-url-1 = {https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70311-0/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s1470-2045(09)70311-0}}

@article{RN294,
	abstract = {On the subject of acute myeloid leukemia (AML), there is little consensus about the target cell within the hematopoietic stem cell hierarchy that is susceptible to leukemic transformation, or about the mechanism that underlies the phenotypic, genotypic and clinical heterogeneity. Here we demonstrate that the cell capable of initiating human AML in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice) - termed the SCID leukemia-initiating cell, or SL-IC - possesses the differentiative and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell. The SL-ICs from all subtypes of AML analyzed, regardless of the heterogeneity in maturation characteristics of the leukemic blasts, were exclusively CD34++ CD38-, similar to the cell-surface phenotype of normal SCID-repopulating cells, suggesting that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation. The SL-ICs were able to differentiate in vivo into leukemic blasts, indicating that the leukemic clone is organized as a hierarchy.},
	author = {Bonnet, D. and Dick, J. E.},
	doi = {10.1038/nm0797-730},
	issn = {1078-8956 (Print) 1078-8956},
	journal = {Nat Med},
	keywords = {ADP-ribosyl Cyclase ADP-ribosyl Cyclase 1 Acute Disease Aged Animals *Antigens, CD Antigens, CD34 Antigens, Differentiation Cell Differentiation Cell Division *Cell Transformation, Neoplastic Clone Cells Disease Models, Animal Female Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cells/*pathology Humans Immunophenotyping Leukemia, Monocytic, Acute/*pathology Leukemia, Myeloid, Acute/*pathology Leukemia, Myelomonocytic, Acute/*pathology Male Membrane Glycoproteins Mice Mice, Inbred NOD Mice, SCID Middle Aged N-Glycosyl Hydrolases Neoplasm Transplantation},
	note = {Bonnet, D Dick, J E Journal Article Research Support, Non-U.S. Gov't United States 1997/07/01 Nat Med. 1997 Jul;3(7):730-7. doi: 10.1038/nm0797-730.},
	number = {7},
	pages = {730-7},
	title = {Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell},
	type = {Journal Article},
	volume = {3},
	year = {1997},
	bdsk-url-1 = {https://doi.org/10.1038/nm0797-730}}

@article{RN75,
	abstract = {On the subject of acute myeloid leukemia (AML), there is little consensus about the target cell within the hematopoietic stem cell hierarchy that is susceptible to leukemic transformation, or about the mechanism that underlies the phenotypic, genotypic and clinical heterogeneity. Here we demonstrate that the cell capable of initiating human AML in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice) - termed the SCID leukemia-initiating cell, or SL-IC - possesses the differentiative and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell. The SL-ICs from all subtypes of AML analyzed, regardless of the heterogeneity in maturation characteristics of the leukemic blasts, were exclusively CD34++ CD38-, similar to the cell-surface phenotype of normal SCID-repopulating cells, suggesting that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation. The SL-ICs were able to differentiate in vivo into leukemic blasts, indicating that the leukemic clone is organized as a hierarchy.},
	author = {Bonnet, D. and Dick, J. E.},
	doi = {10.1038/nm0797-730},
	issn = {1078-8956 (Print) 1078-8956 (Linking)},
	journal = {Nat Med},
	keywords = {ADP-ribosyl Cyclase ADP-ribosyl Cyclase 1 Acute Disease Aged Animals *Antigens, CD Antigens, CD34 Antigens, Differentiation Cell Differentiation Cell Division *Cell Transformation, Neoplastic Clone Cells Disease Models, Animal Female Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cells/*pathology Humans Immunophenotyping Leukemia, Monocytic, Acute/*pathology Leukemia, Myeloid, Acute/*pathology Leukemia, Myelomonocytic, Acute/*pathology Male Membrane Glycoproteins Mice Mice, Inbred NOD Mice, SCID Middle Aged N-Glycosyl Hydrolases Neoplasm Transplantation},
	note = {Bonnet, D Dick, J E eng Research Support, Non-U.S. Gov't 1997/07/01 Nat Med. 1997 Jul;3(7):730-7. doi: 10.1038/nm0797-730.},
	number = {7},
	pages = {730-7},
	title = {Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9212098},
	volume = {3},
	year = {1997},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/9212098},
	bdsk-url-2 = {https://doi.org/10.1038/nm0797-730}}

@article{RN10,
	abstract = {On the subject of acute myeloid leukemia (AML), there is little consensus about the target cell within the hematopoietic stem cell hierarchy that is susceptible to leukemic transformation, or about the mechanism that underlies the phenotypic, genotypic and clinical heterogeneity. Here we demonstrate that the cell capable of initiating human AML in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice) - termed the SCID leukemia-initiating cell, or SL-IC - possesses the differentiative and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell. The SL-ICs from all subtypes of AML analyzed, regardless of the heterogeneity in maturation characteristics of the leukemic blasts, were exclusively CD34++ CD38-, similar to the cell-surface phenotype of normal SCID-repopulating cells, suggesting that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation. The SL-ICs were able to differentiate in vivo into leukemic blasts, indicating that the leukemic clone is organized as a hierarchy.},
	author = {Bonnet, D. and Dick, J. E.},
	doi = {10.1038/nm0797-730},
	issn = {1078-8956 (Print) 1078-8956 (Linking)},
	journal = {Nat Med},
	keywords = {ADP-ribosyl Cyclase ADP-ribosyl Cyclase 1 Acute Disease Aged Animals *Antigens, CD Antigens, CD34 Antigens, Differentiation Cell Differentiation Cell Division *Cell Transformation, Neoplastic Clone Cells Disease Models, Animal Female Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cells/*pathology Humans Immunophenotyping Leukemia, Monocytic, Acute/*pathology Leukemia, Myeloid, Acute/*pathology Leukemia, Myelomonocytic, Acute/*pathology Male Membrane Glycoproteins Mice Mice, Inbred NOD Mice, SCID Middle Aged N-Glycosyl Hydrolases Neoplasm Transplantation},
	note = {Bonnet, D Dick, J E eng Research Support, Non-U.S. Gov't Nat Med. 1997 Jul;3(7):730-7. doi: 10.1038/nm0797-730.},
	number = {7},
	pages = {730-7},
	title = {Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9212098},
	volume = {3},
	year = {1997},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/9212098},
	bdsk-url-2 = {https://doi.org/10.1038/nm0797-730}}

@article{RN9,
	abstract = {On the subject of acute myeloid leukemia (AML), there is little consensus about the target cell within the hematopoietic stem cell hierarchy that is susceptible to leukemic transformation, or about the mechanism that underlies the phenotypic, genotypic and clinical heterogeneity. Here we demonstrate that the cell capable of initiating human AML in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice) - termed the SCID leukemia-initiating cell, or SL-IC - possesses the differentiative and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell. The SL-ICs from all subtypes of AML analyzed, regardless of the heterogeneity in maturation characteristics of the leukemic blasts, were exclusively CD34++ CD38-, similar to the cell-surface phenotype of normal SCID-repopulating cells, suggesting that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation. The SL-ICs were able to differentiate in vivo into leukemic blasts, indicating that the leukemic clone is organized as a hierarchy.},
	author = {Bonnet, D. and Dick, J. E.},
	doi = {10.1038/nm0797-730},
	issn = {1078-8956 (Print) 1078-8956 (Linking)},
	journal = {Nat Med},
	keywords = {ADP-ribosyl Cyclase ADP-ribosyl Cyclase 1 Acute Disease Aged Animals *Antigens, CD Antigens, CD34 Antigens, Differentiation Cell Differentiation Cell Division *Cell Transformation, Neoplastic Clone Cells Disease Models, Animal Female Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cells/*pathology Humans Immunophenotyping Leukemia, Monocytic, Acute/*pathology Leukemia, Myeloid, Acute/*pathology Leukemia, Myelomonocytic, Acute/*pathology Male Membrane Glycoproteins Mice Mice, Inbred NOD Mice, SCID Middle Aged N-Glycosyl Hydrolases Neoplasm Transplantation},
	note = {Bonnet, D Dick, J E eng Research Support, Non-U.S. Gov't Nat Med. 1997 Jul;3(7):730-7. doi: 10.1038/nm0797-730.},
	number = {7},
	pages = {730-7},
	title = {Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell},
	type = {Journal Article},
	url = {https://www.nature.com/articles/nm0797-730.pdf},
	volume = {3},
	year = {1997},
	bdsk-url-1 = {https://www.nature.com/articles/nm0797-730.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/nm0797-730}}

@article{RN422,
	author = {Bonnet, D. and Dick, J. E.},
	doi = {10.1038/nm0797-730},
	issn = {1078-8956 (Print) 1078-8956 (Linking)},
	journal = {Nat Med},
	keywords = {ADP-ribosyl Cyclase ADP-ribosyl Cyclase 1 Acute Disease Aged Animals *Antigens, CD Antigens, CD34 Antigens, Differentiation Cell Differentiation Cell Division *Cell Transformation, Neoplastic Clone Cells Disease Models, Animal Female Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cells/*pathology Humans Immunophenotyping Leukemia, Monocytic, Acute/*pathology Leukemia, Myeloid, Acute/*pathology Leukemia, Myelomonocytic, Acute/*pathology Male Membrane Glycoproteins Mice Mice, Inbred NOD Mice, SCID Middle Aged N-Glycosyl Hydrolases Neoplasm Transplantation},
	number = {7},
	pages = {730-7},
	title = {Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9212098},
	volume = {3},
	year = {1997},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/9212098},
	bdsk-url-2 = {https://doi.org/10.1038/nm0797-730}}

@article{RN446,
	author = {Bootz, F.},
	doi = {10.1007/s00117-020-00760-9},
	issn = {1432-2102 (Electronic) 0033-832X (Linking)},
	journal = {Radiologe},
	keywords = {Follow-Up Studies Germany Humans *Laryngeal Neoplasms/diagnostic imaging/therapy Practice Guidelines as Topic Head and neck neoplasms Health care quality assurance Informed consent Laryngeal neoplasms Practice guideline},
	number = {11},
	pages = {1052-1057},
	title = {[Guideline on diagnosis, treatment, and follow-up of laryngeal cancer]},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/33025133},
	volume = {60},
	year = {2020},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/33025133},
	bdsk-url-2 = {https://doi.org/10.1007/s00117-020-00760-9}}

@article{RN50,
	abstract = {The German S3 guideline on diagnosis, treatment, and follow-up of laryngeal cancer was developed in 2019 as part of the oncology guideline program of the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF) of the German Cancer Society (Deutsche Krebsgesellschaft, DKG) and German Cancer Aid (Deutsche Krebshilfe, DKH), published under the leadership of the German Society for Otorhinolaryngology, Head and Neck Surgery. The guideline was funded by DKH as part of the oncology guideline program. Since guidelines are an important tool for quality assurance and quality management in oncology, they should be incorporated into everyday care in a targeted and sustainable manner. The guideline should generally fulfil the interdisciplinary character of early diagnosis, diagnostics, treatment, rehabilitation, and follow-up, with the aim of developing evidence- and consensus-based recommendations and statements for treatment of laryngeal cancer with the aim of organ preservation, but also show their limits. The main recommendations of the original text are summarized. The guideline is available as a long and a short version in the guideline program of the DKG ( https://www.leitlinienprogramm-onkologie.de/leitlinien/larynxkarzinom/ ) and also as an app ( https://www.leitlinienprogramm-onkologie.de/app/ ).},
	author = {Bootz, F.},
	doi = {10.1007/s00117-020-00760-9},
	issn = {1432-2102 (Electronic) 0033-832X (Linking)},
	journal = {Radiologe},
	keywords = {Follow-Up Studies Germany Humans *Laryngeal Neoplasms/diagnostic imaging/therapy Practice Guidelines as Topic Head and neck neoplasms Health care quality assurance Informed consent Laryngeal neoplasms Practice guideline},
	note = {Bootz, F ger Review Germany Radiologe. 2020 Nov;60(11):1052-1057. doi: 10.1007/s00117-020-00760-9.},
	number = {11},
	pages = {1052-1057},
	title = {[Guideline on diagnosis, treatment, and follow-up of laryngeal cancer]},
	type = {Journal Article},
	url = {https://link.springer.com/content/pdf/10.1007/s00117-020-00760-9.pdf},
	volume = {60},
	year = {2020},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007/s00117-020-00760-9.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/s00117-020-00760-9}}

@article{RN218,
	abstract = {Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is an entity with peculiar clinical and molecular characteristics, which mainly arises from the reticulated epithelium lining the crypts of the palatine tonsils and the base of the tongue. The only head and neck site with a definite etiological association between persistent high-risk (HR) HPV infection and development of SCC is the oropharynx. HPV-positive malignancies represent 5-20% of all HNSCCs and 40-90% of those arising from the oropharynx, with widely variable rates depending on the geographic area, population, relative prevalence of environment-related SCC and detection assay. HPV-16 is by far the most common HR HPV genotype detected in oropharyngeal SCC (OPSCC), and the only definitely carcinogenic genotype for the head and neck region. Patients with HPV-induced OPSCC are more likely to be middle-aged white men, non-smokers, non-drinkers or mild to moderate drinkers, with higher socioeconomic status and better performance status than subjects with HPV-unrelated SCC. HPV-induced HNSCCs are often described as non-keratinizing, poorly differentiated or basaloid carcinomas, and are diagnosed in earlier T-category with a trend for a more advanced N-category, with cystic degeneration, than the HPV-unrelated carcinomas. HPV positivity is associated with better response to treatment and modality-independent survival benefit. Treatment selection in HPV-related oropharyngeal carcinoma is becoming a critical issue, and although there is no evidence from randomized, controlled trials to support a treatment de-escalation in HPV-positive SCC, some investigators argue that intensive combined modality strategies may represent an overtreatment.},
	author = {Boscolo-Rizzo, P. and Del Mistro, A. and Bussu, F. and Lupato, V. and Baboci, L. and Almadori, G. and MC, D. A. Mosto and Paludetti, G.},
	issn = {0392-100X (Print) 0392-100x},
	journal = {Acta Otorhinolaryngol Ital},
	keywords = {Carcinoma, Squamous Cell/diagnosis/epidemiology/therapy/*virology DNA Probes, HPV Head and Neck Neoplasms/diagnosis/epidemiology/therapy/*virology Humans Papillomavirus Infections/*complications/diagnosis/epidemiology/therapy Prognosis Squamous Cell Carcinoma of Head and Neck Head and neck cancer Human papillomavirus Oropharynx Squamous cell carcinoma Treatment de-escalation},
	note = {1827-675x Boscolo-Rizzo, P Del Mistro, A Bussu, F Lupato, V Baboci, L Almadori, G DA Mosto, M C Paludetti, G Journal Article Review 2013/07/16 Acta Otorhinolaryngol Ital. 2013 Apr;33(2):77-87.},
	number = {2},
	pages = {77-87},
	title = {New insights into human papillomavirus-associated head and neck squamous cell carcinoma},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665382/pdf/0392-100X-33-77.pdf},
	volume = {33},
	year = {2013},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665382/pdf/0392-100X-33-77.pdf}}

@article{RN284,
	abstract = {Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is an entity with peculiar clinical and molecular characteristics, which mainly arises from the reticulated epithelium lining the crypts of the palatine tonsils and the base of the tongue. The only head and neck site with a definite etiological association between persistent high-risk (HR) HPV infection and development of SCC is the oropharynx. HPV-positive malignancies represent 5-20% of all HNSCCs and 40-90% of those arising from the oropharynx, with widely variable rates depending on the geographic area, population, relative prevalence of environment-related SCC and detection assay. HPV-16 is by far the most common HR HPV genotype detected in oropharyngeal SCC (OPSCC), and the only definitely carcinogenic genotype for the head and neck region. Patients with HPV-induced OPSCC are more likely to be middle-aged white men, non-smokers, non-drinkers or mild to moderate drinkers, with higher socioeconomic status and better performance status than subjects with HPV-unrelated SCC. HPV-induced HNSCCs are often described as non-keratinizing, poorly differentiated or basaloid carcinomas, and are diagnosed in earlier T-category with a trend for a more advanced N-category, with cystic degeneration, than the HPV-unrelated carcinomas. HPV positivity is associated with better response to treatment and modality-independent survival benefit. Treatment selection in HPV-related oropharyngeal carcinoma is becoming a critical issue, and although there is no evidence from randomized, controlled trials to support a treatment de-escalation in HPV-positive SCC, some investigators argue that intensive combined modality strategies may represent an overtreatment.},
	author = {Boscolo-Rizzo, P. and Del Mistro, A. and Bussu, F. and Lupato, V. and Baboci, L. and Almadori, G. and MC, D. A. Mosto and Paludetti, G.},
	issn = {0392-100X (Print) 0392-100x},
	journal = {Acta Otorhinolaryngol Ital},
	keywords = {Carcinoma, Squamous Cell/diagnosis/epidemiology/therapy/*virology DNA Probes, HPV Head and Neck Neoplasms/diagnosis/epidemiology/therapy/*virology Humans Papillomavirus Infections/*complications/diagnosis/epidemiology/therapy Prognosis Squamous Cell Carcinoma of Head and Neck Head and neck cancer Human papillomavirus Oropharynx Squamous cell carcinoma Treatment de-escalation},
	note = {1827-675x Boscolo-Rizzo, P Del Mistro, A Bussu, F Lupato, V Baboci, L Almadori, G DA Mosto, M C Paludetti, G Journal Article Review 2013/07/16 Acta Otorhinolaryngol Ital. 2013 Apr;33(2):77-87.},
	number = {2},
	pages = {77-87},
	title = {New insights into human papillomavirus-associated head and neck squamous cell carcinoma},
	type = {Journal Article},
	volume = {33},
	year = {2013}}

@article{RN150,
	abstract = {The hypothesis that the Mediterranean diet has a beneficial role on the risk of cancers of the upper aerodigestive tract has been evaluated using data from three case-control studies conducted in Italy between 1992 and 2000. The first study included 598 cases with incident, histologically confirmed cancers of the oral cavity and pharynx and 1491 hospital controls admitted to the same network of hospitals as cases for acute, nonneoplastic diseases. The second one included 304 subjects with squamous cell carcinoma of the esophagus and 743 controls. The third one included 460 laryngeal cancer cases and 1088 controls. A score summarizing eight of the major characteristics of the Mediterranean diet was used. Odds ratios and corresponding 95% confidence intervals (CIs) for increasing levels of this score were estimated using unconditional regression models, adjusted for age, sex, study center, years of education, tobacco consumption, body mass index, and total energy intake. For all cancers considered, a reduced risk was found for increasing levels of the Mediterranean score: the odds ratios for subjects with six or more Mediterranean characteristics, compared with those with less than three characteristics, were 0.40 (95% CI, 0.26-0.62) for oral and pharyngeal, 0.26 (95% CI, 0.13-0.51) for esophageal, and 0.23 (95% CI, 0.13-0.40) for laryngeal cancer. All of the estimates were consistent in strata of the major identified risk factors for these neoplasms. This study provides evidence that an a priori defined nutritional pattern, which includes several aspects of the Mediterranean diet, favorably affects the risk of cancers of the upper aerodigestive tract.},
	author = {Bosetti, C. and Gallus, S. and Trichopoulou, A. and Talamini, R. and Franceschi, S. and Negri, E. and La Vecchia, C.},
	issn = {1055-9965 (Print) 1055-9965},
	journal = {Cancer Epidemiol Biomarkers Prev},
	keywords = {Aged Carcinoma, Squamous Cell/etiology/*prevention & control Case-Control Studies *Diet Dietary Fiber Esophageal Neoplasms/etiology/*prevention & control Female Humans Italy/epidemiology Male Mediterranean Region Middle Aged Mouth Neoplasms/etiology/*prevention & control Nutritional Status Odds Ratio Olive Oil Pharyngeal Neoplasms/etiology/*prevention & control Plant Oils Risk Factors},
	note = {Bosetti, Cristina Gallus, Silvano Trichopoulou, Antonia Talamini, Renato Franceschi, Silvia Negri, Eva La Vecchia, Carlo Journal Article Research Support, Non-U.S. Gov't United States 2003/10/28 Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1091-4.},
	number = {10},
	pages = {1091-4},
	title = {Influence of the Mediterranean diet on the risk of cancers of the upper aerodigestive tract},
	type = {Journal Article},
	url = {https://cebp.aacrjournals.org/content/cebp/12/10/1091.full.pdf},
	volume = {12},
	year = {2003},
	bdsk-url-1 = {https://cebp.aacrjournals.org/content/cebp/12/10/1091.full.pdf}}

@article{RN230,
	abstract = {BACKGROUND: Several trials have studied the role of unconventional fractionated radiotherapy in head and neck squamous cell carcinoma, but the effect of such treatment on survival is not clear. The aim of this meta-analysis was to assess whether this type of radiotherapy could improve survival. METHODS: Randomised trials comparing conventional radiotherapy with hyperfractionated or accelerated radiotherapy, or both, in patients with non-metastatic HNSCC were identified and updated individual patient data were obtained. Overall survival was the main endpoint. Trials were grouped in three pre-specified categories: hyperfractionated, accelerated, and accelerated with total dose reduction. FINDINGS: 15 trials with 6515 patients were included. The median follow-up was 6 years. Tumours sites were mostly oropharynx and larynx; 5221 (74%) patients had stage III-IV disease (International Union Against Cancer, 1987). There was a significant survival benefit with altered fractionated radiotherapy, corresponding to an absolute benefit of 3.4% at 5 years (hazard ratio 0.92, 95% CI 0.86-0.97; p=0.003). The benefit was significantly higher with hyperfractionated radiotherapy (8% at 5 years) than with accelerated radiotherapy (2% with accelerated fractionation without total dose reduction and 1.7% with total dose reduction at 5 years, p=0.02). There was a benefit on locoregional control in favour of altered fractionation versus conventional radiotherapy (6.4% at 5 years; p<0.0001), which was particularly efficient in reducing local failure, whereas the benefit on nodal control was less pronounced. The benefit was significantly higher in the youngest patients (hazard ratio 0.78 [0.65-0.94] for under 50 year olds, 0.95 [0.83-1.09] for 51-60 year olds, 0.92 [0.81-1.06] for 61-70 year olds, and 1.08 [0.89-1.30] for over 70 year olds; test for trends p=0.007). INTERPRETATION: Altered fractionated radiotherapy improves survival in patients with head and neck squamous cell carcinoma. Comparison of the different types of altered radiotherapy suggests that hyperfractionation has the greatest benefit.},
	author = {Bourhis, J. and Overgaard, J. and Audry, H. and Ang, K. K. and Saunders, M. and Bernier, J. and Horiot, J. C. and Le Ma{\^\i}tre, A. and Pajak, T. F. and Poulsen, M. G. and O'Sullivan, B. and Dobrowsky, W. and Hliniak, A. and Skladowski, K. and Hay, J. H. and Pinto, L. H. and Fallai, C. and Fu, K. K. and Sylvester, R. and Pignon, J. P.},
	doi = {10.1016/s0140-6736(06)69121-6},
	issn = {0140-6736},
	journal = {Lancet},
	keywords = {Aged Carcinoma, Squamous Cell/mortality/pathology/*radiotherapy *Dose Fractionation, Radiation Female Follow-Up Studies Head and Neck Neoplasms/mortality/pathology/*radiotherapy Humans Male Middle Aged Randomized Controlled Trials as Topic Survival Rate/trends},
	note = {1474-547x Bourhis, Jean Overgaard, Jens Audry, H{\'e}l{\`e}ne Ang, Kian K Saunders, Michele Bernier, Jacques Horiot, Jean-Claude Le Ma{\^\i}tre, Aur{\'e}lie Pajak, Thomas F Poulsen, Michael G O'Sullivan, Brian Dobrowsky, Werner Hliniak, Andrzej Skladowski, Krzysztof Hay, John H Pinto, Luiz H J Fallai, Carlo Fu, Karen K Sylvester, Richard Pignon, Jean-Pierre Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group 2U10CA11488-36/CA/NCI NIH HHS/United States Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review England 2006/09/05 Lancet. 2006 Sep 2;368(9538):843-54. doi: 10.1016/S0140-6736(06)69121-6.},
	number = {9538},
	pages = {843-54},
	title = {Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis},
	type = {Journal Article},
	url = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(06)69121-6/fulltext},
	volume = {368},
	year = {2006},
	bdsk-url-1 = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(06)69121-6/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s0140-6736(06)69121-6}}

@article{RN231,
	abstract = {BACKGROUND: Several trials have studied the role of unconventional fractionated radiotherapy in head and neck squamous cell carcinoma, but the effect of such treatment on survival is not clear. The aim of this meta-analysis was to assess whether this type of radiotherapy could improve survival. METHODS: Randomised trials comparing conventional radiotherapy with hyperfractionated or accelerated radiotherapy, or both, in patients with non-metastatic HNSCC were identified and updated individual patient data were obtained. Overall survival was the main endpoint. Trials were grouped in three pre-specified categories: hyperfractionated, accelerated, and accelerated with total dose reduction. FINDINGS: 15 trials with 6515 patients were included. The median follow-up was 6 years. Tumours sites were mostly oropharynx and larynx; 5221 (74%) patients had stage III-IV disease (International Union Against Cancer, 1987). There was a significant survival benefit with altered fractionated radiotherapy, corresponding to an absolute benefit of 3.4% at 5 years (hazard ratio 0.92, 95% CI 0.86-0.97; p=0.003). The benefit was significantly higher with hyperfractionated radiotherapy (8% at 5 years) than with accelerated radiotherapy (2% with accelerated fractionation without total dose reduction and 1.7% with total dose reduction at 5 years, p=0.02). There was a benefit on locoregional control in favour of altered fractionation versus conventional radiotherapy (6.4% at 5 years; p<0.0001), which was particularly efficient in reducing local failure, whereas the benefit on nodal control was less pronounced. The benefit was significantly higher in the youngest patients (hazard ratio 0.78 [0.65-0.94] for under 50 year olds, 0.95 [0.83-1.09] for 51-60 year olds, 0.92 [0.81-1.06] for 61-70 year olds, and 1.08 [0.89-1.30] for over 70 year olds; test for trends p=0.007). INTERPRETATION: Altered fractionated radiotherapy improves survival in patients with head and neck squamous cell carcinoma. Comparison of the different types of altered radiotherapy suggests that hyperfractionation has the greatest benefit.},
	author = {Bourhis, J. and Overgaard, J. and Audry, H. and Ang, K. K. and Saunders, M. and Bernier, J. and Horiot, J. C. and Le Ma{\^\i}tre, A. and Pajak, T. F. and Poulsen, M. G. and O'Sullivan, B. and Dobrowsky, W. and Hliniak, A. and Skladowski, K. and Hay, J. H. and Pinto, L. H. and Fallai, C. and Fu, K. K. and Sylvester, R. and Pignon, J. P.},
	doi = {10.1016/s0140-6736(06)69121-6},
	issn = {0140-6736},
	journal = {Lancet},
	keywords = {Aged Carcinoma, Squamous Cell/mortality/pathology/*radiotherapy *Dose Fractionation, Radiation Female Follow-Up Studies Head and Neck Neoplasms/mortality/pathology/*radiotherapy Humans Male Middle Aged Randomized Controlled Trials as Topic Survival Rate/trends},
	note = {1474-547x Bourhis, Jean Overgaard, Jens Audry, H{\'e}l{\`e}ne Ang, Kian K Saunders, Michele Bernier, Jacques Horiot, Jean-Claude Le Ma{\^\i}tre, Aur{\'e}lie Pajak, Thomas F Poulsen, Michael G O'Sullivan, Brian Dobrowsky, Werner Hliniak, Andrzej Skladowski, Krzysztof Hay, John H Pinto, Luiz H J Fallai, Carlo Fu, Karen K Sylvester, Richard Pignon, Jean-Pierre Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group 2U10CA11488-36/CA/NCI NIH HHS/United States Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review England 2006/09/05 Lancet. 2006 Sep 2;368(9538):843-54. doi: 10.1016/S0140-6736(06)69121-6.},
	number = {9538},
	pages = {843-54},
	title = {Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis},
	type = {Journal Article},
	volume = {368},
	year = {2006},
	bdsk-url-1 = {https://doi.org/10.1016/s0140-6736(06)69121-6}}

@article{RN445,
	author = {Bouvard, V. and Baan, R. and Straif, K. and Grosse, Y. and Secretan, B. and El Ghissassi, F. and Benbrahim-Tallaa, L. and Guha, N. and Freeman, C. and Galichet, L. and Cogliano, V. and Group, W. H. O. International Agency for Research on Cancer Monograph Working},
	doi = {10.1016/s1470-2045(09)70096-8},
	issn = {1474-5488 (Electronic) 1470-2045 (Linking)},
	journal = {Lancet Oncol},
	keywords = {Biological Products/adverse effects Carcinogens/*toxicity Humans Neoplasms/*etiology Tumor Virus Infections/*complications},
	number = {4},
	pages = {321-2},
	title = {A review of human carcinogens--Part B: biological agents},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/19350698},
	volume = {10},
	year = {2009},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/19350698},
	bdsk-url-2 = {https://doi.org/10.1016/s1470-2045(09)70096-8}}

@article{RN49,
	author = {Bouvard, V. and Baan, R. and Straif, K. and Grosse, Y. and Secretan, B. and El Ghissassi, F. and Benbrahim-Tallaa, L. and Guha, N. and Freeman, C. and Galichet, L. and Cogliano, V. and Group, W. H. O. International Agency for Research on Cancer Monograph Working},
	doi = {10.1016/s1470-2045(09)70096-8},
	issn = {1474-5488 (Electronic) 1470-2045 (Linking)},
	journal = {Lancet Oncol},
	keywords = {Biological Products/adverse effects Carcinogens/*toxicity Humans Neoplasms/*etiology Tumor Virus Infections/*complications},
	note = {Bouvard, Veronique Baan, Robert Straif, Kurt Grosse, Yann Secretan, Beatrice El Ghissassi, Fatiha Benbrahim-Tallaa, Lamia Guha, Neela Freeman, Crystal Galichet, Laurent Cogliano, Vincent eng News England Lancet Oncol. 2009 Apr;10(4):321-2. doi: 10.1016/s1470-2045(09)70096-8.},
	number = {4},
	pages = {321-2},
	title = {A review of human carcinogens--Part B: biological agents},
	type = {Journal Article},
	url = {https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70096-8/fulltext},
	volume = {10},
	year = {2009},
	bdsk-url-1 = {https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70096-8/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s1470-2045(09)70096-8}}

@article{RN98,
	abstract = {BACKGROUND: Transcriptionally active high-risk human papilloma viruses (HPVs), particularly HPV type 16 (HPV16), are found in a subset of head and neck squamous-cell carcinomas (HNSCCs). HPV16-associated carcinogenesis is mediated by expression of the viral E6 and E7 oncoproteins, which cause deregulation of the cell cycle by inactivating p53 and pRb, respectively. We tested the hypothesis that HPV-associated HNSCCs display a pattern of genetic alterations different from those of HNSCCs without HPV DNA. METHODS: Polymerase chain reaction-based assays were used to examine 143 consecutive HNSCCs (106 of the oral cavity and 37 of the oropharynx) for the presence of HPV DNA and for viral E6 and/or E7 messenger RNA (mRNA) expression. The HPV DNA-and E6 and E7 mRNA-positive HNSCCs and an equal number of HPV DNA-negative HNSCCs were further analyzed for mutations in TP53, the gene encoding p53, and for allelic loss of 28 microsatellite markers at chromosome arms 3p, 6q, 8p, 9p, 13q, 17p, and 18q, including markers located in regions of chromosome arms 9p and 17p that harbor genes involved the p53 and pRb pathways. All statistical tests were two-sided. RESULTS: Twenty-four (16.7%) of the 143 HNSCCs were positive for HPV16 DNA, and 12 of these HNSCCs (8.4% of total number) expressed E6 and E7 mRNAs. None of the HPV DNA-and E6/E7 mRNA-positive tumors had TP53 gene mutations, whereas nine (75%) of the 12 HPV DNA-negative tumors had such mutations (P<.001). Compared with the HPV DNA-negative HNSCCs, the E6/E7 mRNA-positive HNSCCs had statistically significantly lower levels of allelic loss for 13 of the 15 markers on 3p, 9p, and 17p. CONCLUSIONS: HNSCCs with transcriptionally active HPV16 DNA are characterized by occasional chromosomal loss, whereas HNSCCs lacking HPV DNA are characterized by gross deletions that involve whole or large parts of chromosomal arms and that already occur early in HNSCC development. These distinct patterns of genetic alterations suggest that HPV16 infection is an early event in HNSCC development.},
	author = {Braakhuis, B. J. and Snijders, P. J. and Keune, W. J. and Meijer, C. J. and Ruijter-Schippers, H. J. and Leemans, C. R. and Brakenhoff, R. H.},
	doi = {10.1093/jnci/djh183},
	issn = {0027-8874},
	journal = {J Natl Cancer Inst},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/*genetics/virology Case-Control Studies DNA, Viral/genetics Female Gene Expression Regulation, Neoplastic *Genes, p53 Head and Neck Neoplasms/*genetics/virology Humans Loss of Heterozygosity Male Microsatellite Repeats Middle Aged *Mutation Oncogene Proteins, Viral/genetics Papillomaviridae/*genetics/isolation & purification Papillomavirus E7 Proteins Papillomavirus Infections/*complications/virology RNA, Messenger/isolation & purification *Repressor Proteins *Transcription, Genetic},
	note = {1460-2105 Braakhuis, Boudewijn J M Snijders, Peter J F Keune, Willem-Jan H Meijer, Chris J L M Ruijter-Schippers, Henrique J Leemans, C Ren{\'e} Brakenhoff, Ruud H Journal Article United States 2004/07/09 J Natl Cancer Inst. 2004 Jul 7;96(13):998-1006. doi: 10.1093/jnci/djh183.},
	number = {13},
	pages = {998-1006},
	title = {Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus},
	type = {Journal Article},
	url = {https://watermark.silverchair.com/djh183.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsMwggK_BgkqhkiG9w0BBwagggKwMIICrAIBADCCAqUGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMK7BXgjVNTH7acVa1AgEQgIICdp3XCmeZ7GhC3AyWy6i0b1T3bluhJYFZRDftcLmyUZxmmq3hZegMhBdzQO8XXeasYBAsAkITNQGl8b2vjlrEfqFN-xYdsTuRNPU83H987xCfY11gtoEBu7E7Iepc5Nk1KXZqe3Tn1km1Y-sMcLdUnF5ObFKmp9LUyE6ymcNmjnyJXYWhJjfuEUv7NDItqVJ6mCmUeOHhUZnHYE-dLC9wDe3B1b0oIhow4SrbLwZb_3sRFa-2kL3xQfKtjs5oS5NYHdNaMlRqQCrUyhFueY1xrllDpNuGQTXyqijMsMzROK9bBZHv2PwZ37Stezv8UzDx-WDUkSvIC-BjNALr8aR6f7O-BU5LUW8_iNsY2UZfCJv2y9G2UNY-upOS3QtTIsAF_gwY67xrH7bFnL7eM6gj8QRWi4wG8glP4-YCyV_ntmJtk510qFirkaa_WQl_XCjZVE4gskHvcZJpiaI1Y3mWcBNSuMvxu8iV-7uma3qs3BgGBUIZRQg005Fjl4xBLgzi4-je0ZOJskHorvJof69Oqy3v9tVQA9EbTknF37dcj1gOlWHoLwcY2i3M-3p-vW6Xz-7yxN7mkdK6oEKM44vPvQdoPgxc3q06TZy9SoO1XphI3sVT8-kXN39OB_ng06IJ7M_LVN84fg3IUgI8ncr_woXsdNbQbbpCVfgFCnSKXB4EWd13Qwi_PJQ3Tr80m4Y9Pz4Vi-8FZF5wCnhiECPC66_wE3ByfeP3uitwxSg_m2FviixoDvy5cj46nmbHBTpSvGiG20l9naY7wuD2E7mCepv5inrjaFZqED2UzgLY4yzEQm_H_lV5rSrekEAS8S2tuT-7yVbUiQ},
	volume = {96},
	year = {2004},
	bdsk-url-1 = {https://watermark.silverchair.com/djh183.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsMwggK_BgkqhkiG9w0BBwagggKwMIICrAIBADCCAqUGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMK7BXgjVNTH7acVa1AgEQgIICdp3XCmeZ7GhC3AyWy6i0b1T3bluhJYFZRDftcLmyUZxmmq3hZegMhBdzQO8XXeasYBAsAkITNQGl8b2vjlrEfqFN-xYdsTuRNPU83H987xCfY11gtoEBu7E7Iepc5Nk1KXZqe3Tn1km1Y-sMcLdUnF5ObFKmp9LUyE6ymcNmjnyJXYWhJjfuEUv7NDItqVJ6mCmUeOHhUZnHYE-dLC9wDe3B1b0oIhow4SrbLwZb_3sRFa-2kL3xQfKtjs5oS5NYHdNaMlRqQCrUyhFueY1xrllDpNuGQTXyqijMsMzROK9bBZHv2PwZ37Stezv8UzDx-WDUkSvIC-BjNALr8aR6f7O-BU5LUW8_iNsY2UZfCJv2y9G2UNY-upOS3QtTIsAF_gwY67xrH7bFnL7eM6gj8QRWi4wG8glP4-YCyV_ntmJtk510qFirkaa_WQl_XCjZVE4gskHvcZJpiaI1Y3mWcBNSuMvxu8iV-7uma3qs3BgGBUIZRQg005Fjl4xBLgzi4-je0ZOJskHorvJof69Oqy3v9tVQA9EbTknF37dcj1gOlWHoLwcY2i3M-3p-vW6Xz-7yxN7mkdK6oEKM44vPvQdoPgxc3q06TZy9SoO1XphI3sVT8-kXN39OB_ng06IJ7M_LVN84fg3IUgI8ncr_woXsdNbQbbpCVfgFCnSKXB4EWd13Qwi_PJQ3Tr80m4Y9Pz4Vi-8FZF5wCnhiECPC66_wE3ByfeP3uitwxSg_m2FviixoDvy5cj46nmbHBTpSvGiG20l9naY7wuD2E7mCepv5inrjaFZqED2UzgLY4yzEQm_H_lV5rSrekEAS8S2tuT-7yVbUiQ},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/djh183}}

@article{RN297,
	author = {Bruce, W. R. and Van Der Gaag, H.},
	doi = {10.1038/199079a0},
	issn = {0028-0836 (Print) 0028-0836},
	journal = {Nature},
	keywords = {Animals *Biological Assay *Leukemia *Leukemia, Experimental *Lymphoma Mice *Radiation Effects *Research *Splenic Neoplasms *Thymus Neoplasms *experimental lab study *mice},
	note = {Bruce, w r Van der gaag, h Journal Article England 1963/07/06 Nature. 1963 Jul 6;199:79-80. doi: 10.1038/199079a0.},
	pages = {79-80},
	title = {A QUANTITATIVE ASSAY FOR THE NUMBER OF MURINE LYMPHOMA CELLS CAPABLE OF PROLIFERATION IN VIVO},
	type = {Journal Article},
	url = {https://www.nature.com/articles/199079a0.pdf},
	volume = {199},
	year = {1963},
	bdsk-url-1 = {https://www.nature.com/articles/199079a0.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/199079a0}}

@article{RN252,
	abstract = {BACKGROUND: Former meta-analyses have shown a survival benefit for the addition of chemotherapy (CHX) to radiotherapy (RT) and to some extent also for the use of hyperfractionated radiation therapy (HFRT) and accelerated radiation therapy (AFRT) in locally advanced squamous cell carcinoma (SCC) of the head and neck. However, the publication of new studies and the fact that many older studies that were included in these former meta-analyses used obsolete radiation doses, CHX schedules or study designs prompted us to carry out a new analysis using strict inclusion criteria. METHODS: Randomised trials testing curatively intended RT (> or =60 Gy in >4 weeks/>50 Gy in <4 weeks) on SCC of the oral cavity, oropharynx, hypopharynx, and larynx published as full paper or in abstract form between 1975 and 2003 were eligible. Trials comparing RT alone with concurrent or alternating chemoradiation (5-fluorouracil (5-FU), cisplatin, carboplatin, mitomycin C) were analyzed according to the employed radiation schedule and the used CHX regimen. Studies comparing conventionally fractionated radiotherapy (CFRT) with either HFRT or AFRT without CHX were separately examined. End point of the meta-analysis was overall survival. RESULTS: Thirty-two trials with a total of 10 225 patients were included into the meta-analysis. An overall survival benefit of 12.0 months was observed for the addition of simultaneous CHX to either CFRT or HFRT/AFRT (p < 0.001). Separate analyses by cytostatic drug indicate a prolongation of survival of 24.0 months, 16.8 months, 6.7 months, and 4.0 months, respectively, for the simultaneous administration of 5-FU, cisplatin-based, carboplatin-based, and mitomycin C-based CHX to RT (each p < 0.01). Whereas no significant gain in overall survival was observed for AFRT in comparison to CFRT, a substantial prolongation of median survival (14.2 months, p < 0.001) was seen for HFRT compared to CFRT (both without CHX). CONCLUSION: RT combined with simultaneous 5-FU, cisplatin, carboplatin, and mitomycin C as single drug or combinations of 5-FU with one of the other drugs results in a large survival advantage irrespective the employed radiation schedule. If radiation therapy is used as single modality, hyperfractionation leads to a significant improvement of overall survival. Accelerated radiation therapy alone, especially when given as split course radiation schedule or extremely accelerated treatments with decreased total dose, does not increase overall survival.},
	author = {Budach, W. and Hehr, T. and Budach, V. and Belka, C. and Dietz, K.},
	doi = {10.1186/1471-2407-6-28},
	issn = {1471-2407},
	journal = {BMC Cancer},
	keywords = {Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carboplatin/administration & dosage Carcinoma, Squamous Cell/*drug therapy/*radiotherapy Cisplatin/administration & dosage Combined Modality Therapy Dose Fractionation, Radiation Fluorouracil/administration & dosage Head and Neck Neoplasms/*drug therapy/*radiotherapy Humans Mitomycin/administration & dosage Randomized Controlled Trials as Topic Survival Analysis Treatment Outcome},
	note = {1471-2407 Budach, W Hehr, T Budach, V Belka, C Dietz, K Journal Article Meta-Analysis 2006/02/02 BMC Cancer. 2006 Jan 31;6:28. doi: 10.1186/1471-2407-6-28.},
	pages = {28},
	title = {A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1379652/pdf/1471-2407-6-28.pdf},
	volume = {6},
	year = {2006},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1379652/pdf/1471-2407-6-28.pdf},
	bdsk-url-2 = {https://doi.org/10.1186/1471-2407-6-28}}

@book{RN369,
	author = {B{\"o}cker, W.},
	isbn = {9783437423826},
	publisher = {Elsevier, Urban & Fischer},
	title = {Pathologie: mit {\"u}ber 200 Tabellen},
	type = {Book},
	url = {https://books.google.de/books?id=_aKIKlvq3KoC},
	year = {2008},
	bdsk-url-1 = {https://books.google.de/books?id=_aKIKlvq3KoC}}

@book{RN117,
	author = {B{\"o}cker, W.},
	isbn = {9783437423826},
	publisher = {Elsevier, Urban & Fischer},
	title = {Pathologie: mit {\"u}ber 200 Tabellen},
	type = {Book},
	url = {https://books.google.de/books?id=_aKIKlvq3KoC},
	year = {2008},
	bdsk-url-1 = {https://books.google.de/books?id=_aKIKlvq3KoC}}

@article{RN389,
	author = {Cabrera Rodriguez, J. and Cacicedo, J. and Giralt, J. and Garcia Miragall, E. and Lloret, M. and Arias, F. and Gonzalez Ruiz, M. A. and Contreras, J.},
	doi = {10.1016/j.critrevonc.2018.07.006},
	issn = {1879-0461 (Electronic) 1040-8428 (Linking)},
	journal = {Crit Rev Oncol Hematol},
	keywords = {Head and Neck Neoplasms/*radiotherapy Humans Neoplasms, Unknown Primary/*radiotherapy Practice Guidelines as Topic/*standards Radiotherapy Dosage Radiotherapy Planning, Computer-Assisted/*methods Radiotherapy, Intensity-Modulated/*methods Clinical target volume Guideline Head and neck cancer Intensity-modulated radiotherapy Unknown primary},
	pages = {51-59},
	title = {GEORCC recommendations on target volumes in radiotherapy for Head Neck Cancer of Unkown Primary},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30196912},
	volume = {130},
	year = {2018},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/30196912},
	bdsk-url-2 = {https://doi.org/10.1016/j.critrevonc.2018.07.006}}

@article{RN69,
	abstract = {Head Neck Cancer of Unknown Primary (HNCUP) is a rare condition, representing approximately 5-10% of all head neck cancers. Radiotherapy, adjuvant or radical, is usually employed in the treatment of those patients. To date, no specific guidelines for the optimal definition of the target volume to be irradiated have been published. In recent years, there have been advances in the knowledge of the molecular biology of HNCUP, its diagnostic imaging and the implementation of sophisticated radiotherapy techniques with enhanced precision in target localization and treatment delivery. These progresses have provided valuable information about the natural history of HNCUP that will allow for establishment of the best treatment for each patient, including standardized, consistent and reproducible target volumes definitions. Several recommendations regarding how to choose volumes when contouring HNCUP in clinical practice are reported, in order to achieve a high rate of loco-regional control while avoiding unnecessary toxicity.},
	author = {Cabrera Rodriguez, J. and Cacicedo, J. and Giralt, J. and Garcia Miragall, E. and Lloret, M. and Arias, F. and Gonzalez Ruiz, M. A. and Contreras, J.},
	doi = {10.1016/j.critrevonc.2018.07.006},
	issn = {1879-0461 (Electronic) 1040-8428 (Linking)},
	journal = {Crit Rev Oncol Hematol},
	keywords = {Head and Neck Neoplasms/*radiotherapy Humans Neoplasms, Unknown Primary/*radiotherapy Practice Guidelines as Topic/*standards Radiotherapy Dosage Radiotherapy Planning, Computer-Assisted/*methods Radiotherapy, Intensity-Modulated/*methods Clinical target volume Guideline Head and neck cancer Intensity-modulated radiotherapy Unknown primary},
	note = {Cabrera Rodriguez, Joaquin Cacicedo, Jon Giralt, Jordi Garcia Miragall, Enrique Lloret, Marta Arias, Fernando Gonzalez Ruiz, Maria Angeles Contreras, Jorge eng Review Netherlands 2018/09/11 Crit Rev Oncol Hematol. 2018 Oct;130:51-59. doi: 10.1016/j.critrevonc.2018.07.006. Epub 2018 Jul 24.},
	pages = {51-59},
	title = {GEORCC recommendations on target volumes in radiotherapy for Head Neck Cancer of Unkown Primary},
	type = {Journal Article},
	url = {https://www.sciencedirect.com/science/article/abs/pii/S1040842817305668?via%3Dihub},
	volume = {130},
	year = {2018},
	bdsk-url-1 = {https://www.sciencedirect.com/science/article/abs/pii/S1040842817305668?via%3Dihub},
	bdsk-url-2 = {https://doi.org/10.1016/j.critrevonc.2018.07.006}}

@article{RN238,
	abstract = {BACKGROUND: We designed a randomized clinical trial to test whether the addition of three cycles of chemotherapy during standard radiation therapy would improve disease-free survival in patients with stages III and IV (i.e., advanced oropharynx carcinoma). METHODS: A total of 226 patients have been entered in a phase III multicenter, randomized trial comparing radiotherapy alone (arm A) with radiotherapy with concomitant chemotherapy (arm B). Radiotherapy was identical in the two arms, delivering, with conventional fractionation, 70 Gy in 35 fractions. In arm B, patients received during the period of radiotherapy three cycles of a 4-day regimen containing carboplatin (70 mg/m(2) per day) and 5-fluorouracil (600 mg/m(2) per day) by continuous infusion. The two arms were equally balanced with regard to age, sex, stage, performance status, histology, and primary tumor site. RESULTS: Radiotherapy compliance was similar in the two arms with respect to total dose, treatment duration, and treatment interruption. The rate of grades 3 and 4 mucositis was statistically significantly higher in arm B (71%; 95% confidence interval [CI] = 54%-85%) than in arm A (39%; 95% CI = 29%-56%). Skin toxicity was not different between the two arms. Hematologic toxicity was higher in arm B as measured by neutrophil count and hemoglobin level. Three-year overall actuarial survival and disease-free survival rates were, respectively, 51% (95% CI = 39%-68%) versus 31% (95% CI = 18%-49%) and 42% (95% CI = 30%-57%) versus 20% (95% CI = 10%-33%) for patients treated with combined modality versus radiation therapy alone (P =.02 and.04, respectively). The locoregional control rate was improved in arm B (66%; 95% CI = 51%-78%) versus arm A (42%; 95% CI = 31%-56%). CONCLUSION: The statistically significant improvement in overall survival that was obtained supports the use of concomitant chemotherapy as an adjunct to radiotherapy in the management of carcinoma of the oropharynx.},
	author = {Calais, G. and Alfonsi, M. and Bardet, E. and Sire, C. and Germain, T. and Bergerot, P. and Rhein, B. and Tortochaux, J. and Oudinot, P. and Bertrand, P.},
	doi = {10.1093/jnci/91.24.2081},
	issn = {0027-8874 (Print) 0027-8874},
	journal = {J Natl Cancer Inst},
	keywords = {Adult Aged Antimetabolites, Antineoplastic/administration & dosage Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use Carboplatin/administration & dosage Chemotherapy, Adjuvant Drug Administration Schedule Female Fluorouracil/administration & dosage Humans Infusions, Intravenous Male Middle Aged Neoplasm Staging Oropharyngeal Neoplasms/*drug therapy/pathology/*radiotherapy Radiotherapy Dosage Radiotherapy, Adjuvant Survival Analysis Treatment Outcome},
	note = {Calais, G Alfonsi, M Bardet, E Sire, C Germain, T Bergerot, P Rhein, B Tortochaux, J Oudinot, P Bertrand, P Clinical Trial Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't United States 1999/12/22 J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6. doi: 10.1093/jnci/91.24.2081.},
	number = {24},
	pages = {2081-6},
	title = {Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma},
	type = {Journal Article},
	url = {https://watermark.silverchair.com/2081.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsYwggLCBgkqhkiG9w0BBwagggKzMIICrwIBADCCAqgGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM1JbX-jW4KOlMjCFWAgEQgIICeRB_gf3Qny0Se7x4l9BjiudfszM9m99Tvva4Y9C6Um1Za1mFZrBOyYYr4Dho-VaKludkagGhRMFNANI8T59A1Q9TDvzK6QebpjJ7oGQDZ_9yngorIgsA-FhMaryMFX5LaItYsFrZs_LcNu0BkmqzvxCRJSHHG_4PncCncKCf8fAfN6_r2PHKCvWVkYsf0GfL-iRaXxqGl_xq0sI6eFeh5fCRjME5ripQm6N9TjubTH7PkiCFMLj04kW1IX_o7pizw1gyHg3TFWwYxYgkciZ_IbtmVhhWkaAGFRn1nZgA8A18r_0dDdbipnFXngJa3r89KLBnvBphwWw1pwfuoz_npnTScmueXHxoZmxcKZiY2S5RHzVfJv9Ncwrq48I25yM7cUvEr6DU7eaaY17_7nOFLYPgoLQwAgb9gLZZSDMehMaxOt-M8OuGvkQn293TV2AZDMzLbHx1wYF5CtBpJcZTdF2ux3lgQJvjFBYML6_7B1JhIAkuWBCdlAv6Q-TSPuWoubb6Khg8u4BG6oDEYKtNToHA7fBmpfmbSacjm1Ca6_EA-OXIOL7WIM1gjHVHbKN7imabbK8jwPB-eSQ2is7tifnUKaFMuAO8oN4923mWzp6d-RHM5x_Jq29q1SHgJAyzrpPsUIzkYrbx8Hr51KpjRS8IabILYe_hFJkHLq6dBuBHTTn3uBCHFqY0xRbSFhHSid2PLgbrbeM1TbA5Dy4H6A85WIY4RRrHVhv58F39A0RSpcxENUJ0CIFqbTqqHIdDpNqj45KwA8HCO7gG27FMIR2vFJUzsa0wMyZkyp9q_wP0kQzUbHGNPnHxyTYsYX7LyQfLxvOZo6kyTw},
	volume = {91},
	year = {1999},
	bdsk-url-1 = {https://watermark.silverchair.com/2081.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsYwggLCBgkqhkiG9w0BBwagggKzMIICrwIBADCCAqgGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM1JbX-jW4KOlMjCFWAgEQgIICeRB_gf3Qny0Se7x4l9BjiudfszM9m99Tvva4Y9C6Um1Za1mFZrBOyYYr4Dho-VaKludkagGhRMFNANI8T59A1Q9TDvzK6QebpjJ7oGQDZ_9yngorIgsA-FhMaryMFX5LaItYsFrZs_LcNu0BkmqzvxCRJSHHG_4PncCncKCf8fAfN6_r2PHKCvWVkYsf0GfL-iRaXxqGl_xq0sI6eFeh5fCRjME5ripQm6N9TjubTH7PkiCFMLj04kW1IX_o7pizw1gyHg3TFWwYxYgkciZ_IbtmVhhWkaAGFRn1nZgA8A18r_0dDdbipnFXngJa3r89KLBnvBphwWw1pwfuoz_npnTScmueXHxoZmxcKZiY2S5RHzVfJv9Ncwrq48I25yM7cUvEr6DU7eaaY17_7nOFLYPgoLQwAgb9gLZZSDMehMaxOt-M8OuGvkQn293TV2AZDMzLbHx1wYF5CtBpJcZTdF2ux3lgQJvjFBYML6_7B1JhIAkuWBCdlAv6Q-TSPuWoubb6Khg8u4BG6oDEYKtNToHA7fBmpfmbSacjm1Ca6_EA-OXIOL7WIM1gjHVHbKN7imabbK8jwPB-eSQ2is7tifnUKaFMuAO8oN4923mWzp6d-RHM5x_Jq29q1SHgJAyzrpPsUIzkYrbx8Hr51KpjRS8IabILYe_hFJkHLq6dBuBHTTn3uBCHFqY0xRbSFhHSid2PLgbrbeM1TbA5Dy4H6A85WIY4RRrHVhv58F39A0RSpcxENUJ0CIFqbTqqHIdDpNqj45KwA8HCO7gG27FMIR2vFJUzsa0wMyZkyp9q_wP0kQzUbHGNPnHxyTYsYX7LyQfLxvOZo6kyTw},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/91.24.2081}}

@book{RN382,
	author = {Cardesa, A. and Remmele, W. and Kl{\"o}ppel, G. and Mentzel, T. and Kreipe, H.H. and Rudolph, P. and Slootweg, P.},
	isbn = {9783540728849},
	publisher = {Springer Berlin Heidelberg},
	title = {Pathologie: Kopf-Hals-Region, Weichgewebstumoren, Haut},
	type = {Book},
	url = {https://books.google.de/books?id=IBJSDIxrSUUC},
	year = {2008},
	bdsk-url-1 = {https://books.google.de/books?id=IBJSDIxrSUUC}}

@book{RN393,
	author = {Cardesa, A. and Remmele, W. and Kl{\"o}ppel, G. and Mentzel, T. and Kreipe, H.H. and Rudolph, P. and Slootweg, P.},
	isbn = {9783540728849},
	publisher = {Springer Berlin Heidelberg},
	title = {Pathologie: Kopf-Hals-Region, Weichgewebstumoren, Haut},
	type = {Book},
	url = {https://books.google.de/books?id=IBJSDIxrSUUC},
	year = {2008},
	bdsk-url-1 = {https://books.google.de/books?id=IBJSDIxrSUUC}}

@book{RN403,
	author = {Cardesa, A. and Remmele, W. and Kl{\"o}ppel, G. and Mentzel, T. and Kreipe, H.H. and Rudolph, P. and Slootweg, P.},
	isbn = {9783540728849},
	publisher = {Springer Berlin Heidelberg},
	title = {Pathologie: Kopf-Hals-Region, Weichgewebstumoren, Haut},
	type = {Book},
	url = {https://books.google.de/books?id=IBJSDIxrSUUC},
	year = {2008},
	bdsk-url-1 = {https://books.google.de/books?id=IBJSDIxrSUUC}}

@book{RN110,
	author = {Cardesa, A. and Remmele, W. and Kl{\"o}ppel, G. and Mentzel, T. and Kreipe, H.H. and Rudolph, P. and Slootweg, P.},
	isbn = {9783540728849},
	publisher = {Springer Berlin Heidelberg},
	title = {Pathologie: Kopf-Hals-Region, Weichgewebstumoren, Haut},
	type = {Book},
	url = {https://books.google.de/books?id=IBJSDIxrSUUC},
	year = {2008},
	bdsk-url-1 = {https://books.google.de/books?id=IBJSDIxrSUUC}}

@article{RN418,
	author = {Carvalho, A. L. and Nishimoto, I. N. and Califano, J. A. and Kowalski, L. P.},
	doi = {10.1002/ijc.20740},
	issn = {0020-7136 (Print) 0020-7136 (Linking)},
	journal = {Int J Cancer},
	keywords = {Adult Aged Cohort Studies Databases as Topic Female Head and Neck Neoplasms/diagnosis/*epidemiology Humans Incidence Linear Models Male Middle Aged Models, Statistical Neoplasms/metabolism Prognosis Registries *SEER Program Survival Rate Time Factors Treatment Outcome},
	number = {5},
	pages = {806-16},
	title = {Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15609302},
	volume = {114},
	year = {2005},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/15609302},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.20740}}

@article{RN71,
	abstract = {Despite recent advances in the diagnosis and treatment of head and neck cancer, there has been little evidence of improvement in 5-year survival rates over the last few decades. To determine more accurate trends in site-specific outcomes as opposed to a more general overview of head and neck cancer patients, we analyzed the site-specific data collected in the Surveillance, Epidemiology, and End Results-SEER Public-Use Database 1973-1999. Based on the selection criteria, 96,232 cases were evaluated for trend analysis in incidence, clinical stage, treatment and 5-year survival. During the period 1973-1999, site-specific incidence rates for head and neck cancer changed significantly. Site-specific analysis of survival from 1974-1997 showed significant improvements in 5-year survival rates for cancers of the nasopharynx, oropharynx and hypopharynx (38.1% to 56.7% for nasopharynx, p < 0.001; 36.3% to 49.1% for oropharynx, p = 0.001 and 28.3% to 33.3% for hypopharynx, p = 0.015). The prognosis for early-stage salivary gland cancer during 1983-1997 and late-stage larynx cancer during 1974-1997 also demonstrated improvement (82.7% to 88.5%, p = 0.012 and 22.2% to 38.3%, p = 0.013, respectively). On the other hand, the prognosis for regional stage oral cavity cancer as well as early-stage larynx cancer patients declined during 1983-1997 (49.2% to 43.8%, p = 0.032 and 82.3% to 74.3%, p = 0.002, respectively). Site-specific changes in treatment and staging were also noted. Site-specific analysis allows for a more accurate description of incidence, staging, treatment, and prognostic trends for head and neck cancer.},
	author = {Carvalho, A. L. and Nishimoto, I. N. and Califano, J. A. and Kowalski, L. P.},
	doi = {10.1002/ijc.20740},
	issn = {0020-7136 (Print) 0020-7136 (Linking)},
	journal = {Int J Cancer},
	keywords = {Adult Aged Cohort Studies Databases as Topic Female Head and Neck Neoplasms/diagnosis/*epidemiology Humans Incidence Linear Models Male Middle Aged Models, Statistical Neoplasms/metabolism Prognosis Registries *SEER Program Survival Rate Time Factors Treatment Outcome},
	note = {Carvalho, Andre Lopes Nishimoto, Ines Nobuko Califano, Joseph A Kowalski, Luiz Paulo eng 2004/12/21 Int J Cancer. 2005 May 1;114(5):806-16. doi: 10.1002/ijc.20740.},
	number = {5},
	pages = {806-16},
	title = {Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.20740?download=true},
	volume = {114},
	year = {2005},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.20740?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.20740}}

@article{RN158,
	abstract = {Oral squamous cell carcinomas comprise 2-3% of all new malignancies diagnosed in the United States, making it the 10th most common malignancy. However, for the last few decades, the average five-year survival rate of 50% has not changed significantly. This article reviews the risk factors associated with the development of oral cancer and how premalignant (leukoplakia and erythroplakia) and actual cancerous lesions may appear. Diagnostic tools and aids to diagnosis are discussed, as are treatment modalities. It is imperative that all dental professionals perform a simple head and neck examination in addition to an oral examination during each new patient visit and each six-month recall appointment. Early detection saves lives.},
	author = {Casiglia, J. and Woo, S. B.},
	issn = {0363-6771 (Print) 0363-6771},
	journal = {Gen Dent},
	keywords = {Age Factors Alcohol Drinking/adverse effects Areca/adverse effects Carcinoma, Squamous Cell/diagnosis/*etiology/therapy Erythroplasia/diagnosis Female Humans Leukoplakia, Oral/diagnosis Male Mass Screening Mouth Neoplasms/diagnosis/*etiology/pathology/therapy Neoadjuvant Therapy Neoplasm Staging Nutritional Physiological Phenomena Precancerous Conditions/diagnosis Prognosis Racial Groups Risk Factors Sex Factors Smoking/adverse effects Social Class Sunlight/adverse effects Survival Rate},
	note = {Casiglia, J Woo, S B Journal Article Research Support, Non-U.S. Gov't Review United States 2002/05/15 Gen Dent. 2001 Jan-Feb;49(1):72-82.},
	number = {1},
	pages = {72-82},
	title = {A comprehensive review of oral cancer},
	type = {Journal Article},
	volume = {49},
	year = {2001}}

@book{RN149,
	author = {Cawson, R.A. and Odell, E.W.},
	isbn = {9780702040016},
	publisher = {Elsevier Health Sciences},
	title = {Cawson's Essentials of Oral Pathology and Oral Medicine E-Book},
	type = {Book},
	url = {https://books.google.de/books?id=K035mlSXAAsC},
	year = {2008},
	bdsk-url-1 = {https://books.google.de/books?id=K035mlSXAAsC}}

@book{RN119,
	author = {Cawson, R.A. and Odell, E.W.},
	isbn = {9780702040016},
	publisher = {Elsevier Health Sciences},
	title = {Cawson's Essentials of Oral Pathology and Oral Medicine E-Book},
	type = {Book},
	url = {https://books.google.de/books?id=K035mlSXAAsC},
	year = {2008},
	bdsk-url-1 = {https://books.google.de/books?id=K035mlSXAAsC}}

@book{RN371,
	author = {Cawson, R.A. and Odell, E.W.},
	isbn = {9780702040016},
	publisher = {Elsevier Health Sciences},
	title = {Cawson's Essentials of Oral Pathology and Oral Medicine E-Book},
	type = {Book},
	url = {https://books.google.de/books?id=K035mlSXAAsC},
	year = {2008},
	bdsk-url-1 = {https://books.google.de/books?id=K035mlSXAAsC}}

@book{RN391,
	author = {Cawson, R.A. and Odell, E.W.},
	isbn = {9780702073915},
	publisher = {Elsevier Health Sciences UK},
	title = {Cawson's Essentials of Oral Pathology and Oral Medicine},
	type = {Book},
	url = {https://books.google.de/books?id=pAdLzQEACAAJ},
	year = {2017},
	bdsk-url-1 = {https://books.google.de/books?id=pAdLzQEACAAJ}}

@book{RN112,
	author = {Cawson, R.A. and Odell, E.W.},
	isbn = {9780702073915},
	publisher = {Elsevier Health Sciences UK},
	title = {Cawson's Essentials of Oral Pathology and Oral Medicine},
	type = {Book},
	url = {https://books.google.de/books?id=pAdLzQEACAAJ},
	year = {2017},
	bdsk-url-1 = {https://books.google.de/books?id=pAdLzQEACAAJ}}

@article{RN300,
	abstract = {OBJECTIVES: Questions regarding the cell source and mechanisms in the initiation and progression of prostate cancer are today still open for debate. Indeed, our knowledge regarding prostate cell regulation, self-renewal, and cytodifferentiation is presently rather limited. In this study, we investigated these processes in the normal adult human prostate. METHODS: Dynamic expression patterns in prostate stem/progenitor cells, intermediate/transit-amplifying cells, and cell lineages were immunohistochemically identified in an in situ explant renewal model of the human normal/benign adult prostate (n=6). RESULTS: Cells with a basal phenotype proliferated significantly in explant cultures, whereas luminal cells went into apoptosis. Results further show down-regulation in tissue cultures of the basal and hypothetical stem cell marker Bcl-2 in the majority of cells, except in rare putative epithelial stem cells. Investigation of established (AC133) and novel candidate prostate stem/progenitor markers, including the cell surface receptor tyrosine kinase KIT and its ligand stem cell factor (SCF), showed that these rare epithelial cells are AC133(+)/CD133(low)/Bcl-2(high)/cytokeratin(+)/vimentin(-)/KIT(low)/SCF(low). In addition, we report on a stromal population that expresses the mesenchymal marker vimentin and that is AC133(-)/CD133(high)/Bcl-2(-)/cytokeratin(-)/KIT(high)/SCF(high). CONCLUSIONS: We provide evidence for epithelial renewal in response to tissue culture and for basal and epithelial stem/progenitor cell recruitment leading to an expansion of an intermediate luminal precursor phenotype. Data further suggest that SCF regulates prostate epithelial stem/progenitor cells in an autocrine manner and that all or a subset of the identified novel stromal phenotype represents prostate stromal progenitor cells or interstitial pacemaker cells or both.},
	author = {Ceder, J. A. and Jansson, L. and Ehrnstr{\"o}m, R. A. and R{\"o}nnstrand, L. and Abrahamsson, P. A.},
	doi = {10.1016/j.eururo.2007.11.028},
	issn = {0302-2838 (Print) 0302-2838},
	journal = {Eur Urol},
	keywords = {AC133 Antigen Adult Antigens, CD/immunology/metabolism Cell Count Cell Differentiation Cells, Cultured Epithelial Cells/*cytology/immunology/metabolism Fluorescent Antibody Technique Glycoproteins/immunology/metabolism Humans Ki-67 Antigen/immunology Male Peptides/immunology/metabolism Phenotype Prostate/*cytology/metabolism Proto-Oncogene Proteins c-bcl-2/biosynthesis/immunology Reference Values Stem Cell Factor/biosynthesis Stem Cells/*cytology/immunology/metabolism Stromal Cells/*cytology/immunology/metabolism},
	note = {Ceder, Jens A Jansson, Linda Ehrnstr{\"o}m, Roy A R{\"o}nnstrand, Lars Abrahamsson, Per-Anders Comparative Study Journal Article Research Support, Non-U.S. Gov't Switzerland 2007/12/07 Eur Urol. 2008 Mar;53(3):524-31. doi: 10.1016/j.eururo.2007.11.028. Epub 2007 Nov 21.},
	number = {3},
	pages = {524-31},
	title = {The characterization of epithelial and stromal subsets of candidate stem/progenitor cells in the human adult prostate},
	type = {Journal Article},
	volume = {53},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1016/j.eururo.2007.11.028}}

@article{RN145,
	abstract = {Head and neck cancer (HNC) is one of the 10 most frequent cancers worldwide, with an estimated over 500,000 new cases being diagnosed annually. The overall 5-year survival rate in patients with HNC is one of the lowest among common malignant neoplasms and has not significantly changed during the last two decades. Oral cavity squamous cell carcinoma (OSCC) shares part of HNC and has been reported to be increasing in the betel quid chewing area in recent years. During 2006, OSCC has become the sixth most common type of cancer in Taiwan, and it is also the fourth most common type of cancer among men. It follows that this type of cancer wreaks a high social and personal cost. Environmental carcinogens such as betel quid chewing, tobacco smoking and alcohol drinking have been identified as major risk factors for head and neck cancer. There is growing interest in understanding the relationship between genetic susceptibility and the prevalent environmental carcinogens for HNC prevention. Within this review, we discuss the molecular and cellular aspects of HNC carcinogenesis in Taiwan, an endemic betel quid chewing area. Knowledge of molecular carcinogenesis of HNC may provide critical clues for diagnosis, prognosis, individualization of therapy and molecular therapeutics.},
	author = {Chen, Y. J. and Chang, J. T. and Liao, C. T. and Wang, H. M. and Yen, T. C. and Chiu, C. C. and Lu, Y. C. and Li, H. F. and Cheng, A. J.},
	doi = {10.1111/j.1349-7006.2008.00863.x},
	issn = {1347-9032},
	journal = {Cancer Sci},
	keywords = {Adult Alcohol Drinking/adverse effects Areca/*adverse effects Carcinoma, Squamous Cell/etiology/*genetics/metabolism Female Genetic Predisposition to Disease Head and Neck Neoplasms/*etiology/genetics/metabolism Humans Male Middle Aged Mouth Neoplasms/etiology/genetics/metabolism Mutation Papillomavirus Infections/*complications Polymorphism, Genetic Precancerous Conditions/etiology/*genetics/metabolism Risk Factors Smoking/adverse effects Survival Analysis Taiwan/epidemiology},
	note = {1349-7006 Chen, Yin-Ju Chang, Joseph Tung-Chieh Liao, Chun-Ta Wang, Hung-Ming Yen, Tzu-Chen Chiu, Ching-Chi Lu, Ya-Ching Li, Hsiao-Fang Cheng, Ann-Joy Journal Article Review England 2008/08/30 Cancer Sci. 2008 Aug;99(8):1507-14. doi: 10.1111/j.1349-7006.2008.00863.x.},
	number = {8},
	pages = {1507-14},
	title = {Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1349-7006.2008.00863.x?download=true},
	volume = {99},
	year = {2008},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1349-7006.2008.00863.x?download=true},
	bdsk-url-2 = {https://doi.org/10.1111/j.1349-7006.2008.00863.x}}

@article{RN426,
	author = {Chen, Y. W. and Chen, K. H. and Huang, P. I. and Chen, Y. C. and Chiou, G. Y. and Lo, W. L. and Tseng, L. M. and Hsu, H. S. and Chang, K. W. and Chiou, S. H.},
	doi = {10.1158/1535-7163.MCT-10-0504},
	issn = {1538-8514 (Electronic) 1535-7163 (Linking)},
	journal = {Mol Cancer Ther},
	keywords = {Aldehyde Dehydrogenase/*metabolism Aldehyde Dehydrogenase 1 Family Animals Apoptosis/*drug effects/radiation effects Carcinoma/pathology/radiotherapy Carcinoma, Squamous Cell Down-Regulation/drug effects Gamma Rays/therapeutic use Head and Neck Neoplasms/pathology/radiotherapy Humans Hyaluronan Receptors/*metabolism Isoenzymes/*metabolism Mice Mice, Inbred BALB C Mice, Nude Neoplasms, Squamous Cell/pathology/radiotherapy Neoplastic Stem Cells/*drug effects/metabolism/pathology/physiology Radiation Tolerance/*drug effects Radiation-Sensitizing Agents/pharmacology Retinal Dehydrogenase Squamous Cell Carcinoma of Head and Neck Triterpenes/*pharmacology Tumor Cells, Cultured Xenograft Model Antitumor Assays},
	number = {11},
	pages = {2879-92},
	title = {Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21062915},
	volume = {9},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/21062915},
	bdsk-url-2 = {https://doi.org/10.1158/1535-7163.MCT-10-0504}}

@article{RN77,
	abstract = {Head and neck squamous cell carcinoma (HNSCC) is a prevalent cancer worldwide. Signal transducers and activators of transcription 3 (STAT3) signaling is reported to promote tumor malignancy and recurrence in HNSCC. Cucurbitacins, triterpenoid derivatives, are strong STAT3 inhibitors with anticancer properties. Recent studies have shown aldehyde dehydrogenase 1 (ALDH1) to be a marker of cancer stem cells (CSC) in HNSCC. The aim of this study was to investigate the therapeutic effect of cucurbitacin I in HNSCC-derived CSCs. Using immunohistochemical analysis, we firstly showed that CD44, ALDH1, and phosphorylated STAT3 (p-STAT3) were higher in high-grade HNSCCs, and that triple positivity for CD44/ALDH1/p-STAT3 indicated a worse prognosis for HNSCC patients. Secondly, CD44(+)ALDH1(+) cells isolated from seven HNSCC patients showed greater tumorigenicity, radioresistance, and high expression of stemness (Bmi-1/Oct-4/Nanog) and epithelial-mesenchymal-transitional (Snail/Twist) genes as p-STAT3 level increased. Furthermore, we found that cucurbitacin I (JSI-124) can effectively inhibit the expression of p-STAT3 and capacities for tumorigenicity, sphere formation, and radioresistance in HNSCC-CD44(+)ALDH1(+). Notably, 150 nmol/L cucurbitacin I effectively blocked STAT3 signaling and downstream survivin and Bcl-2 expression, and it induced apoptosis in HNSCC-CD44(+)ALDH1(+). Moreover, microarray data indicated that 100 nmol/L cucurbitacin I facilitated CD44(+)ALDH1(+) cells to differentiate into CD44(-)ALDH1(-) and enhanced the radiosensitivity of HNSCC-CD44(+)ALDH1(+). Xenotransplant experiments revealed that cucurbitacin I combined with radiotherapy significantly suppressed tumorigenesis and lung metastasis and further improved the survival rate in HNSCC-CD44(+)ALDH1(+)-transplanted immunocompromised mice. Taken together, our data show that cucurbitacin I, STAT3 inhibitor, reduces radioresistant, distant-metastatic, and CSC-like properties of HNSCC-CD44(+)ALDH1(+) cells. The potential of cucurbitacin I as a radiosensitizer should be verified in future anti-CSC therapy.},
	author = {Chen, Y. W. and Chen, K. H. and Huang, P. I. and Chen, Y. C. and Chiou, G. Y. and Lo, W. L. and Tseng, L. M. and Hsu, H. S. and Chang, K. W. and Chiou, S. H.},
	doi = {10.1158/1535-7163.MCT-10-0504},
	issn = {1538-8514 (Electronic) 1535-7163 (Linking)},
	journal = {Mol Cancer Ther},
	keywords = {Aldehyde Dehydrogenase/*metabolism Aldehyde Dehydrogenase 1 Family Animals Apoptosis/*drug effects/radiation effects Carcinoma/pathology/radiotherapy Carcinoma, Squamous Cell Down-Regulation/drug effects Gamma Rays/therapeutic use Head and Neck Neoplasms/pathology/radiotherapy Humans Hyaluronan Receptors/*metabolism Isoenzymes/*metabolism Mice Mice, Inbred BALB C Mice, Nude Neoplasms, Squamous Cell/pathology/radiotherapy Neoplastic Stem Cells/*drug effects/metabolism/pathology/physiology Radiation Tolerance/*drug effects Radiation-Sensitizing Agents/pharmacology Retinal Dehydrogenase Squamous Cell Carcinoma of Head and Neck Triterpenes/*pharmacology Tumor Cells, Cultured Xenograft Model Antitumor Assays},
	note = {Chen, Yi-Wei Chen, Kuan-Hsuan Huang, Pin-I Chen, Yu-Chih Chiou, Guang-Yu Lo, Wen-Liang Tseng, Ling-Ming Hsu, Han-Sui Chang, Kuo-Wei Chiou, Shih-Hwa eng Research Support, Non-U.S. Gov't 2010/11/11 Mol Cancer Ther. 2010 Nov;9(11):2879-92. doi: 10.1158/1535-7163.MCT-10-0504. Epub 2010 Nov 9.},
	number = {11},
	pages = {2879-92},
	title = {Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells},
	type = {Journal Article},
	url = {https://mct.aacrjournals.org/content/molcanther/9/11/2879.full.pdf},
	volume = {9},
	year = {2010},
	bdsk-url-1 = {https://mct.aacrjournals.org/content/molcanther/9/11/2879.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1535-7163.MCT-10-0504}}

@article{RN313,
	abstract = {Head and neck squamous cell carcinoma (HNSCC) is a prevalent cancer worldwide. Signal transducers and activators of transcription 3 (STAT3) signaling is reported to promote tumor malignancy and recurrence in HNSCC. Cucurbitacins, triterpenoid derivatives, are strong STAT3 inhibitors with anticancer properties. Recent studies have shown aldehyde dehydrogenase 1 (ALDH1) to be a marker of cancer stem cells (CSC) in HNSCC. The aim of this study was to investigate the therapeutic effect of cucurbitacin I in HNSCC-derived CSCs. Using immunohistochemical analysis, we firstly showed that CD44, ALDH1, and phosphorylated STAT3 (p-STAT3) were higher in high-grade HNSCCs, and that triple positivity for CD44/ALDH1/p-STAT3 indicated a worse prognosis for HNSCC patients. Secondly, CD44(+)ALDH1(+) cells isolated from seven HNSCC patients showed greater tumorigenicity, radioresistance, and high expression of stemness (Bmi-1/Oct-4/Nanog) and epithelial-mesenchymal-transitional (Snail/Twist) genes as p-STAT3 level increased. Furthermore, we found that cucurbitacin I (JSI-124) can effectively inhibit the expression of p-STAT3 and capacities for tumorigenicity, sphere formation, and radioresistance in HNSCC-CD44(+)ALDH1(+). Notably, 150 nmol/L cucurbitacin I effectively blocked STAT3 signaling and downstream survivin and Bcl-2 expression, and it induced apoptosis in HNSCC-CD44(+)ALDH1(+). Moreover, microarray data indicated that 100 nmol/L cucurbitacin I facilitated CD44(+)ALDH1(+) cells to differentiate into CD44ALDH1 and enhanced the radiosensitivity of HNSCC-CD44(+)ALDH1(+). Xenotransplant experiments revealed that cucurbitacin I combined with radiotherapy significantly suppressed tumorigenesis and lung metastasis and further improved the survival rate in HNSCC-CD44(+)ALDH1(+)-transplanted immunocompromised mice. Taken together, our data show that cucurbitacin I, STAT3 inhibitor, reduces radioresistant, distant-metastatic, and CSC-like properties of HNSCC-CD44(+)ALDH1(+) cells. The potential of cucurbitacin I as a radiosensitizer should be verified in future anti-CSC therapy.},
	author = {Chen, Y. W. and Chen, K. H. and Huang, P. I. and Chen, Y. C. and Chiou, G. Y. and Lo, W. L. and Tseng, L. M. and Hsu, H. S. and Chang, K. W. and Chiou, S. H.},
	doi = {10.1158/1535-7163.Mct-10-0504},
	issn = {1535-7163},
	journal = {Mol Cancer Ther},
	keywords = {Aldehyde Dehydrogenase/*metabolism Aldehyde Dehydrogenase 1 Family Animals Apoptosis/*drug effects/radiation effects Carcinoma/pathology/radiotherapy Carcinoma, Squamous Cell Down-Regulation/drug effects Gamma Rays/therapeutic use Head and Neck Neoplasms/pathology/radiotherapy Humans Hyaluronan Receptors/*metabolism Isoenzymes/*metabolism Mice Mice, Inbred BALB C Mice, Nude Neoplasms, Squamous Cell/pathology/radiotherapy Neoplastic Stem Cells/*drug effects/metabolism/pathology/physiology Radiation Tolerance/*drug effects Radiation-Sensitizing Agents/pharmacology Retinal Dehydrogenase Squamous Cell Carcinoma of Head and Neck Triterpenes/*pharmacology Tumor Cells, Cultured Xenograft Model Antitumor Assays},
	note = {1538-8514 Chen, Yi-Wei Chen, Kuan-Hsuan Huang, Pin-I Chen, Yu-Chih Chiou, Guang-Yu Lo, Wen-Liang Tseng, Ling-Ming Hsu, Han-Sui Chang, Kuo-Wei Chiou, Shih-Hwa Journal Article Research Support, Non-U.S. Gov't United States 2010/11/11 Mol Cancer Ther. 2010 Nov;9(11):2879-92. doi: 10.1158/1535-7163.MCT-10-0504. Epub 2010 Nov 9.},
	number = {11},
	pages = {2879-92},
	title = {Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells},
	type = {Journal Article},
	url = {https://mct.aacrjournals.org/content/molcanther/9/11/2879.full.pdf},
	volume = {9},
	year = {2010},
	bdsk-url-1 = {https://mct.aacrjournals.org/content/molcanther/9/11/2879.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1535-7163.Mct-10-0504}}

@article{RN154,
	abstract = {Oral cavity squamous cell carcinoma (OC-SCC) is the most common malignancy of the head and neck (excluding nonmelanoma skin cancer). Recent trends have shown a dramatic rise in the incidence of oropharyngeal squamous cell carcinoma (OP-SCC), with a marked increase in lesions related to human papillomavirus infection. This update presents the latest evidence regarding OC-SCC and OP-SCC. In particular, the authors compare and contrast tumors at these two sites with respect to epidemiology, etiopathogenesis, clinicopathologic presentation, clinical assessment, imaging, management, and prognosis. It is important for clinicians to be aware of differences between OC-SCC and OP-SCC so that appropriate patient education and multidisciplinary care can be provided to optimize outcomes.},
	author = {Chi, A. C. and Day, T. A. and Neville, B. W.},
	doi = {10.3322/caac.21293},
	issn = {0007-9235},
	journal = {CA Cancer J Clin},
	keywords = {Carcinoma, Squamous Cell/*epidemiology Global Health Humans Morbidity/trends Mouth Neoplasms/*epidemiology Oropharyngeal Neoplasms/*epidemiology Prognosis cancer human papillomavirus oral cavity oropharynx squamous cell carcinoma},
	note = {1542-4863 Chi, Angela C Day, Terry A Neville, Brad W Journal Article Review United States 2015/07/29 CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21. doi: 10.3322/caac.21293. Epub 2015 Jul 27.},
	number = {5},
	pages = {401-21},
	title = {Oral cavity and oropharyngeal squamous cell carcinoma--an update},
	type = {Journal Article},
	url = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.3322/caac.21293?download=true},
	volume = {65},
	year = {2015},
	bdsk-url-1 = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.3322/caac.21293?download=true},
	bdsk-url-2 = {https://doi.org/10.3322/caac.21293}}

@article{RN169,
	abstract = {Oral cavity squamous cell carcinoma (OC-SCC) is the most common malignancy of the head and neck (excluding nonmelanoma skin cancer). Recent trends have shown a dramatic rise in the incidence of oropharyngeal squamous cell carcinoma (OP-SCC), with a marked increase in lesions related to human papillomavirus infection. This update presents the latest evidence regarding OC-SCC and OP-SCC. In particular, the authors compare and contrast tumors at these two sites with respect to epidemiology, etiopathogenesis, clinicopathologic presentation, clinical assessment, imaging, management, and prognosis. It is important for clinicians to be aware of differences between OC-SCC and OP-SCC so that appropriate patient education and multidisciplinary care can be provided to optimize outcomes.},
	author = {Chi, A. C. and Day, T. A. and Neville, B. W.},
	doi = {10.3322/caac.21293},
	issn = {0007-9235},
	journal = {CA Cancer J Clin},
	keywords = {Carcinoma, Squamous Cell/*epidemiology Global Health Humans Morbidity/trends Mouth Neoplasms/*epidemiology Oropharyngeal Neoplasms/*epidemiology Prognosis cancer human papillomavirus oral cavity oropharynx squamous cell carcinoma},
	note = {1542-4863 Chi, Angela C Day, Terry A Neville, Brad W Journal Article Review United States 2015/07/29 CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21. doi: 10.3322/caac.21293. Epub 2015 Jul 27.},
	number = {5},
	pages = {401-21},
	title = {Oral cavity and oropharyngeal squamous cell carcinoma--an update},
	type = {Journal Article},
	volume = {65},
	year = {2015},
	bdsk-url-1 = {https://doi.org/10.3322/caac.21293}}

@article{RN220,
	abstract = {Oral cavity squamous cell carcinoma (OC-SCC) is the most common malignancy of the head and neck (excluding nonmelanoma skin cancer). Recent trends have shown a dramatic rise in the incidence of oropharyngeal squamous cell carcinoma (OP-SCC), with a marked increase in lesions related to human papillomavirus infection. This update presents the latest evidence regarding OC-SCC and OP-SCC. In particular, the authors compare and contrast tumors at these two sites with respect to epidemiology, etiopathogenesis, clinicopathologic presentation, clinical assessment, imaging, management, and prognosis. It is important for clinicians to be aware of differences between OC-SCC and OP-SCC so that appropriate patient education and multidisciplinary care can be provided to optimize outcomes.},
	author = {Chi, A. C. and Day, T. A. and Neville, B. W.},
	doi = {10.3322/caac.21293},
	issn = {0007-9235},
	journal = {CA Cancer J Clin},
	keywords = {Carcinoma, Squamous Cell/*epidemiology Global Health Humans Morbidity/trends Mouth Neoplasms/*epidemiology Oropharyngeal Neoplasms/*epidemiology Prognosis cancer human papillomavirus oral cavity oropharynx squamous cell carcinoma},
	note = {1542-4863 Chi, Angela C Day, Terry A Neville, Brad W Journal Article Review United States 2015/07/29 CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21. doi: 10.3322/caac.21293. Epub 2015 Jul 27.},
	number = {5},
	pages = {401-21},
	title = {Oral cavity and oropharyngeal squamous cell carcinoma--an update},
	type = {Journal Article},
	volume = {65},
	year = {2015},
	bdsk-url-1 = {https://doi.org/10.3322/caac.21293}}

@article{RN221,
	abstract = {Oral cavity squamous cell carcinoma (OC-SCC) is the most common malignancy of the head and neck (excluding nonmelanoma skin cancer). Recent trends have shown a dramatic rise in the incidence of oropharyngeal squamous cell carcinoma (OP-SCC), with a marked increase in lesions related to human papillomavirus infection. This update presents the latest evidence regarding OC-SCC and OP-SCC. In particular, the authors compare and contrast tumors at these two sites with respect to epidemiology, etiopathogenesis, clinicopathologic presentation, clinical assessment, imaging, management, and prognosis. It is important for clinicians to be aware of differences between OC-SCC and OP-SCC so that appropriate patient education and multidisciplinary care can be provided to optimize outcomes.},
	author = {Chi, A. C. and Day, T. A. and Neville, B. W.},
	doi = {10.3322/caac.21293},
	issn = {0007-9235},
	journal = {CA Cancer J Clin},
	keywords = {Carcinoma, Squamous Cell/*epidemiology Global Health Humans Morbidity/trends Mouth Neoplasms/*epidemiology Oropharyngeal Neoplasms/*epidemiology Prognosis cancer human papillomavirus oral cavity oropharynx squamous cell carcinoma},
	note = {1542-4863 Chi, Angela C Day, Terry A Neville, Brad W Journal Article Review United States 2015/07/29 CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21. doi: 10.3322/caac.21293. Epub 2015 Jul 27.},
	number = {5},
	pages = {401-21},
	title = {Oral cavity and oropharyngeal squamous cell carcinoma--an update},
	type = {Journal Article},
	volume = {65},
	year = {2015},
	bdsk-url-1 = {https://doi.org/10.3322/caac.21293}}

@article{RN212,
	abstract = {Soft-tissue defects of the mouth floor need thin, foldable, and pliable tissues able to preserve local anatomy as well as chewing, phonation, and deglutition. The oral mucosa is made of a stratified, nonkeratinized, epithelium-secreting mucus, which lubricates the oral cavity and facilitates tongue movements. No flap exists that can reproduce the physiology of the oral mucosa better than the oral mucosa itself. Prefabrication of mucosal flaps may represent the best solution. Therefore, 10 consecutive cases of mouth floor cancer were treated with prelamination of the fascia antibrachialis with mucosal grafts obtained from the healthy cheek, and with subsequent transplantation 3 weeks later. A significant increase in mucosal graft surface was seen in all cases, with a mean size twice the original. All flaps healed uneventfully. Follow-up time ranged between 2-60 months (average, 26.6 months). Morphological and functional results were excellent. Tongue motility, speech intelligibility, and swallowing were reestablished in all treated cases. Mucosal prelamination of the forearm fascia is feasible and allows physiological reconstruction of oral cavity defects up to 6 x 4 cm.},
	author = {Chiarini, L. and De Santis, G. and Bedogni, A. and Nocini, P. F.},
	doi = {10.1002/micr.22511},
	issn = {0738-1085 (Print) 0738-1085},
	journal = {Microsurgery},
	keywords = {Carcinoma, Squamous Cell/*surgery Fasciotomy Female Follow-Up Studies Forearm Humans Male Middle Aged Mouth Floor Mouth Mucosa/surgery Mouth Neoplasms/*surgery *Surgical Flaps Time Factors},
	note = {Chiarini, L De Santis, G Bedogni, A Nocini, P F Case Reports Journal Article United States 2002/09/05 Microsurgery. 2002;22(5):177-86. doi: 10.1002/micr.22511.},
	number = {5},
	pages = {177-86},
	title = {Lining the mouth floor with prelaminated fascio-mucosal free flaps: clinical experience},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/micr.22511?download=true},
	volume = {22},
	year = {2002},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/micr.22511?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/micr.22511}}

@article{RN283,
	abstract = {Head and neck cancer consists of a diverse group of cancers that ranges from cutaneous, lip, salivary glands, sinuses, oral cavity, pharynx and larynx. Each group dictates different management. In this review, the primary focus is on head and neck squamous cell carcinoma (HNSCC) arising from the mucosal lining of the oral cavity and pharynx, excluding nasopharyngeal cancer. Presently, HNSCC is the sixth most prevalent neoplasm in the world, with approximately 900,000 cases diagnosed worldwide. Prognosis has improved little in the past 30 years. In those who have survived, pain, disfigurement and physical disability from treatment have had an enormous psychosocial impact on their lives. Management of these patients remains a challenge, especially in developing countries where this disease is most common. Of all human cancers, HNSCC is the most distressing since the head and neck is the site of the most complex functional anatomy in the human body. Its areas of responsibility include breathing, the CNS, vision, hearing, balance, olfaction, taste, swallowing, voice, endocrine and cosmesis. Cancers that occur in this area impact on these important human functions. Consequently, in treating cancers of the head and neck, the effects of the treatment on the functional outcome of the patient need the most serious consideration. In assessing the success of HNSCC treatment, consideration of both the survival and functional deficits that the patient may suffer as a consequence of their treatment are of paramount importance. For this reason, the modern-day management of head and neck patients should be carried out in a multidisciplinary head and neck clinic.},
	author = {Chin, D. and Boyle, G. M. and Porceddu, S. and Theile, D. R. and Parsons, P. G. and Coman, W. B.},
	doi = {10.1586/14737140.6.7.1111},
	issn = {1473-7140},
	journal = {Expert Rev Anticancer Ther},
	keywords = {Antineoplastic Combined Chemotherapy Protocols Carcinoma, Squamous Cell/epidemiology/*pathology/*therapy Combined Modality Therapy Head and Neck Neoplasms/epidemiology/*pathology/*therapy Humans Incidence Neoplasm Staging Palliative Care Prognosis Survival Analysis},
	note = {1744-8328 Chin, David Boyle, Glen M Porceddu, Sandro Theile, David R Parsons, Peter G Coman, William B Journal Article Research Support, Non-U.S. Gov't Review England 2006/07/13 Expert Rev Anticancer Ther. 2006 Jul;6(7):1111-8. doi: 10.1586/14737140.6.7.1111.},
	number = {7},
	pages = {1111-8},
	title = {Head and neck cancer: past, present and future},
	type = {Journal Article},
	volume = {6},
	year = {2006},
	bdsk-url-1 = {https://doi.org/10.1586/14737140.6.7.1111}}

@article{RN108,
	abstract = {Head and neck cancer consists of a diverse group of cancers that ranges from cutaneous, lip, salivary glands, sinuses, oral cavity, pharynx and larynx. Each group dictates different management. In this review, the primary focus is on head and neck squamous cell carcinoma (HNSCC) arising from the mucosal lining of the oral cavity and pharynx, excluding nasopharyngeal cancer. Presently, HNSCC is the sixth most prevalent neoplasm in the world, with approximately 900,000 cases diagnosed worldwide. Prognosis has improved little in the past 30 years. In those who have survived, pain, disfigurement and physical disability from treatment have had an enormous psychosocial impact on their lives. Management of these patients remains a challenge, especially in developing countries where this disease is most common. Of all human cancers, HNSCC is the most distressing since the head and neck is the site of the most complex functional anatomy in the human body. Its areas of responsibility include breathing, the CNS, vision, hearing, balance, olfaction, taste, swallowing, voice, endocrine and cosmesis. Cancers that occur in this area impact on these important human functions. Consequently, in treating cancers of the head and neck, the effects of the treatment on the functional outcome of the patient need the most serious consideration. In assessing the success of HNSCC treatment, consideration of both the survival and functional deficits that the patient may suffer as a consequence of their treatment are of paramount importance. For this reason, the modern-day management of head and neck patients should be carried out in a multidisciplinary head and neck clinic.},
	author = {Chin, D. and Boyle, G. M. and Porceddu, S. and Theile, D. R. and Parsons, P. G. and Coman, W. B.},
	doi = {10.1586/14737140.6.7.1111},
	issn = {1473-7140},
	journal = {Expert Rev Anticancer Ther},
	keywords = {Antineoplastic Combined Chemotherapy Protocols Carcinoma, Squamous Cell/epidemiology/*pathology/*therapy Combined Modality Therapy Head and Neck Neoplasms/epidemiology/*pathology/*therapy Humans Incidence Neoplasm Staging Palliative Care Prognosis Survival Analysis},
	note = {1744-8328 Chin, David Boyle, Glen M Porceddu, Sandro Theile, David R Parsons, Peter G Coman, William B Journal Article Research Support, Non-U.S. Gov't Review England 2006/07/13 Expert Rev Anticancer Ther. 2006 Jul;6(7):1111-8. doi: 10.1586/14737140.6.7.1111.},
	number = {7},
	pages = {1111-8},
	title = {Head and neck cancer: past, present and future},
	type = {Journal Article},
	url = {https://www.tandfonline.com/doi/pdf/10.1586/14737140.6.7.1111?needAccess=true},
	volume = {6},
	year = {2006},
	bdsk-url-1 = {https://www.tandfonline.com/doi/pdf/10.1586/14737140.6.7.1111?needAccess=true},
	bdsk-url-2 = {https://doi.org/10.1586/14737140.6.7.1111}}

@article{RN378,
	author = {Chin, D. and Boyle, G. M. and Porceddu, S. and Theile, D. R. and Parsons, P. G. and Coman, W. B.},
	doi = {10.1586/14737140.6.7.1111},
	issn = {1473-7140},
	journal = {Expert Rev Anticancer Ther},
	keywords = {Antineoplastic Combined Chemotherapy Protocols Carcinoma, Squamous Cell/epidemiology/*pathology/*therapy Combined Modality Therapy Head and Neck Neoplasms/epidemiology/*pathology/*therapy Humans Incidence Neoplasm Staging Palliative Care Prognosis Survival Analysis},
	number = {7},
	pages = {1111-8},
	title = {Head and neck cancer: past, present and future},
	type = {Journal Article},
	volume = {6},
	year = {2006},
	bdsk-url-1 = {https://doi.org/10.1586/14737140.6.7.1111}}

@book{RN203,
	author = {Christiansen, H. and Bremer, M.},
	isbn = {9783865419736},
	publisher = {Lehmanns Media},
	title = {Strahlentherapie und Radioonkologie aus interdisziplin{\"a}rer Sicht},
	type = {Book},
	url = {https://books.google.de/books?id=lWtgDwAAQBAJ},
	year = {2018},
	bdsk-url-1 = {https://books.google.de/books?id=lWtgDwAAQBAJ}}

@book{RN204,
	author = {Christiansen, H. and Bremer, M.},
	isbn = {9783865419736},
	publisher = {Lehmanns Media},
	title = {Strahlentherapie und Radioonkologie aus interdisziplin{\"a}rer Sicht},
	type = {Book},
	url = {https://books.google.de/books?id=lWtgDwAAQBAJ},
	year = {2018},
	bdsk-url-1 = {https://books.google.de/books?id=lWtgDwAAQBAJ}}

@book{RN234,
	author = {Christiansen, H. and Bremer, M.},
	isbn = {9783865419736},
	publisher = {Lehmanns Media},
	title = {Strahlentherapie und Radioonkologie aus interdisziplin{\"a}rer Sicht},
	type = {Book},
	url = {https://books.google.de/books?id=lWtgDwAAQBAJ},
	year = {2018},
	bdsk-url-1 = {https://books.google.de/books?id=lWtgDwAAQBAJ}}

@article{RN343,
	author = {Chung, C. H. and Gillison, M. L.},
	doi = {10.1158/1078-0432.CCR-09-0784},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Adolescent Adult Biomarkers, Tumor Carcinoma, Squamous Cell/*complications/*virology Female Gene Expression Regulation, Neoplastic Head and Neck Neoplasms/*complications/*virology Humans Male Medical Oncology/methods Middle Aged Models, Biological Mutation Papillomaviridae/*metabolism Papillomavirus Infections/*complications Treatment Outcome},
	number = {22},
	pages = {6758-62},
	title = {Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/19861444},
	volume = {15},
	year = {2009},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/19861444},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-09-0784}}

@article{RN85,
	abstract = {Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer with an annual incidence of approximately 400,000 worldwide. Although the principal risk factors for head and neck cancer remain tobacco and alcohol use, human papillomavirus (HPV) has recently been found to be etiologically associated with 20 to 25% of HNSCC, mostly in the oropharynx. HPV causes human cancers by expressing two viral oncoproteins, E6 and E7. These oncoproteins degrade and destabilize two major tumor suppressor proteins, p53 and pRb, through ubiquitination. Additional studies have shown that E6 and E7 can directly bind to multiple host proteins other than p53 and pRb (e.g., Bak and p21(Cip1)), further contributing to genetic instability. However, expression of E6 and E7 alone is not sufficient for cellular transformation, and the additional genetic alterations necessary for malignant progression in the setting of virus-induced genomic instability are unknown. In addition to the etiological differences, HPV-positive cancers are clinically distinct when compared with HPV-negative cancers with regard to treatment response and survival outcome, with tumor HPV-positivity being a favorable prognostic biomarker. Further understanding of carcinogenesis and clinical behavior of HPV-positive cancers will improve disease prevention, patient care, and surveillance strategies for HNSCC patients.},
	author = {Chung, C. H. and Gillison, M. L.},
	doi = {10.1158/1078-0432.CCR-09-0784},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Adolescent Adult Biomarkers, Tumor Carcinoma, Squamous Cell/*complications/*virology Female Gene Expression Regulation, Neoplastic Head and Neck Neoplasms/*complications/*virology Humans Male Medical Oncology/methods Middle Aged Models, Biological Mutation Papillomaviridae/*metabolism Papillomavirus Infections/*complications Treatment Outcome},
	note = {Chung, Christine H Gillison, Maura L eng Review 2009/10/29 Clin Cancer Res. 2009 Nov 15;15(22):6758-62. doi: 10.1158/1078-0432.CCR-09-0784. Epub 2009 Oct 27.},
	number = {22},
	pages = {6758-62},
	title = {Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications},
	type = {Journal Article},
	url = {https://clincancerres.aacrjournals.org/content/clincanres/15/22/6758.full.pdf},
	volume = {15},
	year = {2009},
	bdsk-url-1 = {https://clincancerres.aacrjournals.org/content/clincanres/15/22/6758.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-09-0784}}

@article{RN430,
	author = {Clarke, A. R. and Meniel, V.},
	doi = {10.1007/2789_2007_046},
	journal = {Ernst Schering Found Symp Proc},
	keywords = {Animals Homeostasis Intestines/*cytology Radiation, Ionizing Stem Cells/*cytology *Transgenes},
	number = {5},
	pages = {99-108},
	title = {The intestinal stem cell niche studied through conditional transgenesis},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17939297},
	year = {2006},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/17939297},
	bdsk-url-2 = {https://doi.org/10.1007/2789_2007_046}}

@article{RN431,
	author = {Clarke, A. R. and Meniel, V.},
	doi = {10.1007/2789_2007_046},
	journal = {Ernst Schering Found Symp Proc},
	keywords = {Animals Homeostasis Intestines/*cytology Radiation, Ionizing Stem Cells/*cytology *Transgenes},
	number = {5},
	pages = {99-108},
	title = {The intestinal stem cell niche studied through conditional transgenesis},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17939297},
	year = {2006},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/17939297},
	bdsk-url-2 = {https://doi.org/10.1007/2789_2007_046}}

@article{RN43,
	abstract = {Despite a wealth of experimental data, the precise mechanisms governing the maintenance and regeneration of the intestine remain relatively poorly elucidated. After physical or genetic injury, stem cells from the intestinal crypt are killed and the subsequent repopulation process recruits new stem cells from sources currently unknown. Understanding the genetic elements that determine stem cell fate and the basis by which repopulation occurs will greatly aid our understanding of both stem cell plasticity and the contribution made by the stem cell compartment to malignant disease. It would also provide a better platform to develop therapies to regenerate damaged intestinal epithelia as seen after radiation injuries or inflammatory bowel disease such as Crohn's disease. In this review we discuss some of the basic mechanisms that regulate intestinal stem cell viability and maintenance, and also summarise recent data from our laboratory on the requirement for the Wnt pathway in these processes.},
	author = {Clarke, A. R. and Meniel, V.},
	doi = {10.1007/2789_2007_046},
	journal = {Ernst Schering Found Symp Proc},
	keywords = {Animals Homeostasis Intestines/*cytology Radiation, Ionizing Stem Cells/*cytology *Transgenes},
	note = {Clarke, A R Meniel, V eng Review Germany Ernst Schering Found Symp Proc. 2006;(5):99-108. doi: 10.1007/2789_2007_046.},
	number = {5},
	pages = {99-108},
	title = {The intestinal stem cell niche studied through conditional transgenesis},
	type = {Journal Article},
	url = {https://link.springer.com/content/pdf/10.1007%2F2789_2007_046.pdf},
	year = {2006},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007%2F2789_2007_046.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/2789_2007_046}}

@article{RN310,
	author = {Clarke, M. F. and Dick, J. E. and Dirks, P. B. and Eaves, C. J. and Jamieson, C. H. and Jones, D. L. and Visvader, J. and Weissman, I. L. and Wahl, G. M.},
	doi = {10.1158/0008-5472.Can-06-3126},
	issn = {0008-5472},
	journal = {Cancer Res},
	keywords = {Animals Biomarkers, Tumor/analysis Disease Progression Epigenesis, Genetic Humans Mice Mice, Inbred NOD Mice, SCID Models, Biological Neoplasm Metastasis Neoplasm Transplantation Neoplasms/pathology/therapy *Neoplastic Stem Cells/chemistry/cytology/transplantation Transplantation, Heterologous Tumor Stem Cell Assay},
	note = {1538-7445 Clarke, Michael F Dick, John E Dirks, Peter B Eaves, Connie J Jamieson, Catriona H M Jones, D Leanne Visvader, Jane Weissman, Irving L Wahl, Geoffrey M R01 AG028092/AG/NIA NIH HHS/United States Congress United States 2006/09/23 Cancer Res. 2006 Oct 1;66(19):9339-44. doi: 10.1158/0008-5472.CAN-06-3126. Epub 2006 Sep 21.},
	number = {19},
	pages = {9339-44},
	title = {Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells},
	type = {Journal Article},
	url = {https://cancerres.aacrjournals.org/content/canres/66/19/9339.full.pdf},
	volume = {66},
	year = {2006},
	bdsk-url-1 = {https://cancerres.aacrjournals.org/content/canres/66/19/9339.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/0008-5472.Can-06-3126}}

@article{RN311,
	author = {Clarke, M. F. and Dick, J. E. and Dirks, P. B. and Eaves, C. J. and Jamieson, C. H. and Jones, D. L. and Visvader, J. and Weissman, I. L. and Wahl, G. M.},
	doi = {10.1158/0008-5472.Can-06-3126},
	issn = {0008-5472},
	journal = {Cancer Res},
	keywords = {Animals Biomarkers, Tumor/analysis Disease Progression Epigenesis, Genetic Humans Mice Mice, Inbred NOD Mice, SCID Models, Biological Neoplasm Metastasis Neoplasm Transplantation Neoplasms/pathology/therapy *Neoplastic Stem Cells/chemistry/cytology/transplantation Transplantation, Heterologous Tumor Stem Cell Assay},
	note = {1538-7445 Clarke, Michael F Dick, John E Dirks, Peter B Eaves, Connie J Jamieson, Catriona H M Jones, D Leanne Visvader, Jane Weissman, Irving L Wahl, Geoffrey M R01 AG028092/AG/NIA NIH HHS/United States Congress United States 2006/09/23 Cancer Res. 2006 Oct 1;66(19):9339-44. doi: 10.1158/0008-5472.CAN-06-3126. Epub 2006 Sep 21.},
	number = {19},
	pages = {9339-44},
	title = {Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells},
	type = {Journal Article},
	url = {https://cancerres.aacrjournals.org/content/canres/66/19/9339.full.pdf},
	volume = {66},
	year = {2006},
	bdsk-url-1 = {https://cancerres.aacrjournals.org/content/canres/66/19/9339.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/0008-5472.Can-06-3126}}

@article{RN309,
	abstract = {BACKGROUND: In accord with the cancer stem cell (CSC) theory, only a small subset of cancer cells are capable of forming tumors. We previously reported that CD44 isolates tumorigenic cells from head and neck squamous cell cancer (HNSCC). Recent studies indicate that aldehyde dehydrogenase (ALDH) activity may represent a more specific marker of CSCs. METHODS: Six primary HNSCCs were collected. Cells with high and low ALDH activity (ALDH(high)/ALDH(low)) were isolated. ALDH(high) and ALDH(low) populations were implanted into NOD/SCID mice and monitored for tumor development. RESULTS: ALDH(high) cells represented a small percentage of the tumor cells (1% to 7.8%). ALDH(high) cells formed tumors from as few as 500 cells in 24/45 implantations, whereas only 3/37 implantations of ALDH(low) cells formed tumors. CONCLUSIONS: ALDH(high) cells comprise a subpopulation cells in HNSCCs that are tumorigenic and capable of producing tumors at very low numbers. This finding indicates that ALDH activity on its own is a highly selective marker for CSCs in HNSCC.},
	author = {Clay, M. R. and Tabor, M. and Owen, J. H. and Carey, T. E. and Bradford, C. R. and Wolf, G. T. and Wicha, M. S. and Prince, M. E.},
	doi = {10.1002/hed.21315},
	issn = {1043-3074 (Print) 1043-3074},
	journal = {Head Neck},
	keywords = {Aged Aldehyde Dehydrogenase/analysis/*metabolism Animals Biomarkers, Tumor/*analysis Carcinoma, Squamous Cell/*pathology Cell Line, Tumor Cell Separation Cell Survival Female Flow Cytometry Head and Neck Neoplasms/*pathology Humans Male Mice Mice, Inbred NOD Middle Aged Models, Animal Neoplastic Stem Cells/*pathology Sensitivity and Specificity},
	note = {1097-0347 Clay, Matthew R Tabor, Mark Owen, John Henry Carey, Thomas E Bradford, Carol R Wolf, Gregory T Wicha, Max S Prince, Mark E P50 CA097248/CA/NCI NIH HHS/United States P50 CA097248-07/CA/NCI NIH HHS/United States P50 CA-097248/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2010/01/15 Head Neck. 2010 Sep;32(9):1195-201. doi: 10.1002/hed.21315.},
	number = {9},
	pages = {1195-201},
	title = {Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase},
	type = {Journal Article},
	url = {https://deepblue.lib.umich.edu/bitstream/handle/2027.42/77970/21315_ftp.pdf?sequence=1},
	volume = {32},
	year = {2010},
	bdsk-url-1 = {https://deepblue.lib.umich.edu/bitstream/handle/2027.42/77970/21315_ftp.pdf?sequence=1},
	bdsk-url-2 = {https://doi.org/10.1002/hed.21315}}

@article{RN279,
	abstract = {BACKGROUND: With squamous cell carcinoma of the upper aerodigestive tract the presence or absence of neck metastases is the most important prognostic factor. This makes the histopathologic assessment of neck dissections of paramount importance. With the clinically N0 neck the prevalence of microscopic extracapsular spread and soft tissue deposits has not previously been described. METHODS: We have prospectively analyzed 96 elective neck dissections in 63 patients with upper aerodigestive tract squamous cell carcinoma and clinically N0 necks to assess the prevalence of microscopic extracapsular spread and soft tissue deposits. The dissections were separated peroperatively into nodal levels; these were sectioned at 6-microm sections and stained with H & E. RESULTS: Nineteen patients (30.2%) were upstaged to pN+ve. Twelve of these had microscopic extracapsular spread, which was 19.0% of the clinically N0 necks and 63.2% of the pN+ve. Five had soft tissue deposits, which was 7.9% of the clinically N0 necks. Fourteen patients had microscopic extracapsular spread and/or soft tissue deposits, which represented 22.2% of all necks examined and 73.7% of the pN+ve necks. CONCLUSIONS: Microscopic extracapsular spread and soft tissue deposits have a high prevalence in patients with clinically N0 necks. Extracapsular spread can occur at an early stage in metastasis from upper aerodigestive tract squamous cell carcinoma. Soft tissue deposits can also occur at an early stage. Soft tissue deposits may occur by the same process as lymph node metastasis with total effacement of the lymph node or may occur by some other process such as lymphatic tumor embolization.},
	author = {Coatesworth, A. P. and MacLennan, K.},
	doi = {10.1002/hed.10020},
	issn = {1043-3074 (Print) 1043-3074},
	journal = {Head Neck},
	keywords = {Carcinoma, Squamous Cell/*pathology/secondary Head and Neck Neoplasms/*secondary Humans Laryngeal Neoplasms/*pathology Lymphatic Metastasis Mouth Neoplasms/*pathology Neck/pathology Neck Dissection Neoplasm Invasiveness Neoplasm Staging Pharyngeal Neoplasms/*pathology Prospective Studies},
	note = {Coatesworth, Andrew P MacLennan, Ken Journal Article Research Support, Non-U.S. Gov't United States 2002/03/14 Head Neck. 2002 Mar;24(3):258-61. doi: 10.1002/hed.10020.},
	number = {3},
	pages = {258-61},
	title = {Squamous cell carcinoma of the upper aerodigestive tract: the prevalence of microscopic extracapsular spread and soft tissue deposits in the clinically N0 neck},
	type = {Journal Article},
	volume = {24},
	year = {2002},
	bdsk-url-1 = {https://doi.org/10.1002/hed.10020}}

@article{RN197,
	abstract = {BACKGROUND: With squamous cell carcinoma of the upper aerodigestive tract the presence or absence of neck metastases is the most important prognostic factor. This makes the histopathologic assessment of neck dissections of paramount importance. With the clinically N0 neck the prevalence of microscopic extracapsular spread and soft tissue deposits has not previously been described. METHODS: We have prospectively analyzed 96 elective neck dissections in 63 patients with upper aerodigestive tract squamous cell carcinoma and clinically N0 necks to assess the prevalence of microscopic extracapsular spread and soft tissue deposits. The dissections were separated peroperatively into nodal levels; these were sectioned at 6-microm sections and stained with H & E. RESULTS: Nineteen patients (30.2%) were upstaged to pN+ve. Twelve of these had microscopic extracapsular spread, which was 19.0% of the clinically N0 necks and 63.2% of the pN+ve. Five had soft tissue deposits, which was 7.9% of the clinically N0 necks. Fourteen patients had microscopic extracapsular spread and/or soft tissue deposits, which represented 22.2% of all necks examined and 73.7% of the pN+ve necks. CONCLUSIONS: Microscopic extracapsular spread and soft tissue deposits have a high prevalence in patients with clinically N0 necks. Extracapsular spread can occur at an early stage in metastasis from upper aerodigestive tract squamous cell carcinoma. Soft tissue deposits can also occur at an early stage. Soft tissue deposits may occur by the same process as lymph node metastasis with total effacement of the lymph node or may occur by some other process such as lymphatic tumor embolization.},
	author = {Coatesworth, A. P. and MacLennan, K.},
	doi = {10.1002/hed.10020},
	issn = {1043-3074 (Print) 1043-3074},
	journal = {Head Neck},
	keywords = {Carcinoma, Squamous Cell/*pathology/secondary Head and Neck Neoplasms/*secondary Humans Laryngeal Neoplasms/*pathology Lymphatic Metastasis Mouth Neoplasms/*pathology Neck/pathology Neck Dissection Neoplasm Invasiveness Neoplasm Staging Pharyngeal Neoplasms/*pathology Prospective Studies},
	note = {Coatesworth, Andrew P MacLennan, Ken Journal Article Research Support, Non-U.S. Gov't United States 2002/03/14 Head Neck. 2002 Mar;24(3):258-61. doi: 10.1002/hed.10020.},
	number = {3},
	pages = {258-61},
	title = {Squamous cell carcinoma of the upper aerodigestive tract: the prevalence of microscopic extracapsular spread and soft tissue deposits in the clinically N0 neck},
	type = {Journal Article},
	volume = {24},
	year = {2002},
	bdsk-url-1 = {https://doi.org/10.1002/hed.10020}}

@article{RN165,
	abstract = {BACKGROUND: With squamous cell carcinoma of the upper aerodigestive tract the presence or absence of neck metastases is the most important prognostic factor. This makes the histopathologic assessment of neck dissections of paramount importance. With the clinically N0 neck the prevalence of microscopic extracapsular spread and soft tissue deposits has not previously been described. METHODS: We have prospectively analyzed 96 elective neck dissections in 63 patients with upper aerodigestive tract squamous cell carcinoma and clinically N0 necks to assess the prevalence of microscopic extracapsular spread and soft tissue deposits. The dissections were separated peroperatively into nodal levels; these were sectioned at 6-microm sections and stained with H & E. RESULTS: Nineteen patients (30.2%) were upstaged to pN+ve. Twelve of these had microscopic extracapsular spread, which was 19.0% of the clinically N0 necks and 63.2% of the pN+ve. Five had soft tissue deposits, which was 7.9% of the clinically N0 necks. Fourteen patients had microscopic extracapsular spread and/or soft tissue deposits, which represented 22.2% of all necks examined and 73.7% of the pN+ve necks. CONCLUSIONS: Microscopic extracapsular spread and soft tissue deposits have a high prevalence in patients with clinically N0 necks. Extracapsular spread can occur at an early stage in metastasis from upper aerodigestive tract squamous cell carcinoma. Soft tissue deposits can also occur at an early stage. Soft tissue deposits may occur by the same process as lymph node metastasis with total effacement of the lymph node or may occur by some other process such as lymphatic tumor embolization.},
	author = {Coatesworth, A. P. and MacLennan, K.},
	doi = {10.1002/hed.10020},
	issn = {1043-3074 (Print) 1043-3074},
	journal = {Head Neck},
	keywords = {Carcinoma, Squamous Cell/*pathology/secondary Head and Neck Neoplasms/*secondary Humans Laryngeal Neoplasms/*pathology Lymphatic Metastasis Mouth Neoplasms/*pathology Neck/pathology Neck Dissection Neoplasm Invasiveness Neoplasm Staging Pharyngeal Neoplasms/*pathology Prospective Studies},
	note = {Coatesworth, Andrew P MacLennan, Ken Journal Article Research Support, Non-U.S. Gov't United States 2002/03/14 Head Neck. 2002 Mar;24(3):258-61. doi: 10.1002/hed.10020.},
	number = {3},
	pages = {258-61},
	title = {Squamous cell carcinoma of the upper aerodigestive tract: the prevalence of microscopic extracapsular spread and soft tissue deposits in the clinically N0 neck},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hed.10020?download=true},
	volume = {24},
	year = {2002},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hed.10020?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/hed.10020}}

@article{RN219,
	abstract = {PURPOSE OF REVIEW: The goals of this article are: to briefly review oropharyngeal anatomy; to provide a review of the epidemiology of oropharyngeal cancer in the Western Hemisphere; to review the literature on the association of human papilloma virus with oropharyngeal cancer; to review the recent literature on evolving diagnostic techniques for oropharyngeal cancer; and to summarize accepted management strategies for oropharyngeal cancer by subsite. RECENT FINDINGS: The incidence of oropharyngeal cancer may be increasing among younger age groups in the Western Hemisphere, and this may be related to an increased association with human papillomavirus 16. The implications of this viral association with regard to outcomes and management strategies remain under investigation. Screening with toluidine blue, autofluorescence, or both may be useful adjuncts to physical examination and panendoscopy in assessing potentially invasive or dysplastic lesions of the oropharynx. These techniques remain under study. MRI and PET scan are proving to be useful techniques for assessing local extension, regional metastases, and recurrences of squamous cell carcinoma (SCC) of the oropharynx in selected cases. However, serial computed tomography scanning remains the imaging modality of choice in the United States. Early SCCs of the oropharynx (T1-2), in general, may be managed effectively with either surgery or primary irradiation, though, with either technique, clinicians must have a management plan for the neck. Advanced SCCs of the oropharynx (T3-4, nodally aggressive, or both) require multimodal approaches consisting of either surgery along with adjuvant irradiation or concurrent chemoradiation along with salvage surgery (as necessary). SUMMARY: Management of SCC of the oropharynx is in a period of transition because of evolving changes in our understanding of the oncogenic process; evolving diagnostic techniques; and evolving combinations of therapies, both surgical and nonsurgical. For the time being, we propose using local subsite and disease stage to guide therapeutic decision-making.},
	author = {Cohan, D. M. and Popat, S. and Kaplan, S. E. and Rigual, N. and Loree, T. and Hicks, W. L., Jr.},
	doi = {10.1097/moo.0b013e32832984c0},
	issn = {1068-9508},
	journal = {Curr Opin Otolaryngol Head Neck Surg},
	keywords = {Carcinoma, Squamous Cell/*diagnosis/epidemiology/*surgery Combined Modality Therapy Humans Incidence Magnetic Resonance Imaging Mandibular Neoplasms/pathology Neck Dissection Neoplasm Staging Oropharyngeal Neoplasms/*diagnosis/epidemiology/*therapy Oropharynx/diagnostic imaging/metabolism/pathology Palate, Soft/pathology Papillomavirus Infections/epidemiology/virology Positron-Emission Tomography Tomography, X-Ray Computed Tonsillar Neoplasms/pathology},
	note = {1531-6998 Cohan, David M Popat, Saurin Kaplan, Seth E Rigual, Nestor Loree, Thom Hicks, Wesley L Jr Journal Article Review United States 2009/04/18 Curr Opin Otolaryngol Head Neck Surg. 2009 Apr;17(2):88-94. doi: 10.1097/moo.0b013e32832984c0.},
	number = {2},
	pages = {88-94},
	title = {Oropharyngeal cancer: current understanding and management},
	type = {Journal Article},
	volume = {17},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1097/moo.0b013e32832984c0}}

@article{RN263,
	abstract = {BACKGROUND: Despite the use of resection and postoperative radiotherapy, high-risk squamous-cell carcinoma of the head and neck frequently recurs in the original tumor bed. We tested the hypothesis that concurrent postoperative administration of cisplatin and radiotherapy would improve the rate of local and regional control. METHODS: Between September 9, 1995, and April 28, 2000, 459 patients were enrolled. After undergoing total resection of all visible and palpable disease, 231 patients were randomly assigned to receive radiotherapy alone (60 to 66 Gy in 30 to 33 fractions over a period of 6 to 6.6 weeks) and 228 patients to receive the identical treatment plus concurrent cisplatin (100 mg per square meter of body-surface area intravenously on days 1, 22, and 43). RESULTS: After a median follow-up of 45.9 months, the rate of local and regional control was significantly higher in the combined-therapy group than in the group given radiotherapy alone (hazard ratio for local or regional recurrence, 0.61; 95 percent confidence interval, 0.41 to 0.91; P=0.01). The estimated two-year rate of local and regional control was 82 percent in the combined-therapy group, as compared with 72 percent in the radiotherapy group. Disease-free survival was significantly longer in the combined-therapy group than in the radiotherapy group (hazard ratio for disease or death, 0.78; 95 percent confidence interval, 0.61 to 0.99; P=0.04), but overall survival was not (hazard ratio for death, 0.84; 95 percent confidence interval, 0.65 to 1.09; P=0.19). The incidence of acute adverse effects of grade 3 or greater was 34 percent in the radiotherapy group and 77 percent in the combined-therapy group (P<0.001). Four patients who received combined therapy died as a direct result of the treatment. CONCLUSIONS: Among high-risk patients with resected head and neck cancer, concurrent postoperative chemotherapy and radiotherapy significantly improve the rates of local and regional control and disease-free survival. However, the combined treatment is associated with a substantial increase in adverse effects.},
	author = {Cooper, J. S. and Pajak, T. F. and Forastiere, A. A. and Jacobs, J. and Campbell, B. H. and Saxman, S. B. and Kish, J. A. and Kim, H. E. and Cmelak, A. J. and Rotman, M. and Machtay, M. and Ensley, J. F. and Chao, K. S. and Schultz, C. J. and Lee, N. and Fu, K. K.},
	doi = {10.1056/NEJMoa032646},
	issn = {0028-4793},
	journal = {N Engl J Med},
	keywords = {Adolescent Adult Aged Antineoplastic Agents/adverse effects/*therapeutic use Carcinoma, Squamous Cell/*drug therapy/mortality/*radiotherapy/surgery Cisplatin/adverse effects/*therapeutic use Combined Modality Therapy/adverse effects/mortality Disease-Free Survival Female Follow-Up Studies Head and Neck Neoplasms/*drug therapy/mortality/*radiotherapy/surgery Humans Male Middle Aged Radiotherapy/adverse effects Risk Survival Analysis},
	note = {1533-4406 Cooper, Jay S Pajak, Thomas F Forastiere, Arlene A Jacobs, John Campbell, Bruce H Saxman, Scott B Kish, Julie A Kim, Harold E Cmelak, Anthony J Rotman, Marvin Machtay, Mitchell Ensley, John F Chao, K S Clifford Schultz, Christopher J Lee, Nancy Fu, Karen K Radiation Therapy Oncology Group 9501/Intergroup CA21661/CA/NCI NIH HHS/United States CA32115/CA/NCI NIH HHS/United States Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S. United States 2004/05/07 N Engl J Med. 2004 May 6;350(19):1937-44. doi: 10.1056/NEJMoa032646.},
	number = {19},
	pages = {1937-44},
	title = {Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck},
	type = {Journal Article},
	url = {https://www.nejm.org/doi/pdf/10.1056/NEJMoa032646?articleTools=true},
	volume = {350},
	year = {2004},
	bdsk-url-1 = {https://www.nejm.org/doi/pdf/10.1056/NEJMoa032646?articleTools=true},
	bdsk-url-2 = {https://doi.org/10.1056/NEJMoa032646}}

@article{RN415,
	author = {Cooper, J. S. and Zhang, Q. and Pajak, T. F. and Forastiere, A. A. and Jacobs, J. and Saxman, S. B. and Kish, J. A. and Kim, H. E. and Cmelak, A. J. and Rotman, M. and Lustig, R. and Ensley, J. F. and Thorstad, W. and Schultz, C. J. and Yom, S. S. and Ang, K. K.},
	doi = {10.1016/j.ijrobp.2012.05.008},
	issn = {1879-355X (Electronic) 0360-3016 (Linking)},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Antineoplastic Agents/adverse effects/*therapeutic use Carcinoma, Squamous Cell/drug therapy/mortality/*radiotherapy/surgery Cisplatin/*therapeutic use Disease-Free Survival Head and Neck Neoplasms/drug therapy/mortality/*radiotherapy/surgery Humans Lymphatic Metastasis Neoplasm Recurrence, Local/mortality Postoperative Care/methods Prospective Studies Radiation-Sensitizing Agents/adverse effects/*therapeutic use Radiotherapy/adverse effects Smoking/adverse effects Time Factors},
	number = {5},
	pages = {1198-205},
	title = {Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22749632},
	volume = {84},
	year = {2012},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/22749632},
	bdsk-url-2 = {https://doi.org/10.1016/j.ijrobp.2012.05.008}}

@article{RN48,
	abstract = {PURPOSE: Previous analysis of this Intergroup trial demonstrated that with a median follow-up among surviving patients of 45.9 months, the concurrent postoperative administration of cisplatin and radiation therapy improved local-regional control and disease-free survival of patients who had high-risk resectable head-and-neck carcinomas. With a minimum of 10 years of follow-up potentially now available for all patients, these results are updated here to examine long-term outcomes. METHODS AND MATERIALS: A total of 410 analyzable patients who had high-risk resected head-and-neck cancers were prospectively randomized to receive either radiation therapy (RT: 60 Gy in 6 weeks) or identical RT plus cisplatin, 100 mg/m(2)i.v. on days 1, 22, and 43 (RT + CT). RESULTS: At 10 years, the local-regional failure rates were 28.8% vs 22.3% (P=.10), disease-free survival was 19.1% vs 20.1% (P=.25), and overall survival was 27.0% vs 29.1% (P=.31) for patients treated by RT vs RT + CT, respectively. In the unplanned subset analysis limited to patients who had microscopically involved resection margins and/or extracapsular spread of disease, local-regional failure occurred in 33.1% vs 21.0% (P=.02), disease-free survival was 12.3% vs 18.4% (P=.05), and overall survival was 19.6% vs 27.1% (P=.07), respectively. CONCLUSION: At a median follow-up of 9.4 years for surviving patients, no significant differences in outcome were observed in the analysis of all randomized eligible patients. However, analysis of the subgroup of patients who had either microscopically involved resection margins and/or extracapsular spread of disease showed improved local-regional control and disease-free survival with concurrent administration of chemotherapy. The remaining subgroup of patients who were enrolled only because they had tumor in 2 or more lymph nodes did not benefit from the addition of CT to RT.},
	author = {Cooper, J. S. and Zhang, Q. and Pajak, T. F. and Forastiere, A. A. and Jacobs, J. and Saxman, S. B. and Kish, J. A. and Kim, H. E. and Cmelak, A. J. and Rotman, M. and Lustig, R. and Ensley, J. F. and Thorstad, W. and Schultz, C. J. and Yom, S. S. and Ang, K. K.},
	doi = {10.1016/j.ijrobp.2012.05.008},
	issn = {1879-355X (Electronic) 0360-3016 (Linking)},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Antineoplastic Agents/adverse effects/*therapeutic use Carcinoma, Squamous Cell/drug therapy/mortality/*radiotherapy/surgery Cisplatin/*therapeutic use Disease-Free Survival Head and Neck Neoplasms/drug therapy/mortality/*radiotherapy/surgery Humans Lymphatic Metastasis Neoplasm Recurrence, Local/mortality Postoperative Care/methods Prospective Studies Radiation-Sensitizing Agents/adverse effects/*therapeutic use Radiotherapy/adverse effects Smoking/adverse effects Time Factors},
	note = {Cooper, Jay S Zhang, Qiang Pajak, Thomas F Forastiere, Arlene A Jacobs, John Saxman, Scott B Kish, Julie A Kim, Harold E Cmelak, Anthony J Rotman, Marvin Lustig, Robert Ensley, John F Thorstad, Wade Schultz, Christopher J Yom, Sue S Ang, K Kian eng U10 CA021661/CA/NCI NIH HHS/ U10 CA32115/CA/NCI NIH HHS/ U10 CA37422/CA/NCI NIH HHS/ U10 CA21661/CA/NCI NIH HHS/ Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205. doi: 10.1016/j.ijrobp.2012.05.008. Epub 2012 Jun 30.},
	number = {5},
	pages = {1198-205},
	title = {Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465463/pdf/nihms376521.pdf},
	volume = {84},
	year = {2012},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465463/pdf/nihms376521.pdf},
	bdsk-url-2 = {https://doi.org/10.1016/j.ijrobp.2012.05.008}}

@article{RN267,
	author = {Crile, George},
	issn = {0002-9955},
	journal = {Journal of the American Medical Association},
	number = {22},
	pages = {1780-1786},
	title = {EXCISION OF CANCER OF THE HEAD AND NECK. WITH SPECIAL REFERENCE TO THE PLAN OF DISSECTION BASED ON ONE HUNDRED AND THIRTY-TWO OPERATIONS},
	type = {Journal Article},
	volume = {47},
	year = {1906}}

@article{RN336,
	author = {Curado, M. P. and Boyle, P.},
	doi = {10.1097/CCO.0b013e32835ff48c},
	issn = {1531-703X (Electronic) 1040-8746 (Linking)},
	journal = {Curr Opin Oncol},
	keywords = {Adult Age Factors Alcohol Drinking/*epidemiology Carcinoma, Squamous Cell/*epidemiology/virology Female Global Health/statistics & numerical data Head and Neck Neoplasms/*epidemiology/virology Humans Male Middle Aged Papillomavirus Infections/epidemiology Sex Factors Smoking/*epidemiology Squamous Cell Carcinoma of Head and Neck},
	number = {3},
	pages = {229-34},
	title = {Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23511666},
	volume = {25},
	year = {2013},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/23511666},
	bdsk-url-2 = {https://doi.org/10.1097/CCO.0b013e32835ff48c}}

@article{RN67,
	abstract = {PURPOSE OF REVIEW: This review intends to present some epidemiological findings regarding the epidemiology of head and neck squamous cell carcinoma not related to alcohol or tobacco (HNSCCNAT). RECENT FINDINGS: Twenty-five percent of squamous cell carcinomas of head and neck are not related to tobacco or alcohol consumption. The risk factors for this group of malignancies are not very well established yet. HNSCCNAT are more likely to occur in the oropharynx. The diagnosis is more frequent at young age (before 50). The prevalence of human papillomavirus (HPV-positive) infection is high. SUMMARY: Monitoring HPV status in head and neck cancer patients who are not tobacco or alcohol consumers will enable physicians to better plan treatment.},
	author = {Curado, M. P. and Boyle, P.},
	doi = {10.1097/CCO.0b013e32835ff48c},
	issn = {1531-703X (Electronic) 1040-8746 (Linking)},
	journal = {Curr Opin Oncol},
	keywords = {Adult Age Factors Alcohol Drinking/*epidemiology Carcinoma, Squamous Cell/*epidemiology/virology Female Global Health/statistics & numerical data Head and Neck Neoplasms/*epidemiology/virology Humans Male Middle Aged Papillomavirus Infections/epidemiology Sex Factors Smoking/*epidemiology Squamous Cell Carcinoma of Head and Neck},
	note = {Curado, Maria P Boyle, Peter eng Review 2013/03/21 Curr Opin Oncol. 2013 May;25(3):229-34. doi: 10.1097/CCO.0b013e32835ff48c.},
	number = {3},
	pages = {229-34},
	title = {Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23511666},
	volume = {25},
	year = {2013},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/23511666},
	bdsk-url-2 = {https://doi.org/10.1097/CCO.0b013e32835ff48c}}

@article{RN362,
	author = {D'Souza, G. and Agrawal, Y. and Halpern, J. and Bodison, S. and Gillison, M. L.},
	doi = {10.1086/597755},
	issn = {0022-1899 (Print) 0022-1899},
	journal = {J Infect Dis},
	keywords = {Adolescent Adult Analysis of Variance Cross-Sectional Studies Ethnicity Female Head and Neck Neoplasms/epidemiology/immunology/virology Heterosexuality Homosexuality Humans Male Middle Aged Mouth Diseases/*epidemiology/*virology Multivariate Analysis Oropharyngeal Neoplasms/epidemiology/immunology/*virology Papillomavirus Infections/*epidemiology/immunology Papillomavirus Vaccines/*therapeutic use Prevalence Racial Groups Sexual Behavior/*statistics & numerical data Young Adult},
	number = {9},
	pages = {1263-9},
	title = {Oral sexual behaviors associated with prevalent oral human papillomavirus infection},
	type = {Journal Article},
	volume = {199},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1086/597755}}

@article{RN97,
	abstract = {Oral human papillomavirus (HPV) infection is a cause of oropharyngeal cancer. We investigated whether sexual behaviors that elevated the odds of oropharyngeal cancer developing in a case-control study similarly elevated the odds of oral HPV infection developing among control patients. HPV infection was detected in 4.8% of 332 control patients from an outpatient clinic and in 2.9% of 210 college-aged men (age range, 18-23 years). Among control patients, the odds of infection developing independently increased with increases in the lifetime number of oral (P = .007, for trend) or vaginal sex partners (P = .003, for trend). Among college-aged men, the odds of oral HPV infection developing increased with increases in the number of recent oral sex partners (P = .046, for trend) or open-mouthed kissing partners (P = .023, for trend) but not vaginal sex partners. Oral sex and open-mouthed kissing are associated with the development of oral HPV infection.},
	author = {D'Souza, G. and Agrawal, Y. and Halpern, J. and Bodison, S. and Gillison, M. L.},
	doi = {10.1086/597755},
	issn = {0022-1899 (Print) 0022-1899},
	journal = {J Infect Dis},
	keywords = {Adolescent Adult Analysis of Variance Cross-Sectional Studies Ethnicity Female Head and Neck Neoplasms/epidemiology/immunology/virology Heterosexuality Homosexuality Humans Male Middle Aged Mouth Diseases/*epidemiology/*virology Multivariate Analysis Oropharyngeal Neoplasms/epidemiology/immunology/*virology Papillomavirus Infections/*epidemiology/immunology Papillomavirus Vaccines/*therapeutic use Prevalence Racial Groups Sexual Behavior/*statistics & numerical data Young Adult},
	note = {1537-6613 D'Souza, Gypsyamber Agrawal, Yuri Halpern, Jane Bodison, Sacared Gillison, Maura L P30 CA006973/CA/NCI NIH HHS/United States Journal Article Research Support, Non-U.S. Gov't 2009/03/27 J Infect Dis. 2009 May 1;199(9):1263-9. doi: 10.1086/597755.},
	number = {9},
	pages = {1263-9},
	title = {Oral sexual behaviors associated with prevalent oral human papillomavirus infection},
	type = {Journal Article},
	url = {https://watermark.silverchair.com/199-9-1263.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAr8wggK7BgkqhkiG9w0BBwagggKsMIICqAIBADCCAqEGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMPn5NKbUO7qG75fHRAgEQgIICck2L5HI0kjXXVeV6Nk_vnZQiaBFO_dBCrYjoWR-rAB5ggEWYfBwh6dMwpWfwEa7p6xsOv-8jShodqz3j55VHHA7EVNZQRSva0AidI0bHdHqS1LHVYvUsiT-pNFweSqCwAGRD-YbVXbENIJvmOqZYZ2Z4zPPKuMTwEs4p5h-GgjpnnodHNpQWJAt1FymIfq03JDca1aALcgkBXzL_7C05UhrBBjqF5sbriYywWaWJzSK7EGl5oAhZpwvCUWpMZyA5OF78CbdPgH9y0dHmUpx9lxu4ydwLwc2zFHXs81NSrKtAQYVS87IwQ3e8mx7A-cDcYEaHDFmjcnmDrjaYb_eDXAVcL54lv7TtuSLpkkLZilbss8AQgQAkxn2bM7CDOFNDCU7pPUjICMc4yLVgXQFdaAuRZp7N-mkJnz3iw7-Ukjns79s4xvP_gPMesfPa1-My5A9VtEPiyjoheALDm2IwHbIxuKHOXSkytJwtAgfW2zXQfarHB5jcuVyvZf8zCfMxUQu6H40OMbCQkIf_3g1efziNWa3w5iUtT5LSzHyWiQEf6HQfwnCetIi797RIEKf6hXX1HK3X-dqLRSclqGh_d8BmMFfqmpinfYMALEQ-sKJ540D6je3BLNp_DpS9MDlx5nHKx7edSd84h_Tqg4NzSH356ihlRyzS3rBRb8oNoJhQXLTbGbDX4DrkptRCvBXh-Yfun9SSGq8ZVm2lMFu_vfM3WUUO_3K2-DARC-XWdTaiMmAW0dDH5U1RuJIjGMA1b3XYWsCacD9jwiY9ecedBMq2tNZgpVWpvBLtbxFOKS9pVptQ8WWOsMNPZaEKQJXbCATV},
	volume = {199},
	year = {2009},
	bdsk-url-1 = {https://watermark.silverchair.com/199-9-1263.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAr8wggK7BgkqhkiG9w0BBwagggKsMIICqAIBADCCAqEGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMPn5NKbUO7qG75fHRAgEQgIICck2L5HI0kjXXVeV6Nk_vnZQiaBFO_dBCrYjoWR-rAB5ggEWYfBwh6dMwpWfwEa7p6xsOv-8jShodqz3j55VHHA7EVNZQRSva0AidI0bHdHqS1LHVYvUsiT-pNFweSqCwAGRD-YbVXbENIJvmOqZYZ2Z4zPPKuMTwEs4p5h-GgjpnnodHNpQWJAt1FymIfq03JDca1aALcgkBXzL_7C05UhrBBjqF5sbriYywWaWJzSK7EGl5oAhZpwvCUWpMZyA5OF78CbdPgH9y0dHmUpx9lxu4ydwLwc2zFHXs81NSrKtAQYVS87IwQ3e8mx7A-cDcYEaHDFmjcnmDrjaYb_eDXAVcL54lv7TtuSLpkkLZilbss8AQgQAkxn2bM7CDOFNDCU7pPUjICMc4yLVgXQFdaAuRZp7N-mkJnz3iw7-Ukjns79s4xvP_gPMesfPa1-My5A9VtEPiyjoheALDm2IwHbIxuKHOXSkytJwtAgfW2zXQfarHB5jcuVyvZf8zCfMxUQu6H40OMbCQkIf_3g1efziNWa3w5iUtT5LSzHyWiQEf6HQfwnCetIi797RIEKf6hXX1HK3X-dqLRSclqGh_d8BmMFfqmpinfYMALEQ-sKJ540D6je3BLNp_DpS9MDlx5nHKx7edSd84h_Tqg4NzSH356ihlRyzS3rBRb8oNoJhQXLTbGbDX4DrkptRCvBXh-Yfun9SSGq8ZVm2lMFu_vfM3WUUO_3K2-DARC-XWdTaiMmAW0dDH5U1RuJIjGMA1b3XYWsCacD9jwiY9ecedBMq2tNZgpVWpvBLtbxFOKS9pVptQ8WWOsMNPZaEKQJXbCATV},
	bdsk-url-2 = {https://doi.org/10.1086/597755}}

@article{RN292,
	abstract = {Recent observations indicate that, in several types of human cancer, only a phenotypic subset of cancer cells within each tumor is capable of initiating tumor growth. This functional subset of cancer cells is operationally defined as the "cancer stem cell" (CSC) subset. Here we developed a CSC model for the study of human colorectal cancer (CRC). Solid CRC tissues, either primary tissues collected from surgical specimens or xenografts established in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, were disaggregated into single-cell suspensions and analyzed by flow cytometry. Surface markers that displayed intratumor heterogeneous expression among epithelial cancer cells were selected for cell sorting and tumorigenicity experiments. Individual phenotypic cancer cell subsets were purified, and their tumor-initiating properties were investigated by injection in NOD/SCID mice. Our observations indicate that, in six of six human CRC tested, the ability to engraft in vivo in immunodeficient mice was restricted to a minority subpopulation of epithelial cell adhesion molecule (EpCAM)(high)/CD44+ epithelial cells. Tumors originated from EpCAM(high)/CD44+ cells maintained a differentiated phenotype and reproduced the full morphologic and phenotypic heterogeneity of their parental lesions. Analysis of the surface molecule repertoire of EpCAM(high)/CD44+ cells led to the identification of CD166 as an additional differentially expressed marker, useful for CSC isolation in three of three CRC tested. These results validate the stem cell working model in human CRC and provide a highly robust surface marker profile for CRC stem cell isolation.},
	author = {Dalerba, P. and Dylla, S. J. and Park, I. K. and Liu, R. and Wang, X. and Cho, R. W. and Hoey, T. and Gurney, A. and Huang, E. H. and Simeone, D. M. and Shelton, A. A. and Parmiani, G. and Castelli, C. and Clarke, M. F.},
	doi = {10.1073/pnas.0703478104},
	issn = {0027-8424 (Print) 0027-8424},
	journal = {Proc Natl Acad Sci U S A},
	keywords = {Activated-Leukocyte Cell Adhesion Molecule/immunology Animals *Antigens, Neoplasm/immunology Biomarkers, Tumor/*immunology Cell Separation Colorectal Neoplasms/genetics/*immunology/*pathology/surgery Epithelial Cells/immunology Flow Cytometry Humans Hyaluronan Receptors/immunology Mice Mice, Inbred NOD Mice, SCID Neoplasm Transplantation Phenotype Stem Cells/*immunology Transplantation, Heterologous Tumor Stem Cell Assay},
	note = {1091-6490 Dalerba, Piero Dylla, Scott J Park, In-Kyung Liu, Rui Wang, Xinhao Cho, Robert W Hoey, Timothy Gurney, Austin Huang, Emina H Simeone, Diane M Shelton, Andrew A Parmiani, Giorgio Castelli, Chiara Clarke, Michael F CA 126524/CA/NCI NIH HHS/United States K08 CA091975/CA/NCI NIH HHS/United States U54 CA126524/CA/NCI NIH HHS/United States CA 104987/CA/NCI NIH HHS/United States R01 CA104987/CA/NCI NIH HHS/United States Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2007/06/06 Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63. doi: 10.1073/pnas.0703478104. Epub 2007 Jun 4.},
	number = {24},
	pages = {10158-63},
	title = {Phenotypic characterization of human colorectal cancer stem cells},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891215/pdf/zpq10158.pdf},
	volume = {104},
	year = {2007},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891215/pdf/zpq10158.pdf},
	bdsk-url-2 = {https://doi.org/10.1073/pnas.0703478104}}

@article{RN274,
	author = {Daly, Tiffany and Poulsen, Michael G and Denham, James W and Peters, Lester J and Lamb, David S and Krawitz, Hedley and Hamilton, Chris and Keller, Jacqui and Tripcony, Lee and Walker, Quenten},
	issn = {0167-8140},
	journal = {Radiotherapy and oncology},
	number = {2},
	pages = {113-122},
	title = {The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck},
	type = {Journal Article},
	url = {https://www.thegreenjournal.com/article/S0167-8140(03)00198-1/fulltext},
	volume = {68},
	year = {2003},
	bdsk-url-1 = {https://www.thegreenjournal.com/article/S0167-8140(03)00198-1/fulltext}}

@article{RN185,
	abstract = {OBJECTIVE: We sought to evaluate the efficiency of (18)FDG PET, CT, and MRI for the preoperative staging of squamous cell carcinoma (SCC) of the head and neck region. CONCLUSION: MRI is recommended as the method of choice in the preoperative evaluation of SCC of the oral cavity and the oropharynx. PET can provide relevant diagnostic information in case of equivocal findings by MRI or CT. Routine use of PET, however, does not appear to be necessary if optimized MRI is available.},
	author = {Dammann, F. and Horger, M. and Mueller-Berg, M. and Schlemmer, H. and Claussen, C. D. and Hoffman, J. and Eschmann, S. and Bares, R.},
	doi = {10.2214/ajr.184.4.01841326},
	issn = {0361-803X (Print) 0361-803x},
	journal = {AJR Am J Roentgenol},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/*diagnosis/diagnostic imaging Diagnosis, Differential Female Fluorodeoxyglucose F18 Humans Lymphatic Metastasis Magnetic Resonance Imaging Male Middle Aged Mouth Neoplasms/*diagnosis/diagnostic imaging Neoplasm Staging Pharyngeal Neoplasms/*diagnosis/diagnostic imaging ROC Curve Radiopharmaceuticals Sensitivity and Specificity Tomography, Emission-Computed Tomography, X-Ray Computed},
	note = {Dammann, Florian Horger, Marius Mueller-Berg, Marcus Schlemmer, Heinz Claussen, Claus D Hoffman, Juergen Eschmann, Susanne Bares, Roland Comparative Study Journal Article United States 2005/03/25 AJR Am J Roentgenol. 2005 Apr;184(4):1326-31. doi: 10.2214/ajr.184.4.01841326.},
	number = {4},
	pages = {1326-31},
	title = {Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET},
	type = {Journal Article},
	url = {https://www.ajronline.org/doi/pdfplus/10.2214/ajr.184.4.01841326},
	volume = {184},
	year = {2005},
	bdsk-url-1 = {https://www.ajronline.org/doi/pdfplus/10.2214/ajr.184.4.01841326},
	bdsk-url-2 = {https://doi.org/10.2214/ajr.184.4.01841326}}

@article{RN413,
	author = {de Jong, M. C. and Pramana, J. and van der Wal, J. E. and Lacko, M. and Peutz-Kootstra, C. J. and de Jong, J. M. and Takes, R. P. and Kaanders, J. H. and van der Laan, B. F. and Wachters, J. and Jansen, J. C. and Rasch, C. R. and van Velthuysen, M. L. and Grenman, R. and Hoebers, F. J. and Schuuring, E. and van den Brekel, M. W. and Begg, A. C.},
	doi = {10.1158/1078-0432.CCR-10-0799},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Biomarkers, Tumor/genetics/metabolism Carcinoma/*diagnosis/genetics/pathology/*radiotherapy Case-Control Studies Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Hyaluronan Receptors/*genetics/metabolism Laryngeal Neoplasms/*diagnosis/genetics/pathology/*radiotherapy Male Microarray Analysis Neoplasm Recurrence, Local/*diagnosis/genetics/metabolism Prognosis Tumor Cells, Cultured Validation Studies as Topic},
	number = {21},
	pages = {5329-38},
	title = {CD44 expression predicts local recurrence after radiotherapy in larynx cancer},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20837694},
	volume = {16},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/20837694},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-10-0799}}

@article{RN427,
	author = {de Jong, M. C. and Pramana, J. and van der Wal, J. E. and Lacko, M. and Peutz-Kootstra, C. J. and de Jong, J. M. and Takes, R. P. and Kaanders, J. H. and van der Laan, B. F. and Wachters, J. and Jansen, J. C. and Rasch, C. R. and van Velthuysen, M. L. and Grenman, R. and Hoebers, F. J. and Schuuring, E. and van den Brekel, M. W. and Begg, A. C.},
	doi = {10.1158/1078-0432.CCR-10-0799},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Biomarkers, Tumor/genetics/metabolism Carcinoma/*diagnosis/genetics/pathology/*radiotherapy Case-Control Studies Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Hyaluronan Receptors/*genetics/metabolism Laryngeal Neoplasms/*diagnosis/genetics/pathology/*radiotherapy Male Microarray Analysis Neoplasm Recurrence, Local/*diagnosis/genetics/metabolism Prognosis Tumor Cells, Cultured Validation Studies as Topic},
	number = {21},
	pages = {5329-38},
	title = {CD44 expression predicts local recurrence after radiotherapy in larynx cancer},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20837694},
	volume = {16},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/20837694},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-10-0799}}

@article{RN23,
	abstract = {PURPOSE: To find molecular markers from expression profiling data to predict recurrence of laryngeal cancer after radiotherapy. EXPERIMENTAL DESIGN: We generated gene expression data on pre-treatment biopsies from 52 larynx cancer patients. Patients developing a local recurrence were matched for T-stage, subsite, treatment, gender and age with non-recurrence patients. Candidate genes were then tested by immunohistochemistry on tumor material from a second series of 76 patients. Both series comprised early stage cancer treated with radiotherapy alone. Finally, gene expression data of eight larynx cancer cell lines with known radiosensitivity were analyzed. RESULTS: Nineteen patients with a local recurrence were matched with 33 controls. Gene sets for hypoxia, proliferation and intrinsic radiosensitivity did not correlate with recurrence, whereas expression of the putative stem cell marker CD44 did. In a supervised analysis, probes for all three splice variants of CD44 on the array appeared in the top 10 most significantly correlated with local recurrence. Immunohistochemical analysis of CD44 expression on the independent validation series confirmed CD44's predictive potential. In 8 larynx cancer cell lines, CD44 gene expression did not correlate with intrinsic radiosensitivity although it did correlate significantly with plating efficiency, consistent with a relationship with stem cell content. CONCLUSIONS: CD44 was the only biological factor tested which significantly correlated with response to radiotherapy in early stage larynx cancer patients, both at the mRNA and protein levels. Further studies are needed to confirm this and to assess how general these findings are for other head and neck tumor stages and sites.},
	author = {de Jong, M. C. and Pramana, J. and van der Wal, J. E. and Lacko, M. and Peutz-Kootstra, C. J. and de Jong, J. M. and Takes, R. P. and Kaanders, J. H. and van der Laan, B. F. and Wachters, J. and Jansen, J. C. and Rasch, C. R. and van Velthuysen, M. L. and Grenman, R. and Hoebers, F. J. and Schuuring, E. and van den Brekel, M. W. and Begg, A. C.},
	doi = {10.1158/1078-0432.CCR-10-0799},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Biomarkers, Tumor/genetics/metabolism Carcinoma/*diagnosis/genetics/pathology/*radiotherapy Case-Control Studies Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Hyaluronan Receptors/*genetics/metabolism Laryngeal Neoplasms/*diagnosis/genetics/pathology/*radiotherapy Male Microarray Analysis Neoplasm Recurrence, Local/*diagnosis/genetics/metabolism Prognosis Tumor Cells, Cultured Validation Studies as Topic},
	note = {de Jong, Monique C Pramana, Jimmy van der Wal, Jacqueline E Lacko, Martin Peutz-Kootstra, Carine J de Jong, Jos M Takes, Robert P Kaanders, Johannes H van der Laan, Bernard F Wachters, Jasper Jansen, Jeroen C Rasch, Coen R van Velthuysen, Marie-Louise F Grenman, Reidar Hoebers, Frank J Schuuring, Ed van den Brekel, Michiel W Begg, Adrian C eng Multicenter Study Research Support, Non-U.S. Gov't Clin Cancer Res. 2010 Nov 1;16(21):5329-38. doi: 10.1158/1078-0432.CCR-10-0799. Epub 2010 Sep 13.},
	number = {21},
	pages = {5329-38},
	title = {CD44 expression predicts local recurrence after radiotherapy in larynx cancer},
	type = {Journal Article},
	url = {https://clincancerres.aacrjournals.org/content/clincanres/16/21/5329.full.pdf},
	volume = {16},
	year = {2010},
	bdsk-url-1 = {https://clincancerres.aacrjournals.org/content/clincanres/16/21/5329.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-10-0799}}

@article{RN181,
	abstract = {In 210 cases of oral cancer, 38 (17.6%) second primary tumours were found. Males had a higher chance of developing a second primary than females (21.4% versus 12%). The difference was not statistically significant (p = 0.11). When the index tumour was in the lower part of the oral cavity (floor of mouth, retromolar trigone, inferior alveolar process), a higher rate of second primaries was found than in cancer of the rest of the oral cavity (tongue, buccal mucosa and palate) (26.6% versus 11.5%). In male patients, this difference was statistically significant (p less than 0.05). 4 tumours were synchronous. In those 4 patients, panendoscopy would not have contributed to an earlier diagnosis. Routine panendoscopy in oral cancer therefore seems not valid.},
	author = {de Vries, N. and Van der Waal, I. and Snow, G. B.},
	doi = {10.1016/s0300-9785(86)80015-1},
	issn = {0901-5027 (Print) 0901-5027},
	journal = {Int J Oral Maxillofac Surg},
	keywords = {Female Humans Male Mouth Mucosa/pathology Mouth Neoplasms/*pathology Neoplasms, Multiple Primary/*pathology Sex Factors Time Factors Tongue Neoplasms/pathology},
	note = {de Vries, N Van der Waal, I Snow, G B Journal Article Denmark 1986/02/01 Int J Oral Maxillofac Surg. 1986 Feb;15(1):85-7. doi: 10.1016/s0300-9785(86)80015-1.},
	number = {1},
	pages = {85-7},
	title = {Multiple primary tumours in oral cancer},
	type = {Journal Article},
	url = {https://www.ijoms.com/article/S0300-9785(86)80015-1/pdf},
	volume = {15},
	year = {1986},
	bdsk-url-1 = {https://www.ijoms.com/article/S0300-9785(86)80015-1/pdf},
	bdsk-url-2 = {https://doi.org/10.1016/s0300-9785(86)80015-1}}

@article{RN450,
	author = {DeLellis, R. A. and Sternberger, L. A. and Mann, R. B. and Banks, P. M. and Nakane, P. K.},
	doi = {10.1093/ajcp/71.5.483},
	issn = {0002-9173 (Print) 0002-9173 (Linking)},
	journal = {Am J Clin Pathol},
	keywords = {Absorption Clinical Laboratory Techniques/*methods Frozen Sections Humans Immune Sera/pharmacology *Immunoenzyme Techniques National Institutes of Health (U.S.) Neoplasms/*diagnosis Staining and Labeling United States},
	number = {5},
	pages = {483-8},
	title = {Immunoperoxidase technics in diagnostic pathology. Report of a workshop sponsored by the National Cancer Institute},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/88175},
	volume = {71},
	year = {1979},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/88175},
	bdsk-url-2 = {https://doi.org/10.1093/ajcp/71.5.483}}

@article{RN60,
	author = {DeLellis, R. A. and Sternberger, L. A. and Mann, R. B. and Banks, P. M. and Nakane, P. K.},
	doi = {10.1093/ajcp/71.5.483},
	issn = {0002-9173 (Print) 0002-9173 (Linking)},
	journal = {Am J Clin Pathol},
	keywords = {Absorption Clinical Laboratory Techniques/*methods Frozen Sections Humans Immune Sera/pharmacology *Immunoenzyme Techniques National Institutes of Health (U.S.) Neoplasms/*diagnosis Staining and Labeling United States},
	note = {DeLellis, R A Sternberger, L A Mann, R B Banks, P M Nakane, P K eng England 1979/05/01 Am J Clin Pathol. 1979 May;71(5):483-8. doi: 10.1093/ajcp/71.5.483.},
	number = {5},
	pages = {483-8},
	title = {Immunoperoxidase technics in diagnostic pathology. Report of a workshop sponsored by the National Cancer Institute},
	type = {Journal Article},
	url = {https://watermark.silverchair.com/ajcpath71-0483.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAtYwggLSBgkqhkiG9w0BBwagggLDMIICvwIBADCCArgGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMhsXyE_vV_jNzS04MAgEQgIICicE6yqjGKmy75qXGClel_TeDJIQh_2flw0aXqzJ9vSLix0R3trAQKs2SYP2_6Khm2BztsHfj1OiILTXxqUHvc2L7xAFf4SNe8YJKg7kIzk0_N3RUrb44G-Pt7DkNKV7-IyXUTUmTGgLUzaTUAVFU0IrMMt9FWc_UgUO2n9lqMO28WKyS_JZsZR--f02CY7FXvC12dyAsYF2ULQBzPbSKr7A86iu9V6yjRBqwsg_P6sjvsuXtvv5wlOj8CFPRPiE0MJboovWwFM6J0QnfsNrg7F-OJ0XcjE9d2BbAi5C_RAIXXE-iCJG14N1iVBeXwB3cplDKgIXSynkiWmS-JtEsn7kXEsjBvB2cM3dErTA36EXFZkXeotGWZkBkRhbSpcuuOC-EdRSEQL7St-GlHtVbNBlQXH8maMCpNw5TpF-5JOf45-2KzYe5IeGRqvoTzNzfMSrQlN22mr1xfoexgh0tS6O3QBi5NQAru-UYMw8qb4AKvAPEB4w2sP_vOhUhRC0-Ez7FyraPQMbmrakQhXO6zEGvfRQdeKq3mH1J2XKzfuTjr37pbC6alwZQlFK1GqoX1k9iE_PEFTT8wSPBzMQuwTBUlbraU3SqhuIeQLWy3DvwSxERgSEx2OS4cWQCyE5HtE1NiwraT6_f622xRi_ifwJ2MSDAA0UWQ2jUH6m4l7zifImYeBPSvNyizGTMW02Di0oFMdHm2VhMWpFC1COkCgEj2IPyLm390IdlG8U4NYphXkCQziaR9dD-16-_K0tXMbxvUfQj_izAb6GhvdC7B_3SdnWjyE8Mo0GlQD1pyYZluus3O2Yqcnq9EPcR6qbh07fraOvVMUNjSqAiR3LSGUhD2Y7e7_TX7l4},
	volume = {71},
	year = {1979},
	bdsk-url-1 = {https://watermark.silverchair.com/ajcpath71-0483.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAtYwggLSBgkqhkiG9w0BBwagggLDMIICvwIBADCCArgGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMhsXyE_vV_jNzS04MAgEQgIICicE6yqjGKmy75qXGClel_TeDJIQh_2flw0aXqzJ9vSLix0R3trAQKs2SYP2_6Khm2BztsHfj1OiILTXxqUHvc2L7xAFf4SNe8YJKg7kIzk0_N3RUrb44G-Pt7DkNKV7-IyXUTUmTGgLUzaTUAVFU0IrMMt9FWc_UgUO2n9lqMO28WKyS_JZsZR--f02CY7FXvC12dyAsYF2ULQBzPbSKr7A86iu9V6yjRBqwsg_P6sjvsuXtvv5wlOj8CFPRPiE0MJboovWwFM6J0QnfsNrg7F-OJ0XcjE9d2BbAi5C_RAIXXE-iCJG14N1iVBeXwB3cplDKgIXSynkiWmS-JtEsn7kXEsjBvB2cM3dErTA36EXFZkXeotGWZkBkRhbSpcuuOC-EdRSEQL7St-GlHtVbNBlQXH8maMCpNw5TpF-5JOf45-2KzYe5IeGRqvoTzNzfMSrQlN22mr1xfoexgh0tS6O3QBi5NQAru-UYMw8qb4AKvAPEB4w2sP_vOhUhRC0-Ez7FyraPQMbmrakQhXO6zEGvfRQdeKq3mH1J2XKzfuTjr37pbC6alwZQlFK1GqoX1k9iE_PEFTT8wSPBzMQuwTBUlbraU3SqhuIeQLWy3DvwSxERgSEx2OS4cWQCyE5HtE1NiwraT6_f622xRi_ifwJ2MSDAA0UWQ2jUH6m4l7zifImYeBPSvNyizGTMW02Di0oFMdHm2VhMWpFC1COkCgEj2IPyLm390IdlG8U4NYphXkCQziaR9dD-16-_K0tXMbxvUfQj_izAb6GhvdC7B_3SdnWjyE8Mo0GlQD1pyYZluus3O2Yqcnq9EPcR6qbh07fraOvVMUNjSqAiR3LSGUhD2Y7e7_TX7l4},
	bdsk-url-2 = {https://doi.org/10.1093/ajcp/71.5.483}}

@article{RN208,
	abstract = {OBJECTIVES: Intraoperative frozen section analysis of surgical margins is widely used in head and neck cancer surgery. This study evaluates frozen section accuracy relative to permanent controls and final margins from the entire specimen, the rate at which frozen sections impact intraoperative management, and the resultant cost. STUDY DESIGN: Retrospective. METHODS: From 1997 to 1999 the frozen section results, permanent controls, and final tumor margins from 80 consecutive patients undergoing 420 intraoperative frozen section margins for head and neck malignancy were reviewed. RESULTS: A 98.3% accuracy rate (sensitivity, 88.8%; specificity, 98.9%) was found compared with permanent sections of the same tissue. However, 40% (8 of 20) of patients with positive final margins on the resection specimen, and 100% (15 of 15) with close (<5 mm) margins were not detected by frozen section analysis. The overall accuracy of frozen section in the evaluation of close or positive final margins was 71.3% (sensitivity, 34.3%; specificity, 100%). In addition, 5% (4 of 80) of patients potentially benefited from intraoperative frozen section by virtue of immediate margin revision. The estimated cost of intraoperative frozen section averaged as much as $3,123 per patient, with a cost-benefit ratio of 20:1. CONCLUSIONS: Intraoperative frozen section margins are accurate, but they are costly and cannot reliably eradicate positive final margins. Patients with early-stage lesions and those undergoing re-resection for recurrence or salvage surgery after radiation failure derived the greatest potential benefit from frozen section margins.},
	author = {DiNardo, L. J. and Lin, J. and Karageorge, L. S. and Powers, C. N.},
	doi = {10.1097/00005537-200010000-00039},
	issn = {0023-852X (Print) 0023-852x},
	journal = {Laryngoscope},
	keywords = {Cost-Benefit Analysis *Frozen Sections/economics Head and Neck Neoplasms/*pathology/*surgery Humans Intraoperative Care Retrospective Studies Sensitivity and Specificity},
	note = {DiNardo, L J Lin, J Karageorge, L S Powers, C N Journal Article United States 2000/10/19 Laryngoscope. 2000 Oct;110(10 Pt 1):1773-6. doi: 10.1097/00005537-200010000-00039.},
	number = {10 Pt 1},
	pages = {1773-6},
	title = {Accuracy, utility, and cost of frozen section margins in head and neck cancer surgery},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1097/00005537-200010000-00039?download=true},
	volume = {110},
	year = {2000},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1097/00005537-200010000-00039?download=true},
	bdsk-url-2 = {https://doi.org/10.1097/00005537-200010000-00039}}

@article{RN307,
	abstract = {A new transgenic mouse has been generated in which the proto-oncogene BCL-2 is ubiquitously overexpressed. H2K-BCL-2 transgenic mice overexpress BCL-2 in all cells of the hematolymphoid system and have been used to assess the role of BCL-2 in protecting cells of the hematolymphoid system from the consequences of ionizing radiation. We have expanded on previous studies that have demonstrated protection for specific (lymphoid) cell populations and show that systemic overexpression of BCL-2 can protect the hematopoietic system as a whole, including hematopoietic stem cells (HSC), thus increasing the radioresistance of the animal. The increase in radioresistance in H2K-BCL-2 transgenic mice has two components: an increase in the radioresistance of individual cells and, to a lesser extent, an increase in the size of certain critically important cell populations, such as HSC. Bone marrow transplantation experiments show that the increased radioresistance of the transgenic animals is provided by cells of the hematopoietic system. Protection against the consequences of irradiation is not limited to the increased expression levels of BCL-2 in transgenic mice; levels of endogenous BCL-2 are higher in lymphocyte populations that survive irradiation in wild-type mice. We show that ubiquitous overexpression of BCL-2 in the hematopoietic system can be used to increase the resistance of animals to lethal challenges such as irradiation.},
	author = {Domen, J. and Gandy, K. L. and Weissman, I. L.},
	issn = {0006-4971 (Print) 0006-4971},
	journal = {Blood},
	keywords = {Animals Bone Marrow Cells/*physiology/radiation effects *Gene Expression Regulation Gene Transfer Techniques Genes, bcl-2 Hematopoiesis/*genetics/radiation effects Mice Mice, Transgenic Proto-Oncogene Proteins c-bcl-2/*biosynthesis/*genetics Radiation Tolerance/*genetics},
	note = {Domen, J Gandy, K L Weissman, I L Journal Article Research Support, Non-U.S. Gov't United States 1998/04/18 Blood. 1998 Apr 1;91(7):2272-82.},
	number = {7},
	pages = {2272-82},
	title = {Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation},
	type = {Journal Article},
	volume = {91},
	year = {1998}}

@article{RN114,
	author = {Duvvuri, U. and Myers, J. N.},
	doi = {10.1067/j.cpsurg.2008.10.003},
	issn = {0011-3840},
	journal = {Curr Probl Surg},
	keywords = {Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use Carcinoma, Squamous Cell/pathology/physiopathology/therapy Clinical Trials as Topic Deglutition Disorders/etiology/therapy Enteral Nutrition/methods *Human papillomavirus 16/isolation & purification Humans Neoplasm Staging Oropharyngeal Neoplasms/drug therapy/pathology/physiopathology/radiotherapy/surgery/*therapy/virology Oropharynx/*pathology/*physiopathology Papillomavirus Infections/*complications Treatment Outcome},
	note = {1535-6337 Duvvuri, Umamaheswar Myers, Jeffrey N Journal Article Review United States 2008/12/30 Curr Probl Surg. 2009 Feb;46(2):119-84. doi: 10.1067/j.cpsurg.2008.10.003.},
	number = {2},
	pages = {119-84},
	title = {Contemporary management of oropharyngeal cancer: anatomy and physiology of the oropharynx},
	type = {Journal Article},
	url = {https://www.sciencedirect.com/science/article/abs/pii/S001138400800155X?via%3Dihub},
	volume = {46},
	year = {2009},
	bdsk-url-1 = {https://www.sciencedirect.com/science/article/abs/pii/S001138400800155X?via%3Dihub},
	bdsk-url-2 = {https://doi.org/10.1067/j.cpsurg.2008.10.003}}

@article{RN400,
	author = {Duvvuri, U. and Myers, J. N.},
	doi = {10.1067/j.cpsurg.2008.10.003},
	issn = {0011-3840},
	journal = {Curr Probl Surg},
	keywords = {Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use Carcinoma, Squamous Cell/pathology/physiopathology/therapy Clinical Trials as Topic Deglutition Disorders/etiology/therapy Enteral Nutrition/methods *Human papillomavirus 16/isolation & purification Humans Neoplasm Staging Oropharyngeal Neoplasms/drug therapy/pathology/physiopathology/radiotherapy/surgery/*therapy/virology Oropharynx/*pathology/*physiopathology Papillomavirus Infections/*complications Treatment Outcome},
	number = {2},
	pages = {119-84},
	title = {Contemporary management of oropharyngeal cancer: anatomy and physiology of the oropharynx},
	type = {Journal Article},
	volume = {46},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1067/j.cpsurg.2008.10.003}}

@article{RN399,
	author = {Duvvuri, U. and Myers, J. N.},
	doi = {10.1067/j.cpsurg.2008.10.003},
	issn = {0011-3840},
	journal = {Curr Probl Surg},
	keywords = {Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use Carcinoma, Squamous Cell/pathology/physiopathology/therapy Clinical Trials as Topic Deglutition Disorders/etiology/therapy Enteral Nutrition/methods *Human papillomavirus 16/isolation & purification Humans Neoplasm Staging Oropharyngeal Neoplasms/drug therapy/pathology/physiopathology/radiotherapy/surgery/*therapy/virology Oropharynx/*pathology/*physiopathology Papillomavirus Infections/*complications Treatment Outcome},
	number = {2},
	pages = {119-84},
	title = {Contemporary management of oropharyngeal cancer: anatomy and physiology of the oropharynx},
	type = {Journal Article},
	volume = {46},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1067/j.cpsurg.2008.10.003}}

@article{RN398,
	author = {Duvvuri, U. and Myers, J. N.},
	doi = {10.1067/j.cpsurg.2008.10.003},
	issn = {0011-3840},
	journal = {Curr Probl Surg},
	keywords = {Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use Carcinoma, Squamous Cell/pathology/physiopathology/therapy Clinical Trials as Topic Deglutition Disorders/etiology/therapy Enteral Nutrition/methods *Human papillomavirus 16/isolation & purification Humans Neoplasm Staging Oropharyngeal Neoplasms/drug therapy/pathology/physiopathology/radiotherapy/surgery/*therapy/virology Oropharynx/*pathology/*physiopathology Papillomavirus Infections/*complications Treatment Outcome},
	number = {2},
	pages = {119-84},
	title = {Contemporary management of oropharyngeal cancer: anatomy and physiology of the oropharynx},
	type = {Journal Article},
	volume = {46},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1067/j.cpsurg.2008.10.003}}

@article{RN395,
	author = {Duvvuri, U. and Myers, J. N.},
	doi = {10.1067/j.cpsurg.2008.10.003},
	issn = {0011-3840},
	journal = {Curr Probl Surg},
	keywords = {Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use Carcinoma, Squamous Cell/pathology/physiopathology/therapy Clinical Trials as Topic Deglutition Disorders/etiology/therapy Enteral Nutrition/methods *Human papillomavirus 16/isolation & purification Humans Neoplasm Staging Oropharyngeal Neoplasms/drug therapy/pathology/physiopathology/radiotherapy/surgery/*therapy/virology Oropharynx/*pathology/*physiopathology Papillomavirus Infections/*complications Treatment Outcome},
	number = {2},
	pages = {119-84},
	title = {Contemporary management of oropharyngeal cancer: anatomy and physiology of the oropharynx},
	type = {Journal Article},
	volume = {46},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1067/j.cpsurg.2008.10.003}}

@article{RN394,
	author = {Duvvuri, U. and Myers, J. N.},
	doi = {10.1067/j.cpsurg.2008.10.003},
	issn = {0011-3840},
	journal = {Curr Probl Surg},
	keywords = {Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use Carcinoma, Squamous Cell/pathology/physiopathology/therapy Clinical Trials as Topic Deglutition Disorders/etiology/therapy Enteral Nutrition/methods *Human papillomavirus 16/isolation & purification Humans Neoplasm Staging Oropharyngeal Neoplasms/drug therapy/pathology/physiopathology/radiotherapy/surgery/*therapy/virology Oropharynx/*pathology/*physiopathology Papillomavirus Infections/*complications Treatment Outcome},
	number = {2},
	pages = {119-84},
	title = {Contemporary management of oropharyngeal cancer: anatomy and physiology of the oropharynx},
	type = {Journal Article},
	volume = {46},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1067/j.cpsurg.2008.10.003}}

@book{RN390,
	author = {El-Naggar, A.K. and Chan, J.K.C. and Grandis, J.R. and Takata, T. and Slootweg, P.J.},
	isbn = {9789283224389},
	publisher = {International Agency for Research on Cancer},
	title = {WHO Classification of Head and Neck Tumours},
	type = {Book},
	url = {https://books.google.de/books?id=EDo5MQAACAAJ},
	year = {2017},
	bdsk-url-1 = {https://books.google.de/books?id=EDo5MQAACAAJ}}

@book{RN392,
	author = {El-Naggar, A.K. and Chan, J.K.C. and Grandis, J.R. and Takata, T. and Slootweg, P.J.},
	isbn = {9789283224389},
	publisher = {International Agency for Research on Cancer},
	title = {WHO Classification of Head and Neck Tumours},
	type = {Book},
	url = {https://books.google.de/books?id=EDo5MQAACAAJ},
	year = {2017},
	bdsk-url-1 = {https://books.google.de/books?id=EDo5MQAACAAJ}}

@book{RN111,
	author = {El-Naggar, A.K. and Chan, J.K.C. and Grandis, J.R. and Takata, T. and Slootweg, P.J.},
	isbn = {9789283224389},
	publisher = {International Agency for Research on Cancer},
	title = {WHO Classification of Head and Neck Tumours},
	type = {Book},
	url = {https://books.google.de/books?id=EDo5MQAACAAJ},
	year = {2017},
	bdsk-url-1 = {https://books.google.de/books?id=EDo5MQAACAAJ}}

@misc{RN171,
	author = {Erdmann, Friederike and Spix, Claudia and Katalinic, Alexander and Christ, Monika and Folkerts, Juliane and Hansmann, Jutta and Kranzh{\"o}fer, Kristine and Kunz, Beatrice and Manegold, Katrin and Penzkofer, Andrea and Treml, Kornelia and Vollmer, Grit and Weg-Remers, Susanne and Barnes, Benjamin and Buttmann-Schweiger, Nina and Dahm, Stefan and Fiebig, Julia and Franke, Manuela and Gurung-Sch{\"o}nfeld, Ina and Haberland, J{\"o}rg and Imhoff, Maren and Kraywinkel, Klaus and Starker, Anne and von Berenberg-Gossler, Petra and Wienecke, Antje},
	doi = {http://dx.doi.org/10.25646/8353},
	keywords = {610 Medizin und Gesundheit},
	number = {13},
	pages = {172},
	publisher = {Robert Koch-Institut},
	title = {Krebs in Deutschland f{\"u}r 2017/2018},
	type = {Generic},
	url = {http://jsessionid=3B7086E853920E599859A5232A68DFA9.pdf?sequence=1|},
	year = {2021},
	bdsk-url-1 = {http://jsessionid=3B7086E853920E599859A5232A68DFA9.pdf?sequence=1%7C},
	bdsk-url-2 = {http://dx.doi.org/10.25646/8353}}

@article{RN306,
	abstract = {In an increasing number of cancers, tumor populations called cancer stem cells (CSCs), or tumor-initiating cells, have been defined in functional assays of self-renewal and tumor initiation. Moreover, recent work in several different cancers has suggested the CSC population as a source of chemotherapy and radiation-therapy resistance within tumors. Work in glioblastoma and breast cancers supports the idea that CSCs may possess innate resistance mechanisms against radiation- and chemotherapy-induced cancer cell death, allowing them to survive and initiate tumor recurrence. Several resistance mechanisms have been proposed, including amplified checkpoint activation and DNA damage repair as well as increased Wnt/beta-catenin and Notch signaling. Novel targeted therapies against the DNA damage checkpoint or stem-cell maintenance pathways may sensitize CSCs to radiation or other therapies. Another important category of cancer therapies are antiangiogenic and vascular targeting agents, which are also becoming integrated in the treatment paradigm of an increasing number of cancers. Recent results from our laboratory and others support a role for CSCs in the angiogenic drive as well as the mechanism of antiangiogenic agents. Identifying and targeting the molecular mechanisms responsible for CSC therapeutic resistance may improve the efficacy of current cancer therapies.},
	author = {Eyler, C. E. and Rich, J. N.},
	doi = {10.1200/jco.2007.15.1829},
	issn = {0732-183X (Print) 0732-183x},
	journal = {J Clin Oncol},
	keywords = {Angiogenesis Inhibitors/pharmacology/*therapeutic use Animals Antineoplastic Agents/pharmacology/*therapeutic use Cell Differentiation/drug effects/radiation effects Cell Proliferation/drug effects/radiation effects Cell Survival/drug effects/radiation effects *Drug Resistance, Neoplasm Humans Neoplasms/blood supply/pathology/*therapy *Neoplastic Stem Cells/drug effects/pathology/radiation effects Neovascularization, Pathologic/pathology/*therapy Radiotherapy Treatment Failure},
	note = {1527-7755 Eyler, Christine E Rich, Jeremy N NS054276/NS/NINDS NIH HHS/United States R01 CA116659/CA/NCI NIH HHS/United States R01 NS054276-03/NS/NINDS NIH HHS/United States CA116659/CA/NCI NIH HHS/United States K02 NS047409-04/NS/NINDS NIH HHS/United States R01 CA116659-03/CA/NCI NIH HHS/United States T32 GM007171/GM/NIGMS NIH HHS/United States 2T32GM007171/GM/NIGMS NIH HHS/United States R01 NS054276/NS/NINDS NIH HHS/United States K02 NS047409/NS/NINDS NIH HHS/United States NS047409/NS/NINDS NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review 2008/06/10 J Clin Oncol. 2008 Jun 10;26(17):2839-45. doi: 10.1200/JCO.2007.15.1829.},
	number = {17},
	pages = {2839-45},
	title = {Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739000/pdf/nihms-123201.pdf},
	volume = {26},
	year = {2008},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739000/pdf/nihms-123201.pdf},
	bdsk-url-2 = {https://doi.org/10.1200/jco.2007.15.1829}}

@article{RN100,
	abstract = {BACKGROUND: The improved prognosis for patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) relative to HPV-negative HNSCC observed in retrospective analyses remains to be confirmed in a prospective clinical trial. METHODS: We prospectively evaluated the association of tumor HPV status with therapeutic response and survival among 96 patients with stage III or IV HNSCC of the oropharynx or larynx who participated in an Eastern Cooperative Oncology Group (ECOG) phase II trial and who received two cycles of induction chemotherapy with intravenous paclitaxel and carboplatin followed by concomitant weekly intravenous paclitaxel and standard fractionation radiation therapy. The presence or absence of HPV oncogenic types in tumors was determined by multiplex polymerase chain reaction (PCR) and in situ hybridization. Two-year overall and progression-free survival for HPV-positive and HPV-negative patients were estimated by Kaplan-Meier analysis. The relative hazard of mortality and progression for HPV-positive vs HPV-negative patients after adjustment for age, ECOG performance status, stage, and other covariables was estimated by use of a multivariable Cox proportional hazards model. All statistical tests were two-sided. RESULTS: Genomic DNA of oncogenic HPV types 16, 33, or 35 was located within tumor cell nuclei of 40% (95% confidence interval [CI] = 30% to 50%) of patients with HNSCC of the oropharynx or larynx by in situ hybridization and PCR. Compared with patients with HPV-negative tumors, patients with HPV-positive tumors had higher response rates after induction chemotherapy (82% vs 55%, difference = 27%, 95% CI = 9.3% to 44.7%, P = .01) and after chemoradiation treatment (84% vs 57%, difference = 27%, 95% CI = 9.7% to 44.3%, P = .007). After a median follow-up of 39.1 months, patients with HPV-positive tumors had improved overall survival (2-year overall survival = 95% [95% CI = 87% to 100%] vs 62% [95% CI = 49% to 74%], difference = 33%, 95% CI = 18.6% to 47.4%, P = .005, log-rank test) and, after adjustment for age, tumor stage, and ECOG performance status, lower risks of progression (hazard ratio [HR] = 0.27, 95% CI = 0.10 to 0.75), and death from any cause (HR = 0.36, 95% CI = 0.15 to 0.85) than those with HPV-negative tumors. CONCLUSION: For patients with HNSCC of the oropharynx, tumor HPV status is strongly associated with therapeutic response and survival.},
	author = {Fakhry, C. and Westra, W. H. and Li, S. and Cmelak, A. and Ridge, J. A. and Pinto, H. and Forastiere, A. and Gillison, M. L.},
	doi = {10.1093/jnci/djn011},
	issn = {0027-8874},
	journal = {J Natl Cancer Inst},
	keywords = {Adult Aged Aged, 80 and over Analysis of Variance Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carboplatin/administration & dosage Carcinoma, Squamous Cell/*mortality/pathology/therapy/*virology Chemotherapy, Adjuvant Dose Fractionation, Radiation Drug Administration Schedule Female Head and Neck Neoplasms/*mortality/pathology/therapy/*virology Human papillomavirus 16/genetics/*isolation & purification Humans In Situ Hybridization Infusions, Intravenous Kaplan-Meier Estimate Male Middle Aged Neoplasm Staging Odds Ratio Paclitaxel/administration & dosage Papillomavirus Infections/*complications Polymerase Chain Reaction Prospective Studies Radiotherapy, Adjuvant Remission Induction Treatment Outcome},
	note = {1460-2105 Fakhry, Carole Westra, William H Li, Sigui Cmelak, Anthony Ridge, John A Pinto, Harlan Forastiere, Arlene Gillison, Maura L Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't United States 2008/02/14 J Natl Cancer Inst. 2008 Feb 20;100(4):261-9. doi: 10.1093/jnci/djn011. Epub 2008 Feb 12.},
	number = {4},
	pages = {261-9},
	title = {Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial},
	type = {Journal Article},
	volume = {100},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1093/jnci/djn011}}

@article{RN54,
	abstract = {BACKGROUND: The improved prognosis for patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) relative to HPV-negative HNSCC observed in retrospective analyses remains to be confirmed in a prospective clinical trial. METHODS: We prospectively evaluated the association of tumor HPV status with therapeutic response and survival among 96 patients with stage III or IV HNSCC of the oropharynx or larynx who participated in an Eastern Cooperative Oncology Group (ECOG) phase II trial and who received two cycles of induction chemotherapy with intravenous paclitaxel and carboplatin followed by concomitant weekly intravenous paclitaxel and standard fractionation radiation therapy. The presence or absence of HPV oncogenic types in tumors was determined by multiplex polymerase chain reaction (PCR) and in situ hybridization. Two-year overall and progression-free survival for HPV-positive and HPV-negative patients were estimated by Kaplan-Meier analysis. The relative hazard of mortality and progression for HPV-positive vs HPV-negative patients after adjustment for age, ECOG performance status, stage, and other covariables was estimated by use of a multivariable Cox proportional hazards model. All statistical tests were two-sided. RESULTS: Genomic DNA of oncogenic HPV types 16, 33, or 35 was located within tumor cell nuclei of 40% (95% confidence interval [CI] = 30% to 50%) of patients with HNSCC of the oropharynx or larynx by in situ hybridization and PCR. Compared with patients with HPV-negative tumors, patients with HPV-positive tumors had higher response rates after induction chemotherapy (82% vs 55%, difference = 27%, 95% CI = 9.3% to 44.7%, P = .01) and after chemoradiation treatment (84% vs 57%, difference = 27%, 95% CI = 9.7% to 44.3%, P = .007). After a median follow-up of 39.1 months, patients with HPV-positive tumors had improved overall survival (2-year overall survival = 95% [95% CI = 87% to 100%] vs 62% [95% CI = 49% to 74%], difference = 33%, 95% CI = 18.6% to 47.4%, P = .005, log-rank test) and, after adjustment for age, tumor stage, and ECOG performance status, lower risks of progression (hazard ratio [HR] = 0.27, 95% CI = 0.10 to 0.75), and death from any cause (HR = 0.36, 95% CI = 0.15 to 0.85) than those with HPV-negative tumors. CONCLUSION: For patients with HNSCC of the oropharynx, tumor HPV status is strongly associated with therapeutic response and survival.},
	author = {Fakhry, C. and Westra, W. H. and Li, S. and Cmelak, A. and Ridge, J. A. and Pinto, H. and Forastiere, A. and Gillison, M. L.},
	doi = {10.1093/jnci/djn011},
	issn = {1460-2105 (Electronic) 0027-8874 (Linking)},
	journal = {J Natl Cancer Inst},
	keywords = {Adult Aged Aged, 80 and over Analysis of Variance Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carboplatin/administration & dosage Carcinoma, Squamous Cell/*mortality/pathology/therapy/*virology Chemotherapy, Adjuvant Dose Fractionation, Radiation Drug Administration Schedule Female Head and Neck Neoplasms/*mortality/pathology/therapy/*virology Human papillomavirus 16/genetics/*isolation & purification Humans In Situ Hybridization Infusions, Intravenous Kaplan-Meier Estimate Male Middle Aged Neoplasm Staging Odds Ratio Paclitaxel/administration & dosage Papillomavirus Infections/*complications Polymerase Chain Reaction Prospective Studies Radiotherapy, Adjuvant Remission Induction Treatment Outcome},
	note = {Fakhry, Carole Westra, William H Li, Sigui Cmelak, Anthony Ridge, John A Pinto, Harlan Forastiere, Arlene Gillison, Maura L eng Clinical Trial, Phase II Research Support, Non-U.S. Gov't 2008/02/14 J Natl Cancer Inst. 2008 Feb 20;100(4):261-9. doi: 10.1093/jnci/djn011. Epub 2008 Feb 12.},
	number = {4},
	pages = {261-9},
	title = {Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial},
	type = {Journal Article},
	url = {https://watermark.silverchair.com/djn011.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsIwggK-BgkqhkiG9w0BBwagggKvMIICqwIBADCCAqQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMBjK0Wh3Bc5IIoLFpAgEQgIICdU9GDoVjBou2eC11YgxCN1BqhX_hF50oxQMZc1AVq-Q71AEo6zpG8hAEsQ_LGICFYPrfvXTCf6f_Zf4viU9SOOTDQn5pZOOcrdHTVEMwyav-je85SilKhADd-CZwuJrIBZdWfex2IdjSMunvbnZTx6-zfqnUO6I_kd2hlTsoJ9Jz_Yaq0_sEZajjEq2VPkywLIN1_03iOZVC-KNVnB5fNBTra1cd8zNUGpYNg2yfX3sLaxBCbI-XyLPEPT23dDJcdYUZqFDdem9mEXW4Qkfv8PY5_D8zB4eac4eCgo4E4A3CvrjH0wqtmIzKu5khjdv14ChRSUP-6QrynJIRli1kMt2mK6d0q2rMJ9x-RKzTU7liwGfLwqBDiXJ3fqtQE0PtY6TFi5l86Rz9TEKj3WJ0wYDHNjemoyfat1EA3NEYQkP8YaMo4SolAV44xK8ahI2Fq43k1XPPobE9YEOQH7ZZKyj8REWdJHcOFOz3lrl9ZaImoIGlhiuOe5PSpDVC-g9QzYiJkvbv6Wj1wqPvI9gVZXhQRy16-LEqfq_hXiGuL1xTPZkTcUJUihQzfypPaLKEAztmTVfIMBWR9ZbdG9q9PU9fSggDzpSuONOh8j69FSaRW5mNDBx594aeIpisGqRkbkfMknBZ8zjaqmUhshfo-m4_SDKVr_8zUzKgL73r3jbx2QTQ1_uMB-Yygc9LDRRW26dZGvwLwttdA5wfWq74MjnypU2tBQjuRyEvl7SarAtZqr9xCCjGZWqQz2QgiAZ7wUsCR0OFOAEydmrP9GtVijG3rOlg2TLWgSp6nJ3glh5i9sDaoOieeiVPEOn1evmM5dOwRnJn},
	volume = {100},
	year = {2008},
	bdsk-url-1 = {https://watermark.silverchair.com/djn011.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsIwggK-BgkqhkiG9w0BBwagggKvMIICqwIBADCCAqQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMBjK0Wh3Bc5IIoLFpAgEQgIICdU9GDoVjBou2eC11YgxCN1BqhX_hF50oxQMZc1AVq-Q71AEo6zpG8hAEsQ_LGICFYPrfvXTCf6f_Zf4viU9SOOTDQn5pZOOcrdHTVEMwyav-je85SilKhADd-CZwuJrIBZdWfex2IdjSMunvbnZTx6-zfqnUO6I_kd2hlTsoJ9Jz_Yaq0_sEZajjEq2VPkywLIN1_03iOZVC-KNVnB5fNBTra1cd8zNUGpYNg2yfX3sLaxBCbI-XyLPEPT23dDJcdYUZqFDdem9mEXW4Qkfv8PY5_D8zB4eac4eCgo4E4A3CvrjH0wqtmIzKu5khjdv14ChRSUP-6QrynJIRli1kMt2mK6d0q2rMJ9x-RKzTU7liwGfLwqBDiXJ3fqtQE0PtY6TFi5l86Rz9TEKj3WJ0wYDHNjemoyfat1EA3NEYQkP8YaMo4SolAV44xK8ahI2Fq43k1XPPobE9YEOQH7ZZKyj8REWdJHcOFOz3lrl9ZaImoIGlhiuOe5PSpDVC-g9QzYiJkvbv6Wj1wqPvI9gVZXhQRy16-LEqfq_hXiGuL1xTPZkTcUJUihQzfypPaLKEAztmTVfIMBWR9ZbdG9q9PU9fSggDzpSuONOh8j69FSaRW5mNDBx594aeIpisGqRkbkfMknBZ8zjaqmUhshfo-m4_SDKVr_8zUzKgL73r3jbx2QTQ1_uMB-Yygc9LDRRW26dZGvwLwttdA5wfWq74MjnypU2tBQjuRyEvl7SarAtZqr9xCCjGZWqQz2QgiAZ7wUsCR0OFOAEydmrP9GtVijG3rOlg2TLWgSp6nJ3glh5i9sDaoOieeiVPEOn1evmM5dOwRnJn},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/djn011}}

@article{RN441,
	author = {Fakhry, C. and Westra, W. H. and Li, S. and Cmelak, A. and Ridge, J. A. and Pinto, H. and Forastiere, A. and Gillison, M. L.},
	doi = {10.1093/jnci/djn011},
	issn = {1460-2105 (Electronic) 0027-8874 (Linking)},
	journal = {J Natl Cancer Inst},
	keywords = {Adult Aged Aged, 80 and over Analysis of Variance Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carboplatin/administration & dosage Carcinoma, Squamous Cell/*mortality/pathology/therapy/*virology Chemotherapy, Adjuvant Dose Fractionation, Radiation Drug Administration Schedule Female Head and Neck Neoplasms/*mortality/pathology/therapy/*virology Human papillomavirus 16/genetics/*isolation & purification Humans In Situ Hybridization Infusions, Intravenous Kaplan-Meier Estimate Male Middle Aged Neoplasm Staging Odds Ratio Paclitaxel/administration & dosage Papillomavirus Infections/*complications Polymerase Chain Reaction Prospective Studies Radiotherapy, Adjuvant Remission Induction Treatment Outcome},
	number = {4},
	pages = {261-9},
	title = {Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18270337},
	volume = {100},
	year = {2008},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/18270337},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/djn011}}

@article{RN366,
	author = {Fakhry, C. and Westra, W. H. and Li, S. and Cmelak, A. and Ridge, J. A. and Pinto, H. and Forastiere, A. and Gillison, M. L.},
	doi = {10.1093/jnci/djn011},
	issn = {0027-8874},
	journal = {J Natl Cancer Inst},
	keywords = {Adult Aged Aged, 80 and over Analysis of Variance Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carboplatin/administration & dosage Carcinoma, Squamous Cell/*mortality/pathology/therapy/*virology Chemotherapy, Adjuvant Dose Fractionation, Radiation Drug Administration Schedule Female Head and Neck Neoplasms/*mortality/pathology/therapy/*virology Human papillomavirus 16/genetics/*isolation & purification Humans In Situ Hybridization Infusions, Intravenous Kaplan-Meier Estimate Male Middle Aged Neoplasm Staging Odds Ratio Paclitaxel/administration & dosage Papillomavirus Infections/*complications Polymerase Chain Reaction Prospective Studies Radiotherapy, Adjuvant Remission Induction Treatment Outcome},
	number = {4},
	pages = {261-9},
	title = {Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial},
	type = {Journal Article},
	volume = {100},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1093/jnci/djn011}}

@article{RN62,
	abstract = {Estimates of the worldwide incidence and mortality from 36 cancers and for all cancers combined for the year 2018 are now available in the GLOBOCAN 2018 database, compiled and disseminated by the International Agency for Research on Cancer (IARC). This paper reviews the sources and methods used in compiling the cancer statistics in 185 countries. The validity of the national estimates depends upon the representativeness of the source information, and to take into account possible sources of bias, uncertainty intervals are now provided for the estimated sex- and site-specific all-ages number of new cancer cases and cancer deaths. We briefly describe the key results globally and by world region. There were an estimated 18.1 million (95% UI: 17.5-18.7 million) new cases of cancer (17 million excluding non-melanoma skin cancer) and 9.6 million (95% UI: 9.3-9.8 million) deaths from cancer (9.5 million excluding non-melanoma skin cancer) worldwide in 2018.},
	author = {Ferlay, J. and Colombet, M. and Soerjomataram, I. and Mathers, C. and Parkin, D. M. and Pineros, M. and Znaor, A. and Bray, F.},
	doi = {10.1002/ijc.31937},
	issn = {1097-0215 (Electronic) 0020-7136 (Linking)},
	journal = {Int J Cancer},
	keywords = {Adolescent Adult Aged Aged, 80 and over *Cause of Death Child Child, Preschool Databases, Factual/statistics & numerical data Female *Global Burden of Disease Humans Incidence Infant Infant, Newborn Male Middle Aged Neoplasms/*epidemiology Risk Factors Sex Distribution Survival Rate Young Adult *globocan *cancer *global estimates *incidence *mortality},
	note = {Ferlay, J Colombet, M Soerjomataram, I Mathers, C Parkin, D M Pineros, M Znaor, A Bray, F eng 001/World Health Organization/International 2018/10/24 Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.},
	number = {8},
	pages = {1941-1953},
	title = {Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.31937?download=true},
	volume = {144},
	year = {2019},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.31937?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.31937}}

@article{RN334,
	author = {Ferlay, J. and Colombet, M. and Soerjomataram, I. and Parkin, D. M. and Pineros, M. and Znaor, A. and Bray, F.},
	doi = {10.1002/ijc.33588},
	issn = {1097-0215 (Electronic) 0020-7136 (Linking)},
	journal = {Int J Cancer},
	keywords = {Globocan cancer global estimates incidence mortality},
	title = {Cancer statistics for the year 2020: An overview},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/33818764},
	year = {2021},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/33818764},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.33588}}

@article{RN63,
	abstract = {Our study briefly reviews the data sources and methods used in compiling the International Agency for Research on Cancer (IARC) GLOBOCAN cancer statistics for the year 2020 and summarises the main results. National estimates were calculated based on the best available data on cancer incidence from population-based cancer registries (PBCR) and mortality from the World Health Organization mortality database. Cancer incidence and mortality rates for 2020 by sex and age groups were estimated for 38 cancer sites and 185 countries or territories worldwide. There were an estimated 19.3 million (95% uncertainty interval [UI]: 19.0-19.6 million) new cases of cancer (18.1 million excluding non-melanoma skin cancer) and almost 10.0 million (95% UI: 9.7-10.2 million) deaths from cancer (9.9 million excluding non-melanoma skin cancer) worldwide in 2020. The most commonly diagnosed cancers worldwide were female breast cancer (2.26 million cases), lung (2.21) and prostate cancers (1.41); the most common causes of cancer death were lung (1.79 million deaths), liver (830000) and stomach cancers (769000).},
	author = {Ferlay, J. and Colombet, M. and Soerjomataram, I. and Parkin, D. M. and Pineros, M. and Znaor, A. and Bray, F.},
	doi = {10.1002/ijc.33588},
	issn = {1097-0215 (Electronic) 0020-7136 (Linking)},
	journal = {Int J Cancer},
	keywords = {Globocan cancer global estimates incidence mortality},
	note = {Ferlay, Jacques Colombet, Murielle Soerjomataram, Isabelle Parkin, Donald M Pineros, Marion Znaor, Ariana Bray, Freddie eng 2021/04/06 Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588.},
	title = {Cancer statistics for the year 2020: An overview},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.33588?download=true},
	year = {2021},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.33588?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.33588}}

@article{RN64,
	abstract = {Our study briefly reviews the data sources and methods used in compiling the International Agency for Research on Cancer (IARC) GLOBOCAN cancer statistics for the year 2020 and summarises the main results. National estimates were calculated based on the best available data on cancer incidence from population-based cancer registries (PBCR) and mortality from the World Health Organization mortality database. Cancer incidence and mortality rates for 2020 by sex and age groups were estimated for 38 cancer sites and 185 countries or territories worldwide. There were an estimated 19.3 million (95% uncertainty interval [UI]: 19.0-19.6 million) new cases of cancer (18.1 million excluding non-melanoma skin cancer) and almost 10.0 million (95% UI: 9.7-10.2 million) deaths from cancer (9.9 million excluding non-melanoma skin cancer) worldwide in 2020. The most commonly diagnosed cancers worldwide were female breast cancer (2.26 million cases), lung (2.21) and prostate cancers (1.41); the most common causes of cancer death were lung (1.79 million deaths), liver (830000) and stomach cancers (769000).},
	author = {Ferlay, J. and Colombet, M. and Soerjomataram, I. and Parkin, D. M. and Pineros, M. and Znaor, A. and Bray, F.},
	doi = {10.1002/ijc.33588},
	issn = {1097-0215 (Electronic) 0020-7136 (Linking)},
	journal = {Int J Cancer},
	keywords = {Globocan cancer global estimates incidence mortality},
	note = {Ferlay, Jacques Colombet, Murielle Soerjomataram, Isabelle Parkin, Donald M Pineros, Marion Znaor, Ariana Bray, Freddie eng 2021/04/06 Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588.},
	title = {Cancer statistics for the year 2020: An overview},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/33818764},
	year = {2021},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/33818764},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.33588}}

@article{RN194,
	abstract = {The incidence of distant metastases in head and neck squamous cell carcinoma (SCC) is relatively small in comparison to other malignancies. Distant metastases adversely impact survival and may significantly affect treatment planning. The incidence of distant metastases is influenced by location of the primary tumor, initial T and N stage of the neoplasm, and the presence or absence of regional control above the clavicle. Patients with advanced nodal disease have a high incidence of distant metastases, particularly in the presence of jugular vein invasion or extensive soft tissue disease in the neck. Primary tumors of advanced T stages in the hypopharynx, oropharynx and oral cavity are associated with the highest incidence of distant metastases. Pulmonary metastases are the most frequent in SCC, accounting for 66% of distant metastases. It may be difficult to distinguish pulmonary metastasis from a new primary tumor, particularly if solitary. Other metastatic sites include bone (22%), liver (10%), skin, mediastinum and bone marrow. An important question remains as to how intensely pre- and postoperative screening for distant metastases should be performed. Preoperative chest X-ray is warranted in all cases. If the primary tumor and nodal status place the patient at high risk for pulmonary metastasis, then preoperative computed tomography scan of the chest should be done. Screening for distant metastases at other sites is usually not indicated in SCC of the upper aerodigestive tract. Postoperatively, annual X-rays of the chest are usually sufficient, but in high-risk situations a chest X-ray performed every 3-6 months may be beneficial. Certain histologic types of primary tumor have greater or lesser propensity to metastasize distantly, and have a different natural history. Adenoid cystic carcinoma metastasizes frequently, even in the absence of extensive local or regional disease. Basaloid squamous cell carcinoma and neuroendocrine carcinomas also metastasize widely. Extensive evaluation for distant metastases is justified for these tumors. Knowledge of the natural history of various neoplasms and the factors that contribute to distant metastases as well as good judgement are essential for cost-effective treatment planning and decision-making with regard to pre- and postoperative evaluation for distant metastases in cancer of the head and neck.},
	author = {Ferlito, A. and Shaha, A. R. and Silver, C. E. and Rinaldo, A. and Mondin, V.},
	doi = {10.1159/000055740},
	issn = {0301-1569 (Print) 0301-1569},
	journal = {ORL J Otorhinolaryngol Relat Spec},
	keywords = {Bone Neoplasms/epidemiology/*secondary Carcinoma/epidemiology/*secondary Head and Neck Neoplasms/*pathology Humans Incidence Liver Neoplasms/epidemiology/*secondary Lung Neoplasms/epidemiology/*secondary Neoplasm Staging Neoplasms, Second Primary/epidemiology Neoplastic Cells, Circulating},
	note = {Ferlito, A Shaha, A R Silver, C E Rinaldo, A Mondin, V Journal Article Review Switzerland 2001/06/16 ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):202-7. doi: 10.1159/000055740.},
	number = {4},
	pages = {202-7},
	title = {Incidence and sites of distant metastases from head and neck cancer},
	type = {Journal Article},
	url = {https://www.karger.com/Article/Pdf/55740},
	volume = {63},
	year = {2001},
	bdsk-url-1 = {https://www.karger.com/Article/Pdf/55740},
	bdsk-url-2 = {https://doi.org/10.1159/000055740}}

@article{RN264,
	abstract = {5507 Background: Despite resection and postoperative irradiation high-risk (3 or more involved lymph nodes, extra-capsular disease and/or microscopically involved mucosal margins of resection) squamous cell carcinomas (SCCAs) of the head and neck frequently recur in the tumor bed. Postoperatively radiochemotherapy (RCT) with cis-Platin (CDDP)/5-FU versus radiotherapy (RT) alone was compared in a randomized trial. Methods: Between 5/97 and 12/04, 440 patients who had high-risk SCCAs of the head and neck were enrolled in this prospectively randomized phase III trial. Following resection and neck dissection, 214 patients were randomly assigned to RT (66 Gy/33 Fx/6.6 weeks) and 226 patients to identical RT plus CDDP (20 mg/m2 on day 1--5, 29--33) and 5-FU (600 mg/m2 on day 1--5, 29--33). Results: The 5 year local-regional control rate is 72.2 $\pm$ 3.7% following RT and 88.6 $\pm$ 2.4% for the RCT group (p = 0.00259; 5-year progression free survival 50.1 $\pm$ 4.0% and 62.4 $\pm$ 4.4% (p = 0.024) and 5-year overall survival 48.6 $\pm$ 4.4% vs. 58.1 $\pm$ 4.6% (p = 0.11). There was no difference in the 5 year incidence of distant metastases (19.3 $\pm$ 3.6% vs 25.5 $\pm$ 4.6%; p = 0.45). The incidence of grade 3+ acute toxicity was higher during RCT: mucositis 12.6% vs. 20.8% (p = 0.04), leucopenia 0% vs. 4.4% (p = 0.007). Conclusions: Acute toxicity is increased to an acceptable level by RCT. Postoperative RCT compared to RT improves locoregional control and progression free survival; thus survival as a trend is improved by 10% after 5 years. Supported by Deutsche Krebshilfe 70--2140. No significant financial relationships to disclose.},
	author = {Fietkau, R. and Lautenschl{\"a}ger, C. and Sauer, R. and Dunst, J. and Becker, A. and Baumann, M. and Wendt, T. and Gr{\"u}schow, K. and Hess, C. and Budach, V. and Iro, H.},
	doi = {10.1200/jco.2006.24.18_suppl.5507},
	journal = {Journal of Clinical Oncology},
	number = {18_suppl},
	pages = {5507-5507},
	title = {Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96--3},
	type = {Journal Article},
	url = {https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.5507},
	volume = {24},
	year = {2006},
	bdsk-url-1 = {https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.5507},
	bdsk-url-2 = {https://doi.org/10.1200/jco.2006.24.18_suppl.5507}}

@article{RN265,
	abstract = {5507 Background: Despite resection and postoperative irradiation high-risk (3 or more involved lymph nodes, extra-capsular disease and/or microscopically involved mucosal margins of resection) squamous cell carcinomas (SCCAs) of the head and neck frequently recur in the tumor bed. Postoperatively radiochemotherapy (RCT) with cis-Platin (CDDP)/5-FU versus radiotherapy (RT) alone was compared in a randomized trial. Methods: Between 5/97 and 12/04, 440 patients who had high-risk SCCAs of the head and neck were enrolled in this prospectively randomized phase III trial. Following resection and neck dissection, 214 patients were randomly assigned to RT (66 Gy/33 Fx/6.6 weeks) and 226 patients to identical RT plus CDDP (20 mg/m2 on day 1--5, 29--33) and 5-FU (600 mg/m2 on day 1--5, 29--33). Results: The 5 year local-regional control rate is 72.2 $\pm$ 3.7% following RT and 88.6 $\pm$ 2.4% for the RCT group (p = 0.00259; 5-year progression free survival 50.1 $\pm$ 4.0% and 62.4 $\pm$ 4.4% (p = 0.024) and 5-year overall survival 48.6 $\pm$ 4.4% vs. 58.1 $\pm$ 4.6% (p = 0.11). There was no difference in the 5 year incidence of distant metastases (19.3 $\pm$ 3.6% vs 25.5 $\pm$ 4.6%; p = 0.45). The incidence of grade 3+ acute toxicity was higher during RCT: mucositis 12.6% vs. 20.8% (p = 0.04), leucopenia 0% vs. 4.4% (p = 0.007). Conclusions: Acute toxicity is increased to an acceptable level by RCT. Postoperative RCT compared to RT improves locoregional control and progression free survival; thus survival as a trend is improved by 10% after 5 years. Supported by Deutsche Krebshilfe 70--2140. No significant financial relationships to disclose.},
	author = {Fietkau, R. and Lautenschl{\"a}ger, C. and Sauer, R. and Dunst, J. and Becker, A. and Baumann, M. and Wendt, T. and Gr{\"u}schow, K. and Hess, C. and Budach, V. and Iro, H.},
	doi = {10.1200/jco.2006.24.18_suppl.5507},
	journal = {Journal of Clinical Oncology},
	number = {18_suppl},
	pages = {5507-5507},
	title = {Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96--3},
	type = {Journal Article},
	url = {https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.5507},
	volume = {24},
	year = {2006},
	bdsk-url-1 = {https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.5507},
	bdsk-url-2 = {https://doi.org/10.1200/jco.2006.24.18_suppl.5507}}

@article{RN242,
	author = {Fletcher, G. H. and Evers, W. T.},
	doi = {10.1148/95.1.185},
	issn = {0033-8419 (Print) 0033-8419},
	journal = {Radiology},
	keywords = {Adult Aged Cobalt Isotopes Facial Neoplasms/*radiotherapy Female Head and Neck Neoplasms/*radiotherapy Humans Laryngeal Neoplasms/radiotherapy Lip Neoplasms/radiotherapy Male Middle Aged Mouth Neoplasms/radiotherapy Neoplasm Recurrence, Local Palliative Care Paranasal Sinus Neoplasms/radiotherapy Parotid Neoplasms/radiotherapy Pharyngeal Neoplasms/radiotherapy Radioisotope Teletherapy Radiotherapy Dosage Radiotherapy, High-Energy Skin Neoplasms/radiotherapy},
	note = {Fletcher, G H Evers, W T Journal Article United States 1970/04/01 Radiology. 1970 Apr;95(1):185-8. doi: 10.1148/95.1.185.},
	number = {1},
	pages = {185-8},
	title = {Radiotherapeutic management of surgical recurrences and postoperative residuals in tumors of the head and neck},
	type = {Journal Article},
	url = {https://pubs.rsna.org/doi/10.1148/95.1.185?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed},
	volume = {95},
	year = {1970},
	bdsk-url-1 = {https://pubs.rsna.org/doi/10.1148/95.1.185?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed},
	bdsk-url-2 = {https://doi.org/10.1148/95.1.185}}

@article{RN207,
	author = {Forastiere, A. and Koch, W. and Trotti, A. and Sidransky, D.},
	doi = {10.1056/NEJMra001375},
	issn = {0028-4793 (Print) 0028-4793},
	journal = {N Engl J Med},
	keywords = {Antineoplastic Agents/adverse effects/*therapeutic use Chemotherapy, Adjuvant Combined Modality Therapy/adverse effects Disease Progression Head and Neck Neoplasms/diagnosis/etiology/*therapy Humans Neoplasm Metastasis/drug therapy Neoplasm Recurrence, Local/drug therapy/prevention & control Neoplasm Staging Neoplasms, Multiple Primary},
	note = {Forastiere, A Koch, W Trotti, A Sidransky, D R01 DE12588/DE/NIDCR NIH HHS/United States Journal Article Research Support, U.S. Gov't, P.H.S. Review United States 2002/01/05 N Engl J Med. 2001 Dec 27;345(26):1890-900. doi: 10.1056/NEJMra001375.},
	number = {26},
	pages = {1890-900},
	title = {Head and neck cancer},
	type = {Journal Article},
	url = {https://www.nejm.org/doi/pdf/10.1056/NEJMra001375?articleTools=true},
	volume = {345},
	year = {2001},
	bdsk-url-1 = {https://www.nejm.org/doi/pdf/10.1056/NEJMra001375?articleTools=true},
	bdsk-url-2 = {https://doi.org/10.1056/NEJMra001375}}

@article{RN198,
	abstract = {PURPOSE: High histologic grade is usually associated with a greater propensity to distant metastases (DM). Its role to predict DM in head and neck cancer is not yet defined. The aim of this study is to evaluate the role of histologic grade as an independent predictor of DM and to determine a subgroup of patients who may benefit from systemic chemotherapy. PATIENTS AND METHODS: This is a retrospective study of 1,266 consecutive patients treated by definitive or postoperative radiotherapy between 1989 and 1997. All patients received at least 50 Gy. All stages and subsites of head/neck were included. DM rates were evaluated by the Kaplan-Meier method with a subsequent Cox analysis. RESULTS: There is a strong correlation of grade with N stage (P <.000001). The metastases-free survival (MFS) was 98%, 90%, and 72% for grades 1, 2, and 3, respectively (P <.000001). In patients with N0 stage, MFS is always greater than 90%, whatever the grade. In the 222 N1 patients, MFS was more than 90% in grade 1 and 2 but dropped to 75% for grade 3 (P =.001). In patients with N2 and N3, MFS was 91%, 79%, and 59% for grades 1, 2, and 3, respectively (P =.008). The same conclusion is applicable when only patients with neck control are analyzed. In a Cox model, grade was an independent predictor of DM (P =.000001) as well as T stage (P =.003), N stage (P =.000001), and neck failure (P =.0003). Higher grade was also an independent predictor of survival (P =.02). CONCLUSION: Patients with histologic grade 1 and grade 2 (except N3) are at low risk of DM. Patients with grade 2 and N3 or patients with grade 3 and N1 to N3 have a higher risk of distant metastases and should be considered for systemic treatment.},
	author = {Fortin, A. and Couture, C. and Doucet, R. and Albert, M. and Allard, J. and Tetu, B.},
	doi = {10.1200/jco.2001.19.21.4107},
	issn = {0732-183X (Print) 0732-183x},
	journal = {J Clin Oncol},
	keywords = {Aged Combined Modality Therapy Female Glutathione S-Transferase pi Glutathione Transferase/metabolism Head and Neck Neoplasms/metabolism/*pathology/radiotherapy/surgery Humans Isoenzymes/metabolism Ki-67 Antigen/metabolism Male Middle Aged Neoplasm Metastasis Neoplasm Staging Proportional Hazards Models Retrospective Studies Survival Analysis Tumor Suppressor Protein p53/metabolism},
	note = {Fortin, A Couture, C Doucet, R Albert, M Allard, J Tetu, B Journal Article United States 2001/11/02 J Clin Oncol. 2001 Nov 1;19(21):4107-16. doi: 10.1200/JCO.2001.19.21.4107.},
	number = {21},
	pages = {4107-16},
	title = {Does histologic grade have a role in the management of head and neck cancers?},
	type = {Journal Article},
	volume = {19},
	year = {2001},
	bdsk-url-1 = {https://doi.org/10.1200/jco.2001.19.21.4107}}

@article{RN278,
	abstract = {PURPOSE: High histologic grade is usually associated with a greater propensity to distant metastases (DM). Its role to predict DM in head and neck cancer is not yet defined. The aim of this study is to evaluate the role of histologic grade as an independent predictor of DM and to determine a subgroup of patients who may benefit from systemic chemotherapy. PATIENTS AND METHODS: This is a retrospective study of 1,266 consecutive patients treated by definitive or postoperative radiotherapy between 1989 and 1997. All patients received at least 50 Gy. All stages and subsites of head/neck were included. DM rates were evaluated by the Kaplan-Meier method with a subsequent Cox analysis. RESULTS: There is a strong correlation of grade with N stage (P <.000001). The metastases-free survival (MFS) was 98%, 90%, and 72% for grades 1, 2, and 3, respectively (P <.000001). In patients with N0 stage, MFS is always greater than 90%, whatever the grade. In the 222 N1 patients, MFS was more than 90% in grade 1 and 2 but dropped to 75% for grade 3 (P =.001). In patients with N2 and N3, MFS was 91%, 79%, and 59% for grades 1, 2, and 3, respectively (P =.008). The same conclusion is applicable when only patients with neck control are analyzed. In a Cox model, grade was an independent predictor of DM (P =.000001) as well as T stage (P =.003), N stage (P =.000001), and neck failure (P =.0003). Higher grade was also an independent predictor of survival (P =.02). CONCLUSION: Patients with histologic grade 1 and grade 2 (except N3) are at low risk of DM. Patients with grade 2 and N3 or patients with grade 3 and N1 to N3 have a higher risk of distant metastases and should be considered for systemic treatment.},
	author = {Fortin, A. and Couture, C. and Doucet, R. and Albert, M. and Allard, J. and Tetu, B.},
	doi = {10.1200/jco.2001.19.21.4107},
	issn = {0732-183X (Print) 0732-183x},
	journal = {J Clin Oncol},
	keywords = {Aged Combined Modality Therapy Female Glutathione S-Transferase pi Glutathione Transferase/metabolism Head and Neck Neoplasms/metabolism/*pathology/radiotherapy/surgery Humans Isoenzymes/metabolism Ki-67 Antigen/metabolism Male Middle Aged Neoplasm Metastasis Neoplasm Staging Proportional Hazards Models Retrospective Studies Survival Analysis Tumor Suppressor Protein p53/metabolism},
	note = {Fortin, A Couture, C Doucet, R Albert, M Allard, J Tetu, B Journal Article United States 2001/11/02 J Clin Oncol. 2001 Nov 1;19(21):4107-16. doi: 10.1200/JCO.2001.19.21.4107.},
	number = {21},
	pages = {4107-16},
	title = {Does histologic grade have a role in the management of head and neck cancers?},
	type = {Journal Article},
	volume = {19},
	year = {2001},
	bdsk-url-1 = {https://doi.org/10.1200/jco.2001.19.21.4107}}

@article{RN141,
	abstract = {A hospital-based case-control study of upper aerodigestive tract tumors was conducted between June 1986 and June 1989 in Northern Italy. One hundred fifty-seven male cases of oral cavity cancer, 134 of pharyngeal cancer, 162 of laryngeal cancer, and 288 of esophageal cancer, and 1272 male inpatients with acute conditions unrelated to tobacco and alcohol were interviewed. Odds ratios for current smokers of cigarettes were 11.1 for oral cavity, 12.9 for pharynx, 4.6 for larynx, and 3.8 for esophagus. For all 4 sites, the risk increased with increasing number of cigarettes and duration of smoking habits and, with the exception of esophageal cancer, decreased with increasing age at the start of and years since quitting smoking. Smokers of pipes and cigars showed a more elevated risk of cancer of the oral cavity and esophagus than did cigarette smokers. Significantly increased risks emerged also in heavy drinkers (odds ratio greater than 60 versus greater than or equal to 19 drinks/week = 3.4, 3.6, 2.1, and 6.0 for oral cavity, pharynx, larynx, and esophagus, respectively), deriving predominantly from wine consumption.},
	author = {Franceschi, S. and Talamini, R. and Barra, S. and Bar{\'o}n, A. E. and Negri, E. and Bidoli, E. and Serraino, D. and La Vecchia, C.},
	issn = {0008-5472 (Print) 0008-5472},
	journal = {Cancer Res},
	keywords = {Adult Aged Alcohol Drinking/*adverse effects Esophageal Neoplasms/*etiology Humans Italy/epidemiology Laryngeal Neoplasms/*etiology Male Middle Aged Mouth Neoplasms/*etiology Pharyngeal Neoplasms/*etiology Risk Smoking/*adverse effects},
	note = {Franceschi, S Talamini, R Barra, S Bar{\'o}n, A E Negri, E Bidoli, E Serraino, D La Vecchia, C Journal Article Research Support, Non-U.S. Gov't United States 1990/10/15 Cancer Res. 1990 Oct 15;50(20):6502-7.},
	number = {20},
	pages = {6502-7},
	title = {Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy},
	type = {Journal Article},
	url = {https://cancerres.aacrjournals.org/content/canres/50/20/6502.full.pdf},
	volume = {50},
	year = {1990},
	bdsk-url-1 = {https://cancerres.aacrjournals.org/content/canres/50/20/6502.full.pdf}}

@article{RN232,
	abstract = {PURPOSE: The optimal fractionation schedule for radiotherapy of head and neck cancer has been controversial. The objective of this randomized trial was to test the efficacy of hyperfractionation and two types of accelerated fractionation individually against standard fractionation. METHODS AND MATERIALS: Patients with locally advanced head and neck cancer were randomly assigned to receive radiotherapy delivered with: 1) standard fractionation at 2 Gy/fraction/day, 5 days/week, to 70 Gy/35 fractions/7 weeks; 2) hyperfractionation at 1. 2 Gy/fraction, twice daily, 5 days/week to 81.6 Gy/68 fractions/7 weeks; 3) accelerated fractionation with split at 1.6 Gy/fraction, twice daily, 5 days/week, to 67.2 Gy/42 fractions/6 weeks including a 2-week rest after 38.4 Gy; or 4) accelerated fractionation with concomitant boost at 1.8 Gy/fraction/day, 5 days/week and 1.5 Gy/fraction/day to a boost field as a second daily treatment for the last 12 treatment days to 72 Gy/42 fractions/6 weeks. Of the 1113 patients entered, 1073 patients were analyzable for outcome. The median follow-up was 23 months for all analyzable patients and 41.2 months for patients alive. RESULTS: Patients treated with hyperfractionation and accelerated fractionation with concomitant boost had significantly better local-regional control (p = 0.045 and p = 0.050 respectively) than those treated with standard fractionation. There was also a trend toward improved disease-free survival (p = 0.067 and p = 0.054 respectively) although the difference in overall survival was not significant. Patients treated with accelerated fractionation with split had similar outcome to those treated with standard fractionation. All three altered fractionation groups had significantly greater acute side effects compared to standard fractionation. However, there was no significant increase of late effects. CONCLUSIONS: Hyperfractionation and accelerated fractionation with concomitant boost are more efficacious than standard fractionation for locally advanced head and neck cancer. Acute but not late effects are also increased.},
	author = {Fu, K. K. and Pajak, T. F. and Trotti, A. and Jones, C. U. and Spencer, S. A. and Phillips, T. L. and Garden, A. S. and Ridge, J. A. and Cooper, J. S. and Ang, K. K.},
	doi = {10.1016/s0360-3016(00)00663-5},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/*radiotherapy Disease-Free Survival *Dose Fractionation, Radiation Female Head and Neck Neoplasms/*radiotherapy Humans Male Middle Aged Radiation Injuries/etiology Time Factors Treatment Failure},
	note = {Fu, K K Pajak, T F Trotti, A Jones, C U Spencer, S A Phillips, T L Garden, A S Ridge, J A Cooper, J S Ang, K K CA21661/CA/NCI NIH HHS/United States CA32115/CA/NCI NIH HHS/United States CA37422/CA/NCI NIH HHS/United States etc. Clinical Trial Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S. United States 2000/08/05 Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16. doi: 10.1016/s0360-3016(00)00663-5.},
	number = {1},
	pages = {7-16},
	title = {A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003},
	type = {Journal Article},
	url = {https://www.redjournal.org/article/S0360-3016(00)00663-5/fulltext},
	volume = {48},
	year = {2000},
	bdsk-url-1 = {https://www.redjournal.org/article/S0360-3016(00)00663-5/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s0360-3016(00)00663-5}}

@article{RN323,
	abstract = {PURPOSE: To assess clinical outcomes and patterns of loco-regional failure (LRF) in relation to clinical target volumes (CTV) in patients with locally advanced hypopharyngeal and laryngeal squamous cell carcinoma (HL-SCC) treated with definitive intensity modulated radiotherapy (IMRT) and concurrent systemic therapy. METHODS: Data from HL-SCC patients treated from 2007 to 2010 were retrospectively evaluated. Primary endpoint was loco-regional control (LRC). Secondary endpoints included local (LC) and regional (RC) controls, distant metastasis free survival (DMFS), laryngectomy free survival (LFS), overall survival (OS), and acute and late toxicities. Time-to-event endpoints were estimated using Kaplan-Meier method, and univariate and multivariate analyses were performed using Cox proportional hazards models. Recurrent gross tumor volume (RTV) on post-treatment diagnostic imaging was analyzed in relation to corresponding CTV (in-volume, > 95% of RTV inside CTV; marginal, 20-95% inside CTV; out-volume, < 20% inside CTV). RESULTS: Fifty patients (stage III: 14, IVa: 33, IVb: 3) completed treatment and were included in the analysis (median follow-up of 4.2 years). Three-year LRC, DMFS and overall survival (OS) were 77%, 96% and 63%, respectively. Grade 2 and 3 acute toxicity were 38% and 62%, respectively; grade 2 and 3 late toxicity were 23% and 15%, respectively. We identified 10 patients with LRF (8 local, 1 regional, 1 local + regional). Six out of 10 RTVs were fully included in both elective and high-dose CTVs, and 4 RTVs were marginal to the high-dose CTVs. CONCLUSION: The treatment of locally advanced HL-SCC with definitive IMRT and concurrent systemic therapy provides good LRC rates with acceptable toxicity profile. Nevertheless, the analysis of LRFs in relation to CTVs showed in-volume relapses to be the major mode of recurrence indicating that novel strategies to overcome radioresistance are required.},
	author = {Geretschlager, A. and Bojaxhiu, B. and Dal Pra, A. and Leiser, D. and Schmucking, M. and Arnold, A. and Ghadjar, P. and Aebersold, D. M.},
	doi = {10.1186/s13014-014-0323-2},
	issn = {1748-717X (Electronic) 1748-717X (Linking)},
	journal = {Radiat Oncol},
	keywords = {Aged Aged, 80 and over Carcinoma, Squamous Cell/mortality/*radiotherapy/secondary Female Follow-Up Studies Humans Hypopharyngeal Neoplasms/mortality/pathology/*radiotherapy Laryngeal Neoplasms/mortality/pathology/*radiotherapy Lung Neoplasms/mortality/*radiotherapy/secondary Lymphatic Metastasis Male Middle Aged Neoplasm Recurrence, Local/mortality/pathology/*radiotherapy Neoplasm Staging Prognosis Radiotherapy Dosage Radiotherapy, Intensity-Modulated/*methods Retrospective Studies Survival Rate},
	note = {Geretschlager, Andreas Bojaxhiu, Beat Dal Pra, Alan Leiser, Dominic Schmucking, Michael Arnold, Andreas Ghadjar, Pirus Aebersold, Daniel M eng England 2015/01/18 Radiat Oncol. 2015 Jan 17;10:20. doi: 10.1186/s13014-014-0323-2.},
	pages = {20},
	title = {Definitive intensity modulated radiotherapy in locally advanced hypopharygeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308085/pdf/13014_2014_Article_323.pdf},
	volume = {10},
	year = {2015},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308085/pdf/13014_2014_Article_323.pdf},
	bdsk-url-2 = {https://doi.org/10.1186/s13014-014-0323-2}}

@article{RN132,
	abstract = {Oral cancer incidence rates rose dramatically during the twentieth century in the United States and Europe, especially among individuals under the age of 60 years. Although influenced by age, sex, and country of origin, incidence trends were most strongly affected by elevated risk among individuals born after approximately 1915. This cohort effect was indicative of strong behavioral influences on oral cancer risk. In this article, associations between oral cancer risk and established behavioral risk factors including alcohol and tobacco use are reviewed. Additionally, possible associations between oral cancer risk and oral hygiene, diet, nutritional status, and sexual behavior as well as the influence of genetic factors on oral cancer risk are considered. Special emphasis is placed on evaluating possible risk differences in individuals above and below the age of 45 and in users and nonusers of alcohol and tobacco.},
	author = {Gillison, M. L.},
	doi = {10.1002/hed.20573},
	issn = {1043-3074 (Print) 1043-3074},
	journal = {Head Neck},
	keywords = {Alcohol Drinking/adverse effects Body Mass Index Cohort Studies Feeding Behavior Genetic Predisposition to Disease Humans Incidence Maryland/epidemiology Mouth Neoplasms/*epidemiology/*etiology/virology Nutritional Status Oral Hygiene Oropharyngeal Neoplasms/*epidemiology/*etiology/virology Papillomavirus Infections/complications Risk Factors Sexual Behavior Smoking/adverse effects Tumor Virus Infections/complications},
	note = {Gillison, Maura L DE016631-02/DE/NIDCR NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Review United States 2007/01/19 Head Neck. 2007 Aug;29(8):779-92. doi: 10.1002/hed.20573.},
	number = {8},
	pages = {779-92},
	title = {Current topics in the epidemiology of oral cavity and oropharyngeal cancers},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hed.20573?download=true},
	volume = {29},
	year = {2007},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hed.20573?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/hed.20573}}

@article{RN359,
	author = {Gillison, M. L. and D'Souza, G. and Westra, W. and Sugar, E. and Xiao, W. and Begum, S. and Viscidi, R.},
	doi = {10.1093/jnci/djn025},
	issn = {0027-8874},
	journal = {J Natl Cancer Inst},
	keywords = {Adult Aged Alcohol Drinking/adverse effects Alphapapillomavirus/isolation & purification Antibodies, Viral/blood Capsid Proteins/blood Carcinoma, Squamous Cell/etiology/*virology Case-Control Studies DNA, Viral/isolation & purification Female Head and Neck Neoplasms/etiology/*virology Human papillomavirus 16/genetics/immunology/*isolation & purification Humans Male Marijuana Smoking/adverse effects Middle Aged Odds Ratio Oral Hygiene/adverse effects Risk Assessment Risk Factors Sexual Behavior Smoking/adverse effects Viral Load},
	number = {6},
	pages = {407-20},
	title = {Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers},
	type = {Journal Article},
	volume = {100},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1093/jnci/djn025}}

@article{RN95,
	abstract = {BACKGROUND: High-risk types of human papillomavirus (HPV), including HPV-16, cause a subgroup of head and neck squamous cell carcinomas (HNSCCs). We examined whether the risk factors for HPV-16-positive HNSCCs are similar to those for HPV-16-negative HNSCCs in a hospital-based case-control study. METHODS: Case subjects (n = 240) diagnosed with HNSCC at the Johns Hopkins Hospital from 2000 through 2006 were stratified by tumor HPV-16 status as determined by in situ hybridization. Two control subjects (n = 322) without cancer were individually matched by age and sex to each HPV-16-positive and HPV-16-negative case subject. Data on risk behaviors were obtained by use of audio computer-assisted self-interview technology. Multivariable conditional logistic regression models were used to estimate the odds ratios (ORs) for HPV-16-positive HNSCC and HPV-16-negative HNSCC associated with risk factors. All statistical tests were two-sided. RESULTS: HPV-16 was detected in 92 of 240 case subjects. HPV-16-positive HNSCC was independently associated with several measures of sexual behavior and exposure to marijuana but not with cumulative measures of tobacco smoking, alcohol drinking, or poor oral hygiene. Associations increased in strength with increasing number of oral sex partners (P(trend) = .01) and with increasing intensity (joints per month, P(trend) = .007), duration (in years, P(trend) = .01), and cumulative joint-years (P(trend) = .003) of marijuana use. By contrast, HPV-16-negative HNSCC was associated with measures of tobacco smoking, alcohol drinking, and poor oral hygiene but not with any measure of sexual behavior or marijuana use. Associations increased in strength with increasing intensity (cigarettes per day), duration, and cumulative pack-years of tobacco smoking (for all, P(trend) < .001), increasing years of heavy alcohol drinking (> or = 15 years of 14 drinks per week; P(trend) = .03), and increasing number of lost teeth (P(trend) = .001). Compared with subjects who neither smoked tobacco nor drank alcohol, those with heavy use of tobacco (> or = 20 pack-years) and alcohol had an increased risk of HPV-16-negative HNSCC (OR = 4.8, 95% confidence interval [CI] = 1.8 to 12) but not of HPV-16-positive HNSCC (OR = 0.67, 95% CI = 0.29 to 1.9). CONCLUSIONS: HPV-16-positive HNSCCs and HPV-16-negative HNSCCs have different risk factor profiles, indicating that they should be considered to be distinct cancers.},
	author = {Gillison, M. L. and D'Souza, G. and Westra, W. and Sugar, E. and Xiao, W. and Begum, S. and Viscidi, R.},
	doi = {10.1093/jnci/djn025},
	issn = {0027-8874},
	journal = {J Natl Cancer Inst},
	keywords = {Adult Aged Alcohol Drinking/adverse effects Alphapapillomavirus/isolation & purification Antibodies, Viral/blood Capsid Proteins/blood Carcinoma, Squamous Cell/etiology/*virology Case-Control Studies DNA, Viral/isolation & purification Female Head and Neck Neoplasms/etiology/*virology Human papillomavirus 16/genetics/immunology/*isolation & purification Humans Male Marijuana Smoking/adverse effects Middle Aged Odds Ratio Oral Hygiene/adverse effects Risk Assessment Risk Factors Sexual Behavior Smoking/adverse effects Viral Load},
	note = {1460-2105 Gillison, Maura L D'Souza, Gypsyamber Westra, William Sugar, Elizabeth Xiao, Weihong Begum, Shahnaz Viscidi, Raphael DE016631-01/DE/NIDCR NIH HHS/United States Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States 2008/03/13 J Natl Cancer Inst. 2008 Mar 19;100(6):407-20. doi: 10.1093/jnci/djn025. Epub 2008 Mar 11.},
	number = {6},
	pages = {407-20},
	title = {Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers},
	type = {Journal Article},
	url = {https://watermark.silverchair.com/djn025.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsIwggK-BgkqhkiG9w0BBwagggKvMIICqwIBADCCAqQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM-fUrtBe8YpNWiNkQAgEQgIICdZBpDFGrioX2ElFgNm0ELv7qb-b3mJXU16eN9DgzHPzmND-KZ3vCT3_IqMC_xF3bEmwPZEkojHHqTn2lf7KrJuyEM6QapDcBKmU4eIuAH9r6sl6WiTeRWwR4JEDjlIBxRhAZkyw352QSzlSy44RVodb9ydXJSQuaopJV-lofgfHV3EEnW-9loSYLBFGfs1tPqxBNB5irYP4lBmHk3LqhRUYRDkVpvNG7_JZUE6_GiGTUbLDc4SCeB0y9_UiJpf5SbSZhJWMPJm88SZpqc9wXSqUTlv46S7Vb8QYsmGsWB6EZN0EmmWRafYfNS1TgwEUZBfod9-d9GLn2lYoWIaDpHbDhwO5VupdV55vHwSJUT2fT-2LnVvYzfjTzyPsujtX5Q50-kZ9FKHwC6yfaVgV-DaLHLZKytng9mL2XY9so2rxWaz_vwVSE9W9OmJ4Xc5-nHQOY9L1woRnGKJQmjLCnDeDmqkLQH-JcCVQsvw59u2A2xbdXseLMHtQsR3_0edtVghGCToNxkC5VS_5bVPjyjwW8_7OAH5L6N12rknIOH2WR07MpHqCEqE715VnFw12OeoHiW0f7NOVkiZkc2Xyyw7RuaQjqvckzZhOQt5JMg1qk9Eb-khBKNBYzvjwJwew-c84PH6RwZ4rsVBhDgFWgjCYd4D8ABawEqKD3fjmCQF6av-ukjQMrP45YXEU9PbGq8WLOuzFPB6Z7qPjBLjkR-UHZG-zbPXcNBnfJ4D2jW5PHZXpQHuZyv-NKuZuz6Uw8XLlDpI8yXEQ0idGpw5lRV6ynsppdw05sMcyUbA2MBp5LCBiBFREHw2qIlh-_p2x4QSm5fdHo},
	volume = {100},
	year = {2008},
	bdsk-url-1 = {https://watermark.silverchair.com/djn025.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsIwggK-BgkqhkiG9w0BBwagggKvMIICqwIBADCCAqQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM-fUrtBe8YpNWiNkQAgEQgIICdZBpDFGrioX2ElFgNm0ELv7qb-b3mJXU16eN9DgzHPzmND-KZ3vCT3_IqMC_xF3bEmwPZEkojHHqTn2lf7KrJuyEM6QapDcBKmU4eIuAH9r6sl6WiTeRWwR4JEDjlIBxRhAZkyw352QSzlSy44RVodb9ydXJSQuaopJV-lofgfHV3EEnW-9loSYLBFGfs1tPqxBNB5irYP4lBmHk3LqhRUYRDkVpvNG7_JZUE6_GiGTUbLDc4SCeB0y9_UiJpf5SbSZhJWMPJm88SZpqc9wXSqUTlv46S7Vb8QYsmGsWB6EZN0EmmWRafYfNS1TgwEUZBfod9-d9GLn2lYoWIaDpHbDhwO5VupdV55vHwSJUT2fT-2LnVvYzfjTzyPsujtX5Q50-kZ9FKHwC6yfaVgV-DaLHLZKytng9mL2XY9so2rxWaz_vwVSE9W9OmJ4Xc5-nHQOY9L1woRnGKJQmjLCnDeDmqkLQH-JcCVQsvw59u2A2xbdXseLMHtQsR3_0edtVghGCToNxkC5VS_5bVPjyjwW8_7OAH5L6N12rknIOH2WR07MpHqCEqE715VnFw12OeoHiW0f7NOVkiZkc2Xyyw7RuaQjqvckzZhOQt5JMg1qk9Eb-khBKNBYzvjwJwew-c84PH6RwZ4rsVBhDgFWgjCYd4D8ABawEqKD3fjmCQF6av-ukjQMrP45YXEU9PbGq8WLOuzFPB6Z7qPjBLjkR-UHZG-zbPXcNBnfJ4D2jW5PHZXpQHuZyv-NKuZuz6Uw8XLlDpI8yXEQ0idGpw5lRV6ynsppdw05sMcyUbA2MBp5LCBiBFREHw2qIlh-_p2x4QSm5fdHo},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/djn025}}

@article{RN86,
	abstract = {BACKGROUND: High-risk human papillomaviruses (HPVs) are etiologic agents for anogenital tract cancers and have been detected in head and neck squamous cell carcinomas (HNSCCs). We investigated, retrospectively, an etiologic role for HPVs in a large series of patients with HNSCC. METHODS: Tumor tissues from 253 patients with newly diagnosed or recurrent HNSCC were tested for the presence of HPV genome by use of polymerase chain reaction (PCR)-based assays, Southern blot hybridization, and in situ hybridization. The viral E6 coding region was sequenced to confirm the presence of tumor-specific viral isolates. Exons 5-9 of the TP53 gene were sequenced from 166 specimens. The hazard of death from HNSCC in patients with and without HPV-positive tumors was determined by proportional hazards regression analysis. RESULTS: HPV was detected in 62 (25%) of 253 cases (95% confidence interval [CI] = 19%-30%). High-risk, tumorigenic type HPV16 was identified in 90% of the HPV-positive tumors. HPV16 was localized specifically by in situ hybridization within the nuclei of cancer cells in preinvasive, invasive, and lymph node disease. Southern blot hybridization patterns were consistent with viral integration. Poor tumor grade (odds ratio [OR] = 2.4; 95% CI = 1.2- 4.9) and oropharyngeal site (OR = 6.2; 95% CI = 3.1-12.1) independently increased the probability of HPV presence. As compared with HPV-negative oropharyngeal cancers, HPV-positive oropharyngeal cancers were less likely to occur among moderate to heavy drinkers (OR = 0.17; 95% CI = 0.05-0.61) and smokers (OR = 0.16; 95% CI = 0.02-1.4), had a characteristic basaloid morphology (OR = 18.7; 95% CI = 2.1-167), were less likely to have TP53 mutations (OR = 0.06; 95% CI = 0.01-0. 36), and had improved disease-specific survival (hazard ratio [HR] = 0.26; 95% CI = 0.07-0.98). After adjustment for the presence of lymph node disease (HR = 2.3; 95% CI = 1.4- 3.8), heavy alcohol consumption (HR = 2.6; 95% CI = 1.4-4.7), and age greater than 60 years old (HR = 1.4; 95% CI = 0.8-2.3), all patients with HPV-positive tumors had a 59% reduction in risk of death from cancer when compared with HPV-negative HNSCC patients (HR = 0.41; 95% CI = 0.20-0.88). CONCLUSIONS: These data extend recent molecular and epidemiologic studies and strongly suggest that HPV-positive oropharyngeal cancers comprise a distinct molecular, clinical, and pathologic disease entity that is likely causally associated with HPV infection and that has a markedly improved prognosis.},
	author = {Gillison, M. L. and Koch, W. M. and Capone, R. B. and Spafford, M. and Westra, W. H. and Wu, L. and Zahurak, M. L. and Daniel, R. W. and Viglione, M. and Symer, D. E. and Shah, K. V. and Sidransky, D.},
	doi = {10.1093/jnci/92.9.709},
	issn = {0027-8874 (Print) 0027-8874 (Linking)},
	journal = {J Natl Cancer Inst},
	keywords = {Adolescent Adult Aged Aged, 80 and over Blotting, Southern Carcinoma, Squamous Cell/etiology/mortality/*virology DNA, Viral/chemistry/genetics Female Genetic Variation HeLa Cells Head and Neck Neoplasms/etiology/mortality/*virology Humans In Situ Hybridization K562 Cells Male Middle Aged Multivariate Analysis Oncogene Proteins, Viral/genetics Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*complications Proportional Hazards Models *Repressor Proteins Sequence Analysis, DNA Survival Analysis Tumor Cells, Cultured Tumor Virus Infections/*complications},
	note = {Gillison, M L Koch, W M Capone, R B Spafford, M Westra, W H Wu, L Zahurak, M L Daniel, R W Viglione, M Symer, D E Shah, K V Sidransky, D eng CA01709/CA/NCI NIH HHS/ DE012588-03/DE/NIDCR NIH HHS/ U19AI38533/AI/NIAID NIH HHS/ Research Support, U.S. Gov't, P.H.S. 2000/05/04 J Natl Cancer Inst. 2000 May 3;92(9):709-20. doi: 10.1093/jnci/92.9.709.},
	number = {9},
	pages = {709-20},
	title = {Evidence for a causal association between human papillomavirus and a subset of head and neck cancers},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10793107},
	volume = {92},
	year = {2000},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/10793107},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/92.9.709}}

@article{RN52,
	abstract = {BACKGROUND: High-risk human papillomaviruses (HPVs) are etiologic agents for anogenital tract cancers and have been detected in head and neck squamous cell carcinomas (HNSCCs). We investigated, retrospectively, an etiologic role for HPVs in a large series of patients with HNSCC. METHODS: Tumor tissues from 253 patients with newly diagnosed or recurrent HNSCC were tested for the presence of HPV genome by use of polymerase chain reaction (PCR)-based assays, Southern blot hybridization, and in situ hybridization. The viral E6 coding region was sequenced to confirm the presence of tumor-specific viral isolates. Exons 5-9 of the TP53 gene were sequenced from 166 specimens. The hazard of death from HNSCC in patients with and without HPV-positive tumors was determined by proportional hazards regression analysis. RESULTS: HPV was detected in 62 (25%) of 253 cases (95% confidence interval [CI] = 19%-30%). High-risk, tumorigenic type HPV16 was identified in 90% of the HPV-positive tumors. HPV16 was localized specifically by in situ hybridization within the nuclei of cancer cells in preinvasive, invasive, and lymph node disease. Southern blot hybridization patterns were consistent with viral integration. Poor tumor grade (odds ratio [OR] = 2.4; 95% CI = 1.2- 4.9) and oropharyngeal site (OR = 6.2; 95% CI = 3.1-12.1) independently increased the probability of HPV presence. As compared with HPV-negative oropharyngeal cancers, HPV-positive oropharyngeal cancers were less likely to occur among moderate to heavy drinkers (OR = 0.17; 95% CI = 0.05-0.61) and smokers (OR = 0.16; 95% CI = 0.02-1.4), had a characteristic basaloid morphology (OR = 18.7; 95% CI = 2.1-167), were less likely to have TP53 mutations (OR = 0.06; 95% CI = 0.01-0. 36), and had improved disease-specific survival (hazard ratio [HR] = 0.26; 95% CI = 0.07-0.98). After adjustment for the presence of lymph node disease (HR = 2.3; 95% CI = 1.4- 3.8), heavy alcohol consumption (HR = 2.6; 95% CI = 1.4-4.7), and age greater than 60 years old (HR = 1.4; 95% CI = 0.8-2.3), all patients with HPV-positive tumors had a 59% reduction in risk of death from cancer when compared with HPV-negative HNSCC patients (HR = 0.41; 95% CI = 0.20-0.88). CONCLUSIONS: These data extend recent molecular and epidemiologic studies and strongly suggest that HPV-positive oropharyngeal cancers comprise a distinct molecular, clinical, and pathologic disease entity that is likely causally associated with HPV infection and that has a markedly improved prognosis.},
	author = {Gillison, M. L. and Koch, W. M. and Capone, R. B. and Spafford, M. and Westra, W. H. and Wu, L. and Zahurak, M. L. and Daniel, R. W. and Viglione, M. and Symer, D. E. and Shah, K. V. and Sidransky, D.},
	doi = {10.1093/jnci/92.9.709},
	issn = {0027-8874 (Print) 0027-8874 (Linking)},
	journal = {J Natl Cancer Inst},
	keywords = {Adolescent Adult Aged Aged, 80 and over Blotting, Southern Carcinoma, Squamous Cell/etiology/mortality/*virology DNA, Viral/chemistry/genetics Female Genetic Variation HeLa Cells Head and Neck Neoplasms/etiology/mortality/*virology Humans In Situ Hybridization K562 Cells Male Middle Aged Multivariate Analysis Oncogene Proteins, Viral/genetics Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*complications Proportional Hazards Models *Repressor Proteins Sequence Analysis, DNA Survival Analysis Tumor Cells, Cultured Tumor Virus Infections/*complications},
	note = {Gillison, M L Koch, W M Capone, R B Spafford, M Westra, W H Wu, L Zahurak, M L Daniel, R W Viglione, M Symer, D E Shah, K V Sidransky, D eng CA01709/CA/NCI NIH HHS/ DE012588-03/DE/NIDCR NIH HHS/ U19AI38533/AI/NIAID NIH HHS/ Research Support, U.S. Gov't, P.H.S. 2000/05/04 J Natl Cancer Inst. 2000 May 3;92(9):709-20. doi: 10.1093/jnci/92.9.709.},
	number = {9},
	pages = {709-20},
	title = {Evidence for a causal association between human papillomavirus and a subset of head and neck cancers},
	type = {Journal Article},
	url = {https://watermark.silverchair.com/709.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsAwggK8BgkqhkiG9w0BBwagggKtMIICqQIBADCCAqIGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM1eQbqosAkpNfGNktAgEQgIICc6LSu6JQ9_p5kE1fEvc-pSENvc8UTziF0OcIfg7aR0ONQVGUvAAvQg3VvLTy1r1ru3dJG5Ju8-CjDUfMXhzjUfnIs-SRhILujAH5XpG3k79-kFkbzpm6bAs8TlybJL6t_4EAuC71jkRUizwWmDki9lajNBNhOOMeSz0dGgM7SNY0VAyklo1AnXJctedOvJH2Mc4Ckpt_crYv96xSZuJ7RqwqnCVPAs1fQM-2zUrS9E5Stm6L_UECif4jCkrOlMeZJlZ6mm8wYZ3VFjn_hj2rXOYnDWTu7y1Qw4h-Tdu_9m8uaVoHNVXB2isbU3e8EIRN0cUk6JhfkuenDLW1NDqh2cZqWXzvTBuxhyiuxMtcFpOU8k1zZrMJnnUFDzdwuKpAov7rf3H0hMzqBn2qo-hOERyKSKCElD6mfq4X3CzP6u3Xqj4pXkuN3q4vDgRN8C5hWQwHlZAI1fp5unV9VxMD2WieH3dzAiiEejdIzIsaoEyFRaGISwbPXIpOsUvK6E_1JmO8gPz42kput1KKLLrui6v2LcAK_RQBXEmtXUCAKdujMo2k7J1i1SUmTA_KRkR1W_pqwCoavRRb3kdM77yv_vOu_hLX8ZrJO4eqtdCY-TDQIRIlAwinRkbc0YCdLI8vl8VCnl-xiw5LGrML_cqNGqW272AtL_Tnb7Z3mCnXBy68AFWWqUgfW_X_mVcKVv8W8mOBEvK-5sONPfBwiKJ9V8RtMfKbrigv5i_bu4C9gtsKlBh25tGZWLPb9Q4l9NzpuVcpbLQR_ahFJUWFXXZdMaPg3dZfKqbvEC3upUU9CxW4a2Tvr09QJuTHOHdje980IhkZfw},
	volume = {92},
	year = {2000},
	bdsk-url-1 = {https://watermark.silverchair.com/709.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsAwggK8BgkqhkiG9w0BBwagggKtMIICqQIBADCCAqIGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM1eQbqosAkpNfGNktAgEQgIICc6LSu6JQ9_p5kE1fEvc-pSENvc8UTziF0OcIfg7aR0ONQVGUvAAvQg3VvLTy1r1ru3dJG5Ju8-CjDUfMXhzjUfnIs-SRhILujAH5XpG3k79-kFkbzpm6bAs8TlybJL6t_4EAuC71jkRUizwWmDki9lajNBNhOOMeSz0dGgM7SNY0VAyklo1AnXJctedOvJH2Mc4Ckpt_crYv96xSZuJ7RqwqnCVPAs1fQM-2zUrS9E5Stm6L_UECif4jCkrOlMeZJlZ6mm8wYZ3VFjn_hj2rXOYnDWTu7y1Qw4h-Tdu_9m8uaVoHNVXB2isbU3e8EIRN0cUk6JhfkuenDLW1NDqh2cZqWXzvTBuxhyiuxMtcFpOU8k1zZrMJnnUFDzdwuKpAov7rf3H0hMzqBn2qo-hOERyKSKCElD6mfq4X3CzP6u3Xqj4pXkuN3q4vDgRN8C5hWQwHlZAI1fp5unV9VxMD2WieH3dzAiiEejdIzIsaoEyFRaGISwbPXIpOsUvK6E_1JmO8gPz42kput1KKLLrui6v2LcAK_RQBXEmtXUCAKdujMo2k7J1i1SUmTA_KRkR1W_pqwCoavRRb3kdM77yv_vOu_hLX8ZrJO4eqtdCY-TDQIRIlAwinRkbc0YCdLI8vl8VCnl-xiw5LGrML_cqNGqW272AtL_Tnb7Z3mCnXBy68AFWWqUgfW_X_mVcKVv8W8mOBEvK-5sONPfBwiKJ9V8RtMfKbrigv5i_bu4C9gtsKlBh25tGZWLPb9Q4l9NzpuVcpbLQR_ahFJUWFXXZdMaPg3dZfKqbvEC3upUU9CxW4a2Tvr09QJuTHOHdje980IhkZfw},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/92.9.709}}

@article{RN344,
	author = {Gillison, M. L. and Koch, W. M. and Capone, R. B. and Spafford, M. and Westra, W. H. and Wu, L. and Zahurak, M. L. and Daniel, R. W. and Viglione, M. and Symer, D. E. and Shah, K. V. and Sidransky, D.},
	doi = {10.1093/jnci/92.9.709},
	issn = {0027-8874 (Print) 0027-8874 (Linking)},
	journal = {J Natl Cancer Inst},
	keywords = {Adolescent Adult Aged Aged, 80 and over Blotting, Southern Carcinoma, Squamous Cell/etiology/mortality/*virology DNA, Viral/chemistry/genetics Female Genetic Variation HeLa Cells Head and Neck Neoplasms/etiology/mortality/*virology Humans In Situ Hybridization K562 Cells Male Middle Aged Multivariate Analysis Oncogene Proteins, Viral/genetics Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*complications Proportional Hazards Models *Repressor Proteins Sequence Analysis, DNA Survival Analysis Tumor Cells, Cultured Tumor Virus Infections/*complications},
	number = {9},
	pages = {709-20},
	title = {Evidence for a causal association between human papillomavirus and a subset of head and neck cancers},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10793107},
	volume = {92},
	year = {2000},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/10793107},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/92.9.709}}

@article{RN349,
	author = {Gillison, M. L. and Koch, W. M. and Capone, R. B. and Spafford, M. and Westra, W. H. and Wu, L. and Zahurak, M. L. and Daniel, R. W. and Viglione, M. and Symer, D. E. and Shah, K. V. and Sidransky, D.},
	doi = {10.1093/jnci/92.9.709},
	issn = {0027-8874 (Print) 0027-8874 (Linking)},
	journal = {J Natl Cancer Inst},
	keywords = {Adolescent Adult Aged Aged, 80 and over Blotting, Southern Carcinoma, Squamous Cell/etiology/mortality/*virology DNA, Viral/chemistry/genetics Female Genetic Variation HeLa Cells Head and Neck Neoplasms/etiology/mortality/*virology Humans In Situ Hybridization K562 Cells Male Middle Aged Multivariate Analysis Oncogene Proteins, Viral/genetics Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*complications Proportional Hazards Models *Repressor Proteins Sequence Analysis, DNA Survival Analysis Tumor Cells, Cultured Tumor Virus Infections/*complications},
	number = {9},
	pages = {709-20},
	title = {Evidence for a causal association between human papillomavirus and a subset of head and neck cancers},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10793107},
	volume = {92},
	year = {2000},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/10793107},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/92.9.709}}

@article{RN439,
	author = {Gillison, M. L. and Koch, W. M. and Capone, R. B. and Spafford, M. and Westra, W. H. and Wu, L. and Zahurak, M. L. and Daniel, R. W. and Viglione, M. and Symer, D. E. and Shah, K. V. and Sidransky, D.},
	doi = {10.1093/jnci/92.9.709},
	issn = {0027-8874 (Print) 0027-8874 (Linking)},
	journal = {J Natl Cancer Inst},
	keywords = {Adolescent Adult Aged Aged, 80 and over Blotting, Southern Carcinoma, Squamous Cell/etiology/mortality/*virology DNA, Viral/chemistry/genetics Female Genetic Variation HeLa Cells Head and Neck Neoplasms/etiology/mortality/*virology Humans In Situ Hybridization K562 Cells Male Middle Aged Multivariate Analysis Oncogene Proteins, Viral/genetics Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*complications Proportional Hazards Models *Repressor Proteins Sequence Analysis, DNA Survival Analysis Tumor Cells, Cultured Tumor Virus Infections/*complications},
	number = {9},
	pages = {709-20},
	title = {Evidence for a causal association between human papillomavirus and a subset of head and neck cancers},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10793107},
	volume = {92},
	year = {2000},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/10793107},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/92.9.709}}

@article{RN364,
	author = {Gillison, M. L. and Koch, W. M. and Capone, R. B. and Spafford, M. and Westra, W. H. and Wu, L. and Zahurak, M. L. and Daniel, R. W. and Viglione, M. and Symer, D. E. and Shah, K. V. and Sidransky, D.},
	doi = {10.1093/jnci/92.9.709},
	issn = {0027-8874 (Print) 0027-8874 (Linking)},
	journal = {J Natl Cancer Inst},
	keywords = {Adolescent Adult Aged Aged, 80 and over Blotting, Southern Carcinoma, Squamous Cell/etiology/mortality/*virology DNA, Viral/chemistry/genetics Female Genetic Variation HeLa Cells Head and Neck Neoplasms/etiology/mortality/*virology Humans In Situ Hybridization K562 Cells Male Middle Aged Multivariate Analysis Oncogene Proteins, Viral/genetics Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*complications Proportional Hazards Models *Repressor Proteins Sequence Analysis, DNA Survival Analysis Tumor Cells, Cultured Tumor Virus Infections/*complications},
	number = {9},
	pages = {709-20},
	title = {Evidence for a causal association between human papillomavirus and a subset of head and neck cancers},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10793107},
	volume = {92},
	year = {2000},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/10793107},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/92.9.709}}

@article{RN448,
	author = {Giltnane, J. M. and Rimm, D. L.},
	doi = {10.1038/ncponc0046},
	issn = {1743-4254 (Print) 1743-4254 (Linking)},
	journal = {Nat Clin Pract Oncol},
	keywords = {Biomarkers, Tumor/*metabolism *Gene Expression Profiling Humans Neoplasms/metabolism/pathology *Tissue Array Analysis},
	number = {2},
	pages = {104-11},
	title = {Technology insight: Identification of biomarkers with tissue microarray technology},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16264828},
	volume = {1},
	year = {2004},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/16264828},
	bdsk-url-2 = {https://doi.org/10.1038/ncponc0046}}

@article{RN58,
	abstract = {High-throughput technologies have been developed in the hope of increasing the pace of biomedical research, and accelerating the rate of translation from bench to bedside. Using such technology in target discovery has resulted in the need for systematic validation of the targets in an equally rapid manner. For example, gene expression microarrays have highlighted many potential targets in cancer, and tissue microarrays have emerged as a powerful tool to validate these targets by measuring tumor-specific protein expression and linking it to clinical outcome. Automated quantitative analysis of the tissue microarray 'spots' is beginning to take the technology a step further, removing observer bias, and providing standards for quality control and the potential for high-throughput analysis. The validation required for translation of tissue biomarkers from the research lab to the clinical lab will probably rely heavily on the combination of tissue microarray technology with automated quantitative analysis.},
	author = {Giltnane, J. M. and Rimm, D. L.},
	doi = {10.1038/ncponc0046},
	issn = {1743-4254 (Print) 1743-4254 (Linking)},
	journal = {Nat Clin Pract Oncol},
	keywords = {Biomarkers, Tumor/*metabolism *Gene Expression Profiling Humans Neoplasms/metabolism/pathology *Tissue Array Analysis},
	note = {Giltnane, Jena M Rimm, David L eng GM07205/GM/NIGMS NIH HHS/ R21 CA 100825/CA/NCI NIH HHS/ R33 CA 106709/CA/NCI NIH HHS/ Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. Review England 2005/11/03 Nat Clin Pract Oncol. 2004 Dec;1(2):104-11. doi: 10.1038/ncponc0046.},
	number = {2},
	pages = {104-11},
	title = {Technology insight: Identification of biomarkers with tissue microarray technology},
	type = {Journal Article},
	url = {https://www.nature.com/articles/ncponc0046.pdf},
	volume = {1},
	year = {2004},
	bdsk-url-1 = {https://www.nature.com/articles/ncponc0046.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/ncponc0046}}

@article{RN428,
	author = {Ginestier, C. and Hur, M. H. and Charafe-Jauffret, E. and Monville, F. and Dutcher, J. and Brown, M. and Jacquemier, J. and Viens, P. and Kleer, C. G. and Liu, S. and Schott, A. and Hayes, D. and Birnbaum, D. and Wicha, M. S. and Dontu, G.},
	doi = {10.1016/j.stem.2007.08.014},
	issn = {1934-5909 (Print) 1875-9777 (Linking)},
	journal = {Cell Stem Cell},
	keywords = {Adult Stem Cells/*enzymology/immunology Aldehyde Dehydrogenase/*metabolism Aldehyde Dehydrogenase 1 Family Animals Biomarkers/analysis Breast Neoplasms/*enzymology/immunology/pathology/therapy CD24 Antigen/analysis Cell Differentiation Cell Lineage Cell Proliferation Cell Separation Cells, Cultured Female Flow Cytometry Humans Hyaluronan Receptors/analysis Immunohistochemistry Isoenzymes/*metabolism Mammary Glands, Human/*enzymology/immunology Mice Mice, Inbred NOD Mice, SCID Neoplastic Stem Cells/*enzymology/immunology/pathology Phenotype Retinal Dehydrogenase Stem Cell Transplantation Survival Analysis Tissue Array Analysis Treatment Outcome Up-Regulation Xenograft Model Antitumor Assays},
	number = {5},
	pages = {555-67},
	title = {ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18371393},
	volume = {1},
	year = {2007},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/18371393},
	bdsk-url-2 = {https://doi.org/10.1016/j.stem.2007.08.014}}

@article{RN78,
	abstract = {Application of stem cell biology to breast cancer research has been limited by the lack of simple methods for identification and isolation of normal and malignant stem cells. Utilizing in vitro and in vivo experimental systems, we show that normal and cancer human mammary epithelial cells with increased aldehyde dehydrogenase activity (ALDH) have stem/progenitor properties. These cells contain the subpopulation of normal breast epithelium with the broadest lineage differentiation potential and greatest growth capacity in a xenotransplant model. In breast carcinomas, high ALDH activity identifies the tumorigenic cell fraction, capable of self-renewal and of generating tumors that recapitulate the heterogeneity of the parental tumor. In a series of 577 breast carcinomas, expression of ALDH1 detected by immunostaining correlated with poor prognosis. These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts.},
	author = {Ginestier, C. and Hur, M. H. and Charafe-Jauffret, E. and Monville, F. and Dutcher, J. and Brown, M. and Jacquemier, J. and Viens, P. and Kleer, C. G. and Liu, S. and Schott, A. and Hayes, D. and Birnbaum, D. and Wicha, M. S. and Dontu, G.},
	doi = {10.1016/j.stem.2007.08.014},
	issn = {1934-5909 (Print) 1875-9777 (Linking)},
	journal = {Cell Stem Cell},
	keywords = {Adult Stem Cells/*enzymology/immunology Aldehyde Dehydrogenase/*metabolism Aldehyde Dehydrogenase 1 Family Animals Biomarkers/analysis Breast Neoplasms/*enzymology/immunology/pathology/therapy CD24 Antigen/analysis Cell Differentiation Cell Lineage Cell Proliferation Cell Separation Cells, Cultured Female Flow Cytometry Humans Hyaluronan Receptors/analysis Immunohistochemistry Isoenzymes/*metabolism Mammary Glands, Human/*enzymology/immunology Mice Mice, Inbred NOD Mice, SCID Neoplastic Stem Cells/*enzymology/immunology/pathology Phenotype Retinal Dehydrogenase Stem Cell Transplantation Survival Analysis Tissue Array Analysis Treatment Outcome Up-Regulation Xenograft Model Antitumor Assays},
	note = {Ginestier, Christophe Hur, Min Hee Charafe-Jauffret, Emmanuelle Monville, Florence Dutcher, Julie Brown, Marty Jacquemier, Jocelyne Viens, Patrice Kleer, Celina G Liu, Suling Schott, Anne Hayes, Dan Birnbaum, Daniel Wicha, Max S Dontu, Gabriela eng R01 CA101860-01A1/CA/NCI NIH HHS/ R01 CA101860-04/CA/NCI NIH HHS/ CA66233/CA/NCI NIH HHS/ R01 CA101860-03/CA/NCI NIH HHS/ R01 CA101860/CA/NCI NIH HHS/ CA101860/CA/NCI NIH HHS/ 5 P 30 CA46592/CA/NCI NIH HHS/ R01 CA101860-02/CA/NCI NIH HHS/ Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2008/03/29 Cell Stem Cell. 2007 Nov;1(5):555-67. doi: 10.1016/j.stem.2007.08.014.},
	number = {5},
	pages = {555-67},
	title = {ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome},
	type = {Journal Article},
	url = {https://www.cell.com/cell-stem-cell/pdf/S1934-5909(07)00133-6.pdf},
	volume = {1},
	year = {2007},
	bdsk-url-1 = {https://www.cell.com/cell-stem-cell/pdf/S1934-5909(07)00133-6.pdf},
	bdsk-url-2 = {https://doi.org/10.1016/j.stem.2007.08.014}}

@article{RN314,
	abstract = {Application of stem cell biology to breast cancer research has been limited by the lack of simple methods for identification and isolation of normal and malignant stem cells. Utilizing in vitro and in vivo experimental systems, we show that normal and cancer human mammary epithelial cells with increased aldehyde dehydrogenase activity (ALDH) have stem/progenitor properties. These cells contain the subpopulation of normal breast epithelium with the broadest lineage differentiation potential and greatest growth capacity in a xenotransplant model. In breast carcinomas, high ALDH activity identifies the tumorigenic cell fraction, capable of self-renewal and of generating tumors that recapitulate the heterogeneity of the parental tumor. In a series of 577 breast carcinomas, expression of ALDH1 detected by immunostaining correlated with poor prognosis. These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts.},
	author = {Ginestier, C. and Hur, M. H. and Charafe-Jauffret, E. and Monville, F. and Dutcher, J. and Brown, M. and Jacquemier, J. and Viens, P. and Kleer, C. G. and Liu, S. and Schott, A. and Hayes, D. and Birnbaum, D. and Wicha, M. S. and Dontu, G.},
	doi = {10.1016/j.stem.2007.08.014},
	issn = {1934-5909 (Print) 1875-9777},
	journal = {Cell Stem Cell},
	keywords = {Adult Stem Cells/*enzymology/immunology Aldehyde Dehydrogenase/*metabolism Aldehyde Dehydrogenase 1 Family Animals Biomarkers/analysis Breast Neoplasms/*enzymology/immunology/pathology/therapy CD24 Antigen/analysis Cell Differentiation Cell Lineage Cell Proliferation Cell Separation Cells, Cultured Female Flow Cytometry Humans Hyaluronan Receptors/analysis Immunohistochemistry Isoenzymes/*metabolism Mammary Glands, Human/*enzymology/immunology Mice Mice, Inbred NOD Mice, SCID Neoplastic Stem Cells/*enzymology/immunology/pathology Phenotype Retinal Dehydrogenase Stem Cell Transplantation Survival Analysis Tissue Array Analysis Treatment Outcome Up-Regulation Xenograft Model Antitumor Assays},
	note = {Ginestier, Christophe Hur, Min Hee Charafe-Jauffret, Emmanuelle Monville, Florence Dutcher, Julie Brown, Marty Jacquemier, Jocelyne Viens, Patrice Kleer, Celina G Liu, Suling Schott, Anne Hayes, Dan Birnbaum, Daniel Wicha, Max S Dontu, Gabriela R01 CA101860-01A1/CA/NCI NIH HHS/United States R01 CA101860-04/CA/NCI NIH HHS/United States CA66233/CA/NCI NIH HHS/United States R01 CA101860-03/CA/NCI NIH HHS/United States R01 CA101860/CA/NCI NIH HHS/United States CA101860/CA/NCI NIH HHS/United States 5 P 30 CA46592/CA/NCI NIH HHS/United States R01 CA101860-02/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2008/03/29 Cell Stem Cell. 2007 Nov;1(5):555-67. doi: 10.1016/j.stem.2007.08.014.},
	number = {5},
	pages = {555-67},
	title = {ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2423808/pdf/nihms43965.pdf},
	volume = {1},
	year = {2007},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2423808/pdf/nihms43965.pdf},
	bdsk-url-2 = {https://doi.org/10.1016/j.stem.2007.08.014}}

@article{RN354,
	author = {Hafkamp, H. C. and Manni, J. J. and Haesevoets, A. and Voogd, A. C. and Schepers, M. and Bot, F. J. and Hopman, A. H. and Ramaekers, F. C. and Speel, E. J.},
	doi = {10.1002/ijc.23458},
	issn = {0020-7136},
	journal = {Int J Cancer},
	keywords = {Carcinoma, Squamous Cell/pathology/*virology Cyclin-Dependent Kinase Inhibitor p16/genetics DNA, Viral/genetics Female Humans Immunohistochemistry In Situ Hybridization, Fluorescence Male Middle Aged Neoplasm Metastasis Papillomaviridae/genetics/*isolation & purification Polymerase Chain Reaction Prognosis Smoking/*adverse effects *Survival Rate Tonsillar Neoplasms/pathology/*virology},
	number = {12},
	pages = {2656-64},
	title = {Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas},
	type = {Journal Article},
	volume = {122},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1002/ijc.23458}}

@article{RN357,
	author = {Hafkamp, H. C. and Manni, J. J. and Haesevoets, A. and Voogd, A. C. and Schepers, M. and Bot, F. J. and Hopman, A. H. and Ramaekers, F. C. and Speel, E. J.},
	doi = {10.1002/ijc.23458},
	issn = {0020-7136},
	journal = {Int J Cancer},
	keywords = {Carcinoma, Squamous Cell/pathology/*virology Cyclin-Dependent Kinase Inhibitor p16/genetics DNA, Viral/genetics Female Humans Immunohistochemistry In Situ Hybridization, Fluorescence Male Middle Aged Neoplasm Metastasis Papillomaviridae/genetics/*isolation & purification Polymerase Chain Reaction Prognosis Smoking/*adverse effects *Survival Rate Tonsillar Neoplasms/pathology/*virology},
	number = {12},
	pages = {2656-64},
	title = {Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas},
	type = {Journal Article},
	volume = {122},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1002/ijc.23458}}

@article{RN93,
	abstract = {Oncogenic human papillomavirus (HPV) is a causative agent in a subgroup of head and neck carcinomas, particularly tonsillar squamous cell carcinomas (TSCC). This study was undertaken because controversial data exist on the physical status of HPV-DNA and the use of p16(INK4A) overexpression as surrogate HPV marker, and to examine the impact of HPV and tobacco consumption on the clinical course of TSCC. Tissue sections of 81 TSCC were analyzed by HPV 16-specific fluorescence in situ hybridization (FISH) and p16(INK4A)-specific immunohistochemistry. Results were correlated with clinical and demographic data. HPV 16 integration was detected by FISH as punctate signals in 33 out of 81 (41%) TSCC, 32 of which showed p16(INK4A) accumulation. Only 5 out of 48 HPV-negative tumors showed p16(INK4A) immunostaining (p < 0.0001). The presence of HPV furthermore correlates significantly with low tobacco (p = 0.002) and alcohol intake (p = 0.011), poor differentiation grade (p = 0.019), small tumor size (p = 0.024), presence of a local metastasis (p = 0.001) and a decreased (loco)regional recurrence rate (p = 0.039). Statistical analysis revealed that smoking significantly increases the risk of cancer death from TSCC and that non-smoking patients with HPV-containing TSCC show a remarkably better disease-specific survival rate. HPV 16 is integrated in 41% of TSCC and strongly correlates with p16(INK4A) overexpression, implicating the latter to be a reliable HPV biomarker. Patients with HPV-positive tumors show a favorable prognosis as compared to those with HPV-negative tumors, but tobacco use is the strongest prognostic indicator. These findings indicate that oncogenic processes in the tonsils of non-smokers differ from those occurring in smokers, the former being related to HPV 16 infection.},
	author = {Hafkamp, H. C. and Manni, J. J. and Haesevoets, A. and Voogd, A. C. and Schepers, M. and Bot, F. J. and Hopman, A. H. and Ramaekers, F. C. and Speel, E. J.},
	doi = {10.1002/ijc.23458},
	issn = {0020-7136},
	journal = {Int J Cancer},
	keywords = {Carcinoma, Squamous Cell/pathology/*virology Cyclin-Dependent Kinase Inhibitor p16/genetics DNA, Viral/genetics Female Humans Immunohistochemistry In Situ Hybridization, Fluorescence Male Middle Aged Neoplasm Metastasis Papillomaviridae/genetics/*isolation & purification Polymerase Chain Reaction Prognosis Smoking/*adverse effects *Survival Rate Tonsillar Neoplasms/pathology/*virology},
	note = {1097-0215 Hafkamp, Harri{\"e}t C Manni, J J Haesevoets, A Voogd, A C Schepers, M Bot, F J Hopman, A H N Ramaekers, F C S Speel, Ernst-Jan M Comparative Study Journal Article Research Support, Non-U.S. Gov't United States 2008/03/25 Int J Cancer. 2008 Jun 15;122(12):2656-64. doi: 10.1002/ijc.23458.},
	number = {12},
	pages = {2656-64},
	title = {Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.23458?download=true},
	volume = {122},
	year = {2008},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.23458?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.23458}}

@article{RN135,
	abstract = {BACKGROUND: At least 75% of head and neck cancers are attributable to a combination of cigarette smoking and alcohol drinking. A precise understanding of the independent association of each of these factors in the absence of the other with the risk of head and neck cancer is needed to elucidate mechanisms of head and neck carcinogenesis and to assess the efficacy of interventions aimed at controlling either risk factor. METHODS: We examined the extent to which head and neck cancer is associated with cigarette smoking among never drinkers and with alcohol drinking among never users of tobacco. We pooled individual-level data from 15 case-control studies that included 10,244 head and neck cancer case subjects and 15,227 control subjects, of whom 1072 case subjects and 5775 control subjects were never users of tobacco and 1598 case subjects and 4051 control subjects were never drinkers of alcohol. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression models. All statistical tests were two-sided. RESULTS: Among never drinkers, cigarette smoking was associated with an increased risk of head and neck cancer (OR for ever versus never smoking = 2.13, 95% CI = 1.52 to 2.98), and there were clear dose-response relationships for the frequency, duration, and number of pack-years of cigarette smoking. Approximately 24% (95% CI = 16% to 31%) of head and neck cancer cases among nondrinkers in this study would have been prevented if these individuals had not smoked cigarettes. Among never users of tobacco, alcohol consumption was associated with an increased risk of head and neck cancer only when alcohol was consumed at high frequency (OR for three or more drinks per day versus never drinking = 2.04, 95% CI = 1.29 to 3.21). The association with high-frequency alcohol intake was limited to cancers of the oropharynx/hypopharynx and larynx. CONCLUSIONS: Our results represent the most precise estimates available of the independent association of each of the two main risk factors of head and neck cancer, and they exemplify the strengths of large-scale consortia in cancer epidemiology.},
	author = {Hashibe, M. and Brennan, P. and Benhamou, S. and Castellsague, X. and Chen, C. and Curado, M. P. and Dal Maso, L. and Daudt, A. W. and Fabianova, E. and Fernandez, L. and W{\"u}nsch-Filho, V. and Franceschi, S. and Hayes, R. B. and Herrero, R. and Koifman, S. and La Vecchia, C. and Lazarus, P. and Levi, F. and Mates, D. and Matos, E. and Menezes, A. and Muscat, J. and Eluf-Neto, J. and Olshan, A. F. and Rudnai, P. and Schwartz, S. M. and Smith, E. and Sturgis, E. M. and Szeszenia-Dabrowska, N. and Talamini, R. and Wei, Q. and Winn, D. M. and Zaridze, D. and Zatonski, W. and Zhang, Z. F. and Berthiller, J. and Boffetta, P.},
	doi = {10.1093/jnci/djk179},
	issn = {0027-8874},
	journal = {J Natl Cancer Inst},
	keywords = {Adolescent Adult Aged Aged, 80 and over Alcohol Drinking/*adverse effects Case-Control Studies Female Head and Neck Neoplasms/*chemically induced Humans Male Middle Aged Risk Factors Smoking/*adverse effects},
	note = {1460-2105 Hashibe, Mia Brennan, Paul Benhamou, Simone Castellsague, Xavier Chen, Chu Curado, Maria Paula Dal Maso, Luigino Daudt, Alexander W Fabianova, Eleonora Fernandez, Leticia W{\"u}nsch-Filho, Victor Franceschi, Silvia Hayes, Richard B Herrero, Rolando Koifman, Sergio La Vecchia, Carlo Lazarus, Philip Levi, Fabio Mates, Dana Matos, Elena Menezes, Ana Muscat, Joshua Eluf-Neto, Jose Olshan, Andrew F Rudnai, Peter Schwartz, Stephen M Smith, Elaine Sturgis, Erich M Szeszenia-Dabrowska, Neonilia Talamini, Renato Wei, Qingyi Winn, Deborah M Zaridze, David Zatonski, Witold Zhang, Zuo-Feng Berthiller, Julien Boffetta, Paolo P50CA90388/CA/NCI NIH HHS/United States R01CA100264/CA/NCI NIH HHS/United States R01DE13110/DE/NIDCR NIH HHS/United States R01DE012609/DE/NIDCR NIH HHS/United States R01DE11979/DE/NIDCR NIH HHS/United States R01CA61188/CA/NCI NIH HHS/United States P01CA068384/CA/NCI NIH HHS/United States R21ES011667/ES/NIEHS NIH HHS/United States T32 CA009142/CA/NCI NIH HHS/United States R03CA113157/CA/NCI NIH HHS/United States U01CA96134/CA/NCI NIH HHS/United States TW01500/TW/FIC NIH HHS/United States R01ES11740/ES/NIEHS NIH HHS/United States R03CA77954/CA/NCI NIH HHS/United States R01DA11386/DA/NIDA NIH HHS/United States R01CA048896/CA/NCI NIH HHS/United States K07CA104231/CA/NCI NIH HHS/United States P30ES010126/ES/NIEHS NIH HHS/United States T32CA09142/CA/NCI NIH HHS/United States Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. United States 2007/05/17 J Natl Cancer Inst. 2007 May 16;99(10):777-89. doi: 10.1093/jnci/djk179.},
	number = {10},
	pages = {777-89},
	title = {Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium},
	type = {Journal Article},
	url = {https://watermark.silverchair.com/djk179.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsIwggK-BgkqhkiG9w0BBwagggKvMIICqwIBADCCAqQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM0k1uHJ2Jwsrzj4bFAgEQgIICdYfs8g0Yp0SQ-eITHyPO5v0pKOrBembDGhCmW-64xecpdBnA8fBIv9ggrU16lkDuvl_Cbz-LBj87MH56PRpLX-4d7GPQnVCbqDPowtKArADE9Jp92royIjkmG6P_DReP6VKUKac8RuA9T3SJAW9wZq2I1DcI1oprliqmIu94yM0jSH_FlhrlM_1xWP_Ls6qhuH500rHxTozXtoG0i2OBOhz-yCGSTncnvnqr6EsZw2YsClfYoreocgejn9vXdfZe0AdLNSdSIiKbOEzitRVXxwJzlb2ziJVNl-bYHied7fs6qjlg0F5MpPN1I5rrbELJcIUE95SUwE0FcrvwNiHy7MihgHLY8TDiYlWUddaNM58iSFlvTKoNXkEgo-iDrTTw5GuC9k4--_dm8y3mrCB0jzfHMk8aDHREvXB8Bsnba-481_OEeeEtWrqAgHFmJZORDMEoNJzP2QGLfjH-qvon655zQI4JxLQ9r0X84aPmqEhS50lKaJ-4vYOKTzKp0pODe0e-jVsb_hvqo1V7EwpTsviJP9IbJIsqi9kWJGTS03Yl_hj4ooKvcdIb1T953Sh4_scwXUgZ9gsmlCdH6ZRCDUQw5rCPJoUPCN_GVC_Df0zwbkXWElhLreKJWxbfGFnrw_E13VMDHJdtdxTc6U1XOY7ELv8p4t5ipakhnE7MHqY9_TPxjxRF-GZWTjoy4SyZQoxY76LfBlCaG9I9aYujB7hm0eES1tfU7yXWn5ahreSNQPmoPwZ1_hAsU3MlZBY2vNbPRWJn4B_YBrvuCXMfwGJU5JaJUh_mQjs6S-ky8EIZIiICNJ0n0IHdj1-mncaqIg7bx_9J},
	volume = {99},
	year = {2007},
	bdsk-url-1 = {https://watermark.silverchair.com/djk179.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsIwggK-BgkqhkiG9w0BBwagggKvMIICqwIBADCCAqQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM0k1uHJ2Jwsrzj4bFAgEQgIICdYfs8g0Yp0SQ-eITHyPO5v0pKOrBembDGhCmW-64xecpdBnA8fBIv9ggrU16lkDuvl_Cbz-LBj87MH56PRpLX-4d7GPQnVCbqDPowtKArADE9Jp92royIjkmG6P_DReP6VKUKac8RuA9T3SJAW9wZq2I1DcI1oprliqmIu94yM0jSH_FlhrlM_1xWP_Ls6qhuH500rHxTozXtoG0i2OBOhz-yCGSTncnvnqr6EsZw2YsClfYoreocgejn9vXdfZe0AdLNSdSIiKbOEzitRVXxwJzlb2ziJVNl-bYHied7fs6qjlg0F5MpPN1I5rrbELJcIUE95SUwE0FcrvwNiHy7MihgHLY8TDiYlWUddaNM58iSFlvTKoNXkEgo-iDrTTw5GuC9k4--_dm8y3mrCB0jzfHMk8aDHREvXB8Bsnba-481_OEeeEtWrqAgHFmJZORDMEoNJzP2QGLfjH-qvon655zQI4JxLQ9r0X84aPmqEhS50lKaJ-4vYOKTzKp0pODe0e-jVsb_hvqo1V7EwpTsviJP9IbJIsqi9kWJGTS03Yl_hj4ooKvcdIb1T953Sh4_scwXUgZ9gsmlCdH6ZRCDUQw5rCPJoUPCN_GVC_Df0zwbkXWElhLreKJWxbfGFnrw_E13VMDHJdtdxTc6U1XOY7ELv8p4t5ipakhnE7MHqY9_TPxjxRF-GZWTjoy4SyZQoxY76LfBlCaG9I9aYujB7hm0eES1tfU7yXWn5ahreSNQPmoPwZ1_hAsU3MlZBY2vNbPRWJn4B_YBrvuCXMfwGJU5JaJUh_mQjs6S-ky8EIZIiICNJ0n0IHdj1-mncaqIg7bx_9J},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/djk179}}

@article{RN138,
	abstract = {BACKGROUND: The magnitude of risk conferred by the interaction between tobacco and alcohol use on the risk of head and neck cancers is not clear because studies have used various methods to quantify the excess head and neck cancer burden. METHODS: We analyzed individual-level pooled data from 17 European and American case-control studies (11,221 cases and 16,168 controls) participating in the International Head and Neck Cancer Epidemiology consortium. We estimated the multiplicative interaction parameter (psi) and population attributable risks (PAR). RESULTS: A greater than multiplicative joint effect between ever tobacco and alcohol use was observed for head and neck cancer risk (psi = 2.15; 95% confidence interval, 1.53-3.04). The PAR for tobacco or alcohol was 72% (95% confidence interval, 61-79%) for head and neck cancer, of which 4% was due to alcohol alone, 33% was due to tobacco alone, and 35% was due to tobacco and alcohol combined. The total PAR differed by subsite (64% for oral cavity cancer, 72% for pharyngeal cancer, 89% for laryngeal cancer), by sex (74% for men, 57% for women), by age (33% for cases <45 years, 73% for cases >60 years), and by region (84% in Europe, 51% in North America, 83% in Latin America). CONCLUSIONS: Our results confirm that the joint effect between tobacco and alcohol use is greater than multiplicative on head and neck cancer risk. However, a substantial proportion of head and neck cancers cannot be attributed to tobacco or alcohol use, particularly for oral cavity cancer and for head and neck cancer among women and among young-onset cases.},
	author = {Hashibe, M. and Brennan, P. and Chuang, S. C. and Boccia, S. and Castellsague, X. and Chen, C. and Curado, M. P. and Dal Maso, L. and Daudt, A. W. and Fabianova, E. and Fernandez, L. and W{\"u}nsch-Filho, V. and Franceschi, S. and Hayes, R. B. and Herrero, R. and Kelsey, K. and Koifman, S. and La Vecchia, C. and Lazarus, P. and Levi, F. and Lence, J. J. and Mates, D. and Matos, E. and Menezes, A. and McClean, M. D. and Muscat, J. and Eluf-Neto, J. and Olshan, A. F. and Purdue, M. and Rudnai, P. and Schwartz, S. M. and Smith, E. and Sturgis, E. M. and Szeszenia-Dabrowska, N. and Talamini, R. and Wei, Q. and Winn, D. M. and Shangina, O. and Pilarska, A. and Zhang, Z. F. and Ferro, G. and Berthiller, J. and Boffetta, P.},
	doi = {10.1158/1055-9965.Epi-08-0347},
	issn = {1055-9965 (Print) 1055-9965},
	journal = {Cancer Epidemiol Biomarkers Prev},
	keywords = {Adult Aged Alcohol Drinking/*adverse effects/epidemiology Case-Control Studies Europe/epidemiology Female Head and Neck Neoplasms/*epidemiology/*etiology Humans Logistic Models Male Middle Aged North America/epidemiology Risk Factors Tobacco Use Disorder/*complications/epidemiology},
	note = {1538-7755 Hashibe, Mia Brennan, Paul Chuang, Shu-Chun Boccia, Stefania Castellsague, Xavier Chen, Chu Curado, Maria Paula Dal Maso, Luigino Daudt, Alexander W Fabianova, Eleonora Fernandez, Leticia W{\"u}nsch-Filho, Victor Franceschi, Silvia Hayes, Richard B Herrero, Rolando Kelsey, Karl Koifman, Sergio La Vecchia, Carlo Lazarus, Philip Levi, Fabio Lence, Juan J Mates, Dana Matos, Elena Menezes, Ana McClean, Michael D Muscat, Joshua Eluf-Neto, Jose Olshan, Andrew F Purdue, Mark Rudnai, Peter Schwartz, Stephen M Smith, Elaine Sturgis, Erich M Szeszenia-Dabrowska, Neonilia Talamini, Renato Wei, Qingyi Winn, Deborah M Shangina, Oxana Pilarska, Agnieszka Zhang, Zuo-Feng Ferro, Gilles Berthiller, Julien Boffetta, Paolo R01 DE13110/DE/NIDCR NIH HHS/United States T32 CA09142/CA/NCI NIH HHS/United States P30 ES010126/ES/NIEHS NIH HHS/United States P01 CA068384/CA/NCI NIH HHS/United States R01 DA011386/DA/NIDA NIH HHS/United States R03 TW001500/TW/FIC NIH HHS/United States R01 CA048896/CA/NCI NIH HHS/United States R01 ES11740/ES/NIEHS NIH HHS/United States R01 CA61188/CA/NCI NIH HHS/United States R01 CA100679/CA/NCI NIH HHS/United States R03 CA113157/CA/NCI NIH HHS/United States R24 HD050924/HD/NICHD NIH HHS/United States R01 CA100264/CA/NCI NIH HHS/United States R01 DE11979/DE/NIDCR NIH HHS/United States U01 CA96134/CA/NCI NIH HHS/United States R03 CA113157-02/CA/NCI NIH HHS/United States R01 ES011740/ES/NIEHS NIH HHS/United States R01 DE012609/DE/NIDCR NIH HHS/United States R01 CA078609/CA/NCI NIH HHS/United States K07 CA104231/CA/NCI NIH HHS/United States P50 CA90388/CA/NCI NIH HHS/United States T32 CA009142/CA/NCI NIH HHS/United States U01 CA096134/CA/NCI NIH HHS/United States ImNIH/Intramural NIH HHS/United States R01 DA11386/DA/NIDA NIH HHS/United States R03 CA077954/CA/NCI NIH HHS/United States R21 ES011667/ES/NIEHS NIH HHS/United States TW01500/TW/FIC NIH HHS/United States R03 CA113157-01/CA/NCI NIH HHS/United States R03 CA77954/CA/NCI NIH HHS/United States P50 CA090388/CA/NCI NIH HHS/United States R01 DE013110/DE/NIDCR NIH HHS/United States Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. 2009/02/05 Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):541-50. doi: 10.1158/1055-9965.EPI-08-0347. Epub 2009 Feb 3.},
	number = {2},
	pages = {541-50},
	title = {Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium},
	type = {Journal Article},
	url = {https://cebp.aacrjournals.org/content/cebp/18/2/541.full.pdf},
	volume = {18},
	year = {2009},
	bdsk-url-1 = {https://cebp.aacrjournals.org/content/cebp/18/2/541.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1055-9965.Epi-08-0347}}

@article{RN144,
	abstract = {BACKGROUND: Despite several lines of evidence suggesting the biological plausibility of marijuana being carcinogenic, epidemiologic findings are inconsistent. We conducted a population-based case-control study of the association between marijuana use and the risk of lung and upper aerodigestive tract cancers in Los Angeles. METHODS: Our study included 1,212 incident cancer cases and 1,040 cancer-free controls matched to cases on age, gender, and neighborhood. Subjects were interviewed with a standardized questionnaire. The cumulative use of marijuana was expressed in joint-years, where 1 joint-year is equivalent to smoking one joint per day for 1 year. RESULTS: Although using marijuana for > or =30 joint-years was positively associated in the crude analyses with each cancer type (except pharyngeal cancer), no positive associations were observed when adjusting for several confounders including cigarette smoking. The adjusted odds ratio estimate (and 95% confidence limits) for > or =60 versus 0 joint-years was 1.1 (0.56, 2.1) for oral cancer, 0.84 (0.28, 2.5) for laryngeal cancer, and 0.62 (0.32, 1.2) for lung cancer; the adjusted odds ratio estimate for > or =30 versus 0 joint-years was 0.57 (0.20, 1.6) for pharyngeal cancer, and 0.53 (0.22, 1.3) for esophageal cancer. No association was consistently monotonic across exposure categories, and restriction to subjects who never smoked cigarettes yielded similar findings. CONCLUSIONS: Our results may have been affected by selection bias or error in measuring lifetime exposure and confounder histories; but they suggest that the association of these cancers with marijuana, even long-term or heavy use, is not strong and may be below practically detectable limits.},
	author = {Hashibe, M. and Morgenstern, H. and Cui, Y. and Tashkin, D. P. and Zhang, Z. F. and Cozen, W. and Mack, T. M. and Greenland, S.},
	doi = {10.1158/1055-9965.Epi-06-0330},
	issn = {1055-9965 (Print) 1055-9965},
	journal = {Cancer Epidemiol Biomarkers Prev},
	keywords = {Adenocarcinoma/epidemiology/etiology Adolescent Adult Aged Alcohol Drinking/adverse effects Carcinoma, Large Cell/epidemiology/etiology Carcinoma, Squamous Cell/epidemiology/etiology Case-Control Studies Confounding Factors, Epidemiologic Digestive System Neoplasms/*epidemiology/*etiology Esophageal Neoplasms/epidemiology/etiology Female Humans Incidence Laryngeal Neoplasms/epidemiology/etiology Los Angeles/epidemiology Male Marijuana Smoking/*adverse effects/*epidemiology Middle Aged Mouth Neoplasms/epidemiology/etiology Pharyngeal Neoplasms/epidemiology/etiology Population Surveillance Respiratory Tract Neoplasms/*epidemiology/*etiology Risk Factors Time Factors},
	note = {Hashibe, Mia Morgenstern, Hal Cui, Yan Tashkin, Donald P Zhang, Zuo-Feng Cozen, Wendy Mack, Thomas M Greenland, Sander DA11386/DA/NIDA NIH HHS/United States CA96134/CA/NCI NIH HHS/United States T32 CA009142/CA/NCI NIH HHS/United States CA77954/CA/NCI NIH HHS/United States ES011667/ES/NIEHS NIH HHS/United States CA90833/CA/NCI NIH HHS/United States CA09142/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States 2006/10/13 Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1829-34. doi: 10.1158/1055-9965.EPI-06-0330.},
	number = {10},
	pages = {1829-34},
	title = {Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study},
	type = {Journal Article},
	url = {https://cebp.aacrjournals.org/content/cebp/15/10/1829.full.pdf},
	volume = {15},
	year = {2006},
	bdsk-url-1 = {https://cebp.aacrjournals.org/content/cebp/15/10/1829.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1055-9965.Epi-06-0330}}

@book{RN131,
	author = {Hausamen, J.E. and Machtens, E. and Reuther, J.F. and Eufinger, H. and K{\"u}bler, A. and Schliephake, H.},
	isbn = {9783642178016},
	publisher = {Springer Berlin Heidelberg},
	title = {Mund-, Kiefer- und Gesichtschirurgie},
	type = {Book},
	url = {https://books.google.de/books?id=UugfBAAAQBAJ},
	year = {2012},
	bdsk-url-1 = {https://books.google.de/books?id=UugfBAAAQBAJ}}

@book{RN370,
	author = {Heinrich, P.C. and M{\"u}ller, M. and Graeve, L.},
	isbn = {9783642179716},
	publisher = {Springer Berlin Heidelberg},
	title = {L{\"o}ffler/Petrides Biochemie und Pathobiochemie},
	type = {Book},
	url = {https://books.google.de/books?id=EUj_ugAACAAJ},
	year = {2014},
	bdsk-url-1 = {https://books.google.de/books?id=EUj_ugAACAAJ}}

@book{RN118,
	author = {Heinrich, P.C. and M{\"u}ller, M. and Graeve, L.},
	isbn = {9783642179716},
	publisher = {Springer Berlin Heidelberg},
	title = {L{\"o}ffler/Petrides Biochemie und Pathobiochemie},
	type = {Book},
	url = {https://books.google.de/books?id=EUj_ugAACAAJ},
	year = {2014},
	bdsk-url-1 = {https://books.google.de/books?id=EUj_ugAACAAJ}}

@article{RN282,
	abstract = {This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. It introduces the current best practice in histopathology and cytopathology as it pertains to head and neck and thyroid cancers. Recommendations * Accurate diagnosis of the type of malignancy is a key component of effective management. (R) * Surgeons and oncologists should understand the scope and limitations of cellular pathology in order to inform multidisciplinary discussions. (R) * A clinically suspected diagnosis of malignancy should be confirmed by biopsy or cytology before operation. (R) * Cytopathological diagnoses should be discussed with surgeons and radiologists to maximise the information gained from each modality of investigation. (R) * Pathological investigations are the basis for accurate cancer staging and stratification of clinical outcomes. (R).},
	author = {Helliwell, T. R. and Giles, T. E.},
	doi = {10.1017/s0022215116000451},
	issn = {0022-2151 (Print) 0022-2151},
	journal = {J Laryngol Otol},
	keywords = {Adenocarcinoma, Follicular/diagnosis/pathology Biopsy, Needle/standards Carcinoma, Medullary/diagnosis/pathology Carcinoma, Papillary/diagnosis/pathology Carcinoma, Squamous Cell/diagnosis/pathology Head and Neck Neoplasms/diagnosis/*pathology Humans Interdisciplinary Communication Lymphatic Metastasis/pathology Patient Care Team/standards Salivary Gland Neoplasms/diagnosis/pathology Thyroid Neoplasms/diagnosis/pathology United Kingdom},
	note = {1748-5460 Helliwell, T R Giles, T E Journal Article Practice Guideline 2016/11/15 J Laryngol Otol. 2016 May;130(S2):S59-S65. doi: 10.1017/S0022215116000451.},
	number = {S2},
	pages = {S59-s65},
	title = {Pathological aspects of the assessment of head and neck cancers: United Kingdom National Multidisciplinary Guidelines},
	type = {Journal Article},
	url = {https://www.cambridge.org/core/services/aop-cambridge-core/content/view/6F2E77B3E9E41639D31D72E546830162/S0022215116000451a.pdf/div-class-title-pathological-aspects-of-the-assessment-of-head-and-neck-cancers-united-kingdom-national-multidisciplinary-guidelines-div.pdf},
	volume = {130},
	year = {2016},
	bdsk-url-1 = {https://www.cambridge.org/core/services/aop-cambridge-core/content/view/6F2E77B3E9E41639D31D72E546830162/S0022215116000451a.pdf/div-class-title-pathological-aspects-of-the-assessment-of-head-and-neck-cancers-united-kingdom-national-multidisciplinary-guidelines-div.pdf},
	bdsk-url-2 = {https://doi.org/10.1017/s0022215116000451}}

@article{RN275,
	abstract = {BACKGROUND: Anaemia is associated with poor cancer control, particularly in patients undergoing radiotherapy. We investigated whether anaemia correction with epoetin beta could improve outcome of curative radiotherapy among patients with head and neck cancer. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled trial in 351 patients (haemoglobin <120 g/L in women or <130 g/L in men) with carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Patients received curative radiotherapy at 60 Gy for completely (R0) and histologically incomplete (R1) resected disease, or 70 Gy for macroscopically incompletely resected (R2) advanced disease (T3, T4, or nodal involvement) or for primary definitive treatment. All patients were assigned to subcutaneous placebo (n=171) or epoetin beta 300 IU/kg (n=180) three times weekly, from 10-14 days before and continuing throughout radiotherapy. The primary endpoint was locoregional progression-free survival. We assessed also time to locoregional progression and survival. Analysis was by intention to treat. FINDINGS: 148 (82%) patients given epoetin beta achieved haemoglobin concentrations higher than 140 g/L (women) or 150 g/L (men) compared with 26 (15%) given placebo. However, locoregional progression-free survival was poorer with epoetin beta than with placebo (adjusted relative risk 1.62 [95% CI 1.22-2.14]; p=0.0008). For locoregional progression the relative risk was 1.69 (1.16-2.47, p=0.007) and for survival was 1.39 (1.05-1.84, p=0.02). INTERPRETATION: Epoetin beta corrects anaemia but does not improve cancer control or survival. Disease control might even be impaired. Patients receiving curative cancer treatment and given erythropoietin should be studied in carefully controlled trials.},
	author = {Henke, M. and Laszig, R. and R{\"u}be, C. and Sch{\"a}fer, U. and Haase, K. D. and Schilcher, B. and Mose, S. and Beer, K. T. and Burger, U. and Dougherty, C. and Frommhold, H.},
	doi = {10.1016/s0140-6736(03)14567-9},
	issn = {0140-6736},
	journal = {Lancet},
	keywords = {Anemia/*drug therapy/epidemiology Antineoplastic Protocols/standards Carcinoma, Squamous Cell/epidemiology/*radiotherapy Comorbidity Disease-Free Survival Erythropoietin/*therapeutic use Head and Neck Neoplasms/epidemiology/*radiotherapy Humans Proportional Hazards Models Radiation Oncology/standards Recombinant Proteins Treatment Outcome},
	note = {1474-547x Henke, Michael Laszig, Roland R{\"u}be, Christian Sch{\"a}fer, Ulrich Haase, Klaus-Dieter Schilcher, Burkhard Mose, Stephan Beer, Karl T Burger, Ulrich Dougherty, Chris Frommhold, Hermann Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't England 2003/10/25 Lancet. 2003 Oct 18;362(9392):1255-60. doi: 10.1016/S0140-6736(03)14567-9.},
	number = {9392},
	pages = {1255-60},
	title = {Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial},
	type = {Journal Article},
	url = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14567-9/fulltext},
	volume = {362},
	year = {2003},
	bdsk-url-1 = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14567-9/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s0140-6736(03)14567-9}}

@article{RN276,
	abstract = {BACKGROUND: Anaemia is associated with poor cancer control, particularly in patients undergoing radiotherapy. We investigated whether anaemia correction with epoetin beta could improve outcome of curative radiotherapy among patients with head and neck cancer. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled trial in 351 patients (haemoglobin <120 g/L in women or <130 g/L in men) with carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Patients received curative radiotherapy at 60 Gy for completely (R0) and histologically incomplete (R1) resected disease, or 70 Gy for macroscopically incompletely resected (R2) advanced disease (T3, T4, or nodal involvement) or for primary definitive treatment. All patients were assigned to subcutaneous placebo (n=171) or epoetin beta 300 IU/kg (n=180) three times weekly, from 10-14 days before and continuing throughout radiotherapy. The primary endpoint was locoregional progression-free survival. We assessed also time to locoregional progression and survival. Analysis was by intention to treat. FINDINGS: 148 (82%) patients given epoetin beta achieved haemoglobin concentrations higher than 140 g/L (women) or 150 g/L (men) compared with 26 (15%) given placebo. However, locoregional progression-free survival was poorer with epoetin beta than with placebo (adjusted relative risk 1.62 [95% CI 1.22-2.14]; p=0.0008). For locoregional progression the relative risk was 1.69 (1.16-2.47, p=0.007) and for survival was 1.39 (1.05-1.84, p=0.02). INTERPRETATION: Epoetin beta corrects anaemia but does not improve cancer control or survival. Disease control might even be impaired. Patients receiving curative cancer treatment and given erythropoietin should be studied in carefully controlled trials.},
	author = {Henke, M. and Laszig, R. and R{\"u}be, C. and Sch{\"a}fer, U. and Haase, K. D. and Schilcher, B. and Mose, S. and Beer, K. T. and Burger, U. and Dougherty, C. and Frommhold, H.},
	doi = {10.1016/s0140-6736(03)14567-9},
	issn = {0140-6736},
	journal = {Lancet},
	keywords = {Anemia/*drug therapy/epidemiology Antineoplastic Protocols/standards Carcinoma, Squamous Cell/epidemiology/*radiotherapy Comorbidity Disease-Free Survival Erythropoietin/*therapeutic use Head and Neck Neoplasms/epidemiology/*radiotherapy Humans Proportional Hazards Models Radiation Oncology/standards Recombinant Proteins Treatment Outcome},
	note = {1474-547x Henke, Michael Laszig, Roland R{\"u}be, Christian Sch{\"a}fer, Ulrich Haase, Klaus-Dieter Schilcher, Burkhard Mose, Stephan Beer, Karl T Burger, Ulrich Dougherty, Chris Frommhold, Hermann Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't England 2003/10/25 Lancet. 2003 Oct 18;362(9392):1255-60. doi: 10.1016/S0140-6736(03)14567-9.},
	number = {9392},
	pages = {1255-60},
	title = {Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial},
	type = {Journal Article},
	volume = {362},
	year = {2003},
	bdsk-url-1 = {https://doi.org/10.1016/s0140-6736(03)14567-9}}

@article{RN151,
	abstract = {BACKGROUND: Human papillomavirus (HPV), the causal agent of cervical cancer, appears to be involved in the etiology of cancer of the oral cavity and oropharynx. To investigate these associations, we conducted a multicenter case-control study of cancer of the oral cavity and oropharynx in nine countries. METHODS: We recruited 1670 case patients (1415 with cancer of the oral cavity and 255 with cancer of the oropharynx) and 1732 control subjects and obtained an interview, oral exfoliated cells, and blood from all participants and fresh biopsy specimens from case patients. HPV DNA was detected by polymerase chain reaction (PCR). Antibodies against HPV16 L1, E6, and E7 proteins in plasma were detected with enzyme-linked immunosorbent assays. Multivariable models were used for case-control and case-case comparisons. RESULTS: HPV DNA was detected in biopsy specimens of 3.9% (95% confidence interval [CI] = 2.5% to 5.3%) of 766 cancers of the oral cavity with valid PCR results and 18.3% (95% CI = 12.0% to 24.7%) of 142 cancers of the oropharynx (oropharynx and tonsil combined) with valid PCR results. HPV DNA in cancer biopsy specimens was detected less frequently among tobacco smokers and paan chewers and more frequently among subjects who reported more than one sexual partner or who practiced oral sex. HPV16 DNA was found in 94.7% of HPV DNA-positive case patients. HPV DNA in exfoliated cells was not associated with cancer risk or with HPV DNA detection in biopsy specimens. Antibodies against HPV16 L1 were associated with risk for cancers of the oral cavity (odds ratio [OR] = 1.5, 95% CI = 1.1 to 2.1) and the oropharynx (OR = 3.5, 95% CI = 2.1 to 5.9). Antibodies against HPV16 E6 or E7 were also associated with risk for cancers of the oral cavity (OR = 2.9, 95% CI = 1.7 to 4.8) and the oropharynx (OR = 9.2, 95% CI = 4.8 to 17.7). CONCLUSIONS: HPV appears to play an etiologic role in many cancers of the oropharynx and possibly a small subgroup of cancers of the oral cavity. The most common HPV type in genital cancers (HPV16) was also the most common in these tumors. The mechanism of transmission of HPV to the oral cavity warrants further investigation.},
	author = {Herrero, R. and Castellsagu{\'e}, X. and Pawlita, M. and Lissowska, J. and Kee, F. and Balaram, P. and Rajkumar, T. and Sridhar, H. and Rose, B. and Pintos, J. and Fern{\'a}ndez, L. and Idris, A. and S{\'a}nchez, M. J. and Nieto, A. and Talamini, R. and Tavani, A. and Bosch, F. X. and Reidel, U. and Snijders, P. J. and Meijer, C. J. and Viscidi, R. and Mu{\~n}oz, N. and Franceschi, S.},
	doi = {10.1093/jnci/djg107},
	issn = {0027-8874},
	journal = {J Natl Cancer Inst},
	keywords = {Adult Aged Antibodies, Viral/blood Case-Control Studies DNA, Viral/isolation & purification Enzyme-Linked Immunosorbent Assay Female Humans International Cooperation Life Style Male Middle Aged Odds Ratio Oropharyngeal Neoplasms/*virology Papillomaviridae/genetics/immunology/*isolation & purification Papillomavirus Infections/*complications/virology Polymerase Chain Reaction Risk Assessment Risk Factors Seroepidemiologic Studies Sexual Behavior Smoking/adverse effects Tumor Virus Infections/*complications/virology},
	note = {1460-2105 Herrero, Rolando Castellsagu{\'e}, Xavier Pawlita, Michael Lissowska, Jolanta Kee, Frank Balaram, Prabda Rajkumar, Thangarajan Sridhar, Hema Rose, Barbara Pintos, Javier Fern{\'a}ndez, Leticia Idris, Ali S{\'a}nchez, Mar{\'\i}a Jos{\'e} Nieto, Adoraci{\'o}n Talamini, Renato Tavani, Alessandra Bosch, F Xavier Reidel, Ulrich Snijders, Peter J F Meijer, Chris J L M Viscidi, Raphael Mu{\~n}oz, Nubia Franceschi, Silvia IARC Multicenter Oral Cancer Study Group Journal Article Multicenter Study Research Support, Non-U.S. Gov't United States 2003/12/05 J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83. doi: 10.1093/jnci/djg107.},
	number = {23},
	pages = {1772-83},
	title = {Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study},
	type = {Journal Article},
	url = {https://watermark.silverchair.com/zv802303001772.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAswwggLIBgkqhkiG9w0BBwagggK5MIICtQIBADCCAq4GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMaZJUbsauibH9iYMgAgEQgIICf-xQ6w4GL0dIAmdJSYdAPRxvy2KstqPXj13wCd07chVweDVbgLcybrqwo8rCO7ZkEwjE1j5mBeC4GlB6qMG_X_XqTZeolMYzWtZyhdbM6jFgHsJBb91s3N9DaCxQF-whuCDjKu3Im299PY1gghvS-UU0ubTOIKUlXAExrkPzPGLdCUxPA4hKWPpjzRtFYCj2iLS_CvwO361YiDBpgjWZFGdOOilaS64zFWH8lKBW3j-uVF1WehKmAD95QFhH3A6PljGhsyGH0tiggJPXFzcqIdLfGXH5eyeJQF7inZrMEKRN3uLZM-QVFAZ5Gy6_5iiD8AbpJp80EPvZBr0T8MYu3oezYeFTcXa3HXIqbPYJwOxB4jDQmek5DuRtrkA7h9s42QEgi01HJ0FYZANZAzsHLLCJ8DulF4p7Y1_5mqQmmiEqeZvvLyfGnANQtMuRWXea3YzSvosj21piRH4uJgLmVYS9D-A93tI6df8kWtb_Ja_jmz5-LWWJ3LAm7YdU2JmAyQN9dr05dYxwj5M4SUtVcHBQ4Iq7Jyx_SczXpAdtSm2bNPmwOqzxgynpRr964q16kyx8tddx_wrP1F7uSZcNlNx3Tp2W7lENQHA36zVtL0A6rQaj3m5-tsAipxL19Cw5MXfM3dSY1-jbCIWGwzzQoFMPShSw-V0BZdrgR8L0kOf8ObgI3clIF0UsMK8ecq5TopXZlf8GM2QqY1kBaJOdZX5wi8SlPkToH4JSrgvZa9VhZF_UpXrM2bYOYsJKOnv5OjJ0NSlgnqdWPdpXr10MR5eS8lAwC8-YOUqJBKEEC2n8NMJJCbwSvA4mn_V_JFDuDLaf42n7J_oEw1qILeaX9w},
	volume = {95},
	year = {2003},
	bdsk-url-1 = {https://watermark.silverchair.com/zv802303001772.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAswwggLIBgkqhkiG9w0BBwagggK5MIICtQIBADCCAq4GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMaZJUbsauibH9iYMgAgEQgIICf-xQ6w4GL0dIAmdJSYdAPRxvy2KstqPXj13wCd07chVweDVbgLcybrqwo8rCO7ZkEwjE1j5mBeC4GlB6qMG_X_XqTZeolMYzWtZyhdbM6jFgHsJBb91s3N9DaCxQF-whuCDjKu3Im299PY1gghvS-UU0ubTOIKUlXAExrkPzPGLdCUxPA4hKWPpjzRtFYCj2iLS_CvwO361YiDBpgjWZFGdOOilaS64zFWH8lKBW3j-uVF1WehKmAD95QFhH3A6PljGhsyGH0tiggJPXFzcqIdLfGXH5eyeJQF7inZrMEKRN3uLZM-QVFAZ5Gy6_5iiD8AbpJp80EPvZBr0T8MYu3oezYeFTcXa3HXIqbPYJwOxB4jDQmek5DuRtrkA7h9s42QEgi01HJ0FYZANZAzsHLLCJ8DulF4p7Y1_5mqQmmiEqeZvvLyfGnANQtMuRWXea3YzSvosj21piRH4uJgLmVYS9D-A93tI6df8kWtb_Ja_jmz5-LWWJ3LAm7YdU2JmAyQN9dr05dYxwj5M4SUtVcHBQ4Iq7Jyx_SczXpAdtSm2bNPmwOqzxgynpRr964q16kyx8tddx_wrP1F7uSZcNlNx3Tp2W7lENQHA36zVtL0A6rQaj3m5-tsAipxL19Cw5MXfM3dSY1-jbCIWGwzzQoFMPShSw-V0BZdrgR8L0kOf8ObgI3clIF0UsMK8ecq5TopXZlf8GM2QqY1kBaJOdZX5wi8SlPkToH4JSrgvZa9VhZF_UpXrM2bYOYsJKOnv5OjJ0NSlgnqdWPdpXr10MR5eS8lAwC8-YOUqJBKEEC2n8NMJJCbwSvA4mn_V_JFDuDLaf42n7J_oEw1qILeaX9w},
	bdsk-url-2 = {https://doi.org/10.1093/jnci/djg107}}

@article{RN408,
	author = {Herrmann, K. and Niedobitek, G.},
	doi = {10.1002/path.1296},
	issn = {0022-3417 (Print) 0022-3417},
	journal = {J Pathol},
	keywords = {Breast Neoplasms/virology Carcinoma, Hepatocellular/virology DNA, Neoplasm/analysis DNA, Viral/analysis Epithelium Female Herpesvirus 4, Human/*physiology Humans In Situ Hybridization Liver Neoplasms/virology Lymphoma/virology Nasopharyngeal Neoplasms/pathology/virology Neoplasms/*virology RNA, Neoplasm/analysis RNA, Viral/analysis Stomach Neoplasms/virology Uterine Cervical Neoplasms/virology},
	number = {2},
	pages = {140-5},
	title = {Epstein-Barr virus-associated carcinomas: facts and fiction},
	type = {Journal Article},
	volume = {199},
	year = {2003},
	bdsk-url-1 = {https://doi.org/10.1002/path.1296}}

@article{RN126,
	abstract = {The Epstein-Barr virus (EBV) is associated with several human tumours including lymphoid and epithelial malignancies. Most EBV-associated tumours are rare or occur at higher incidence only in certain geographical regions. The recently reported detection of EBV in gastric, breast, and hepatocellular carcinomas raises the possibility of involvement of the virus in the pathogenesis of common cancers. This article reviews the evidence linking EBV infection to epithelial tumours. It is concluded that at present, there is no convincing evidence to suggest that breast carcinoma and hepatocellular carcinoma are EBV-associated tumours.},
	author = {Herrmann, K. and Niedobitek, G.},
	doi = {10.1002/path.1296},
	issn = {0022-3417 (Print) 0022-3417},
	journal = {J Pathol},
	keywords = {Breast Neoplasms/virology Carcinoma, Hepatocellular/virology DNA, Neoplasm/analysis DNA, Viral/analysis Epithelium Female Herpesvirus 4, Human/*physiology Humans In Situ Hybridization Liver Neoplasms/virology Lymphoma/virology Nasopharyngeal Neoplasms/pathology/virology Neoplasms/*virology RNA, Neoplasm/analysis RNA, Viral/analysis Stomach Neoplasms/virology Uterine Cervical Neoplasms/virology},
	note = {Herrmann, Kathrin Niedobitek, Gerald Journal Article Review England 2003/01/21 J Pathol. 2003 Feb;199(2):140-5. doi: 10.1002/path.1296.},
	number = {2},
	pages = {140-5},
	title = {Epstein-Barr virus-associated carcinomas: facts and fiction},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/path.1296?download=true},
	volume = {199},
	year = {2003},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/path.1296?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/path.1296}}

@article{RN152,
	abstract = {It is now clear that the two separate entitles of tonsillar cancer, HPV induced and non-HPV induced (smoking induced), have significantly different presenting stage and outcomes. A significant proportion of patients with human papillomavirus positive tonsillar cancer have had exposure to smoking. We examined the combined effect of human papillomavirus and smoking on the outcomes and determined whether smoking can modify the beneficial effect of human papillomavirus. A total of 403 patients from nine centers were followed up for recurrence or death for a median of 38 months. Determinants of the rate of loco-regional recurrence, death from tonsillar cancer and overall survival were modeled using Cox regression. Smoking status was a significant predictor of overall survival (p = 0.04). There were nonstatistically significant trends favoring never smokers for loco-regional recurrence and disease specific survival. In addition, there was no statistically significant interactions between smoking and human papillomavirus (p-values for the interaction were 0.26 for loco-regional recurrence, 0.97 for disease specific survival and 0.73 for overall survival). The effect of smoking on loco-regional recurrence and disease specific survival outcomes was not statistically significant, nor was there significant evidence that the effect of smoking status on these outcomes was modified by HPV status. Irrespective of HPV status, however, smokers did have poorer overall survival than never-smokers, presumably due to effects of smoking that are unrelated to the primary cancer.},
	author = {Hong, A. M. and Martin, A. and Chatfield, M. and Jones, D. and Zhang, M. and Armstrong, B. and Lee, C. S. and Harnett, G. and Milross, C. and Clark, J. and Elliott, M. and Smee, R. and Corry, J. and Liu, C. and Porceddu, S. and Rees, G. and Rose, B.},
	doi = {10.1002/ijc.27956},
	issn = {0020-7136},
	journal = {Int J Cancer},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/*etiology/*mortality Female Humans Male Middle Aged Papillomaviridae/classification/*genetics Prognosis *Smoking Tonsillar Neoplasms/*etiology/*mortality},
	note = {1097-0215 Hong, Angela M Martin, Andrew Chatfield, Mark Jones, Deanna Zhang, Mei Armstrong, Bruce Lee, C Soon Harnett, Gerald Milross, Christopher Clark, Jonathan Elliott, Michael Smee, Robert Corry, June Liu, Chen Porceddu, Sandro Rees, Guy Rose, Barbara Journal Article Research Support, Non-U.S. Gov't United States 2012/11/28 Int J Cancer. 2013 Jun 15;132(12):2748-54. doi: 10.1002/ijc.27956. Epub 2012 Dec 13.},
	number = {12},
	pages = {2748-54},
	title = {Human papillomavirus, smoking status and outcomes in tonsillar squamous cell carcinoma},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.27956?download=true},
	volume = {132},
	year = {2013},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.27956?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.27956}}

@article{RN225,
	abstract = {BACKGROUND AND PURPOSE: A 5 week-hyperfractionated and accelerated radiotherapy regimen without reduction of the total dose was developed to fight tumour repopulation during treatment and tumour hypoxia. The purpose of the study was to try to improve loco-regional control in high risk head and neck carcinoma treated with curative radiotherapy. METHODS AND MATERIALS: From 1985 to 1995, a randomised controlled trial of the EORTC Cooperative Group of Radiotherapy (EORTC 22851) compared the experimental regimen (72 Gy/45 fractions/5 weeks) to standard fractionation and overall treatment time (70 Gy/35 fractions/7 weeks) in T2, T3 and T4 head and neck cancers (hypopharynx excluded). The end-point criteria were local and loco-regional control, overall and disease-free survival, and acute and late toxicities. Five hundred twelve patients were accrued. RESULTS: Patients in the AF (accelerated fractionation) arm did significantly better with regard to loco-regional control (P = 0.02) resulting at 5 years in a 13% gain (95% CI 3-23% gain) in loco-regional control over the CF (conventional fractionation) arm. This improvement is of larger magnitude in patients with poorer prognosis (N2-3 any T, T4 any N) than in patients with more favourable stage. Multivariate analysis confirmed AF as an independent prognostic factor of good prognosis for loco-regional control (P = 0.03). Specific survival shows a trend (P = 0.06) in favour of the AF arm. ACUTE AND LATE TOXICITIES: Acute and late toxicity were increased in the AF arm. Late severe functional irradiation damage occurred in 14% of patients of the AF arm versus 4% in the CF arm. Two cases of radiation-induced myelitis occurred after doses of 42 and 48 Gy to the spinal cord. CONCLUSIONS: This trial shows that accelerated radiotherapy improves loco-regional control in head and neck squamous cell carcinomas. A less toxic scheme should, however, be investigated and documented before using accelerated radiotherapy as a standard regimen of curative radiotherapy for head and neck cancers.},
	author = {Horiot, J. C. and Bontemps, P. and van den Bogaert, W. and Le Fur, R. and van den Weijngaert, D. and Bolla, M. and Bernier, J. and Lusinchi, A. and Stuschke, M. and Lopez-Torrecilla, J. and Begg, A. C. and Pierart, M. and Collette, L.},
	doi = {10.1016/s0167-8140(97)00079-0},
	issn = {0167-8140 (Print) 0167-8140},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Female Head and Neck Neoplasms/mortality/*radiotherapy Humans Male Middle Aged Patient Compliance Radiotherapy/adverse effects/methods Survival Rate},
	note = {Horiot, J C Bontemps, P van den Bogaert, W Le Fur, R van den Weijngaert, D Bolla, M Bernier, J Lusinchi, A Stuschke, M Lopez-Torrecilla, J Begg, A C Pierart, M Collette, L Clinical Trial Clinical Trial, Phase III Comparative Study Journal Article Randomized Controlled Trial Ireland 1997/08/01 Radiother Oncol. 1997 Aug;44(2):111-21. doi: 10.1016/s0167-8140(97)00079-0.},
	number = {2},
	pages = {111-21},
	title = {Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial},
	type = {Journal Article},
	url = {https://www.thegreenjournal.com/article/S0167-8140(97)00079-0/pdf},
	volume = {44},
	year = {1997},
	bdsk-url-1 = {https://www.thegreenjournal.com/article/S0167-8140(97)00079-0/pdf},
	bdsk-url-2 = {https://doi.org/10.1016/s0167-8140(97)00079-0}}

@article{RN226,
	abstract = {BACKGROUND AND PURPOSE: A 5 week-hyperfractionated and accelerated radiotherapy regimen without reduction of the total dose was developed to fight tumour repopulation during treatment and tumour hypoxia. The purpose of the study was to try to improve loco-regional control in high risk head and neck carcinoma treated with curative radiotherapy. METHODS AND MATERIALS: From 1985 to 1995, a randomised controlled trial of the EORTC Cooperative Group of Radiotherapy (EORTC 22851) compared the experimental regimen (72 Gy/45 fractions/5 weeks) to standard fractionation and overall treatment time (70 Gy/35 fractions/7 weeks) in T2, T3 and T4 head and neck cancers (hypopharynx excluded). The end-point criteria were local and loco-regional control, overall and disease-free survival, and acute and late toxicities. Five hundred twelve patients were accrued. RESULTS: Patients in the AF (accelerated fractionation) arm did significantly better with regard to loco-regional control (P = 0.02) resulting at 5 years in a 13% gain (95% CI 3-23% gain) in loco-regional control over the CF (conventional fractionation) arm. This improvement is of larger magnitude in patients with poorer prognosis (N2-3 any T, T4 any N) than in patients with more favourable stage. Multivariate analysis confirmed AF as an independent prognostic factor of good prognosis for loco-regional control (P = 0.03). Specific survival shows a trend (P = 0.06) in favour of the AF arm. ACUTE AND LATE TOXICITIES: Acute and late toxicity were increased in the AF arm. Late severe functional irradiation damage occurred in 14% of patients of the AF arm versus 4% in the CF arm. Two cases of radiation-induced myelitis occurred after doses of 42 and 48 Gy to the spinal cord. CONCLUSIONS: This trial shows that accelerated radiotherapy improves loco-regional control in head and neck squamous cell carcinomas. A less toxic scheme should, however, be investigated and documented before using accelerated radiotherapy as a standard regimen of curative radiotherapy for head and neck cancers.},
	author = {Horiot, J. C. and Bontemps, P. and van den Bogaert, W. and Le Fur, R. and van den Weijngaert, D. and Bolla, M. and Bernier, J. and Lusinchi, A. and Stuschke, M. and Lopez-Torrecilla, J. and Begg, A. C. and Pierart, M. and Collette, L.},
	doi = {10.1016/s0167-8140(97)00079-0},
	issn = {0167-8140 (Print) 0167-8140},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Female Head and Neck Neoplasms/mortality/*radiotherapy Humans Male Middle Aged Patient Compliance Radiotherapy/adverse effects/methods Survival Rate},
	note = {Horiot, J C Bontemps, P van den Bogaert, W Le Fur, R van den Weijngaert, D Bolla, M Bernier, J Lusinchi, A Stuschke, M Lopez-Torrecilla, J Begg, A C Pierart, M Collette, L Clinical Trial Clinical Trial, Phase III Comparative Study Journal Article Randomized Controlled Trial Ireland 1997/08/01 Radiother Oncol. 1997 Aug;44(2):111-21. doi: 10.1016/s0167-8140(97)00079-0.},
	number = {2},
	pages = {111-21},
	title = {Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial},
	type = {Journal Article},
	volume = {44},
	year = {1997},
	bdsk-url-1 = {https://doi.org/10.1016/s0167-8140(97)00079-0}}

@book{RN170,
	author = {H{\"o}lzer, D.},
	isbn = {9783886036882},
	publisher = {W. Zuckschwerdt},
	title = {Tumorregister M{\"u}nchen: Jahresbericht 1998 des klinisch-epidemiologischen Krebsregisters am Tumorzentrum M{\"u}nchen. Schwerpunkt: Kolorektale Karzinome},
	type = {Book},
	url = {https://books.google.de/books?id=ANeQNwAACAAJ},
	year = {1999},
	bdsk-url-1 = {https://books.google.de/books?id=ANeQNwAACAAJ}}

@article{RN1,
	abstract = {PURPOSE: Cancer stem cells (CSCs) are held accountable for the progress of head and neck squamous cell carcinoma (HNSCC). In the presented study, the authors evaluated the prognostic value of CSC markers in two particular HNSCC cohorts. METHODS: This two cohort study consisted of 85 patients with advanced stage HNSCC, treated with primary radio(chemo)therapy (pRCT), and 95 patients with HNSCC, treated with surgery and partially adjuvant radio(chemo)therapy. Overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) were assessed. Samples were assessed for the expression of different molecular stem cell markers (ALDH1, BCL11B, BMI1, and CD44). RESULTS: In the pRCT cohort, none of the baseline patient and tumor features exhibited a statistically significant relation with survival in either the cohort or the human papillomavirus (HPV)-stratified subcohorts. High expression of BMI1 significantly decreased OS and DFS, while high expression of CD44 decreased all modes of survival. Multivariate analysis showed significant prognostic influence for all tested CSC markers, with high BMI1 and CD44 decreasing survival (BMI-1: OS, DFS, DSS; CD44: OS, DFS) and high ALDH1 and BCL11B showing a beneficial effect on survival (ALDH1: OS, DFS; BCL11B: OS, DSS). In the surgical cohort, classical prognosticators such as HPV status, R1 resection, and nodal status in HPV-negative HNSCC played a significant role, but the tested CSC markers showed no significant effect on prognosis. CONCLUSION: Although validation in independent cohorts is still needed, testing for CSC markers in patients with advanced or late stage HNSCC might be beneficial, especially if many comorbidities exist or disease is irresectable. The findings might guide the development and earlier use of targeted therapies in the future.},
	author = {Jakob, M. and Sharaf, K. and Schirmer, M. and Leu, M. and Kuffer, S. and Bertlich, M. and Ihler, F. and Haubner, F. and Canis, M. and Kitz, J.},
	doi = {10.1007/s00066-020-01653-5},
	issn = {1439-099X (Electronic) 0179-7158 (Linking)},
	journal = {Strahlenther Onkol},
	keywords = {Head and neck cancer Molecular markers Primary radiochemotherapy Surgical treatment Survival},
	note = {Jakob, Mark Sharaf, Kariem Schirmer, Markus Leu, Martin Kuffer, Stefan Bertlich, Mattis Ihler, Friedrich Haubner, Frank Canis, Martin Kitz, Julia eng Germany Strahlenther Onkol. 2021 Mar;197(3):231-245. doi: 10.1007/s00066-020-01653-5. Epub 2020 Jun 25.},
	number = {3},
	pages = {231-245},
	title = {Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892527/pdf/66_2020_Article_1653.pdf},
	volume = {197},
	year = {2021},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892527/pdf/66_2020_Article_1653.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/s00066-020-01653-5}}

@article{RN35,
	abstract = {PURPOSE: Cancer stem cells (CSCs) are held accountable for the progress of head and neck squamous cell carcinoma (HNSCC). In the presented study, the authors evaluated the prognostic value of CSC markers in two particular HNSCC cohorts. METHODS: This two cohort study consisted of 85 patients with advanced stage HNSCC, treated with primary radio(chemo)therapy (pRCT), and 95 patients with HNSCC, treated with surgery and partially adjuvant radio(chemo)therapy. Overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) were assessed. Samples were assessed for the expression of different molecular stem cell markers (ALDH1, BCL11B, BMI1, and CD44). RESULTS: In the pRCT cohort, none of the baseline patient and tumor features exhibited a statistically significant relation with survival in either the cohort or the human papillomavirus (HPV)-stratified subcohorts. High expression of BMI1 significantly decreased OS and DFS, while high expression of CD44 decreased all modes of survival. Multivariate analysis showed significant prognostic influence for all tested CSC markers, with high BMI1 and CD44 decreasing survival (BMI-1: OS, DFS, DSS; CD44: OS, DFS) and high ALDH1 and BCL11B showing a beneficial effect on survival (ALDH1: OS, DFS; BCL11B: OS, DSS). In the surgical cohort, classical prognosticators such as HPV status, R1 resection, and nodal status in HPV-negative HNSCC played a significant role, but the tested CSC markers showed no significant effect on prognosis. CONCLUSION: Although validation in independent cohorts is still needed, testing for CSC markers in patients with advanced or late stage HNSCC might be beneficial, especially if many comorbidities exist or disease is irresectable. The findings might guide the development and earlier use of targeted therapies in the future.},
	author = {Jakob, M. and Sharaf, K. and Schirmer, M. and Leu, M. and Kuffer, S. and Bertlich, M. and Ihler, F. and Haubner, F. and Canis, M. and Kitz, J.},
	doi = {10.1007/s00066-020-01653-5},
	issn = {1439-099X (Electronic) 0179-7158 (Linking)},
	journal = {Strahlenther Onkol},
	keywords = {Aged Aldehyde Dehydrogenase 1 Family/*analysis Female Head and Neck Neoplasms/*diagnosis/pathology Humans Hyaluronan Receptors/*analysis Male Middle Aged Neoplastic Stem Cells/*pathology Polycomb Repressive Complex 1/*analysis Prognosis Repressor Proteins/*analysis Retrospective Studies Squamous Cell Carcinoma of Head and Neck/*diagnosis/pathology Survival Analysis Tumor Suppressor Proteins/*analysis Head and neck cancer Molecular markers Primary radiochemotherapy Surgical treatment Survival},
	note = {Jakob, Mark Sharaf, Kariem Schirmer, Markus Leu, Martin Kuffer, Stefan Bertlich, Mattis Ihler, Friedrich Haubner, Frank Canis, Martin Kitz, Julia eng Germany Strahlenther Onkol. 2021 Mar;197(3):231-245. doi: 10.1007/s00066-020-01653-5. Epub 2020 Jun 25.},
	number = {3},
	pages = {231-245},
	title = {Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/32588101},
	volume = {197},
	year = {2021},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/32588101},
	bdsk-url-2 = {https://doi.org/10.1007/s00066-020-01653-5}}

@article{RN243,
	abstract = {To determine whether combining radiation therapy and a surgical procedure was superior to either modality alone, the authors reviewed the records of 345 patients who had primary cancers of the base of the tongue, tonsillar fossa, or pyriform sinus associated with clinically positive nodes at the time of their first observation. Combining the two modalities of therapy produced a local and regional control of the disease in twice as many patients as did one modality alone. The absolute 5-year survival did not reflect this same trend, however, since as local and regional control increased, more patients lived longer but died before five years from distant metastases. Immunochemotherapy is suggested as a possible adjunct therapy to prevent distant metastases.},
	author = {Jesse, R. H. and Lindberg, R. D.},
	doi = {10.1002/1097-0142(197504)35:4<1163::aid-cncr2820350422>3.0.co;2-c},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Carcinoma, Squamous Cell/radiotherapy/surgery/*therapy Evaluation Studies as Topic Humans Lymphatic Metastasis/*therapy Neoplasm Metastasis Pharyngeal Neoplasms/radiotherapy/surgery/*therapy Prognosis Time Factors Tongue Neoplasms/radiotherapy/surgery/*therapy},
	note = {Jesse, R H Lindberg, R D Journal Article United States 1975/04/01 Cancer. 1975 Apr;35(4):1163-6. doi: 10.1002/1097-0142(197504)35:4<1163::aid-cncr2820350422>3.0.co;2-c.},
	number = {4},
	pages = {1163-6},
	title = {The efficacy of combining radiation therapy with a surgical procedure in patients with cervical metastasis from squamous cancer of the oropharynx and hypopharynx},
	type = {Journal Article},
	url = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%28197504%2935%3A4%3C1163%3A%3AAID-CNCR2820350422%3E3.0.CO%3B2-C?download=true},
	volume = {35},
	year = {1975},
	bdsk-url-1 = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%28197504%2935%3A4%3C1163%3A%3AAID-CNCR2820350422%3E3.0.CO%3B2-C?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/1097-0142(197504)35:4%3C1163::aid-cncr2820350422%3E3.0.co;2-c}}

@article{RN434,
	author = {Joos, S. and Nettelbeck, D. M. and Reil-Held, A. and Engelmann, K. and Moosmann, A. and Eggert, A. and Hiddemann, W. and Krause, M. and Peters, C. and Schuler, M. and Schulze-Osthoff, K. and Serve, H. and Wick, W. and Puchta, J. and Baumann, M.},
	doi = {10.1002/1878-0261.12430},
	issn = {1878-0261 (Electronic) 1574-7891 (Linking)},
	journal = {Mol Oncol},
	keywords = {Germany Humans Medical Oncology Neoplasms/*therapy Physicians *Translational Medical Research *Germany *multisite cooperation *personalized oncology *research consortium *translational cancer research},
	number = {3},
	pages = {535-542},
	title = {German Cancer Consortium (DKTK) - A national consortium for translational cancer research},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30561127},
	volume = {13},
	year = {2019},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/30561127},
	bdsk-url-2 = {https://doi.org/10.1002/1878-0261.12430}}

@article{RN46,
	abstract = {The German Cancer Consortium ('Deutsches Konsortium fur Translationale Krebsforschung', DKTK) is a long-term cancer consortium, bringing together the German Cancer Research Center (DKFZ), Germany's largest life science research center, and the leading University Medical Center-based Comprehensive Cancer Centers (CCCs) at seven sites across Germany. DKTK was founded in 2012 following international peer review and has positioned itself since then as the leading network for translational cancer research in Germany. DKTK is long term funded by the German Ministry of Research and Education and the federal states of each DKTK partner site. DKTK acts at the interface between basic and clinical cancer research, one major focus being to generate suitable multisite cooperation structures and provide the basis for including higher numbers of patients and facilitate effective collaborative forward and reverse translational cancer research. The consortium addresses areas of high scientific and medical relevance and develops critical infrastructures, for example, for omics technologies, clinical and research big data exchange and analysis, imaging, and clinical grade drug manufacturing. Moreover, DKTK provides a very attractive environment for interdisciplinary and interinstitutional training and career development for clinician and medical scientists.},
	author = {Joos, S. and Nettelbeck, D. M. and Reil-Held, A. and Engelmann, K. and Moosmann, A. and Eggert, A. and Hiddemann, W. and Krause, M. and Peters, C. and Schuler, M. and Schulze-Osthoff, K. and Serve, H. and Wick, W. and Puchta, J. and Baumann, M.},
	doi = {10.1002/1878-0261.12430},
	issn = {1878-0261 (Electronic) 1574-7891 (Linking)},
	journal = {Mol Oncol},
	keywords = {Germany Humans Medical Oncology Neoplasms/*therapy Physicians *Translational Medical Research *Germany *multisite cooperation *personalized oncology *research consortium *translational cancer research},
	note = {Joos, Stefan Nettelbeck, Dirk M Reil-Held, Anette Engelmann, Katja Moosmann, Alexandra Eggert, Angelika Hiddemann, Wolfgang Krause, Mechthild Peters, Christoph Schuler, Martin Schulze-Osthoff, Klaus Serve, Hubert Wick, Wolfgang Puchta, Josef Baumann, Michael eng Review Mol Oncol. 2019 Mar;13(3):535-542. doi: 10.1002/1878-0261.12430. Epub 2019 Jan 9.},
	number = {3},
	pages = {535-542},
	title = {German Cancer Consortium (DKTK) - A national consortium for translational cancer research},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396349/pdf/MOL2-13-535.pdf},
	volume = {13},
	year = {2019},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396349/pdf/MOL2-13-535.pdf},
	bdsk-url-2 = {https://doi.org/10.1002/1878-0261.12430}}

@article{RN178,
	abstract = {BACKGROUND: The neck lymph nodes are a common site of metastases from carcinoma of unknown primary (CUP syndrome). 2[(18) F]-fluoro-2-deoxy-D-glucose positron emission tomography (18-FDG-PET) has been shown to be a sensitive tool for detecting primary malignant lesions as well as metastatic spread. We have prospectively investigated the sensitivity of 18-FDG-PET in detecting occult primary carcinomas with manifestation in the head and neck lymph nodes. METHODS: From May 1994 to July 1998, in 723 patients a cancer of the head and neck was diagnosed at the University of Cologne ENT outpatient clinic. The routinely performed staging procedures were chest radiography; full blood count; cervical and liver ultrasound; endoscopy of the nasopharynx, oropharynx, hypopharynx, larynx, and esophagus; and laboratory analyses. After the staging workup, in 27 of 723 patients (3.7%) CUP syndrome had to be presumed because the primary cancer could not be detected. In these patients 18-FDG-PET was performed, and images were reconstructed with a transmission-emission fusion technique. RESULTS: In 7 of 27 patients (26%) 18-FDG-PET revealed an unknown primary: in 2 a bronchial carcinoma, in 2 a nasopharyngeal carcinoma, in 1 a squamous cell carcinoma of the parotid gland, in 1 a squamous cell carcinoma of the hypopharynx, and in 1 a carcinoma of the tonsil. In 4 of 7 patients the occult primary tumor was removed surgically. In 8 of 27 patients therapeutic strategy was changed as a result of the 18-FDG-PET findings. CONCLUSION: 18-FDG-PET should be performed in all patients with CUP syndrome after conventional diagnostic workup fails to identify the primary.},
	author = {Jungeh{\"u}lsing, M. and Scheidhauer, K. and Damm, M. and Pietrzyk, U. and Eckel, H. and Schicha, H. and Stennert, E.},
	doi = {10.1067/mhn.2000.104807},
	issn = {0194-5998 (Print) 0194-5998},
	journal = {Otolaryngol Head Neck Surg},
	keywords = {Adenocarcinoma/secondary Adult Aged Carcinoma, Squamous Cell/*secondary Female *Fluorodeoxyglucose F18 Head and Neck Neoplasms/*secondary Humans Lymphatic Metastasis Male Middle Aged Neoplasms, Unknown Primary/*diagnostic imaging Prospective Studies *Radiopharmaceuticals *Tomography, Emission-Computed},
	note = {Jungeh{\"u}lsing, M Scheidhauer, K Damm, M Pietrzyk, U Eckel, H Schicha, H Stennert, E Journal Article England 2000/08/30 Otolaryngol Head Neck Surg. 2000 Sep;123(3):294-301. doi: 10.1067/mhn.2000.104807.},
	number = {3},
	pages = {294-301},
	title = {2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation},
	type = {Journal Article},
	url = {https://journals.sagepub.com/doi/pdf/10.1067/mhn.2000.104807},
	volume = {123},
	year = {2000},
	bdsk-url-1 = {https://journals.sagepub.com/doi/pdf/10.1067/mhn.2000.104807},
	bdsk-url-2 = {https://doi.org/10.1067/mhn.2000.104807}}

@inproceedings{RN451,
	author = {J{\"u}tz, M. and Linge, A. and von Neubeck, C. and Lohaus, F. and Tinhofer, I. and Budach, V. and Gkika, E. and Stuschke, M. and Balermpas, P. and R{\"o}del, C. and Avlar, M. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and M{\"o}nnich, D. and Zips, D. and L{\"o}ck, S. and Gudziol, V. and Baretton, G. B. and Baumann, M. and Krause, M. and DKTK-ROG},
	booktitle = {Symposium Experimentelle Strahlentherapie und klinische Strahlenbiologie},
	isbn = {1432-864X},
	pages = {150-53},
	title = {Prognostisches Potential von CD44 als Tumorstammzellmarker f{\"u}r die kombinierte Radiochemotherapie des lokal fortgeschrittenen Kopf-Hals-Plattenepithelkarzinoms},
	type = {Conference Proceedings},
	volume = {24}}

@inproceedings{RN44,
	author = {J{\"u}tz, M. and Linge, A. and von Neubeck, C. and Lohaus, F. and Tinhofer, I. and Budach, V. and Gkika, E. and Stuschke, M. and Balermpas, P. and R{\"o}del, C. and Avlar, M. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and M{\"o}nnich, D. and Zips, D. and L{\"o}ck, S. and Gudziol, V. and Baretton, G. B. and Baumann, M. and Krause, M. and DKTK-ROG},
	booktitle = {Symposium Experimentelle Strahlentherapie und klinische Strahlenbiologie},
	isbn = {1432-864X},
	pages = {150-53},
	title = {Prognostisches Potential von CD44 als Tumorstammzellmarker f{\"u}r die kombinierte Radiochemotherapie des lokal fortgeschrittenen Kopf-Hals-Plattenepithelkarzinoms},
	type = {Conference Proceedings},
	volume = {24}}

@article{RN183,
	abstract = {PURPOSE: This evidence based guideline aims to facilitate proper management and to prevent diverging views concerning diagnosis, treatment and follow-up of carcinoma of the larynx between the major referral centers for head and neck cancer in The Netherlands. METHOD: A multidisciplinary committee was formed representing all medical and paramedical disciplines involved in the management of laryngeal cancer and all head and neck oncology centers in The Netherlands. This committee reviewed the literature and formulated statements and recommendations based on the level of evidence and consistency of the literature data. Where reliable literature data were not available, recommendations were based on expert opinion. RESULTS: Strict criteria have been proposed for the radiological diagnostic procedures as well as for the pathology report. For carcinoma in situ and severe dysplasia, microsurgery, preferably by laser, is proposed. For all other stages of invasive carcinoma, a full course of radiotherapy as a voice conserving therapy is the treatment of choice. Only in cases with massive tumor volumes with invasion through the laryngeal skeleton, primary surgery is inevitable. For rehabilitation and supportive care, minimal criteria are described. Due to the complexity of therapy and relative rarity of larynx carcinoma, all patients should be seen at least once in a dedicated head and neck clinic. CONCLUSION: This guideline for the management of larynx carcinoma was produced by a multidisciplinary national committee and based on scientific evidence wherever possible. This procedure of guideline development has created the optimal conditions for nationwide acceptance and implementation of the guideline.},
	author = {Kaanders, J. H. and Hordijk, G. J.},
	doi = {10.1016/s0167-8140(02)00073-7},
	issn = {0167-8140 (Print) 0167-8140},
	journal = {Radiother Oncol},
	keywords = {Carcinoma/*diagnosis/rehabilitation/*therapy Evidence-Based Medicine Health Policy Humans Laryngeal Neoplasms/*diagnosis/rehabilitation/*therapy Larynx Netherlands Practice Guidelines as Topic Social Support},
	note = {Kaanders, Johannes H A M Hordijk, Gerrit Jan Dutch Cooperative Head and Neck Oncology Group Journal Article Ireland 2002/07/27 Radiother Oncol. 2002 Jun;63(3):299-307. doi: 10.1016/s0167-8140(02)00073-7.},
	number = {3},
	pages = {299-307},
	title = {Carcinoma of the larynx: the Dutch national guideline for diagnostics, treatment, supportive care and rehabilitation},
	type = {Journal Article},
	url = {https://www.thegreenjournal.com/article/S0167-8140(02)00073-7/fulltext},
	volume = {63},
	year = {2002},
	bdsk-url-1 = {https://www.thegreenjournal.com/article/S0167-8140(02)00073-7/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s0167-8140(02)00073-7}}

@article{RN256,
	abstract = {BACKGROUND AND PURPOSE: In recent years, various therapeutic concepts have been developed for treating oral cancer, these include preoperative simultaneous "neoadjuvant" radio-chemotherapy and one-stage-surgery with tumour ablation and reconstruction. When considering long-term survival, there is substantial evidence that the neoadjuvant therapy is superior to the primary surgical approach with postoperative radiation. Both treatment concepts, however, have a strong impact on the quality of life. PATIENTS AND METHODS: This study prospectively evaluates and compares quality of life in 53 patients with oral cancer treated according to a neoadjuvant concept or primarily surgically, using the questionnaires QLQ C-30 and H and N35 by the EORTC. RESULTS: Initially both groups showed a marked reduction in the quality of life. Despite a clear improvement in the first postoperative year baseline values were not reached in most of the scores. Specific long-lasting impairments in the symptom scales concerning oral functions were found in both treatment arms. In the neoadjuvant therapy group, however, especially global health and the emotional status were reduced to a higher degree than in the other group. This was particularly noticeable in the early treatment phase. CONCLUSIONS: Following an initial deterioration of quality-of-life after 3 months a gradual improvement of physical and psychological function was observed in the course of the first post-treatment year in both groups. Severe side effects can be observed. These side effects vary strongly in their individual expression. Limitations in the quality of life can be justified, if the more aggressive therapy resulted in a better disease free survival.},
	author = {Kessler, P. A. and Bloch-Birkholz, A. and Leher, A. and Neukam, F. W. and Wiltfang, J.},
	doi = {10.1016/j.radonc.2003.11.017},
	issn = {0167-8140 (Print) 0167-8140},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Carcinoma, Squamous Cell/surgery/*therapy Combined Modality Therapy Female Humans Male Middle Aged Mouth Neoplasms/surgery/*therapy Neoadjuvant Therapy *Quality of Life Surveys and Questionnaires},
	note = {Kessler, Peter A Bloch-Birkholz, Alexandra Leher, Anna Neukam, Friedrich Wilhelm Wiltfang, J{\"o}rg Clinical Trial Comparative Study Journal Article Ireland 2004/04/06 Radiother Oncol. 2004 Mar;70(3):275-82. doi: 10.1016/j.radonc.2003.11.017.},
	number = {3},
	pages = {275-82},
	title = {Evaluation of quality of life of patients with oral squamous cell carcinoma. Comparison of two treatment protocols in a prospective study},
	type = {Journal Article},
	url = {https://www.thegreenjournal.com/article/S0167-8140(03)00444-4/fulltext},
	volume = {70},
	year = {2004},
	bdsk-url-1 = {https://www.thegreenjournal.com/article/S0167-8140(03)00444-4/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2003.11.017}}

@article{RN258,
	abstract = {BACKGROUND AND PURPOSE: In recent years, various therapeutic concepts have been developed for treating oral cancer, these include preoperative simultaneous "neoadjuvant" radio-chemotherapy and one-stage-surgery with tumour ablation and reconstruction. When considering long-term survival, there is substantial evidence that the neoadjuvant therapy is superior to the primary surgical approach with postoperative radiation. Both treatment concepts, however, have a strong impact on the quality of life. PATIENTS AND METHODS: This study prospectively evaluates and compares quality of life in 53 patients with oral cancer treated according to a neoadjuvant concept or primarily surgically, using the questionnaires QLQ C-30 and H and N35 by the EORTC. RESULTS: Initially both groups showed a marked reduction in the quality of life. Despite a clear improvement in the first postoperative year baseline values were not reached in most of the scores. Specific long-lasting impairments in the symptom scales concerning oral functions were found in both treatment arms. In the neoadjuvant therapy group, however, especially global health and the emotional status were reduced to a higher degree than in the other group. This was particularly noticeable in the early treatment phase. CONCLUSIONS: Following an initial deterioration of quality-of-life after 3 months a gradual improvement of physical and psychological function was observed in the course of the first post-treatment year in both groups. Severe side effects can be observed. These side effects vary strongly in their individual expression. Limitations in the quality of life can be justified, if the more aggressive therapy resulted in a better disease free survival.},
	author = {Kessler, P. A. and Bloch-Birkholz, A. and Leher, A. and Neukam, F. W. and Wiltfang, J.},
	doi = {10.1016/j.radonc.2003.11.017},
	issn = {0167-8140 (Print) 0167-8140},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Carcinoma, Squamous Cell/surgery/*therapy Combined Modality Therapy Female Humans Male Middle Aged Mouth Neoplasms/surgery/*therapy Neoadjuvant Therapy *Quality of Life Surveys and Questionnaires},
	note = {Kessler, Peter A Bloch-Birkholz, Alexandra Leher, Anna Neukam, Friedrich Wilhelm Wiltfang, J{\"o}rg Clinical Trial Comparative Study Journal Article Ireland 2004/04/06 Radiother Oncol. 2004 Mar;70(3):275-82. doi: 10.1016/j.radonc.2003.11.017.},
	number = {3},
	pages = {275-82},
	title = {Evaluation of quality of life of patients with oral squamous cell carcinoma. Comparison of two treatment protocols in a prospective study},
	type = {Journal Article},
	volume = {70},
	year = {2004},
	bdsk-url-1 = {https://doi.org/10.1016/j.radonc.2003.11.017}}

@book{RN202,
	author = {Kielbassa, A.M. and Blochberger, P.},
	isbn = {9783877068700},
	publisher = {Schl{\"u}tersche},
	title = {Strahlentherapie im Kopf- und Halsbereich: Implikationen f{\"u}r Zahn{\"a}rzte, HNO-{\"A}rzte und Radiotherapeuten},
	type = {Book},
	url = {https://books.google.de/books?id=jRdWPiRfnQoC},
	year = {2004},
	bdsk-url-1 = {https://books.google.de/books?id=jRdWPiRfnQoC}}

@article{RN405,
	author = {Klijanienko, J. and el-Naggar, A. and Ponzio-Prion, A. and Marandas, P. and Micheau, C. and Caillaud, J. M.},
	doi = {10.1001/archotol.1993.01880200093013},
	issn = {0886-4470 (Print) 0886-4470},
	journal = {Arch Otolaryngol Head Neck Surg},
	keywords = {Aged Biopsy Carcinoma, Adenoid Cystic/*diagnosis/pathology Carcinoma, Basosquamous/*diagnosis/pathology Carcinoma, Squamous Cell/*diagnosis/pathology Diagnosis, Differential Female Head and Neck Neoplasms/*diagnosis/pathology Humans Immunohistochemistry Lymph Nodes/pathology Male Middle Aged Neoplasm Staging},
	number = {8},
	pages = {887-90},
	title = {Basaloid squamous carcinoma of the head and neck. Immunohistochemical comparison with adenoid cystic carcinoma and squamous cell carcinoma},
	type = {Journal Article},
	volume = {119},
	year = {1993},
	bdsk-url-1 = {https://doi.org/10.1001/archotol.1993.01880200093013}}

@article{RN122,
	abstract = {Basaloid squamous carcinoma (BSC) is a rare distinct variant of squamous cell carcinoma of the head and neck region. This entity may commonly pose diagnostic difficulties, especially on small biopsy material. We report the clinicopathological characteristics of 12 new cases and compare their immunohistochemical features with those of solid adenoid cystic carcinomas and conventional squamous cell carcinomas. Our results show that neoplastic BSCs and squamous cell carcinomas do not react to vimentin and S100 protein, while adenoid cystic carcinomas manifest both. The BSCs, however, are S100 protein-positive in intratumoral dendritic Langerhans' cells that are lacking in squamous cell and adenoid cystic carcinomas. Our findings indicate that the immunohistochemical differences between BSC and adenoid cystic carcinoma could assist in their differential diagnosis.},
	author = {Klijanienko, J. and el-Naggar, A. and Ponzio-Prion, A. and Marandas, P. and Micheau, C. and Caillaud, J. M.},
	doi = {10.1001/archotol.1993.01880200093013},
	issn = {0886-4470 (Print) 0886-4470},
	journal = {Arch Otolaryngol Head Neck Surg},
	keywords = {Aged Biopsy Carcinoma, Adenoid Cystic/*diagnosis/pathology Carcinoma, Basosquamous/*diagnosis/pathology Carcinoma, Squamous Cell/*diagnosis/pathology Diagnosis, Differential Female Head and Neck Neoplasms/*diagnosis/pathology Humans Immunohistochemistry Lymph Nodes/pathology Male Middle Aged Neoplasm Staging},
	note = {Klijanienko, J el-Naggar, A Ponzio-Prion, A Marandas, P Micheau, C Caillaud, J M Comparative Study Journal Article United States 1993/08/01 Arch Otolaryngol Head Neck Surg. 1993 Aug;119(8):887-90. doi: 10.1001/archotol.1993.01880200093013.},
	number = {8},
	pages = {887-90},
	title = {Basaloid squamous carcinoma of the head and neck. Immunohistochemical comparison with adenoid cystic carcinoma and squamous cell carcinoma},
	type = {Journal Article},
	url = {https://jamanetwork.com/journals/jamaotolaryngology/article-abstract/621789},
	volume = {119},
	year = {1993},
	bdsk-url-1 = {https://jamanetwork.com/journals/jamaotolaryngology/article-abstract/621789},
	bdsk-url-2 = {https://doi.org/10.1001/archotol.1993.01880200093013}}

@article{RN345,
	author = {Klussmann, J. P. and Weissenborn, S. J. and Wieland, U. and Dries, V. and Eckel, H. E. and Pfister, H. J. and Fuchs, P. G.},
	doi = {10.1007/s00430-002-0126-1},
	issn = {0300-8584 (Print) 0300-8584 (Linking)},
	journal = {Med Microbiol Immunol},
	keywords = {Carcinoma, Squamous Cell/*virology DNA, Viral/analysis Head and Neck Neoplasms/virology Humans Papillomaviridae/classification/*isolation & purification/pathogenicity Papillomavirus Infections/*virology Polymerase Chain Reaction Sequence Analysis, DNA Tonsillar Neoplasms/*virology Tumor Virus Infections/*virology Viral Load},
	number = {3},
	pages = {129-32},
	title = {Human papillomavirus-positive tonsillar carcinomas: a different tumor entity?},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/12920586},
	volume = {192},
	year = {2003},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/12920586},
	bdsk-url-2 = {https://doi.org/10.1007/s00430-002-0126-1}}

@article{RN352,
	author = {Klussmann, J. P. and Weissenborn, S. J. and Wieland, U. and Dries, V. and Eckel, H. E. and Pfister, H. J. and Fuchs, P. G.},
	doi = {10.1007/s00430-002-0126-1},
	issn = {0300-8584 (Print) 0300-8584 (Linking)},
	journal = {Med Microbiol Immunol},
	keywords = {Carcinoma, Squamous Cell/*virology DNA, Viral/analysis Head and Neck Neoplasms/virology Humans Papillomaviridae/classification/*isolation & purification/pathogenicity Papillomavirus Infections/*virology Polymerase Chain Reaction Sequence Analysis, DNA Tonsillar Neoplasms/*virology Tumor Virus Infections/*virology Viral Load},
	number = {3},
	pages = {129-32},
	title = {Human papillomavirus-positive tonsillar carcinomas: a different tumor entity?},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/12920586},
	volume = {192},
	year = {2003},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/12920586},
	bdsk-url-2 = {https://doi.org/10.1007/s00430-002-0126-1}}

@article{RN87,
	abstract = {Human papillomavirus (HPV) infections are thought to be one of the causal factors in the development of head and neck squamous cell carcinomas (HNSCC), particularly in tumors arising from the Waldeyer's tonsillar ring. We screened 98 carefully stratified HNSCC and different control tissues for the presence of HPV DNA by nested polymerase chain reaction (PCR) specific for genital- and Epidermodysplasia verruciformis (EV)-associated HPVs and by HPV16-specific single step PCR. Typing was performed by direct sequencing and/or sequencing of cloned amplimers. On average HNSCC showed rather low HPV DNA prevalences; 18% of the oral cavity cancers, 8% of nasopharyngeal cancers, 25% of hypopharyngeal cancers and 7% of laryngeal cancers were HPV DNA positive. In contrast, HPV sequences could be detected in 45% of the oropharyngeal cancers, particularly tonsillar carcinomas (58%). Tonsillar carcinomas were significantly more likely to be HPV positive than tumors from any other site ( P<0.001). All tonsillar cancers contained oncogenic HPV types, predominantly HPV16 (13 of 14; 93%). Unaffected tonsils were available from two of these patients, but both tested negative for HPV DNA. Furthermore, no HPV DNA could be found in tonsillar biopsy specimens from control groups. Localization and load of HPV DNA was determined in HPV16-positive tonsillar carcinomas, their metastases and in unaffected mucosa using laser-assisted microdissection and subsequent real time fluorescence PCR. We demonstrated that the HPV genome is located in the cancer cells, whereas the infection of normal mucosa is a rare event. Quantification of HPV16 DNA in samples of seven patients yielded viral loads from 6 to 153 HPV DNA copies per beta-globin gene copy and the load values in both locations were roughly comparable. These loads are comparable with data shown for other HPV-associated lesions. Statistical evaluation of data related to clinicopathological parameters showed a significant correlation of the HPV positivity of tonsillar carcinomas with tumor grading ( P=0.008) and alcohol consumption ( P=0.029). Taken together our findings show a preferential association of HPV DNA with tonsillar carcinomas. Furthermore our results argue for HPV-positive tonsillar carcinomas representing a separate tumor entity, which is less dependent on conventional HNSCC risk factors.},
	author = {Klussmann, J. P. and Weissenborn, S. J. and Wieland, U. and Dries, V. and Eckel, H. E. and Pfister, H. J. and Fuchs, P. G.},
	doi = {10.1007/s00430-002-0126-1},
	issn = {0300-8584 (Print) 0300-8584 (Linking)},
	journal = {Med Microbiol Immunol},
	keywords = {Carcinoma, Squamous Cell/*virology DNA, Viral/analysis Head and Neck Neoplasms/virology Humans Papillomaviridae/classification/*isolation & purification/pathogenicity Papillomavirus Infections/*virology Polymerase Chain Reaction Sequence Analysis, DNA Tonsillar Neoplasms/*virology Tumor Virus Infections/*virology Viral Load},
	note = {Klussmann, Jens P Weissenborn, Soenke J Wieland, Ulrike Dries, Volker Eckel, Hans E Pfister, Herbert J Fuchs, Pawel G eng Research Support, Non-U.S. Gov't Germany 2003/08/16 Med Microbiol Immunol. 2003 Aug;192(3):129-32. doi: 10.1007/s00430-002-0126-1. Epub 2002 Sep 14.},
	number = {3},
	pages = {129-32},
	title = {Human papillomavirus-positive tonsillar carcinomas: a different tumor entity?},
	type = {Journal Article},
	url = {https://link.springer.com/content/pdf/10.1007/s00430-002-0126-1.pdf},
	volume = {192},
	year = {2003},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007/s00430-002-0126-1.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/s00430-002-0126-1}}

@article{RN346,
	author = {Klussmann, J. P. and Weissenborn, S. J. and Wieland, U. and Dries, V. and Kolligs, J. and Jungehuelsing, M. and Eckel, H. E. and Dienes, H. P. and Pfister, H. J. and Fuchs, P. G.},
	doi = {10.1002/1097-0142(20011201)92:11<2875::aid-cncr10130>3.0.co;2-7},
	issn = {0008-543X (Print) 0008-543X (Linking)},
	journal = {Cancer},
	keywords = {Adult Aged Aged, 80 and over DNA, Viral/*analysis Female Humans Male Middle Aged *Papillomaviridae/genetics/physiology Papillomavirus Infections/*epidemiology/etiology Prevalence Sequence Analysis, DNA Statistics as Topic Tonsillar Neoplasms/complications/*virology Tumor Virus Infections/*epidemiology/etiology Viral Load},
	number = {11},
	pages = {2875-84},
	title = {Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11753961},
	volume = {92},
	year = {2001},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/11753961},
	bdsk-url-2 = {https://doi.org/10.1002/1097-0142(20011201)92:11%3C2875::aid-cncr10130%3E3.0.co;2-7}}

@article{RN88,
	abstract = {BACKGROUND: Oncogenic human papillomaviruses (HPV) DNA have repeatedly been observed in many head and neck carcinomas (HNSCCs), and HPV infections are currently considered a possible factor in the etiology of these tumors. However, the reported prevalences of HPV-DNA in HNSCC are variable. In the current study the authors used highly sensitive polymerase chain reactions (PCRs) to analyze the occurrence of viral sequences in 98 carefully stratified HNSCCs. The authors determined the load and localization of HPV DNA in a subset of tonsillar carcinomas and their metastases. METHODS: Nested PCR and an HPV16 specific single step PCR were used to screen 98 HNSCCs for HPV DNA for genital- and Epidermodysplasia verruciformis (EV)-associated HPVs. Typing was performed by direct sequencing and/or sequencing of cloned amplimers. In two patients HPV16 subtypes in tonsillar carcinomas and their metastases were compared by amplification and sequencing of the long control region of the virus. In a subset of HPV16 positive tonsillar carcinomas and their metastases, localization and viral load were determined using laser assisted microdissection and real time fluorescent PCR, respectively. RESULTS: Altogether 25 HNSCCs (26%) were found to be HPV positive. Stratified according to the tumor localization, the frequency of HPV positive lesions was 18% in the oral cavity, 45% for oropharynx, 25% for hypopharynx, 8% for nasopharynx, and 7% for larynx. The highest HPV DNA prevalence (58%) was found in tonsillar carcinomas. The high risk HPV type 16 was found in 84% of positive HNSCCs, in 14% of which EV-associated HPVs were detected. Human papillomavirus sequences were detected in 64% of biopsies with normal mucosa from 11 patients with positive carcinomas. As a control group, 14 tumor free tonsils were analyzed. In none of these specimens were HPV sequences detected. Viral long transcriptional control region sequences in homologous metastases were identical with those in primary tumors and the load values in both locations were roughly comparable. Viral loads differed substantially in different areas of one tumor. Statistical evaluation of data related to clinicopathologic parameters showed a significant linkage of HPV with tonsillar carcinomas compared to other locations. Furthermore, a significant correlation of HPV status of tonsillar carcinomas with tumor grading and alcohol consumption was found. CONCLUSIONS: Our study shows a preferential association of HPV-DNA with tonsillar carcinomas. The data support the view of HPV negative and positive tonsillar carcinomas being different tumor entities and conventional cancer risk factors being of less importance in HPV-infected individuals. The HPV genome is located in the cancer cells, whereas the infection of normal mucosa is a rare event. Data on quantification of HPV16 in tonsillar tumors and their metastases showed mean viral loads comparable to other HPV associated malignancies.},
	author = {Klussmann, J. P. and Weissenborn, S. J. and Wieland, U. and Dries, V. and Kolligs, J. and Jungehuelsing, M. and Eckel, H. E. and Dienes, H. P. and Pfister, H. J. and Fuchs, P. G.},
	doi = {10.1002/1097-0142(20011201)92:11<2875::aid-cncr10130>3.0.co;2-7},
	issn = {0008-543X (Print) 0008-543X (Linking)},
	journal = {Cancer},
	keywords = {Adult Aged Aged, 80 and over DNA, Viral/*analysis Female Humans Male Middle Aged *Papillomaviridae/genetics/physiology Papillomavirus Infections/*epidemiology/etiology Prevalence Sequence Analysis, DNA Statistics as Topic Tonsillar Neoplasms/complications/*virology Tumor Virus Infections/*epidemiology/etiology Viral Load},
	note = {Klussmann, J P Weissenborn, S J Wieland, U Dries, V Kolligs, J Jungehuelsing, M Eckel, H E Dienes, H P Pfister, H J Fuchs, P G eng Research Support, Non-U.S. Gov't 2001/12/26 Cancer. 2001 Dec 1;92(11):2875-84. doi: 10.1002/1097-0142(20011201)92:11<2875::aid-cncr10130>3.0.co;2-7.},
	number = {11},
	pages = {2875-84},
	title = {Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas},
	type = {Journal Article},
	url = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2820011201%2992%3A11%3C2875%3A%3AAID-CNCR10130%3E3.0.CO%3B2-7?download=true},
	volume = {92},
	year = {2001},
	bdsk-url-1 = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2820011201%2992%3A11%3C2875%3A%3AAID-CNCR10130%3E3.0.CO%3B2-7?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/1097-0142(20011201)92:11%3C2875::aid-cncr10130%3E3.0.co;2-7}}

@article{RN268,
	abstract = {BACKGROUND: The purpose of this study was to evaluate the oncologic effectiveness of radical and different types of modified neck dissections with preservation of n. accessorius, v. jugularis interna, and m. sternocleidomastoideus and to identify prognostic factors for regional control and survival in univariate and multivariate analysis. METHODS: This retrospective study included 373 patients with squamous cell carcinoma of the oral cavity who underwent 401 neck dissections between January 1986 and December 1995 at the Department for Oral and Maxillofacial Surgery, Hanover Medical School. RESULTS: The 5-year regional control was estimated at 87%. Relapse occurred only within the first 2 years after neck dissection. The number of positive nodes, metastases without lymphatic tissue, preparation of metastases from the carotid artery and cranial base, and preoperative radiochemotherapy were analyzed as prognostic factors with significant influence. The grade of metastases, extracapsular spread, lymphangiosis carcinomatosa, and postoperative radiation showed no prognostic significance. DISCUSSION: The comparison of recurrent metastases after radical and modified neck dissection demonstrated that as the extent of neck disease increased there was a tendency toward improved regional control after radical neck dissection.},
	author = {Kokem{\"u}ller, H. and Brachvogel, P. and Eckardt, A. and Hausamen, J. E.},
	doi = {10.1007/s10006-001-0359-y},
	issn = {1432-9417 (Print) 1432-9417},
	journal = {Mund Kiefer Gesichtschir},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/pathology/*secondary/surgery Disease-Free Survival Female Head and Neck Neoplasms/pathology/*secondary/surgery Humans Lymphatic Metastasis Male Middle Aged Mouth Neoplasms/pathology/*surgery Neck Dissection/*methods Neoplasm Staging Prognosis Reoperation Treatment Outcome},
	note = {Kokem{\"u}ller, H Brachvogel, P Eckardt, A Hausamen, J E English Abstract Journal Article Germany 2002/05/23 Mund Kiefer Gesichtschir. 2002 Mar;6(2):91-7. doi: 10.1007/s10006-001-0359-y.},
	number = {2},
	pages = {91-7},
	title = {[Effectiveness of neck dissection in metastasizing mouth carcinoma. Uni- and multivariate analysis of factors of influence]},
	type = {Journal Article},
	url = {https://link.springer.com/content/pdf/10.1007/s10006-001-0359-y.pdf},
	volume = {6},
	year = {2002},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007/s10006-001-0359-y.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/s10006-001-0359-y}}

@article{RN447,
	author = {Kononen, J. and Bubendorf, L. and Kallioniemi, A. and Barlund, M. and Schraml, P. and Leighton, S. and Torhorst, J. and Mihatsch, M. J. and Sauter, G. and Kallioniemi, O. P.},
	doi = {10.1038/nm0798-844},
	issn = {1078-8956 (Print) 1078-8956 (Linking)},
	journal = {Nat Med},
	keywords = {Animals Biomarkers, Tumor/genetics/metabolism Breast Neoplasms/*genetics/metabolism/pathology Cyclin D1/genetics/metabolism Female *Genetic Techniques Humans Immunoenzyme Techniques In Situ Hybridization, Fluorescence Mice Oncogene Proteins v-myb Proto-Oncogene Proteins c-myc/genetics/metabolism Rabbits Receptor, ErbB-2/genetics/metabolism Receptors, Estrogen/genetics/metabolism Retroviridae Proteins, Oncogenic/genetics/metabolism Tumor Suppressor Protein p53/genetics/metabolism},
	number = {7},
	pages = {844-7},
	title = {Tissue microarrays for high-throughput molecular profiling of tumor specimens},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9662379},
	volume = {4},
	year = {1998},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/9662379},
	bdsk-url-2 = {https://doi.org/10.1038/nm0798-844}}

@article{RN40,
	abstract = {Many genes and signalling pathways controlling cell proliferation, death and differentiation, as well as genomic integrity, are involved in cancer development. New techniques, such as serial analysis of gene expression and cDNA microarrays, have enabled measurement of the expression of thousands of genes in a single experiment, revealing many new, potentially important cancer genes. These genome screening tools can comprehensively survey one tumor at a time; however, analysis of hundreds of specimens from patients in different stages of disease is needed to establish the diagnostic, prognostic and therapeutic importance of each of the emerging cancer gene candidates. Here we have developed an array-based high-throughput technique that facilitates gene expression and copy number surveys of very large numbers of tumors. As many as 1000 cylindrical tissue biopsies from individual tumors can be distributed in a single tumor tissue microarray. Sections of the microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array, and consecutive sections allow the rapid analysis of hundreds of molecular markers in the same set of specimens. Our detection of six gene amplifications as well as p53 and estrogen receptor expression in breast cancer demonstrates the power of this technique for defining new subgroups of tumors.},
	author = {Kononen, J. and Bubendorf, L. and Kallioniemi, A. and Barlund, M. and Schraml, P. and Leighton, S. and Torhorst, J. and Mihatsch, M. J. and Sauter, G. and Kallioniemi, O. P.},
	doi = {10.1038/nm0798-844},
	issn = {1078-8956 (Print) 1078-8956 (Linking)},
	journal = {Nat Med},
	keywords = {Animals Biomarkers, Tumor/genetics/metabolism Breast Neoplasms/*genetics/metabolism/pathology Cyclin D1/genetics/metabolism Female *Genetic Techniques Humans Immunoenzyme Techniques In Situ Hybridization, Fluorescence Mice Oncogene Proteins v-myb Proto-Oncogene Proteins c-myc/genetics/metabolism Rabbits Receptor, ErbB-2/genetics/metabolism Receptors, Estrogen/genetics/metabolism Retroviridae Proteins, Oncogenic/genetics/metabolism Tumor Suppressor Protein p53/genetics/metabolism},
	note = {Kononen, J Bubendorf, L Kallioniemi, A Barlund, M Schraml, P Leighton, S Torhorst, J Mihatsch, M J Sauter, G Kallioniemi, O P eng Research Support, Non-U.S. Gov't Nat Med. 1998 Jul;4(7):844-7. doi: 10.1038/nm0798-844.},
	number = {7},
	pages = {844-7},
	title = {Tissue microarrays for high-throughput molecular profiling of tumor specimens},
	type = {Journal Article},
	url = {https://www.nature.com/articles/nm0798-844.pdf},
	volume = {4},
	year = {1998},
	bdsk-url-1 = {https://www.nature.com/articles/nm0798-844.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/nm0798-844}}

@article{RN57,
	abstract = {Many genes and signalling pathways controlling cell proliferation, death and differentiation, as well as genomic integrity, are involved in cancer development. New techniques, such as serial analysis of gene expression and cDNA microarrays, have enabled measurement of the expression of thousands of genes in a single experiment, revealing many new, potentially important cancer genes. These genome screening tools can comprehensively survey one tumor at a time; however, analysis of hundreds of specimens from patients in different stages of disease is needed to establish the diagnostic, prognostic and therapeutic importance of each of the emerging cancer gene candidates. Here we have developed an array-based high-throughput technique that facilitates gene expression and copy number surveys of very large numbers of tumors. As many as 1000 cylindrical tissue biopsies from individual tumors can be distributed in a single tumor tissue microarray. Sections of the microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array, and consecutive sections allow the rapid analysis of hundreds of molecular markers in the same set of specimens. Our detection of six gene amplifications as well as p53 and estrogen receptor expression in breast cancer demonstrates the power of this technique for defining new subgroups of tumors.},
	author = {Kononen, J. and Bubendorf, L. and Kallioniemi, A. and Barlund, M. and Schraml, P. and Leighton, S. and Torhorst, J. and Mihatsch, M. J. and Sauter, G. and Kallioniemi, O. P.},
	doi = {10.1038/nm0798-844},
	issn = {1078-8956 (Print) 1078-8956 (Linking)},
	journal = {Nat Med},
	keywords = {Animals Biomarkers, Tumor/genetics/metabolism Breast Neoplasms/*genetics/metabolism/pathology Cyclin D1/genetics/metabolism Female *Genetic Techniques Humans Immunoenzyme Techniques In Situ Hybridization, Fluorescence Mice Oncogene Proteins v-myb Proto-Oncogene Proteins c-myc/genetics/metabolism Rabbits Receptor, ErbB-2/genetics/metabolism Receptors, Estrogen/genetics/metabolism Retroviridae Proteins, Oncogenic/genetics/metabolism Tumor Suppressor Protein p53/genetics/metabolism},
	note = {Kononen, J Bubendorf, L Kallioniemi, A Barlund, M Schraml, P Leighton, S Torhorst, J Mihatsch, M J Sauter, G Kallioniemi, O P eng Research Support, Non-U.S. Gov't 1998/07/14 Nat Med. 1998 Jul;4(7):844-7. doi: 10.1038/nm0798-844.},
	number = {7},
	pages = {844-7},
	title = {Tissue microarrays for high-throughput molecular profiling of tumor specimens},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9662379},
	volume = {4},
	year = {1998},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/9662379},
	bdsk-url-2 = {https://doi.org/10.1038/nm0798-844}}

@article{RN436,
	author = {Kononen, J. and Bubendorf, L. and Kallioniemi, A. and Barlund, M. and Schraml, P. and Leighton, S. and Torhorst, J. and Mihatsch, M. J. and Sauter, G. and Kallioniemi, O. P.},
	doi = {10.1038/nm0798-844},
	issn = {1078-8956 (Print) 1078-8956 (Linking)},
	journal = {Nat Med},
	keywords = {Animals Biomarkers, Tumor/genetics/metabolism Breast Neoplasms/*genetics/metabolism/pathology Cyclin D1/genetics/metabolism Female *Genetic Techniques Humans Immunoenzyme Techniques In Situ Hybridization, Fluorescence Mice Oncogene Proteins v-myb Proto-Oncogene Proteins c-myc/genetics/metabolism Rabbits Receptor, ErbB-2/genetics/metabolism Receptors, Estrogen/genetics/metabolism Retroviridae Proteins, Oncogenic/genetics/metabolism Tumor Suppressor Protein p53/genetics/metabolism},
	number = {7},
	pages = {844-7},
	title = {Tissue microarrays for high-throughput molecular profiling of tumor specimens},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9662379},
	volume = {4},
	year = {1998},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/9662379},
	bdsk-url-2 = {https://doi.org/10.1038/nm0798-844}}

@article{RN192,
	abstract = {This retrospective study on 832 head and neck cancer patients who died between 1961 and 1985 was carried out to determine the incidence and sites of distant metastases. All patients were staged prior to definitive treatment and were autopsied. The overall incidence of distant metastases was 47 percent. The hypopharynx had the highest incidence of distant metastases (60 percent), followed by the base of the tongue (53 percent) and the anterior tongue (50 percent). Of the 387 patients with distant metastases, 91 percent died with uncontrolled tumor either at the primary site or in the neck. The lung was the most common site of distant metastases (80 percent), followed by the mediastinal nodes (34 percent), the liver (31 percent), and bone (31 percent). Overall, 6 percent of the patients had stage I disease, 20 percent had stage II disease, 32 percent had stage III disease, and 43 percent had stage IV disease. The highest incidence of distant metastases was found in those patients with stage IV disease (193 of 350 patients, 55 percent). We believe that the initial stage of disease does appear to be related to the ultimate development of the distant metastases.},
	author = {Kotwall, C. and Sako, K. and Razack, M. S. and Rao, U. and Bakamjian, V. and Shedd, D. P.},
	doi = {10.1016/0002-9610(89)90020-2},
	issn = {0002-9610 (Print) 0002-9610},
	journal = {Am J Surg},
	keywords = {Carcinoma, Squamous Cell/pathology/*secondary Female Head and Neck Neoplasms/*pathology Humans Lymphatic Metastasis Male Middle Aged Retrospective Studies},
	note = {Kotwall, C Sako, K Razack, M S Rao, U Bakamjian, V Shedd, D P Journal Article United States 1987/10/01 Am J Surg. 1987 Oct;154(4):439-42. doi: 10.1016/0002-9610(89)90020-2.},
	number = {4},
	pages = {439-42},
	title = {Metastatic patterns in squamous cell cancer of the head and neck},
	type = {Journal Article},
	url = {https://www.americanjournalofsurgery.com/article/0002-9610(89)90020-2/pdf},
	volume = {154},
	year = {1987},
	bdsk-url-1 = {https://www.americanjournalofsurgery.com/article/0002-9610(89)90020-2/pdf},
	bdsk-url-2 = {https://doi.org/10.1016/0002-9610(89)90020-2}}

@article{RN180,
	abstract = {Improved diagnostic techniques and more effective treatment concepts have resulted in a growing number of patients with oropharyngeal cancer diagnosed with second primary tumours. In order to evaluate the relative number of patients with second primary tumours and to estimate the efficacy of diagnostic procedures, a retrospective evaluation of 981 patients with oropharyngeal cancer, who were treated during 20 years in one single medical centre, was performed. In total, 9.2% of the patients were affected by secondary cancer, 1.5% from tertiary cancer and 0.2% from quartary cancer. Of the multiple cancers, 27.8% occurred synchronously and 72.2% metachronously. If the index tumour was located at the oral floor or the pharynx, the risk of second primary tumours was enhanced; if the index tumour was located at the lips or the tongue, the risk was reduced. The 5-year survival of all examined patients was 34.1%; the survival of patients with multiple cancers was 62.3% at the diagnosis of the index tumour and dropped to 30.5% at the diagnosis of an additional malignancy. Of the second primary tumours, 23.2% were diagnosed by panendoscopy. We conclude that among patients with oropharyngeal cancer, the presence of second primary tumours always has to be considered and that panendoscopy is a valuable tool for their diagnosis.},
	author = {Kramer, F. J. and Janssen, M. and Eckardt, A.},
	doi = {10.1007/s00784-003-0246-z},
	issn = {1432-6981 (Print) 1432-6981},
	journal = {Clin Oral Investig},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/*epidemiology Endoscopy/statistics & numerical data Female Follow-Up Studies Germany/epidemiology Humans Lip Neoplasms/epidemiology Male Middle Aged Mouth Neoplasms/epidemiology Neoplasms, Multiple Primary/epidemiology Neoplasms, Second Primary/*epidemiology Oropharyngeal Neoplasms/*epidemiology Pharyngeal Neoplasms/epidemiology Retrospective Studies Risk Factors Sex Factors Survival Rate Tongue Neoplasms/epidemiology},
	note = {Kramer, Franz-Josef Janssen, Marcel Eckardt, Andre Journal Article Germany 2004/03/17 Clin Oral Investig. 2004 Jun;8(2):56-62. doi: 10.1007/s00784-003-0246-z. Epub 2004 Mar 16.},
	number = {2},
	pages = {56-62},
	title = {Second primary tumours in oropharyngeal squamous cell carcinoma},
	type = {Journal Article},
	url = {https://link.springer.com/content/pdf/10.1007/s00784-003-0246-z.pdf},
	volume = {8},
	year = {2004},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007/s00784-003-0246-z.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/s00784-003-0246-z}}

@article{RN241,
	abstract = {Between March 1973 and June 1979, patients with advanced operable squamous cell carcinoma of the supraglottic larynx or hypopharynx were randomly allocated to receive either preoperative radiation therapy (5,000 rad) or postoperative radiation therapy (6,000 rad). Patients with oral cavity or oropharynx lesions were randomly assigned either preoperative radiation, postoperative radiation, or definitive radiation therapy (6,500-7,000 rad), with surgery reserved for salvage if residual disease was present 6 weeks after completion of irradiation. Three hundred twenty patients were evaluable with a median follow-up of 60 months. Based on results in 277 patients across all four regions combined, locoregional control was significantly better for patients assigned to receive postoperative radiation therapy (65%) compared with those assigned to receive preoperative radiation therapy (48%, P = 0.04). This was due to a higher rate of both persistent and recurrent local and regional disease in the preoperative group. Survival also showed a trend to be better in the postoperative group (38%) compared with the preoperative group (33%, P = 0.10). Rates of severe surgical and radiation therapy complications were similar overall. Forty-three patients were evaluable for each of the three treatment regimens assigned to patients with oral cavity or oropharynx lesions. Due to the small number of patients available for this portion of the trial, the observed differences for overall survival (4-year percentage 33% overall; 30% preoperative, 36% postoperative, 33% definitive radiation therapy) and for locoregional control (45% overall; 43% preoperative, 52% postoperative, 38% definitive radiation therapy) were not statistically significant. The use of definitive radiation therapy with surgical rescue as an ethically justified alternative treatment for these tumors remains a question for further research.},
	author = {Kramer, S. and Gelber, R. D. and Snow, J. B. and Marcial, V. A. and Lowry, L. D. and Davis, L. W. and Chandler, R.},
	doi = {10.1002/hed.2890100105},
	issn = {0148-6403 (Print) 0148-6403},
	journal = {Head Neck Surg},
	keywords = {Carcinoma, Squamous Cell/mortality/radiotherapy/surgery/*therapy Combined Modality Therapy Female Head and Neck Neoplasms/mortality/radiotherapy/surgery/*therapy Humans Male Postoperative Complications Prospective Studies Random Allocation},
	note = {Kramer, S Gelber, R D Snow, J B Marcial, V A Lowry, L D Davis, L W Chandler, R CA 21661/CA/NCI NIH HHS/United States Clinical Trial Journal Article Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S. United States 1987/09/01 Head Neck Surg. 1987 Sep-Oct;10(1):19-30. doi: 10.1002/hed.2890100105.},
	number = {1},
	pages = {19-30},
	title = {Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hed.2890100105?download=true},
	volume = {10},
	year = {1987},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hed.2890100105?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/hed.2890100105}}

@article{RN18,
	abstract = {Inactivation of cancer stem cells (CSCs) is of utmost importance for tumor cure after radiotherapy. An increasing body of evidence complies with a higher radioresistance of CSCs compared to the mass of tumor cells, supporting the use of CSC related biomarkers for prediction of radiotherapy outcome. Treatment individualization strategies for patient groups with vastly different risk of recurrence will most likely require application of more than one biomarker. Specifically, inclusion of established biomarkers like tumor size for primary radio(chemo)therapy or human papilloma virus (HPV) infection status in head and neck squamous cell carcinoma seems to be of very high relevance. The high heterogeneity of CSC subclones along with changes of the functional behavior of individual tumors under treatment underlines the importance of the selection of the optimal timepoint(s) of biomarker evaluation, but also provides a potential therapeutic target for combined treatment approaches with irradiation.},
	author = {Krause, M. and Dubrovska, A. and Linge, A. and Baumann, M.},
	doi = {10.1016/j.addr.2016.02.002},
	issn = {1872-8294 (Electronic) 0169-409X (Linking)},
	journal = {Adv Drug Deliv Rev},
	keywords = {Animals Combined Modality Therapy Head and Neck Neoplasms/complications/pathology/radiotherapy Humans Neoplasms/*pathology/*radiotherapy Neoplastic Stem Cells/*radiation effects Papillomavirus Infections/complications/radiotherapy Treatment Outcome *Biomarker *Cancer stem cells *Prediction *Prognosis *Radiotherapy},
	note = {Krause, Mechthild Dubrovska, Anna Linge, Annett Baumann, Michael eng Review Netherlands Adv Drug Deliv Rev. 2017 Jan 15;109:63-73. doi: 10.1016/j.addr.2016.02.002. Epub 2016 Feb 12.},
	pages = {63-73},
	title = {Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26877102},
	volume = {109},
	year = {2017},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/26877102},
	bdsk-url-2 = {https://doi.org/10.1016/j.addr.2016.02.002}}

@article{RN416,
	author = {Krause, M. and Yaromina, A. and Eicheler, W. and Koch, U. and Baumann, M.},
	doi = {10.1158/1078-0432.CCR-10-2639},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Biomarkers, Tumor Combined Modality Therapy Humans Neoplasm Recurrence, Local/drug therapy/radiotherapy Neoplasms/drug therapy/pathology/*radiotherapy *Neoplastic Stem Cells/metabolism/pathology/radiation effects *Radiation Tolerance Signal Transduction/drug effects},
	number = {23},
	pages = {7224-9},
	title = {Cancer stem cells: targets and potential biomarkers for radiotherapy},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21976536},
	volume = {17},
	year = {2011},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/21976536},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-10-2639}}

@article{RN412,
	author = {Krause, M. and Yaromina, A. and Eicheler, W. and Koch, U. and Baumann, M.},
	doi = {10.1158/1078-0432.CCR-10-2639},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Biomarkers, Tumor Combined Modality Therapy Humans Neoplasm Recurrence, Local/drug therapy/radiotherapy Neoplasms/drug therapy/pathology/*radiotherapy *Neoplastic Stem Cells/metabolism/pathology/radiation effects *Radiation Tolerance Signal Transduction/drug effects},
	number = {23},
	pages = {7224-9},
	title = {Cancer stem cells: targets and potential biomarkers for radiotherapy},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21976536},
	volume = {17},
	year = {2011},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/21976536},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-10-2639}}

@article{RN22,
	abstract = {Cancer stem cells (CSC) have the unique ability to cause tumor recurrences if they survive treatment. Radiotherapy has curative potential because it has been functionally shown to sufficiently inactivate CSCs. It is well known that CSCs mediate the radiation resistance of tumors by tumor-specific factors, such as the pretreatment number of CSCs and repopulation or reoxygenation during fractionated radiotherapy. CSCs appear to have a higher intrinsic radioresistance than non-CSCs, a factor that is especially important for the development of predictive biomarkers that, if this finding holds true, can only be successfully established if they are stem-cell specific. Recent clinical data imply that stem-cell-related surface markers may be directly used as predictors for the radiocurability of tumors with comparable risk factors, such as histology and size. Future studies need to address the question of which additional markers need to be considered if more heterogeneous patient collectives are investigated. With the goal of developing a direct targeting approach, investigators are currently evaluating several drugs that are intended to target CSCs by inhibiting stem-cell-related signal transduction pathways. We need to preclinically test such drugs as combined-modality therapies in combination with radiotherapy to evaluate their curative potential, and optimize them by increasing their specificity to CSCs over normal tissue stem cells to avoid increased radiation toxicity.},
	author = {Krause, M. and Yaromina, A. and Eicheler, W. and Koch, U. and Baumann, M.},
	doi = {10.1158/1078-0432.CCR-10-2639},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Biomarkers, Tumor Combined Modality Therapy Humans Neoplasm Recurrence, Local/drug therapy/radiotherapy Neoplasms/drug therapy/pathology/*radiotherapy *Neoplastic Stem Cells/metabolism/pathology/radiation effects *Radiation Tolerance Signal Transduction/drug effects},
	note = {Krause, Mechthild Yaromina, Ala Eicheler, Wolfgang Koch, Ulrike Baumann, Michael eng Research Support, Non-U.S. Gov't Clin Cancer Res. 2011 Dec 1;17(23):7224-9. doi: 10.1158/1078-0432.CCR-10-2639. Epub 2011 Oct 5.},
	number = {23},
	pages = {7224-9},
	title = {Cancer stem cells: targets and potential biomarkers for radiotherapy},
	type = {Journal Article},
	url = {https://clincancerres.aacrjournals.org/content/clincanres/17/23/7224.full.pdf},
	volume = {17},
	year = {2011},
	bdsk-url-1 = {https://clincancerres.aacrjournals.org/content/clincanres/17/23/7224.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-10-2639}}

@article{RN153,
	abstract = {Mucosal human papillomaviruses (HPV) are the cause of cervical cancer and likely a subset of head and neck squamous cell carcinomas (HNSCC), yet the global prevalence and type distribution of HPV in HNSCC remains unclear. We systematically reviewed published studies of HNSCC biopsies that employed PCR-based methods to detect and genotype HPV to describe the prevalence and type distribution of HPV by anatomic cancer site. Geographic location and study size were investigated as possible sources of variability. In the 5,046 HNSCC cancer specimens from 60 studies, the overall HPV prevalence was 25.9% [95% confidence interval (95% CI), 24.7-27.2]. HPV prevalence was significantly higher in oropharyngeal SCCs (35.6% of 969; 95% CI, 32.6-38.7) than oral SCCs (23.5% of 2,642; 95% CI, 21.9-25.1) or laryngeal SCCs (24.0% of 1,435; 95% CI, 21.8-26.3). HPV16 accounted for a larger majority of HPV-positive oropharyngeal SCCs (86.7%; 95% CI, 82.6-90.1) compared with HPV-positive oral SCCs (68.2%; 95% CI, 64.4-71.9) and laryngeal SCCs (69.2%; 95% CI, 64.0-74.0). Conversely, HPV18 was rare in HPV-positive oropharyngeal SCCs (2.8%; 95% CI, 1.3-5.3) compared with other head and neck sites [34.1% (95% CI, 30.4-38.0) of oral SCCs and 17.0% (95% CI, 13.0-21.6) of laryngeal SCCs]. Aside from HPV16 and HPV18, other oncogenic HPVs were rarely detected in HNSCC. Tumor site-specific HPV prevalence was higher among studies from North America compared with Europe and Asia. The high HPV16 prevalence and the lack of HPV18 in oropharyngeal compared with other HNSCCs may point to specific virus-tissue interactions. Small sample size and publication bias complicate the assessment of the prevalence of HPV in head and neck sites beyond the oropharynx.},
	author = {Kreimer, A. R. and Clifford, G. M. and Boyle, P. and Franceschi, S.},
	doi = {10.1158/1055-9965.Epi-04-0551},
	issn = {1055-9965 (Print) 1055-9965},
	journal = {Cancer Epidemiol Biomarkers Prev},
	keywords = {Carcinoma, Squamous Cell/*virology DNA, Viral/analysis Head and Neck Neoplasms/*virology Humans Laryngeal Neoplasms/virology Mouth Neoplasms/virology Oropharyngeal Neoplasms/virology Papillomaviridae/*isolation & purification Papillomavirus Infections/*diagnosis},
	note = {Kreimer, Aimee R Clifford, Gary M Boyle, Peter Franceschi, Silvia Journal Article Review Systematic Review United States 2005/03/01 Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75. doi: 10.1158/1055-9965.EPI-04-0551.},
	number = {2},
	pages = {467-75},
	title = {Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review},
	type = {Journal Article},
	url = {https://cebp.aacrjournals.org/content/cebp/14/2/467.full.pdf},
	volume = {14},
	year = {2005},
	bdsk-url-1 = {https://cebp.aacrjournals.org/content/cebp/14/2/467.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1055-9965.Epi-04-0551}}

@article{RN222,
	abstract = {Primary radiochemotherapy is a treatment option for patients with locally advanced or unresectable head and neck cancer. Compared to conventional radiotherapy, intensity-modulated radiotherapy (IMRT) is associated with fewer long-term toxicities and better quality of life. Whether IMRT improves local control in these patients needs to be further investigated. The risk factors and treatment toxicities must be taken into consideration and discussed with the patients. New approaches combining radiotherapy and biological targets are a treatment option. The implementation of these substances in treatment protocols is increasing. Sensitive and specific prognostic biomarkers for patient identification to optimize treatment selection are important, but reliable parameters are still missing.},
	author = {Laban, S. and Wang, C. J. and Knecht, R. and Tribius, S. and M{\"u}nscher, A.},
	doi = {10.1007/s00106-011-2463-0},
	issn = {0017-6192},
	journal = {Hno},
	keywords = {Antineoplastic Agents/*therapeutic use Chemoradiotherapy/*methods/*trends Germany Head and Neck Neoplasms/*therapy Humans Radiotherapy, Conformal/*trends},
	note = {1433-0458 Laban, S Wang, C J Knecht, R Tribius, S M{\"u}nscher, A Congress Germany 2012/05/10 HNO. 2012 May;60(5):393-7. doi: 10.1007/s00106-011-2463-0.},
	number = {5},
	pages = {393-7},
	title = {[New aspects of primary radiochemotherapy in head and neck cancer. Highlights from the 2011 ASCO Congress]},
	type = {Journal Article},
	url = {https://link.springer.com/content/pdf/10.1007/s00106-011-2463-0.pdf},
	volume = {60},
	year = {2012},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007/s00106-011-2463-0.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/s00106-011-2463-0}}

@article{RN259,
	abstract = {PURPOSE: To investigate the impact of treatment-related toxicity on health-related quality of life (HRQoL) among patients with head and neck squamous cell carcinoma treated with radiotherapy either alone or in combination with chemotherapy or surgery. PATIENTS AND METHODS: The study sample was composed of 425 disease-free patients. Toxicity was scored according to the European Organisation for Research and Treatment of Cancer (EORTC)/Radiation Therapy Oncology Group (RTOG) late radiation-induced morbidity scoring system. HRQoL was assessed using the EORTC Quality of Life Questionnaire C30. These assessments took place at 6, 12, 18, and 24 months after completion of radiotherapy. The analysis was performed using a multivariate analysis of variance. RESULTS: Of the six RTOG scales investigated, two significantly affected self-reported HRQoL, salivary gland (RTOG(xerostomia)) and esophagus/pharynx (RTOG(swallowing)). Although RTOG(xerostomia) was reported most frequently, HRQoL was most affected by RTOG(swallowing), particularly in the first 18 months after completion of radiotherapy. CONCLUSION: Late radiation-induced toxicity, particularly RTOG(swallowing) and RTOG(xerostomia), has a significant impact on the more general dimensions of HRQoL. These findings suggest that the development of new radiation-induced delivery techniques should not only focus on reduction of the dose to the salivary glands, but also on anatomic structures that are involved in swallowing.},
	author = {Langendijk, J. A. and Doornaert, P. and Verdonck-de Leeuw, I. M. and Leemans, C. R. and Aaronson, N. K. and Slotman, B. J.},
	doi = {10.1200/jco.2007.14.6647},
	issn = {0732-183x},
	journal = {J Clin Oncol},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/drug therapy/physiopathology/*radiotherapy/surgery Chemotherapy, Adjuvant Deglutition/radiation effects Female Head and Neck Neoplasms/drug therapy/physiopathology/*radiotherapy/surgery Health Status Indicators Humans Male Middle Aged Patient Compliance Prospective Studies *Quality of Life Radiation Injuries/*etiology/physiopathology Radiotherapy/adverse effects Surveys and Questionnaires Time Factors Treatment Outcome Xerostomia/etiology},
	note = {1527-7755 Langendijk, Johannes A Doornaert, Patricia Verdonck-de Leeuw, Irma M Leemans, Charles R Aaronson, Neil K Slotman, Ben J Clinical Trial Journal Article United States 2008/08/02 J Clin Oncol. 2008 Aug 1;26(22):3770-6. doi: 10.1200/JCO.2007.14.6647.},
	number = {22},
	pages = {3770-6},
	title = {Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy},
	type = {Journal Article},
	volume = {26},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1200/jco.2007.14.6647}}

@article{RN271,
	abstract = {BACKGROUND: The objective of this study was to define different prognostic groups with regard to locoregional control (LRC) derived from recursive partitioning analysis (RPA). METHODS: Eight hundred one patients with squamous cell head and neck carcinoma underwent with primary surgery and received postoperative radiotherapy. For the definition of prognostic groups, the method of classification and regression trees was performed, including a large number of well known prognostic factors. RESULTS: The final model was composed of six prognostic factors for LRC, resulting in seven terminal nodes. RPA Class I (intermediate risk) consisted of 381 patients who had no N3 lymph nodes, free surgical margins (> 5 mm), and no extranodal spread (ENS). RPA Class II (high risk) consisted of 189 patients who had 1 positive lymph node with ENS or had T1, T2, or T4 tumors with close or positive surgical margins. RPA Class III (very high risk) consisted of 231 patients who had a N3 neck, > or = 2 positive lymph nodes with ENS, or a T3 tumor with close or positive surgical margins. The 5-year LRC rate was 88%, 73% and 58%, in RPA Class I, II, and III, respectively (P < 0.0001). The hazard ratio (HR) relative to RPA Class I was 2.3 (95% confidence interval [95%CI], 1.5-3.6) for RPA Class II and 4.2 (95%CI, 2.8-6.1) for RPA Class III. CONCLUSIONS: The RPA classification scheme studied allowed for the clear definition of three prognostic groups with regard to LRC and OS. These groups may be useful in the design of future prospective, randomized studies investigating new treatment modalities.},
	author = {Langendijk, J. A. and Slotman, B. J. and van der Waal, I. and Doornaert, P. and Berkof, J. and Leemans, C. R.},
	doi = {10.1002/cncr.21340},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Adolescent Adult Age Distribution Aged Analysis of Variance Carcinoma, Squamous Cell/mortality/pathology/*radiotherapy/*surgery Cohort Studies Combined Modality Therapy Female Head and Neck Neoplasms/mortality/pathology/*radiotherapy/*surgery Humans Male Middle Aged Multivariate Analysis Neoplasm Recurrence, Local/*epidemiology/pathology Neoplasm Staging Postoperative Care/methods Prognosis Proportional Hazards Models Radiotherapy Dosage Radiotherapy, Adjuvant Regression Analysis Retrospective Studies Risk Assessment Sex Distribution Survival Analysis Treatment Outcome},
	note = {Langendijk, Johannes A Slotman, Ben J van der Waal, Isaac Doornaert, P Berkof, Johannes Leemans, Charles R Comparative Study Journal Article United States 2005/09/01 Cancer. 2005 Oct 1;104(7):1408-17. doi: 10.1002/cncr.21340.},
	number = {7},
	pages = {1408-17},
	title = {Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy},
	type = {Journal Article},
	url = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.21340?download=true},
	volume = {104},
	year = {2005},
	bdsk-url-1 = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.21340?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/cncr.21340}}

@article{RN148,
	abstract = {OBJECTIVES: Asbestos is the name given to a group of naturally occurring silicate mineral fibres that were widely used in industry during the 20th century due to their desirable physical properties. Although use in the USA has fallen over the last three decades, significant exposure in the developing world continues and the burden of disease is considerable. Asbestos is a known risk factor for several malignant diseases, including lung cancer and mesothelioma, and has more recently been implicated in pharyngeal and laryngeal cancer. However, studies of asbestos and cancers of the larynx or pharynx with adequate sample size that control for major head and neck squamous cell carcinoma (HNSCC) risk factors remain relatively sparse. METHODS: We report findings from a case-control study of 674 incident male HNSCC cases from the greater Boston region and 857 population-based male controls, matched on age ($\pm$3 years), sex, and town or neighbourhood of residence. Multivariable logistic regression was used to assess the association between occupational asbestos exposure and HNSCC by primary tumour site. RESULTS: 190 cases (28.2%) and 203 controls (23.7%) reported occupational exposure to asbestos. Occupational asbestos exposure was associated with elevated risk of pharyngeal carcinoma in men (OR 1.41, 95% CI 1.01 to 1.97), adjusted for age, race, smoking, alcohol consumption, education, income and HPV16 serology, with borderline increasing risk for each decade in the exposed occupation (OR 1.10, 95% CI 0.99 to 1.23). CONCLUSIONS: These observations are consistent with mounting evidence that asbestos is a risk factor for pharyngeal cancer.},
	author = {Langevin, S. M. and O'Sullivan, M. H. and Valerio, J. L. and Pawlita, M. and Applebaum, K. M. and Eliot, M. and McClean, M. D. and Kelsey, K. T.},
	doi = {10.1136/oemed-2013-101528},
	issn = {1351-0711 (Print) 1351-0711},
	journal = {Occup Environ Med},
	keywords = {Asbestos/*toxicity Boston/epidemiology Carcinoma, Squamous Cell/epidemiology/*etiology Case-Control Studies Humans Incidence Male Middle Aged Occupational Diseases/epidemiology/*etiology Occupational Exposure/*adverse effects Pharyngeal Neoplasms/epidemiology/*etiology Risk Factors},
	note = {1470-7926 Langevin, Scott M O'Sullivan, Mattie H Valerio, Jennifer L Pawlita, Michael Applebaum, Katie M Eliot, Melissa McClean, Michael D Kelsey, Karl T T32ES07272/ES/NIEHS NIH HHS/United States K01 OH009390/OH/NIOSH CDC HHS/United States R01CA078609/CA/NCI NIH HHS/United States R01CA100679/CA/NCI NIH HHS/United States R01CA121147/CA/NCI NIH HHS/United States T32 ES007272/ES/NIEHS NIH HHS/United States R01 CA078609/CA/NCI NIH HHS/United States R01 CA121147/CA/NCI NIH HHS/United States R01 CA100679/CA/NCI NIH HHS/United States K01OH009390/OH/NIOSH CDC HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. 2013/10/22 Occup Environ Med. 2013 Dec;70(12):858-63. doi: 10.1136/oemed-2013-101528. Epub 2013 Sep 27.},
	number = {12},
	pages = {858-63},
	title = {Occupational asbestos exposure is associated with pharyngeal squamous cell carcinoma in men from the greater Boston area},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227396/pdf/nihms630904.pdf},
	volume = {70},
	year = {2013},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227396/pdf/nihms630904.pdf},
	bdsk-url-2 = {https://doi.org/10.1136/oemed-2013-101528}}

@article{RN245,
	abstract = {BACKGROUND: Although adjuvant radiotherapy (RT) is often recommended for locally advanced squamous cell carcinoma of the head and neck (HNSCC), its effect on overall or cancer-specific survival has not been clearly demonstrated. In the current study, the frequency and effect of adjuvant RT on overall survival was investigated in patients with resected lymph node-positive head and neck cancer. METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) database, patients were selected with lymph node-positive HNSCC (American Joint Committee on Cancer and SEER stage 3/4) who were treated either with surgery alone or surgery and RT and were diagnosed between 1988 and 2001. A total of 8795 patients who met the inclusion criteria for analysis comprised the study population, with a median follow-up of 4.3 years for patients still alive at the time of last follow-up. RESULTS: Adjuvant RT was utilized in 84% of patients. Adjuvant RT improved the 5-year overall survival (43.2% [95% confidence interval (95% CI), 41.9-44.4%] for surgery + RT vs 33.4% [95% CI, 30.7-36.0%] for surgery alone; P < .001) and cancer-specific survival (50.9% for surgery + RT vs 42.1% for surgery) on univariate analysis. On multivariate analysis, adjuvant RT (hazards ratio [HR] of 0.78; 95% CI, 0.71-0.86 [P < .001]) remained a significant predictor of improved survival. The significant benefit of radiation on overall survival was noted for lymph node-positive patients with both primary tumors localized to the involved organ (HR of 0.81; 95% CI, 0.71-0.94 [P = .007]) and more locally invasive primary tumors (HR of 0.77; 95% CI, 0.68-0.87 [P < .001]). CONCLUSIONS: In what to the authors' knowledge is the largest reported analysis of adjuvant RT in patients with locally advanced HNSCC published to date, adjuvant RT resulted in an approximately 10% absolute increase in 5-year cancer-specific survival and overall survival for patients with lymph node-positive HNSCC compared with surgery alone. Despite combined surgery and adjuvant RT, outcomes in this high-risk population remain suboptimal, emphasizing the need for continued investigation of innovative treatment approaches.},
	author = {Lavaf, A. and Genden, E. M. and Cesaretti, J. A. and Packer, S. and Kao, J.},
	doi = {10.1002/cncr.23206},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/mortality/*radiotherapy/surgery Combined Modality Therapy Female Head and Neck Neoplasms/mortality/*radiotherapy/surgery Humans Lymphatic Metastasis/*radiotherapy Male Middle Aged Multivariate Analysis Radiotherapy, Adjuvant Retrospective Studies SEER Program Survival Analysis Treatment Outcome United States},
	note = {Lavaf, Amir Genden, Eric M Cesaretti, Jamie A Packer, Stuart Kao, Johnny Comparative Study Journal Article United States 2007/12/14 Cancer. 2008 Feb 1;112(3):535-43. doi: 10.1002/cncr.23206.},
	number = {3},
	pages = {535-43},
	title = {Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma},
	type = {Journal Article},
	url = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23206?download=true},
	volume = {112},
	year = {2008},
	bdsk-url-1 = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23206?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/cncr.23206}}

@article{RN176,
	abstract = {Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3-5% of all malignant neoplasms. CUP represents a heterogeneous group of metastatic tumors for which no primary site can be detected following a thorough medical history, careful clinical examination, and extensive diagnostic work-up. Several authors have reported poor prognosis of this malignancy, because there is no consensus on diagnostic guidelines and optimal therapy. Historically, chemotherapy has been the cornerstone of treatment for patients with CUP. We experienced a case of inguinal lymph node squamous cell carcinoma of unknown origin, accompanied with carcinoma in situ of the cervix. We report this case with a brief review of the literatures.},
	author = {Lee, S. H. and Kim, M. J. and Lee, H. J. and Kim, S. J. and Park, J. S. and Hur, S. Y.},
	doi = {10.3802/jgo.2008.19.2.145},
	issn = {2005-0380 (Print) 2005-0380},
	journal = {J Gynecol Oncol},
	keywords = {Inguinal lymph node Metastatic cancer of unknown primary site},
	note = {2005-0399 Lee, Sung-Ha Kim, Min-Jung Lee, Hee-Jung Kim, Sa-Jin Park, Jong-Sup Hur, Soo-Young Journal Article 2009/05/28 J Gynecol Oncol. 2008 Jun;19(2):145-9. doi: 10.3802/jgo.2008.19.2.145. Epub 2008 Jun 20.},
	number = {2},
	pages = {145-9},
	title = {A case of inguinal lymph node squamous cell carcinoma of unknown origin, accompanied with carcinoma in situ of cervix},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676454/pdf/jgo-19-145.pdf},
	volume = {19},
	year = {2008},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676454/pdf/jgo-19-145.pdf},
	bdsk-url-2 = {https://doi.org/10.3802/jgo.2008.19.2.145}}

@book{RN106,
	author = {Lenarz, T. and Boenninghaus, H.G.},
	isbn = {9783642211317},
	publisher = {Springer Berlin Heidelberg},
	title = {Hals-Nasen-Ohren-Heilkunde},
	type = {Book},
	url = {https://books.google.ne/books?id=RLGr7gRB0kUC},
	year = {2012},
	bdsk-url-1 = {https://books.google.ne/books?id=RLGr7gRB0kUC}}

@book{RN387,
	author = {Lenarz, T. and Boenninghaus, H.G.},
	isbn = {9783642211317},
	publisher = {Springer Berlin Heidelberg},
	title = {Hals-Nasen-Ohren-Heilkunde},
	type = {Book},
	url = {https://books.google.ne/books?id=RLGr7gRB0kUC},
	year = {2012},
	bdsk-url-1 = {https://books.google.ne/books?id=RLGr7gRB0kUC}}

@book{RN375,
	author = {Lenarz, T. and Boenninghaus, H.G.},
	isbn = {9783642211317},
	publisher = {Springer Berlin Heidelberg},
	title = {Hals-Nasen-Ohren-Heilkunde},
	type = {Book},
	url = {https://books.google.ne/books?id=RLGr7gRB0kUC},
	year = {2012},
	bdsk-url-1 = {https://books.google.ne/books?id=RLGr7gRB0kUC}}

@book{RN377,
	author = {Lenarz, T. and Boenninghaus, H.G.},
	isbn = {9783642211317},
	publisher = {Springer Berlin Heidelberg},
	title = {Hals-Nasen-Ohren-Heilkunde},
	type = {Book},
	url = {https://books.google.ne/books?id=RLGr7gRB0kUC},
	year = {2012},
	bdsk-url-1 = {https://books.google.ne/books?id=RLGr7gRB0kUC}}

@book{RN384,
	author = {Lenarz, T. and Boenninghaus, H.G.},
	isbn = {9783642211317},
	publisher = {Springer Berlin Heidelberg},
	title = {Hals-Nasen-Ohren-Heilkunde},
	type = {Book},
	url = {https://books.google.ne/books?id=RLGr7gRB0kUC},
	year = {2012},
	bdsk-url-1 = {https://books.google.ne/books?id=RLGr7gRB0kUC}}

@book{RN381,
	author = {Lenarz, T. and Boenninghaus, H.G.},
	isbn = {9783642211317},
	publisher = {Springer Berlin Heidelberg},
	title = {Hals-Nasen-Ohren-Heilkunde},
	type = {Book},
	url = {https://books.google.ne/books?id=RLGr7gRB0kUC},
	year = {2012},
	bdsk-url-1 = {https://books.google.ne/books?id=RLGr7gRB0kUC}}

@article{RN301,
	abstract = {Emerging evidence has suggested that the capability of a tumor to grow and propagate is dependent on a small subset of cells within a tumor, termed cancer stem cells. Although data have been provided to support this theory in human blood, brain, and breast cancers, the identity of pancreatic cancer stem cells has not been determined. Using a xenograft model in which primary human pancreatic adenocarcinomas were grown in immunocompromised mice, we identified a highly tumorigenic subpopulation of pancreatic cancer cells expressing the cell surface markers CD44, CD24, and epithelial-specific antigen (ESA). Pancreatic cancer cells with the CD44(+)CD24(+)ESA(+) phenotype (0.2-0.8% of pancreatic cancer cells) had a 100-fold increased tumorigenic potential compared with nontumorigenic cancer cells, with 50% of animals injected with as few as 100 CD44(+)CD24(+)ESA(+) cells forming tumors that were histologically indistinguishable from the human tumors from which they originated. The enhanced ability of CD44(+)CD24(+)ESA(+) pancreatic cancer cells to form tumors was confirmed in an orthotopic pancreatic tail injection model. The CD44(+)CD24(+)ESA(+) pancreatic cancer cells showed the stem cell properties of self-renewal, the ability to produce differentiated progeny, and increased expression of the developmental signaling molecule sonic hedgehog. Identification of pancreatic cancer stem cells and further elucidation of the signaling pathways that regulate their growth and survival may provide novel therapeutic approaches to treat pancreatic cancer, which is notoriously resistant to standard chemotherapy and radiation.},
	author = {Li, C. and Heidt, D. G. and Dalerba, P. and Burant, C. F. and Zhang, L. and Adsay, V. and Wicha, M. and Clarke, M. F. and Simeone, D. M.},
	doi = {10.1158/0008-5472.Can-06-2030},
	issn = {0008-5472 (Print) 0008-5472},
	journal = {Cancer Res},
	keywords = {Adenocarcinoma/immunology/*pathology Animals Antigens, Neoplasm/biosynthesis CD24 Antigen/biosynthesis Disease Models, Animal Humans Hyaluronan Receptors/biosynthesis Male Mice Mice, Inbred NOD Mice, SCID Neoplastic Stem Cells/immunology/*parasitology Pancreatic Neoplasms/immunology/*pathology Signal Transduction Transplantation, Heterologous Up-Regulation},
	note = {Li, Chenwei Heidt, David G Dalerba, Piero Burant, Charles F Zhang, Lanjing Adsay, Volkan Wicha, Max Clarke, Michael F Simeone, Diane M Journal Article Research Support, Non-U.S. Gov't United States 2007/02/07 Cancer Res. 2007 Feb 1;67(3):1030-7. doi: 10.1158/0008-5472.CAN-06-2030.},
	number = {3},
	pages = {1030-7},
	title = {Identification of pancreatic cancer stem cells},
	type = {Journal Article},
	url = {https://cancerres.aacrjournals.org/content/canres/67/3/1030.full.pdf},
	volume = {67},
	year = {2007},
	bdsk-url-1 = {https://cancerres.aacrjournals.org/content/canres/67/3/1030.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/0008-5472.Can-06-2030}}

@article{RN175,
	abstract = {Squamous cell carcinoma of the head and neck is complicated by a second primary carcinoma of the head and neck, esophagus (the upper aerodigestive tract, or UADT), or lung in 10-40% of patients. Routine panendoscopy will identify a simultaneous second primary in 9-14% of the patients. Metachronous second cancers most often involve the esophagus or lung, whereas synchronous second cancers are more common in the head and neck as occult lesions. For the highest-risk subgroups, second primary cancers occur in 4% of patients per year. In cancer of the floor of the mouth the excess mortality rate is 5-6% per year. Risk is independent of stage of the first primary and the survival impact is the greatest in groups of patients with early-stage disease. Head and neck cancer almost always results from the heavy use of tobacco for many years, either with or without the concomitant heavy use of alcohol, and these same agents are directly responsible for the second cancers of the UADT and lung. All head and neck cancer patients should be advised to avoid these agents. The clinician must diagnose and treat second cancers to extend the survival of patients with a good prognosis for control of the initial head and neck cancer. We need further progress in eliminating the use of known carcinogens in these patients, paradigms for cost-effective diagnosis and treatment of second primary cancers, effective treatment of the head and neck primary cancer devoid of long-lasting tissue toxicities, effective chemopreventive agents to retard established processes of carcinogenesis that place the patient at continued risk after cigarette and alcohol use has been eliminated, and continued efforts to control the medical illnesses to which these patients are susceptible.},
	author = {Licciardello, J. T. and Spitz, M. R. and Hong, W. K.},
	doi = {10.1016/0360-3016(89)90096-5},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Carcinoma, Squamous Cell/*epidemiology Esophageal Neoplasms/*epidemiology Head and Neck Neoplasms/*epidemiology Humans Lung Neoplasms/*epidemiology Neoplasms, Multiple Primary/*epidemiology Prognosis Risk United States},
	note = {Licciardello, J T Spitz, M R Hong, W K Journal Article Review United States 1989/09/01 Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):467-76. doi: 10.1016/0360-3016(89)90096-5.},
	number = {3},
	pages = {467-76},
	title = {Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung},
	type = {Journal Article},
	url = {https://www.redjournal.org/article/0360-3016(89)90096-5/pdf},
	volume = {17},
	year = {1989},
	bdsk-url-1 = {https://www.redjournal.org/article/0360-3016(89)90096-5/pdf},
	bdsk-url-2 = {https://doi.org/10.1016/0360-3016(89)90096-5}}

@article{RN236,
	abstract = {BACKGROUND: To study prospectively the activity of primary chemotherapy with cisplatin, fluorouracil and leucovorin (PFL) in patients with paranasal cancer receiving surgery and postoperative radiotherapy. PATIENTS AND METHODS: Forty-nine patients, previously untreated, with resectable paranasal carcinoma were enrolled. PFL (leucovorin 250 mg/m2/day for 5 days as a 120 h continuous infusion (c.i.), 5-fluorouracil 800 mg/m2/day from day 2 as a 96 h c.i. and cisplatin 100 mg/m2 day 2 q 3 weeks) was planned for five courses. RESULTS: Thirty-two patients (65%) completed three or more chemotherapy courses. Two deaths from thrombotic events were observed after the first cycle. Eight cardiac toxicities were recorded during chemotherapy causing treatment discontinuation. Objective response to PFL was observed in 21 patients [43%; 95% confidence interval (CI) 29% to 58%], including four complete responses (CRs) (8%; 95% CI 2% to 20%) and 17 partial responses (PRs) (35%). Pathological complete remission (pCR) was achieved in eight of 49 patients (16%). At 3 years, overall survival was 69% and event-free survival 57%. Overall and event-free survival in patients achieving pCR is 100%. CONCLUSIONS: PFL is active in paranasal cancer. Patients who attain a pathological complete remission have a favorable prognosis. Cardiovascular complications represent the limiting toxicity. Primary chemotherapy combined with surgery-sparing treatment approaches deserves further investigation.},
	author = {Licitra, L. and Locati, L. D. and Cavina, R. and Garassino, I. and Mattavelli, F. and Pizzi, N. and Quattrone, P. and Valagussa, P. and Gianni, L. and Bonadonna, G. and Solero, C. L. and Cantu, G.},
	doi = {10.1093/annonc/mdg113},
	issn = {0923-7534 (Print) 0923-7534},
	journal = {Ann Oncol},
	keywords = {Adult Aged Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use Carcinoma/*drug therapy/pathology/radiotherapy/*surgery Cisplatin/administration & dosage Female Fluorouracil/administration & dosage Humans Infusions, Intravenous Leucovorin/administration & dosage Male Middle Aged Paranasal Sinus Neoplasms/*drug therapy/pathology/radiotherapy/*surgery Prospective Studies Survival Analysis Treatment Outcome},
	note = {Licitra, L Locati, L D Cavina, R Garassino, I Mattavelli, F Pizzi, N Quattrone, P Valagussa, P Gianni, L Bonadonna, G Solero, C L Cantu, G Clinical Trial Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't England 2003/02/25 Ann Oncol. 2003 Mar;14(3):367-72. doi: 10.1093/annonc/mdg113.},
	number = {3},
	pages = {367-72},
	title = {Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer},
	type = {Journal Article},
	url = {https://air.unimi.it/retrieve/handle/2434/577756/1037009/pmid%2012598339.pdf},
	volume = {14},
	year = {2003},
	bdsk-url-1 = {https://air.unimi.it/retrieve/handle/2434/577756/1037009/pmid%2012598339.pdf},
	bdsk-url-2 = {https://doi.org/10.1093/annonc/mdg113}}

@article{RN130,
	abstract = {BACKGROUND: After the introduction of ICI treatment, data about feasibility and activity of a cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and neck cancer (R/M HNSCC) are still not available. We sought to analyze the clinical outcomes in the real-world setting. MATERIAL METHODS: This retrospective study was conducted at two tertiary medical centers in Taiwan. Patients with R/M HNSCC receiving cetuximab-containing first-line therapy were included between January 2017 and July 2019. The study endpoints were the response, Progression-Free Survival (PFS), and Overall Survival (OS). Subgroup analyses were conducted to evaluate survival outcomes by platinum resistance and the use of immunotherapy. RESULTS: We identified 290 patients treated with cetuximab-containing first-line therapy. The most primary tumor site was oral cavity cancer (59.3%). 44% of patients were resistant to platinum. The median PFS and OS were 5.0 months and 9.1 months, respectively, for the total population. In patients with platinum resistance, the median OS was 10.4 months with ICIs versus 6.3 months without ICIs; p = 0.01. In patients with platinum sensitivity, the median OS was 20.6 months with ICIs versus 9.1 months without ICs; p < 0.01. OS benefit with ICIs was similar between patients who received ICIs after progression on Cetuximab and receiving Cetuximab in combination with ICIs. Independent favorable prognostic factors for OS were platinum-sensitive, better response to cetuximab, and ICIs use. CONCLUSION: ICIs are indicated to improve OS in R/M HNSCC receiving cetuximab-containing first-line therapy, even in platinum-resistant populations. The reduction in risk of death with ICIs was similar regarding the combination or sequencing of cetuximab.},
	author = {Lien, M. Y. and Wang, T. H. and Hsieh, C. Y. and Tsai, M. H. and Hua, C. H. and Cheng, F. M. and Chung, W. H. and Tang, C. H. and Chia-Hsun Hsieh, J.},
	doi = {10.1016/j.oraloncology.2021.105380},
	issn = {1368-8375},
	journal = {Oral Oncol},
	keywords = {*Cetuximab *Head and neck cancer *Immune checkpoint inhibitor *Metastasis *Platinum-resistance *Recurrence},
	note = {1879-0593 Lien, Ming-Yu Wang, Ti-Hao Hsieh, Ching-Yun Tsai, Ming-Hsui Hua, Chun-Hung Cheng, Fu-Ming Chung, Wen-Hui Tang, Chih-Hsin Chia-Hsun Hsieh, Jason Journal Article Research Support, Non-U.S. Gov't England 2021/06/20 Oral Oncol. 2021 Aug;119:105380. doi: 10.1016/j.oraloncology.2021.105380. Epub 2021 Jun 17.},
	pages = {105380},
	title = {Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival},
	type = {Journal Article},
	url = {https://www.sciencedirect.com/science/article/abs/pii/S1368837521002037?via%3Dihub},
	volume = {119},
	year = {2021},
	bdsk-url-1 = {https://www.sciencedirect.com/science/article/abs/pii/S1368837521002037?via%3Dihub},
	bdsk-url-2 = {https://doi.org/10.1016/j.oraloncology.2021.105380}}

@article{RN102,
	abstract = {BACKGROUND: Epidemiologic evidence points to a connection between viral infection by the human papillomavirus (HPV) and a subgroup of squamous cell carcinoma of the oropharynx. To assess the impact of HPV infection on the response of these tumors toward radiotherapy, the authors retrospectively determined the presence of the virus and the integrity of the viral E2 gene in tumors of patients who have undergone curative irradiation. METHODS: Paraffin embedded biopsies from 99 patients were analyzed for HPV infection and E2 gene integrity by multiplex PCR. The experimental findings were correlated with clinical characteristics, known risk factors, and treatment outcome. RESULTS: Fourteen of 99 tumors were HPV positive (11 HPV16, 1 HPV33, 1 HPV35, and 1 HPV45). Human papillomavirus positivity was closely linked to female gender (odds ratio [OR], 5.75; P = 0.004), age older than 56 years (OR, 7.42; P = 0.012), nonsmokers (OR, 21.33; P = 0.00001), and alcohol abstainers (OR, 5.35; P = 0.012). There was an inverse association with p53 nuclear immunoreactivity (OR, 0.06; P = 0.008). The Kaplan-Meier survival estimates showed a better local control (P = 0.050, log-rank) and a better overall survival (P = 0.046, log-rank) for patients with HPV positive tumors. In the multivariate analysis, HPV positivity remained to be associated with a lower risk of local failure (risk ratio [RR], 0.31; P = 0.048). Four of 11 HPV16 positive tumors had a disrupted E2 gene. Only tumors with a disrupted E2 gene manifested local treatment failure. CONCLUSIONS: Human papillomavirus positivity designates a specific subgroup of oropharyngeal squamous cell carcinomas of the oropharynx that arise preferentially among individuals with no consumption of tobacco and alcohol and that have a favorable outcome attributable to an increased sensitivity toward radiotherapy.},
	author = {Lindel, K. and Beer, K. T. and Laissue, J. and Greiner, R. H. and Aebersold, D. M.},
	doi = {10.1002/1097-0142(20010815)92:4<805::aid-cncr1386>3.0.co;2-9},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Carcinoma, Squamous Cell/pathology/radiotherapy/*virology Female Genome, Viral Humans Male Middle Aged Oropharyngeal Neoplasms/pathology/radiotherapy/*virology Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*diagnosis Polymerase Chain Reaction Proportional Hazards Models Retrospective Studies Survival Analysis Tumor Suppressor Protein p53/metabolism Tumor Virus Infections/*diagnosis},
	note = {Lindel, K Beer, K T Laissue, J Greiner, R H Aebersold, D M Journal Article Research Support, Non-U.S. Gov't United States 2001/09/11 Cancer. 2001 Aug 15;92(4):805-13. doi: 10.1002/1097-0142(20010815)92:4<805::aid-cncr1386>3.0.co;2-9.},
	number = {4},
	pages = {805-13},
	title = {Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma},
	type = {Journal Article},
	volume = {92},
	year = {2001},
	bdsk-url-1 = {https://doi.org/10.1002/1097-0142(20010815)92:4%3C805::aid-cncr1386%3E3.0.co;2-9}}

@article{RN90,
	abstract = {BACKGROUND: Epidemiologic evidence points to a connection between viral infection by the human papillomavirus (HPV) and a subgroup of squamous cell carcinoma of the oropharynx. To assess the impact of HPV infection on the response of these tumors toward radiotherapy, the authors retrospectively determined the presence of the virus and the integrity of the viral E2 gene in tumors of patients who have undergone curative irradiation. METHODS: Paraffin embedded biopsies from 99 patients were analyzed for HPV infection and E2 gene integrity by multiplex PCR. The experimental findings were correlated with clinical characteristics, known risk factors, and treatment outcome. RESULTS: Fourteen of 99 tumors were HPV positive (11 HPV16, 1 HPV33, 1 HPV35, and 1 HPV45). Human papillomavirus positivity was closely linked to female gender (odds ratio [OR], 5.75; P = 0.004), age older than 56 years (OR, 7.42; P = 0.012), nonsmokers (OR, 21.33; P = 0.00001), and alcohol abstainers (OR, 5.35; P = 0.012). There was an inverse association with p53 nuclear immunoreactivity (OR, 0.06; P = 0.008). The Kaplan-Meier survival estimates showed a better local control (P = 0.050, log-rank) and a better overall survival (P = 0.046, log-rank) for patients with HPV positive tumors. In the multivariate analysis, HPV positivity remained to be associated with a lower risk of local failure (risk ratio [RR], 0.31; P = 0.048). Four of 11 HPV16 positive tumors had a disrupted E2 gene. Only tumors with a disrupted E2 gene manifested local treatment failure. CONCLUSIONS: Human papillomavirus positivity designates a specific subgroup of oropharyngeal squamous cell carcinomas of the oropharynx that arise preferentially among individuals with no consumption of tobacco and alcohol and that have a favorable outcome attributable to an increased sensitivity toward radiotherapy.},
	author = {Lindel, K. and Beer, K. T. and Laissue, J. and Greiner, R. H. and Aebersold, D. M.},
	doi = {10.1002/1097-0142(20010815)92:4<805::aid-cncr1386>3.0.co;2-9},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Carcinoma, Squamous Cell/pathology/radiotherapy/*virology Female Genome, Viral Humans Male Middle Aged Oropharyngeal Neoplasms/pathology/radiotherapy/*virology Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*diagnosis Polymerase Chain Reaction Proportional Hazards Models Retrospective Studies Survival Analysis Tumor Suppressor Protein p53/metabolism Tumor Virus Infections/*diagnosis},
	note = {Lindel, K Beer, K T Laissue, J Greiner, R H Aebersold, D M Journal Article Research Support, Non-U.S. Gov't United States 2001/09/11 Cancer. 2001 Aug 15;92(4):805-13. doi: 10.1002/1097-0142(20010815)92:4<805::aid-cncr1386>3.0.co;2-9.},
	number = {4},
	pages = {805-13},
	title = {Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma},
	type = {Journal Article},
	volume = {92},
	year = {2001},
	bdsk-url-1 = {https://doi.org/10.1002/1097-0142(20010815)92:4%3C805::aid-cncr1386%3E3.0.co;2-9}}

@article{RN347,
	author = {Lindel, K. and Beer, K. T. and Laissue, J. and Greiner, R. H. and Aebersold, D. M.},
	doi = {10.1002/1097-0142(20010815)92:4<805::aid-cncr1386>3.0.co;2-9},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Carcinoma, Squamous Cell/pathology/radiotherapy/*virology Female Genome, Viral Humans Male Middle Aged Oropharyngeal Neoplasms/pathology/radiotherapy/*virology Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*diagnosis Polymerase Chain Reaction Proportional Hazards Models Retrospective Studies Survival Analysis Tumor Suppressor Protein p53/metabolism Tumor Virus Infections/*diagnosis},
	number = {4},
	pages = {805-13},
	title = {Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma},
	type = {Journal Article},
	volume = {92},
	year = {2001},
	bdsk-url-1 = {https://doi.org/10.1002/1097-0142(20010815)92:4%3C805::aid-cncr1386%3E3.0.co;2-9}}

@article{RN351,
	author = {Lindel, K. and Beer, K. T. and Laissue, J. and Greiner, R. H. and Aebersold, D. M.},
	doi = {10.1002/1097-0142(20010815)92:4<805::aid-cncr1386>3.0.co;2-9},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Carcinoma, Squamous Cell/pathology/radiotherapy/*virology Female Genome, Viral Humans Male Middle Aged Oropharyngeal Neoplasms/pathology/radiotherapy/*virology Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*diagnosis Polymerase Chain Reaction Proportional Hazards Models Retrospective Studies Survival Analysis Tumor Suppressor Protein p53/metabolism Tumor Virus Infections/*diagnosis},
	number = {4},
	pages = {805-13},
	title = {Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma},
	type = {Journal Article},
	volume = {92},
	year = {2001},
	bdsk-url-1 = {https://doi.org/10.1002/1097-0142(20010815)92:4%3C805::aid-cncr1386%3E3.0.co;2-9}}

@article{RN53,
	abstract = {BACKGROUND: Epidemiologic evidence points to a connection between viral infection by the human papillomavirus (HPV) and a subgroup of squamous cell carcinoma of the oropharynx. To assess the impact of HPV infection on the response of these tumors toward radiotherapy, the authors retrospectively determined the presence of the virus and the integrity of the viral E2 gene in tumors of patients who have undergone curative irradiation. METHODS: Paraffin embedded biopsies from 99 patients were analyzed for HPV infection and E2 gene integrity by multiplex PCR. The experimental findings were correlated with clinical characteristics, known risk factors, and treatment outcome. RESULTS: Fourteen of 99 tumors were HPV positive (11 HPV16, 1 HPV33, 1 HPV35, and 1 HPV45). Human papillomavirus positivity was closely linked to female gender (odds ratio [OR], 5.75; P = 0.004), age older than 56 years (OR, 7.42; P = 0.012), nonsmokers (OR, 21.33; P = 0.00001), and alcohol abstainers (OR, 5.35; P = 0.012). There was an inverse association with p53 nuclear immunoreactivity (OR, 0.06; P = 0.008). The Kaplan-Meier survival estimates showed a better local control (P = 0.050, log-rank) and a better overall survival (P = 0.046, log-rank) for patients with HPV positive tumors. In the multivariate analysis, HPV positivity remained to be associated with a lower risk of local failure (risk ratio [RR], 0.31; P = 0.048). Four of 11 HPV16 positive tumors had a disrupted E2 gene. Only tumors with a disrupted E2 gene manifested local treatment failure. CONCLUSIONS: Human papillomavirus positivity designates a specific subgroup of oropharyngeal squamous cell carcinomas of the oropharynx that arise preferentially among individuals with no consumption of tobacco and alcohol and that have a favorable outcome attributable to an increased sensitivity toward radiotherapy.},
	author = {Lindel, K. and Beer, K. T. and Laissue, J. and Greiner, R. H. and Aebersold, D. M.},
	doi = {10.1002/1097-0142(20010815)92:4<805::aid-cncr1386>3.0.co;2-9},
	issn = {0008-543X (Print) 0008-543X (Linking)},
	journal = {Cancer},
	keywords = {Carcinoma, Squamous Cell/pathology/radiotherapy/*virology Female Genome, Viral Humans Male Middle Aged Oropharyngeal Neoplasms/pathology/radiotherapy/*virology Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*diagnosis Polymerase Chain Reaction Proportional Hazards Models Retrospective Studies Survival Analysis Tumor Suppressor Protein p53/metabolism Tumor Virus Infections/*diagnosis},
	note = {Lindel, K Beer, K T Laissue, J Greiner, R H Aebersold, D M eng Research Support, Non-U.S. Gov't 2001/09/11 Cancer. 2001 Aug 15;92(4):805-13. doi: 10.1002/1097-0142(20010815)92:4<805::aid-cncr1386>3.0.co;2-9.},
	number = {4},
	pages = {805-13},
	title = {Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma},
	type = {Journal Article},
	url = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2820010815%2992%3A4%3C805%3A%3AAID-CNCR1386%3E3.0.CO%3B2-9?download=true},
	volume = {92},
	year = {2001},
	bdsk-url-1 = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2820010815%2992%3A4%3C805%3A%3AAID-CNCR1386%3E3.0.CO%3B2-9?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/1097-0142(20010815)92:4%3C805::aid-cncr1386%3E3.0.co;2-9}}

@article{RN440,
	author = {Lindel, K. and Beer, K. T. and Laissue, J. and Greiner, R. H. and Aebersold, D. M.},
	doi = {10.1002/1097-0142(20010815)92:4<805::aid-cncr1386>3.0.co;2-9},
	issn = {0008-543X (Print) 0008-543X (Linking)},
	journal = {Cancer},
	keywords = {Carcinoma, Squamous Cell/pathology/radiotherapy/*virology Female Genome, Viral Humans Male Middle Aged Oropharyngeal Neoplasms/pathology/radiotherapy/*virology Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*diagnosis Polymerase Chain Reaction Proportional Hazards Models Retrospective Studies Survival Analysis Tumor Suppressor Protein p53/metabolism Tumor Virus Infections/*diagnosis},
	number = {4},
	pages = {805-13},
	title = {Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11550151},
	volume = {92},
	year = {2001},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/11550151},
	bdsk-url-2 = {https://doi.org/10.1002/1097-0142(20010815)92:4%3C805::aid-cncr1386%3E3.0.co;2-9}}

@article{RN365,
	author = {Lindel, K. and Beer, K. T. and Laissue, J. and Greiner, R. H. and Aebersold, D. M.},
	doi = {10.1002/1097-0142(20010815)92:4<805::aid-cncr1386>3.0.co;2-9},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Carcinoma, Squamous Cell/pathology/radiotherapy/*virology Female Genome, Viral Humans Male Middle Aged Oropharyngeal Neoplasms/pathology/radiotherapy/*virology Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/*diagnosis Polymerase Chain Reaction Proportional Hazards Models Retrospective Studies Survival Analysis Tumor Suppressor Protein p53/metabolism Tumor Virus Infections/*diagnosis},
	number = {4},
	pages = {805-13},
	title = {Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma},
	type = {Journal Article},
	volume = {92},
	year = {2001},
	bdsk-url-1 = {https://doi.org/10.1002/1097-0142(20010815)92:4%3C805::aid-cncr1386%3E3.0.co;2-9}}

@article{RN355,
	author = {Lindquist, D. and Romanitan, M. and Hammarstedt, L. and N{\"a}sman, A. and Dahlstrand, H. and Lindholm, J. and Onel{\"o}v, L. and Ramqvist, T. and Ye, W. and Munck-Wikland, E. and Dalianis, T.},
	doi = {10.1016/j.molonc.2007.08.005},
	issn = {1574-7891 (Print) 1574-7891},
	journal = {Mol Oncol},
	keywords = {Adult Aged Aged, 80 and over Biopsy Female Human papillomavirus 16/*genetics/metabolism Humans Incidence Male Middle Aged Oncogene Proteins, Viral/*genetics Papillomavirus E7 Proteins/*genetics Papillomavirus Infections/genetics/*virology Prognosis RNA, Messenger/analysis RNA, Viral/analysis Sweden/epidemiology Tonsillar Neoplasms/*epidemiology/genetics/surgery/*virology Viral Load},
	number = {3},
	pages = {350-5},
	title = {Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7},
	type = {Journal Article},
	volume = {1},
	year = {2007},
	bdsk-url-1 = {https://doi.org/10.1016/j.molonc.2007.08.005}}

@article{RN94,
	abstract = {From 1970 to 2002 in the Stockholm area, we revealed a parallel three-fold increase in the incidence of tonsillar cancer and the proportion of human papillomavirus (HPV) positive tonsillar cancer cases, indicating a possible role of HPV infection in this disease. We have now examined whether HPV and viral load in pre-treatment tonsillar cancer biopsies correlates to disease prognosis, and whether the presence of HPV-16 E6 and E7 mRNA could be ascertained. The presence of HPV-16, but not viral load, in tonsillar cancer was shown to be a favourable prognostic factor for clinical outcome. Moreover, E6 and/or E7 were expressed in almost all assessable HPV-16 positive cases, supporting an oncogenic role of HPV-16 in tonsillar cancer.},
	author = {Lindquist, D. and Romanitan, M. and Hammarstedt, L. and N{\"a}sman, A. and Dahlstrand, H. and Lindholm, J. and Onel{\"o}v, L. and Ramqvist, T. and Ye, W. and Munck-Wikland, E. and Dalianis, T.},
	doi = {10.1016/j.molonc.2007.08.005},
	issn = {1574-7891 (Print) 1574-7891},
	journal = {Mol Oncol},
	keywords = {Adult Aged Aged, 80 and over Biopsy Female Human papillomavirus 16/*genetics/metabolism Humans Incidence Male Middle Aged Oncogene Proteins, Viral/*genetics Papillomavirus E7 Proteins/*genetics Papillomavirus Infections/genetics/*virology Prognosis RNA, Messenger/analysis RNA, Viral/analysis Sweden/epidemiology Tonsillar Neoplasms/*epidemiology/genetics/surgery/*virology Viral Load},
	note = {1878-0261 Lindquist, David Romanitan, Mircea Hammarstedt, Lalle N{\"a}sman, Anders Dahlstrand, Hanna Lindholm, Johan Onel{\"o}v, Liselotte Ramqvist, Torbj{\"o}rn Ye, Weimin Munck-Wikland, Eva Dalianis, Tina Journal Article Research Support, Non-U.S. Gov't 2007/12/01 Mol Oncol. 2007 Dec;1(3):350-5. doi: 10.1016/j.molonc.2007.08.005. Epub 2007 Sep 1.},
	number = {3},
	pages = {350-5},
	title = {Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543872/pdf/MOL2-1-350.pdf},
	volume = {1},
	year = {2007},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543872/pdf/MOL2-1-350.pdf},
	bdsk-url-2 = {https://doi.org/10.1016/j.molonc.2007.08.005}}

@article{RN2,
	abstract = {PURPOSE: To investigate the impact of hypoxia-induced gene expression and cancer stem cell (CSC) marker expression on outcome of postoperative cisplatin-based radiochemotherapy (PORT-C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). EXPERIMENTAL DESIGN: Expression of the CSC markers CD44, MET, and SLC3A2, and hypoxia gene signatures were analyzed in the resected primary tumors using RT-PCR and nanoString technology in a multicenter retrospective cohort of 195 patients. CD44 protein expression was further analyzed in tissue microarrays. Primary endpoint was locoregional tumor control. RESULTS: Univariate analysis showed that hypoxia-induced gene expression was significantly associated with a high risk of locoregional recurrence using the 15-gene signature (P = 0.010) or the 26-gene signature (P = 0.002). In multivariate analyses, in patients with HPV16 DNA-negative but not with HPV16 DNA-positive tumors the effect of hypoxia-induced genes on locoregional control was apparent (15-gene signature: HR 4.54, P = 0.006; 26-gene signature: HR 10.27, P = 0.024). Furthermore, MET, SLC3A2, CD44, and CD44 protein showed an association with locoregional tumor control in multivariate analyses (MET: HR 3.71, P = 0.016; SLC3A2: HR 8.54, P = 0.037; CD44: HR 3.36, P = 0.054; CD44 protein n/a because of no event in the CD44-negative group) in the HPV16 DNA-negative subgroup. CONCLUSIONS: We have shown for the first time that high hypoxia-induced gene expression and high CSC marker expression levels correlate with tumor recurrence after PORT-C in patients with HPV16 DNA-negative HNSCC. After validation in a currently ongoing prospective trial, these parameters may help to further stratify patients for individualized treatment de-escalation or intensification strategies. Clin Cancer Res; 22(11); 2639-49. (c)2016 AACR.},
	author = {Linge, A. and Lock, S. and Gudziol, V. and Nowak, A. and Lohaus, F. and von Neubeck, C. and Jutz, M. and Abdollahi, A. and Debus, J. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Welz, S. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Baumann, M. and Krause, M. and Dktk, R. O. G.},
	doi = {10.1158/1078-0432.CCR-15-1990},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Antineoplastic Agents/therapeutic use Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/*metabolism/mortality/pathology/therapy Cell Hypoxia Chemoradiotherapy Cisplatin/therapeutic use Fusion Regulatory Protein 1, Heavy Chain/metabolism Human papillomavirus 16/genetics Humans Hyaluronan Receptors/metabolism Kaplan-Meier Estimate Mouth Neoplasms/*metabolism/mortality/pathology/therapy Multivariate Analysis Neoplastic Stem Cells/*metabolism Papillomavirus Infections/diagnosis Prognosis Prospective Studies Transcriptome Treatment Outcome},
	note = {Linge, Annett Lock, Steffen Gudziol, Volker Nowak, Alexander Lohaus, Fabian von Neubeck, Clare Jutz, Martin Abdollahi, Amir Debus, Jurgen Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Avlar, Melanie Grosu, Anca-Ligia Bayer, Christine Belka, Claus Pigorsch, Steffi Combs, Stephanie E Welz, Stefan Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Baumann, Michael Krause, Mechthild eng Multicenter Study Research Support, Non-U.S. Gov't Clin Cancer Res. 2016 Jun 1;22(11):2639-49. doi: 10.1158/1078-0432.CCR-15-1990. Epub 2016 Jan 11.},
	number = {11},
	pages = {2639-49},
	title = {Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	volume = {22},
	year = {2016},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-15-1990}}

@article{RN30,
	abstract = {PURPOSE: To investigate the impact of hypoxia-induced gene expression and cancer stem cell (CSC) marker expression on outcome of postoperative cisplatin-based radiochemotherapy (PORT-C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). EXPERIMENTAL DESIGN: Expression of the CSC markers CD44, MET, and SLC3A2, and hypoxia gene signatures were analyzed in the resected primary tumors using RT-PCR and nanoString technology in a multicenter retrospective cohort of 195 patients. CD44 protein expression was further analyzed in tissue microarrays. Primary endpoint was locoregional tumor control. RESULTS: Univariate analysis showed that hypoxia-induced gene expression was significantly associated with a high risk of locoregional recurrence using the 15-gene signature (P = 0.010) or the 26-gene signature (P = 0.002). In multivariate analyses, in patients with HPV16 DNA-negative but not with HPV16 DNA-positive tumors the effect of hypoxia-induced genes on locoregional control was apparent (15-gene signature: HR 4.54, P = 0.006; 26-gene signature: HR 10.27, P = 0.024). Furthermore, MET, SLC3A2, CD44, and CD44 protein showed an association with locoregional tumor control in multivariate analyses (MET: HR 3.71, P = 0.016; SLC3A2: HR 8.54, P = 0.037; CD44: HR 3.36, P = 0.054; CD44 protein n/a because of no event in the CD44-negative group) in the HPV16 DNA-negative subgroup. CONCLUSIONS: We have shown for the first time that high hypoxia-induced gene expression and high CSC marker expression levels correlate with tumor recurrence after PORT-C in patients with HPV16 DNA-negative HNSCC. After validation in a currently ongoing prospective trial, these parameters may help to further stratify patients for individualized treatment de-escalation or intensification strategies. Clin Cancer Res; 22(11); 2639-49. (c)2016 AACR.},
	author = {Linge, A. and Lock, S. and Gudziol, V. and Nowak, A. and Lohaus, F. and von Neubeck, C. and Jutz, M. and Abdollahi, A. and Debus, J. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Welz, S. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Baumann, M. and Krause, M. and Dktk, R. O. G.},
	doi = {10.1158/1078-0432.CCR-15-1990},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Antineoplastic Agents/therapeutic use Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/*metabolism/mortality/pathology/therapy Cell Hypoxia Chemoradiotherapy Cisplatin/therapeutic use Fusion Regulatory Protein 1, Heavy Chain/metabolism Human papillomavirus 16/genetics Humans Hyaluronan Receptors/metabolism Kaplan-Meier Estimate Mouth Neoplasms/*metabolism/mortality/pathology/therapy Multivariate Analysis Neoplastic Stem Cells/*metabolism Papillomavirus Infections/diagnosis Prognosis Prospective Studies Transcriptome Treatment Outcome},
	note = {Linge, Annett Lock, Steffen Gudziol, Volker Nowak, Alexander Lohaus, Fabian von Neubeck, Clare Jutz, Martin Abdollahi, Amir Debus, Jurgen Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Avlar, Melanie Grosu, Anca-Ligia Bayer, Christine Belka, Claus Pigorsch, Steffi Combs, Stephanie E Welz, Stefan Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Baumann, Michael Krause, Mechthild eng Multicenter Study Research Support, Non-U.S. Gov't Clin Cancer Res. 2016 Jun 1;22(11):2639-49. doi: 10.1158/1078-0432.CCR-15-1990. Epub 2016 Jan 11.},
	number = {11},
	pages = {2639-49},
	title = {Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	volume = {22},
	year = {2016},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-15-1990}}

@article{RN26,
	abstract = {PURPOSE: To investigate the impact of hypoxia-induced gene expression and cancer stem cell (CSC) marker expression on outcome of postoperative cisplatin-based radiochemotherapy (PORT-C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). EXPERIMENTAL DESIGN: Expression of the CSC markers CD44, MET, and SLC3A2, and hypoxia gene signatures were analyzed in the resected primary tumors using RT-PCR and nanoString technology in a multicenter retrospective cohort of 195 patients. CD44 protein expression was further analyzed in tissue microarrays. Primary endpoint was locoregional tumor control. RESULTS: Univariate analysis showed that hypoxia-induced gene expression was significantly associated with a high risk of locoregional recurrence using the 15-gene signature (P = 0.010) or the 26-gene signature (P = 0.002). In multivariate analyses, in patients with HPV16 DNA-negative but not with HPV16 DNA-positive tumors the effect of hypoxia-induced genes on locoregional control was apparent (15-gene signature: HR 4.54, P = 0.006; 26-gene signature: HR 10.27, P = 0.024). Furthermore, MET, SLC3A2, CD44, and CD44 protein showed an association with locoregional tumor control in multivariate analyses (MET: HR 3.71, P = 0.016; SLC3A2: HR 8.54, P = 0.037; CD44: HR 3.36, P = 0.054; CD44 protein n/a because of no event in the CD44-negative group) in the HPV16 DNA-negative subgroup. CONCLUSIONS: We have shown for the first time that high hypoxia-induced gene expression and high CSC marker expression levels correlate with tumor recurrence after PORT-C in patients with HPV16 DNA-negative HNSCC. After validation in a currently ongoing prospective trial, these parameters may help to further stratify patients for individualized treatment de-escalation or intensification strategies. Clin Cancer Res; 22(11); 2639-49. (c)2016 AACR.},
	author = {Linge, A. and Lock, S. and Gudziol, V. and Nowak, A. and Lohaus, F. and von Neubeck, C. and Jutz, M. and Abdollahi, A. and Debus, J. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Welz, S. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Baumann, M. and Krause, M. and Dktk, R. O. G.},
	doi = {10.1158/1078-0432.CCR-15-1990},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Antineoplastic Agents/therapeutic use Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/*metabolism/mortality/pathology/therapy Cell Hypoxia Chemoradiotherapy Cisplatin/therapeutic use Fusion Regulatory Protein 1, Heavy Chain/metabolism Human papillomavirus 16/genetics Humans Hyaluronan Receptors/metabolism Kaplan-Meier Estimate Mouth Neoplasms/*metabolism/mortality/pathology/therapy Multivariate Analysis Neoplastic Stem Cells/*metabolism Papillomavirus Infections/diagnosis Prognosis Prospective Studies Transcriptome Treatment Outcome},
	note = {Linge, Annett Lock, Steffen Gudziol, Volker Nowak, Alexander Lohaus, Fabian von Neubeck, Clare Jutz, Martin Abdollahi, Amir Debus, Jurgen Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Avlar, Melanie Grosu, Anca-Ligia Bayer, Christine Belka, Claus Pigorsch, Steffi Combs, Stephanie E Welz, Stefan Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Baumann, Michael Krause, Mechthild eng Multicenter Study Research Support, Non-U.S. Gov't Clin Cancer Res. 2016 Jun 1;22(11):2639-49. doi: 10.1158/1078-0432.CCR-15-1990. Epub 2016 Jan 11.},
	number = {11},
	pages = {2639-49},
	title = {Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	volume = {22},
	year = {2016},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-15-1990}}

@article{RN4,
	abstract = {PURPOSE: To investigate the impact of hypoxia-induced gene expression and cancer stem cell (CSC) marker expression on outcome of postoperative cisplatin-based radiochemotherapy (PORT-C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). EXPERIMENTAL DESIGN: Expression of the CSC markers CD44, MET, and SLC3A2, and hypoxia gene signatures were analyzed in the resected primary tumors using RT-PCR and nanoString technology in a multicenter retrospective cohort of 195 patients. CD44 protein expression was further analyzed in tissue microarrays. Primary endpoint was locoregional tumor control. RESULTS: Univariate analysis showed that hypoxia-induced gene expression was significantly associated with a high risk of locoregional recurrence using the 15-gene signature (P = 0.010) or the 26-gene signature (P = 0.002). In multivariate analyses, in patients with HPV16 DNA-negative but not with HPV16 DNA-positive tumors the effect of hypoxia-induced genes on locoregional control was apparent (15-gene signature: HR 4.54, P = 0.006; 26-gene signature: HR 10.27, P = 0.024). Furthermore, MET, SLC3A2, CD44, and CD44 protein showed an association with locoregional tumor control in multivariate analyses (MET: HR 3.71, P = 0.016; SLC3A2: HR 8.54, P = 0.037; CD44: HR 3.36, P = 0.054; CD44 protein n/a because of no event in the CD44-negative group) in the HPV16 DNA-negative subgroup. CONCLUSIONS: We have shown for the first time that high hypoxia-induced gene expression and high CSC marker expression levels correlate with tumor recurrence after PORT-C in patients with HPV16 DNA-negative HNSCC. After validation in a currently ongoing prospective trial, these parameters may help to further stratify patients for individualized treatment de-escalation or intensification strategies. Clin Cancer Res; 22(11); 2639-49. (c)2016 AACR.},
	author = {Linge, A. and Lock, S. and Gudziol, V. and Nowak, A. and Lohaus, F. and von Neubeck, C. and Jutz, M. and Abdollahi, A. and Debus, J. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Welz, S. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Baumann, M. and Krause, M. and Dktk, R. O. G.},
	doi = {10.1158/1078-0432.CCR-15-1990},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Antineoplastic Agents/therapeutic use Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/*metabolism/mortality/pathology/therapy Cell Hypoxia Chemoradiotherapy Cisplatin/therapeutic use Fusion Regulatory Protein 1, Heavy Chain/metabolism Human papillomavirus 16/genetics Humans Hyaluronan Receptors/metabolism Kaplan-Meier Estimate Mouth Neoplasms/*metabolism/mortality/pathology/therapy Multivariate Analysis Neoplastic Stem Cells/*metabolism Papillomavirus Infections/diagnosis Prognosis Prospective Studies Transcriptome Treatment Outcome},
	note = {Linge, Annett Lock, Steffen Gudziol, Volker Nowak, Alexander Lohaus, Fabian von Neubeck, Clare Jutz, Martin Abdollahi, Amir Debus, Jurgen Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Avlar, Melanie Grosu, Anca-Ligia Bayer, Christine Belka, Claus Pigorsch, Steffi Combs, Stephanie E Welz, Stefan Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Baumann, Michael Krause, Mechthild eng Multicenter Study Research Support, Non-U.S. Gov't Clin Cancer Res. 2016 Jun 1;22(11):2639-49. doi: 10.1158/1078-0432.CCR-15-1990. Epub 2016 Jan 11.},
	number = {11},
	pages = {2639-49},
	title = {Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG},
	type = {Journal Article},
	url = {https://clincancerres.aacrjournals.org/content/clincanres/22/11/2639.full.pdf},
	volume = {22},
	year = {2016},
	bdsk-url-1 = {https://clincancerres.aacrjournals.org/content/clincanres/22/11/2639.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-15-1990}}

@article{RN5,
	abstract = {PURPOSE: To investigate the impact of hypoxia-induced gene expression and cancer stem cell (CSC) marker expression on outcome of postoperative cisplatin-based radiochemotherapy (PORT-C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). EXPERIMENTAL DESIGN: Expression of the CSC markers CD44, MET, and SLC3A2, and hypoxia gene signatures were analyzed in the resected primary tumors using RT-PCR and nanoString technology in a multicenter retrospective cohort of 195 patients. CD44 protein expression was further analyzed in tissue microarrays. Primary endpoint was locoregional tumor control. RESULTS: Univariate analysis showed that hypoxia-induced gene expression was significantly associated with a high risk of locoregional recurrence using the 15-gene signature (P = 0.010) or the 26-gene signature (P = 0.002). In multivariate analyses, in patients with HPV16 DNA-negative but not with HPV16 DNA-positive tumors the effect of hypoxia-induced genes on locoregional control was apparent (15-gene signature: HR 4.54, P = 0.006; 26-gene signature: HR 10.27, P = 0.024). Furthermore, MET, SLC3A2, CD44, and CD44 protein showed an association with locoregional tumor control in multivariate analyses (MET: HR 3.71, P = 0.016; SLC3A2: HR 8.54, P = 0.037; CD44: HR 3.36, P = 0.054; CD44 protein n/a because of no event in the CD44-negative group) in the HPV16 DNA-negative subgroup. CONCLUSIONS: We have shown for the first time that high hypoxia-induced gene expression and high CSC marker expression levels correlate with tumor recurrence after PORT-C in patients with HPV16 DNA-negative HNSCC. After validation in a currently ongoing prospective trial, these parameters may help to further stratify patients for individualized treatment de-escalation or intensification strategies. Clin Cancer Res; 22(11); 2639-49. (c)2016 AACR.},
	author = {Linge, A. and Lock, S. and Gudziol, V. and Nowak, A. and Lohaus, F. and von Neubeck, C. and Jutz, M. and Abdollahi, A. and Debus, J. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Welz, S. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Baumann, M. and Krause, M. and Dktk, R. O. G.},
	doi = {10.1158/1078-0432.CCR-15-1990},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Antineoplastic Agents/therapeutic use Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/*metabolism/mortality/pathology/therapy Cell Hypoxia Chemoradiotherapy Cisplatin/therapeutic use Fusion Regulatory Protein 1, Heavy Chain/metabolism Human papillomavirus 16/genetics Humans Hyaluronan Receptors/metabolism Kaplan-Meier Estimate Mouth Neoplasms/*metabolism/mortality/pathology/therapy Multivariate Analysis Neoplastic Stem Cells/*metabolism Papillomavirus Infections/diagnosis Prognosis Prospective Studies Transcriptome Treatment Outcome},
	note = {Linge, Annett Lock, Steffen Gudziol, Volker Nowak, Alexander Lohaus, Fabian von Neubeck, Clare Jutz, Martin Abdollahi, Amir Debus, Jurgen Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Avlar, Melanie Grosu, Anca-Ligia Bayer, Christine Belka, Claus Pigorsch, Steffi Combs, Stephanie E Welz, Stefan Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Baumann, Michael Krause, Mechthild eng Multicenter Study Research Support, Non-U.S. Gov't Clin Cancer Res. 2016 Jun 1;22(11):2639-49. doi: 10.1158/1078-0432.CCR-15-1990. Epub 2016 Jan 11.},
	number = {11},
	pages = {2639-49},
	title = {Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	volume = {22},
	year = {2016},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-15-1990}}

@article{RN8,
	abstract = {PURPOSE: To investigate the impact of hypoxia-induced gene expression and cancer stem cell (CSC) marker expression on outcome of postoperative cisplatin-based radiochemotherapy (PORT-C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). EXPERIMENTAL DESIGN: Expression of the CSC markers CD44, MET, and SLC3A2, and hypoxia gene signatures were analyzed in the resected primary tumors using RT-PCR and nanoString technology in a multicenter retrospective cohort of 195 patients. CD44 protein expression was further analyzed in tissue microarrays. Primary endpoint was locoregional tumor control. RESULTS: Univariate analysis showed that hypoxia-induced gene expression was significantly associated with a high risk of locoregional recurrence using the 15-gene signature (P = 0.010) or the 26-gene signature (P = 0.002). In multivariate analyses, in patients with HPV16 DNA-negative but not with HPV16 DNA-positive tumors the effect of hypoxia-induced genes on locoregional control was apparent (15-gene signature: HR 4.54, P = 0.006; 26-gene signature: HR 10.27, P = 0.024). Furthermore, MET, SLC3A2, CD44, and CD44 protein showed an association with locoregional tumor control in multivariate analyses (MET: HR 3.71, P = 0.016; SLC3A2: HR 8.54, P = 0.037; CD44: HR 3.36, P = 0.054; CD44 protein n/a because of no event in the CD44-negative group) in the HPV16 DNA-negative subgroup. CONCLUSIONS: We have shown for the first time that high hypoxia-induced gene expression and high CSC marker expression levels correlate with tumor recurrence after PORT-C in patients with HPV16 DNA-negative HNSCC. After validation in a currently ongoing prospective trial, these parameters may help to further stratify patients for individualized treatment de-escalation or intensification strategies. Clin Cancer Res; 22(11); 2639-49. (c)2016 AACR.},
	author = {Linge, A. and Lock, S. and Gudziol, V. and Nowak, A. and Lohaus, F. and von Neubeck, C. and Jutz, M. and Abdollahi, A. and Debus, J. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Welz, S. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Baumann, M. and Krause, M. and Dktk, R. O. G.},
	doi = {10.1158/1078-0432.CCR-15-1990},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Antineoplastic Agents/therapeutic use Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/*metabolism/mortality/pathology/therapy Cell Hypoxia Chemoradiotherapy Cisplatin/therapeutic use Fusion Regulatory Protein 1, Heavy Chain/metabolism Human papillomavirus 16/genetics Humans Hyaluronan Receptors/metabolism Kaplan-Meier Estimate Mouth Neoplasms/*metabolism/mortality/pathology/therapy Multivariate Analysis Neoplastic Stem Cells/*metabolism Papillomavirus Infections/diagnosis Prognosis Prospective Studies Transcriptome Treatment Outcome},
	note = {Linge, Annett Lock, Steffen Gudziol, Volker Nowak, Alexander Lohaus, Fabian von Neubeck, Clare Jutz, Martin Abdollahi, Amir Debus, Jurgen Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Avlar, Melanie Grosu, Anca-Ligia Bayer, Christine Belka, Claus Pigorsch, Steffi Combs, Stephanie E Welz, Stefan Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Baumann, Michael Krause, Mechthild eng Multicenter Study Research Support, Non-U.S. Gov't Clin Cancer Res. 2016 Jun 1;22(11):2639-49. doi: 10.1158/1078-0432.CCR-15-1990. Epub 2016 Jan 11.},
	number = {11},
	pages = {2639-49},
	title = {Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	volume = {22},
	year = {2016},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-15-1990}}

@article{RN6,
	abstract = {PURPOSE: To investigate the impact of hypoxia-induced gene expression and cancer stem cell (CSC) marker expression on outcome of postoperative cisplatin-based radiochemotherapy (PORT-C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). EXPERIMENTAL DESIGN: Expression of the CSC markers CD44, MET, and SLC3A2, and hypoxia gene signatures were analyzed in the resected primary tumors using RT-PCR and nanoString technology in a multicenter retrospective cohort of 195 patients. CD44 protein expression was further analyzed in tissue microarrays. Primary endpoint was locoregional tumor control. RESULTS: Univariate analysis showed that hypoxia-induced gene expression was significantly associated with a high risk of locoregional recurrence using the 15-gene signature (P = 0.010) or the 26-gene signature (P = 0.002). In multivariate analyses, in patients with HPV16 DNA-negative but not with HPV16 DNA-positive tumors the effect of hypoxia-induced genes on locoregional control was apparent (15-gene signature: HR 4.54, P = 0.006; 26-gene signature: HR 10.27, P = 0.024). Furthermore, MET, SLC3A2, CD44, and CD44 protein showed an association with locoregional tumor control in multivariate analyses (MET: HR 3.71, P = 0.016; SLC3A2: HR 8.54, P = 0.037; CD44: HR 3.36, P = 0.054; CD44 protein n/a because of no event in the CD44-negative group) in the HPV16 DNA-negative subgroup. CONCLUSIONS: We have shown for the first time that high hypoxia-induced gene expression and high CSC marker expression levels correlate with tumor recurrence after PORT-C in patients with HPV16 DNA-negative HNSCC. After validation in a currently ongoing prospective trial, these parameters may help to further stratify patients for individualized treatment de-escalation or intensification strategies. Clin Cancer Res; 22(11); 2639-49. (c)2016 AACR.},
	author = {Linge, A. and Lock, S. and Gudziol, V. and Nowak, A. and Lohaus, F. and von Neubeck, C. and Jutz, M. and Abdollahi, A. and Debus, J. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Welz, S. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Baumann, M. and Krause, M. and Dktk, R. O. G.},
	doi = {10.1158/1078-0432.CCR-15-1990},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Antineoplastic Agents/therapeutic use Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/*metabolism/mortality/pathology/therapy Cell Hypoxia Chemoradiotherapy Cisplatin/therapeutic use Fusion Regulatory Protein 1, Heavy Chain/metabolism Human papillomavirus 16/genetics Humans Hyaluronan Receptors/metabolism Kaplan-Meier Estimate Mouth Neoplasms/*metabolism/mortality/pathology/therapy Multivariate Analysis Neoplastic Stem Cells/*metabolism Papillomavirus Infections/diagnosis Prognosis Prospective Studies Transcriptome Treatment Outcome},
	note = {Linge, Annett Lock, Steffen Gudziol, Volker Nowak, Alexander Lohaus, Fabian von Neubeck, Clare Jutz, Martin Abdollahi, Amir Debus, Jurgen Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Avlar, Melanie Grosu, Anca-Ligia Bayer, Christine Belka, Claus Pigorsch, Steffi Combs, Stephanie E Welz, Stefan Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Baumann, Michael Krause, Mechthild eng Multicenter Study Research Support, Non-U.S. Gov't Clin Cancer Res. 2016 Jun 1;22(11):2639-49. doi: 10.1158/1078-0432.CCR-15-1990. Epub 2016 Jan 11.},
	number = {11},
	pages = {2639-49},
	title = {Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	volume = {22},
	year = {2016},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/26755529},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-15-1990}}

@article{RN31,
	abstract = {Objective: To validate the impact of HPV status, cancer stem cell (CSC) marker expression and tumour hypoxia status in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received postoperative radiotherapy. The results of the exploration cohort have previously been reported by the German Cancer Consortium Radiation Oncology Group (DKTK-ROG; Lohaus et al., 2014; Linge et al., 2016). Materials and methods: For 152 patients with locally advanced HNSCC the impact of HPV16 DNA status, CSC marker expression and hypoxia-associated gene signatures on outcome of postoperative radiotherapy were retrospectively analysed. Out of them, 40 patients received postoperative radiochemotherapy. Cox models presented in a previous study were validated using the concordance index as a performance measure. The primary endpoint of this study was loco-regional control. Results were compared to those previously reported by DKTK-ROG. Results: Loco-regional control, freedom from distant metastases and overall survival were inferior to the previously reported cohort. Despite of this, the prognostic value of the combination of HPV infection status, CSC marker expression (SLC3A2) and tumour hypoxia status could be validated in univariate analyses using an independent validation cohort. For multivariate models, the concordance index was between 0.58 and 0.69 in validation, indicating a good prognostic performance of the models. The inclusion of CD44 and the 15-gene hypoxia signature moderately improved the performance compared to a baseline model without CSC markers or hypoxia classifiers. Conclusions: The HPV status, CSC marker expression of CD44 and SLC3A2 as well as hypoxia status are potential prognostic biomarkers for patients with locally advanced HNSCC treated by postoperative radiotherapy.},
	author = {Linge, A. and Lock, S. and Krenn, C. and Appold, S. and Lohaus, F. and Nowak, A. and Gudziol, V. and Baretton, G. B. and Buchholz, F. and Baumann, M. and Krause, M.},
	doi = {10.1016/j.ctro.2016.10.002},
	issn = {2405-6308 (Electronic) 2405-6308 (Linking)},
	journal = {Clin Transl Radiat Oncol},
	keywords = {Biomarker Cancer stem cells Hnscc Hpv Hypoxia Postoperative radiochemotherapy Validation},
	note = {Linge, Annett Lock, Steffen Krenn, Constanze Appold, Steffen Lohaus, Fabian Nowak, Alexander Gudziol, Volker Baretton, Gustavo B Buchholz, Frank Baumann, Michael Krause, Mechthild eng Ireland Clin Transl Radiat Oncol. 2016 Dec 22;1:19-26. doi: 10.1016/j.ctro.2016.10.002. eCollection 2016 Dec.},
	pages = {19-26},
	title = {Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893482/pdf/main.pdf},
	volume = {1},
	year = {2016},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893482/pdf/main.pdf},
	bdsk-url-2 = {https://doi.org/10.1016/j.ctro.2016.10.002}}

@article{RN7,
	abstract = {OBJECTIVE: To investigate the impact of the tumour volume, HPV status, cancer stem cell (CSC) marker expression and hypoxia gene signatures, as potential markers of radiobiological mechanisms of radioresistance, in a contemporary cohort of patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received primary radiochemotherapy (RCTx). MATERIALS AND METHODS: For 158 patients with locally advanced HNSCC of the oral cavity, oropharynx or hypopharynx who were treated at six DKTK partner sites, the impact of tumour volume, HPV DNA, p16 overexpression, p53 expression, CSC marker expression and hypoxia-associated gene signatures on outcome of primary RCTx was retrospectively analyzed. The primary endpoint of this study was loco-regional control (LRC). RESULTS: Univariate Cox regression revealed a significant impact of tumour volume, p16 overexpression, and SLC3A2 and CD44 protein expression on LRC. The tumour hypoxia classification showed a significant impact only for small tumours. In multivariate analyses an independent correlation of tumour volume, SLC3A2 expression, and the 15-gene hypoxia signature with LRC was identified (CD44 protein n/a because of no event in the CD44-negative group). Logistic modelling showed that inclusion of CD44 protein expression and p16 overexpression significantly improved the performance to predict LRC at 2years compared to the model with tumour volume alone. CONCLUSIONS: Tumour volume, HPV status, CSC marker expression and hypoxia gene signatures are potential prognostic biomarkers for patients with locally advanced HNSCC, who were treated by primary RCTx. The study also supports that the individual tumour volumes should generally be included in biomarker studies and that panels of biomarkers are superior to individual parameters.},
	author = {Linge, A. and Lohaus, F. and Lock, S. and Nowak, A. and Gudziol, V. and Valentini, C. and von Neubeck, C. and Jutz, M. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Ganswindt, U. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Krause, M. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2016.11.008},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/genetics/pathology/*therapy/virology Cell Hypoxia/genetics Chemoradiotherapy Female Gene Expression Profiling/methods Head and Neck Neoplasms/genetics/pathology/*therapy/virology Humans Hyaluronan Receptors/metabolism Male Middle Aged Neoplastic Stem Cells/*metabolism Papillomaviridae/*isolation & purification Prognosis Radiation Tolerance/genetics Retrospective Studies Squamous Cell Carcinoma of Head and Neck Tumor Burden *Biomarkers for radiotherapy *Cancer stem cells *hnscc *hpv *Hypoxia *Primary radiochemotherapy},
	note = {Linge, Annett Lohaus, Fabian Lock, Steffen Nowak, Alexander Gudziol, Volker Valentini, Chiara von Neubeck, Clare Jutz, Martin Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Grosu, Anca-Ligia Abdollahi, Amir Debus, Jurgen Ganswindt, Ute Belka, Claus Pigorsch, Steffi Combs, Stephanie E Monnich, David Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Krause, Mechthild Baumann, Michael eng Multicenter Study Ireland Radiother Oncol. 2016 Dec;121(3):364-373. doi: 10.1016/j.radonc.2016.11.008. Epub 2016 Nov 29.},
	number = {3},
	pages = {364-373},
	title = {HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27913065},
	volume = {121},
	year = {2016},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/27913065},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2016.11.008}}

@article{RN3,
	abstract = {OBJECTIVE: To investigate the impact of the tumour volume, HPV status, cancer stem cell (CSC) marker expression and hypoxia gene signatures, as potential markers of radiobiological mechanisms of radioresistance, in a contemporary cohort of patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received primary radiochemotherapy (RCTx). MATERIALS AND METHODS: For 158 patients with locally advanced HNSCC of the oral cavity, oropharynx or hypopharynx who were treated at six DKTK partner sites, the impact of tumour volume, HPV DNA, p16 overexpression, p53 expression, CSC marker expression and hypoxia-associated gene signatures on outcome of primary RCTx was retrospectively analyzed. The primary endpoint of this study was loco-regional control (LRC). RESULTS: Univariate Cox regression revealed a significant impact of tumour volume, p16 overexpression, and SLC3A2 and CD44 protein expression on LRC. The tumour hypoxia classification showed a significant impact only for small tumours. In multivariate analyses an independent correlation of tumour volume, SLC3A2 expression, and the 15-gene hypoxia signature with LRC was identified (CD44 protein n/a because of no event in the CD44-negative group). Logistic modelling showed that inclusion of CD44 protein expression and p16 overexpression significantly improved the performance to predict LRC at 2years compared to the model with tumour volume alone. CONCLUSIONS: Tumour volume, HPV status, CSC marker expression and hypoxia gene signatures are potential prognostic biomarkers for patients with locally advanced HNSCC, who were treated by primary RCTx. The study also supports that the individual tumour volumes should generally be included in biomarker studies and that panels of biomarkers are superior to individual parameters.},
	author = {Linge, A. and Lohaus, F. and Lock, S. and Nowak, A. and Gudziol, V. and Valentini, C. and von Neubeck, C. and Jutz, M. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Ganswindt, U. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Krause, M. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2016.11.008},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/genetics/pathology/*therapy/virology Cell Hypoxia/genetics Chemoradiotherapy Female Gene Expression Profiling/methods Head and Neck Neoplasms/genetics/pathology/*therapy/virology Humans Hyaluronan Receptors/metabolism Male Middle Aged Neoplastic Stem Cells/*metabolism Papillomaviridae/*isolation & purification Prognosis Radiation Tolerance/genetics Retrospective Studies Squamous Cell Carcinoma of Head and Neck Tumor Burden *Biomarkers for radiotherapy *Cancer stem cells *hnscc *hpv *Hypoxia *Primary radiochemotherapy},
	note = {Linge, Annett Lohaus, Fabian Lock, Steffen Nowak, Alexander Gudziol, Volker Valentini, Chiara von Neubeck, Clare Jutz, Martin Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Grosu, Anca-Ligia Abdollahi, Amir Debus, Jurgen Ganswindt, Ute Belka, Claus Pigorsch, Steffi Combs, Stephanie E Monnich, David Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Krause, Mechthild Baumann, Michael eng Multicenter Study Ireland Radiother Oncol. 2016 Dec;121(3):364-373. doi: 10.1016/j.radonc.2016.11.008. Epub 2016 Nov 29.},
	number = {3},
	pages = {364-373},
	title = {HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	url = {https://www.thegreenjournal.com/article/S0167-8140(16)34383-3/fulltext},
	volume = {121},
	year = {2016},
	bdsk-url-1 = {https://www.thegreenjournal.com/article/S0167-8140(16)34383-3/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2016.11.008}}

@article{RN32,
	abstract = {OBJECTIVE: To investigate the impact of the tumour volume, HPV status, cancer stem cell (CSC) marker expression and hypoxia gene signatures, as potential markers of radiobiological mechanisms of radioresistance, in a contemporary cohort of patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received primary radiochemotherapy (RCTx). MATERIALS AND METHODS: For 158 patients with locally advanced HNSCC of the oral cavity, oropharynx or hypopharynx who were treated at six DKTK partner sites, the impact of tumour volume, HPV DNA, p16 overexpression, p53 expression, CSC marker expression and hypoxia-associated gene signatures on outcome of primary RCTx was retrospectively analyzed. The primary endpoint of this study was loco-regional control (LRC). RESULTS: Univariate Cox regression revealed a significant impact of tumour volume, p16 overexpression, and SLC3A2 and CD44 protein expression on LRC. The tumour hypoxia classification showed a significant impact only for small tumours. In multivariate analyses an independent correlation of tumour volume, SLC3A2 expression, and the 15-gene hypoxia signature with LRC was identified (CD44 protein n/a because of no event in the CD44-negative group). Logistic modelling showed that inclusion of CD44 protein expression and p16 overexpression significantly improved the performance to predict LRC at 2years compared to the model with tumour volume alone. CONCLUSIONS: Tumour volume, HPV status, CSC marker expression and hypoxia gene signatures are potential prognostic biomarkers for patients with locally advanced HNSCC, who were treated by primary RCTx. The study also supports that the individual tumour volumes should generally be included in biomarker studies and that panels of biomarkers are superior to individual parameters.},
	author = {Linge, A. and Lohaus, F. and Lock, S. and Nowak, A. and Gudziol, V. and Valentini, C. and von Neubeck, C. and Jutz, M. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Ganswindt, U. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Krause, M. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2016.11.008},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/genetics/pathology/*therapy/virology Cell Hypoxia/genetics Chemoradiotherapy Female Gene Expression Profiling/methods Head and Neck Neoplasms/genetics/pathology/*therapy/virology Humans Hyaluronan Receptors/metabolism Male Middle Aged Neoplastic Stem Cells/*metabolism Papillomaviridae/*isolation & purification Prognosis Radiation Tolerance/genetics Retrospective Studies Squamous Cell Carcinoma of Head and Neck Tumor Burden *Biomarkers for radiotherapy *Cancer stem cells *hnscc *hpv *Hypoxia *Primary radiochemotherapy},
	note = {Linge, Annett Lohaus, Fabian Lock, Steffen Nowak, Alexander Gudziol, Volker Valentini, Chiara von Neubeck, Clare Jutz, Martin Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Grosu, Anca-Ligia Abdollahi, Amir Debus, Jurgen Ganswindt, Ute Belka, Claus Pigorsch, Steffi Combs, Stephanie E Monnich, David Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Krause, Mechthild Baumann, Michael eng Multicenter Study Ireland Radiother Oncol. 2016 Dec;121(3):364-373. doi: 10.1016/j.radonc.2016.11.008. Epub 2016 Nov 29.},
	number = {3},
	pages = {364-373},
	title = {HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27913065},
	volume = {121},
	year = {2016},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/27913065},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2016.11.008}}

@article{RN326,
	abstract = {OBJECTIVE: To investigate the impact of the tumour volume, HPV status, cancer stem cell (CSC) marker expression and hypoxia gene signatures, as potential markers of radiobiological mechanisms of radioresistance, in a contemporary cohort of patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received primary radiochemotherapy (RCTx). MATERIALS AND METHODS: For 158 patients with locally advanced HNSCC of the oral cavity, oropharynx or hypopharynx who were treated at six DKTK partner sites, the impact of tumour volume, HPV DNA, p16 overexpression, p53 expression, CSC marker expression and hypoxia-associated gene signatures on outcome of primary RCTx was retrospectively analyzed. The primary endpoint of this study was loco-regional control (LRC). RESULTS: Univariate Cox regression revealed a significant impact of tumour volume, p16 overexpression, and SLC3A2 and CD44 protein expression on LRC. The tumour hypoxia classification showed a significant impact only for small tumours. In multivariate analyses an independent correlation of tumour volume, SLC3A2 expression, and the 15-gene hypoxia signature with LRC was identified (CD44 protein n/a because of no event in the CD44-negative group). Logistic modelling showed that inclusion of CD44 protein expression and p16 overexpression significantly improved the performance to predict LRC at 2years compared to the model with tumour volume alone. CONCLUSIONS: Tumour volume, HPV status, CSC marker expression and hypoxia gene signatures are potential prognostic biomarkers for patients with locally advanced HNSCC, who were treated by primary RCTx. The study also supports that the individual tumour volumes should generally be included in biomarker studies and that panels of biomarkers are superior to individual parameters.},
	author = {Linge, A. and Lohaus, F. and L{\"o}ck, S. and Nowak, A. and Gudziol, V. and Valentini, C. and von Neubeck, C. and J{\"u}tz, M. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and R{\"o}del, C. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Ganswindt, U. and Belka, C. and Pigorsch, S. and Combs, S. E. and M{\"o}nnich, D. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Krause, M. and Baumann, M.},
	doi = {10.1016/j.radonc.2016.11.008},
	issn = {0167-8140},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/genetics/pathology/*therapy/virology Cell Hypoxia/genetics Chemoradiotherapy Female Gene Expression Profiling/methods Head and Neck Neoplasms/genetics/pathology/*therapy/virology Humans Hyaluronan Receptors/metabolism Male Middle Aged Neoplastic Stem Cells/*metabolism Papillomaviridae/*isolation & purification Prognosis Radiation Tolerance/genetics Retrospective Studies Squamous Cell Carcinoma of Head and Neck Tumor Burden *Biomarkers for radiotherapy *Cancer stem cells *hnscc *hpv *Hypoxia *Primary radiochemotherapy},
	note = {1879-0887 Linge, Annett Lohaus, Fabian L{\"o}ck, Steffen Nowak, Alexander Gudziol, Volker Valentini, Chiara von Neubeck, Cl{\"a}re J{\"u}tz, Martin Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis R{\"o}del, Claus Grosu, Anca-Ligia Abdollahi, Amir Debus, J{\"u}rgen Ganswindt, Ute Belka, Claus Pigorsch, Steffi Combs, Stephanie E M{\"o}nnich, David Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Krause, Mechthild Baumann, Michael Dktk-rog Journal Article Multicenter Study Ireland 2016/12/04 Radiother Oncol. 2016 Dec;121(3):364-373. doi: 10.1016/j.radonc.2016.11.008. Epub 2016 Nov 29.},
	number = {3},
	pages = {364-373},
	title = {HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	volume = {121},
	year = {2016},
	bdsk-url-1 = {https://doi.org/10.1016/j.radonc.2016.11.008}}

@article{RN330,
	abstract = {OBJECTIVE: To investigate the impact of the tumour volume, HPV status, cancer stem cell (CSC) marker expression and hypoxia gene signatures, as potential markers of radiobiological mechanisms of radioresistance, in a contemporary cohort of patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received primary radiochemotherapy (RCTx). MATERIALS AND METHODS: For 158 patients with locally advanced HNSCC of the oral cavity, oropharynx or hypopharynx who were treated at six DKTK partner sites, the impact of tumour volume, HPV DNA, p16 overexpression, p53 expression, CSC marker expression and hypoxia-associated gene signatures on outcome of primary RCTx was retrospectively analyzed. The primary endpoint of this study was loco-regional control (LRC). RESULTS: Univariate Cox regression revealed a significant impact of tumour volume, p16 overexpression, and SLC3A2 and CD44 protein expression on LRC. The tumour hypoxia classification showed a significant impact only for small tumours. In multivariate analyses an independent correlation of tumour volume, SLC3A2 expression, and the 15-gene hypoxia signature with LRC was identified (CD44 protein n/a because of no event in the CD44-negative group). Logistic modelling showed that inclusion of CD44 protein expression and p16 overexpression significantly improved the performance to predict LRC at 2years compared to the model with tumour volume alone. CONCLUSIONS: Tumour volume, HPV status, CSC marker expression and hypoxia gene signatures are potential prognostic biomarkers for patients with locally advanced HNSCC, who were treated by primary RCTx. The study also supports that the individual tumour volumes should generally be included in biomarker studies and that panels of biomarkers are superior to individual parameters.},
	author = {Linge, A. and Lohaus, F. and L{\"o}ck, S. and Nowak, A. and Gudziol, V. and Valentini, C. and von Neubeck, C. and J{\"u}tz, M. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and R{\"o}del, C. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Ganswindt, U. and Belka, C. and Pigorsch, S. and Combs, S. E. and M{\"o}nnich, D. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Krause, M. and Baumann, M.},
	doi = {10.1016/j.radonc.2016.11.008},
	issn = {0167-8140},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/genetics/pathology/*therapy/virology Cell Hypoxia/genetics Chemoradiotherapy Female Gene Expression Profiling/methods Head and Neck Neoplasms/genetics/pathology/*therapy/virology Humans Hyaluronan Receptors/metabolism Male Middle Aged Neoplastic Stem Cells/*metabolism Papillomaviridae/*isolation & purification Prognosis Radiation Tolerance/genetics Retrospective Studies Squamous Cell Carcinoma of Head and Neck Tumor Burden Biomarkers for radiotherapy Cancer stem cells Hnscc Hpv Hypoxia Primary radiochemotherapy},
	note = {1879-0887 Linge, Annett Lohaus, Fabian L{\"o}ck, Steffen Nowak, Alexander Gudziol, Volker Valentini, Chiara von Neubeck, Cl{\"a}re J{\"u}tz, Martin Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis R{\"o}del, Claus Grosu, Anca-Ligia Abdollahi, Amir Debus, J{\"u}rgen Ganswindt, Ute Belka, Claus Pigorsch, Steffi Combs, Stephanie E M{\"o}nnich, David Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Krause, Mechthild Baumann, Michael Dktk-rog Journal Article Multicenter Study Ireland 2016/12/04 Radiother Oncol. 2016 Dec;121(3):364-373. doi: 10.1016/j.radonc.2016.11.008. Epub 2016 Nov 29.},
	number = {3},
	pages = {364-373},
	title = {HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	volume = {121},
	year = {2016},
	bdsk-url-1 = {https://doi.org/10.1016/j.radonc.2016.11.008}}

@article{RN329,
	abstract = {PURPOSE: To investigate the impact of hypoxia-induced gene expression and cancer stem cell (CSC) marker expression on outcome of postoperative cisplatin-based radiochemotherapy (PORT-C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). EXPERIMENTAL DESIGN: Expression of the CSC markers CD44, MET, and SLC3A2, and hypoxia gene signatures were analyzed in the resected primary tumors using RT-PCR and nanoString technology in a multicenter retrospective cohort of 195 patients. CD44 protein expression was further analyzed in tissue microarrays. Primary endpoint was locoregional tumor control. RESULTS: Univariate analysis showed that hypoxia-induced gene expression was significantly associated with a high risk of locoregional recurrence using the 15-gene signature (P = 0.010) or the 26-gene signature (P = 0.002). In multivariate analyses, in patients with HPV16 DNA-negative but not with HPV16 DNA-positive tumors the effect of hypoxia-induced genes on locoregional control was apparent (15-gene signature: HR 4.54, P = 0.006; 26-gene signature: HR 10.27, P = 0.024). Furthermore, MET, SLC3A2, CD44, and CD44 protein showed an association with locoregional tumor control in multivariate analyses (MET: HR 3.71, P = 0.016; SLC3A2: HR 8.54, P = 0.037; CD44: HR 3.36, P = 0.054; CD44 protein n/a because of no event in the CD44-negative group) in the HPV16 DNA-negative subgroup. CONCLUSIONS: We have shown for the first time that high hypoxia-induced gene expression and high CSC marker expression levels correlate with tumor recurrence after PORT-C in patients with HPV16 DNA-negative HNSCC. After validation in a currently ongoing prospective trial, these parameters may help to further stratify patients for individualized treatment de-escalation or intensification strategies. Clin Cancer Res; 22(11); 2639-49. {\copyright}2016 AACR.},
	author = {Linge, A. and L{\"o}ck, S. and Gudziol, V. and Nowak, A. and Lohaus, F. and von Neubeck, C. and J{\"u}tz, M. and Abdollahi, A. and Debus, J. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and R{\"o}del, C. and Avlar, M. and Grosu, A. L. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Welz, S. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Baumann, M. and Krause, M.},
	doi = {10.1158/1078-0432.Ccr-15-1990},
	issn = {1078-0432},
	journal = {Clin Cancer Res},
	keywords = {Antineoplastic Agents/therapeutic use Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/*metabolism/mortality/pathology/therapy Cell Hypoxia Chemoradiotherapy Cisplatin/therapeutic use Fusion Regulatory Protein 1, Heavy Chain/metabolism Human papillomavirus 16/genetics Humans Hyaluronan Receptors/metabolism Kaplan-Meier Estimate Mouth Neoplasms/*metabolism/mortality/pathology/therapy Multivariate Analysis Neoplastic Stem Cells/*metabolism Papillomavirus Infections/diagnosis Prognosis Prospective Studies Transcriptome Treatment Outcome},
	note = {1557-3265 Linge, Annett L{\"o}ck, Steffen Gudziol, Volker Nowak, Alexander Lohaus, Fabian von Neubeck, Cl{\"a}re J{\"u}tz, Martin Abdollahi, Amir Debus, J{\"u}rgen Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis R{\"o}del, Claus Avlar, Melanie Grosu, Anca-Ligia Bayer, Christine Belka, Claus Pigorsch, Steffi Combs, Stephanie E Welz, Stefan Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Baumann, Michael Krause, Mechthild Dktk-rog Journal Article Multicenter Study Research Support, Non-U.S. Gov't United States 2016/01/13 Clin Cancer Res. 2016 Jun 1;22(11):2639-49. doi: 10.1158/1078-0432.CCR-15-1990. Epub 2016 Jan 11.},
	number = {11},
	pages = {2639-49},
	title = {Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG},
	type = {Journal Article},
	volume = {22},
	year = {2016},
	bdsk-url-1 = {https://doi.org/10.1158/1078-0432.Ccr-15-1990}}

@article{RN328,
	abstract = {PURPOSE: To investigate the impact of hypoxia-induced gene expression and cancer stem cell (CSC) marker expression on outcome of postoperative cisplatin-based radiochemotherapy (PORT-C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). EXPERIMENTAL DESIGN: Expression of the CSC markers CD44, MET, and SLC3A2, and hypoxia gene signatures were analyzed in the resected primary tumors using RT-PCR and nanoString technology in a multicenter retrospective cohort of 195 patients. CD44 protein expression was further analyzed in tissue microarrays. Primary endpoint was locoregional tumor control. RESULTS: Univariate analysis showed that hypoxia-induced gene expression was significantly associated with a high risk of locoregional recurrence using the 15-gene signature (P = 0.010) or the 26-gene signature (P = 0.002). In multivariate analyses, in patients with HPV16 DNA-negative but not with HPV16 DNA-positive tumors the effect of hypoxia-induced genes on locoregional control was apparent (15-gene signature: HR 4.54, P = 0.006; 26-gene signature: HR 10.27, P = 0.024). Furthermore, MET, SLC3A2, CD44, and CD44 protein showed an association with locoregional tumor control in multivariate analyses (MET: HR 3.71, P = 0.016; SLC3A2: HR 8.54, P = 0.037; CD44: HR 3.36, P = 0.054; CD44 protein n/a because of no event in the CD44-negative group) in the HPV16 DNA-negative subgroup. CONCLUSIONS: We have shown for the first time that high hypoxia-induced gene expression and high CSC marker expression levels correlate with tumor recurrence after PORT-C in patients with HPV16 DNA-negative HNSCC. After validation in a currently ongoing prospective trial, these parameters may help to further stratify patients for individualized treatment de-escalation or intensification strategies. Clin Cancer Res; 22(11); 2639-49. {\copyright}2016 AACR.},
	author = {Linge, A. and L{\"o}ck, S. and Gudziol, V. and Nowak, A. and Lohaus, F. and von Neubeck, C. and J{\"u}tz, M. and Abdollahi, A. and Debus, J. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and R{\"o}del, C. and Avlar, M. and Grosu, A. L. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Welz, S. and Zips, D. and Buchholz, F. and Aust, D. E. and Baretton, G. B. and Thames, H. D. and Dubrovska, A. and Alsner, J. and Overgaard, J. and Baumann, M. and Krause, M.},
	doi = {10.1158/1078-0432.Ccr-15-1990},
	issn = {1078-0432},
	journal = {Clin Cancer Res},
	keywords = {Antineoplastic Agents/therapeutic use Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/*metabolism/mortality/pathology/therapy Cell Hypoxia Chemoradiotherapy Cisplatin/therapeutic use Fusion Regulatory Protein 1, Heavy Chain/metabolism Human papillomavirus 16/genetics Humans Hyaluronan Receptors/metabolism Kaplan-Meier Estimate Mouth Neoplasms/*metabolism/mortality/pathology/therapy Multivariate Analysis Neoplastic Stem Cells/*metabolism Papillomavirus Infections/diagnosis Prognosis Prospective Studies Transcriptome Treatment Outcome},
	note = {1557-3265 Linge, Annett L{\"o}ck, Steffen Gudziol, Volker Nowak, Alexander Lohaus, Fabian von Neubeck, Cl{\"a}re J{\"u}tz, Martin Abdollahi, Amir Debus, J{\"u}rgen Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis R{\"o}del, Claus Avlar, Melanie Grosu, Anca-Ligia Bayer, Christine Belka, Claus Pigorsch, Steffi Combs, Stephanie E Welz, Stefan Zips, Daniel Buchholz, Frank Aust, Daniela E Baretton, Gustavo B Thames, Howard D Dubrovska, Anna Alsner, Jan Overgaard, Jens Baumann, Michael Krause, Mechthild Dktk-rog Journal Article Multicenter Study Research Support, Non-U.S. Gov't United States 2016/01/13 Clin Cancer Res. 2016 Jun 1;22(11):2639-49. doi: 10.1158/1078-0432.CCR-15-1990. Epub 2016 Jan 11.},
	number = {11},
	pages = {2639-49},
	title = {Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG},
	type = {Journal Article},
	volume = {22},
	year = {2016},
	bdsk-url-1 = {https://doi.org/10.1158/1078-0432.Ccr-15-1990}}

@article{RN325,
	abstract = {OBJECTIVE: To validate the impact of HPV status, cancer stem cell (CSC) marker expression and tumour hypoxia status in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received postoperative radiotherapy. The results of the exploration cohort have previously been reported by the German Cancer Consortium Radiation Oncology Group (DKTK-ROG; Lohaus et al., 2014; Linge et al., 2016). MATERIALS AND METHODS: For 152 patients with locally advanced HNSCC the impact of HPV16 DNA status, CSC marker expression and hypoxia-associated gene signatures on outcome of postoperative radiotherapy were retrospectively analysed. Out of them, 40 patients received postoperative radiochemotherapy. Cox models presented in a previous study were validated using the concordance index as a performance measure. The primary endpoint of this study was loco-regional control. Results were compared to those previously reported by DKTK-ROG. RESULTS: Loco-regional control, freedom from distant metastases and overall survival were inferior to the previously reported cohort. Despite of this, the prognostic value of the combination of HPV infection status, CSC marker expression (SLC3A2) and tumour hypoxia status could be validated in univariate analyses using an independent validation cohort. For multivariate models, the concordance index was between 0.58 and 0.69 in validation, indicating a good prognostic performance of the models. The inclusion of CD44 and the 15-gene hypoxia signature moderately improved the performance compared to a baseline model without CSC markers or hypoxia classifiers. CONCLUSIONS: The HPV status, CSC marker expression of CD44 and SLC3A2 as well as hypoxia status are potential prognostic biomarkers for patients with locally advanced HNSCC treated by postoperative radiotherapy.},
	author = {Linge, A. and L{\"o}ck, S. and Krenn, C. and Appold, S. and Lohaus, F. and Nowak, A. and Gudziol, V. and Baretton, G. B. and Buchholz, F. and Baumann, M. and Krause, M.},
	doi = {10.1016/j.ctro.2016.10.002},
	issn = {2405-6308},
	journal = {Clin Transl Radiat Oncol},
	keywords = {Biomarker Cancer stem cells Hnscc Hpv Hypoxia Postoperative radiochemotherapy Validation},
	note = {2405-6308 Linge, Annett L{\"o}ck, Steffen Krenn, Constanze Appold, Steffen Lohaus, Fabian Nowak, Alexander Gudziol, Volker Baretton, Gustavo B Buchholz, Frank Baumann, Michael Krause, Mechthild Journal Article 2016/12/22 Clin Transl Radiat Oncol. 2016 Dec 22;1:19-26. doi: 10.1016/j.ctro.2016.10.002. eCollection 2016 Dec.},
	pages = {19-26},
	title = {Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy},
	type = {Journal Article},
	volume = {1},
	year = {2016},
	bdsk-url-1 = {https://doi.org/10.1016/j.ctro.2016.10.002}}

@article{RN13,
	abstract = {Objective: To independently validate the impact of tumour volume, p16 status, cancer stem cell (CSC) marker expression and hypoxia-associated gene signatures as potential prognostic biomarkers for patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who underwent primary radiotherapy or radiochemotherapy (RCTx). These markers have previously been reported in a study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) (Linge et al., 2016). Materials and methods: In this retrospective monocentric study, 92 patients with locally advanced HNSCC were included. Univariable and multivariable logistic regressions and Cox models presented in the study of the DKTK-ROG were validated using the area under the curve (AUC) and the concordance index (ci), respectively. The primary endpoint of this study was loco-regional tumour control (LRC) after primary RCTx. Results: Although both cohorts significantly differed in the proportion of the tumour subsites, the parameters tumour volume, p16 status and N stage could be validated regarding LRC and overall survival (OS) using multivariable Cox regression (LRC ci: 0.59, OS ci: 0.63). These models were slightly improved by combination with the putative CSC marker CD44 (LRC ci: 0.61, OS ci: 0.69). The logistic regression model for 2-year LRC based on tumour volume, p16 status and CD44 protein was validated with an AUC of 0.64. The patient stratification based on hypoxia-associated gene signatures status was similar to the original study but without significant differences in LRC and OS. Conclusions: In this validation study, the inclusion of the putative CSC marker CD44 slightly improved the prognostic performance of the baseline parameters tumour volume, p16 status and N stage. No improvement was observed when including expressions of the hypoxia-associated gene signatures. Prospective validation on a larger cohort is warranted to assess the clinical relevance of these markers.},
	author = {Linge, A. and Schmidt, S. and Lohaus, F. and Krenn, C. and Bandurska-Luque, A. and Platzek, I. and von Neubeck, C. and Appold, S. and Nowak, A. and Gudziol, V. and Buchholz, F. and Baretton, G. B. and Baumann, M. and Lock, S. and Krause, M.},
	doi = {10.1016/j.ctro.2019.03.002},
	issn = {2405-6308 (Electronic) 2405-6308 (Linking)},
	journal = {Clin Transl Radiat Oncol},
	keywords = {Biomarker Cancer stem cells Hnscc Hpv Hypoxia Primary radiochemotherapy},
	note = {Linge, Annett Schmidt, Stefan Lohaus, Fabian Krenn, Constanze Bandurska-Luque, Anna Platzek, Ivan von Neubeck, Clare Appold, Steffen Nowak, Alexander Gudziol, Volker Buchholz, Frank Baretton, Gustavo B Baumann, Michael Lock, Steffen Krause, Mechthild eng Ireland Clin Transl Radiat Oncol. 2019 Mar 18;16:40-47. doi: 10.1016/j.ctro.2019.03.002. eCollection 2019 May.},
	pages = {40-47},
	title = {Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449705/pdf/main.pdf},
	volume = {16},
	year = {2019},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449705/pdf/main.pdf},
	bdsk-url-2 = {https://doi.org/10.1016/j.ctro.2019.03.002}}

@article{RN16,
	abstract = {Objective: To independently validate the impact of tumour volume, p16 status, cancer stem cell (CSC) marker expression and hypoxia-associated gene signatures as potential prognostic biomarkers for patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who underwent primary radiotherapy or radiochemotherapy (RCTx). These markers have previously been reported in a study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) (Linge et al., 2016). Materials and methods: In this retrospective monocentric study, 92 patients with locally advanced HNSCC were included. Univariable and multivariable logistic regressions and Cox models presented in the study of the DKTK-ROG were validated using the area under the curve (AUC) and the concordance index (ci), respectively. The primary endpoint of this study was loco-regional tumour control (LRC) after primary RCTx. Results: Although both cohorts significantly differed in the proportion of the tumour subsites, the parameters tumour volume, p16 status and N stage could be validated regarding LRC and overall survival (OS) using multivariable Cox regression (LRC ci: 0.59, OS ci: 0.63). These models were slightly improved by combination with the putative CSC marker CD44 (LRC ci: 0.61, OS ci: 0.69). The logistic regression model for 2-year LRC based on tumour volume, p16 status and CD44 protein was validated with an AUC of 0.64. The patient stratification based on hypoxia-associated gene signatures status was similar to the original study but without significant differences in LRC and OS. Conclusions: In this validation study, the inclusion of the putative CSC marker CD44 slightly improved the prognostic performance of the baseline parameters tumour volume, p16 status and N stage. No improvement was observed when including expressions of the hypoxia-associated gene signatures. Prospective validation on a larger cohort is warranted to assess the clinical relevance of these markers.},
	author = {Linge, A. and Schmidt, S. and Lohaus, F. and Krenn, C. and Bandurska-Luque, A. and Platzek, I. and von Neubeck, C. and Appold, S. and Nowak, A. and Gudziol, V. and Buchholz, F. and Baretton, G. B. and Baumann, M. and Lock, S. and Krause, M.},
	doi = {10.1016/j.ctro.2019.03.002},
	issn = {2405-6308 (Electronic) 2405-6308 (Linking)},
	journal = {Clin Transl Radiat Oncol},
	keywords = {Biomarker Cancer stem cells Hnscc Hpv Hypoxia Primary radiochemotherapy},
	note = {Linge, Annett Schmidt, Stefan Lohaus, Fabian Krenn, Constanze Bandurska-Luque, Anna Platzek, Ivan von Neubeck, Clare Appold, Steffen Nowak, Alexander Gudziol, Volker Buchholz, Frank Baretton, Gustavo B Baumann, Michael Lock, Steffen Krause, Mechthild eng Ireland Clin Transl Radiat Oncol. 2019 Mar 18;16:40-47. doi: 10.1016/j.ctro.2019.03.002. eCollection 2019 May.},
	pages = {40-47},
	title = {Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30993218},
	volume = {16},
	year = {2019},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/30993218},
	bdsk-url-2 = {https://doi.org/10.1016/j.ctro.2019.03.002}}

@article{RN37,
	abstract = {Objective: To independently validate the impact of tumour volume, p16 status, cancer stem cell (CSC) marker expression and hypoxia-associated gene signatures as potential prognostic biomarkers for patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who underwent primary radiotherapy or radiochemotherapy (RCTx). These markers have previously been reported in a study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) (Linge et al., 2016). Materials and methods: In this retrospective monocentric study, 92 patients with locally advanced HNSCC were included. Univariable and multivariable logistic regressions and Cox models presented in the study of the DKTK-ROG were validated using the area under the curve (AUC) and the concordance index (ci), respectively. The primary endpoint of this study was loco-regional tumour control (LRC) after primary RCTx. Results: Although both cohorts significantly differed in the proportion of the tumour subsites, the parameters tumour volume, p16 status and N stage could be validated regarding LRC and overall survival (OS) using multivariable Cox regression (LRC ci: 0.59, OS ci: 0.63). These models were slightly improved by combination with the putative CSC marker CD44 (LRC ci: 0.61, OS ci: 0.69). The logistic regression model for 2-year LRC based on tumour volume, p16 status and CD44 protein was validated with an AUC of 0.64. The patient stratification based on hypoxia-associated gene signatures status was similar to the original study but without significant differences in LRC and OS. Conclusions: In this validation study, the inclusion of the putative CSC marker CD44 slightly improved the prognostic performance of the baseline parameters tumour volume, p16 status and N stage. No improvement was observed when including expressions of the hypoxia-associated gene signatures. Prospective validation on a larger cohort is warranted to assess the clinical relevance of these markers.},
	author = {Linge, A. and Schmidt, S. and Lohaus, F. and Krenn, C. and Bandurska-Luque, A. and Platzek, I. and von Neubeck, C. and Appold, S. and Nowak, A. and Gudziol, V. and Buchholz, F. and Baretton, G. B. and Baumann, M. and Lock, S. and Krause, M.},
	doi = {10.1016/j.ctro.2019.03.002},
	issn = {2405-6308 (Electronic) 2405-6308 (Linking)},
	journal = {Clin Transl Radiat Oncol},
	keywords = {Biomarker Cancer stem cells Hnscc Hpv Hypoxia Primary radiochemotherapy},
	note = {Linge, Annett Schmidt, Stefan Lohaus, Fabian Krenn, Constanze Bandurska-Luque, Anna Platzek, Ivan von Neubeck, Clare Appold, Steffen Nowak, Alexander Gudziol, Volker Buchholz, Frank Baretton, Gustavo B Baumann, Michael Lock, Steffen Krause, Mechthild eng Ireland Clin Transl Radiat Oncol. 2019 Mar 18;16:40-47. doi: 10.1016/j.ctro.2019.03.002. eCollection 2019 May.},
	pages = {40-47},
	title = {Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30993218},
	volume = {16},
	year = {2019},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/30993218},
	bdsk-url-2 = {https://doi.org/10.1016/j.ctro.2019.03.002}}

@article{RN327,
	abstract = {OBJECTIVE: To independently validate the impact of tumour volume, p16 status, cancer stem cell (CSC) marker expression and hypoxia-associated gene signatures as potential prognostic biomarkers for patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who underwent primary radiotherapy or radiochemotherapy (RCTx). These markers have previously been reported in a study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) (Linge et al., 2016). MATERIALS AND METHODS: In this retrospective monocentric study, 92 patients with locally advanced HNSCC were included. Univariable and multivariable logistic regressions and Cox models presented in the study of the DKTK-ROG were validated using the area under the curve (AUC) and the concordance index (ci), respectively. The primary endpoint of this study was loco-regional tumour control (LRC) after primary RCTx. RESULTS: Although both cohorts significantly differed in the proportion of the tumour subsites, the parameters tumour volume, p16 status and N stage could be validated regarding LRC and overall survival (OS) using multivariable Cox regression (LRC ci: 0.59, OS ci: 0.63). These models were slightly improved by combination with the putative CSC marker CD44 (LRC ci: 0.61, OS ci: 0.69). The logistic regression model for 2-year LRC based on tumour volume, p16 status and CD44 protein was validated with an AUC of 0.64. The patient stratification based on hypoxia-associated gene signatures status was similar to the original study but without significant differences in LRC and OS. CONCLUSIONS: In this validation study, the inclusion of the putative CSC marker CD44 slightly improved the prognostic performance of the baseline parameters tumour volume, p16 status and N stage. No improvement was observed when including expressions of the hypoxia-associated gene signatures. Prospective validation on a larger cohort is warranted to assess the clinical relevance of these markers.},
	author = {Linge, A. and Schmidt, S. and Lohaus, F. and Krenn, C. and Bandurska-Luque, A. and Platzek, I. and von Neubeck, C. and Appold, S. and Nowak, A. and Gudziol, V. and Buchholz, F. and Baretton, G. B. and Baumann, M. and L{\"o}ck, S. and Krause, M.},
	doi = {10.1016/j.ctro.2019.03.002},
	issn = {2405-6308},
	journal = {Clin Transl Radiat Oncol},
	keywords = {Biomarker Cancer stem cells Hnscc Hpv Hypoxia Primary radiochemotherapy},
	note = {2405-6308 Linge, Annett Schmidt, Stefan Lohaus, Fabian Krenn, Constanze Bandurska-Luque, Anna Platzek, Ivan von Neubeck, Cl{\"a}re Appold, Steffen Nowak, Alexander Gudziol, Volker Buchholz, Frank Baretton, Gustavo B Baumann, Michael L{\"o}ck, Steffen Krause, Mechthild Journal Article 2019/04/18 Clin Transl Radiat Oncol. 2019 Mar 18;16:40-47. doi: 10.1016/j.ctro.2019.03.002. eCollection 2019 May.},
	pages = {40-47},
	title = {Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy},
	type = {Journal Article},
	volume = {16},
	year = {2019},
	bdsk-url-1 = {https://doi.org/10.1016/j.ctro.2019.03.002}}

@article{RN33,
	abstract = {OBJECTIVE: To compare six HPV detection methods in pre-treatment FFPE tumour samples from patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who received postoperative (N=175) or primary (N=90) radiochemotherapy. MATERIALS AND METHODS: HPV analyses included detection of (i) HPV16 E6/E7 RNA, (ii) HPV16 DNA (PCR-based arrays, A-PCR), (iii) HPV DNA (GP5+/GP6+ qPCR, (GP-PCR)), (iv) p16 (immunohistochemistry, p16 IHC), (v) combining p16 IHC and the A-PCR result and (vi) combining p16 IHC and the GP-PCR result. Differences between HPV positive and negative subgroups were evaluated for the primary endpoint loco-regional control (LRC) using Cox regression. RESULTS: Correlation between the HPV detection methods was high (chi-squared test, p<0.001). While p16 IHC analysis resulted in several false positive classifications, A-PCR, GP-PCR and the combination of p16 IHC and A-PCR or GP-PCR led to results comparable to RNA analysis. In both cohorts, Cox regression analyses revealed significantly prolonged LRC for patients with HPV positive tumours irrespective of the detection method. CONCLUSIONS: The most stringent classification was obtained by detection of HPV16 RNA, or combining p16 IHC with A-PCR or GP-PCR. This approach revealed the lowest rate of recurrence in patients with tumours classified as HPV positive and therefore appears most suited for patient stratification in HPV-based clinical studies.},
	author = {Linge, A. and Schotz, U. and Lock, S. and Lohaus, F. and von Neubeck, C. and Gudziol, V. and Nowak, A. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Bunea, H. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Ganswindt, U. and Lauber, K. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and Baretton, G. B. and Buchholz, F. and Krause, M. and Belka, C. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2017.12.007},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Carcinoma, Squamous Cell/drug therapy/pathology/radiotherapy/*virology Chemoradiotherapy Female Head and Neck Neoplasms/drug therapy/pathology/radiotherapy/*virology Human papillomavirus 16/genetics/*isolation & purification/metabolism Humans Immunohistochemistry Male Middle Aged Neoplasm Recurrence, Local/drug therapy/pathology/radiotherapy/*virology Oncogene Proteins, Viral/genetics/metabolism Papillomavirus E7 Proteins/genetics/metabolism Papillomavirus Infections/metabolism/*virology Prognosis RNA, Viral/genetics Real-Time Polymerase Chain Reaction Repressor Proteins/genetics/metabolism Retrospective Studies Squamous Cell Carcinoma of Head and Neck *dktk-rog *hnscc *hpv *Loco-regional control *Radiochemotherapy *p16},
	note = {Linge, Annett Schotz, Ulrike Lock, Steffen Lohaus, Fabian von Neubeck, Clare Gudziol, Volker Nowak, Alexander Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Bunea, Hatice Grosu, Anca-Ligia Abdollahi, Amir Debus, Jurgen Ganswindt, Ute Lauber, Kirsten Pigorsch, Steffi Combs, Stephanie E Monnich, David Zips, Daniel Baretton, Gustavo B Buchholz, Frank Krause, Mechthild Belka, Claus Baumann, Michael eng Comparative Study Multicenter Study Research Support, Non-U.S. Gov't Ireland Radiother Oncol. 2018 Apr;127(1):27-35. doi: 10.1016/j.radonc.2017.12.007. Epub 2017 Dec 30.},
	number = {1},
	pages = {27-35},
	title = {Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29295747},
	volume = {127},
	year = {2018},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/29295747},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2017.12.007}}

@article{RN38,
	abstract = {OBJECTIVE: To compare six HPV detection methods in pre-treatment FFPE tumour samples from patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who received postoperative (N=175) or primary (N=90) radiochemotherapy. MATERIALS AND METHODS: HPV analyses included detection of (i) HPV16 E6/E7 RNA, (ii) HPV16 DNA (PCR-based arrays, A-PCR), (iii) HPV DNA (GP5+/GP6+ qPCR, (GP-PCR)), (iv) p16 (immunohistochemistry, p16 IHC), (v) combining p16 IHC and the A-PCR result and (vi) combining p16 IHC and the GP-PCR result. Differences between HPV positive and negative subgroups were evaluated for the primary endpoint loco-regional control (LRC) using Cox regression. RESULTS: Correlation between the HPV detection methods was high (chi-squared test, p<0.001). While p16 IHC analysis resulted in several false positive classifications, A-PCR, GP-PCR and the combination of p16 IHC and A-PCR or GP-PCR led to results comparable to RNA analysis. In both cohorts, Cox regression analyses revealed significantly prolonged LRC for patients with HPV positive tumours irrespective of the detection method. CONCLUSIONS: The most stringent classification was obtained by detection of HPV16 RNA, or combining p16 IHC with A-PCR or GP-PCR. This approach revealed the lowest rate of recurrence in patients with tumours classified as HPV positive and therefore appears most suited for patient stratification in HPV-based clinical studies.},
	author = {Linge, A. and Schotz, U. and Lock, S. and Lohaus, F. and von Neubeck, C. and Gudziol, V. and Nowak, A. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Bunea, H. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Ganswindt, U. and Lauber, K. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and Baretton, G. B. and Buchholz, F. and Krause, M. and Belka, C. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2017.12.007},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Carcinoma, Squamous Cell/drug therapy/pathology/radiotherapy/*virology Chemoradiotherapy Female Head and Neck Neoplasms/drug therapy/pathology/radiotherapy/*virology Human papillomavirus 16/genetics/*isolation & purification/metabolism Humans Immunohistochemistry Male Middle Aged Neoplasm Recurrence, Local/drug therapy/pathology/radiotherapy/*virology Oncogene Proteins, Viral/genetics/metabolism Papillomavirus E7 Proteins/genetics/metabolism Papillomavirus Infections/metabolism/*virology Prognosis RNA, Viral/genetics Real-Time Polymerase Chain Reaction Repressor Proteins/genetics/metabolism Retrospective Studies Squamous Cell Carcinoma of Head and Neck *dktk-rog *hnscc *hpv *Loco-regional control *Radiochemotherapy *p16},
	note = {Linge, Annett Schotz, Ulrike Lock, Steffen Lohaus, Fabian von Neubeck, Clare Gudziol, Volker Nowak, Alexander Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Bunea, Hatice Grosu, Anca-Ligia Abdollahi, Amir Debus, Jurgen Ganswindt, Ute Lauber, Kirsten Pigorsch, Steffi Combs, Stephanie E Monnich, David Zips, Daniel Baretton, Gustavo B Buchholz, Frank Krause, Mechthild Belka, Claus Baumann, Michael eng Comparative Study Multicenter Study Research Support, Non-U.S. Gov't Ireland Radiother Oncol. 2018 Apr;127(1):27-35. doi: 10.1016/j.radonc.2017.12.007. Epub 2017 Dec 30.},
	number = {1},
	pages = {27-35},
	title = {Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29295747},
	volume = {127},
	year = {2018},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/29295747},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2017.12.007}}

@article{RN14,
	abstract = {OBJECTIVE: To compare six HPV detection methods in pre-treatment FFPE tumour samples from patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who received postoperative (N=175) or primary (N=90) radiochemotherapy. MATERIALS AND METHODS: HPV analyses included detection of (i) HPV16 E6/E7 RNA, (ii) HPV16 DNA (PCR-based arrays, A-PCR), (iii) HPV DNA (GP5+/GP6+ qPCR, (GP-PCR)), (iv) p16 (immunohistochemistry, p16 IHC), (v) combining p16 IHC and the A-PCR result and (vi) combining p16 IHC and the GP-PCR result. Differences between HPV positive and negative subgroups were evaluated for the primary endpoint loco-regional control (LRC) using Cox regression. RESULTS: Correlation between the HPV detection methods was high (chi-squared test, p<0.001). While p16 IHC analysis resulted in several false positive classifications, A-PCR, GP-PCR and the combination of p16 IHC and A-PCR or GP-PCR led to results comparable to RNA analysis. In both cohorts, Cox regression analyses revealed significantly prolonged LRC for patients with HPV positive tumours irrespective of the detection method. CONCLUSIONS: The most stringent classification was obtained by detection of HPV16 RNA, or combining p16 IHC with A-PCR or GP-PCR. This approach revealed the lowest rate of recurrence in patients with tumours classified as HPV positive and therefore appears most suited for patient stratification in HPV-based clinical studies.},
	author = {Linge, A. and Schotz, U. and Lock, S. and Lohaus, F. and von Neubeck, C. and Gudziol, V. and Nowak, A. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Bunea, H. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Ganswindt, U. and Lauber, K. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and Baretton, G. B. and Buchholz, F. and Krause, M. and Belka, C. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2017.12.007},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Carcinoma, Squamous Cell/drug therapy/pathology/radiotherapy/*virology Chemoradiotherapy Female Head and Neck Neoplasms/drug therapy/pathology/radiotherapy/*virology Human papillomavirus 16/genetics/*isolation & purification/metabolism Humans Immunohistochemistry Male Middle Aged Neoplasm Recurrence, Local/drug therapy/pathology/radiotherapy/*virology Oncogene Proteins, Viral/genetics/metabolism Papillomavirus E7 Proteins/genetics/metabolism Papillomavirus Infections/metabolism/*virology Prognosis RNA, Viral/genetics Real-Time Polymerase Chain Reaction Repressor Proteins/genetics/metabolism Retrospective Studies Squamous Cell Carcinoma of Head and Neck *dktk-rog *hnscc *hpv *Loco-regional control *Radiochemotherapy *p16},
	note = {Linge, Annett Schotz, Ulrike Lock, Steffen Lohaus, Fabian von Neubeck, Clare Gudziol, Volker Nowak, Alexander Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Bunea, Hatice Grosu, Anca-Ligia Abdollahi, Amir Debus, Jurgen Ganswindt, Ute Lauber, Kirsten Pigorsch, Steffi Combs, Stephanie E Monnich, David Zips, Daniel Baretton, Gustavo B Buchholz, Frank Krause, Mechthild Belka, Claus Baumann, Michael eng Comparative Study Multicenter Study Research Support, Non-U.S. Gov't Ireland Radiother Oncol. 2018 Apr;127(1):27-35. doi: 10.1016/j.radonc.2017.12.007. Epub 2017 Dec 30.},
	number = {1},
	pages = {27-35},
	title = {Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29295747},
	volume = {127},
	year = {2018},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/29295747},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2017.12.007}}

@article{RN17,
	abstract = {OBJECTIVE: To compare six HPV detection methods in pre-treatment FFPE tumour samples from patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who received postoperative (N=175) or primary (N=90) radiochemotherapy. MATERIALS AND METHODS: HPV analyses included detection of (i) HPV16 E6/E7 RNA, (ii) HPV16 DNA (PCR-based arrays, A-PCR), (iii) HPV DNA (GP5+/GP6+ qPCR, (GP-PCR)), (iv) p16 (immunohistochemistry, p16 IHC), (v) combining p16 IHC and the A-PCR result and (vi) combining p16 IHC and the GP-PCR result. Differences between HPV positive and negative subgroups were evaluated for the primary endpoint loco-regional control (LRC) using Cox regression. RESULTS: Correlation between the HPV detection methods was high (chi-squared test, p<0.001). While p16 IHC analysis resulted in several false positive classifications, A-PCR, GP-PCR and the combination of p16 IHC and A-PCR or GP-PCR led to results comparable to RNA analysis. In both cohorts, Cox regression analyses revealed significantly prolonged LRC for patients with HPV positive tumours irrespective of the detection method. CONCLUSIONS: The most stringent classification was obtained by detection of HPV16 RNA, or combining p16 IHC with A-PCR or GP-PCR. This approach revealed the lowest rate of recurrence in patients with tumours classified as HPV positive and therefore appears most suited for patient stratification in HPV-based clinical studies.},
	author = {Linge, A. and Schotz, U. and Lock, S. and Lohaus, F. and von Neubeck, C. and Gudziol, V. and Nowak, A. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Bunea, H. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Ganswindt, U. and Lauber, K. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and Baretton, G. B. and Buchholz, F. and Krause, M. and Belka, C. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2017.12.007},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Adult Aged Carcinoma, Squamous Cell/drug therapy/pathology/radiotherapy/*virology Chemoradiotherapy Female Head and Neck Neoplasms/drug therapy/pathology/radiotherapy/*virology Human papillomavirus 16/genetics/*isolation & purification/metabolism Humans Immunohistochemistry Male Middle Aged Neoplasm Recurrence, Local/drug therapy/pathology/radiotherapy/*virology Oncogene Proteins, Viral/genetics/metabolism Papillomavirus E7 Proteins/genetics/metabolism Papillomavirus Infections/metabolism/*virology Prognosis RNA, Viral/genetics Real-Time Polymerase Chain Reaction Repressor Proteins/genetics/metabolism Retrospective Studies Squamous Cell Carcinoma of Head and Neck *dktk-rog *hnscc *hpv *Loco-regional control *Radiochemotherapy *p16},
	note = {Linge, Annett Schotz, Ulrike Lock, Steffen Lohaus, Fabian von Neubeck, Clare Gudziol, Volker Nowak, Alexander Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Bunea, Hatice Grosu, Anca-Ligia Abdollahi, Amir Debus, Jurgen Ganswindt, Ute Lauber, Kirsten Pigorsch, Steffi Combs, Stephanie E Monnich, David Zips, Daniel Baretton, Gustavo B Buchholz, Frank Krause, Mechthild Belka, Claus Baumann, Michael eng Comparative Study Multicenter Study Research Support, Non-U.S. Gov't Ireland Radiother Oncol. 2018 Apr;127(1):27-35. doi: 10.1016/j.radonc.2017.12.007. Epub 2017 Dec 30.},
	number = {1},
	pages = {27-35},
	title = {Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC},
	type = {Journal Article},
	url = {https://www.thegreenjournal.com/article/S0167-8140(17)32762-7/fulltext},
	volume = {127},
	year = {2018},
	bdsk-url-1 = {https://www.thegreenjournal.com/article/S0167-8140(17)32762-7/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2017.12.007}}

@article{RN386,
	author = {Lingen, M. W.},
	issn = {1543-2165 (Electronic) 0003-9985 (Linking)},
	journal = {Arch Pathol Lab Med},
	number = {3},
	pages = {475},
	title = {Lucas' pathology of tumors of the oral tissues},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10705417},
	volume = {124},
	year = {2000},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/10705417}}

@article{RN65,
	author = {Lingen, M. W.},
	issn = {1543-2165 (Electronic) 0003-9985 (Linking)},
	journal = {Arch Pathol Lab Med},
	note = {Lingen eng 2000/03/08 Arch Pathol Lab Med. 2000 Mar;124(3):475.},
	number = {3},
	pages = {475},
	title = {Lucas' pathology of tumors of the oral tissues},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10705417},
	volume = {124},
	year = {2000},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/10705417}}

@article{RN89,
	author = {Lingen, M. W.},
	issn = {0003-9985},
	journal = {Arch Pathol Lab Med},
	note = {1543-2165 Lingen, MW Journal Article United States 2000/03/08 Arch Pathol Lab Med. 2000 Mar;124(3):475.},
	number = {3},
	pages = {475},
	title = {Lucas' pathology of tumors of the oral tissues},
	type = {Journal Article},
	volume = {124},
	year = {2000}}

@article{RN160,
	abstract = {Historically, the screening of patients for signs of oral cancer and precancerous lesions has relied upon the conventional oral examination. A variety of commercial diagnostic aids and adjunctive techniques are available to potentially assist in the screening of healthy patients for evidence of otherwise occult cancerous change or to assess the biologic potential of clinically abnormal mucosal lesions. This manuscript systematically and critically examines the literature associated with current oral cancer screening and case-finding aids or adjuncts such as toluidine blue, brush cytology, tissue reflectance and autofluorescence. The characteristics of an ideal screening test are outlined and the authors pose several questions for clinicians and scientists to consider in the evaluation of current and future studies of oral cancer detection and diagnosis. Although the increased public awareness of oral cancer made possible by the marketing of recently-introduced screening adjuncts is commendable, the tantalizing implication that such technologies may improve detection of oral cancers and precancers beyond conventional oral examination alone has yet to be rigorously confirmed.},
	author = {Lingen, M. W. and Kalmar, J. R. and Karrison, T. and Speight, P. M.},
	doi = {10.1016/j.oraloncology.2007.06.011},
	issn = {1368-8375 (Print) 1368-8375},
	journal = {Oral Oncol},
	keywords = {Coloring Agents Cytological Techniques Fluorescence Humans Mass Screening/*methods Mouth Neoplasms/*diagnosis Precancerous Conditions/*diagnosis Spectrophotometry/methods Tolonium Chloride},
	note = {Lingen, Mark W Kalmar, John R Karrison, Theodore Speight, Paul M R01 DE015830-03/DE/NIDCR NIH HHS/United States DE015830/DE/NIDCR NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Review 2007/09/11 Oral Oncol. 2008 Jan;44(1):10-22. doi: 10.1016/j.oraloncology.2007.06.011. Epub 2007 Sep 6.},
	number = {1},
	pages = {10-22},
	title = {Critical evaluation of diagnostic aids for the detection of oral cancer},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2424250/pdf/nihms50039.pdf},
	volume = {44},
	year = {2008},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2424250/pdf/nihms50039.pdf},
	bdsk-url-2 = {https://doi.org/10.1016/j.oraloncology.2007.06.011}}

@article{RN161,
	abstract = {Historically, the screening of patients for signs of oral cancer and precancerous lesions has relied upon the conventional oral examination. A variety of commercial diagnostic aids and adjunctive techniques are available to potentially assist in the screening of healthy patients for evidence of otherwise occult cancerous change or to assess the biologic potential of clinically abnormal mucosal lesions. This manuscript systematically and critically examines the literature associated with current oral cancer screening and case-finding aids or adjuncts such as toluidine blue, brush cytology, tissue reflectance and autofluorescence. The characteristics of an ideal screening test are outlined and the authors pose several questions for clinicians and scientists to consider in the evaluation of current and future studies of oral cancer detection and diagnosis. Although the increased public awareness of oral cancer made possible by the marketing of recently-introduced screening adjuncts is commendable, the tantalizing implication that such technologies may improve detection of oral cancers and precancers beyond conventional oral examination alone has yet to be rigorously confirmed.},
	author = {Lingen, M. W. and Kalmar, J. R. and Karrison, T. and Speight, P. M.},
	doi = {10.1016/j.oraloncology.2007.06.011},
	issn = {1368-8375 (Print) 1368-8375},
	journal = {Oral Oncol},
	keywords = {Coloring Agents Cytological Techniques Fluorescence Humans Mass Screening/*methods Mouth Neoplasms/*diagnosis Precancerous Conditions/*diagnosis Spectrophotometry/methods Tolonium Chloride},
	note = {Lingen, Mark W Kalmar, John R Karrison, Theodore Speight, Paul M R01 DE015830-03/DE/NIDCR NIH HHS/United States DE015830/DE/NIDCR NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Review 2007/09/11 Oral Oncol. 2008 Jan;44(1):10-22. doi: 10.1016/j.oraloncology.2007.06.011. Epub 2007 Sep 6.},
	number = {1},
	pages = {10-22},
	title = {Critical evaluation of diagnostic aids for the detection of oral cancer},
	type = {Journal Article},
	volume = {44},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1016/j.oraloncology.2007.06.011}}

@article{RN25,
	author = {Lohaus, F. and Linge, A. and Baumann, M.},
	doi = {10.3978/j.issn.2305-5839.2015.09.35},
	issn = {2305-5839 (Print) 2305-5839 (Linking)},
	journal = {Ann Transl Med},
	note = {Lohaus, Fabian Linge, Annett Baumann, Michael eng China Ann Transl Med. 2015 Oct;3(17):255. doi: 10.3978/j.issn.2305-5839.2015.09.35.},
	number = {17},
	pages = {255},
	title = {HPV and beyond-looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCC},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620098/pdf/atm-03-17-255.pdf},
	volume = {3},
	year = {2015},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620098/pdf/atm-03-17-255.pdf},
	bdsk-url-2 = {https://doi.org/10.3978/j.issn.2305-5839.2015.09.35}}

@article{RN29,
	author = {Lohaus, F. and Linge, A. and Baumann, M.},
	doi = {10.3978/j.issn.2305-5839.2015.09.35},
	issn = {2305-5839 (Print) 2305-5839 (Linking)},
	journal = {Ann Transl Med},
	note = {Lohaus, Fabian Linge, Annett Baumann, Michael eng China Ann Transl Med. 2015 Oct;3(17):255. doi: 10.3978/j.issn.2305-5839.2015.09.35.},
	number = {17},
	pages = {255},
	title = {HPV and beyond-looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCC},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26605301},
	volume = {3},
	year = {2015},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/26605301},
	bdsk-url-2 = {https://doi.org/10.3978/j.issn.2305-5839.2015.09.35}}

@article{RN332,
	author = {Lohaus, F. and Linge, A. and Tinhofer, I. and Budach, V. and Gkika, E. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and von Neubeck, C. and Baretton, G. B. and Lock, S. and Thames, H. D. and Krause, M. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2014.11.011},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Carcinoma, Squamous Cell/*genetics/*therapy/virology Chemoradiotherapy/methods Cyclin-Dependent Kinase Inhibitor p16/*genetics DNA/genetics Female Head and Neck Neoplasms/*genetics/*therapy/virology Humans Male Oropharyngeal Neoplasms/*genetics/*therapy/virology Papillomaviridae/genetics Postoperative Period Prognosis Prospective Studies Retrospective Studies Squamous Cell Carcinoma of Head and Neck Survival Analysis Treatment Outcome Dktk-rog Hnscc Hpv Postoperative radiochemotherapy p16 p53},
	number = {3},
	pages = {317-23},
	title = {HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	volume = {113},
	year = {2014},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2014.11.011}}

@article{RN433,
	author = {Lohaus, F. and Linge, A. and Tinhofer, I. and Budach, V. and Gkika, E. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and von Neubeck, C. and Baretton, G. B. and Lock, S. and Thames, H. D. and Krause, M. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2014.11.011},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Carcinoma, Squamous Cell/*genetics/*therapy/virology Chemoradiotherapy/methods Cyclin-Dependent Kinase Inhibitor p16/*genetics DNA/genetics Female Head and Neck Neoplasms/*genetics/*therapy/virology Humans Male Oropharyngeal Neoplasms/*genetics/*therapy/virology Papillomaviridae/genetics Postoperative Period Prognosis Prospective Studies Retrospective Studies Squamous Cell Carcinoma of Head and Neck Survival Analysis Treatment Outcome Dktk-rog Hnscc Hpv Postoperative radiochemotherapy p16 p53},
	number = {3},
	pages = {317-23},
	title = {HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	volume = {113},
	year = {2014},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2014.11.011}}

@article{RN435,
	author = {Lohaus, F. and Linge, A. and Tinhofer, I. and Budach, V. and Gkika, E. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and von Neubeck, C. and Baretton, G. B. and Lock, S. and Thames, H. D. and Krause, M. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2014.11.011},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Carcinoma, Squamous Cell/*genetics/*therapy/virology Chemoradiotherapy/methods Cyclin-Dependent Kinase Inhibitor p16/*genetics DNA/genetics Female Head and Neck Neoplasms/*genetics/*therapy/virology Humans Male Oropharyngeal Neoplasms/*genetics/*therapy/virology Papillomaviridae/genetics Postoperative Period Prognosis Prospective Studies Retrospective Studies Squamous Cell Carcinoma of Head and Neck Survival Analysis Treatment Outcome Dktk-rog Hnscc Hpv Postoperative radiochemotherapy p16 p53},
	number = {3},
	pages = {317-23},
	title = {HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	volume = {113},
	year = {2014},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2014.11.011}}

@article{RN437,
	author = {Lohaus, F. and Linge, A. and Tinhofer, I. and Budach, V. and Gkika, E. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and von Neubeck, C. and Baretton, G. B. and Lock, S. and Thames, H. D. and Krause, M. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2014.11.011},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Carcinoma, Squamous Cell/*genetics/*therapy/virology Chemoradiotherapy/methods Cyclin-Dependent Kinase Inhibitor p16/*genetics DNA/genetics Female Head and Neck Neoplasms/*genetics/*therapy/virology Humans Male Oropharyngeal Neoplasms/*genetics/*therapy/virology Papillomaviridae/genetics Postoperative Period Prognosis Prospective Studies Retrospective Studies Squamous Cell Carcinoma of Head and Neck Survival Analysis Treatment Outcome Dktk-rog Hnscc Hpv Postoperative radiochemotherapy p16 p53},
	number = {3},
	pages = {317-23},
	title = {HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	volume = {113},
	year = {2014},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2014.11.011}}

@article{RN444,
	author = {Lohaus, F. and Linge, A. and Tinhofer, I. and Budach, V. and Gkika, E. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and von Neubeck, C. and Baretton, G. B. and Lock, S. and Thames, H. D. and Krause, M. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2014.11.011},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Carcinoma, Squamous Cell/*genetics/*therapy/virology Chemoradiotherapy/methods Cyclin-Dependent Kinase Inhibitor p16/*genetics DNA/genetics Female Head and Neck Neoplasms/*genetics/*therapy/virology Humans Male Oropharyngeal Neoplasms/*genetics/*therapy/virology Papillomaviridae/genetics Postoperative Period Prognosis Prospective Studies Retrospective Studies Squamous Cell Carcinoma of Head and Neck Survival Analysis Treatment Outcome Dktk-rog Hnscc Hpv Postoperative radiochemotherapy p16 p53},
	number = {3},
	pages = {317-23},
	title = {HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	volume = {113},
	year = {2014},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2014.11.011}}

@article{RN27,
	abstract = {OBJECTIVE: To investigate the impact of HPV status in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received surgery and cisplatin-based postoperative radiochemotherapy. MATERIALS AND METHODS: For 221 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity treated at the 8 partner sites of the German Cancer Consortium, the impact of HPV DNA, p16 overexpression and p53 expression on outcome were retrospectively analysed. The primary endpoint was loco-regional tumour control; secondary endpoints were distant metastases and overall survival. RESULTS: In the total patient population, univariate analyses revealed a significant impact of HPV16 DNA positivity, p16 overexpression, p53 positivity and tumour site on loco-regional tumour control. Multivariate analysis stratified for tumour site showed that positive HPV 16 DNA status correlated with loco-regional tumour control in patients with oropharyngeal carcinoma (p=0.02) but not in the oral cavity carcinoma group. Multivariate evaluation of the secondary endpoints in the total population revealed a significant association of HPV16 DNA positivity with overall survival (p<0.01) but not with distant metastases. CONCLUSIONS: HPV16 DNA status appears to be a strong prognosticator of loco-regional tumour control after postoperative cisplatin-based radiochemotherapy of locally advanced oropharyngeal carcinoma and is now being explored in a prospective validation trial.},
	author = {Lohaus, F. and Linge, A. and Tinhofer, I. and Budach, V. and Gkika, E. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and von Neubeck, C. and Baretton, G. B. and Lock, S. and Thames, H. D. and Krause, M. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2014.11.011},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Carcinoma, Squamous Cell/*genetics/*therapy/virology Chemoradiotherapy/methods Cyclin-Dependent Kinase Inhibitor p16/*genetics DNA/genetics Female Head and Neck Neoplasms/*genetics/*therapy/virology Humans Male Oropharyngeal Neoplasms/*genetics/*therapy/virology Papillomaviridae/genetics Postoperative Period Prognosis Prospective Studies Retrospective Studies Squamous Cell Carcinoma of Head and Neck Survival Analysis Treatment Outcome Dktk-rog Hnscc Hpv Postoperative radiochemotherapy p16 p53},
	note = {Lohaus, Fabian Linge, Annett Tinhofer, Inge Budach, Volker Gkika, Eleni Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Avlar, Melanie Grosu, Anca-Ligia Abdollahi, Amir Debus, Jurgen Bayer, Christine Belka, Claus Pigorsch, Steffi Combs, Stephanie E Monnich, David Zips, Daniel von Neubeck, Clare Baretton, Gustavo B Lock, Steffen Thames, Howard D Krause, Mechthild Baumann, Michael eng Multicenter Study Research Support, Non-U.S. Gov't Ireland Radiother Oncol. 2014 Dec;113(3):317-23. doi: 10.1016/j.radonc.2014.11.011. Epub 2014 Dec 2.},
	number = {3},
	pages = {317-23},
	title = {HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	volume = {113},
	year = {2014},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/25480095},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2014.11.011}}

@article{RN28,
	abstract = {OBJECTIVE: To investigate the impact of HPV status in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received surgery and cisplatin-based postoperative radiochemotherapy. MATERIALS AND METHODS: For 221 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity treated at the 8 partner sites of the German Cancer Consortium, the impact of HPV DNA, p16 overexpression and p53 expression on outcome were retrospectively analysed. The primary endpoint was loco-regional tumour control; secondary endpoints were distant metastases and overall survival. RESULTS: In the total patient population, univariate analyses revealed a significant impact of HPV16 DNA positivity, p16 overexpression, p53 positivity and tumour site on loco-regional tumour control. Multivariate analysis stratified for tumour site showed that positive HPV 16 DNA status correlated with loco-regional tumour control in patients with oropharyngeal carcinoma (p=0.02) but not in the oral cavity carcinoma group. Multivariate evaluation of the secondary endpoints in the total population revealed a significant association of HPV16 DNA positivity with overall survival (p<0.01) but not with distant metastases. CONCLUSIONS: HPV16 DNA status appears to be a strong prognosticator of loco-regional tumour control after postoperative cisplatin-based radiochemotherapy of locally advanced oropharyngeal carcinoma and is now being explored in a prospective validation trial.},
	author = {Lohaus, F. and Linge, A. and Tinhofer, I. and Budach, V. and Gkika, E. and Stuschke, M. and Balermpas, P. and Rodel, C. and Avlar, M. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Bayer, C. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and von Neubeck, C. and Baretton, G. B. and Lock, S. and Thames, H. D. and Krause, M. and Baumann, M. and Dktk, R. O. G.},
	doi = {10.1016/j.radonc.2014.11.011},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	journal = {Radiother Oncol},
	keywords = {Carcinoma, Squamous Cell/*genetics/*therapy/virology Chemoradiotherapy/methods Cyclin-Dependent Kinase Inhibitor p16/*genetics DNA/genetics Female Head and Neck Neoplasms/*genetics/*therapy/virology Humans Male Oropharyngeal Neoplasms/*genetics/*therapy/virology Papillomaviridae/genetics Postoperative Period Prognosis Prospective Studies Retrospective Studies Squamous Cell Carcinoma of Head and Neck Survival Analysis Treatment Outcome Dktk-rog Hnscc Hpv Postoperative radiochemotherapy p16 p53},
	note = {Lohaus, Fabian Linge, Annett Tinhofer, Inge Budach, Volker Gkika, Eleni Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Avlar, Melanie Grosu, Anca-Ligia Abdollahi, Amir Debus, Jurgen Bayer, Christine Belka, Claus Pigorsch, Steffi Combs, Stephanie E Monnich, David Zips, Daniel von Neubeck, Clare Baretton, Gustavo B Lock, Steffen Thames, Howard D Krause, Mechthild Baumann, Michael eng Multicenter Study Research Support, Non-U.S. Gov't Ireland Radiother Oncol. 2014 Dec;113(3):317-23. doi: 10.1016/j.radonc.2014.11.011. Epub 2014 Dec 2.},
	number = {3},
	pages = {317-23},
	title = {HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)},
	type = {Journal Article},
	url = {https://www.thegreenjournal.com/article/S0167-8140(14)00489-7/pdf},
	volume = {113},
	year = {2014},
	bdsk-url-1 = {https://www.thegreenjournal.com/article/S0167-8140(14)00489-7/pdf},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2014.11.011}}

@article{RN142,
	abstract = {BACKGROUND: Prospective data on alcohol consumption, cigarette smoking and risk of head-neck cancer (HNC) subtypes, i.e. oral cavity cancer (OCC), oro-/hypopharyngeal cancer (OHPC), and laryngeal cancer (LC), are limited. We investigated these associations within the second largest prospective study on this topic so far, the Netherlands Cohort Study. METHODS: 120,852 participants completed a questionnaire on diet and other cancer risk factors in 1986. After 17.3 years of follow-up, 395 HNC (110 OCC, 83 OHPC, and 199 LC) cases and 4288 subcohort members were available for case-cohort analysis using Cox proportional hazards models. RESULTS: For total HNC, the multivariable adjusted incidence rate ratio (RR) was 2.74 (95% confidence interval (CI) 1.85-4.06) for those drinking 30 g ethanol/day compared with abstainers; in subtypes, RRs were 6.39 for OCC, 3.52 for OHPC, and 1.54 for LC. Compared with never cigarette smokers, current cigarette smokers had a RR of 4.49 (95%CI 3.11-6.48) for HNC overall, and 2.11 for OCC, 8.53 for OHPC, and 8.07 for LC. A significant, positive, multiplicative interaction between categories of alcohol consumption and cigarette smoking was found for HNC overall (P interaction 0.03). CONCLUSIONS: Alcohol consumption and cigarette smoking were independently associated with risk of HNC overall, with a positive, multiplicative interaction. The strength of these associations differed among HNC-subtypes: OCC was most strongly associated with alcohol consumption but most weakly with cigarette smoking, whereas LC was not statistically significantly associated with alcohol consumption.},
	author = {Maasland, D. H. and van den Brandt, P. A. and Kremer, B. and Goldbohm, R. A. and Schouten, L. J.},
	doi = {10.1186/1471-2407-14-187},
	issn = {1471-2407},
	journal = {BMC Cancer},
	keywords = {Alcohol Drinking/*adverse effects/epidemiology Female Humans Hypopharyngeal Neoplasms/epidemiology/*etiology Laryngeal Neoplasms/epidemiology/*etiology Male Mouth Neoplasms/epidemiology/*etiology Netherlands/epidemiology Proportional Hazards Models Prospective Studies Smoking/*adverse effects/epidemiology Surveys and Questionnaires},
	note = {1471-2407 Maasland, Denise H E van den Brandt, Piet A Kremer, Bernd Goldbohm, R Alexandra Sandra Schouten, Leo J Journal Article Research Support, Non-U.S. Gov't 2014/03/19 BMC Cancer. 2014 Mar 14;14:187. doi: 10.1186/1471-2407-14-187.},
	pages = {187},
	title = {Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort Study},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004328/pdf/1471-2407-14-187.pdf},
	volume = {14},
	year = {2014},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004328/pdf/1471-2407-14-187.pdf},
	bdsk-url-2 = {https://doi.org/10.1186/1471-2407-14-187}}

@article{RN419,
	author = {Mack, B. and Gires, O.},
	doi = {10.1371/journal.pone.0003360},
	issn = {1932-6203 (Electronic) 1932-6203 (Linking)},
	journal = {PLoS One},
	keywords = {Carcinoma, Squamous Cell/*chemistry/pathology Epithelium/*chemistry Head Head and Neck Neoplasms/*chemistry Humans Hyaluronan Receptors/*analysis Immunohistochemistry Lymphocytes/*chemistry Neck Protein Isoforms Tissue Distribution},
	number = {10},
	pages = {e3360},
	title = {CD44s and CD44v6 expression in head and neck epithelia},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18852874},
	volume = {3},
	year = {2008},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/18852874},
	bdsk-url-2 = {https://doi.org/10.1371/journal.pone.0003360}}

@article{RN72,
	abstract = {BACKGROUND: CD44 splice variants are long-known as being associated with cell transformation. Recently, the standard form of CD44 (CD44s) was shown to be part of the signature of cancer stem cells (CSCs) in colon, breast, and in head and neck squamous cell carcinomas (HNSCC). This is somewhat in contradiction to previous reports on the expression of CD44s in HNSCC. The aim of the present study was to clarify the actual pattern of CD44 expression in head and neck epithelia. METHODS: Expression of CD44s and CD44v6 was analysed by immunohistochemistry with specific antibodies in primary head and neck tissues. Scoring of all specimens followed a two-parameters system, which implemented percentages of positive cells and staining intensities from - to +++ (score = % x intensity; resulting max. score 300). In addition, cell surface expression of CD44s and CD44v6 was assessed in lymphocytes and HNSCC. RESULTS: In normal epithelia CD44s and CD44v6 were expressed in 60-95% and 50-80% of cells and yielded mean scores with a standard error of a mean (SEM) of 249.5+/-14.5 and 198+/-11.13, respectively. In oral leukoplakia and in moderately differentiated carcinomas CD44s and CD44v6 levels were slightly increased (278.9+/-7.16 and 242+/-11.7; 291.8+/-5.88 and 287.3+/-6.88). Carcinomas in situ displayed unchanged levels of both proteins whereas poorly differentiated carcinomas consistently expressed diminished CD44s and CD44v6 levels. Lymphocytes and HNSCC lines strongly expressed CD44s but not CD44v6. CONCLUSION: CD44s and CD44v6 expression does not distinguish normal from benign or malignant epithelia of the head and neck. CD44s and CD44v6 were abundantly present in the great majority of cells in head and neck tissues, including carcinomas. Hence, the value of CD44s as a marker for the definition of a small subset of cells (i.e. less than 10%) representing head and neck cancer stem cells may need revision.},
	author = {Mack, B. and Gires, O.},
	doi = {10.1371/journal.pone.0003360},
	issn = {1932-6203 (Electronic) 1932-6203 (Linking)},
	journal = {PLoS One},
	keywords = {Carcinoma, Squamous Cell/*chemistry/pathology Epithelium/*chemistry Head Head and Neck Neoplasms/*chemistry Humans Hyaluronan Receptors/*analysis Immunohistochemistry Lymphocytes/*chemistry Neck Protein Isoforms Tissue Distribution},
	note = {Mack, Brigitte Gires, Olivier eng 2008/10/15 PLoS One. 2008;3(10):e3360. doi: 10.1371/journal.pone.0003360. Epub 2008 Oct 9.},
	number = {10},
	pages = {e3360},
	title = {CD44s and CD44v6 expression in head and neck epithelia},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566597/pdf/pone.0003360.pdf},
	volume = {3},
	year = {2008},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566597/pdf/pone.0003360.pdf},
	bdsk-url-2 = {https://doi.org/10.1371/journal.pone.0003360}}

@article{RN305,
	abstract = {BACKGROUND: CD44 splice variants are long-known as being associated with cell transformation. Recently, the standard form of CD44 (CD44s) was shown to be part of the signature of cancer stem cells (CSCs) in colon, breast, and in head and neck squamous cell carcinomas (HNSCC). This is somewhat in contradiction to previous reports on the expression of CD44s in HNSCC. The aim of the present study was to clarify the actual pattern of CD44 expression in head and neck epithelia. METHODS: Expression of CD44s and CD44v6 was analysed by immunohistochemistry with specific antibodies in primary head and neck tissues. Scoring of all specimens followed a two-parameters system, which implemented percentages of positive cells and staining intensities from - to +++ (score = % x intensity; resulting max. score 300). In addition, cell surface expression of CD44s and CD44v6 was assessed in lymphocytes and HNSCC. RESULTS: In normal epithelia CD44s and CD44v6 were expressed in 60-95% and 50-80% of cells and yielded mean scores with a standard error of a mean (SEM) of 249.5+/-14.5 and 198+/-11.13, respectively. In oral leukoplakia and in moderately differentiated carcinomas CD44s and CD44v6 levels were slightly increased (278.9+/-7.16 and 242+/-11.7; 291.8+/-5.88 and 287.3+/-6.88). Carcinomas in situ displayed unchanged levels of both proteins whereas poorly differentiated carcinomas consistently expressed diminished CD44s and CD44v6 levels. Lymphocytes and HNSCC lines strongly expressed CD44s but not CD44v6. CONCLUSION: CD44s and CD44v6 expression does not distinguish normal from benign or malignant epithelia of the head and neck. CD44s and CD44v6 were abundantly present in the great majority of cells in head and neck tissues, including carcinomas. Hence, the value of CD44s as a marker for the definition of a small subset of cells (i.e. less than 10%) representing head and neck cancer stem cells may need revision.},
	author = {Mack, B. and Gires, O.},
	doi = {10.1371/journal.pone.0003360},
	issn = {1932-6203},
	journal = {PLoS One},
	keywords = {Carcinoma, Squamous Cell/*chemistry/pathology Epithelium/*chemistry Head Head and Neck Neoplasms/*chemistry Humans Hyaluronan Receptors/*analysis Immunohistochemistry Lymphocytes/*chemistry Neck Protein Isoforms Tissue Distribution},
	note = {1932-6203 Mack, Brigitte Gires, Olivier Journal Article 2008/10/15 PLoS One. 2008;3(10):e3360. doi: 10.1371/journal.pone.0003360. Epub 2008 Oct 9.},
	number = {10},
	pages = {e3360},
	title = {CD44s and CD44v6 expression in head and neck epithelia},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566597/pdf/pone.0003360.pdf},
	volume = {3},
	year = {2008},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566597/pdf/pone.0003360.pdf},
	bdsk-url-2 = {https://doi.org/10.1371/journal.pone.0003360}}

@article{RN409,
	author = {MacMillan, C. and Kapadia, S. B. and Finkelstein, S. D. and Nalesnik, M. A. and Barnes, L.},
	doi = {10.1016/s0046-8177(96)90311-1},
	issn = {0046-8177 (Print) 0046-8177},
	journal = {Hum Pathol},
	keywords = {Aged Aged, 80 and over Carcinoma, Squamous Cell/*pathology/secondary/surgery/virology Female Genes, p53/*genetics Herpesvirus 4, Human/*isolation & purification Humans Laryngeal Neoplasms/*pathology/surgery/virology Lymphatic Metastasis Male Middle Aged Neoplasm Recurrence, Local Pharyngeal Neoplasms/*pathology/surgery/virology},
	number = {11},
	pages = {1172-9},
	title = {Lymphoepithelial carcinoma of the larynx and hypopharynx: study of eight cases with relationship to Epstein-Barr virus and p53 gene alterations, and review of the literature},
	type = {Journal Article},
	volume = {27},
	year = {1996},
	bdsk-url-1 = {https://doi.org/10.1016/s0046-8177(96)90311-1}}

@article{RN127,
	abstract = {Eight cases of lymphoepithelial carcinoma (LEC) of the larynx and hypopharynx were evaluated for clinicopathologic features, and the presence of the Epstein-Barr virus (EBV) and p53 alterations. The seven men and one woman, all of non-Asian descent, averaged 64 years of age. Eighty-eight percent had histologically confirmed cervical lymph node metastasis at diagnosis. None had systemic disease. Seven of eight patients available for follow-up (mean, 17.7 months) were alive and free of disease, although one did develop recurrent tumor in the neck. Four tumors were composed, histologically, of pure LEC. Four others had foci of both LEC and conventional squamous cell carcinoma. All eight tumors exhibited alterations in p53 expression, but none was positive for EBV. Combining these 8 cases with the 15 previously published cases in the English literature indicate that LEC in this site is a rare, rather aggressive tumor, primarily of older adults (mean, 62 years) with a propensity for early cervical lymph node metastasis and eventual distant dissemination and death from disease in about one third of patients. Although p53 alterations are common and of no apparent prognostic significance, LEC at this site seems to have little, if any, relationship to the EBV in patients of non-Asian origin.},
	author = {MacMillan, C. and Kapadia, S. B. and Finkelstein, S. D. and Nalesnik, M. A. and Barnes, L.},
	doi = {10.1016/s0046-8177(96)90311-1},
	issn = {0046-8177 (Print) 0046-8177},
	journal = {Hum Pathol},
	keywords = {Aged Aged, 80 and over Carcinoma, Squamous Cell/*pathology/secondary/surgery/virology Female Genes, p53/*genetics Herpesvirus 4, Human/*isolation & purification Humans Laryngeal Neoplasms/*pathology/surgery/virology Lymphatic Metastasis Male Middle Aged Neoplasm Recurrence, Local Pharyngeal Neoplasms/*pathology/surgery/virology},
	note = {MacMillan, C Kapadia, S B Finkelstein, S D Nalesnik, M A Barnes, L Case Reports Journal Article Review United States 1996/11/01 Hum Pathol. 1996 Nov;27(11):1172-9. doi: 10.1016/s0046-8177(96)90311-1.},
	number = {11},
	pages = {1172-9},
	title = {Lymphoepithelial carcinoma of the larynx and hypopharynx: study of eight cases with relationship to Epstein-Barr virus and p53 gene alterations, and review of the literature},
	type = {Journal Article},
	url = {https://www.sciencedirect.com/science/article/abs/pii/S0046817796903111?via%3Dihub},
	volume = {27},
	year = {1996},
	bdsk-url-1 = {https://www.sciencedirect.com/science/article/abs/pii/S0046817796903111?via%3Dihub},
	bdsk-url-2 = {https://doi.org/10.1016/s0046-8177(96)90311-1}}

@article{RN320,
	abstract = {Although CD133 has been shown to be a marker for cancer stem cells in various tumours, its expression in pancreatic cancer has not yet been clinically reported. In this study, we investigated the relationship between CD133 expression and clinicopathological factors in pancreatic cancer. Pancreatic head carcinoma specimens from 80 patients who underwent surgical resection were immunohistochemically assessed for CD133, vascular endothelial growth factor (VEGF)-C, CXCR4, CD34, Ki-67, and cytokeratin (CK) expressions. Sixty percentage (48/80) of specimens were CD133-positive, with less than 15% cells per specimen expressing the marker. CD133-positive cells were found at the peripheral site of adenocarcinoma glandular structures and were negative for CK. There was a significant correlation between CD133 expression and clinicopathological factors, including histological type, lymphatic invasion, and lymph node metastasis (P=0.0215, 0.0023, and 0.0024, respectively). Vascular endothelial growth factor-C expression was also significantly correlated with CD133 expression (P=0.0002). Consequently, the 5-year survival rate of CD133-positive patients was significantly lower than that of CD133-negative patients (P=0.0002) and multivariate analysis revealed that CD133 expression was an independent prognostic factor (P=0.0103). These results suggest that CD133 expression in pancreatic cancer was significantly associated with lymphatic metastasis, VEGF-C expression, and prognosis.},
	author = {Maeda, S. and Shinchi, H. and Kurahara, H. and Mataki, Y. and Maemura, K. and Sato, M. and Natsugoe, S. and Aikou, T. and Takao, S.},
	doi = {10.1038/sj.bjc.6604307},
	issn = {0007-0920 (Print) 0007-0920},
	journal = {Br J Cancer},
	keywords = {AC133 Antigen Adult Aged Aged, 80 and over Antigens, CD/*analysis Female Glycoproteins/*analysis Humans Immunohistochemistry Keratins/analysis Ki-67 Antigen/analysis Lymphatic Metastasis Male Middle Aged Pancreatic Neoplasms/blood supply/*chemistry/mortality/*pathology Peptides/*analysis Prognosis Receptors, CXCR4/analysis Vascular Endothelial Growth Factor C/*analysis},
	note = {1532-1827 Maeda, S Shinchi, H Kurahara, H Mataki, Y Maemura, K Sato, M Natsugoe, S Aikou, T Takao, S Journal Article Research Support, Non-U.S. Gov't 2008/03/20 Br J Cancer. 2008 Apr 22;98(8):1389-97. doi: 10.1038/sj.bjc.6604307. Epub 2008 Mar 18.},
	number = {8},
	pages = {1389-97},
	title = {CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer},
	type = {Journal Article},
	volume = {98},
	year = {2008},
	bdsk-url-1 = {https://doi.org/10.1038/sj.bjc.6604307}}

@article{RN303,
	abstract = {There is increasing evidence that the growth and spread of cancer is driven by a small subpopulation of cancer cells, defined as cancer stem cells (CSCs). Recent data indicate that the initiation, growth, recurrence and metastasis of cancers are related to the behavior of a small population of malignant cells with properties of stem cells, and information about them are potentially helpful in identifying the target for the tumor's therapeutic elimination. The presence of subpopulation cells with phenotypic and behavioral characteristics corresponding to both normal epithelial stem cells and to cells capable of initiating tumors has been also reported in head and neck squamous cell carcinomas (HNSCCs).},
	author = {Mannelli, G. and Gallo, O.},
	doi = {10.1016/j.ctrv.2011.11.007},
	issn = {0305-7372},
	journal = {Cancer Treat Rev},
	keywords = {AC133 Antigen Aldehyde Dehydrogenase 1 Family Animals Antigens, CD/metabolism Biomarkers Biomarkers, Tumor/metabolism Carcinoma, Squamous Cell/pathology Cell Transformation, Neoplastic/pathology Drug Resistance, Neoplasm Glycoproteins/metabolism Head and Neck Neoplasms/drug therapy/*pathology/radiotherapy Humans Hyaluronan Receptors/metabolism Isoenzymes/analysis Neoplasm Metastasis/immunology/pathology Neoplastic Stem Cells/*metabolism/*pathology Peptides/metabolism Retinal Dehydrogenase/analysis Squamous Cell Carcinoma of Head and Neck Stem Cells/pathology Treatment Outcome},
	note = {1532-1967 Mannelli, Giuditta Gallo, Oreste Journal Article Review Netherlands 2011/12/27 Cancer Treat Rev. 2012 Aug;38(5):515-39. doi: 10.1016/j.ctrv.2011.11.007. Epub 2011 Dec 23.},
	number = {5},
	pages = {515-39},
	title = {Cancer stem cells hypothesis and stem cells in head and neck cancers},
	type = {Journal Article},
	volume = {38},
	year = {2012},
	bdsk-url-1 = {https://doi.org/10.1016/j.ctrv.2011.11.007}}

@article{RN146,
	abstract = {A rise in incidence of oropharyngeal squamous cell cancer--specifically of the lingual and palatine tonsils--in white men younger than age 50 years who have no history of alcohol or tobacco use has been recorded over the past decade. This malignant disease is associated with human papillomavirus (HPV) 16 infection. The biology of HPV-positive oropharyngeal cancer is distinct with P53 degradation, retinoblastoma RB pathway inactivation, and P16 upregulation. By contrast, tobacco-related oropharyngeal cancer is characterised by TP53 mutation and downregulation of CDKN2A (encoding P16). The best method to detect virus in tumour is controversial, and both in-situ hybridisation and PCR are commonly used; P16 immunohistochemistry could serve as a potential surrogate marker. HPV-positive oropharyngeal cancer seems to be more responsive to chemotherapy and radiation than HPV-negative disease. HPV 16 is a prognostic marker for enhanced overall and disease-free survival, but its use as a predictive marker has not yet been proven. Many questions about the natural history of oral HPV infection remain under investigation. For example, why does the increase in HPV-related oropharyngeal cancer dominate in men? What is the potential of HPV vaccines for primary prevention? Could an accurate method to detect HPV in tumour be developed? Which treatment strategies reduce toxic effects without compromising survival? Our aim with this review is to highlight current understanding of the epidemiology, biology, detection, and management of HPV-related oropharyngeal head and neck squamous cell carcinoma, and to describe unresolved issues.},
	author = {Marur, S. and D'Souza, G. and Westra, W. H. and Forastiere, A. A.},
	doi = {10.1016/s1470-2045(10)70017-6},
	issn = {1470-2045 (Print) 1470-2045},
	journal = {Lancet Oncol},
	keywords = {Biomarkers, Tumor Carcinoma, Squamous Cell/epidemiology/pathology/therapy/*virology Female *Human papillomavirus 16/isolation & purification Humans In Situ Hybridization Incidence Male Middle Aged Oropharyngeal Neoplasms/epidemiology/pathology/therapy/*virology Papillomavirus Infections/*complications/virology Polymerase Chain Reaction Risk Factors Sex Distribution Survival Rate Tumor Virus Infections/*complications/virology},
	note = {1474-5488 Marur, Shanthi D'Souza, Gypsyamber Westra, William H Forastiere, Arlene A R01 DE021395/DE/NIDCR NIH HHS/United States Journal Article Review 2010/05/11 Lancet Oncol. 2010 Aug;11(8):781-9. doi: 10.1016/S1470-2045(10)70017-6. Epub 2010 May 5.},
	number = {8},
	pages = {781-9},
	title = {HPV-associated head and neck cancer: a virus-related cancer epidemic},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242182/pdf/nihms841866.pdf},
	volume = {11},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242182/pdf/nihms841866.pdf},
	bdsk-url-2 = {https://doi.org/10.1016/s1470-2045(10)70017-6}}

@article{RN396,
	author = {Mashberg, A. and Samit, A.},
	doi = {10.3322/canjclin.45.6.328},
	issn = {0007-9235 (Print) 0007-9235},
	journal = {CA Cancer J Clin},
	keywords = {Adult Alcohol Drinking/adverse effects Biopsy Carcinoma/diagnosis/etiology/pathology Carcinoma in Situ/diagnosis/etiology/pathology Carcinoma, Squamous Cell/*diagnosis/etiology/pathology Female Humans Leukoplakia, Oral/diagnosis Male Mouth Neoplasms/*diagnosis/etiology/pathology Oropharyngeal Neoplasms/*diagnosis/etiology/pathology Palatal Neoplasms/diagnosis/etiology Risk Factors Smoking/adverse effects Staining and Labeling/methods Time Factors},
	number = {6},
	pages = {328-51},
	title = {Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers},
	type = {Journal Article},
	volume = {45},
	year = {1995},
	bdsk-url-1 = {https://doi.org/10.3322/canjclin.45.6.328}}

@article{RN397,
	author = {Mashberg, A. and Samit, A.},
	doi = {10.3322/canjclin.45.6.328},
	issn = {0007-9235 (Print) 0007-9235},
	journal = {CA Cancer J Clin},
	keywords = {Adult Alcohol Drinking/adverse effects Biopsy Carcinoma/diagnosis/etiology/pathology Carcinoma in Situ/diagnosis/etiology/pathology Carcinoma, Squamous Cell/*diagnosis/etiology/pathology Female Humans Leukoplakia, Oral/diagnosis Male Mouth Neoplasms/*diagnosis/etiology/pathology Oropharyngeal Neoplasms/*diagnosis/etiology/pathology Palatal Neoplasms/diagnosis/etiology Risk Factors Smoking/adverse effects Staining and Labeling/methods Time Factors},
	number = {6},
	pages = {328-51},
	title = {Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers},
	type = {Journal Article},
	volume = {45},
	year = {1995},
	bdsk-url-1 = {https://doi.org/10.3322/canjclin.45.6.328}}

@article{RN115,
	abstract = {An examination of the oral cavity and oropharynx in asymptomatic patients at high risk requires an orderly visual inspection of the entire oral and oropharyngeal mucosa with particular attention to the tongue, floor of mouth, soft palate, uvula, tonsillar pillars, and the lingual aspects of the retromolar trigones. Completion and clear documentation of the entire examination should be recorded. Detected lesions that do not resolve in a reasonable length of time--two to three weeks--require intense and assiduous investigation. The following specifics should be considered. 1. Alcohol drinkers and cigarette smokers, especially those 40 years of age and older, are at very high risk for the development of upper aerodigestive tract and lung squamous carcinomas. 2. The floor of the mouth, the ventrolateral tongue, and the soft palate complex are the high-risk sites within the oral cavity and oropharynx. 3. Persistent mucosal erythroplasia rather than leukoplakia is the earliest visual sign of oral and oropharyngeal carcinoma. These lesions should not be regarded merely as precancerous changes. The evidence indicates that these lesions in high-risk sites should be considered to be invasive carcinoma or carcinoma in situ unless proven otherwise by biopsy. 4. Toluidine blue staining is a useful diagnostic adjunct, particularly as a method of ruling out false-negative clinical impressions. It may also be used as a rinse in high-risk patients to encompass the entire oral mucosa after a negative clinical examination and as a guide to improve biopsy yields. 5. If oral or oropharyngeal cancer is identified, evaluations of the larynx, hypopharynx, esophagus, and lungs should be performed to rule out multiple primary cancers.(ABSTRACT TRUNCATED AT 250 WORDS)},
	author = {Mashberg, A. and Samit, A.},
	doi = {10.3322/canjclin.45.6.328},
	issn = {0007-9235 (Print) 0007-9235},
	journal = {CA Cancer J Clin},
	keywords = {Adult Alcohol Drinking/adverse effects Biopsy Carcinoma/diagnosis/etiology/pathology Carcinoma in Situ/diagnosis/etiology/pathology Carcinoma, Squamous Cell/*diagnosis/etiology/pathology Female Humans Leukoplakia, Oral/diagnosis Male Mouth Neoplasms/*diagnosis/etiology/pathology Oropharyngeal Neoplasms/*diagnosis/etiology/pathology Palatal Neoplasms/diagnosis/etiology Risk Factors Smoking/adverse effects Staining and Labeling/methods Time Factors},
	note = {Mashberg, A Samit, A Comparative Study Journal Article Review United States 1995/11/01 CA Cancer J Clin. 1995 Nov-Dec;45(6):328-51. doi: 10.3322/canjclin.45.6.328.},
	number = {6},
	pages = {328-51},
	title = {Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers},
	type = {Journal Article},
	url = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.3322/canjclin.45.6.328?download=true},
	volume = {45},
	year = {1995},
	bdsk-url-1 = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.3322/canjclin.45.6.328?download=true},
	bdsk-url-2 = {https://doi.org/10.3322/canjclin.45.6.328}}

@article{RN159,
	abstract = {An examination of the oral cavity and oropharynx in asymptomatic patients at high risk requires an orderly visual inspection of the entire oral and oropharyngeal mucosa with particular attention to the tongue, floor of mouth, soft palate, uvula, tonsillar pillars, and the lingual aspects of the retromolar trigones. Completion and clear documentation of the entire examination should be recorded. Detected lesions that do not resolve in a reasonable length of time--two to three weeks--require intense and assiduous investigation. The following specifics should be considered. 1. Alcohol drinkers and cigarette smokers, especially those 40 years of age and older, are at very high risk for the development of upper aerodigestive tract and lung squamous carcinomas. 2. The floor of the mouth, the ventrolateral tongue, and the soft palate complex are the high-risk sites within the oral cavity and oropharynx. 3. Persistent mucosal erythroplasia rather than leukoplakia is the earliest visual sign of oral and oropharyngeal carcinoma. These lesions should not be regarded merely as precancerous changes. The evidence indicates that these lesions in high-risk sites should be considered to be invasive carcinoma or carcinoma in situ unless proven otherwise by biopsy. 4. Toluidine blue staining is a useful diagnostic adjunct, particularly as a method of ruling out false-negative clinical impressions. It may also be used as a rinse in high-risk patients to encompass the entire oral mucosa after a negative clinical examination and as a guide to improve biopsy yields. 5. If oral or oropharyngeal cancer is identified, evaluations of the larynx, hypopharynx, esophagus, and lungs should be performed to rule out multiple primary cancers.(ABSTRACT TRUNCATED AT 250 WORDS)},
	author = {Mashberg, A. and Samit, A.},
	doi = {10.3322/canjclin.45.6.328},
	issn = {0007-9235 (Print) 0007-9235},
	journal = {CA Cancer J Clin},
	keywords = {Adult Alcohol Drinking/adverse effects Biopsy Carcinoma/diagnosis/etiology/pathology Carcinoma in Situ/diagnosis/etiology/pathology Carcinoma, Squamous Cell/*diagnosis/etiology/pathology Female Humans Leukoplakia, Oral/diagnosis Male Mouth Neoplasms/*diagnosis/etiology/pathology Oropharyngeal Neoplasms/*diagnosis/etiology/pathology Palatal Neoplasms/diagnosis/etiology Risk Factors Smoking/adverse effects Staining and Labeling/methods Time Factors},
	note = {Mashberg, A Samit, A Comparative Study Journal Article Review United States 1995/11/01 CA Cancer J Clin. 1995 Nov-Dec;45(6):328-51. doi: 10.3322/canjclin.45.6.328.},
	number = {6},
	pages = {328-51},
	title = {Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers},
	type = {Journal Article},
	volume = {45},
	year = {1995},
	bdsk-url-1 = {https://doi.org/10.3322/canjclin.45.6.328}}

@article{RN173,
	abstract = {An examination of the oral cavity and oropharynx in asymptomatic patients at high risk requires an orderly visual inspection of the entire oral and oropharyngeal mucosa with particular attention to the tongue, floor of mouth, soft palate, uvula, tonsillar pillars, and the lingual aspects of the retromolar trigones. Completion and clear documentation of the entire examination should be recorded. Detected lesions that do not resolve in a reasonable length of time--two to three weeks--require intense and assiduous investigation. The following specifics should be considered. 1. Alcohol drinkers and cigarette smokers, especially those 40 years of age and older, are at very high risk for the development of upper aerodigestive tract and lung squamous carcinomas. 2. The floor of the mouth, the ventrolateral tongue, and the soft palate complex are the high-risk sites within the oral cavity and oropharynx. 3. Persistent mucosal erythroplasia rather than leukoplakia is the earliest visual sign of oral and oropharyngeal carcinoma. These lesions should not be regarded merely as precancerous changes. The evidence indicates that these lesions in high-risk sites should be considered to be invasive carcinoma or carcinoma in situ unless proven otherwise by biopsy. 4. Toluidine blue staining is a useful diagnostic adjunct, particularly as a method of ruling out false-negative clinical impressions. It may also be used as a rinse in high-risk patients to encompass the entire oral mucosa after a negative clinical examination and as a guide to improve biopsy yields. 5. If oral or oropharyngeal cancer is identified, evaluations of the larynx, hypopharynx, esophagus, and lungs should be performed to rule out multiple primary cancers.(ABSTRACT TRUNCATED AT 250 WORDS)},
	author = {Mashberg, A. and Samit, A.},
	doi = {10.3322/canjclin.45.6.328},
	issn = {0007-9235 (Print) 0007-9235},
	journal = {CA Cancer J Clin},
	keywords = {Adult Alcohol Drinking/adverse effects Biopsy Carcinoma/diagnosis/etiology/pathology Carcinoma in Situ/diagnosis/etiology/pathology Carcinoma, Squamous Cell/*diagnosis/etiology/pathology Female Humans Leukoplakia, Oral/diagnosis Male Mouth Neoplasms/*diagnosis/etiology/pathology Oropharyngeal Neoplasms/*diagnosis/etiology/pathology Palatal Neoplasms/diagnosis/etiology Risk Factors Smoking/adverse effects Staining and Labeling/methods Time Factors},
	note = {Mashberg, A Samit, A Comparative Study Journal Article Review United States 1995/11/01 CA Cancer J Clin. 1995 Nov-Dec;45(6):328-51. doi: 10.3322/canjclin.45.6.328.},
	number = {6},
	pages = {328-51},
	title = {Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers},
	type = {Journal Article},
	volume = {45},
	year = {1995},
	bdsk-url-1 = {https://doi.org/10.3322/canjclin.45.6.328}}

@article{RN281,
	abstract = {BACKGROUND: The clearance of surgical margins at the primary site is widely thought to influence the subsequent course of the disease in patients operated on for oral and oropharyngeal carcinoma. In some reports the adverse impact of close or involved margins was not negated by postoperative radiotherapy. These findings, in addition to descriptive histopathological studies, have led some authors to recommend margins of more than a macroscopic clearance of 1cm at certain subsites. We have therefore examined the relation between the condition of surgical margins and local recurrence and disease-specific survival. METHODS: Identical treatment protocols were used to treat two independent groups of patients (Sydney, Australia, n=237; Lanarkshire, n=95) who presented with previously untreated carcinoma of the mouth or oropharynx. All patients were operated on with the primary objective of achieving a macroscopic clearance of 1cm. Postoperative radiotherapy was used according to a protocol. Data about patients were entered into comprehensive computerised databases prospectively. Known clinical and pathological prognostic indicators, in addition to the condition of surgical margins, were analysed to find out if they were predictive of local recurrence and disease-specific survival using the Cox proportional hazard model. RESULTS: Local recurrence was predicted by the presence of perineural invasion at the primary site in both groups. Disease-specific survival was predicted by the presence and extent of regional lymph node metastases in both groups. The condition of surgical margins (clear, close, or involved) did not predict local recurrence, or disease-specific survival on multivariate analysis. CONCLUSIONS: A macroscopic margin of 1cm seems adequate in the surgical management of oral and oropharyngeal carcinoma. For most patients who have close or involved margins the biology of the disease influences the subsequent course irrespective of the width of clearance of tumour.},
	author = {McMahon, J. and O'Brien, C. J. and Pathak, I. and Hamill, R. and McNeil, E. and Hammersley, N. and Gardiner, S. and Junor, E.},
	doi = {10.1016/s0266-4356(03)00119-0},
	issn = {0266-4356 (Print) 0266-4356},
	journal = {Br J Oral Maxillofac Surg},
	keywords = {Carcinoma, Squamous Cell/pathology/radiotherapy/*surgery Humans Lymphatic Metastasis Mouth Neoplasms/pathology/radiotherapy/*surgery Multivariate Analysis Neck Dissection *Neoplasm Recurrence, Local Neoplasm Staging Neoplasm, Residual New South Wales Oral Surgical Procedures/*methods Oropharyngeal Neoplasms/pathology/radiotherapy/*surgery Proportional Hazards Models Prospective Studies Radiotherapy, Adjuvant Regression Analysis Scotland Survival Analysis},
	note = {McMahon, J O'Brien, C J Pathak, I Hamill, R McNeil, E Hammersley, N Gardiner, S Junor, E Journal Article Multicenter Study Scotland 2003/08/30 Br J Oral Maxillofac Surg. 2003 Aug;41(4):224-31. doi: 10.1016/s0266-4356(03)00119-0.},
	number = {4},
	pages = {224-31},
	title = {Influence of condition of surgical margins on local recurrence and disease-specific survival in oral and oropharyngeal cancer},
	type = {Journal Article},
	url = {https://www.bjoms.com/article/S0266-4356(03)00119-0/fulltext},
	volume = {41},
	year = {2003},
	bdsk-url-1 = {https://www.bjoms.com/article/S0266-4356(03)00119-0/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s0266-4356(03)00119-0}}

@article{RN201,
	abstract = {BACKGROUND: The role of image-guided surveillance as compared with planned neck dissection in the treatment of patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment is a matter of debate. METHODS: In this prospective, randomized, controlled trial, we assessed the noninferiority of positron-emission tomography-computed tomography (PET-CT)-guided surveillance (performed 12 weeks after the end of chemoradiotherapy, with neck dissection performed only if PET-CT showed an incomplete or equivocal response) to planned neck dissection in patients with stage N2 or N3 disease. The primary end point was overall survival. RESULTS: From 2007 through 2012, we recruited 564 patients (282 patients in the planned-surgery group and 282 patients in the surveillance group) from 37 centers in the United Kingdom. Among these patients, 17% had nodal stage N2a disease and 61% had stage N2b disease. A total of 84% of the patients had oropharyngeal cancer, and 75% had tumor specimens that stained positive for the p16 protein, an indicator that human papillomavirus had a role in the causation of the cancer. The median follow-up was 36 months. PET-CT-guided surveillance resulted in fewer neck dissections than did planned dissection surgery (54 vs. 221); rates of surgical complications were similar in the two groups (42% and 38%, respectively). The 2-year overall survival rate was 84.9% (95% confidence interval [CI], 80.7 to 89.1) in the surveillance group and 81.5% (95% CI, 76.9 to 86.3) in the planned-surgery group. The hazard ratio for death slightly favored PET-CT-guided surveillance and indicated noninferiority (upper boundary of the 95% CI for the hazard ratio, <1.50; P=0.004). There was no significant difference between the groups with respect to p16 expression. Quality of life was similar in the two groups. PET-CT-guided surveillance, as compared with neck dissection, resulted in savings of 1,492 (approximately $2,190 in U.S. dollars) per person over the duration of the trial. CONCLUSIONS: Survival was similar among patients who underwent PET-CT-guided surveillance and those who underwent planned neck dissection, but surveillance resulted in considerably fewer operations and it was more cost-effective. (Funded by the National Institute for Health Research Health Technology Assessment Programme and Cancer Research UK; PET-NECK Current Controlled Trials number, ISRCTN13735240.).},
	author = {Mehanna, H. and Wong, W. L. and McConkey, C. C. and Rahman, J. K. and Robinson, M. and Hartley, A. G. and Nutting, C. and Powell, N. and Al-Booz, H. and Robinson, M. and Junor, E. and Rizwanullah, M. and von Zeidler, S. V. and Wieshmann, H. and Hulme, C. and Smith, A. F. and Hall, P. and Dunn, J.},
	doi = {10.1056/NEJMoa1514493},
	issn = {0028-4793},
	journal = {N Engl J Med},
	keywords = {Carcinoma, Squamous Cell/diagnosis/surgery/*therapy Chemoradiotherapy Female Follow-Up Studies Head and Neck Neoplasms/diagnosis/surgery/*therapy Humans Intention to Treat Analysis Kaplan-Meier Estimate Lymphatic Metastasis/diagnosis Male Middle Aged *Neck Dissection Neoplasm Recurrence, Local Neoplasm Staging *Positron-Emission Tomography Prospective Studies Quality of Life Survival Rate *Tomography, X-Ray Computed},
	note = {1533-4406 Mehanna, Hisham Wong, Wai-Lup McConkey, Christopher C Rahman, Joy K Robinson, Max Hartley, Andrew G J Nutting, Christopher Powell, Ned Al-Booz, Hoda Robinson, Martin Junor, Elizabeth Rizwanullah, Mohammed von Zeidler, Sandra V Wieshmann, Hulya Hulme, Claire Smith, Alison F Hall, Peter Dunn, Janet PET-NECK Trial Management Group 06/302/129/DH_/Department of Health/United Kingdom C19677/A9674/CRUK_/Cancer Research UK/United Kingdom Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't United States 2016/03/24 N Engl J Med. 2016 Apr 14;374(15):1444-54. doi: 10.1056/NEJMoa1514493. Epub 2016 Mar 23.},
	number = {15},
	pages = {1444-54},
	title = {PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer},
	type = {Journal Article},
	url = {https://www.nejm.org/doi/pdf/10.1056/NEJMoa1514493?articleTools=true},
	volume = {374},
	year = {2016},
	bdsk-url-1 = {https://www.nejm.org/doi/pdf/10.1056/NEJMoa1514493?articleTools=true},
	bdsk-url-2 = {https://doi.org/10.1056/NEJMoa1514493}}

@article{RN11,
	author = {Nelson, A. D. and Grandis, J. R.},
	doi = {10.4161/cbt.6.1.3898},
	issn = {1538-4047 (Print) 1538-4047 (Linking)},
	journal = {Cancer Biol Ther},
	keywords = {Carcinoma, Squamous Cell/*genetics Head and Neck Neoplasms/*genetics Humans Hyaluronan Receptors/genetics/*physiology Protein Isoforms/genetics/physiology},
	note = {Nelson, Aaron D Grandis, Jennifer R eng Comment Cancer Biol Ther. 2007 Jan;6(1):125-6. doi: 10.4161/cbt.6.1.3898.},
	number = {1},
	pages = {125-6},
	title = {The role of CD44 in HNSCC},
	type = {Journal Article},
	url = {https://www.tandfonline.com/doi/pdf/10.4161/cbt.6.1.3898?needAccess=true},
	volume = {6},
	year = {2007},
	bdsk-url-1 = {https://www.tandfonline.com/doi/pdf/10.4161/cbt.6.1.3898?needAccess=true},
	bdsk-url-2 = {https://doi.org/10.4161/cbt.6.1.3898}}

@article{RN449,
	author = {Nocito, A. and Kononen, J. and Kallioniemi, O. P. and Sauter, G.},
	doi = {10.1002/ijc.1385},
	issn = {0020-7136 (Print) 0020-7136 (Linking)},
	journal = {Int J Cancer},
	keywords = {Humans Neoplasms/*genetics/pathology *Oligonucleotide Array Sequence Analysis Prognosis},
	number = {1},
	pages = {1-5},
	title = {Tissue microarrays (TMAs) for high-throughput molecular pathology research},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11668471},
	volume = {94},
	year = {2001},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/11668471},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.1385}}

@article{RN59,
	abstract = {A rapidly increasing number of genes are being suspected to play a role in cancer biology. To evaluate the clinical significance of newly detected potential cancer genes, it is usually required to examine a high number of well-characterized primary tumors. Using traditional methods of molecular pathology, this is a time consuming endeavor rapidly exhausting precious tissue resources. To allow for a high throughput tissue analysis we have developed a "tissue chip" approach (Kononen et al., Nat. Med. 1998;4:844-7). Using this tissue microarray (TMA) technology, samples from up to 1,000 different tumors are arrayed in one recipient paraffin block, sections of which can be used for all kind of in situ analyses. Section from TMA blocks can then be utilized for the simultaneous analysis of up to 1,000 different tumors on the DNA, RNA or protein level. TMAs allow a high throughput molecular analysis of thousands of tumors within a few hours. All currently available data have suggested that minute arrayed tissue specimens are highly representative of their donor tissues. There are multiple different types of TMAs that can be utilized in cancer research including multi tumor arrays (containing different tumor types), tumor progression arrays (tumors of different stages) and prognostic arrays (tumors with clinical endpoints). The combination of multiple different TMAs allows a very quick but comprehensive characterization of biomarkers of interest. We anticipate that the use of TMAs will greatly accelerate the transition of basic research findings to clinical applications.},
	author = {Nocito, A. and Kononen, J. and Kallioniemi, O. P. and Sauter, G.},
	doi = {10.1002/ijc.1385},
	issn = {0020-7136 (Print) 0020-7136 (Linking)},
	journal = {Int J Cancer},
	keywords = {Humans Neoplasms/*genetics/pathology *Oligonucleotide Array Sequence Analysis Prognosis},
	note = {Nocito, A Kononen, J Kallioniemi, O P Sauter, G eng 2001/10/23 Int J Cancer. 2001 Oct 1;94(1):1-5. doi: 10.1002/ijc.1385.},
	number = {1},
	pages = {1-5},
	title = {Tissue microarrays (TMAs) for high-throughput molecular pathology research},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.1385?download=true},
	volume = {94},
	year = {2001},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.1385?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.1385}}

@article{RN290,
	abstract = {Colon cancer is one of the best-understood neoplasms from a genetic perspective, yet it remains the second most common cause of cancer-related death, indicating that some of its cancer cells are not eradicated by current therapies. What has yet to be established is whether every colon cancer cell possesses the potential to initiate and sustain tumour growth, or whether the tumour is hierarchically organized so that only a subset of cells--cancer stem cells--possess such potential. Here we use renal capsule transplantation in immunodeficient NOD/SCID mice to identify a human colon cancer-initiating cell (CC-IC). Purification experiments established that all CC-ICs were CD133+; the CD133- cells that comprised the majority of the tumour were unable to initiate tumour growth. We calculated by limiting dilution analysis that there was one CC-IC in 5.7 x 10(4) unfractionated tumour cells, whereas there was one CC-IC in 262 CD133+ cells, representing >200-fold enrichment. CC-ICs within the CD133+ population were able to maintain themselves as well as differentiate and re-establish tumour heterogeneity upon serial transplantation. The identification of colon cancer stem cells that are distinct from the bulk tumour cells provides strong support for the hierarchical organization of human colon cancer, and their existence suggests that for therapeutic strategies to be effective, they must target the cancer stem cells.},
	author = {O'Brien, C. A. and Pollett, A. and Gallinger, S. and Dick, J. E.},
	doi = {10.1038/nature05372},
	issn = {0028-0836},
	journal = {Nature},
	keywords = {AC133 Antigen Aged Aged, 80 and over Animals Antigens, CD/*metabolism Cell Line, Tumor Cell Proliferation Colonic Neoplasms/*metabolism/*pathology Female Glycoproteins/*metabolism Humans Male Mice Mice, Inbred NOD Mice, SCID Middle Aged Neoplasm Transplantation Neoplastic Stem Cells/*metabolism/*pathology Peptides/*metabolism Transplantation, Heterologous},
	note = {1476-4687 O'Brien, Catherine A Pollett, Aaron Gallinger, Steven Dick, John E Journal Article Research Support, Non-U.S. Gov't England 2006/11/24 Nature. 2007 Jan 4;445(7123):106-10. doi: 10.1038/nature05372. Epub 2006 Nov 19.},
	number = {7123},
	pages = {106-10},
	title = {A human colon cancer cell capable of initiating tumour growth in immunodeficient mice},
	type = {Journal Article},
	url = {https://www.nature.com/articles/nature05372.pdf},
	volume = {445},
	year = {2007},
	bdsk-url-1 = {https://www.nature.com/articles/nature05372.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/nature05372}}

@article{RN291,
	abstract = {Colon cancer is one of the best-understood neoplasms from a genetic perspective, yet it remains the second most common cause of cancer-related death, indicating that some of its cancer cells are not eradicated by current therapies. What has yet to be established is whether every colon cancer cell possesses the potential to initiate and sustain tumour growth, or whether the tumour is hierarchically organized so that only a subset of cells--cancer stem cells--possess such potential. Here we use renal capsule transplantation in immunodeficient NOD/SCID mice to identify a human colon cancer-initiating cell (CC-IC). Purification experiments established that all CC-ICs were CD133+; the CD133- cells that comprised the majority of the tumour were unable to initiate tumour growth. We calculated by limiting dilution analysis that there was one CC-IC in 5.7 x 10(4) unfractionated tumour cells, whereas there was one CC-IC in 262 CD133+ cells, representing >200-fold enrichment. CC-ICs within the CD133+ population were able to maintain themselves as well as differentiate and re-establish tumour heterogeneity upon serial transplantation. The identification of colon cancer stem cells that are distinct from the bulk tumour cells provides strong support for the hierarchical organization of human colon cancer, and their existence suggests that for therapeutic strategies to be effective, they must target the cancer stem cells.},
	author = {O'Brien, C. A. and Pollett, A. and Gallinger, S. and Dick, J. E.},
	doi = {10.1038/nature05372},
	issn = {0028-0836},
	journal = {Nature},
	keywords = {AC133 Antigen Aged Aged, 80 and over Animals Antigens, CD/*metabolism Cell Line, Tumor Cell Proliferation Colonic Neoplasms/*metabolism/*pathology Female Glycoproteins/*metabolism Humans Male Mice Mice, Inbred NOD Mice, SCID Middle Aged Neoplasm Transplantation Neoplastic Stem Cells/*metabolism/*pathology Peptides/*metabolism Transplantation, Heterologous},
	note = {1476-4687 O'Brien, Catherine A Pollett, Aaron Gallinger, Steven Dick, John E Journal Article Research Support, Non-U.S. Gov't England 2006/11/24 Nature. 2007 Jan 4;445(7123):106-10. doi: 10.1038/nature05372. Epub 2006 Nov 19.},
	number = {7123},
	pages = {106-10},
	title = {A human colon cancer cell capable of initiating tumour growth in immunodeficient mice},
	type = {Journal Article},
	volume = {445},
	year = {2007},
	bdsk-url-1 = {https://doi.org/10.1038/nature05372}}

@article{RN312,
	abstract = {Colon cancer is one of the best-understood neoplasms from a genetic perspective, yet it remains the second most common cause of cancer-related death, indicating that some of its cancer cells are not eradicated by current therapies. What has yet to be established is whether every colon cancer cell possesses the potential to initiate and sustain tumour growth, or whether the tumour is hierarchically organized so that only a subset of cells--cancer stem cells--possess such potential. Here we use renal capsule transplantation in immunodeficient NOD/SCID mice to identify a human colon cancer-initiating cell (CC-IC). Purification experiments established that all CC-ICs were CD133+; the CD133- cells that comprised the majority of the tumour were unable to initiate tumour growth. We calculated by limiting dilution analysis that there was one CC-IC in 5.7 x 10(4) unfractionated tumour cells, whereas there was one CC-IC in 262 CD133+ cells, representing >200-fold enrichment. CC-ICs within the CD133+ population were able to maintain themselves as well as differentiate and re-establish tumour heterogeneity upon serial transplantation. The identification of colon cancer stem cells that are distinct from the bulk tumour cells provides strong support for the hierarchical organization of human colon cancer, and their existence suggests that for therapeutic strategies to be effective, they must target the cancer stem cells.},
	author = {O'Brien, C. A. and Pollett, A. and Gallinger, S. and Dick, J. E.},
	doi = {10.1038/nature05372},
	issn = {0028-0836},
	journal = {Nature},
	keywords = {AC133 Antigen Aged Aged, 80 and over Animals Antigens, CD/*metabolism Cell Line, Tumor Cell Proliferation Colonic Neoplasms/*metabolism/*pathology Female Glycoproteins/*metabolism Humans Male Mice Mice, Inbred NOD Mice, SCID Middle Aged Neoplasm Transplantation Neoplastic Stem Cells/*metabolism/*pathology Peptides/*metabolism Transplantation, Heterologous},
	note = {1476-4687 O'Brien, Catherine A Pollett, Aaron Gallinger, Steven Dick, John E Journal Article Research Support, Non-U.S. Gov't England 2006/11/24 Nature. 2007 Jan 4;445(7123):106-10. doi: 10.1038/nature05372. Epub 2006 Nov 19.},
	number = {7123},
	pages = {106-10},
	title = {A human colon cancer cell capable of initiating tumour growth in immunodeficient mice},
	type = {Journal Article},
	url = {https://www.nature.com/articles/nature05372.pdf},
	volume = {445},
	year = {2007},
	bdsk-url-1 = {https://www.nature.com/articles/nature05372.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/nature05372}}

@article{RN280,
	abstract = {BACKGROUND: Previous studies have demonstrated that tumor thickness might influence prognosis in oral cancer, but the significant point at which outcome changes has varied from 1.5 mm to 6 mm. The clinical relevance of thickness remains unclear, and a reproducible prognostic "breakpoint" needs to be defined. METHODS: Tumor thickness was measured in 145 oral cavity squamous cancers, clinically staged T1 (n = 62) or T2 (n = 83). Clinical and pathologic data were collected prospectively between 1988 and 2000, but thickness was measured on paraffin sections for this study. Minimum follow-up was 2 years, and thickness was correlated with local control, cervical node involvement, and survival. Patients with clinically positive nodes (n = 21) were not excluded. Overall, 55 patients had pathologic node involvement at some time in their disease. RESULTS: Median tumor thickness was 6.2 mm, and there was little variation between sites: tongue, 6.4 mm; floor of mouth, 6.6 mm; and other sites, 5.7 mm. Median thickness for T1 tumors was 4.3 mm, significantly less than the T2 group, 8 mm (p <.01). Median thickness also varied significantly for tumors with associated nodal disease (8.5 mm) and without nodal disease (5.8 mm) (p <.01). Prognosis changed significantly at a cutoff of 4 mm with local control, nodal disease, and survival rates of 91%, 8%, and 100%, respectively, for tumors <4 mm compared with 84%, 48%, and 74% for those 4 mm or more thick (p <.01). Subgrouping greater than and less than 3 mm and 5 mm also showed a difference but with poorer discrimination. Thickness and pathologic nodal involvement were highly significant independent prognostic factors. CONCLUSIONS: Tumor thickness is a highly significant, objectively measurable prognostic factor in early stage oral cancers. There is a need to standardize techniques of measurement to allow a multi-institutional study to be carried out. This will facilitate the development of strategies aimed at improving the outcome of higher risk patients.},
	author = {O'Brien, C. J. and Lauer, C. S. and Fredricks, S. and Clifford, A. R. and McNeil, E. B. and Bagia, J. S. and Koulmandas, C.},
	doi = {10.1002/hed.10324},
	issn = {1043-3074 (Print) 1043-3074},
	journal = {Head Neck},
	keywords = {Adult Aged Aged, 80 and over Female Humans Lymphatic Metastasis Male Middle Aged Mouth Neoplasms/*mortality/*pathology Multivariate Analysis Prognosis Survival Analysis Tongue Neoplasms/mortality/pathology},
	note = {O'Brien, Christopher J Lauer, Christopher S Fredricks, Susanne Clifford, Anthony R McNeil, Edward B Bagia, Jai S Koulmandas, Christina Journal Article United States 2003/11/07 Head Neck. 2003 Nov;25(11):937-45. doi: 10.1002/hed.10324.},
	number = {11},
	pages = {937-45},
	title = {Tumor thickness influences prognosis of T1 and T2 oral cavity cancer--but what thickness?},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hed.10324?download=true},
	volume = {25},
	year = {2003},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hed.10324?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/hed.10324}}

@article{RN385,
	author = {Odell, E. W. and Farthing, P. M. and High, A. and Potts, J. and Soames, J. and Thakker, N. and Toner, M. and Williams, H. K.},
	doi = {10.1111/j.1600-0579.2004.00350.x},
	issn = {1396-5883 (Print) 1396-5883 (Linking)},
	journal = {Eur J Dent Educ},
	keywords = {Curriculum/*standards Education, Dental/*standards Humans Pathology, Oral/*education Societies, Dental United Kingdom},
	number = {4},
	pages = {177-84},
	title = {British Society for Oral and Maxillofacial Pathology, UK: minimum curriculum in oral pathology},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15469445},
	volume = {8},
	year = {2004},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/15469445},
	bdsk-url-2 = {https://doi.org/10.1111/j.1600-0579.2004.00350.x}}

@article{RN66,
	abstract = {This paper describes a minimum curriculum in oral pathology for undergraduate dental education in the United Kingdom prepared by the Teachers Group of The British Society of Oral and Maxillofacial Pathology. Curricular development in UK dental schools is overseen by the General Dental Council (GDC), the Quality Assurance Agency for Higher Education (QAA) and the European Union. These organisations define the framework for education and learning outcomes but provide little or no detailed guidance on syllabus or curriculum. This recommended minimum curriculum has been drawn up by a consensus process involving teachers of oral pathology from all 13 UK and one Irish dental schools and is cross-referenced to the GDC and QAA published requirements for undergraduate dental education.},
	author = {Odell, E. W. and Farthing, P. M. and High, A. and Potts, J. and Soames, J. and Thakker, N. and Toner, M. and Williams, H. K.},
	doi = {10.1111/j.1600-0579.2004.00350.x},
	issn = {1396-5883 (Print) 1396-5883 (Linking)},
	journal = {Eur J Dent Educ},
	keywords = {Curriculum/*standards Education, Dental/*standards Humans Pathology, Oral/*education Societies, Dental United Kingdom},
	note = {Odell, E W Farthing, P M High, A Potts, J Soames, J Thakker, N Toner, M Williams, H K eng England 2004/10/08 Eur J Dent Educ. 2004 Nov;8(4):177-84. doi: 10.1111/j.1600-0579.2004.00350.x.},
	number = {4},
	pages = {177-84},
	title = {British Society for Oral and Maxillofacial Pathology, UK: minimum curriculum in oral pathology},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1600-0579.2004.00350.x?download=true},
	volume = {8},
	year = {2004},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1600-0579.2004.00350.x?download=true},
	bdsk-url-2 = {https://doi.org/10.1111/j.1600-0579.2004.00350.x}}

@article{RN321,
	abstract = {CD44(+) /CD24(+) /EpCAM(+) cells have been reported to be cancer stem cells in pancreatic cancer; however, the histological and clinical importance of these cells has not yet been investigated. Here we clarified the characteristics of CD44(+) /CD24(+) /EpCAM(+) cells in clinical specimens of pancreatic cancer using immunohistochemical assay. We used surgical specimens of pancreatic ductal adenocarcinoma from 101 patients. In view of tumor heterogeneity, we randomly selected 10 high-power fields per case, and triple-positive CD44(+) /CD24(+) /EpCAM(+) expression was identified using our scoring system. The distribution, histological characteristics, and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) cells were then analyzed. As a result, the distribution of CD44(+) /CD24(+) /EpCAM(+) cells varied widely among the 101 cases examined, and CD44(+) /CD24(+) /EpCAM(+) expression was correlated with poor glandular differentiation and high proliferation. Survival analysis showed that CD44(+) /CD24(+) /EpCAM(+) expression was not correlated with patient outcome; however, CD44(+) /CD24(+) expression appeared to be correlated with poor prognosis. In conclusion, CD44(+) /CD24(+) /EpCAM(+) expression overlapped with poorly differentiated cells and possessed high proliferative potential in clinical pancreatic cancer. In particular, the presence of double-positive CD44(+) /CD24(+) expression seemed to have clinical relevance, associating with poor prognosis.},
	author = {Ohara, Y. and Oda, T. and Sugano, M. and Hashimoto, S. and Enomoto, T. and Yamada, K. and Akashi, Y. and Miyamoto, R. and Kobayashi, A. and Fukunaga, K. and Morishita, Y. and Ohkohchi, N.},
	doi = {10.1111/cas.12198},
	issn = {1347-9032 (Print) 1347-9032},
	journal = {Cancer Sci},
	keywords = {Adenocarcinoma/genetics/metabolism/pathology Adult Aged Aged, 80 and over Antigens, Neoplasm/*biosynthesis/genetics/metabolism CD24 Antigen/*biosynthesis/genetics/metabolism Carcinoma, Pancreatic Ductal/genetics/metabolism/pathology Cell Adhesion Molecules/*biosynthesis/genetics/metabolism Cell Differentiation/genetics Cell Growth Processes/genetics Epithelial Cell Adhesion Molecule Female Humans Hyaluronan Receptors/*biosynthesis/genetics/metabolism Male Middle Aged Pancreatic Neoplasms/genetics/*metabolism/*pathology Prognosis Survival Analysis},
	note = {1349-7006 Ohara, Yusuke Oda, Tatsuya Sugano, Masato Hashimoto, Shinji Enomoto, Tsuyoshi Yamada, Keiichi Akashi, Yoshimasa Miyamoto, Ryoichi Kobayashi, Akihiko Fukunaga, Kiyoshi Morishita, Yukio Ohkohchi, Nobuhiro Journal Article Research Support, Non-U.S. Gov't 2013/05/18 Cancer Sci. 2013 Aug;104(8):1127-34. doi: 10.1111/cas.12198. Epub 2013 Jun 24.},
	number = {8},
	pages = {1127-34},
	title = {Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer},
	type = {Journal Article},
	volume = {104},
	year = {2013},
	bdsk-url-1 = {https://doi.org/10.1111/cas.12198}}

@article{RN227,
	abstract = {BACKGROUND: Although head and neck cancer can be cured by radiotherapy, the optimum treatment time for locoregional control is unclear. We aimed to find out whether shortening of treatment time by use of six instead of five radiotherapy fractions per week improves the tumour response in squamous-cell carcinoma. METHODS: We did a multicentre, controlled, randomised trial. Between January, 1992, and December, 1999, of 1485 patients treated with primary radiotherapy alone, 1476 eligible patients were randomly assigned five (n=726) or six (n=750) fractions per week at the same total dose and fraction number (66-68 Gy in 33-34 fractions to all tumour sites except well-differentiated T1 glottic tumours, which were treated with 62 Gy). All patients, except those with glottic cancers, also received the hypoxic radiosensitiser nimorazole. Analysis was by intention to treat. FINDINGS: More than 97% of the patients received the planned total dose. Median overall treatment times were 39 days (six-fraction group) and 46 days (five-fraction group). Overall 5-year locoregional control rates were 70% and 60% for the six-fraction and five-fraction groups, respectively (p=0.0005). The whole benefit of shortening of treatment time was seen for primary tumour control (76 vs 64% for six and five fractions, p=0.0001), but was non-significant for neck-node control. Six compared with five fractions per week improved preservation of the voice among patients with laryngeal cancer (80 vs 68%, p=0.007). Disease-specific survival improved (73 vs 66% for six and five fractions, p=0.01) but not overall survival. Acute morbidity was significantly more frequent with six than with five fractions, but was transient. INTERPRETATION: The shortening of overall treatment time by increase of the weekly number of fractions is beneficial in patients with head and neck cancer. The six-fractions-weekly regimen has become the standard treatment in Denmark.},
	author = {Overgaard, J. and Hansen, H. S. and Specht, L. and Overgaard, M. and Grau, C. and Andersen, E. and Bentzen, J. and Bastholt, L. and Hansen, O. and Johansen, J. and Andersen, L. and Evensen, J. F.},
	doi = {10.1016/s0140-6736(03)14361-9},
	issn = {0140-6736},
	journal = {Lancet},
	keywords = {Adult Aged Carcinoma, Squamous Cell/*radiotherapy Denmark Dose Fractionation, Radiation Dose-Response Relationship, Radiation Female Follow-Up Studies Head and Neck Neoplasms/*radiotherapy Humans Male Middle Aged Nimorazole/therapeutic use Proportional Hazards Models Radiation-Sensitizing Agents/therapeutic use Radiotherapy Dosage/*standards Survival Rate Treatment Outcome},
	note = {1474-547x Overgaard, Jens Hansen, Hanne Sand Specht, Lena Overgaard, Marie Grau, Cai Andersen, Elo Bentzen, Jens Bastholt, Lars Hansen, Olfred Johansen, J{\o}rgen Andersen, Lisbeth Evensen, Jan F Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't England 2003/09/27 Lancet. 2003 Sep 20;362(9388):933-40. doi: 10.1016/s0140-6736(03)14361-9.},
	number = {9388},
	pages = {933-40},
	title = {Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial},
	type = {Journal Article},
	url = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14361-9/fulltext},
	volume = {362},
	year = {2003},
	bdsk-url-1 = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14361-9/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s0140-6736(03)14361-9}}

@article{RN228,
	abstract = {BACKGROUND: Although head and neck cancer can be cured by radiotherapy, the optimum treatment time for locoregional control is unclear. We aimed to find out whether shortening of treatment time by use of six instead of five radiotherapy fractions per week improves the tumour response in squamous-cell carcinoma. METHODS: We did a multicentre, controlled, randomised trial. Between January, 1992, and December, 1999, of 1485 patients treated with primary radiotherapy alone, 1476 eligible patients were randomly assigned five (n=726) or six (n=750) fractions per week at the same total dose and fraction number (66-68 Gy in 33-34 fractions to all tumour sites except well-differentiated T1 glottic tumours, which were treated with 62 Gy). All patients, except those with glottic cancers, also received the hypoxic radiosensitiser nimorazole. Analysis was by intention to treat. FINDINGS: More than 97% of the patients received the planned total dose. Median overall treatment times were 39 days (six-fraction group) and 46 days (five-fraction group). Overall 5-year locoregional control rates were 70% and 60% for the six-fraction and five-fraction groups, respectively (p=0.0005). The whole benefit of shortening of treatment time was seen for primary tumour control (76 vs 64% for six and five fractions, p=0.0001), but was non-significant for neck-node control. Six compared with five fractions per week improved preservation of the voice among patients with laryngeal cancer (80 vs 68%, p=0.007). Disease-specific survival improved (73 vs 66% for six and five fractions, p=0.01) but not overall survival. Acute morbidity was significantly more frequent with six than with five fractions, but was transient. INTERPRETATION: The shortening of overall treatment time by increase of the weekly number of fractions is beneficial in patients with head and neck cancer. The six-fractions-weekly regimen has become the standard treatment in Denmark.},
	author = {Overgaard, J. and Hansen, H. S. and Specht, L. and Overgaard, M. and Grau, C. and Andersen, E. and Bentzen, J. and Bastholt, L. and Hansen, O. and Johansen, J. and Andersen, L. and Evensen, J. F.},
	doi = {10.1016/s0140-6736(03)14361-9},
	issn = {0140-6736},
	journal = {Lancet},
	keywords = {Adult Aged Carcinoma, Squamous Cell/*radiotherapy Denmark Dose Fractionation, Radiation Dose-Response Relationship, Radiation Female Follow-Up Studies Head and Neck Neoplasms/*radiotherapy Humans Male Middle Aged Nimorazole/therapeutic use Proportional Hazards Models Radiation-Sensitizing Agents/therapeutic use Radiotherapy Dosage/*standards Survival Rate Treatment Outcome},
	note = {1474-547x Overgaard, Jens Hansen, Hanne Sand Specht, Lena Overgaard, Marie Grau, Cai Andersen, Elo Bentzen, Jens Bastholt, Lars Hansen, Olfred Johansen, J{\o}rgen Andersen, Lisbeth Evensen, Jan F Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't England 2003/09/27 Lancet. 2003 Sep 20;362(9388):933-40. doi: 10.1016/s0140-6736(03)14361-9.},
	number = {9388},
	pages = {933-40},
	title = {Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial},
	type = {Journal Article},
	volume = {362},
	year = {2003},
	bdsk-url-1 = {https://doi.org/10.1016/s0140-6736(03)14361-9}}

@article{RN229,
	abstract = {BACKGROUND: Although head and neck cancer can be cured by radiotherapy, the optimum treatment time for locoregional control is unclear. We aimed to find out whether shortening of treatment time by use of six instead of five radiotherapy fractions per week improves the tumour response in squamous-cell carcinoma. METHODS: We did a multicentre, controlled, randomised trial. Between January, 1992, and December, 1999, of 1485 patients treated with primary radiotherapy alone, 1476 eligible patients were randomly assigned five (n=726) or six (n=750) fractions per week at the same total dose and fraction number (66-68 Gy in 33-34 fractions to all tumour sites except well-differentiated T1 glottic tumours, which were treated with 62 Gy). All patients, except those with glottic cancers, also received the hypoxic radiosensitiser nimorazole. Analysis was by intention to treat. FINDINGS: More than 97% of the patients received the planned total dose. Median overall treatment times were 39 days (six-fraction group) and 46 days (five-fraction group). Overall 5-year locoregional control rates were 70% and 60% for the six-fraction and five-fraction groups, respectively (p=0.0005). The whole benefit of shortening of treatment time was seen for primary tumour control (76 vs 64% for six and five fractions, p=0.0001), but was non-significant for neck-node control. Six compared with five fractions per week improved preservation of the voice among patients with laryngeal cancer (80 vs 68%, p=0.007). Disease-specific survival improved (73 vs 66% for six and five fractions, p=0.01) but not overall survival. Acute morbidity was significantly more frequent with six than with five fractions, but was transient. INTERPRETATION: The shortening of overall treatment time by increase of the weekly number of fractions is beneficial in patients with head and neck cancer. The six-fractions-weekly regimen has become the standard treatment in Denmark.},
	author = {Overgaard, J. and Hansen, H. S. and Specht, L. and Overgaard, M. and Grau, C. and Andersen, E. and Bentzen, J. and Bastholt, L. and Hansen, O. and Johansen, J. and Andersen, L. and Evensen, J. F.},
	doi = {10.1016/s0140-6736(03)14361-9},
	issn = {0140-6736},
	journal = {Lancet},
	keywords = {Adult Aged Carcinoma, Squamous Cell/*radiotherapy Denmark Dose Fractionation, Radiation Dose-Response Relationship, Radiation Female Follow-Up Studies Head and Neck Neoplasms/*radiotherapy Humans Male Middle Aged Nimorazole/therapeutic use Proportional Hazards Models Radiation-Sensitizing Agents/therapeutic use Radiotherapy Dosage/*standards Survival Rate Treatment Outcome},
	note = {1474-547x Overgaard, Jens Hansen, Hanne Sand Specht, Lena Overgaard, Marie Grau, Cai Andersen, Elo Bentzen, Jens Bastholt, Lars Hansen, Olfred Johansen, J{\o}rgen Andersen, Lisbeth Evensen, Jan F Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't England 2003/09/27 Lancet. 2003 Sep 20;362(9388):933-40. doi: 10.1016/s0140-6736(03)14361-9.},
	number = {9388},
	pages = {933-40},
	title = {Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial},
	type = {Journal Article},
	volume = {362},
	year = {2003},
	bdsk-url-1 = {https://doi.org/10.1016/s0140-6736(03)14361-9}}

@article{RN41,
	abstract = {AIMS: To improve the interpretation of immunohistochemistry (IHC) staining results the use of a tissue microarray technique was established in a routine setting. METHODS: A tissue microarray was constructed by harvesting 600 microm tissue cores from paraffin wax embedded samples available in a routine pathology department. The punches originating from non-tumorous tissue were placed on host paraffin wax blocks. The microarray contained 12 different tissue samples, with a wide antigen profile and a dimension of 3.5 x 3 mm. One section of the multitissue array was placed as an "internal" positive control on each slide of the patient tissue to undergo identical immunohistochemical procedures. RESULTS: Using the tissue microarray technique as a tool for internal quality control, the interpretation of immunohistochemical staining of more than 20 different antigens in routine IHC was improved. The tissue microarray did not influence the staining results in conventional IHC or in different automated IHC settings. CONCLUSION: The regular use of an institution adapted tissue microarray would be useful for internal positive control in IHC to enable different laboratory demands. Furthermore, this technique improves the evaluation of staining results in IHC.},
	author = {Packeisen, J. and Buerger, H. and Krech, R. and Boecker, W.},
	doi = {10.1136/jcp.55.8.613},
	issn = {0021-9746 (Print) 0021-9746 (Linking)},
	journal = {J Clin Pathol},
	keywords = {Antigens/*analysis Biopsy, Needle Humans Immunohistochemistry *Oligonucleotide Array Sequence Analysis Paraffin Embedding Quality Control},
	note = {Packeisen, J Buerger, H Krech, R Boecker, W eng Research Support, Non-U.S. Gov't England J Clin Pathol. 2002 Aug;55(8):613-5. doi: 10.1136/jcp.55.8.613.},
	number = {8},
	pages = {613-5},
	title = {Tissue microarrays: a new approach for quality control in immunohistochemistry},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1769722/pdf/jcp05500613.pdf},
	volume = {55},
	year = {2002},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1769722/pdf/jcp05500613.pdf},
	bdsk-url-2 = {https://doi.org/10.1136/jcp.55.8.613}}

@article{RN213,
	abstract = {OBJECTIVES: Laser therapy is becoming a more precise, minimally invasive alternative for tumor ablation. Recent reports confirm successful palliation of pain and functional disabilities in patients with advanced deep carcinoma of the head and neck using interstitial laser phototherapy (ILT). STUDY DESIGN, PATIENTS, AND METHODS: The current study describes an ongoing Phase II trial of neodymium/yttrium-aluminum-garnet (Nd:YAG) laser therapy for palliation of advanced head and neck cancer. A total of 40 advanced cancer patients have been entered into this protocol (25 men and 15 women). RESULTS: Nineteen of these patients had no evidence of recurrence after ILT with an average follow-up of 11 months (range, 2 to 24 mo). Currently, 19 of these patients are alive, 14 with tumor remission and six with persistent disease. A total of 79 tumor sites received ILT with 43 (54.5%) completely ablated. Stratified by tumor site, ILT led to a complete response in 21 of 24 in the oral cavity, eight of 28 neck tumors, four of 10 in skin, and 10 of 17 in other sites. The procedure was well tolerated in most cases and was repeated at intervals in patients with residual disease or recurrences for a total of 118 laser treatments (average, 2.95 treatments per patient). CONCLUSIONS: The results suggest that ILT can be performed safely and repeated as needed, and may be less costly than conventional surgery for head and neck cancer. However, additional follow-up is needed to obtain convincing evidence of long-term therapeutic benefits.},
	author = {Paiva, M. B. and Blackwell, K. E. and Saxton, R. E. and Calcaterra, T. C. and Ward, P. H. and Soudant, J. and Castro, D. J.},
	doi = {10.1097/00005537-199809000-00003},
	issn = {0023-852X (Print) 0023-852x},
	journal = {Laryngoscope},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/diagnostic imaging/*surgery Female Follow-Up Studies Head and Neck Neoplasms/diagnostic imaging/*surgery Humans Laser Therapy/*methods Male Middle Aged Neoplasm Recurrence, Local/*surgery *Palliative Care Preoperative Care Remission Induction Treatment Outcome Ultrasonography},
	note = {Paiva, M B Blackwell, K E Saxton, R E Calcaterra, T C Ward, P H Soudant, J Castro, D J CA65053-O1R/CA/NCI NIH HHS/United States Clinical Trial Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. United States 1998/09/17 Laryngoscope. 1998 Sep;108(9):1277-83. doi: 10.1097/00005537-199809000-00003.},
	number = {9},
	pages = {1277-83},
	title = {Palliative laser therapy for recurrent head and neck cancer: a Phase II clinical study},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1097/00005537-199809000-00003?download=true},
	volume = {108},
	year = {1998},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1097/00005537-199809000-00003?download=true},
	bdsk-url-2 = {https://doi.org/10.1097/00005537-199809000-00003}}

@article{RN214,
	abstract = {BACKGROUND: The conventional treatment for patients with upper airway obstruction secondary to malignancy is a tracheostomy. Although this effectively resolves the problem, a tracheostomy can be associated with complications and is irreversible in most patients. An alternative is to debulk part of the tumor causing airway obstruction to maintain the airway until the definitive procedure. METHODS: The clinical course of 43 patients who underwent laser debulking for airway obstruction caused by laryngeal or hypopharyngeal malignancies was retrospectively studied. We present our technique of laser debulking and the efficacy of the procedure in avoiding a tracheostomy. RESULTS: Fourteen patients who underwent this procedure received palliative treatment only. The number of debulking procedures per patient ranged from one to six, with a mean of 1.9 episodes. Although these patients had a higher comorbid burden, none were thought unsuitable for the procedure. A tracheostomy was avoided in 91% of patients. No laser-related complications were encountered. CONCLUSIONS: Laser debulking is a viable alternative to tracheostomy in patients with malignant upper airway obstruction.},
	author = {Paleri, V. and Stafford, F. W. and Sammut, M. S.},
	doi = {10.1002/hed.20153},
	issn = {1043-3074 (Print) 1043-3074},
	journal = {Head Neck},
	keywords = {Aged Aged, 80 and over Airway Obstruction/etiology/*surgery Female Follow-Up Studies Hemostasis, Surgical Humans Hypopharyngeal Neoplasms/complications/*surgery Laryngeal Neoplasms/complications/*surgery Laryngoscopy Laser Therapy/*methods Male Middle Aged Neoplasm Invasiveness Palliative Care Respiratory Sounds/etiology Retrospective Studies Tracheostomy},
	note = {Paleri, Vinidh Stafford, Frank William Sammut, Mario S Journal Article United States 2005/01/27 Head Neck. 2005 Apr;27(4):296-301. doi: 10.1002/hed.20153.},
	number = {4},
	pages = {296-301},
	title = {Laser debulking in malignant upper airway obstruction},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hed.20153?download=true},
	volume = {27},
	year = {2005},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hed.20153?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/hed.20153}}

@article{RN339,
	author = {Paz, I. B. and Cook, N. and Odom-Maryon, T. and Xie, Y. and Wilczynski, S. P.},
	doi = {10.1002/(sici)1097-0142(19970201)79:3<595::aid-cncr24>3.0.co;2-y},
	issn = {0008-543X (Print) 0008-543X (Linking)},
	journal = {Cancer},
	keywords = {Carcinoma, Squamous Cell/secondary/*virology DNA Probes DNA, Viral/isolation & purification Female Head and Neck Neoplasms/pathology/*virology Humans Incidence Lymphatic Metastasis Male Neoplasm Staging Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/complications Polymerase Chain Reaction Proportional Hazards Models Risk Factors Survival Analysis Tonsillar Neoplasms/pathology/*virology Tumor Virus Infections/complications},
	number = {3},
	pages = {595-604},
	title = {Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9028373},
	volume = {79},
	year = {1997},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/9028373},
	bdsk-url-2 = {https://doi.org/10.1002/(sici)1097-0142(19970201)79:3%3C595::aid-cncr24%3E3.0.co;2-y}}

@article{RN82,
	abstract = {BACKGROUND: Certain strains of human papillomavirus (HPV) have been shown to be etiologically related to the development of uterine cervical and other genital cancers, but their role in the development of malignancies at other sites is less well established. Previous studies have shown HPV DNA in tumors of the head and neck, but its prevalence has varied depending on the detection methods and the types of tumor and/or tissue examined. This study was undertaken to estimate the frequency of HPV DNA in squamous cell carcinoma (SCC) at different sites of the esophagus, head and neck and to compare the clinical behavior of HPV positive and negative tumors. METHODS: DNA was extracted from frozen tissue of 167 SCCs of the esophagus, head and neck. The DNA was screened for HPV sequences by polymerase chain reaction with two sets of consensus primers, one to a conserved region in the L1 gene (MY09/ MY11) and the other to a conserved region in the E1 open reading frame (IU/IWDO). The products were run on agarose gels, detected by ethidium bromide staining, and then the gels were subjected to Southern blot analysis and hybridized with probes specific to HPV 6, 16, and 18. All tumors found to be HPV positive with the consensus primers were amplified with type specific primers, and in selected cases the presence of HPV DNA was confirmed by restriction enzyme digestion of the tumor DNA with conventional Southern blot analysis. RESULTS: Overall, HPV sequences were found in 25 of 167 tumors (15%), but HPV was detected most frequently in tumors in Waldeyer's tonsillar ring. In that area, 9 of 15 (60%) were HPV positive. No HPV DNA was detected in 11 esophageal SCCs, 7 tumors of the pharynx/hypopharynx, or 6 pyriform sinus carcinomas. HPV DNA was detected in the following tumor sites: 1 of 28 (3.6%) in the larynx, 1 of 10 (10%) in the oral cavity, 5 of 39 (12.8%) in the tongue, 2 of 15 (13.5%) in the floor of the mouth, 3 of 21 (14.3%) supraglottic, and 1 of 7 (14.3%) in the lip. A high incidence of HPV DNA was also found in metastatic tumors located in cervical lymph nodes for which no primary site was clinically identified (3 of 8, 37.5%). With respect to age, gender, and tobacco and alcohol consumption, analysis of clinical data obtained by retrospective review showed no difference between patients with HPV DNA in their tumors and those in which no HPV was detected. However, HPV positive patients had larger tumors (P = 0.09) and a higher incidence of lymph node metastasis (P = 0.003). In spite of the higher stage of disease at presentation in HPV positive patients, there was no significant difference in 3-year survival rates between HPV positive patients and HPV negative patients (43.1% vs. 48.8%, respectively). Median follow-up was 27 months. CONCLUSIONS: In the head and neck, HPV-associated SCC had site specificity with the viral DNA frequently found in tumors in Waldeyer's tonsillar ring. Patients with HPV positive tumors presented with a higher stage of disease than patients with HPV negative tumors, but there was no significant difference in the 3-year survival rates between these two groups of patients.},
	author = {Paz, I. B. and Cook, N. and Odom-Maryon, T. and Xie, Y. and Wilczynski, S. P.},
	doi = {10.1002/(sici)1097-0142(19970201)79:3<595::aid-cncr24>3.0.co;2-y},
	issn = {0008-543X (Print) 0008-543X (Linking)},
	journal = {Cancer},
	keywords = {Carcinoma, Squamous Cell/secondary/*virology DNA Probes DNA, Viral/isolation & purification Female Head and Neck Neoplasms/pathology/*virology Humans Incidence Lymphatic Metastasis Male Neoplasm Staging Papillomaviridae/genetics/*isolation & purification Papillomavirus Infections/complications Polymerase Chain Reaction Proportional Hazards Models Risk Factors Survival Analysis Tonsillar Neoplasms/pathology/*virology Tumor Virus Infections/complications},
	note = {Paz, I B Cook, N Odom-Maryon, T Xie, Y Wilczynski, S P eng K12 CA 01727-03/CA/NCI NIH HHS/ R29 CA 53005/CA/NCI NIH HHS/ Research Support, U.S. Gov't, P.H.S. 1997/02/01 Cancer. 1997 Feb 1;79(3):595-604. doi: 10.1002/(sici)1097-0142(19970201)79:3<595::aid-cncr24>3.0.co;2-y.},
	number = {3},
	pages = {595-604},
	title = {Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring},
	type = {Journal Article},
	url = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/%28SICI%291097-0142%2819970201%2979%3A3%3C595%3A%3AAID-CNCR24%3E3.0.CO%3B2-Y?download=true},
	volume = {79},
	year = {1997},
	bdsk-url-1 = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/%28SICI%291097-0142%2819970201%2979%3A3%3C595%3A%3AAID-CNCR24%3E3.0.CO%3B2-Y?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/(sici)1097-0142(19970201)79:3%3C595::aid-cncr24%3E3.0.co;2-y}}

@article{RN250,
	abstract = {PURPOSE: This study was designed to determine in a prospective randomized trial the optimal dose of conventionally fractionated postoperative radiotherapy for advanced head and neck cancer in relation to clinical and pathologic risk factors. METHODS AND MATERIALS: Between January 1983 and March 1991, 302 patients were enrolled on the study. This analysis is based on the first 240 patients entered through September 1989, of whom 221 (92%) had AJC Stage III or IV cancers of the oral cavity, oropharynx, hypopharynx, or larynx. The patients were stratified by postulated risk factors and randomized to one of three dose levels ranging between 52.2 Gy and 68.4 Gy, all given in daily doses of 1.8 Gy. Patients receiving > 57.6 Gy had a field reduction at this dose level such that boosts were only given to sites of increased risk. RESULTS: The overall crude and actuarial 2-year local-regional recurrence rates were 25.4% and 26%, respectively. Patients who received a dose of < or = 54 Gy had a significantly higher primary failure rate than those receiving > or = 57.6 Gy (p = 0.02). No significant dose response could be demonstrated above 57.6 Gy except for patients with extracapsular nodal disease in the neck in whom the recurrence rate was significantly higher at 57.6 Gy than at > or = 63 Gy. Analysis of prognostic factors predictive of local-regional recurrence showed that the only variable of independent significance was extracapsular nodal disease. However, clusters of two or more of the following risk factors were associated with a progressively increased risk of recurrence: oral cavity primary, mucosal margins close or positive, nerve invasion, > or = 2 positive lymph nodes, largest node > 3 cm, treatment delay greater than 6 weeks, and Zubrod performance status > or = 2. Moderate to severe complications of combined treatment occurred in 7.1% of patients; these were more frequent in patients who received > or = 63 Gy. CONCLUSION: With daily fractions of 1.7 Gy, a minimum tumor dose of 57.6 Gy to the whole operative bed should be delivered with a boost of 63 Gy being given to sites of increased risk, especially regions of the neck where extracapsular nodal disease is present. Treatment should be started as soon as possible after surgery. Dose escalation above 63 Gy at 1.8 Gy per day does not appear to improve the therapeutic ratio.},
	author = {Peters, L. J. and Goepfert, H. and Ang, K. K. and Byers, R. M. and Maor, M. H. and Guillamondegui, O. and Morrison, W. H. and Weber, R. S. and Garden, A. S. and Frankenthaler, R. A. and et al.},
	doi = {10.1016/0360-3016(93)90167-t},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/epidemiology/*radiotherapy/surgery Combined Modality Therapy Female Head and Neck Neoplasms/epidemiology/*radiotherapy/surgery Humans Hypopharyngeal Neoplasms/epidemiology/radiotherapy/surgery Laryngeal Neoplasms/epidemiology/radiotherapy/surgery Male Middle Aged Mouth Neoplasms/epidemiology/radiotherapy/surgery Neoplasm Recurrence, Local/epidemiology Oropharyngeal Neoplasms/epidemiology/radiotherapy/surgery Postoperative Period Prospective Studies Radiotherapy Dosage Survival Rate},
	note = {Peters, L J Goepfert, H Ang, K K Byers, R M Maor, M H Guillamondegui, O Morrison, W H Weber, R S Garden, A S Frankenthaler, R A CA06294/CA/NCI NIH HHS/United States CA16627/CA/NCI NIH HHS/United States Clinical Trial Journal Article Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S. United States 1993/04/30 Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):3-11. doi: 10.1016/0360-3016(93)90167-t.},
	number = {1},
	pages = {3-11},
	title = {Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial},
	type = {Journal Article},
	url = {https://www.redjournal.org/article/0360-3016(93)90167-T/pdf},
	volume = {26},
	year = {1993},
	bdsk-url-1 = {https://www.redjournal.org/article/0360-3016(93)90167-T/pdf},
	bdsk-url-2 = {https://doi.org/10.1016/0360-3016(93)90167-t}}

@article{RN251,
	abstract = {PURPOSE: This study was designed to determine in a prospective randomized trial the optimal dose of conventionally fractionated postoperative radiotherapy for advanced head and neck cancer in relation to clinical and pathologic risk factors. METHODS AND MATERIALS: Between January 1983 and March 1991, 302 patients were enrolled on the study. This analysis is based on the first 240 patients entered through September 1989, of whom 221 (92%) had AJC Stage III or IV cancers of the oral cavity, oropharynx, hypopharynx, or larynx. The patients were stratified by postulated risk factors and randomized to one of three dose levels ranging between 52.2 Gy and 68.4 Gy, all given in daily doses of 1.8 Gy. Patients receiving > 57.6 Gy had a field reduction at this dose level such that boosts were only given to sites of increased risk. RESULTS: The overall crude and actuarial 2-year local-regional recurrence rates were 25.4% and 26%, respectively. Patients who received a dose of < or = 54 Gy had a significantly higher primary failure rate than those receiving > or = 57.6 Gy (p = 0.02). No significant dose response could be demonstrated above 57.6 Gy except for patients with extracapsular nodal disease in the neck in whom the recurrence rate was significantly higher at 57.6 Gy than at > or = 63 Gy. Analysis of prognostic factors predictive of local-regional recurrence showed that the only variable of independent significance was extracapsular nodal disease. However, clusters of two or more of the following risk factors were associated with a progressively increased risk of recurrence: oral cavity primary, mucosal margins close or positive, nerve invasion, > or = 2 positive lymph nodes, largest node > 3 cm, treatment delay greater than 6 weeks, and Zubrod performance status > or = 2. Moderate to severe complications of combined treatment occurred in 7.1% of patients; these were more frequent in patients who received > or = 63 Gy. CONCLUSION: With daily fractions of 1.7 Gy, a minimum tumor dose of 57.6 Gy to the whole operative bed should be delivered with a boost of 63 Gy being given to sites of increased risk, especially regions of the neck where extracapsular nodal disease is present. Treatment should be started as soon as possible after surgery. Dose escalation above 63 Gy at 1.8 Gy per day does not appear to improve the therapeutic ratio.},
	author = {Peters, L. J. and Goepfert, H. and Ang, K. K. and Byers, R. M. and Maor, M. H. and Guillamondegui, O. and Morrison, W. H. and Weber, R. S. and Garden, A. S. and Frankenthaler, R. A. and et al.},
	doi = {10.1016/0360-3016(93)90167-t},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/epidemiology/*radiotherapy/surgery Combined Modality Therapy Female Head and Neck Neoplasms/epidemiology/*radiotherapy/surgery Humans Hypopharyngeal Neoplasms/epidemiology/radiotherapy/surgery Laryngeal Neoplasms/epidemiology/radiotherapy/surgery Male Middle Aged Mouth Neoplasms/epidemiology/radiotherapy/surgery Neoplasm Recurrence, Local/epidemiology Oropharyngeal Neoplasms/epidemiology/radiotherapy/surgery Postoperative Period Prospective Studies Radiotherapy Dosage Survival Rate},
	note = {Peters, L J Goepfert, H Ang, K K Byers, R M Maor, M H Guillamondegui, O Morrison, W H Weber, R S Garden, A S Frankenthaler, R A CA06294/CA/NCI NIH HHS/United States CA16627/CA/NCI NIH HHS/United States Clinical Trial Journal Article Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S. United States 1993/04/30 Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):3-11. doi: 10.1016/0360-3016(93)90167-t.},
	number = {1},
	pages = {3-11},
	title = {Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial},
	type = {Journal Article},
	volume = {26},
	year = {1993},
	bdsk-url-1 = {https://doi.org/10.1016/0360-3016(93)90167-t}}

@article{RN177,
	abstract = {DEFINITION: Cancer of unknown primary (CUP) origin refers to patients who present with histologicaly confirmed metastatic cancer in whom a detailed medical history, complete physical examination, including pelvic and rectal examination, full blood count and biochemistry, urinalysis and stool occult blood testing, hisinpathological review oJ biopsy speimens with the use of immunohistochemistry, chest radiography, computed tomography of the abdomen and pelvis, and in certain cases mammography, fail to identify the primary site. EPIDEMIOLOGY OF CUP: The cancer of unknown primary accounts for 3%-5% of all human cancers. DIAGNOSIS OF CUP: The standard diagnostic procedure for the majority of patients includes histopathologic review of biopsy specimens with the use of immunoltistochemistry, chest radiography, computed tomography of the abdomen and pelvis, and in certain cases mamography, fail to identify the abdomen and pelvis. The four common histologic diagnoses are: adenocarcinoma (70%), poorly differentiated carcinoma (20%), squamous carcinoma (10%), and poorly differentiated neoplasms (5%). PROGNOSIS OF CUP: The prognosis for most patients with unknown primary tumors is poor, with survival often less than 6 months from diagnosis. THERAPY OF CUP: Based on clinical and pathologic features, approximately 40% of patients can be categorized within subsets for which specific treatment has been defined. Empiric therapy is an option for the remaining 60% of patients. CONCLUSION: Metastatic tumors of unknown origin have a unique clinical presentation due to a specific biology. Insight into the molecular biology of unknown primary tumors will be essential for the development of more effective treatments.},
	author = {Petrovi{\'c}, D. and Muzikravi{\'c}, L. and Jovanovi{\'c}, D.},
	doi = {10.2298/mpns0702029p},
	issn = {0025-8105 (Print) 0025-8105},
	journal = {Med Pregl},
	keywords = {Humans Neoplasm Metastasis/*diagnosis/*therapy Neoplasms, Unknown Primary/*diagnosis/therapy},
	note = {Petrovi{\'c}, Dragana Muzikravi{\'c}, Ljubomir Jovanovi{\'c}, Darjana English Abstract Journal Article Review Serbia 2007/09/15 Med Pregl. 2007 Jan-Feb;60(1-2):29-36. doi: 10.2298/mpns0702029p.},
	number = {1-2},
	pages = {29-36},
	title = {[Metastases of unknown origin--principles of diagnosis and treatment]},
	type = {Journal Article},
	url = {http://www.doiserbia.nb.rs/img/doi/0025-8105/2007/0025-81050702029P.pdf},
	volume = {60},
	year = {2007},
	bdsk-url-1 = {http://www.doiserbia.nb.rs/img/doi/0025-8105/2007/0025-81050702029P.pdf},
	bdsk-url-2 = {https://doi.org/10.2298/mpns0702029p}}

@article{RN247,
	abstract = {PURPOSE: To evaluate dose concepts in postoperative irradiation of carcinomas of the upper aerodigestive tract according to the radicality of resection. PATIENTS AND METHODS: In a retrospective analysis, the charts of 257 patients with histologically-proven carcinoma of the upper aerodigestive tract (40 T1, 80 T2, 53 T3, 84 T4 tumors, with nodal involvement in 181 cases) were reviewed according to the radicality of resection and dose of irradiation administered. Sixty-four patients had tumor-free resection margins (> 3 mm), 66 patients had close resection margins (< 3 mm), and 101 patients had R1 resections, and 26 patients had R2 resections. A median dose of 56 Gy was applied to the primary tumor bed and the cervical lymphatics (2 Gy/fraction, 5 fractions/week). In cases of R1 or R2 resection, or of close margins (< 3 mm), the tumor bed or, respectively, tumor residuals were boosted with doses up to a median of 66 Gy. Locoregional tumor control and survival was investigated by uni- and multivariate analyses according to T-, N-stage, grade of resection, total dose of radiation, and presence or absence of extracapsular tumor spread and lymphangiosis carcinomatosa. RESULTS: An overall 3- and 5-year survival rate of 60% and 45%, respectively, was achieved. Rates for freedom from locoregional recurrence were 77% and 72% at 3 and 5 years, respectively. The survival rates according to the grade of resection at 5 years were 67% for patients resected with tumor-free margins, 59% for patients resected with close margins, 26% for patients with R1 resection, and 27% for patients with R2 resection. Within a median follow-up period of 4.7 years for living patients, a total of 67 recurrences (26%) were observed (in 9% of patients resected with tumor-free margins, in 27% with close margins, in 37% of R1 resected, and in 19% of R2 resected patients). Freedom from locoregional recurrence at 3 years was achieved in 100% of the patients resected with tumor-free margins, in 92% of patients resected with close surgical margins, in 87% of R1 and 69% of R2 resected patients. In multivariate Cox-regression analysis, the variables grade of resection (p = 0.00031) and total dose of irradiation (p = 0.0046) were found as factors influencing locoregional control. Variables influencing survival according to multivariate analysis are T-stage (p = 0.0057), N-stage (p = 0.024), grade of resection (p = 0.000015), total dose of irradiation (p < 0. 000000). Extracapsular tumor spread and lymphangiosis carcinomatosa are factors of borderline significance (p = 0.055, p = 0.066). CONCLUSION: In postoperative radiotherapy of head and neck carcinomas, doses adapted to the risk of locoregional recurrent disease should be applied. Patients with R1 and R2 resections should be treated with doses of more than 68 Gy (2 Gy/fraction, 5 fractions/week) (with close margins [< 3 mm] more than 66 Gy) to achieve an improvement in locoregional control and survival.},
	author = {Pfreundner, L. and Willner, J. and Marx, A. and Hoppe, F. and Beckmann, G. and Flentje, M.},
	doi = {10.1016/s0360-3016(00)00514-9},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carcinoma/drug therapy/*radiotherapy/*surgery Combined Modality Therapy Female Humans Hypopharyngeal Neoplasms/drug therapy/radiotherapy/surgery Male Middle Aged Multivariate Analysis Neoplasm Recurrence, Local/pathology Neoplasm, Residual Oropharyngeal Neoplasms/drug therapy/radiotherapy/surgery Pharyngeal Neoplasms/drug therapy/*radiotherapy/*surgery Retrospective Studies Survival Rate},
	note = {Pfreundner, L Willner, J Marx, A Hoppe, F Beckmann, G Flentje, M Journal Article Review United States 2000/07/13 Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1287-97. doi: 10.1016/s0360-3016(00)00514-9.},
	number = {5},
	pages = {1287-97},
	title = {The influence of the radicality of resection and dose of postoperative radiation therapy on local control and survival in carcinomas of the upper aerodigestive tract},
	type = {Journal Article},
	url = {https://www.redjournal.org/article/S0360-3016(00)00514-9/fulltext},
	volume = {47},
	year = {2000},
	bdsk-url-1 = {https://www.redjournal.org/article/S0360-3016(00)00514-9/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s0360-3016(00)00514-9}}

@article{RN248,
	abstract = {PURPOSE: To evaluate dose concepts in postoperative irradiation of carcinomas of the upper aerodigestive tract according to the radicality of resection. PATIENTS AND METHODS: In a retrospective analysis, the charts of 257 patients with histologically-proven carcinoma of the upper aerodigestive tract (40 T1, 80 T2, 53 T3, 84 T4 tumors, with nodal involvement in 181 cases) were reviewed according to the radicality of resection and dose of irradiation administered. Sixty-four patients had tumor-free resection margins (> 3 mm), 66 patients had close resection margins (< 3 mm), and 101 patients had R1 resections, and 26 patients had R2 resections. A median dose of 56 Gy was applied to the primary tumor bed and the cervical lymphatics (2 Gy/fraction, 5 fractions/week). In cases of R1 or R2 resection, or of close margins (< 3 mm), the tumor bed or, respectively, tumor residuals were boosted with doses up to a median of 66 Gy. Locoregional tumor control and survival was investigated by uni- and multivariate analyses according to T-, N-stage, grade of resection, total dose of radiation, and presence or absence of extracapsular tumor spread and lymphangiosis carcinomatosa. RESULTS: An overall 3- and 5-year survival rate of 60% and 45%, respectively, was achieved. Rates for freedom from locoregional recurrence were 77% and 72% at 3 and 5 years, respectively. The survival rates according to the grade of resection at 5 years were 67% for patients resected with tumor-free margins, 59% for patients resected with close margins, 26% for patients with R1 resection, and 27% for patients with R2 resection. Within a median follow-up period of 4.7 years for living patients, a total of 67 recurrences (26%) were observed (in 9% of patients resected with tumor-free margins, in 27% with close margins, in 37% of R1 resected, and in 19% of R2 resected patients). Freedom from locoregional recurrence at 3 years was achieved in 100% of the patients resected with tumor-free margins, in 92% of patients resected with close surgical margins, in 87% of R1 and 69% of R2 resected patients. In multivariate Cox-regression analysis, the variables grade of resection (p = 0.00031) and total dose of irradiation (p = 0.0046) were found as factors influencing locoregional control. Variables influencing survival according to multivariate analysis are T-stage (p = 0.0057), N-stage (p = 0.024), grade of resection (p = 0.000015), total dose of irradiation (p < 0. 000000). Extracapsular tumor spread and lymphangiosis carcinomatosa are factors of borderline significance (p = 0.055, p = 0.066). CONCLUSION: In postoperative radiotherapy of head and neck carcinomas, doses adapted to the risk of locoregional recurrent disease should be applied. Patients with R1 and R2 resections should be treated with doses of more than 68 Gy (2 Gy/fraction, 5 fractions/week) (with close margins [< 3 mm] more than 66 Gy) to achieve an improvement in locoregional control and survival.},
	author = {Pfreundner, L. and Willner, J. and Marx, A. and Hoppe, F. and Beckmann, G. and Flentje, M.},
	doi = {10.1016/s0360-3016(00)00514-9},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carcinoma/drug therapy/*radiotherapy/*surgery Combined Modality Therapy Female Humans Hypopharyngeal Neoplasms/drug therapy/radiotherapy/surgery Male Middle Aged Multivariate Analysis Neoplasm Recurrence, Local/pathology Neoplasm, Residual Oropharyngeal Neoplasms/drug therapy/radiotherapy/surgery Pharyngeal Neoplasms/drug therapy/*radiotherapy/*surgery Retrospective Studies Survival Rate},
	note = {Pfreundner, L Willner, J Marx, A Hoppe, F Beckmann, G Flentje, M Journal Article Review United States 2000/07/13 Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1287-97. doi: 10.1016/s0360-3016(00)00514-9.},
	number = {5},
	pages = {1287-97},
	title = {The influence of the radicality of resection and dose of postoperative radiation therapy on local control and survival in carcinomas of the upper aerodigestive tract},
	type = {Journal Article},
	volume = {47},
	year = {2000},
	bdsk-url-1 = {https://doi.org/10.1016/s0360-3016(00)00514-9}}

@article{RN249,
	abstract = {PURPOSE: To evaluate dose concepts in postoperative irradiation of carcinomas of the upper aerodigestive tract according to the radicality of resection. PATIENTS AND METHODS: In a retrospective analysis, the charts of 257 patients with histologically-proven carcinoma of the upper aerodigestive tract (40 T1, 80 T2, 53 T3, 84 T4 tumors, with nodal involvement in 181 cases) were reviewed according to the radicality of resection and dose of irradiation administered. Sixty-four patients had tumor-free resection margins (> 3 mm), 66 patients had close resection margins (< 3 mm), and 101 patients had R1 resections, and 26 patients had R2 resections. A median dose of 56 Gy was applied to the primary tumor bed and the cervical lymphatics (2 Gy/fraction, 5 fractions/week). In cases of R1 or R2 resection, or of close margins (< 3 mm), the tumor bed or, respectively, tumor residuals were boosted with doses up to a median of 66 Gy. Locoregional tumor control and survival was investigated by uni- and multivariate analyses according to T-, N-stage, grade of resection, total dose of radiation, and presence or absence of extracapsular tumor spread and lymphangiosis carcinomatosa. RESULTS: An overall 3- and 5-year survival rate of 60% and 45%, respectively, was achieved. Rates for freedom from locoregional recurrence were 77% and 72% at 3 and 5 years, respectively. The survival rates according to the grade of resection at 5 years were 67% for patients resected with tumor-free margins, 59% for patients resected with close margins, 26% for patients with R1 resection, and 27% for patients with R2 resection. Within a median follow-up period of 4.7 years for living patients, a total of 67 recurrences (26%) were observed (in 9% of patients resected with tumor-free margins, in 27% with close margins, in 37% of R1 resected, and in 19% of R2 resected patients). Freedom from locoregional recurrence at 3 years was achieved in 100% of the patients resected with tumor-free margins, in 92% of patients resected with close surgical margins, in 87% of R1 and 69% of R2 resected patients. In multivariate Cox-regression analysis, the variables grade of resection (p = 0.00031) and total dose of irradiation (p = 0.0046) were found as factors influencing locoregional control. Variables influencing survival according to multivariate analysis are T-stage (p = 0.0057), N-stage (p = 0.024), grade of resection (p = 0.000015), total dose of irradiation (p < 0. 000000). Extracapsular tumor spread and lymphangiosis carcinomatosa are factors of borderline significance (p = 0.055, p = 0.066). CONCLUSION: In postoperative radiotherapy of head and neck carcinomas, doses adapted to the risk of locoregional recurrent disease should be applied. Patients with R1 and R2 resections should be treated with doses of more than 68 Gy (2 Gy/fraction, 5 fractions/week) (with close margins [< 3 mm] more than 66 Gy) to achieve an improvement in locoregional control and survival.},
	author = {Pfreundner, L. and Willner, J. and Marx, A. and Hoppe, F. and Beckmann, G. and Flentje, M.},
	doi = {10.1016/s0360-3016(00)00514-9},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carcinoma/drug therapy/*radiotherapy/*surgery Combined Modality Therapy Female Humans Hypopharyngeal Neoplasms/drug therapy/radiotherapy/surgery Male Middle Aged Multivariate Analysis Neoplasm Recurrence, Local/pathology Neoplasm, Residual Oropharyngeal Neoplasms/drug therapy/radiotherapy/surgery Pharyngeal Neoplasms/drug therapy/*radiotherapy/*surgery Retrospective Studies Survival Rate},
	note = {Pfreundner, L Willner, J Marx, A Hoppe, F Beckmann, G Flentje, M Journal Article Review United States 2000/07/13 Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1287-97. doi: 10.1016/s0360-3016(00)00514-9.},
	number = {5},
	pages = {1287-97},
	title = {The influence of the radicality of resection and dose of postoperative radiation therapy on local control and survival in carcinomas of the upper aerodigestive tract},
	type = {Journal Article},
	volume = {47},
	year = {2000},
	bdsk-url-1 = {https://doi.org/10.1016/s0360-3016(00)00514-9}}

@article{RN235,
	abstract = {BACKGROUND: Despite more than 70 randomised trials, the effect of chemotherapy on non-metastatic head and neck squamous-cell carcinoma remains uncertain. We did three meta-analyses of the impact of survival on chemotherapy added to locoregional treatment. METHODS: We updated data on all patients in randomised trials between 1965 and 1993. We included patients with carcinoma of the oropharynx, oral cavity, larynx, or hypopharynx. FINDINGS: The main meta-analysis of 63 trials (10,741 patients) of locoregional treatment with or without chemotherapy yielded a pooled hazard ratio of death of 0.90 (95% CI 0.85-0.94, p<0.0001), corresponding to an absolute survival benefit of 4% at 2 and 5 years in favour of chemotherapy. There was no significant benefit associated with adjuvant or neoadjuvant chemotherapy. Chemotherapy given concomitantly to radiotherapy gave significant benefits, but heterogeneity of the results prohibits firm conclusions. Meta-analysis of six trials (861 patients) comparing neoadjuvant chemotherapy plus radiotherapy with concomitant or alternating radiochemotherapy yielded a hazard ratio of 0.91 (0.79-1.06) in favour of concomitant or alternating radiochemotherapy. Three larynx-preservation trials (602 patients) compared radical surgery plus radiotherapy with neoadjuvant chemotherapy plus radiotherapy in responders or radical surgery and radiotherapy in non-responders. The hazard ratio of death in the chemotherapy arm as compared with the control arm was 1.19 (0.97-1.46). INTERPRETATION: Because the main meta-analysis showed only a small significant survival benefit in favour of chemotherapy, the routine use of chemotherapy is debatable. For larynx preservation, the non-significant negative effect of chemotherapy in the organ-preservation strategy indicates that this procedure must remain investigational.},
	author = {Pignon, J. P. and Bourhis, J. and Domenge, C. and Design{\'e}, L.},
	issn = {0140-6736 (Print) 0140-6736},
	journal = {Lancet},
	keywords = {Antineoplastic Agents/*therapeutic use Carcinoma, Squamous Cell/*mortality/radiotherapy/surgery/*therapy Chemotherapy, Adjuvant Head and Neck Neoplasms/*mortality/radiotherapy/surgery/*therapy Humans Hypopharyngeal Neoplasms/mortality/therapy Laryngeal Neoplasms/mortality/therapy Oropharyngeal Neoplasms/mortality/therapy Proportional Hazards Models Randomized Controlled Trials as Topic Treatment Outcome},
	note = {Pignon, J P Bourhis, J Domenge, C Design{\'e}, L Journal Article Meta-Analysis Research Support, Non-U.S. Gov't England 2000/04/18 Lancet. 2000 Mar 18;355(9208):949-55.},
	number = {9208},
	pages = {949-55},
	title = {Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer},
	type = {Journal Article},
	url = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)90011-4/fulltext},
	volume = {355},
	year = {2000},
	bdsk-url-1 = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)90011-4/fulltext}}

@article{RN287,
	abstract = {BACKGROUND: Despite more than 70 randomised trials, the effect of chemotherapy on non-metastatic head and neck squamous-cell carcinoma remains uncertain. We did three meta-analyses of the impact of survival on chemotherapy added to locoregional treatment. METHODS: We updated data on all patients in randomised trials between 1965 and 1993. We included patients with carcinoma of the oropharynx, oral cavity, larynx, or hypopharynx. FINDINGS: The main meta-analysis of 63 trials (10,741 patients) of locoregional treatment with or without chemotherapy yielded a pooled hazard ratio of death of 0.90 (95% CI 0.85-0.94, p<0.0001), corresponding to an absolute survival benefit of 4% at 2 and 5 years in favour of chemotherapy. There was no significant benefit associated with adjuvant or neoadjuvant chemotherapy. Chemotherapy given concomitantly to radiotherapy gave significant benefits, but heterogeneity of the results prohibits firm conclusions. Meta-analysis of six trials (861 patients) comparing neoadjuvant chemotherapy plus radiotherapy with concomitant or alternating radiochemotherapy yielded a hazard ratio of 0.91 (0.79-1.06) in favour of concomitant or alternating radiochemotherapy. Three larynx-preservation trials (602 patients) compared radical surgery plus radiotherapy with neoadjuvant chemotherapy plus radiotherapy in responders or radical surgery and radiotherapy in non-responders. The hazard ratio of death in the chemotherapy arm as compared with the control arm was 1.19 (0.97-1.46). INTERPRETATION: Because the main meta-analysis showed only a small significant survival benefit in favour of chemotherapy, the routine use of chemotherapy is debatable. For larynx preservation, the non-significant negative effect of chemotherapy in the organ-preservation strategy indicates that this procedure must remain investigational.},
	author = {Pignon, J. P. and Bourhis, J. and Domenge, C. and Design{\'e}, L.},
	issn = {0140-6736 (Print) 0140-6736},
	journal = {Lancet},
	keywords = {Antineoplastic Agents/*therapeutic use Carcinoma, Squamous Cell/*mortality/radiotherapy/surgery/*therapy Chemotherapy, Adjuvant Head and Neck Neoplasms/*mortality/radiotherapy/surgery/*therapy Humans Hypopharyngeal Neoplasms/mortality/therapy Laryngeal Neoplasms/mortality/therapy Oropharyngeal Neoplasms/mortality/therapy Proportional Hazards Models Randomized Controlled Trials as Topic Treatment Outcome},
	note = {Pignon, J P Bourhis, J Domenge, C Design{\'e}, L Journal Article Meta-Analysis Research Support, Non-U.S. Gov't England 2000/04/18 Lancet. 2000 Mar 18;355(9208):949-55.},
	number = {9208},
	pages = {949-55},
	title = {Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer},
	type = {Journal Article},
	volume = {355},
	year = {2000}}

@article{RN288,
	abstract = {BACKGROUND: Despite more than 70 randomised trials, the effect of chemotherapy on non-metastatic head and neck squamous-cell carcinoma remains uncertain. We did three meta-analyses of the impact of survival on chemotherapy added to locoregional treatment. METHODS: We updated data on all patients in randomised trials between 1965 and 1993. We included patients with carcinoma of the oropharynx, oral cavity, larynx, or hypopharynx. FINDINGS: The main meta-analysis of 63 trials (10,741 patients) of locoregional treatment with or without chemotherapy yielded a pooled hazard ratio of death of 0.90 (95% CI 0.85-0.94, p<0.0001), corresponding to an absolute survival benefit of 4% at 2 and 5 years in favour of chemotherapy. There was no significant benefit associated with adjuvant or neoadjuvant chemotherapy. Chemotherapy given concomitantly to radiotherapy gave significant benefits, but heterogeneity of the results prohibits firm conclusions. Meta-analysis of six trials (861 patients) comparing neoadjuvant chemotherapy plus radiotherapy with concomitant or alternating radiochemotherapy yielded a hazard ratio of 0.91 (0.79-1.06) in favour of concomitant or alternating radiochemotherapy. Three larynx-preservation trials (602 patients) compared radical surgery plus radiotherapy with neoadjuvant chemotherapy plus radiotherapy in responders or radical surgery and radiotherapy in non-responders. The hazard ratio of death in the chemotherapy arm as compared with the control arm was 1.19 (0.97-1.46). INTERPRETATION: Because the main meta-analysis showed only a small significant survival benefit in favour of chemotherapy, the routine use of chemotherapy is debatable. For larynx preservation, the non-significant negative effect of chemotherapy in the organ-preservation strategy indicates that this procedure must remain investigational.},
	author = {Pignon, J. P. and Bourhis, J. and Domenge, C. and Design{\'e}, L.},
	issn = {0140-6736 (Print) 0140-6736},
	journal = {Lancet},
	keywords = {Antineoplastic Agents/*therapeutic use Carcinoma, Squamous Cell/*mortality/radiotherapy/surgery/*therapy Chemotherapy, Adjuvant Head and Neck Neoplasms/*mortality/radiotherapy/surgery/*therapy Humans Hypopharyngeal Neoplasms/mortality/therapy Laryngeal Neoplasms/mortality/therapy Oropharyngeal Neoplasms/mortality/therapy Proportional Hazards Models Randomized Controlled Trials as Topic Treatment Outcome},
	note = {Pignon, J P Bourhis, J Domenge, C Design{\'e}, L Journal Article Meta-Analysis Research Support, Non-U.S. Gov't England 2000/04/18 Lancet. 2000 Mar 18;355(9208):949-55.},
	number = {9208},
	pages = {949-55},
	title = {Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer},
	type = {Journal Article},
	volume = {355},
	year = {2000}}

@article{RN237,
	abstract = {BACKGROUND: Our previous individual patient data (IPD) meta-analysis showed that chemotherapy improved survival in patients curatively treated for non-metastatic head and neck squamous cell carcinoma (HNSCC), with a higher benefit with concomitant chemotherapy. However the heterogeneity of the results limited the conclusions and prompted us to confirm the results on a more complete database by adding the randomised trials conducted between 1994 and 2000. METHODS: The updated IPD meta-analysis included trials comparing loco-regional treatment to loco-regional treatment+chemotherapy in HNSCC patients and conducted between 1965 and 2000. The log-rank-test, stratified by trial, was used to compare treatments. The hazard ratios of death were calculated. RESULTS: Twenty-four new trials, most of them of concomitant chemotherapy, were included with a total of 87 trials and 16,485 patients. The hazard ratio of death was 0.88 (p<0.0001) with an absolute benefit for chemotherapy of 4.5% at 5 years, and a significant interaction (p<0.0001) between chemotherapy timing (adjuvant, induction or concomitant) and treatment. Both direct (6 trials) and indirect comparisons showed a more pronounced benefit of the concomitant chemotherapy as compared to induction chemotherapy. For the 50 concomitant trials, the hazard ratio was 0.81 (p<0.0001) and the absolute benefit 6.5% at 5 years. There was a decreasing effect of chemotherapy with age (p=0.003, test for trend). CONCLUSION: The benefit of concomitant chemotherapy was confirmed and was greater than the benefit of induction chemotherapy.},
	author = {Pignon, J. P. and le Ma{\^\i}tre, A. and Maillard, E. and Bourhis, J.},
	doi = {10.1016/j.radonc.2009.04.014},
	issn = {0167-8140},
	journal = {Radiother Oncol},
	keywords = {Antineoplastic Agents/*therapeutic use Carcinoma, Squamous Cell/*drug therapy/radiotherapy Combined Modality Therapy Head and Neck Neoplasms/*drug therapy/radiotherapy Humans *Meta-Analysis as Topic Randomized Controlled Trials as Topic Treatment Outcome},
	note = {1879-0887 Pignon, Jean-Pierre le Ma{\^\i}tre, Aur{\'e}lie Maillard, Emilie Bourhis, Jean MACH-NC Collaborative Group Journal Article Research Support, Non-U.S. Gov't Ireland 2009/05/19 Radiother Oncol. 2009 Jul;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14.},
	number = {1},
	pages = {4-14},
	title = {Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients},
	type = {Journal Article},
	url = {https://www.thegreenjournal.com/article/S0167-8140(09)00188-1/fulltext},
	volume = {92},
	year = {2009},
	bdsk-url-1 = {https://www.thegreenjournal.com/article/S0167-8140(09)00188-1/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/j.radonc.2009.04.014}}

@article{RN240,
	abstract = {BACKGROUND: Our previous individual patient data (IPD) meta-analysis showed that chemotherapy improved survival in patients curatively treated for non-metastatic head and neck squamous cell carcinoma (HNSCC), with a higher benefit with concomitant chemotherapy. However the heterogeneity of the results limited the conclusions and prompted us to confirm the results on a more complete database by adding the randomised trials conducted between 1994 and 2000. METHODS: The updated IPD meta-analysis included trials comparing loco-regional treatment to loco-regional treatment+chemotherapy in HNSCC patients and conducted between 1965 and 2000. The log-rank-test, stratified by trial, was used to compare treatments. The hazard ratios of death were calculated. RESULTS: Twenty-four new trials, most of them of concomitant chemotherapy, were included with a total of 87 trials and 16,485 patients. The hazard ratio of death was 0.88 (p<0.0001) with an absolute benefit for chemotherapy of 4.5% at 5 years, and a significant interaction (p<0.0001) between chemotherapy timing (adjuvant, induction or concomitant) and treatment. Both direct (6 trials) and indirect comparisons showed a more pronounced benefit of the concomitant chemotherapy as compared to induction chemotherapy. For the 50 concomitant trials, the hazard ratio was 0.81 (p<0.0001) and the absolute benefit 6.5% at 5 years. There was a decreasing effect of chemotherapy with age (p=0.003, test for trend). CONCLUSION: The benefit of concomitant chemotherapy was confirmed and was greater than the benefit of induction chemotherapy.},
	author = {Pignon, J. P. and le Ma{\^\i}tre, A. and Maillard, E. and Bourhis, J.},
	doi = {10.1016/j.radonc.2009.04.014},
	issn = {0167-8140},
	journal = {Radiother Oncol},
	keywords = {Antineoplastic Agents/*therapeutic use Carcinoma, Squamous Cell/*drug therapy/radiotherapy Combined Modality Therapy Head and Neck Neoplasms/*drug therapy/radiotherapy Humans *Meta-Analysis as Topic Randomized Controlled Trials as Topic Treatment Outcome},
	note = {1879-0887 Pignon, Jean-Pierre le Ma{\^\i}tre, Aur{\'e}lie Maillard, Emilie Bourhis, Jean MACH-NC Collaborative Group Journal Article Research Support, Non-U.S. Gov't Ireland 2009/05/19 Radiother Oncol. 2009 Jul;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14.},
	number = {1},
	pages = {4-14},
	title = {Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients},
	type = {Journal Article},
	volume = {92},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1016/j.radonc.2009.04.014}}

@article{RN272,
	abstract = {BACKGROUND: Our previous individual patient data (IPD) meta-analysis showed that chemotherapy improved survival in patients curatively treated for non-metastatic head and neck squamous cell carcinoma (HNSCC), with a higher benefit with concomitant chemotherapy. However the heterogeneity of the results limited the conclusions and prompted us to confirm the results on a more complete database by adding the randomised trials conducted between 1994 and 2000. METHODS: The updated IPD meta-analysis included trials comparing loco-regional treatment to loco-regional treatment+chemotherapy in HNSCC patients and conducted between 1965 and 2000. The log-rank-test, stratified by trial, was used to compare treatments. The hazard ratios of death were calculated. RESULTS: Twenty-four new trials, most of them of concomitant chemotherapy, were included with a total of 87 trials and 16,485 patients. The hazard ratio of death was 0.88 (p<0.0001) with an absolute benefit for chemotherapy of 4.5% at 5 years, and a significant interaction (p<0.0001) between chemotherapy timing (adjuvant, induction or concomitant) and treatment. Both direct (6 trials) and indirect comparisons showed a more pronounced benefit of the concomitant chemotherapy as compared to induction chemotherapy. For the 50 concomitant trials, the hazard ratio was 0.81 (p<0.0001) and the absolute benefit 6.5% at 5 years. There was a decreasing effect of chemotherapy with age (p=0.003, test for trend). CONCLUSION: The benefit of concomitant chemotherapy was confirmed and was greater than the benefit of induction chemotherapy.},
	author = {Pignon, J. P. and le Ma{\^\i}tre, A. and Maillard, E. and Bourhis, J.},
	doi = {10.1016/j.radonc.2009.04.014},
	issn = {0167-8140},
	journal = {Radiother Oncol},
	keywords = {Antineoplastic Agents/*therapeutic use Carcinoma, Squamous Cell/*drug therapy/radiotherapy Combined Modality Therapy Head and Neck Neoplasms/*drug therapy/radiotherapy Humans *Meta-Analysis as Topic Randomized Controlled Trials as Topic Treatment Outcome},
	note = {1879-0887 Pignon, Jean-Pierre le Ma{\^\i}tre, Aur{\'e}lie Maillard, Emilie Bourhis, Jean MACH-NC Collaborative Group Journal Article Research Support, Non-U.S. Gov't Ireland 2009/05/19 Radiother Oncol. 2009 Jul;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14.},
	number = {1},
	pages = {4-14},
	title = {Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients},
	type = {Journal Article},
	volume = {92},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1016/j.radonc.2009.04.014}}

@article{RN285,
	abstract = {BACKGROUND: Our previous individual patient data (IPD) meta-analysis showed that chemotherapy improved survival in patients curatively treated for non-metastatic head and neck squamous cell carcinoma (HNSCC), with a higher benefit with concomitant chemotherapy. However the heterogeneity of the results limited the conclusions and prompted us to confirm the results on a more complete database by adding the randomised trials conducted between 1994 and 2000. METHODS: The updated IPD meta-analysis included trials comparing loco-regional treatment to loco-regional treatment+chemotherapy in HNSCC patients and conducted between 1965 and 2000. The log-rank-test, stratified by trial, was used to compare treatments. The hazard ratios of death were calculated. RESULTS: Twenty-four new trials, most of them of concomitant chemotherapy, were included with a total of 87 trials and 16,485 patients. The hazard ratio of death was 0.88 (p<0.0001) with an absolute benefit for chemotherapy of 4.5% at 5 years, and a significant interaction (p<0.0001) between chemotherapy timing (adjuvant, induction or concomitant) and treatment. Both direct (6 trials) and indirect comparisons showed a more pronounced benefit of the concomitant chemotherapy as compared to induction chemotherapy. For the 50 concomitant trials, the hazard ratio was 0.81 (p<0.0001) and the absolute benefit 6.5% at 5 years. There was a decreasing effect of chemotherapy with age (p=0.003, test for trend). CONCLUSION: The benefit of concomitant chemotherapy was confirmed and was greater than the benefit of induction chemotherapy.},
	author = {Pignon, J. P. and le Ma{\^\i}tre, A. and Maillard, E. and Bourhis, J.},
	doi = {10.1016/j.radonc.2009.04.014},
	issn = {0167-8140},
	journal = {Radiother Oncol},
	keywords = {Antineoplastic Agents/*therapeutic use Carcinoma, Squamous Cell/*drug therapy/radiotherapy Combined Modality Therapy Head and Neck Neoplasms/*drug therapy/radiotherapy Humans *Meta-Analysis as Topic Randomized Controlled Trials as Topic Treatment Outcome},
	note = {1879-0887 Pignon, Jean-Pierre le Ma{\^\i}tre, Aur{\'e}lie Maillard, Emilie Bourhis, Jean MACH-NC Collaborative Group Journal Article Research Support, Non-U.S. Gov't Ireland 2009/05/19 Radiother Oncol. 2009 Jul;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14.},
	number = {1},
	pages = {4-14},
	title = {Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients},
	type = {Journal Article},
	volume = {92},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1016/j.radonc.2009.04.014}}

@article{RN167,
	abstract = {Early detection and treatment improve the prognosis for oral cancer. Delays from the onset of symptoms to clinical diagnosis are common. Our aim is to identify factors associated with this delay. Between 1995 and 1998, we interviewed 105 consecutive patients with histologically confirmed oral cancer in Greece. If 21 or more days elapsed from the time the patient noticed major symptoms to a definitive diagnosis, we called it a delay (52% of cases). We used logistic and linear regression to estimate odds ratios of delayed diagnosis and to identify correlates of length of delay, respectively. Former smokers had a 4.3 times greater risk of delayed diagnosis compared with current smokers (95% confidence interval: 1.1-17.1). The length of delay was greater among single patients, non-smokers, or those with stage IV tumors. Clinicians should be advised that delay in the diagnosis of oral cancer occurs frequently, even in individuals who do not smoke heavily.},
	author = {Pitiphat, W. and Diehl, S. R. and Laskaris, G. and Cartsos, V. and Douglass, C. W. and Zavras, A. I.},
	issn = {0022-0345 (Print) 0022-0345},
	journal = {J Dent Res},
	keywords = {Adult Age Factors Aged Aged, 80 and over Alcohol Drinking Body Weight Carcinoma, Squamous Cell/*diagnosis/genetics Case-Control Studies Confidence Intervals Employment Female Greece Humans Linear Models Logistic Models Male Marital Status Middle Aged Mouth Neoplasms/*diagnosis/genetics Neoplasm Staging Odds Ratio Oral Health Pharyngeal Neoplasms/diagnosis/genetics Risk Factors Sex Factors Smoking Statistics, Nonparametric Time Factors},
	note = {Pitiphat, W Diehl, S R Laskaris, G Cartsos, V Douglass, C W Zavras, A I K23DE00420/DE/NIDCR NIH HHS/United States MD 626829/MD/NIMHD NIH HHS/United States MD 726655/MD/NIMHD NIH HHS/United States Comparative Study Journal Article Multicenter Study Research Support, U.S. Gov't, P.H.S. United States 2002/03/06 J Dent Res. 2002 Mar;81(3):192-7.},
	number = {3},
	pages = {192-7},
	title = {Factors associated with delay in the diagnosis of oral cancer},
	type = {Journal Article},
	volume = {81},
	year = {2002}}

@article{RN273,
	abstract = {PURPOSE: Tumor volume (TV) is one of the main reported factors determining the outcome of treatment in head-and-neck carcinomas. In this study, the prognostic impact of TV was explored in the context of a randomized trial with the patients assigned to receive standard radiotherapy (RT) alone or RT plus platinum compounds (RT alone, RT plus cisplatin, or RT plus carboplatin). METHODS AND MATERIALS: The tumor outlines were traced and digitized on each pretreatment CT slice for each of the 101 patients studied. Taking into account the magnification factor of the scan and CT slice thickness, a computer with specifically designed software calculated the TV in cubic centimeters. RESULTS: The median overall survival for the whole group of patients was 21.6 months (95% confidence interval, 13.0-30.2) and the 3-year survival rate was 40%. The addition of platinum compounds to RT (Groups 2 and 3) significantly improved the survival rate (RT alone vs. RT plus cisplatin, hazard ratio 0.36, p = 0.002; RT alone vs. RT plus carboplatin, hazard ratio 0.53, p = 0.029). In univariate analysis, the most significant parameters for survival were treatment group, total gross tumor volume (TGTV), complete response, nodal GTV, primary GTV, and performance status. In multivariate analysis, treatment group, TGTV, gender, and primary site were independent prognostic factors for survival. A prognostic threshold of 22.8 cm(3) was detected for TGTV. Patients with a TGTV of <22.8 cm(3) were more likely to achieve a complete response and had a median survival of 45.3 months, and those with a TGTV >22.8 cm(3) had a median survival of 12.3 months (log-rank test, p = 0.0102). CONCLUSION: The prognostic significance of the TGTV was confirmed and a cutoff value of 22.8 cm(3) derived. Our data indicated that locally advanced head-and-neck carcinomas should not be treated by standard (once-daily) RT alone. Tumor size and disease subsite should be taken into account in future randomized trials to increase their statistical power.},
	author = {Plataniotis, G. A. and Theofanopoulou, M. E. and Kalogera-Fountzila, A. and Haritanti, A. and Ciuleanou, E. and Ghilezan, N. and Zamboglou, N. and Dimitriadis, A. and Sofroniadis, I. and Fountzilas, G.},
	doi = {10.1016/j.ijrobp.2004.01.021},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Adult Aged Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carcinoma, Squamous Cell/*diagnostic imaging/drug therapy/radiotherapy/*therapy Combined Modality Therapy Female Head and Neck Neoplasms/*diagnostic imaging/drug therapy/radiotherapy/*therapy Humans Male Middle Aged Prognosis Radiography Radiotherapy Dosage Remission Induction},
	note = {Plataniotis, George A Theofanopoulou, Maria-Ekaterini Kalogera-Fountzila, Anna Haritanti, Afroditi Ciuleanou, Elisabeta Ghilezan, Nicolae Zamboglou, Nikolaos Dimitriadis, Athanasios Sofroniadis, Ioannis Fountzilas, George Clinical Trial Journal Article Randomized Controlled Trial United States 2004/07/06 Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1018-26. doi: 10.1016/j.ijrobp.2004.01.021.},
	number = {4},
	pages = {1018-26},
	title = {Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial},
	type = {Journal Article},
	volume = {59},
	year = {2004},
	bdsk-url-1 = {https://doi.org/10.1016/j.ijrobp.2004.01.021}}

@article{RN266,
	abstract = {PURPOSE: Tumor volume (TV) is one of the main reported factors determining the outcome of treatment in head-and-neck carcinomas. In this study, the prognostic impact of TV was explored in the context of a randomized trial with the patients assigned to receive standard radiotherapy (RT) alone or RT plus platinum compounds (RT alone, RT plus cisplatin, or RT plus carboplatin). METHODS AND MATERIALS: The tumor outlines were traced and digitized on each pretreatment CT slice for each of the 101 patients studied. Taking into account the magnification factor of the scan and CT slice thickness, a computer with specifically designed software calculated the TV in cubic centimeters. RESULTS: The median overall survival for the whole group of patients was 21.6 months (95% confidence interval, 13.0-30.2) and the 3-year survival rate was 40%. The addition of platinum compounds to RT (Groups 2 and 3) significantly improved the survival rate (RT alone vs. RT plus cisplatin, hazard ratio 0.36, p = 0.002; RT alone vs. RT plus carboplatin, hazard ratio 0.53, p = 0.029). In univariate analysis, the most significant parameters for survival were treatment group, total gross tumor volume (TGTV), complete response, nodal GTV, primary GTV, and performance status. In multivariate analysis, treatment group, TGTV, gender, and primary site were independent prognostic factors for survival. A prognostic threshold of 22.8 cm(3) was detected for TGTV. Patients with a TGTV of <22.8 cm(3) were more likely to achieve a complete response and had a median survival of 45.3 months, and those with a TGTV >22.8 cm(3) had a median survival of 12.3 months (log-rank test, p = 0.0102). CONCLUSION: The prognostic significance of the TGTV was confirmed and a cutoff value of 22.8 cm(3) derived. Our data indicated that locally advanced head-and-neck carcinomas should not be treated by standard (once-daily) RT alone. Tumor size and disease subsite should be taken into account in future randomized trials to increase their statistical power.},
	author = {Plataniotis, G. A. and Theofanopoulou, M. E. and Kalogera-Fountzila, A. and Haritanti, A. and Ciuleanou, E. and Ghilezan, N. and Zamboglou, N. and Dimitriadis, A. and Sofroniadis, I. and Fountzilas, G.},
	doi = {10.1016/j.ijrobp.2004.01.021},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Adult Aged Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carcinoma, Squamous Cell/*diagnostic imaging/drug therapy/radiotherapy/*therapy Combined Modality Therapy Female Head and Neck Neoplasms/*diagnostic imaging/drug therapy/radiotherapy/*therapy Humans Male Middle Aged Prognosis Radiography Radiotherapy Dosage Remission Induction},
	note = {Plataniotis, George A Theofanopoulou, Maria-Ekaterini Kalogera-Fountzila, Anna Haritanti, Afroditi Ciuleanou, Elisabeta Ghilezan, Nicolae Zamboglou, Nikolaos Dimitriadis, Athanasios Sofroniadis, Ioannis Fountzilas, George Clinical Trial Journal Article Randomized Controlled Trial United States 2004/07/06 Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1018-26. doi: 10.1016/j.ijrobp.2004.01.021.},
	number = {4},
	pages = {1018-26},
	title = {Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial},
	type = {Journal Article},
	url = {https://www.redjournal.org/article/S0360-3016(04)00123-3/fulltext},
	volume = {59},
	year = {2004},
	bdsk-url-1 = {https://www.redjournal.org/article/S0360-3016(04)00123-3/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/j.ijrobp.2004.01.021}}

@article{RN12,
	abstract = {BACKGROUND: Despite significant advances and the use of new diagnosic and therapy methods to treat head and neck squamous cell carcinoma (HNSCC), prognosis has improved only marginally in the last decades. Thus, there is an enormous need for novel immunotherapeutic approaches. It is becoming more and more obvious that stem cells play an important role in tumor development and progression. The identity of these cells and the underlying cellular and molecular mechanisms remain mostly unknown in HNSCC. MATERIAL AND METHODS: Solid tumors as well as cells from the peripheral blood of patients with HNSCC were analyzed by flow cytometry concerning the expression of different putative stem cell marker proteins. RESULTS: Distinct populations of CD44-positive (CD44+), lin-negative (lin-) potential stem cells could be identified in solid tumors of HNSCC patients with strong individual variations. Surprisingly, the potential stem cell marker CD44 was found to be constitutively expressed on the surface of all permanent HNSCC cell lines analyzed. CONCLUSION: These data strongly suggest that CD44+ tumor stem cells may play a key role in establishment of permanent HNSCC cell lines, selecting especially robust cell entities that in real life might drive progression and metastasis of HNSCC. Individual analysis of tumor stem cell markers will be an important tool for innovative therapies and prognosis of patients with HNSCC. Additional stem cell markers will be investigated concerning their expression and cellular function.},
	author = {Pries, R. and Wittkopf, N. and Hasselbacher, K. and Wollenberg, B.},
	doi = {10.1007/s00106-008-1707-0},
	issn = {1433-0458 (Electronic) 0017-6192 (Linking)},
	journal = {HNO},
	keywords = {Biomarkers, Tumor/*metabolism Carcinoma, Squamous Cell/*metabolism/pathology Head and Neck Neoplasms/*metabolism/pathology Humans Hyaluronan Receptors/*metabolism Neoplasm Proteins/*metabolism Stem Cells/*metabolism/pathology Tumor Cells, Cultured},
	note = {Pries, R Wittkopf, N Hasselbacher, K Wollenberg, B ger Germany HNO. 2008 Apr;56(4):461-6. doi: 10.1007/s00106-008-1707-0.},
	number = {4},
	pages = {461-6},
	title = {[Constitutive expression of the potential stem cell marker CD44 in permanent HNSCC cell lines]},
	type = {Journal Article},
	url = {https://link.springer.com/content/pdf/10.1007/s00106-008-1707-0.pdf},
	volume = {56},
	year = {2008},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007/s00106-008-1707-0.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/s00106-008-1707-0}}

@article{RN316,
	abstract = {Appropriate treatment of head and neck squamous cell cancer (HNSCC) remains one of the most difficult challenges in head and neck oncology. Overall survival of patients with HNSCC remains at approximately 50% at 5 years. Surgical therapy can be mutilating and often has significant effects on swallowing, speech, and physical appearance. The addition of chemotherapy to radiation treatment has shown efficacy in organ preservation in some sites in the head and neck, but has resulted in limited improvement in survival rates. HNSCC resistance to chemotherapy has limited the usefulness of chemotherapy in the treatment of this disease. We have recently demonstrated that human head and neck squamous cell cancers contain a tumorigenic, so-called cancer stem cell, subpopulation of cells that can self-renew and produce differentiated cells that form the bulk of the tumor. These tumorigenic HNSCC cells have a distinct phenotype and can be identified by a surface marker. Current treatment for HNSCC regimens may selectively kill the differentiated cancer cells, producing tumor regression while sparing the cancer stem cells, leading to tumor regrowth and relapse. It is important for us to understand why HNSCC does not respond to chemotherapy and to identify new targeted treatments that can overcome resistance and improve patient outcomes. Further study of HNSCC stem cells will increase our knowledge of this devastating disease and allow us to develop novel treatments.},
	author = {Prince, M. E. and Ailles, L. E.},
	doi = {10.1200/JCO.2007.15.1613},
	issn = {1527-7755 (Electronic) 0732-183X (Linking)},
	journal = {J Clin Oncol},
	keywords = {Antineoplastic Agents/pharmacology/therapeutic use Biomarkers, Tumor/metabolism Drug Resistance, Neoplasm Head and Neck Neoplasms/drug therapy/metabolism/*pathology Humans Neoplasms, Squamous Cell/drug therapy/metabolism/*pathology Neoplastic Stem Cells/drug effects/*pathology Phenotype},
	note = {Prince, Mark E P Ailles, Laurie E eng Review 2008/06/10 J Clin Oncol. 2008 Jun 10;26(17):2871-5. doi: 10.1200/JCO.2007.15.1613.},
	number = {17},
	pages = {2871-5},
	title = {Cancer stem cells in head and neck squamous cell cancer},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18539966},
	volume = {26},
	year = {2008},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/18539966},
	bdsk-url-2 = {https://doi.org/10.1200/JCO.2007.15.1613}}

@article{RN421,
	author = {Prince, M. E. and Sivanandan, R. and Kaczorowski, A. and Wolf, G. T. and Kaplan, M. J. and Dalerba, P. and Weissman, I. L. and Clarke, M. F. and Ailles, L. E.},
	doi = {10.1073/pnas.0610117104},
	issn = {0027-8424 (Print) 0027-8424 (Linking)},
	journal = {Proc Natl Acad Sci U S A},
	keywords = {Animals Carcinoma, Squamous Cell/genetics/*metabolism/*pathology Cell Separation/*methods Head and Neck Neoplasms/genetics/*metabolism/*pathology Humans Hyaluronan Receptors/metabolism Immunohistochemistry Mice Phenotype Stem Cells/*metabolism Xenograft Model Antitumor Assays},
	number = {3},
	pages = {973-8},
	title = {Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17210912},
	volume = {104},
	year = {2007},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/17210912},
	bdsk-url-2 = {https://doi.org/10.1073/pnas.0610117104}}

@article{RN424,
	author = {Prince, M. E. and Sivanandan, R. and Kaczorowski, A. and Wolf, G. T. and Kaplan, M. J. and Dalerba, P. and Weissman, I. L. and Clarke, M. F. and Ailles, L. E.},
	doi = {10.1073/pnas.0610117104},
	issn = {0027-8424 (Print) 0027-8424 (Linking)},
	journal = {Proc Natl Acad Sci U S A},
	keywords = {Animals Carcinoma, Squamous Cell/genetics/*metabolism/*pathology Cell Separation/*methods Head and Neck Neoplasms/genetics/*metabolism/*pathology Humans Hyaluronan Receptors/metabolism Immunohistochemistry Mice Phenotype Stem Cells/*metabolism Xenograft Model Antitumor Assays},
	number = {3},
	pages = {973-8},
	title = {Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17210912},
	volume = {104},
	year = {2007},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/17210912},
	bdsk-url-2 = {https://doi.org/10.1073/pnas.0610117104}}

@article{RN425,
	author = {Prince, M. E. and Sivanandan, R. and Kaczorowski, A. and Wolf, G. T. and Kaplan, M. J. and Dalerba, P. and Weissman, I. L. and Clarke, M. F. and Ailles, L. E.},
	doi = {10.1073/pnas.0610117104},
	issn = {0027-8424 (Print) 0027-8424 (Linking)},
	journal = {Proc Natl Acad Sci U S A},
	keywords = {Animals Carcinoma, Squamous Cell/genetics/*metabolism/*pathology Cell Separation/*methods Head and Neck Neoplasms/genetics/*metabolism/*pathology Humans Hyaluronan Receptors/metabolism Immunohistochemistry Mice Phenotype Stem Cells/*metabolism Xenograft Model Antitumor Assays},
	number = {3},
	pages = {973-8},
	title = {Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17210912},
	volume = {104},
	year = {2007},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/17210912},
	bdsk-url-2 = {https://doi.org/10.1073/pnas.0610117104}}

@article{RN24,
	abstract = {Like many epithelial tumors, head and neck squamous cell carcinoma (HNSCC) contains a heterogeneous population of cancer cells. We developed an immunodeficient mouse model to test the tumorigenic potential of different populations of cancer cells derived from primary, unmanipulated human HNSCC samples. We show that a minority population of CD44(+) cancer cells, which typically comprise <10% of the cells in a HNSCC tumor, but not the CD44(-) cancer cells, gave rise to new tumors in vivo. Immunohistochemistry revealed that the CD44(+) cancer cells have a primitive cellular morphology and costain with the basal cell marker Cytokeratin 5/14, whereas the CD44(-) cancer cells resemble differentiated squamous epithelium and express the differentiation marker Involucrin. The tumors that arose from purified CD44(+) cells reproduced the original tumor heterogeneity and could be serially passaged, thus demonstrating the two defining properties of stem cells: ability to self-renew and to differentiate. Furthermore, the tumorigenic CD44(+) cells differentially express the BMI1 gene, at both the RNA and protein levels. By immunohistochemical analysis, the CD44(+) cells in the tumor express high levels of nuclear BMI1, and are arrayed in characteristic tumor microdomains. BMI1 has been demonstrated to play a role in self-renewal in other stem cell types and to be involved in tumorigenesis. Taken together, these data demonstrate that cells within the CD44(+) population of human HNSCC possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation and form unique histological microdomains that may aid in cancer diagnosis.},
	author = {Prince, M. E. and Sivanandan, R. and Kaczorowski, A. and Wolf, G. T. and Kaplan, M. J. and Dalerba, P. and Weissman, I. L. and Clarke, M. F. and Ailles, L. E.},
	doi = {10.1073/pnas.0610117104},
	issn = {0027-8424 (Print) 0027-8424 (Linking)},
	journal = {Proc Natl Acad Sci U S A},
	keywords = {Animals Carcinoma, Squamous Cell/genetics/*metabolism/*pathology Cell Separation/*methods Head and Neck Neoplasms/genetics/*metabolism/*pathology Humans Hyaluronan Receptors/metabolism Immunohistochemistry Mice Phenotype Stem Cells/*metabolism Xenograft Model Antitumor Assays},
	note = {Prince, M E Sivanandan, R Kaczorowski, A Wolf, G T Kaplan, M J Dalerba, P Weissman, I L Clarke, M F Ailles, L E eng P50 CA097248/CA/NCI NIH HHS/ 5P50 CA 097248/CA/NCI NIH HHS/ Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8. doi: 10.1073/pnas.0610117104. Epub 2007 Jan 8.},
	number = {3},
	pages = {973-8},
	title = {Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783424/pdf/zpq973.pdf},
	volume = {104},
	year = {2007},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783424/pdf/zpq973.pdf},
	bdsk-url-2 = {https://doi.org/10.1073/pnas.0610117104}}

@article{RN74,
	abstract = {Like many epithelial tumors, head and neck squamous cell carcinoma (HNSCC) contains a heterogeneous population of cancer cells. We developed an immunodeficient mouse model to test the tumorigenic potential of different populations of cancer cells derived from primary, unmanipulated human HNSCC samples. We show that a minority population of CD44(+) cancer cells, which typically comprise <10% of the cells in a HNSCC tumor, but not the CD44(-) cancer cells, gave rise to new tumors in vivo. Immunohistochemistry revealed that the CD44(+) cancer cells have a primitive cellular morphology and costain with the basal cell marker Cytokeratin 5/14, whereas the CD44(-) cancer cells resemble differentiated squamous epithelium and express the differentiation marker Involucrin. The tumors that arose from purified CD44(+) cells reproduced the original tumor heterogeneity and could be serially passaged, thus demonstrating the two defining properties of stem cells: ability to self-renew and to differentiate. Furthermore, the tumorigenic CD44(+) cells differentially express the BMI1 gene, at both the RNA and protein levels. By immunohistochemical analysis, the CD44(+) cells in the tumor express high levels of nuclear BMI1, and are arrayed in characteristic tumor microdomains. BMI1 has been demonstrated to play a role in self-renewal in other stem cell types and to be involved in tumorigenesis. Taken together, these data demonstrate that cells within the CD44(+) population of human HNSCC possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation and form unique histological microdomains that may aid in cancer diagnosis.},
	author = {Prince, M. E. and Sivanandan, R. and Kaczorowski, A. and Wolf, G. T. and Kaplan, M. J. and Dalerba, P. and Weissman, I. L. and Clarke, M. F. and Ailles, L. E.},
	doi = {10.1073/pnas.0610117104},
	issn = {0027-8424 (Print) 0027-8424 (Linking)},
	journal = {Proc Natl Acad Sci U S A},
	keywords = {Animals Carcinoma, Squamous Cell/genetics/*metabolism/*pathology Cell Separation/*methods Head and Neck Neoplasms/genetics/*metabolism/*pathology Humans Hyaluronan Receptors/metabolism Immunohistochemistry Mice Phenotype Stem Cells/*metabolism Xenograft Model Antitumor Assays},
	note = {Prince, M E Sivanandan, R Kaczorowski, A Wolf, G T Kaplan, M J Dalerba, P Weissman, I L Clarke, M F Ailles, L E eng P50 CA097248/CA/NCI NIH HHS/ 5P50 CA 097248/CA/NCI NIH HHS/ Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2007/01/11 Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8. doi: 10.1073/pnas.0610117104. Epub 2007 Jan 8.},
	number = {3},
	pages = {973-8},
	title = {Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17210912},
	volume = {104},
	year = {2007},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/17210912},
	bdsk-url-2 = {https://doi.org/10.1073/pnas.0610117104}}

@article{RN193,
	author = {Probert, J. C. and Thompson, R. W. and Bagshaw, M. A.},
	doi = {10.1002/1097-0142(197401)33:1<127::aid-cncr2820330119>3.0.co;2-l},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Adult Aged Autopsy Bone Neoplasms Carcinoma, Squamous Cell/radiotherapy/surgery Female Gastrointestinal Neoplasms *Head and Neck Neoplasms/mortality/radiotherapy/surgery Heart Neoplasms Humans Liver Neoplasms Lung Neoplasms Lymphatic Metastasis Male Middle Aged *Mouth Neoplasms/mortality/radiotherapy/surgery *Nasopharyngeal Neoplasms *Neoplasm Metastasis Neoplasms, Multiple Primary Radiotherapy Dosage Splenic Neoplasms},
	note = {Probert, J C Thompson, R W Bagshaw, M A Journal Article United States 1974/01/01 Cancer. 1974 Jan;33(1):127-33. doi: 10.1002/1097-0142(197401)33:1<127::aid-cncr2820330119>3.0.co;2-l.},
	number = {1},
	pages = {127-33},
	title = {Patterns of spread of distant metastases in head and neck cancer},
	type = {Journal Article},
	url = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%28197401%2933%3A1%3C127%3A%3AAID-CNCR2820330119%3E3.0.CO%3B2-L?download=true},
	volume = {33},
	year = {1974},
	bdsk-url-1 = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%28197401%2933%3A1%3C127%3A%3AAID-CNCR2820330119%3E3.0.CO%3B2-L?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/1097-0142(197401)33:1%3C127::aid-cncr2820330119%3E3.0.co;2-l}}

@article{RN322,
	abstract = {Cancer stem cells (CSC) have been identified in a growing number of human malignancies. CSC are functionally defined by their ability to self-renew and recapitulate tumors in the ectopic setting, and a growing number of studies have shown that they display other functional characteristics, such as invasion and drug resistance. These unique functional properties implicate a role for CSC in clinical consequences, such as initial tumor formation, relapse following treatment, metastasis, and resistance, suggesting they are a major factor in directing clinical outcomes. Pancreatic adenocarcinoma is a highly-aggressive disease with a propensity for early metastasis and drug resistance. Tumorigenic pancreatic cancer cells have been identified using the cell surface antigens CD44, CD24, and CD133, as well as the high expression of aldehyde dehydrogenase (ALDH). In vitro and in vivo studies have shown that ALDH- and CD133-expressing pancreatic CSC have a greater propensity for metastasis, and ALDH-expressing CSC have been shown to be resistant to conventional chemotherapy. In clinical samples from patients with resected pancreatic adenocarcinoma, the presence of ALDH-expressing CSC was associated with worse overall survival. The development of CSC-targeting therapies might be important in changing the clinical outcomes of patients with this disease, and others and we have begun to identify novel compounds that block CSC function. This review will discuss the biological and clinical relevance of CSC in pancreatic cancer, and will discuss novel therapeutic strategies to target them.},
	author = {Rasheed, Z. A. and Matsui, W.},
	doi = {10.1111/j.1440-1746.2011.07015.x},
	issn = {0815-9319 (Print) 0815-9319},
	journal = {J Gastroenterol Hepatol},
	keywords = {Adenocarcinoma/metabolism/*pathology/secondary/therapy Animals Biomarkers, Tumor/metabolism Drug Resistance, Neoplasm Humans Neoplastic Stem Cells/drug effects/metabolism/*pathology Pancreatic Neoplasms/metabolism/*pathology/therapy Treatment Outcome},
	note = {1440-1746 Rasheed, Zeshaan A Matsui, William P30 CA006973/CA/NCI NIH HHS/United States R01 CA150142/CA/NCI NIH HHS/United States Journal Article Review 2012/02/15 J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2(Suppl 2):15-8. doi: 10.1111/j.1440-1746.2011.07015.x.},
	number = {Suppl 2},
	pages = {15-8},
	title = {Biological and clinical relevance of stem cells in pancreatic adenocarcinoma},
	type = {Journal Article},
	volume = {27 Suppl 2},
	year = {2012},
	bdsk-url-1 = {https://doi.org/10.1111/j.1440-1746.2011.07015.x}}

@article{RN406,
	author = {Raslan, W. F. and Barnes, L. and Krause, J. R. and Contis, L. and Killeen, R. and Kapadia, S. B.},
	doi = {10.1016/0196-0709(94)90006-x},
	issn = {0196-0709 (Print) 0196-0709},
	journal = {Am J Otolaryngol},
	keywords = {Aged Aneuploidy Carcinoma, Squamous Cell/*genetics/*pathology/secondary Carcinoma, Transitional Cell/*genetics/*pathology/secondary DNA, Neoplasm/*analysis Diploidy Female Flow Cytometry Follow-Up Studies Head and Neck Neoplasms/*genetics/*pathology Humans Lymphatic Metastasis Male Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Survival Rate},
	number = {3},
	pages = {204-11},
	title = {Basaloid squamous cell carcinoma of the head and neck: a clinicopathologic and flow cytometric study of 10 new cases with review of the English literature},
	type = {Journal Article},
	volume = {15},
	year = {1994},
	bdsk-url-1 = {https://doi.org/10.1016/0196-0709(94)90006-x}}

@article{RN123,
	abstract = {INTRODUCTION: We describe the clinicopathologic and flow cytometric features of 10 cases of basaloid squamous cell carcinoma (BSCC) of the head and neck to determine if DNA ploidy is a useful prognostic indicator. We also provide a review of 80 cases previously reported in the English language literature. MATERIALS AND METHODS: The 10 cases were obtained from the surgical pathology files of Presbyterian University Hospital and The Eye and Ear Institute, Pittsburgh, PA (1987-1991). In all 10 cases, the microscopic slides and clinical data were reviewed. Flow cytometry was performed using the Hedley technique and formalin-fixed, paraffin-embedded tissue. RESULTS: The mean age of patients with BSCC was 64 years (range, 49 to 75 years). Tumor involved the base of tongue (n = 5), hypopharynx-epiglottis (n = 3), and tonsil (n = 1). One case presented with cervical lymph node metastasis from an unknown primary site. Histologically, BSCC showed a biphasic pattern with basaloid-squamous elements, comedonecrosis, stromal hyalinization, surface dysplasia, and an in situ and/or invasive squamous cell carcinoma component. Flow cytometry revealed six diploid and four aneuploid tumors. Five of six patients with diploid and all four patients with aneuploid tumors developed early regional and/or distant metastases. Of the two patients who died of disease, one had a diploid and the other an aneuploid tumor. CONCLUSION: Our study reaffirms the predilection of BSCC for the base of tongue, pyriform sinus, and supraglottic larynx, and its aggressive biologic behavior with a high incidence of cervical lymph node metastasis (64%), distant spread (44%), and death from disease (38% mortality at 17 months median follow-up). However, in contrast to previous reports, tumor ploidy by flow cytometry provided no additional prognostic information beyond that supplied by routine histologic evaluation.},
	author = {Raslan, W. F. and Barnes, L. and Krause, J. R. and Contis, L. and Killeen, R. and Kapadia, S. B.},
	doi = {10.1016/0196-0709(94)90006-x},
	issn = {0196-0709 (Print) 0196-0709},
	journal = {Am J Otolaryngol},
	keywords = {Aged Aneuploidy Carcinoma, Squamous Cell/*genetics/*pathology/secondary Carcinoma, Transitional Cell/*genetics/*pathology/secondary DNA, Neoplasm/*analysis Diploidy Female Flow Cytometry Follow-Up Studies Head and Neck Neoplasms/*genetics/*pathology Humans Lymphatic Metastasis Male Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Survival Rate},
	note = {Raslan, W F Barnes, L Krause, J R Contis, L Killeen, R Kapadia, S B Journal Article Research Support, Non-U.S. Gov't Review United States 1994/05/01 Am J Otolaryngol. 1994 May-Jun;15(3):204-11. doi: 10.1016/0196-0709(94)90006-x.},
	number = {3},
	pages = {204-11},
	title = {Basaloid squamous cell carcinoma of the head and neck: a clinicopathologic and flow cytometric study of 10 new cases with review of the English literature},
	type = {Journal Article},
	url = {https://www.sciencedirect.com/science/article/abs/pii/019607099490006X?via%3Dihub},
	volume = {15},
	year = {1994},
	bdsk-url-1 = {https://www.sciencedirect.com/science/article/abs/pii/019607099490006X?via%3Dihub},
	bdsk-url-2 = {https://doi.org/10.1016/0196-0709(94)90006-x}}

@book{RN157,
	author = {Rei{\ss}, M.},
	isbn = {9783662581773},
	publisher = {Springer Berlin Heidelberg},
	title = {Facharztwissen HNO-Heilkunde: Differenzierte Diagnostik und Therapie},
	type = {Book},
	url = {https://books.google.de/books?id=FIbkvwEACAAJ},
	year = {2021},
	bdsk-url-1 = {https://books.google.de/books?id=FIbkvwEACAAJ}}

@article{RN308,
	abstract = {Stem cell biology has come of age. Unequivocal proof that stem cells exist in the haematopoietic system has given way to the prospective isolation of several tissue-specific stem and progenitor cells, the initial delineation of their properties and expressed genetic programmes, and the beginnings of their utility in regenerative medicine. Perhaps the most important and useful property of stem cells is that of self-renewal. Through this property, striking parallels can be found between stem cells and cancer cells: tumours may often originate from the transformation of normal stem cells, similar signalling pathways may regulate self-renewal in stem cells and cancer cells, and cancer cells may include 'cancer stem cells' - rare cells with indefinite potential for self-renewal that drive tumorigenesis.},
	author = {Reya, T. and Morrison, S. J. and Clarke, M. F. and Weissman, I. L.},
	doi = {10.1038/35102167},
	issn = {0028-0836 (Print) 0028-0836},
	journal = {Nature},
	keywords = {Animals Cell Division Cell Transformation, Neoplastic Hematopoietic Stem Cells Humans Leukemia/pathology Mutation Neoplasms/*pathology Regeneration Signal Transduction *Stem Cells},
	note = {Reya, T Morrison, S J Clarke, M F Weissman, I L Journal Article Review England 2001/11/02 Nature. 2001 Nov 1;414(6859):105-11. doi: 10.1038/35102167.},
	number = {6859},
	pages = {105-11},
	title = {Stem cells, cancer, and cancer stem cells},
	type = {Journal Article},
	url = {https://deepblue.lib.umich.edu/bitstream/handle/2027.42/62862/414105a0.pdf?sequence=1},
	volume = {414},
	year = {2001},
	bdsk-url-1 = {https://deepblue.lib.umich.edu/bitstream/handle/2027.42/62862/414105a0.pdf?sequence=1},
	bdsk-url-2 = {https://doi.org/10.1038/35102167}}

@article{RN302,
	abstract = {Stem cell biology has come of age. Unequivocal proof that stem cells exist in the haematopoietic system has given way to the prospective isolation of several tissue-specific stem and progenitor cells, the initial delineation of their properties and expressed genetic programmes, and the beginnings of their utility in regenerative medicine. Perhaps the most important and useful property of stem cells is that of self-renewal. Through this property, striking parallels can be found between stem cells and cancer cells: tumours may often originate from the transformation of normal stem cells, similar signalling pathways may regulate self-renewal in stem cells and cancer cells, and cancer cells may include 'cancer stem cells' - rare cells with indefinite potential for self-renewal that drive tumorigenesis.},
	author = {Reya, T. and Morrison, S. J. and Clarke, M. F. and Weissman, I. L.},
	doi = {10.1038/35102167},
	issn = {0028-0836 (Print) 0028-0836},
	journal = {Nature},
	keywords = {Animals Cell Division Cell Transformation, Neoplastic Hematopoietic Stem Cells Humans Leukemia/pathology Mutation Neoplasms/*pathology Regeneration Signal Transduction *Stem Cells},
	note = {Reya, T Morrison, S J Clarke, M F Weissman, I L Journal Article Review England 2001/11/02 Nature. 2001 Nov 1;414(6859):105-11. doi: 10.1038/35102167.},
	number = {6859},
	pages = {105-11},
	title = {Stem cells, cancer, and cancer stem cells},
	type = {Journal Article},
	url = {https://deepblue.lib.umich.edu/bitstream/handle/2027.42/62862/414105a0.pdf?sequence=1},
	volume = {414},
	year = {2001},
	bdsk-url-1 = {https://deepblue.lib.umich.edu/bitstream/handle/2027.42/62862/414105a0.pdf?sequence=1},
	bdsk-url-2 = {https://doi.org/10.1038/35102167}}

@article{RN293,
	abstract = {Colon carcinoma is the second most common cause of death from cancer. The isolation and characterization of tumorigenic colon cancer cells may help to devise novel diagnostic and therapeutic procedures. Although there is increasing evidence that a rare population of undifferentiated cells is responsible for tumour formation and maintenance, this has not been explored for colorectal cancer. Here, we show that tumorigenic cells in colon cancer are included in the high-density CD133+ population, which accounts for about 2.5% of the tumour cells. Subcutaneous injection of colon cancer CD133+ cells readily reproduced the original tumour in immunodeficient mice, whereas CD133- cells did not form tumours. Such tumours were serially transplanted for several generations, in each of which we observed progressively faster tumour growth without significant phenotypic alterations. Unlike CD133- cells, CD133+ colon cancer cells grew exponentially for more than one year in vitro as undifferentiated tumour spheres in serum-free medium, maintaining the ability to engraft and reproduce the same morphological and antigenic pattern of the original tumour. We conclude that colorectal cancer is created and propagated by a small number of undifferentiated tumorigenic CD133+ cells, which should therefore be the target of future therapies.},
	author = {Ricci-Vitiani, L. and Lombardi, D. G. and Pilozzi, E. and Biffoni, M. and Todaro, M. and Peschle, C. and De Maria, R.},
	doi = {10.1038/nature05384},
	issn = {0028-0836},
	journal = {Nature},
	keywords = {AC133 Antigen Animals Antigens, CD/*metabolism Cell Differentiation Cell Line, Tumor Cell Proliferation Colonic Neoplasms/*metabolism/*pathology Glycoproteins/*metabolism Humans Mice Mice, SCID Neoplasm Transplantation Neoplastic Stem Cells/*metabolism/*pathology Peptides/*metabolism Phenotype Transplantation, Heterologous},
	note = {1476-4687 Ricci-Vitiani, Lucia Lombardi, Dario G Pilozzi, Emanuela Biffoni, Mauro Todaro, Matilde Peschle, Cesare De Maria, Ruggero Journal Article Research Support, Non-U.S. Gov't England 2006/11/24 Nature. 2007 Jan 4;445(7123):111-5. doi: 10.1038/nature05384. Epub 2006 Nov 19.},
	number = {7123},
	pages = {111-5},
	title = {Identification and expansion of human colon-cancer-initiating cells},
	type = {Journal Article},
	url = {https://www.nature.com/articles/nature05384.pdf},
	volume = {445},
	year = {2007},
	bdsk-url-1 = {https://www.nature.com/articles/nature05384.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/nature05384}}

@article{RN299,
	abstract = {Colon carcinoma is the second most common cause of death from cancer. The isolation and characterization of tumorigenic colon cancer cells may help to devise novel diagnostic and therapeutic procedures. Although there is increasing evidence that a rare population of undifferentiated cells is responsible for tumour formation and maintenance, this has not been explored for colorectal cancer. Here, we show that tumorigenic cells in colon cancer are included in the high-density CD133+ population, which accounts for about 2.5% of the tumour cells. Subcutaneous injection of colon cancer CD133+ cells readily reproduced the original tumour in immunodeficient mice, whereas CD133- cells did not form tumours. Such tumours were serially transplanted for several generations, in each of which we observed progressively faster tumour growth without significant phenotypic alterations. Unlike CD133- cells, CD133+ colon cancer cells grew exponentially for more than one year in vitro as undifferentiated tumour spheres in serum-free medium, maintaining the ability to engraft and reproduce the same morphological and antigenic pattern of the original tumour. We conclude that colorectal cancer is created and propagated by a small number of undifferentiated tumorigenic CD133+ cells, which should therefore be the target of future therapies.},
	author = {Ricci-Vitiani, L. and Lombardi, D. G. and Pilozzi, E. and Biffoni, M. and Todaro, M. and Peschle, C. and De Maria, R.},
	doi = {10.1038/nature05384},
	issn = {0028-0836},
	journal = {Nature},
	keywords = {AC133 Antigen Animals Antigens, CD/*metabolism Cell Differentiation Cell Line, Tumor Cell Proliferation Colonic Neoplasms/*metabolism/*pathology Glycoproteins/*metabolism Humans Mice Mice, SCID Neoplasm Transplantation Neoplastic Stem Cells/*metabolism/*pathology Peptides/*metabolism Phenotype Transplantation, Heterologous},
	note = {1476-4687 Ricci-Vitiani, Lucia Lombardi, Dario G Pilozzi, Emanuela Biffoni, Mauro Todaro, Matilde Peschle, Cesare De Maria, Ruggero Journal Article Research Support, Non-U.S. Gov't England 2006/11/24 Nature. 2007 Jan 4;445(7123):111-5. doi: 10.1038/nature05384. Epub 2006 Nov 19.},
	number = {7123},
	pages = {111-5},
	title = {Identification and expansion of human colon-cancer-initiating cells},
	type = {Journal Article},
	url = {https://www.nature.com/articles/nature05384.pdf},
	volume = {445},
	year = {2007},
	bdsk-url-1 = {https://www.nature.com/articles/nature05384.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/nature05384}}

@article{RN348,
	author = {Ritchie, J. M. and Smith, E. M. and Summersgill, K. F. and Hoffman, H. T. and Wang, D. and Klussmann, J. P. and Turek, L. P. and Haugen, T. H.},
	doi = {10.1002/ijc.10960},
	issn = {0020-7136 (Print) 0020-7136},
	journal = {Int J Cancer},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/mortality/*virology Case-Control Studies DNA, Viral/analysis Female Humans Male Middle Aged Mouth Neoplasms/mortality/*virology Neoplasm Staging Odds Ratio Oropharyngeal Neoplasms/mortality/*virology Papillomaviridae/genetics/isolation & purification Papillomavirus Infections/mortality/*virology Prevalence Prognosis Risk Factors Survival Rate Tumor Virus Infections/mortality/*virology},
	number = {3},
	pages = {336-44},
	title = {Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx},
	type = {Journal Article},
	volume = {104},
	year = {2003},
	bdsk-url-1 = {https://doi.org/10.1002/ijc.10960}}

@article{RN91,
	abstract = {Although studies have established human papillomaviruses (HPVs) as a risk factor for oral and oropharyngeal cancer, it is not clear whether viral infection affects survival in head and neck malignancies. This investigation examined the relationship between HPV and survival in carcinomas of the oral cavity and oropharynx. Formalin-fixed, paraffin-embedded tumor specimens from 139 newly diagnosed cases were tested for HPVs by PCR and DNA sequencing. Patient and tumor characteristics were obtained from questionnaires, pathology reports and cancer registries. Odds ratios (ORs) and relative risks (RRs) were based on logistic and Cox regression models, respectively. HPVs were detected in 21% of the tumors; 83% were HPV-16. Greater risk of HPV infection was associated with males (OR = 2.9, 95% CI = 1.0-8.6), a history of oral-genital sex (OR = 4.2, 95% CI = 1.5-11.7), and oropharyngeal tumors (OR = 10.4, 95% CI = 3.5-31.2). As tobacco usage increased, the odds of HPV detection decreased (OR = 0.97/pack-year, 95% CI = 0.96-0.99). HPV infected patients had better overall survival (RR = 0.3, 95% CI = 0.1-0.8) than those with HPV-negative tumors. There was an interaction between gender and HPV for overall (p = 0.05) and disease-specific (p = 0.03) survival that suggested that HPV infected males had better prognosis than HPV-negative males, but this was not the case among females. HPV status was identified as an independent prognostic factor in oral and oropharyngeal cancers. This result appeared to be gender-specific, suggesting the need for further study of the interaction between HPV and gender on survival.},
	author = {Ritchie, J. M. and Smith, E. M. and Summersgill, K. F. and Hoffman, H. T. and Wang, D. and Klussmann, J. P. and Turek, L. P. and Haugen, T. H.},
	doi = {10.1002/ijc.10960},
	issn = {0020-7136 (Print) 0020-7136},
	journal = {Int J Cancer},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/mortality/*virology Case-Control Studies DNA, Viral/analysis Female Humans Male Middle Aged Mouth Neoplasms/mortality/*virology Neoplasm Staging Odds Ratio Oropharyngeal Neoplasms/mortality/*virology Papillomaviridae/genetics/isolation & purification Papillomavirus Infections/mortality/*virology Prevalence Prognosis Risk Factors Survival Rate Tumor Virus Infections/mortality/*virology},
	note = {Ritchie, Justine M Smith, Elaine M Summersgill, Kurt F Hoffman, Henry T Wang, Donghong Klussmann, Jens P Turek, Lubomir P Haugen, Thomas H DE13110-035/DE/NIDCR NIH HHS/United States P20 DE15035 04/DE/NIDCR NIH HHS/United States P60 DC00976-04/DC/NIDCD NIH HHS/United States R01 DE11979-01/DE/NIDCR NIH HHS/United States Journal Article Multicenter Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. United States 2003/02/06 Int J Cancer. 2003 Apr 10;104(3):336-44. doi: 10.1002/ijc.10960.},
	number = {3},
	pages = {336-44},
	title = {Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.10960?download=true},
	volume = {104},
	year = {2003},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.10960?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.10960}}

@techreport{RN335,
	author = {RKI},
	title = {Krebs in Deutschland f{\"u}r 2017/2018 13. Auflage Berlin},
	type = {Report},
	year = {2021}}

@techreport{RN61,
	author = {RKI},
	title = {Krebs in Deutschland f{\"u}r 2017/2018 13. Auflage Berlin},
	type = {Report},
	year = {2021}}

@article{RN191,
	author = {Robbins, K. T. and Clayman, G. and Levine, P. A. and Medina, J. and Sessions, R. and Shaha, A. and Som, P. and Wolf, G. T.},
	doi = {10.1001/archotol.128.7.751},
	issn = {0886-4470 (Print) 0886-4470},
	journal = {Arch Otolaryngol Head Neck Surg},
	keywords = {Head and Neck Neoplasms/surgery Humans Lymph Nodes/anatomy & histology/surgery Neck/anatomy & histology/surgery Neck Dissection/*classification/methods Skin Neoplasms/surgery *Terminology as Topic},
	note = {Robbins, K Thomas Clayman, Garry Levine, Paul A Medina, Jesus Sessions, Roy Shaha, Ashok Som, Peter Wolf, Gregory T American Head and Neck Society American Academy of Otolaryngology--Head and Neck Surgery Guideline Journal Article Practice Guideline United States 2002/07/16 Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8. doi: 10.1001/archotol.128.7.751.},
	number = {7},
	pages = {751-8},
	title = {Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery},
	type = {Journal Article},
	url = {https://jamanetwork.com/journals/jamaotolaryngology/articlepdf/482968/ooa20089.pdf},
	volume = {128},
	year = {2002},
	bdsk-url-1 = {https://jamanetwork.com/journals/jamaotolaryngology/articlepdf/482968/ooa20089.pdf},
	bdsk-url-2 = {https://doi.org/10.1001/archotol.128.7.751}}

@article{RN210,
	author = {Robbins, K. T. and Clayman, G. and Levine, P. A. and Medina, J. and Sessions, R. and Shaha, A. and Som, P. and Wolf, G. T.},
	doi = {10.1001/archotol.128.7.751},
	issn = {0886-4470 (Print) 0886-4470},
	journal = {Arch Otolaryngol Head Neck Surg},
	keywords = {Head and Neck Neoplasms/surgery Humans Lymph Nodes/anatomy & histology/surgery Neck/anatomy & histology/surgery Neck Dissection/*classification/methods Skin Neoplasms/surgery *Terminology as Topic},
	note = {Robbins, K Thomas Clayman, Garry Levine, Paul A Medina, Jesus Sessions, Roy Shaha, Ashok Som, Peter Wolf, Gregory T American Head and Neck Society American Academy of Otolaryngology--Head and Neck Surgery Guideline Journal Article Practice Guideline United States 2002/07/16 Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8. doi: 10.1001/archotol.128.7.751.},
	number = {7},
	pages = {751-8},
	title = {Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery},
	type = {Journal Article},
	volume = {128},
	year = {2002},
	bdsk-url-1 = {https://doi.org/10.1001/archotol.128.7.751}}

@article{RN137,
	author = {Rothman, K. and Keller, A.},
	doi = {10.1016/0021-9681(72)90006-9},
	issn = {0021-9681 (Print) 0021-9681},
	journal = {J Chronic Dis},
	keywords = {Alcohol Drinking Alcoholic Beverages/*adverse effects Drug Interactions Drug Synergism Female Humans Male Mouth Neoplasms/chemically induced/*epidemiology Pharyngeal Neoplasms/chemically induced/*epidemiology Smoking/*complications Statistics as Topic Time Factors},
	note = {Rothman, K Keller, A Journal Article England 1972/12/01 J Chronic Dis. 1972 Dec;25(12):711-6. doi: 10.1016/0021-9681(72)90006-9.},
	number = {12},
	pages = {711-6},
	title = {The effect of joint exposure to alcohol and tobacco on risk of cancer of the mouth and pharynx},
	type = {Journal Article},
	url = {https://www.sciencedirect.com/science/article/abs/pii/0021968172900069?via%3Dihub},
	volume = {25},
	year = {1972},
	bdsk-url-1 = {https://www.sciencedirect.com/science/article/abs/pii/0021968172900069?via%3Dihub},
	bdsk-url-2 = {https://doi.org/10.1016/0021-9681(72)90006-9}}

@article{RN373,
	author = {Sabatini, Maria Elisa and Chiocca, Susanna},
	doi = {10.1038/s41416-019-0602-7},
	issn = {1532-1827},
	journal = {British Journal of Cancer},
	number = {3},
	pages = {306-314},
	title = {Human papillomavirus as a driver of head and neck cancers},
	type = {Journal Article},
	url = {https://doi.org/10.1038/s41416-019-0602-7},
	volume = {122},
	year = {2020},
	bdsk-url-1 = {https://doi.org/10.1038/s41416-019-0602-7}}

@article{RN121,
	abstract = {The human papillomavirus (HPV) family includes more than 170 different types of virus that infect stratified epithelium. High-risk HPV is well established as the primary cause of cervical cancer, but in recent years, a clear role for this virus in other malignancies is also emerging. Indeed, HPV plays a pathogenic role in a subset of head and neck cancers---mostly cancers of the oropharynx---with distinct epidemiological, clinical and molecular characteristics compared with head and neck cancers not caused by HPV. This review summarises our current understanding of HPV in these cancers, specifically detailing HPV infection in head and neck cancers within different racial/ethnic subpopulations, and the differences in various aspects of these diseases between women and men. Finally, we provide an outlook for this disease, in terms of clinical management, and consider the issues of `diagnostic biomarkers' and targeted therapies.},
	author = {Sabatini, Maria Elisa and Chiocca, Susanna},
	doi = {10.1038/s41416-019-0602-7},
	issn = {1532-1827},
	journal = {British Journal of Cancer},
	number = {3},
	pages = {306-314},
	title = {Human papillomavirus as a driver of head and neck cancers},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000688/pdf/41416_2019_Article_602.pdf},
	volume = {122},
	year = {2020},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000688/pdf/41416_2019_Article_602.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/s41416-019-0602-7}}

@article{RN205,
	abstract = {The incidence of head and neck squamous cell carcinoma (HNSCC) is increasing and currently they account for 5% of all malignancies worldwide. Inspite of ongoing developments in diagnostic imaging and new therapeutic options, HNSCC still represents a multidisciplinary challenge.One of the most important prognostic factors in HNSCC is the presence of lymph node metastases. Patients with confirmed nodal involvement have a considerable reduction of their 5-year overall survival rate. In the era of individually optimised surgery, chemotherapy and intensity modulated radiotherapy, the main role of pre- and posttherapeutic imaging remains cancer detection at an early stage and accurate follow-up. The combined effort of early diagnosis and close patient monitoring after surgery and/or radio-chemotherapy influences disease progression and outcome predicition in patients with HNSCC.This review article focuses on currrent oncologic concepts and emerging tools in imaging of head and neck squamous cell cancer. Besides the diagnostic spectrum of the individual imaging modalities, their limitations are also discussed. One main part of this article is dedicated to PET-CT which combines functional and morphological imaging. Furthermore latest developments in MRI are presented with regard to lymph node staging and response prediction. Last but not least, a clinical contribution in this review explains, which information the head and neck surgeon requires from the multimodality imaging and its impact on operation planning.},
	author = {Sadick, M. and Schoenberg, S. O. and Hoermann, K. and Sadick, H.},
	doi = {10.3205/cto000090},
	issn = {1865-1011 (Print) 1865-1011},
	journal = {GMS Curr Top Otorhinolaryngol Head Neck Surg},
	keywords = {Hnscc Mri Pet-ct diffusion weighted imaging head and neck carcinoma hypoxia imaging lymph node staging},
	note = {1865-1011 Sadick, Maliha Schoenberg, Stefan O Hoermann, Karl Sadick, Haneen Journal Article 2013/01/16 GMS Curr Top Otorhinolaryngol Head Neck Surg. 2012;11:Doc08. doi: 10.3205/cto000090. Epub 2012 Dec 20.},
	pages = {Doc08},
	title = {Current oncologic concepts and emerging techniques for imaging of head and neck squamous cell cancer},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544205/pdf/CTO-11-08.pdf},
	volume = {11},
	year = {2012},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544205/pdf/CTO-11-08.pdf},
	bdsk-url-2 = {https://doi.org/10.3205/cto000090}}

@article{RN186,
	abstract = {The incidence of head and neck squamous cell carcinoma (HNSCC) is increasing and currently they account for 5% of all malignancies worldwide. Inspite of ongoing developments in diagnostic imaging and new therapeutic options, HNSCC still represents a multidisciplinary challenge.One of the most important prognostic factors in HNSCC is the presence of lymph node metastases. Patients with confirmed nodal involvement have a considerable reduction of their 5-year overall survival rate. In the era of individually optimised surgery, chemotherapy and intensity modulated radiotherapy, the main role of pre- and posttherapeutic imaging remains cancer detection at an early stage and accurate follow-up. The combined effort of early diagnosis and close patient monitoring after surgery and/or radio-chemotherapy influences disease progression and outcome predicition in patients with HNSCC.This review article focuses on currrent oncologic concepts and emerging tools in imaging of head and neck squamous cell cancer. Besides the diagnostic spectrum of the individual imaging modalities, their limitations are also discussed. One main part of this article is dedicated to PET-CT which combines functional and morphological imaging. Furthermore latest developments in MRI are presented with regard to lymph node staging and response prediction. Last but not least, a clinical contribution in this review explains, which information the head and neck surgeon requires from the multimodality imaging and its impact on operation planning.},
	author = {Sadick, M. and Schoenberg, S. O. and Hoermann, K. and Sadick, H.},
	doi = {10.3205/cto000090},
	issn = {1865-1011 (Print) 1865-1011},
	journal = {GMS Curr Top Otorhinolaryngol Head Neck Surg},
	keywords = {Hnscc Mri Pet-ct diffusion weighted imaging head and neck carcinoma hypoxia imaging lymph node staging},
	note = {1865-1011 Sadick, Maliha Schoenberg, Stefan O Hoermann, Karl Sadick, Haneen Journal Article 2013/01/16 GMS Curr Top Otorhinolaryngol Head Neck Surg. 2012;11:Doc08. doi: 10.3205/cto000090. Epub 2012 Dec 20.},
	pages = {Doc08},
	title = {Current oncologic concepts and emerging techniques for imaging of head and neck squamous cell cancer},
	type = {Journal Article},
	volume = {11},
	year = {2012},
	bdsk-url-1 = {https://doi.org/10.3205/cto000090}}

@article{RN15,
	abstract = {This article compares the expression and applicability of biomarkers, from single genes and gene signatures, identified in patients with locally advanced head and neck squamous cell carcinoma using the GeneChip Human Transcriptome Array 2.0, nCounter, and real-time PCR analyses. Two multicenter, retrospective cohorts of patients with head and neck squamous cell carcinoma from the German Cancer Consortium Radiation Oncology Group who received postoperative radiochemotherapy or primary radiochemotherapy were considered. Real-time PCR was performed for a limited number of 38 genes of the cohort who received postoperative radiochemotherapy only. Correlations between the methods were evaluated by the Spearman rank correlation coefficient. Patients were stratified based on the expression of putative cancer stem cell markers, hypoxia-associated gene signatures, and a previously developed seven-gene signature. Locoregional tumor control was compared between these patient subgroups using log-rank tests. Gene expressions obtained from nCounter analyses were moderately correlated to GeneChip analyses (median rho = approximately 0.68). A higher correlation was obtained between nCounter analyses and real-time PCR (median rho = 0.84). Significant associations with locoregional tumor control were observed for most of the considered biomarkers evaluated by GeneChip and nCounter analyses. In general, all applied biomarkers (single genes and gene signatures) classified approximately 70% to 85% of the patients similarly. Overall, gene signatures seem to be more robust and had a better transferability among different measurement methods.},
	author = {Schmidt, S. and Linge, A. and Grosser, M. and Lohaus, F. and Gudziol, V. and Nowak, A. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Schafer, H. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Ganswindt, U. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and Baretton, G. B. and Buchholz, F. and Baumann, M. and Krause, M. and Lock, S. and German Cancer Consortium Radiation Oncology, Group},
	doi = {10.1016/j.jmoldx.2020.03.005},
	issn = {1943-7811 (Electronic) 1525-1578 (Linking)},
	journal = {J Mol Diagn},
	note = {Schmidt, Stefan Linge, Annett Grosser, Marianne Lohaus, Fabian Gudziol, Volker Nowak, Alexander Tinhofer, Ingeborg Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Schafer, Henning Grosu, Anca-Ligia Abdollahi, Amir Debus, Jurgen Ganswindt, Ute Belka, Claus Pigorsch, Steffi Combs, Stephanie E Monnich, David Zips, Daniel Baretton, Gustavo B Buchholz, Frank Baumann, Michael Krause, Mechthild Lock, Steffen eng Research Support, Non-U.S. Gov't J Mol Diagn. 2020 Jun;22(6):801-810. doi: 10.1016/j.jmoldx.2020.03.005. Epub 2020 Apr 2.},
	number = {6},
	pages = {801-810},
	title = {Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma},
	type = {Journal Article},
	url = {https://www.jmdjournal.org/article/S1525-1578(20)30076-3/pdf},
	volume = {22},
	year = {2020},
	bdsk-url-1 = {https://www.jmdjournal.org/article/S1525-1578(20)30076-3/pdf},
	bdsk-url-2 = {https://doi.org/10.1016/j.jmoldx.2020.03.005}}

@article{RN36,
	abstract = {Purpose: The aim of this study was to identify and independently validate a novel gene signature predicting locoregional tumor control (LRC) for treatment individualization of patients with locally advanced HPV-negative head and neck squamous cell carcinomas (HNSCC) who are treated with postoperative radio(chemo)therapy (PORT-C).Experimental Design: Gene expression analyses were performed using NanoString technology on a multicenter training cohort of 130 patients and an independent validation cohort of 121 patients. The analyzed gene set was composed of genes with a previously reported association with radio(chemo)sensitivity or resistance to radio(chemo)therapy. Gene selection and model building were performed comparing several machine-learning algorithms.Results: We identified a 7-gene signature consisting of the three individual genes HILPDA, CD24, TCF3, and one metagene combining the highly correlated genes SERPINE1, INHBA, P4HA2, and ACTN1 The 7-gene signature was used, in combination with clinical parameters, to fit a multivariable Cox model to the training data (concordance index, ci = 0.82), which was successfully validated (ci = 0.71). The signature showed improved performance compared with clinical parameters alone (ci = 0.66) and with a previously published model including hypoxia-associated genes and cancer stem cell markers (ci = 0.65). It was used to stratify patients into groups with low and high risk of recurrence, leading to significant differences in LRC in training and validation (P < 0.001).Conclusions: We have identified and validated the first hypothesis-based gene signature for HPV-negative HNSCC treated by PORT-C including genes related to several radiobiological aspects. A prospective validation is planned in an ongoing prospective clinical trial before potential application in clinical trials for patient stratification. Clin Cancer Res; 24(6); 1364-74. (c)2018 AACR.},
	author = {Schmidt, S. and Linge, A. and Zwanenburg, A. and Leger, S. and Lohaus, F. and Krenn, C. and Appold, S. and Gudziol, V. and Nowak, A. and von Neubeck, C. and Tinhofer, I. and Budach, V. and Sak, A. and Stuschke, M. and Balermpas, P. and Rodel, C. and Bunea, H. and Grosu, A. L. and Abdollahi, A. and Debus, J. and Ganswindt, U. and Belka, C. and Pigorsch, S. and Combs, S. E. and Monnich, D. and Zips, D. and Baretton, G. B. and Buchholz, F. and Baumann, M. and Krause, M. and Lock, S. and Dktk, R. O. G.},
	doi = {10.1158/1078-0432.CCR-17-2345},
	issn = {1557-3265 (Electronic) 1078-0432 (Linking)},
	journal = {Clin Cancer Res},
	keywords = {Adolescent Adult Aged Aged, 80 and over *Biomarkers, Tumor Chemoradiotherapy Child Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Head and Neck Neoplasms/diagnosis/*genetics/mortality/*therapy Humans Male Middle Aged Neoplasm Grading Neoplasm Metastasis Neoplasm Staging Postoperative Care Retrospective Studies *Transcriptome Treatment Outcome Young Adult},
	note = {Schmidt, Stefan Linge, Annett Zwanenburg, Alex Leger, Stefan Lohaus, Fabian Krenn, Constanze Appold, Steffen Gudziol, Volker Nowak, Alexander von Neubeck, Clare Tinhofer, Inge Budach, Volker Sak, Ali Stuschke, Martin Balermpas, Panagiotis Rodel, Claus Bunea, Hatice Grosu, Anca-Ligia Abdollahi, Amir Debus, Jurgen Ganswindt, Ute Belka, Claus Pigorsch, Steffi Combs, Stephanie E Monnich, David Zips, Daniel Baretton, Gustavo B Buchholz, Frank Baumann, Michael Krause, Mechthild Lock, Steffen eng Multicenter Study Research Support, Non-U.S. Gov't Clin Cancer Res. 2018 Mar 15;24(6):1364-1374. doi: 10.1158/1078-0432.CCR-17-2345. Epub 2018 Jan 3.},
	number = {6},
	pages = {1364-1374},
	title = {Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy},
	type = {Journal Article},
	url = {https://clincancerres.aacrjournals.org/content/clincanres/24/6/1364.full.pdf},
	volume = {24},
	year = {2018},
	bdsk-url-1 = {https://clincancerres.aacrjournals.org/content/clincanres/24/6/1364.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/1078-0432.CCR-17-2345}}

@book{RN407,
	author = {Schmincke, A.},
	publisher = {Gustav Fischer Verlag},
	title = {Beitrage zur pathologischen Anatomie und allgemeinen Pathologie},
	type = {Book},
	url = {https://books.google.de/books?id=F3pMAQAAMAAJ},
	year = {1921},
	bdsk-url-1 = {https://books.google.de/books?id=F3pMAQAAMAAJ}}

@book{RN125,
	author = {Schmincke, A.},
	publisher = {Gustav Fischer Verlag},
	title = {Beitrage zur pathologischen Anatomie und allgemeinen Pathologie},
	type = {Book},
	url = {https://books.google.de/books?id=F3pMAQAAMAAJ},
	year = {1921},
	bdsk-url-1 = {https://books.google.de/books?id=F3pMAQAAMAAJ}}

@article{RN103,
	abstract = {The relationship between human papillomavirus (HPV) type 16 infection and p53 gene mutations was investigated in squamous cell carcinomas of the head and neck (SCCHN). HPV was detected by general primer-mediated and type-specific PCR. Alterations in the p53 gene were investigated using single-strand conformation polymorphism and sequence analysis in 27 SCCHN, of which 12 were HPV 16-positive and 15 were HPV-negative. Mutations were detected in 2/12 (16.7%) HPV 16-positive and 7/15 (46.7%) HPV-negative tumours; this difference was not statistically significant. The predominant mutations were deletions and C --> T transitions; G --> T transversions were found in only 2 tumours. Our results indicate that the presence of HPV 16 and p53 mutations is not mutually exclusive and detection of a p53 mutation does not exclude a potential role for HPV 16 in the pathogenesis of a subset of SCCHN.},
	author = {Scholes, A. G. and Liloglou, T. and Snijders, P. J. and Hart, C. A. and Jones, A. S. and Woolgar, J. A. and Vaughan, E. D. and Walboomers, J. M. and Field, J. K.},
	doi = {10.1002/(sici)1097-0215(19970529)71:5<796::aid-ijc17>3.0.co;2-6},
	issn = {0020-7136 (Print) 0020-7136},
	journal = {Int J Cancer},
	keywords = {Carcinoma, Squamous Cell/genetics/*virology Exons Gene Deletion Genes, p53/*genetics Head and Neck Neoplasms/genetics/*virology Humans Mutation *Papillomaviridae/isolation & purification Papillomavirus Infections/*genetics Polymerase Chain Reaction Polymorphism, Single-Stranded Conformational Smoking Tumor Virus Infections/*genetics},
	note = {Scholes, A G Liloglou, T Snijders, P J Hart, C A Jones, A S Woolgar, J A Vaughan, E D Walboomers, J M Field, J K Journal Article Research Support, Non-U.S. Gov't United States 1997/05/29 Int J Cancer. 1997 May 29;71(5):796-9. doi: 10.1002/(sici)1097-0215(19970529)71:5<796::aid-ijc17>3.0.co;2-6.},
	number = {5},
	pages = {796-9},
	title = {p53 mutations in relation to human papillomavirus type 16 infection in squamous cell carcinomas of the head and neck},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/%28SICI%291097-0215%2819970529%2971%3A5%3C796%3A%3AAID-IJC17%3E3.0.CO%3B2-6?download=true},
	volume = {71},
	year = {1997},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/%28SICI%291097-0215%2819970529%2971%3A5%3C796%3A%3AAID-IJC17%3E3.0.CO%3B2-6?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/(sici)1097-0215(19970529)71:5%3C796::aid-ijc17%3E3.0.co;2-6}}

@article{RN206,
	abstract = {Gegen{\"u}ber einer alleinigen Bestrahlung von fortgeschrittenen inoperablen Kopf-Hals-Tumoren kann eine simultane Radiochemotherapie die lokoregion{\"a}re Tumorkontrolle und das {\"U}berleben der Patienten verbessern. Heute liegt dazu eine Vielzahl randomisierter multizentrischer Phase-III-Studien mit verschiedenen Fraktionierungsschemata vor. Intensivierte Bestrahlungsprotokolle sowie der Einsatz von Taxanen erh{\"o}hen die Effektivit{\"a}t, aber auch die akute Therapietoxizit{\"a}t. Vor diesem Hintergrund sind das optimale Fraktionierungsschema sowie die optimale Substanzkombination Gegenstand aktueller wissenschaftlicher Untersuchungen. Die neoadjuvante Chemotherapie kann nicht als Behandlungsstandard angesehen werden.},
	author = {Semrau, R. and Fietkau, R. and Werner, J. A. and Mueller, R. P.},
	doi = {10.1007/s00761-006-1161-0},
	issn = {1433-0415},
	journal = {Der Onkologe},
	number = {2},
	pages = {165-173},
	title = {Radiochemotherapie als Behandlungsstandard fortgeschrittener Kopf-Hals-Karzinome},
	type = {Journal Article},
	url = {https://link.springer.com/content/pdf/10.1007/s00761-006-1161-0.pdf},
	volume = {13},
	year = {2007},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007/s00761-006-1161-0.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/s00761-006-1161-0}}

@article{RN147,
	abstract = {A multicenter case-control study was conducted during 1999-2002 in four European countries (Poland, Romania, Russia, and Slovakia) to evaluate the role of occupational exposures in risk of laryngeal/hypopharyngeal cancer. Male cancer cases (34 hypopharyngeal, 316 laryngeal) with full data on occupational history and nonoccupational factors were compared with 728 hospital controls for occupational exposure to 73 suspected carcinogens. Occupational history was evaluated by industrial hygienists blinded to case/control status. Elevated risks for ever exposure to coal dust were found for both hypopharyngeal (odds ratio (OR) = 4.19, 95% confidence interval (CI): 1.18, 14.89) and laryngeal (OR = 1.81, 95% CI: 0.94, 3.47) cancer, with clear dose-response patterns. Inclusion of a 20-year lag in the analysis strengthened these associations. Hypopharyngeal cancer risk was also significantly associated with exposure to mild steel dust (OR = 3.04, 95% CI: 1.39, 6.64) and iron compounds and fumes (OR = 2.74, 95% CI: 1.29, 5.84), without clear dose-response relations. Laryngeal cancer was significantly associated with exposure to hard-alloys dust (OR = 2.23, 95% CI: 1.08, 4.57) and chlorinated solvents (OR = 2.18, 95% CI: 1.03, 4.61), without dose-response relations. A possible link between high formaldehyde exposure and laryngeal cancer was suggested. No association was found for exposure to asbestos or inorganic acid mists. These data indicate that occupational exposure to coal dust may play a role in laryngeal and hypopharyngeal cancer. Other possible relations need further evaluation.},
	author = {Shangina, O. and Brennan, P. and Szeszenia-Dabrowska, N. and Mates, D. and Fabi{\'a}nov{\'a}, E. and Fletcher, T. and t'Mannetje, A. and Boffetta, P. and Zaridze, D.},
	doi = {10.1093/aje/kwj208},
	issn = {0002-9262 (Print) 0002-9262},
	journal = {Am J Epidemiol},
	keywords = {Adult Aged Case-Control Studies Europe, Eastern/epidemiology Humans Hypopharyngeal Neoplasms/epidemiology/*etiology Laryngeal Neoplasms/epidemiology/*etiology Male Middle Aged Occupational Exposure/*adverse effects},
	note = {Shangina, Oxana Brennan, Paul Szeszenia-Dabrowska, Neonila Mates, Dana Fabi{\'a}nov{\'a}, Eleon{\'o}ra Fletcher, Tony t'Mannetje, Andrea Boffetta, Paolo Zaridze, David Journal Article Multicenter Study Research Support, Non-U.S. Gov't United States 2006/06/28 Am J Epidemiol. 2006 Aug 15;164(4):367-75. doi: 10.1093/aje/kwj208. Epub 2006 Jun 26.},
	number = {4},
	pages = {367-75},
	title = {Occupational exposure and laryngeal and hypopharyngeal cancer risk in central and eastern Europe},
	type = {Journal Article},
	url = {https://watermark.silverchair.com/kwj208.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAr4wggK6BgkqhkiG9w0BBwagggKrMIICpwIBADCCAqAGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM0n9_NBsBcVUESj0PAgEQgIICcQ5ayTgbV5ZpkF9ooqTuCHTBW6lFMbSoVHDgCpnxBjN9N0Cb12Zglu82fZxXZn2wNdCyg8oPsik-3SF6AqWbESTysr-SegT8QpvMQ32ISF2Akuut40KKnijjIW650TQm1mw97OjltJb6s-j5i1gCRPZHgMkOpc-vXtNcspX0882cE1OXGEWW6tQLgOnxKRIz42Dv1WfN9k_-2QIBG7HOSefRZ9FyJVr7bV_mEeSbF-nIF7zDelVrmNlPmK98a1ArEOhSQPQ9-0KR_Sr8b8PxBwHKc5ekhfec45gVH8m1C35u39V9uSAD2LPoNnZ9qE4fKQtMJ5k7DCcoAOziHZOMKY8vW20dxn3Bugzez4cMIACwHlGY_LFy7IXTJ6JtRawW9Afp7GVljfdFdiv52WtGYqz5x_45ROuKFVAsPGGyMS-_Bj9wtKSdyWMVoktQ_TIbzMt30GV0nZD1L5jl2EWRExyKO2CgBNNDE8-kxDpjzQEirEOLFMBK0gULVpe4ANfGbm84h7ufNyGst7iC7wojlPGfm0In7mwbqW4eNSx6x0TmleYlyS1zZBltQPzo0sFafvHP2uT4iqp72E9gxMTUifLzGe3cxZ6cBvHvp5O9kqz4deJjgkDVapGicagnAMGPsvYTFKr5eescytltkMP5j9lYw6OLhEIs0fExkRAdQtHqfbFDIhmB4bAcYgXLyyPxnWmoFUhnGlj-KOoKfM4Hx2U2Kk-2XfvdOgmSIOFKFv1Ld-h6IMMhQnrDva_2jWAAk1QppsZyo9QQKFVLwFBRWdraJ7MEveDgDcQj9RnzGJEmo8jnuN9DsfJFT4B3Jy20IlY},
	volume = {164},
	year = {2006},
	bdsk-url-1 = {https://watermark.silverchair.com/kwj208.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAr4wggK6BgkqhkiG9w0BBwagggKrMIICpwIBADCCAqAGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM0n9_NBsBcVUESj0PAgEQgIICcQ5ayTgbV5ZpkF9ooqTuCHTBW6lFMbSoVHDgCpnxBjN9N0Cb12Zglu82fZxXZn2wNdCyg8oPsik-3SF6AqWbESTysr-SegT8QpvMQ32ISF2Akuut40KKnijjIW650TQm1mw97OjltJb6s-j5i1gCRPZHgMkOpc-vXtNcspX0882cE1OXGEWW6tQLgOnxKRIz42Dv1WfN9k_-2QIBG7HOSefRZ9FyJVr7bV_mEeSbF-nIF7zDelVrmNlPmK98a1ArEOhSQPQ9-0KR_Sr8b8PxBwHKc5ekhfec45gVH8m1C35u39V9uSAD2LPoNnZ9qE4fKQtMJ5k7DCcoAOziHZOMKY8vW20dxn3Bugzez4cMIACwHlGY_LFy7IXTJ6JtRawW9Afp7GVljfdFdiv52WtGYqz5x_45ROuKFVAsPGGyMS-_Bj9wtKSdyWMVoktQ_TIbzMt30GV0nZD1L5jl2EWRExyKO2CgBNNDE8-kxDpjzQEirEOLFMBK0gULVpe4ANfGbm84h7ufNyGst7iC7wojlPGfm0In7mwbqW4eNSx6x0TmleYlyS1zZBltQPzo0sFafvHP2uT4iqp72E9gxMTUifLzGe3cxZ6cBvHvp5O9kqz4deJjgkDVapGicagnAMGPsvYTFKr5eescytltkMP5j9lYw6OLhEIs0fExkRAdQtHqfbFDIhmB4bAcYgXLyyPxnWmoFUhnGlj-KOoKfM4Hx2U2Kk-2XfvdOgmSIOFKFv1Ld-h6IMMhQnrDva_2jWAAk1QppsZyo9QQKFVLwFBRWdraJ7MEveDgDcQj9RnzGJEmo8jnuN9DsfJFT4B3Jy20IlY},
	bdsk-url-2 = {https://doi.org/10.1093/aje/kwj208}}

@article{RN367,
	author = {Shi, W. and Kato, H. and Perez-Ordonez, B. and Pintilie, M. and Huang, S. and Hui, A. and O'Sullivan, B. and Waldron, J. and Cummings, B. and Kim, J. and Ringash, J. and Dawson, L. A. and Gullane, P. and Siu, L. and Gillison, M. and Liu, F. F.},
	doi = {10.1200/jco.2009.23.1670},
	issn = {0732-183x},
	journal = {J Clin Oncol},
	keywords = {Adult Aged, 80 and over Carcinoma, Squamous Cell/metabolism/*virology Cyclin-Dependent Kinase Inhibitor p16 Disease-Free Survival ErbB Receptors/biosynthesis Female Humans In Situ Hybridization Male Middle Aged Neoplasm Proteins/biosynthesis Oncogene Proteins, Viral/biosynthesis/*genetics Oropharyngeal Neoplasms/metabolism/*virology Papillomaviridae/*genetics/metabolism Papillomavirus Infections/metabolism/virology Polymerase Chain Reaction Prognosis Prospective Studies RNA, Messenger/*biosynthesis/genetics Repressor Proteins/biosynthesis/*genetics Treatment Outcome Tumor Suppressor Protein p53/biosynthesis Young Adult},
	number = {36},
	pages = {6213-21},
	title = {Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma},
	type = {Journal Article},
	volume = {27},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1200/jco.2009.23.1670}}

@article{RN442,
	author = {Shi, W. and Kato, H. and Perez-Ordonez, B. and Pintilie, M. and Huang, S. and Hui, A. and O'Sullivan, B. and Waldron, J. and Cummings, B. and Kim, J. and Ringash, J. and Dawson, L. A. and Gullane, P. and Siu, L. and Gillison, M. and Liu, F. F.},
	doi = {10.1200/JCO.2009.23.1670},
	issn = {1527-7755 (Electronic) 0732-183X (Linking)},
	journal = {J Clin Oncol},
	keywords = {Adult Aged, 80 and over Carcinoma, Squamous Cell/metabolism/*virology Cyclin-Dependent Kinase Inhibitor p16 Disease-Free Survival ErbB Receptors/biosynthesis Female Humans In Situ Hybridization Male Middle Aged Neoplasm Proteins/biosynthesis Oncogene Proteins, Viral/biosynthesis/*genetics Oropharyngeal Neoplasms/metabolism/*virology Papillomaviridae/*genetics/metabolism Papillomavirus Infections/metabolism/virology Polymerase Chain Reaction Prognosis Prospective Studies RNA, Messenger/*biosynthesis/genetics Repressor Proteins/biosynthesis/*genetics Treatment Outcome Tumor Suppressor Protein p53/biosynthesis Young Adult},
	number = {36},
	pages = {6213-21},
	title = {Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/19884544},
	volume = {27},
	year = {2009},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/19884544},
	bdsk-url-2 = {https://doi.org/10.1200/JCO.2009.23.1670}}

@article{RN55,
	abstract = {PURPOSE: A significant proportion of oropharyngeal squamous cell carcinomas (OSCC) are associated with the human papilloma virus (HPV), particularly HPV16. The optimal method for HPV determination on archival materials however, remains unclear. We compared a quantitative real-time polymerase chain reaction (qRT-PCR) assay for HPV16 mRNA to a DNA in situ hybridization (ISH) method, and evaluated their significance for overall (OS) and disease-free (DFS) survival. PATIENTS AND METHODS: Matched, archival biopsies from 111 patients with OSCC were evaluated for HPV16 using a qRT-PCR for E6 mRNA and ISH for DNA. Immunohistochemistry for p16, p53, and epidermal growth factor receptor were also performed. RESULTS: HPV16 E6 mRNA was positive in 73 (66%) of 111 samples; ISH was positive in 62 of 106 samples (58%), with 86% concordance. P16 was overexpressed in 72 samples (65%), which was strongly associated with HPV16 status by either method. E6 mRNA presence or p16 overexpression were significantly associated with superior OS; E6 mRNA, HPV16 ISH, or p16 were all significantly associated with DFS. On multivariate analysis adjusted for age, stage, and treatment, positive E6 mRNA was the only independent predictor for superior OS; for DFS, p16 expression or HPV16 status determined by either method was significant. CONCLUSION: The prevalence of HPV16 in OSCC ranges from 58% to 66%, in a recently treated Canadian cohort. Classification of HPV-positivity by HPV16 E6 mRNA, HPV16 ISH or p16 immunohistochemistry (IHC) is associated with improved DFS. However, the latter two assays are technically easier to perform; hence, HPV16 ISH or p16 IHC should become standard evaluations for all patients with OSCC.},
	author = {Shi, W. and Kato, H. and Perez-Ordonez, B. and Pintilie, M. and Huang, S. and Hui, A. and O'Sullivan, B. and Waldron, J. and Cummings, B. and Kim, J. and Ringash, J. and Dawson, L. A. and Gullane, P. and Siu, L. and Gillison, M. and Liu, F. F.},
	doi = {10.1200/JCO.2009.23.1670},
	issn = {1527-7755 (Electronic) 0732-183X (Linking)},
	journal = {J Clin Oncol},
	keywords = {Adult Aged, 80 and over Carcinoma, Squamous Cell/metabolism/*virology Cyclin-Dependent Kinase Inhibitor p16 Disease-Free Survival ErbB Receptors/biosynthesis Female Humans In Situ Hybridization Male Middle Aged Neoplasm Proteins/biosynthesis Oncogene Proteins, Viral/biosynthesis/*genetics Oropharyngeal Neoplasms/metabolism/*virology Papillomaviridae/*genetics/metabolism Papillomavirus Infections/metabolism/virology Polymerase Chain Reaction Prognosis Prospective Studies RNA, Messenger/*biosynthesis/genetics Repressor Proteins/biosynthesis/*genetics Treatment Outcome Tumor Suppressor Protein p53/biosynthesis Young Adult},
	note = {Shi, Wei Kato, Hisayuki Perez-Ordonez, Bayardo Pintilie, Melania Huang, Shaohui Hui, Angela O'Sullivan, Brian Waldron, John Cummings, Bernard Kim, John Ringash, Jolie Dawson, Laura A Gullane, Patrick Siu, Lillian Gillison, Maura Liu, Fei-Fei eng Canadian Institutes of Health Research/Canada Research Support, Non-U.S. Gov't 2009/11/04 J Clin Oncol. 2009 Dec 20;27(36):6213-21. doi: 10.1200/JCO.2009.23.1670. Epub 2009 Nov 2.},
	number = {36},
	pages = {6213-21},
	title = {Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/19884544},
	volume = {27},
	year = {2009},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/19884544},
	bdsk-url-2 = {https://doi.org/10.1200/JCO.2009.23.1670}}

@article{RN101,
	abstract = {PURPOSE: A significant proportion of oropharyngeal squamous cell carcinomas (OSCC) are associated with the human papilloma virus (HPV), particularly HPV16. The optimal method for HPV determination on archival materials however, remains unclear. We compared a quantitative real-time polymerase chain reaction (qRT-PCR) assay for HPV16 mRNA to a DNA in situ hybridization (ISH) method, and evaluated their significance for overall (OS) and disease-free (DFS) survival. PATIENTS AND METHODS: Matched, archival biopsies from 111 patients with OSCC were evaluated for HPV16 using a qRT-PCR for E6 mRNA and ISH for DNA. Immunohistochemistry for p16, p53, and epidermal growth factor receptor were also performed. RESULTS: HPV16 E6 mRNA was positive in 73 (66%) of 111 samples; ISH was positive in 62 of 106 samples (58%), with 86% concordance. P16 was overexpressed in 72 samples (65%), which was strongly associated with HPV16 status by either method. E6 mRNA presence or p16 overexpression were significantly associated with superior OS; E6 mRNA, HPV16 ISH, or p16 were all significantly associated with DFS. On multivariate analysis adjusted for age, stage, and treatment, positive E6 mRNA was the only independent predictor for superior OS; for DFS, p16 expression or HPV16 status determined by either method was significant. CONCLUSION: The prevalence of HPV16 in OSCC ranges from 58% to 66%, in a recently treated Canadian cohort. Classification of HPV-positivity by HPV16 E6 mRNA, HPV16 ISH or p16 immunohistochemistry (IHC) is associated with improved DFS. However, the latter two assays are technically easier to perform; hence, HPV16 ISH or p16 IHC should become standard evaluations for all patients with OSCC.},
	author = {Shi, W. and Kato, H. and Perez-Ordonez, B. and Pintilie, M. and Huang, S. and Hui, A. and O'Sullivan, B. and Waldron, J. and Cummings, B. and Kim, J. and Ringash, J. and Dawson, L. A. and Gullane, P. and Siu, L. and Gillison, M. and Liu, F. F.},
	doi = {10.1200/jco.2009.23.1670},
	issn = {0732-183x},
	journal = {J Clin Oncol},
	keywords = {Adult Aged, 80 and over Carcinoma, Squamous Cell/metabolism/*virology Cyclin-Dependent Kinase Inhibitor p16 Disease-Free Survival ErbB Receptors/biosynthesis Female Humans In Situ Hybridization Male Middle Aged Neoplasm Proteins/biosynthesis Oncogene Proteins, Viral/biosynthesis/*genetics Oropharyngeal Neoplasms/metabolism/*virology Papillomaviridae/*genetics/metabolism Papillomavirus Infections/metabolism/virology Polymerase Chain Reaction Prognosis Prospective Studies RNA, Messenger/*biosynthesis/genetics Repressor Proteins/biosynthesis/*genetics Treatment Outcome Tumor Suppressor Protein p53/biosynthesis Young Adult},
	note = {1527-7755 Shi, Wei Kato, Hisayuki Perez-Ordonez, Bayardo Pintilie, Melania Huang, Shaohui Hui, Angela O'Sullivan, Brian Waldron, John Cummings, Bernard Kim, John Ringash, Jolie Dawson, Laura A Gullane, Patrick Siu, Lillian Gillison, Maura Liu, Fei-Fei Canadian Institutes of Health Research/Canada Journal Article Research Support, Non-U.S. Gov't United States 2009/11/04 J Clin Oncol. 2009 Dec 20;27(36):6213-21. doi: 10.1200/JCO.2009.23.1670. Epub 2009 Nov 2.},
	number = {36},
	pages = {6213-21},
	title = {Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma},
	type = {Journal Article},
	volume = {27},
	year = {2009},
	bdsk-url-1 = {https://doi.org/10.1200/jco.2009.23.1670}}

@article{RN298,
	abstract = {The cancer stem cell (CSC) hypothesis suggests that neoplastic clones are maintained exclusively by a rare fraction of cells with stem cell properties. Although the existence of CSCs in human leukaemia is established, little evidence exists for CSCs in solid tumours, except for breast cancer. Recently, we prospectively isolated a CD133+ cell subpopulation from human brain tumours that exhibited stem cell properties in vitro. However, the true measures of CSCs are their capacity for self renewal and exact recapitulation of the original tumour. Here we report the development of a xenograft assay that identified human brain tumour initiating cells that initiate tumours in vivo. Only the CD133+ brain tumour fraction contains cells that are capable of tumour initiation in NOD-SCID (non-obese diabetic, severe combined immunodeficient) mouse brains. Injection of as few as 100 CD133+ cells produced a tumour that could be serially transplanted and was a phenocopy of the patient's original tumour, whereas injection of 10(5) CD133- cells engrafted but did not cause a tumour. Thus, the identification of brain tumour initiating cells provides insights into human brain tumour pathogenesis, giving strong support for the CSC hypothesis as the basis for many solid tumours, and establishes a previously unidentified cellular target for more effective cancer therapies.},
	author = {Singh, S. K. and Hawkins, C. and Clarke, I. D. and Squire, J. A. and Bayani, J. and Hide, T. and Henkelman, R. M. and Cusimano, M. D. and Dirks, P. B.},
	doi = {10.1038/nature03128},
	issn = {0028-0836},
	journal = {Nature},
	keywords = {AC133 Antigen Animals Antigens, CD Brain/metabolism/pathology Brain Neoplasms/genetics/metabolism/*pathology Cell Line, Tumor Cell Separation Cell Transplantation Glycoproteins/analysis/metabolism Humans Immunohistochemistry Medulloblastoma/genetics/metabolism/pathology Mice Mice, Inbred NOD Mice, SCID Models, Biological Neoplasm Transplantation Peptides/analysis/metabolism Stem Cells/metabolism/*pathology},
	note = {1476-4687 Singh, Sheila K Hawkins, Cynthia Clarke, Ian D Squire, Jeremy A Bayani, Jane Hide, Takuichiro Henkelman, R Mark Cusimano, Michael D Dirks, Peter B Journal Article Research Support, Non-U.S. Gov't England 2004/11/19 Nature. 2004 Nov 18;432(7015):396-401. doi: 10.1038/nature03128.},
	number = {7015},
	pages = {396-401},
	title = {Identification of human brain tumour initiating cells},
	type = {Journal Article},
	url = {https://www.nature.com/articles/nature03128.pdf},
	volume = {432},
	year = {2004},
	bdsk-url-1 = {https://www.nature.com/articles/nature03128.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/nature03128}}

@article{RN261,
	abstract = {PURPOSE: In a prospective randomized clinical study, simultaneous postoperative application of irradiation (RT), mitomycin C, and bleomycin was tested in a group of patients with operable advanced head-and-neck carcinoma. It was expected that the planned combined postoperative therapy would reduce the number of locoregional recurrences and prolong survival. METHODS AND MATERIALS: A total of 114 eligible patients with Stage III or IV squamous cell head-and-neck carcinoma were randomized to receive postoperative RT alone (Group 1) or RT combined with simultaneous mitomycin C and bleomycin (Group 2). Patients were stratified according to the stage and site of the primary tumor and the presence or absence of high-risk prognostic factors. Primary surgical treatment was performed with curative intent in all patients. Patients in both groups were postoperatively irradiated to the total dose of 56-70 Gy. Chemotherapy included mitomycin C 15 mg/m(2) after 10 Gy and 5 mg of bleomycin twice a week during RT to the planned total dose of 70 mg. RESULTS: At 2 years, patients in the radiochemotherapy group had better locoregional control (86%) than those in the RT alone group (69%; p = 0.037). Disease-free survival and overall survival was also better in the radiochemotherapy group compared with the RT-alone group (76% vs. 60%, p = 0.099; and 74% vs. 64%, p = 0.036, respectively). Patients who benefited from chemotherapy were those with high-risk factors. CONCLUSION: The results of the present study indicate that concomitant postoperative radiochemotherapy with mitomycin C and bleomycin improves locoregional control and survival in patients with advanced head-and-neck carcinoma. The patients who benefited from chemotherapy were those with high-risk factors.},
	author = {Smid, L. and Budihna, M. and Zakotnik, B. and Soba, E. and Strojan, P. and Fajdiga, I. and Zargi, M. and Oblak, I. and Dremelj, M. and LeSnicar, H.},
	doi = {10.1016/s0360-3016(03)00207-4},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Adult Aged Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Bleomycin/administration & dosage/adverse effects Carcinoma, Squamous Cell/*drug therapy/*radiotherapy/surgery Combined Modality Therapy/adverse effects Disease-Free Survival Female Head and Neck Neoplasms/*drug therapy/*radiotherapy/surgery Humans Male Middle Aged Mitomycin/administration & dosage/adverse effects Patient Compliance Postoperative Care Prospective Studies Radiotherapy/adverse effects},
	note = {Smid, Lojze Budihna, Marjan Zakotnik, Branko Soba, Erika Strojan, Primoz Fajdiga, Igor Zargi, Miha Oblak, Irena Dremelj, Marta LeSnicar, Hotimir Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States 2003/06/28 Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1055-62. doi: 10.1016/s0360-3016(03)00207-4.},
	number = {4},
	pages = {1055-62},
	title = {Postoperative concomitant irradiation and chemotherapy with mitomycin C and bleomycin for advanced head-and-neck carcinoma},
	type = {Journal Article},
	url = {https://www.redjournal.org/article/S0360-3016(03)00207-4/pdf},
	volume = {56},
	year = {2003},
	bdsk-url-1 = {https://www.redjournal.org/article/S0360-3016(03)00207-4/pdf},
	bdsk-url-2 = {https://doi.org/10.1016/s0360-3016(03)00207-4}}

@article{RN350,
	author = {Smith, E. M. and Ritchie, J. M. and Summersgill, K. F. and Klussmann, J. P. and Lee, J. H. and Wang, D. and Haugen, T. H. and Turek, L. P.},
	doi = {10.1002/ijc.11633},
	issn = {0020-7136 (Print) 0020-7136},
	journal = {Int J Cancer},
	keywords = {Age Factors DNA, Viral/analysis Female Humans Male Middle Aged Mouth/*virology Mouth Neoplasms/pathology/*virology Oropharyngeal Neoplasms/pathology/*virology *Papillomaviridae Papillomavirus Infections/*complications Risk Factors Sexual Behavior},
	number = {5},
	pages = {766-72},
	title = {Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers},
	type = {Journal Article},
	volume = {108},
	year = {2004},
	bdsk-url-1 = {https://doi.org/10.1002/ijc.11633}}

@article{RN353,
	author = {Smith, E. M. and Ritchie, J. M. and Summersgill, K. F. and Klussmann, J. P. and Lee, J. H. and Wang, D. and Haugen, T. H. and Turek, L. P.},
	doi = {10.1002/ijc.11633},
	issn = {0020-7136 (Print) 0020-7136},
	journal = {Int J Cancer},
	keywords = {Age Factors DNA, Viral/analysis Female Humans Male Middle Aged Mouth/*virology Mouth Neoplasms/pathology/*virology Oropharyngeal Neoplasms/pathology/*virology *Papillomaviridae Papillomavirus Infections/*complications Risk Factors Sexual Behavior},
	number = {5},
	pages = {766-72},
	title = {Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers},
	type = {Journal Article},
	volume = {108},
	year = {2004},
	bdsk-url-1 = {https://doi.org/10.1002/ijc.11633}}

@article{RN356,
	author = {Smith, E. M. and Ritchie, J. M. and Summersgill, K. F. and Klussmann, J. P. and Lee, J. H. and Wang, D. and Haugen, T. H. and Turek, L. P.},
	doi = {10.1002/ijc.11633},
	issn = {0020-7136 (Print) 0020-7136},
	journal = {Int J Cancer},
	keywords = {Age Factors DNA, Viral/analysis Female Humans Male Middle Aged Mouth/*virology Mouth Neoplasms/pathology/*virology Oropharyngeal Neoplasms/pathology/*virology *Papillomaviridae Papillomavirus Infections/*complications Risk Factors Sexual Behavior},
	number = {5},
	pages = {766-72},
	title = {Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers},
	type = {Journal Article},
	volume = {108},
	year = {2004},
	bdsk-url-1 = {https://doi.org/10.1002/ijc.11633}}

@article{RN361,
	author = {Smith, E. M. and Ritchie, J. M. and Summersgill, K. F. and Klussmann, J. P. and Lee, J. H. and Wang, D. and Haugen, T. H. and Turek, L. P.},
	doi = {10.1002/ijc.11633},
	issn = {0020-7136 (Print) 0020-7136},
	journal = {Int J Cancer},
	keywords = {Age Factors DNA, Viral/analysis Female Humans Male Middle Aged Mouth/*virology Mouth Neoplasms/pathology/*virology Oropharyngeal Neoplasms/pathology/*virology *Papillomaviridae Papillomavirus Infections/*complications Risk Factors Sexual Behavior},
	number = {5},
	pages = {766-72},
	title = {Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers},
	type = {Journal Article},
	volume = {108},
	year = {2004},
	bdsk-url-1 = {https://doi.org/10.1002/ijc.11633}}

@article{RN92,
	abstract = {There are few well-established patient risk factors associated with human papillomavirus (HPV) infection in cancers of the oral cavity and oropharynx. The purpose of this study was to determine if there were significant different risk factors and tumor characteristics between HPV-positive and HPV-negative cancer cases. HPV was evaluated in cancer tissue and exfoliated oral cells of 193 oral cavity/oropharynx cancer patients using PCR and direct DNA sequencing. A patient questionnaire collected information about risk factors, sexual practices and medical history. The prevalence of HPV high-risk (HR) types was 20% in cancer cases. Three types were identified: HPV-16 (87%), HPV-18 (3%) and HPV-33 (11%). Risk factors for HPV-HR included younger age (< or = 55 years vs. > 55 years; adjusted OR = 3.4; 95% CI = 1.6-7.3) and younger-age cases who had more lifetime sex partners (adjusted OR = 3.8; 95% CI = 1.4-10.1), practiced oral-genital sex (adjusted OR = 4.3; 95% CI = 1.8-10.4) or oral-anal sex (adjusted OR = 19.5; 95% CI = 3.4-113). Compared to HPV-negative cancers, HPV-HR cancers were more likely to have a positive HPV-HR exfoliated oral cytology test (adjusted OR = 7.8; 95% CI = 3.4-18.4), later stage (adjusted OR = 3.0), nodal involvement (adjusted OR = 4.1) and advanced grade (adjusted OR = 3.0). This study shows new evidence that the prevalence of oncogenic mucosal HPV is higher in younger-age oral cavity/oropharynx cancer cases whose sexual practices are typically associated with sexual transmission of the virus. HPV detection also appears to be an indicator of advanced disease characteristics that may require different clinical treatment for this subset of patients. An exfoliated oral cytology test for HPV was a significant predictor of HR types in the cancers, suggesting that an oral rinse may provide an early biomarker of infected tumors.},
	author = {Smith, E. M. and Ritchie, J. M. and Summersgill, K. F. and Klussmann, J. P. and Lee, J. H. and Wang, D. and Haugen, T. H. and Turek, L. P.},
	doi = {10.1002/ijc.11633},
	issn = {0020-7136 (Print) 0020-7136},
	journal = {Int J Cancer},
	keywords = {Age Factors DNA, Viral/analysis Female Humans Male Middle Aged Mouth/*virology Mouth Neoplasms/pathology/*virology Oropharyngeal Neoplasms/pathology/*virology *Papillomaviridae Papillomavirus Infections/*complications Risk Factors Sexual Behavior},
	note = {Smith, Elaine M Ritchie, Justine M Summersgill, Kurt F Klussmann, Jens P Lee, John H Wang, Donghong Haugen, Thomas H Turek, Lubomir P 5 P0 DE10758/DE/NIDCR NIH HHS/United States K08 DC005627/DC/NIDCD NIH HHS/United States R01 DE13110/DE/NIDCR NIH HHS/United States Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. United States 2003/12/30 Int J Cancer. 2004 Feb 20;108(5):766-72. doi: 10.1002/ijc.11633.},
	number = {5},
	pages = {766-72},
	title = {Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.11633?download=true},
	volume = {108},
	year = {2004},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.11633?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.11633}}

@article{RN340,
	author = {Snijders, P. J. and Cromme, F. V. and van den Brule, A. J. and Schrijnemakers, H. F. and Snow, G. B. and Meijer, C. J. and Walboomers, J. M.},
	doi = {10.1002/ijc.2910510602},
	issn = {0020-7136 (Print) 0020-7136 (Linking)},
	journal = {Int J Cancer},
	keywords = {Amino Acid Sequence Base Sequence Blotting, Southern DNA, Viral/genetics/isolation & purification Genome, Viral Humans Molecular Sequence Data Oligodeoxyribonucleotides Papillomaviridae/genetics/*isolation & purification Polymerase Chain Reaction/methods Prevalence RNA, Viral/analysis/genetics/isolation & purification Restriction Mapping Sequence Homology, Nucleic Acid Tonsillar Neoplasms/genetics/*microbiology/ultrastructure Transcription, Genetic Tumor Virus Infections/epidemiology/genetics/*microbiology/pathology},
	number = {6},
	pages = {845-50},
	title = {Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/1322374},
	volume = {51},
	year = {1992},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/1322374},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.2910510602}}

@article{RN83,
	abstract = {The presence of human papillomavirus (HPV) DNA was assessed in biopsies of tonsillar carcinomas (n = 10) and cases of tonsillitis (n = 7), serving as controls, by general-primer-mediated PCR (GP-PCR). All carcinomas appeared HPV-positive, whereas all cases of tonsillitis were HPV-negative. Additional type-specific PCR for HPV 6, 11, 16, 18, 31 and 33 revealed that 4 carcinomas contained HPV 16 DNA, 4 contained HPV 33 DNA and 1 contained an HPV 16/33 double infection. False positivity was excluded by additional Southern blot analysis of type-specific PCR-positive samples (n = 4). Further characterization of GP-PCR products by sequence analysis revealed that 2 carcinomas contained still uncharacterized HPV genotypes; one of these also contained HPV 33 DNA and one was negative by type-specific PCR. Application of RNA PCR revealed expression of HPV 16 or HPV 33 E7 encoding spliced E6*1 transcripts in all tonsillar carcinomas (n = 4) examined. Additional non-radioactive RNA in situ hybridization performed on 3 biopsies revealed the presence of HPV 16 or HPV 33 E7 transcripts exclusively localized within the carcinoma cells, whereas stroma stained negative. These findings strongly support a role for certain HPV types in the pathogenesis of tonsillar carcinomas.},
	author = {Snijders, P. J. and Cromme, F. V. and van den Brule, A. J. and Schrijnemakers, H. F. and Snow, G. B. and Meijer, C. J. and Walboomers, J. M.},
	doi = {10.1002/ijc.2910510602},
	issn = {0020-7136 (Print) 0020-7136 (Linking)},
	journal = {Int J Cancer},
	keywords = {Amino Acid Sequence Base Sequence Blotting, Southern DNA, Viral/genetics/isolation & purification Genome, Viral Humans Molecular Sequence Data Oligodeoxyribonucleotides Papillomaviridae/genetics/*isolation & purification Polymerase Chain Reaction/methods Prevalence RNA, Viral/analysis/genetics/isolation & purification Restriction Mapping Sequence Homology, Nucleic Acid Tonsillar Neoplasms/genetics/*microbiology/ultrastructure Transcription, Genetic Tumor Virus Infections/epidemiology/genetics/*microbiology/pathology},
	note = {Snijders, P J Cromme, F V van den Brule, A J Schrijnemakers, H F Snow, G B Meijer, C J Walboomers, J M eng Comparative Study Research Support, Non-U.S. Gov't 1992/07/30 Int J Cancer. 1992 Jul 30;51(6):845-50. doi: 10.1002/ijc.2910510602.},
	number = {6},
	pages = {845-50},
	title = {Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.2910510602?download=true},
	volume = {51},
	year = {1992},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.2910510602?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/ijc.2910510602}}

@article{RN189,
	author = {Som, P. M.},
	doi = {10.1148/radiology.165.3.3317494},
	issn = {0033-8419 (Print) 0033-8419},
	journal = {Radiology},
	keywords = {Humans Lymph Nodes/anatomy & histology/*diagnostic imaging Lymphatic Metastasis Magnetic Resonance Imaging Neck Neoplasm Staging Terminology as Topic Tomography, X-Ray Computed},
	note = {Som, P M Journal Article Review United States 1987/12/01 Radiology. 1987 Dec;165(3):593-600. doi: 10.1148/radiology.165.3.3317494.},
	number = {3},
	pages = {593-600},
	title = {Lymph nodes of the neck},
	type = {Journal Article},
	url = {https://pubs.rsna.org/doi/10.1148/radiology.165.3.3317494?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed},
	volume = {165},
	year = {1987},
	bdsk-url-1 = {https://pubs.rsna.org/doi/10.1148/radiology.165.3.3317494?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed},
	bdsk-url-2 = {https://doi.org/10.1148/radiology.165.3.3317494}}

@article{RN200,
	abstract = {Expression of p16(INK4A) (p16 positive) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinoma (HNSCC), however, p16-positivity is not limited to HPV positive tumors and therefore, not a perfect surrogate for HPV. p16 survival outcomes are best documented for the oropharyngeal site (OP); non-OP sites such as the oral cavity (OC), larynx, and hypopharynx (HP) are understudied. The goal of this study was to evaluate p16 in the context of HPV16 and examine p16 survival outcomes in HPV16 positive and HPV16 negative site-specific HNSCC. p16 and HPV16 status were determined by immunohistochemistry and qPCR respectively, on 80 primary HNSCC from four sites: OC, OP, larynx and HP. p16 expression was different across sites (p<0.001), was more frequent in OP than non-OP sites (p<0.0001), and was different between Caucasian Americans (CA) and African Americans (AA) (p=0.031), similar to HPV (p=0.013). p16 was associated with marital status (p=0.008) and smoking (p=0.014). p16 positive patients had improved survival (similar to HPV16 positive cases). Patients with p16 negative/HPV16 negative status had the worst survival for all sites combined as well as for OP. p16 status is an important prognostic indicator in both OPSCC and non-OPSCC and the p16 positive/HPV16 negative group is likely a distinct subgroup lacking any HPV genotype. Cohorts with larger representations of non-OP sites examining multiple molecular markers will be key to deciphering and dissecting out p16's role as a useful prognostic indicator when assessed in combination with HPV status.},
	author = {Stephen, J. K. and Divine, G. and Chen, K. M. and Chitale, D. and Havard, S. and Worsham, M. J.},
	doi = {10.5539/cco.v2n1p51},
	issn = {1927-4858 (Print) 1927-4858},
	journal = {Cancer Clin Oncol},
	keywords = {Hpv head and neck cancer non-oropharyngeal sites p16 expression},
	note = {1927-4866 Stephen, Josena K Divine, George Chen, Kang Mei Chitale, Dhananajay Havard, Shaleta Worsham, Maria J R01 DE015990/DE/NIDCR NIH HHS/United States Journal Article 2013/08/13 Cancer Clin Oncol. 2013;2(1):51-61. doi: 10.5539/cco.v2n1p51.},
	number = {1},
	pages = {51-61},
	title = {Significance of p16 in Site-specific HPV Positive and HPV Negative Head and Neck Squamous Cell Carcinoma},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736998/pdf/nihms-486700.pdf},
	volume = {2},
	year = {2013},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736998/pdf/nihms-486700.pdf},
	bdsk-url-2 = {https://doi.org/10.5539/cco.v2n1p51}}

@book{RN156,
	author = {Strutz, J. and Arndt, O.},
	isbn = {9783131169723},
	publisher = {Thieme},
	title = {Praxis der HNO-Heilkunde, Kopf- und Halschirurgie},
	type = {Book},
	url = {https://books.google.de/books?id=Y-TD3dlDuCcC},
	year = {2010},
	bdsk-url-1 = {https://books.google.de/books?id=Y-TD3dlDuCcC}}

@book{RN168,
	author = {Strutz, J. and Mann, W.J.},
	isbn = {9783132418943},
	publisher = {Thieme},
	title = {Praxis der HNO-Heilkunde, Kopf- und Halschirurgie},
	type = {Book},
	url = {https://books.google.de/books?id=PxArDwAAQBAJ},
	year = {2017},
	bdsk-url-1 = {https://books.google.de/books?id=PxArDwAAQBAJ}}

@article{RN360,
	author = {Sturgis, E. M. and Cinciripini, P. M.},
	doi = {10.1002/cncr.22963},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Adolescent Adult Aged Carcinoma, Squamous Cell/*epidemiology/prevention & control/*virology Female Head and Neck Neoplasms/*epidemiology/prevention & control/*virology Human papillomavirus 16 Humans Incidence Male Middle Aged Papillomavirus Infections/*complications/epidemiology/prevention & control/virology Papillomavirus Vaccines/therapeutic use Prevalence Smoking/*adverse effects/*epidemiology Tumor Virus Infections/*complications/epidemiology/prevention & control/virology United States/epidemiology},
	number = {7},
	pages = {1429-35},
	title = {Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?},
	type = {Journal Article},
	volume = {110},
	year = {2007},
	bdsk-url-1 = {https://doi.org/10.1002/cncr.22963}}

@article{RN96,
	abstract = {The trends in head and neck cancer incidence and smoking prevalence are reviewed, discussing where such trends parallel but also how and why they may not. In the U.S., public health efforts at tobacco control and education have successfully reduced the prevalence of cigarette smoking, resulting in a lower incidence of head and neck cancer. Vigilance at preventing tobacco use and encouraging cessation should continue, and expanded efforts should target particular ethnic and socioeconomic groups. However, an unfortunate stagnation has been observed in oropharyngeal cancer incidence and likely reflects a rising attribution of this disease to oncogenic human papillomavirus, in particular type 16 (HPV-16). For the foreseeable future, this trend in oropharyngeal cancer incidence may continue, but with time the effects of vaccination of the adolescent and young adult female population should result in a lower viral prevalence and hopefully a reduced incidence of oropharyngeal cancer. To hasten the reduction of HPV-16 prevalence in the population, widespread vaccination of adolescent and young adult males should also be considered.},
	author = {Sturgis, E. M. and Cinciripini, P. M.},
	doi = {10.1002/cncr.22963},
	issn = {0008-543X (Print) 0008-543x},
	journal = {Cancer},
	keywords = {Adolescent Adult Aged Carcinoma, Squamous Cell/*epidemiology/prevention & control/*virology Female Head and Neck Neoplasms/*epidemiology/prevention & control/*virology Human papillomavirus 16 Humans Incidence Male Middle Aged Papillomavirus Infections/*complications/epidemiology/prevention & control/virology Papillomavirus Vaccines/therapeutic use Prevalence Smoking/*adverse effects/*epidemiology Tumor Virus Infections/*complications/epidemiology/prevention & control/virology United States/epidemiology},
	note = {Sturgis, Erich M Cinciripini, Paul M Journal Article Review United States 2007/08/29 Cancer. 2007 Oct 1;110(7):1429-35. doi: 10.1002/cncr.22963.},
	number = {7},
	pages = {1429-35},
	title = {Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?},
	type = {Journal Article},
	url = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.22963?download=true},
	volume = {110},
	year = {2007},
	bdsk-url-1 = {https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.22963?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/cncr.22963}}

@article{RN215,
	abstract = {Head and neck cancers encompass a heterogeneous group of tumours that, in general, are biologically aggressive in nature. These cancers remain difficult to treat and treatment can cause severe, long-term side effects. For patients who are not cured by surgery and/or (chemo)radiotherapy, there are few effective treatment options. Targeted therapies and predictive biomarkers are urgently needed in order to improve the management and minimise the treatment toxicity, and to allow selection of patients who are likely to benefit from both nonselective and targeted therapies. This clinical update aims to provide an insight into the current understanding of the molecular pathogenesis of the disease, and explores the novel therapies under development and in clinical trials.},
	author = {Suh, Y. and Amelio, I. and Guerrero Urbano, T. and Tavassoli, M.},
	doi = {10.1038/cddis.2013.548},
	journal = {Cell Death Dis},
	keywords = {Animals Biomarkers Head and Neck Neoplasms/*genetics/metabolism/*therapy Humans *Molecular Targeted Therapy Signal Transduction},
	note = {2041-4889 Suh, Y Amelio, I Guerrero Urbano, T Tavassoli, M Journal Article Research Support, Non-U.S. Gov't Review 2014/01/25 Cell Death Dis. 2014 Jan 23;5(1):e1018. doi: 10.1038/cddis.2013.548.},
	number = {1},
	pages = {e1018},
	title = {Clinical update on cancer: molecular oncology of head and neck cancer},
	type = {Journal Article},
	url = {https://www.nature.com/articles/cddis2013548.pdf},
	volume = {5},
	year = {2014},
	bdsk-url-1 = {https://www.nature.com/articles/cddis2013548.pdf},
	bdsk-url-2 = {https://doi.org/10.1038/cddis.2013.548}}

@article{RN182,
	abstract = {PURPOSE: To compare the diagnostic abilities of magnetic resonance imaging (MRI) and computed tomography (CT) based on the architectural changes in the nodal parenchyma. MATERIALS AND METHODS: We retrospectively studied histologically proven 70 metastatic and 52 reactive nodes in the necks of 38 patients with head and neck squamous cell carcinomas who had undergone both CT and MRI. We assessed the detectability of the architectural changes in the nodal parenchyma that were suggestive of cancer focus (cancer nest, necrosis, and keratinization). The diagnostic abilities of CT and MRI were assessed by three observers separately for the small (<10 mm in minimum axis diameter) and large (>or=10 mm) nodes. RESULTS: MRI was significantly more effective than CT in diagnosing small metastatic nodes, yielding 83% sensitivity, 88% specificity, and 86% accuracy. However, the diagnostic abilities of MRI and CT were similar for large metastatic nodes; MRI yielded 100% sensitivity, 98% specificity, and 99% accuracy. receiver operating characteristic analysis also indicated that the Az values were significantly higher for MRI than for CT (0.927 vs. 0.822, P = 0.00054) for the detection of small nodes. CONCLUSION: MRI is superior to CT in the diagnosis of metastatic nodes from head and neck squamous cell carcinomas.},
	author = {Sumi, M. and Kimura, Y. and Sumi, T. and Nakamura, T.},
	doi = {10.1002/jmri.21187},
	issn = {1053-1807 (Print) 1053-1807},
	journal = {J Magn Reson Imaging},
	keywords = {Aged Analysis of Variance Carcinoma, Squamous Cell/*diagnosis/diagnostic imaging/pathology Contrast Media Female Gadolinium DTPA Head and Neck Neoplasms/*diagnosis/diagnostic imaging/pathology Humans Lymphatic Metastasis Magnetic Resonance Imaging/*methods Male Middle Aged ROC Curve Tomography, Spiral Computed/*methods},
	note = {Sumi, Misa Kimura, Yasuo Sumi, Tadateru Nakamura, Takashi Comparative Study Journal Article United States 2007/10/31 J Magn Reson Imaging. 2007 Dec;26(6):1626-33. doi: 10.1002/jmri.21187.},
	number = {6},
	pages = {1626-33},
	title = {Diagnostic performance of MRI relative to CT for metastatic nodes of head and neck squamous cell carcinomas},
	type = {Journal Article},
	url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jmri.21187?download=true},
	volume = {26},
	year = {2007},
	bdsk-url-1 = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jmri.21187?download=true},
	bdsk-url-2 = {https://doi.org/10.1002/jmri.21187}}

@article{RN337,
	author = {Syrjanen, K. and Syrjanen, S. and Pyrhonen, S.},
	doi = {10.1159/000275612},
	issn = {0301-1569 (Print) 0301-1569 (Linking)},
	journal = {ORL J Otorhinolaryngol Relat Spec},
	keywords = {Animals Antigens, Viral/*analysis Carcinoma, Squamous Cell/*immunology/pathology Epithelium/immunology/pathology Humans Immunoenzyme Techniques Laryngeal Neoplasms/*immunology/pathology Larynx/pathology Papillomaviridae/*immunology Tumor Virus Infections/*immunology/pathology},
	number = {6},
	pages = {323-34},
	title = {Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/6292810},
	volume = {44},
	year = {1982},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/6292810},
	bdsk-url-2 = {https://doi.org/10.1159/000275612}}

@article{RN80,
	abstract = {Paraffin sections from 36 laryngeal squamous cell carcinomas with histological features of coexistent condylomatous changes (the flat, inverted and papillomatous lesions caused by human papilloma virus; HPV) were stained for HPV antigens with an indirect immunoperoxidase technique. The HPV antiserum used was prepared in guinea pigs immunized against the purified HPV virions from human common wart tissue. Of the tumors studied, 36% showed the presence of HPV antigens. In that, one-third of the flat and inverted lesions and 42% of the papillomatous lesions contained cells with intranuclear HPV-staining reaction. The role of HPV as the etiologic agent of laryngeal squamous cell papillomas is discussed, as is the potential malignant transformation of them. Based on the present results, the previously expressed view on the probable role of HPV in the development of laryngeal squamous cell carcinoma seems to gain further substantiation.},
	author = {Syrjanen, K. and Syrjanen, S. and Pyrhonen, S.},
	doi = {10.1159/000275612},
	issn = {0301-1569 (Print) 0301-1569 (Linking)},
	journal = {ORL J Otorhinolaryngol Relat Spec},
	keywords = {Animals Antigens, Viral/*analysis Carcinoma, Squamous Cell/*immunology/pathology Epithelium/immunology/pathology Humans Immunoenzyme Techniques Laryngeal Neoplasms/*immunology/pathology Larynx/pathology Papillomaviridae/*immunology Tumor Virus Infections/*immunology/pathology},
	note = {Syrjanen, K Syrjanen, S Pyrhonen, S eng Switzerland 1982/01/01 ORL J Otorhinolaryngol Relat Spec. 1982;44(6):323-34. doi: 10.1159/000275612.},
	number = {6},
	pages = {323-34},
	title = {Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas},
	type = {Journal Article},
	url = {https://www.karger.com/Article/Abstract/275612},
	volume = {44},
	year = {1982},
	bdsk-url-1 = {https://www.karger.com/Article/Abstract/275612},
	bdsk-url-2 = {https://doi.org/10.1159/000275612}}

@article{RN139,
	abstract = {OBJECTIVE: To provide information on the effects of alcohol and tobacco on laryngeal cancer and its subsites. METHODS: This was a case-control study conducted between 1992 and 2000 in northern Italy and Switzerland. A total of 527 cases of incident squamous-cell carcinoma of the larynx and 1297 hospital controls frequency-matched with cases on age, sex, and area of residence were included. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were estimated using multiple logistic regression. RESULTS: In comparison with never smokers, ORs were 19.8 for current smokers and 7.0 for ex-smokers. The risk increased in relation to the number of cigarettes (OR = 42.9 for > or = 25 cigarettes/day) and for duration of smoking (OR = 37.2 for > or = 40 years). For alcohol, the risk increased in relation to number of drinks (OR = 5.9 for > or = 56 drinks per week). Combined alcohol and tobacco consumption showed a multiplicative (OR = 177) rather than an additive risk. For current smokers and current drinkers the risk was higher for supraglottis (ORs 54.9 and 2.6, respectively) than for glottis (ORs 7.4 and 1.8) and others subsites (ORs 10.9 and 1.9). CONCLUSIONS: Our study shows that both cigarette smoking and alcohol drinking are independent risk factors for laryngeal cancer. Heavy consumption of alcohol and cigarettes determined a multiplicative risk increase, possibly suggesting biological synergy.},
	author = {Talamini, R. and Bosetti, C. and La Vecchia, C. and Dal Maso, L. and Levi, F. and Bidoli, E. and Negri, E. and Pasche, C. and Vaccarella, S. and Barzan, L. and Franceschi, S.},
	doi = {10.1023/a:1021944123914},
	issn = {0957-5243 (Print) 0957-5243},
	journal = {Cancer Causes Control},
	keywords = {Adult Aged Alcohol Drinking/*adverse effects Carcinoma, Squamous Cell/epidemiology/*etiology Case-Control Studies Female Humans Italy/epidemiology Laryngeal Neoplasms/epidemiology/*etiology Logistic Models Male Middle Aged Risk Factors Smoking/*adverse effects Switzerland/epidemiology},
	note = {Talamini, R Bosetti, C La Vecchia, C Dal Maso, L Levi, F Bidoli, E Negri, E Pasche, C Vaccarella, S Barzan, L Franceschi, S Journal Article Research Support, Non-U.S. Gov't Netherlands 2003/02/18 Cancer Causes Control. 2002 Dec;13(10):957-64. doi: 10.1023/a:1021944123914.},
	number = {10},
	pages = {957-64},
	title = {Combined effect of tobacco and alcohol on laryngeal cancer risk: a case-control study},
	type = {Journal Article},
	url = {https://link.springer.com/content/pdf/10.1023/A:1021944123914.pdf},
	volume = {13},
	year = {2002},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1023/A:1021944123914.pdf},
	bdsk-url-2 = {https://doi.org/10.1023/a:1021944123914}}

@article{RN410,
	author = {Thompson, L.},
	issn = {0145-5613 (Print) 0145-5613 (Linking)},
	journal = {Ear Nose Throat J},
	keywords = {Head and Neck Neoplasms/*classification/genetics/pathology Humans World Health Organization},
	number = {2},
	pages = {74},
	title = {World Health Organization classification of tumours: pathology and genetics of head and neck tumours},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16579185},
	volume = {85},
	year = {2006},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/16579185}}

@article{RN19,
	author = {Thompson, L.},
	issn = {0145-5613 (Print) 0145-5613 (Linking)},
	journal = {Ear Nose Throat J},
	keywords = {Head and Neck Neoplasms/*classification/genetics/pathology Humans World Health Organization},
	note = {Thompson, Lester eng Editorial Ear Nose Throat J. 2006 Feb;85(2):74.},
	number = {2},
	pages = {74},
	title = {World Health Organization classification of tumours: pathology and genetics of head and neck tumours},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16579185},
	volume = {85},
	year = {2006},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/16579185}}

@article{RN20,
	author = {Thompson, L.},
	issn = {0145-5613 (Print) 0145-5613 (Linking)},
	journal = {Ear Nose Throat J},
	keywords = {Head and Neck Neoplasms/*classification/genetics/pathology Humans World Health Organization},
	note = {Thompson, Lester eng Editorial Ear Nose Throat J. 2006 Feb;85(2):74.},
	number = {2},
	pages = {74},
	title = {World Health Organization classification of tumours: pathology and genetics of head and neck tumours},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16579185},
	volume = {85},
	year = {2006},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/16579185}}

@article{RN404,
	author = {Thompson, L. D. and Wieneke, J. A. and Miettinen, M. and Heffner, D. K.},
	doi = {10.1097/00000478-200202000-00002},
	issn = {0147-5185 (Print) 0147-5185},
	journal = {Am J Surg Pathol},
	keywords = {Adult Aged Aged, 80 and over Biomarkers, Tumor/analysis Carcinoma/chemistry/*pathology/therapy Female Humans Immunohistochemistry Laryngeal Neoplasms/chemistry/*pathology/therapy Larynx/diagnostic imaging/pathology/surgery Male Middle Aged Neoplasm Recurrence, Local Radiography Radiotherapy, Adjuvant},
	number = {2},
	pages = {153-70},
	title = {Spindle cell (sarcomatoid) carcinomas of the larynx: a clinicopathologic study of 187 cases},
	type = {Journal Article},
	volume = {26},
	year = {2002},
	bdsk-url-1 = {https://doi.org/10.1097/00000478-200202000-00002}}

@article{RN124,
	abstract = {Laryngeal spindle cell (sarcomatoid) carcinomas are uncommon tumors, frequently misdiagnosed as reactive lesions or mesenchymal malignancies. The records of 187 patients with tumors diagnosed as laryngeal spindle cell (sarcomatoid) carcinoma were retrieved from the files of the Otorhinolaryngic Tumor Registry of the Armed Forces Institute of Pathology. There were 174 men and 13 women, 35-92 years of age (average, 65.6 years). Nearly all patients experienced hoarseness (n = 165 [88%] patients) for a mean duration of 11.0 months. Patients admitted to smoking (n = 162 [87%] patients) and/or alcohol use (n = 90 [48%] patients). Most tumors were glottic (n = 132 [71%]), T1 (n = 111 [59%]), 1 and polypoid (n = 185 [99%]), with a mean tumor size of 1.8 cm. Histologically, squamous cell carcinoma (n = 157 [84%]) was noted, ulcerated, and blended with the spindle cell component, which was most frequently arranged in a storiform pattern (n = 92 [49%] tumors). Foci of benign or malignant cartilage and/or bone (n = 13 [7%]) were noted in the spindle cell component. All patients were treated with surgery (n = 90 [48%] patients) or surgery with radiation (n = 97 [52%] patients). Recurrences developed in 85 (45%) patients. Overall, T1 glottic tumors managed by complete surgical eradication had the best outcome (mean follow-up, 7.8 years).},
	author = {Thompson, L. D. and Wieneke, J. A. and Miettinen, M. and Heffner, D. K.},
	doi = {10.1097/00000478-200202000-00002},
	issn = {0147-5185 (Print) 0147-5185},
	journal = {Am J Surg Pathol},
	keywords = {Adult Aged Aged, 80 and over Biomarkers, Tumor/analysis Carcinoma/chemistry/*pathology/therapy Female Humans Immunohistochemistry Laryngeal Neoplasms/chemistry/*pathology/therapy Larynx/diagnostic imaging/pathology/surgery Male Middle Aged Neoplasm Recurrence, Local Radiography Radiotherapy, Adjuvant},
	note = {Thompson, Lester D R Wieneke, Jacqueline A Miettinen, Markku Heffner, Dennis K Journal Article United States 2002/01/29 Am J Surg Pathol. 2002 Feb;26(2):153-70. doi: 10.1097/00000478-200202000-00002.},
	number = {2},
	pages = {153-70},
	title = {Spindle cell (sarcomatoid) carcinomas of the larynx: a clinicopathologic study of 187 cases},
	type = {Journal Article},
	volume = {26},
	year = {2002},
	bdsk-url-1 = {https://doi.org/10.1097/00000478-200202000-00002}}

@book{RN383,
	author = {Thompson, L.D.R. and Bishop, J.A.},
	isbn = {9780323553506},
	publisher = {Elsevier Health Sciences},
	title = {Head and Neck Pathology E-Book: A Volume in the Series: Foundations in Diagnostic Pathology},
	type = {Book},
	url = {https://books.google.de/books?id=zNZCDwAAQBAJ},
	year = {2017},
	bdsk-url-1 = {https://books.google.de/books?id=zNZCDwAAQBAJ}}

@book{RN113,
	author = {Thompson, L.D.R. and Bishop, J.A.},
	isbn = {9780323553506},
	publisher = {Elsevier Health Sciences},
	title = {Head and Neck Pathology E-Book: A Volume in the Series: Foundations in Diagnostic Pathology},
	type = {Book},
	url = {https://books.google.de/books?id=zNZCDwAAQBAJ},
	year = {2017},
	bdsk-url-1 = {https://books.google.de/books?id=zNZCDwAAQBAJ}}

@book{RN105,
	address = {Wien; New York},
	author = {Thurnher, D.},
	pages = {361-380},
	publisher = {Springer},
	title = {HNO-Heilkunde - Ein symptomorientiertes Lehrbuch},
	type = {Book},
	year = {2011}}

@book{RN107,
	author = {Thurnher, D. and Grasl, M. and Erovic, B.M. and Lercher, P.},
	isbn = {9783211889848},
	publisher = {Springer Vienna},
	title = {HNO-Heilkunde: Ein symptomorientiertes Lehrbuch},
	type = {Book},
	url = {https://books.google.de/books?id=RnJovwEACAAJ},
	year = {2010},
	bdsk-url-1 = {https://books.google.de/books?id=RnJovwEACAAJ}}

@book{RN380,
	author = {Thurnher, D. and Grasl, M. and Erovic, B.M. and Lercher, P.},
	isbn = {9783211889848},
	publisher = {Springer Vienna},
	title = {HNO-Heilkunde: Ein symptomorientiertes Lehrbuch},
	type = {Book},
	url = {https://books.google.de/books?id=RnJovwEACAAJ},
	year = {2010},
	bdsk-url-1 = {https://books.google.de/books?id=RnJovwEACAAJ}}

@book{RN376,
	author = {Thurnher, D. and Grasl, M. and Erovic, B.M. and Lercher, P.},
	isbn = {9783211889848},
	publisher = {Springer Vienna},
	title = {HNO-Heilkunde: Ein symptomorientiertes Lehrbuch},
	type = {Book},
	url = {https://books.google.de/books?id=RnJovwEACAAJ},
	year = {2010},
	bdsk-url-1 = {https://books.google.de/books?id=RnJovwEACAAJ}}

@book{RN374,
	author = {Thurnher, D. and Grasl, M. and Erovic, B.M. and Lercher, P.},
	isbn = {9783211889848},
	publisher = {Springer Vienna},
	title = {HNO-Heilkunde: Ein symptomorientiertes Lehrbuch},
	type = {Book},
	url = {https://books.google.de/books?id=RnJovwEACAAJ},
	year = {2010},
	bdsk-url-1 = {https://books.google.de/books?id=RnJovwEACAAJ}}

@article{RN187,
	abstract = {OBJECTIVES: To define the necessity of neck ultrasound for investigation of T1 and T2 oral tongue carcinoma with N0 neck. METHODS: The medical records of all patients with early stage (T1-2 N0) oral tongue cancer treated surgically between January 1985 and December 2000 were reviewed. Patients with 30 neck dissections were identified for analysis. The result of neck ultrasound examination was correlated with the histological examination. RESULTS: The sensitivity, specificity and overall accuracy of ultrasound examination were found to be 47%, 93% and 70%, respectively. The implication of ultrasound examination with respect to elective neck treatment was discussed in the management of the N0 neck. CONCLUSIONS: It is concluded that ultrasound alone is inadequate for making decisions regarding neck management of patients with T1 and T2 N0 carcinoma of the tongue and cannot replace a policy of elective neck dissection.},
	author = {To, E. W. and Tsang, W. M. and Cheng, J. and Lai, E. and Pang, P. and Ahuja, A. T. and Ying, M.},
	doi = {10.1259/dmfr/20155904},
	issn = {0250-832X (Print) 0250-832x},
	journal = {Dentomaxillofac Radiol},
	keywords = {Carcinoma/*diagnostic imaging/pathology Elective Surgical Procedures Female Humans Lymph Node Excision Lymph Nodes/*diagnostic imaging/pathology Lymphatic Metastasis/diagnostic imaging/pathology Male Middle Aged Neck/*diagnostic imaging Neoplasm Staging Sensitivity and Specificity Tongue Neoplasms/*diagnostic imaging/pathology Ultrasonography},
	note = {To, E W H Tsang, W M Cheng, J Lai, E Pang, P Ahuja, A T Ying, M Journal Article England 2003/08/15 Dentomaxillofac Radiol. 2003 May;32(3):156-9. doi: 10.1259/dmfr/20155904.},
	number = {3},
	pages = {156-9},
	title = {Is neck ultrasound necessary for early stage oral tongue carcinoma with clinically N0 neck?},
	type = {Journal Article},
	volume = {32},
	year = {2003},
	bdsk-url-1 = {https://doi.org/10.1259/dmfr/20155904}}

@article{RN253,
	abstract = {The quest for improved fractionation and combined modality regimens in head and neck cancer has also yielded progressively higher rates of toxicity. Time compression of dose delivery in accelerated fractionation has produced high rates of severe mucositis including the early stoppage of two randomized trials. The addition of chemotherapy has introduced systemic toxicity and can exacerbate local tissue reactions when used concurrent with radiotherapy. Mucositis is recognized as the principal impediment to efforts at further treatment intensification. The development and utilization of standardized toxicity grading criteria and accepted reporting standards has lagged toxicity production, impeding a full appreciation of the true extent of both acute and late toxicity. Objective data regarding acute and chronic effects on organ function are also sorely lacking. A better characterization of the frequency, severity, and duration of the various toxicities encountered in head and neck cancer will also allow the rational development of toxicity interventions. New methods are needed to summarize the global or aggregate toxicity of a treatment program. Further research into the assessment and analysis of toxicity is not only crucial to improvements in quality of life (QOL), but perhaps, improved rates of disease control as well.},
	author = {Trotti, A.},
	doi = {10.1016/s0360-3016(99)00558-1},
	issn = {0360-3016 (Print) 0360-3016},
	journal = {Int J Radiat Oncol Biol Phys},
	keywords = {Acute Disease Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use Clinical Trials, Phase III as Topic Combined Modality Therapy/adverse effects Dose Fractionation, Radiation Forecasting Head and Neck Neoplasms/*drug therapy/*radiotherapy/surgery Humans Mucous Membrane/drug effects/radiation effects Postoperative Complications Quality of Life Radiation Injuries/classification/*complications Salvage Therapy/adverse effects Severity of Illness Index Stomatitis/etiology/pathology Terminology as Topic Time Factors},
	note = {Trotti, A Journal Article Review United States 2000/04/12 Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):1-12. doi: 10.1016/s0360-3016(99)00558-1.},
	number = {1},
	pages = {1-12},
	title = {Toxicity in head and neck cancer: a review of trends and issues},
	type = {Journal Article},
	url = {https://www.redjournal.org/article/S0360-3016(99)00558-1/fulltext},
	volume = {47},
	year = {2000},
	bdsk-url-1 = {https://www.redjournal.org/article/S0360-3016(99)00558-1/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s0360-3016(99)00558-1}}

@article{RN254,
	abstract = {BACKGROUND AND PURPOSE: To determine the frequency of mucositis and associated outcomes in patients receiving radiotherapy (RT) for head and neck cancer through a systematic review of recently published literature. MATERIALS AND METHODS: According to the study protocol, databases were searched for randomized clinical trials (English only, 1996-1999) of patients with head and neck cancer receiving RT with or without chemotherapy that reported one or more outcomes of interest. RESULTS: Thirty-three studies (n=6181 patients) met inclusion criteria. Mucositis was defined using a variety of scoring systems. The mean incidence was 80%. Over one-half of patients (56%) who received altered fractionation RT (RT-AF) experienced severe mucositis (grades 3-4) compared to 34% of patients who received conventional RT. Rates of hospitalization due to mucositis, reported in three studies (n=700), were 16% overall and 32% for RT-AF patients. Eleven percent of patients had RT regimens interrupted or modified because of mucositis in five studies (n=1267) reporting this outcome. Data insufficiency or heterogeneity prohibited analysis of mucositis severity and other associated outcomes, such as oral pain, dysphagia and opioid use. CONCLUSIONS: Mucositis is a frequent, severe toxicity in patients treated with RT for head and neck cancer. While it appears that mucositis may lead to hospitalization and treatment interruptions, its overall impact on outcomes has not been adequately investigated.},
	author = {Trotti, A. and Bellm, L. A. and Epstein, J. B. and Frame, D. and Fuchs, H. J. and Gwede, C. K. and Komaroff, E. and Nalysnyk, L. and Zilberberg, M. D.},
	doi = {10.1016/s0167-8140(02)00404-8},
	issn = {0167-8140 (Print) 0167-8140},
	journal = {Radiother Oncol},
	keywords = {Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents/therapeutic use Combined Modality Therapy Female Head and Neck Neoplasms/drug therapy/*radiotherapy Humans Incidence Male Middle Aged Mouth Mucosa/drug effects/radiation effects Outcome Assessment, Health Care Quality of Life Radiation Injuries/classification/*epidemiology/etiology Randomized Controlled Trials as Topic Stomatitis/classification/*epidemiology/etiology},
	note = {Trotti, Andy Bellm, Lisa A Epstein, Joel B Frame, Diana Fuchs, Henry J Gwede, Clement K Komaroff, Eugene Nalysnyk, Luba Zilberberg, Marya D Journal Article Research Support, Non-U.S. Gov't Review Systematic Review Ireland 2003/05/14 Radiother Oncol. 2003 Mar;66(3):253-62. doi: 10.1016/s0167-8140(02)00404-8.},
	number = {3},
	pages = {253-62},
	title = {Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review},
	type = {Journal Article},
	url = {https://www.thegreenjournal.com/article/S0167-8140(02)00404-8/fulltext},
	volume = {66},
	year = {2003},
	bdsk-url-1 = {https://www.thegreenjournal.com/article/S0167-8140(02)00404-8/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s0167-8140(02)00404-8}}

@article{RN255,
	abstract = {BACKGROUND: We aimed to examine deficiencies in established methods of summarising adverse events, and to create a new reporting system (TAME) for summarising the toxicity burden of cancer treatment. TAME consolidates traditional adverse-event data into three risk domains: short-term (acute) Toxicity (T), Adverse long-term (late) effects (A), and Mortality risk (M) generated by a treatment programme (E=End results); and assigns treatments to risk classes for each risk domain. METHODS: We examined formally an established method for summarising adverse events (the max-grade method) in five trials of patients with head and neck cancer done between September, 1991, and August, 2000, by the Radiation Therapy Oncology Group (RTOG) that involved 13 treatment groups (2304 patients). We calculated TAME summary metrics that included time and multiplicity factors in the same patient groups. We compared relative T values with relative values for toxic effects from the max-grade approach. We also calculated the range of individual patient T scores in two groups from one of the trials (the laryngeal-preservation trial). RESULTS: The max-grade method systematically excluded 29-70% of total reported high-grade (grade 3-4) acute adverse events, contained progressive bias, and favoured higher toxicity programmes. Relative T values in the 13 treatment programmes tested showed an increase of almost 500% in acute toxicity burden (100-590) between treatment groups compared with a 170% increase (100-270) between treatment groups by use of the max-grade method. The difference between these two summary systems was statistically significant (mean difference -102 [95% CI -167 to -37], p=0.005, t test for paired differences). Four risk classes were designated for acute and relative late effects: low (100-140), moderate (150-390), high (400-490), and extreme (>or=500). The distribution of individual patient T scores showed that 82 (60%) patients who received concurrent platinum-radiotherapy for larynx preservation reported two or more high-grade events, and 34 (20%) reported four or more high-grade events; these findings differed significantly from the distribution of individual patient T scores for patients who received radiotherapy alone, in which 32 (19%) reported two or more high-grade events and 3 (3%) reported four or more high-grade events (p<0.0001). The max-grade method also systematically excluded 26-48% of high-grade (grade 3-4) late adverse events. However, less variation was noted in the relative risk of late events (100-270) by the TAME method for late effects. INTERPRETATION: Traditional methods for summarising adverse events systematically exclude important data, giving an inaccurate impression of the toxicity burden in complex multimodality trials. By contrast, T values use data on all high-grade adverse events. T values are proportional to the intensity of treatment, showing a 500% increase between treatment groups in acute toxicity burden in RTOG trials of head and neck cancer done during this study interval. TAME reporting provides a concise and uniform method to compare relative risk among treatment options. Future studies should include testing the performance of the TAME system in additional datasets (from different research organisations and disease sites), prospective correlation of TAME endpoints with predefined outcome measures, and assessment of its usefulness in clinical decision making.},
	author = {Trotti, A. and Pajak, T. F. and Gwede, C. K. and Paulus, R. and Cooper, J. and Forastiere, A. and Ridge, J. A. and Watkins-Bruner, D. and Garden, A. S. and Ang, K. K. and Curran, W.},
	doi = {10.1016/s1470-2045(07)70144-4},
	issn = {1470-2045 (Print) 1470-2045},
	journal = {Lancet Oncol},
	keywords = {Antineoplastic Agents/*adverse effects Combined Modality Therapy Head and Neck Neoplasms/*drug therapy/*radiotherapy Humans Radiotherapy/*adverse effects Randomized Controlled Trials as Topic Risk Assessment/*methods},
	note = {Trotti, Andy Pajak, Thomas F Gwede, Clement K Paulus, Rebecca Cooper, Jay Forastiere, Arlene Ridge, John A Watkins-Bruner, Deborah Garden, Adam S Ang, K Kian Curran, Wally Comparative Study Journal Article England 2007/06/05 Lancet Oncol. 2007 Jul;8(7):613-24. doi: 10.1016/S1470-2045(07)70144-4.},
	number = {7},
	pages = {613-24},
	title = {TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group},
	type = {Journal Article},
	url = {https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(07)70144-4/fulltext},
	volume = {8},
	year = {2007},
	bdsk-url-1 = {https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(07)70144-4/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/s1470-2045(07)70144-4}}

@article{RN172,
	abstract = {The 1990s saw an increased use of chemoradiotherapy protocols, commonly referred to as organ-sparing therapy, for the treatment of oropharyngeal cancer after the Groupe d'Oncologie Radioth{\'e}rapie T{\^e}te et Cou trial. Since that time, human papillomavirus-associated oropharyngeal squamous cell carcinoma has been identified as a unique disease, with improved survival regardless of treatment modality. The improved outcomes of this population has led to re-evaluation of treatment paradigms in the past decade, with a desire to spare young, human papillomavirus-positive patients the treatment-related toxicities of chemoradiotherapy and to use new minimally invasive surgical techniques to improve outcomes. Numerous retrospective and prospective studies have investigated the role of surgery in treatment of oropharyngeal carcinoma and have demonstrated equivalent oncologic outcomes and improved functional outcomes compared with chemoradiotherapy protocols. Ongoing and future clinical trials may help delineate the role of surgery in the future.},
	author = {Turner, M. T. and Byrd, J. K. and Ferris, R. L.},
	doi = {10.1200/jop.2016.015263},
	issn = {1554-7477 (Print) 1554-7477},
	journal = {J Oncol Pract},
	keywords = {Humans Lasers Microsurgery Neoplasms, Unknown Primary/surgery Oropharyngeal Neoplasms/epidemiology/secondary/*surgery Robotic Surgical Procedures},
	note = {1935-469x Turner, Meghan T Byrd, J Kenneth Ferris, Robert L P50 CA097190/CA/NCI NIH HHS/United States T32 CA060397/CA/NCI NIH HHS/United States Journal Article Review 2016/11/20 J Oncol Pract. 2016 Nov;12(11):1176-1183. doi: 10.1200/JOP.2016.015263.},
	number = {11},
	pages = {1176-1183},
	title = {Current Role of Surgery in the Management of Oropharyngeal Cancer},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423357/pdf/nihms856347.pdf},
	volume = {12},
	year = {2016},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423357/pdf/nihms856347.pdf},
	bdsk-url-2 = {https://doi.org/10.1200/jop.2016.015263}}

@article{RN190,
	abstract = {The aim of this study was to determine the optimal combination of preoperative examination methods to predict mandibular invasion by squamous cell carcinoma of the oral cavity. Data were gathered prospectively but evaluated retrospectively. The preoperative results of clinical examination, conventional radiography, bone single photon emission computed tomography (SPECT), computed tomography and magnetic resonance imaging were compared to the histological results of resection specimens from 67 patients with tumours, adjacent or fixed to the mandible, histologically confirmed as squamous cell carcinoma. The examination methods with acceptable sensitivity and specificity were selected and diagnostic algorithms were constructed using all possible combinations. The preferred diagnostic algorithm was found to be either computed tomography or magnetic resonance imaging, followed by a bone SPECT in cases where the first scan is negative. A negative bone SPECT rules out mandibular invasion (100% sensitivity). This algorithm accurately predicted mandibular invasion in 85% of the patients, without yielding false negative results. In this study group, application of such an algorithm would have resulted in a reduction of the number of unnecessary mandibular resections by 50%. The suggested, preferred, diagnostic algorithm shortens the preoperative screening process, avoiding unnecessary costs, as well as considerably reducing the number of unnecessary mandibular resections.},
	author = {Van Cann, E. M. and Koole, R. and Oyen, W. J. and de Rooy, J. W. and de Wilde, P. C. and Slootweg, P. J. and Schipper, M. and Merkx, M. A. and Stoelinga, P. J.},
	doi = {10.1016/j.ijom.2008.02.009},
	issn = {0901-5027 (Print) 0901-5027},
	journal = {Int J Oral Maxillofac Surg},
	keywords = {Adult Aged Aged, 80 and over *Algorithms Carcinoma, Squamous Cell/*pathology *Diagnostic Imaging/statistics & numerical data False Negative Reactions False Positive Reactions Female Forecasting Humans Magnetic Resonance Imaging/statistics & numerical data Male Mandible/pathology Mandibular Neoplasms/*pathology Middle Aged Mouth Neoplasms/*pathology Neoplasm Invasiveness Prospective Studies Radiography, Panoramic/statistics & numerical data Retrospective Studies Sensitivity and Specificity Tomography, Emission-Computed, Single-Photon/statistics & numerical data Tomography, X-Ray Computed/statistics & numerical data Unnecessary Procedures/statistics & numerical data},
	note = {Van Cann, E M Koole, R Oyen, W J G de Rooy, J W J de Wilde, P C Slootweg, P J Schipper, M Merkx, M A W Stoelinga, P J W Comparative Study Journal Article Denmark 2008/04/15 Int J Oral Maxillofac Surg. 2008 Jun;37(6):535-41. doi: 10.1016/j.ijom.2008.02.009. Epub 2008 Apr 10.},
	number = {6},
	pages = {535-41},
	title = {Assessment of mandibular invasion of squamous cell carcinoma by various modes of imaging: constructing a diagnostic algorithm},
	type = {Journal Article},
	url = {https://www.ijoms.com/article/S0901-5027(08)00080-5/fulltext},
	volume = {37},
	year = {2008},
	bdsk-url-1 = {https://www.ijoms.com/article/S0901-5027(08)00080-5/fulltext},
	bdsk-url-2 = {https://doi.org/10.1016/j.ijom.2008.02.009}}

@article{RN162,
	abstract = {In a recently held WHO workshop it has been recommended to abandon the distinction between potentially malignant lesions and potentially malignant conditions and to use the term potentially malignant disorders instead. Of these disorders, leukoplakia and erythroplakia are the most common ones. These diagnoses are still defined by exclusion of other known white or red lesions. In spite of tremendous progress in the field of molecular biology there is yet no single marker that reliably enables to predict malignant transformation in an individual patient. The general advice is to excise or laser any oral of oropharyngeal leukoplakia/erythroplakia, if feasible, irrespective of the presence or absence of dysplasia. Nevertheless, it is actually unknown whether such removal truly prevents the possible development of a squamous cell carcinoma. At present, oral lichen planus seems to be accepted in the literature as being a potentially malignant disorder, although the risk of malignant transformation is lower than in leukoplakia. There are no means to prevent such event. The efficacy of follow-up of oral lichen planus is questionable. Finally, brief attention has been paid to oral submucous fibrosis, actinic cheilitis, some inherited cancer syndromes and immunodeficiency in relation to cancer predisposition.},
	author = {van der Waal, I.},
	doi = {10.1016/j.oraloncology.2008.05.016},
	issn = {1368-8375},
	journal = {Oral Oncol},
	keywords = {Carcinoma, Squamous Cell/prevention & control Cell Transformation, Neoplastic Cheilitis/therapy *Erythroplasia/classification/diagnosis/therapy Humans *Leukoplakia, Oral/classification/diagnosis/therapy Lichen Planus, Oral/diagnosis Mouth Mucosa/pathology *Mouth Neoplasms/prevention & control Oral Submucous Fibrosis/diagnosis Practice Guidelines as Topic *Precancerous Conditions/classification/diagnosis/therapy Terminology as Topic World Health Organization},
	note = {1879-0593 van der Waal, Isa{\"a}c Journal Article Review England 2008/08/05 Oral Oncol. 2009 Apr-May;45(4-5):317-23. doi: 10.1016/j.oraloncology.2008.05.016. Epub 2008 Jul 31.},
	number = {4-5},
	pages = {317-23},
	title = {Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management},
	type = {Journal Article},
	url = {https://www.sciencedirect.com/science/article/abs/pii/S1368837508001711?via%3Dihub},
	volume = {45},
	year = {2009},
	bdsk-url-1 = {https://www.sciencedirect.com/science/article/abs/pii/S1368837508001711?via%3Dihub},
	bdsk-url-2 = {https://doi.org/10.1016/j.oraloncology.2008.05.016}}

@article{RN184,
	abstract = {The diagnosis of oral cavity and oropharyngeal tumors can be obtained through clinical examination and biopsy. CT and MRI can then be used to define the extension of the disease. The aim of this study was to define the accuracy of clinical and MRI T staging of oral cavity and base of the tongue tumors and correlate the results with pathological data. Mandibular involvement, in a subgroup of patients, was determined and sensitivity, specificity, accuracy and positive and negative predictive values were evaluated. Fifty-nine patients affected by squamous cell carcinoma and 1 case of adenoido-cystic carcinoma were examined by means of a superconductive MR unit, using SE T1, and fat-suppressed T2 weighted sequences before contrast medium infusion. SE T1 and T1 fat-suppressed sequences after gadolinium-DTPA infusion were used. T stage accuracy of both clinical examination and MRI were found to be respectively 62% (k 0.459) and 82% (k 0.775). The sensitivity, specificity and accuracy of MRI in the detection of mandibular involvement were 94.1%, 60% and 81.5%, while the positive and negative predictive values were 80% and 85.7%, respectively. The sensitivity, specificity and accuracy of clinical examination in the detection of mandibular involvement were 100%, 30% and 74.1%, while the positive and negative predictive values were 70.8% and 100%. In the present study, MRI was seen to be an adequate technique for the assessment of oral cavity malignancies, in the evaluation of depth invasion, presence and extension of mandibular involvement.},
	author = {Vidiri, A. and Ruscito, P. and Pichi, B. and Pellini, R. and Covello, R. and Sperduti, I. and Di Giovanni, S. and Spriano, G. and Crecco, M.},
	issn = {0392-9078 (Print) 0392-9078},
	journal = {J Exp Clin Cancer Res},
	keywords = {Female Humans *Magnetic Resonance Imaging Male Mouth/pathology Mouth Neoplasms/*diagnosis/pathology Neoplasm Staging Tongue Neoplasms/*diagnosis/pathology},
	note = {Vidiri, A Ruscito, P Pichi, B Pellini, R Covello, R Sperduti, I Di Giovanni, S Spriano, G Crecco, M Journal Article England 2008/03/28 J Exp Clin Cancer Res. 2007 Dec;26(4):575-82.},
	number = {4},
	pages = {575-82},
	title = {Oral cavity and base of the tongue tumors. Correlation between clinical, MRI and pathological staging of primary tumor},
	type = {Journal Article},
	volume = {26},
	year = {2007}}

@article{RN289,
	author = {Vochem, R and Einenkel, J and Horn, L-C and Ruschpler, P},
	issn = {1432-1963},
	journal = {Der Pathologe},
	number = {4},
	pages = {361-370},
	title = {Bedeutung der Tumorstammzellhypothese f{\"u}r das Verst{\"a}ndnis des Ovarialkarzinoms},
	type = {Journal Article},
	url = {https://link.springer.com/content/pdf/10.1007/s00292-014-1910-6.pdf},
	volume = {35},
	year = {2014},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007/s00292-014-1910-6.pdf}}

@article{RN196,
	author = {Vokes, E. E. and Weichselbaum, R. R. and Lippman, S. M. and Hong, W. K.},
	doi = {10.1056/nejm199301213280306},
	issn = {0028-4793 (Print) 0028-4793},
	journal = {N Engl J Med},
	keywords = {Carcinoma, Squamous Cell/epidemiology/pathology/therapy Chemotherapy, Adjuvant Combined Modality Therapy *Head and Neck Neoplasms/epidemiology/pathology/therapy Humans Lymphatic Metastasis},
	note = {Vokes, E E Weichselbaum, R R Lippman, S M Hong, W K Journal Article Review United States 1993/01/21 N Engl J Med. 1993 Jan 21;328(3):184-94. doi: 10.1056/NEJM199301213280306.},
	number = {3},
	pages = {184-94},
	title = {Head and neck cancer},
	type = {Journal Article},
	volume = {328},
	year = {1993},
	bdsk-url-1 = {https://doi.org/10.1056/nejm199301213280306}}

@article{RN195,
	author = {Vokes, E. E. and Weichselbaum, R. R. and Lippman, S. M. and Hong, W. K.},
	doi = {10.1056/nejm199301213280306},
	issn = {0028-4793 (Print) 0028-4793},
	journal = {N Engl J Med},
	keywords = {Carcinoma, Squamous Cell/epidemiology/pathology/therapy Chemotherapy, Adjuvant Combined Modality Therapy *Head and Neck Neoplasms/epidemiology/pathology/therapy Humans Lymphatic Metastasis},
	note = {Vokes, E E Weichselbaum, R R Lippman, S M Hong, W K Journal Article Review United States 1993/01/21 N Engl J Med. 1993 Jan 21;328(3):184-94. doi: 10.1056/NEJM199301213280306.},
	number = {3},
	pages = {184-94},
	title = {Head and neck cancer},
	type = {Journal Article},
	volume = {328},
	year = {1993},
	bdsk-url-1 = {https://doi.org/10.1056/nejm199301213280306}}

@article{RN68,
	author = {Vokes, E. E. and Weichselbaum, R. R. and Lippman, S. M. and Hong, W. K.},
	doi = {10.1056/NEJM199301213280306},
	issn = {0028-4793 (Print) 0028-4793 (Linking)},
	journal = {N Engl J Med},
	keywords = {Carcinoma, Squamous Cell/epidemiology/pathology/therapy Chemotherapy, Adjuvant Combined Modality Therapy *Head and Neck Neoplasms/epidemiology/pathology/therapy Humans Lymphatic Metastasis},
	note = {Vokes, E E Weichselbaum, R R Lippman, S M Hong, W K eng Review 1993/01/21 N Engl J Med. 1993 Jan 21;328(3):184-94. doi: 10.1056/NEJM199301213280306.},
	number = {3},
	pages = {184-94},
	title = {Head and neck cancer},
	type = {Journal Article},
	url = {https://www.nejm.org/doi/pdf/10.1056/NEJM199301213280306?articleTools=true},
	volume = {328},
	year = {1993},
	bdsk-url-1 = {https://www.nejm.org/doi/pdf/10.1056/NEJM199301213280306?articleTools=true},
	bdsk-url-2 = {https://doi.org/10.1056/NEJM199301213280306}}

@article{RN388,
	author = {Vokes, E. E. and Weichselbaum, R. R. and Lippman, S. M. and Hong, W. K.},
	doi = {10.1056/NEJM199301213280306},
	issn = {0028-4793 (Print) 0028-4793 (Linking)},
	journal = {N Engl J Med},
	keywords = {Carcinoma, Squamous Cell/epidemiology/pathology/therapy Chemotherapy, Adjuvant Combined Modality Therapy *Head and Neck Neoplasms/epidemiology/pathology/therapy Humans Lymphatic Metastasis},
	number = {3},
	pages = {184-94},
	title = {Head and neck cancer},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8417385},
	volume = {328},
	year = {1993},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/8417385},
	bdsk-url-2 = {https://doi.org/10.1056/NEJM199301213280306}}

@article{RN129,
	abstract = {This review presents data on incidence, mortality, survival and trends in cancers of the lip, oral cavity and oropharynx using available recent data sources around the world. Oral and pharyngeal cancer, grouped together, is the sixth most common cancer in the world. The review focuses primarily on several high-risk countries in an attempt to gain insight into the geographic variations in the incidence of this cancer in the globe and to relate the high incidence in some populations to their life style. With an estimated half a million cases around the globe and the rising trends reported in some populations, particularly in the young, urgent public health measures are needed to reduce the incidence and mortality of oral and oropharyngeal cancer.},
	author = {Warnakulasuriya, S.},
	doi = {10.1016/j.oraloncology.2008.06.002},
	issn = {1368-8375},
	journal = {Oral Oncol},
	keywords = {Age Factors Developed Countries/statistics & numerical data Developing Countries/statistics & numerical data Female *Global Health Humans Incidence Lip Neoplasms/epidemiology Male Mouth Neoplasms/*epidemiology Oropharyngeal Neoplasms/*epidemiology Population Surveillance Risk Factors},
	note = {1879-0593 Warnakulasuriya, Saman Journal Article Review England 2008/09/23 Oral Oncol. 2009 Apr-May;45(4-5):309-16. doi: 10.1016/j.oraloncology.2008.06.002. Epub 2008 Sep 18.},
	number = {4-5},
	pages = {309-16},
	title = {Global epidemiology of oral and oropharyngeal cancer},
	type = {Journal Article},
	url = {https://www.sciencedirect.com/science/article/abs/pii/S1368837508001838?via%3Dihub},
	volume = {45},
	year = {2009},
	bdsk-url-1 = {https://www.sciencedirect.com/science/article/abs/pii/S1368837508001838?via%3Dihub},
	bdsk-url-2 = {https://doi.org/10.1016/j.oraloncology.2008.06.002}}

@article{RN368,
	author = {Weinberger, P. M. and Yu, Z. and Haffty, B. G. and Kowalski, D. and Harigopal, M. and Brandsma, J. and Sasaki, C. and Joe, J. and Camp, R. L. and Rimm, D. L. and Psyrri, A.},
	doi = {10.1200/jco.2004.00.3335},
	issn = {0732-183x},
	journal = {J Clin Oncol},
	keywords = {Adult Aged Carcinoma, Squamous Cell/classification/epidemiology/*pathology/*virology Cohort Studies DNA, Viral Female Human papillomavirus 16/genetics/pathogenicity Humans Male Middle Aged Oropharyngeal Neoplasms/classification/epidemiology/*pathology/*virology Papillomavirus Infections/*complications Polymerase Chain Reaction Prevalence Prognosis Survival Analysis Viral Load},
	number = {5},
	pages = {736-47},
	title = {Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis},
	type = {Journal Article},
	volume = {24},
	year = {2006},
	bdsk-url-1 = {https://doi.org/10.1200/jco.2004.00.3335}}

@article{RN443,
	author = {Weinberger, P. M. and Yu, Z. and Haffty, B. G. and Kowalski, D. and Harigopal, M. and Brandsma, J. and Sasaki, C. and Joe, J. and Camp, R. L. and Rimm, D. L. and Psyrri, A.},
	doi = {10.1200/JCO.2004.00.3335},
	issn = {1527-7755 (Electronic) 0732-183X (Linking)},
	journal = {J Clin Oncol},
	keywords = {Adult Aged Carcinoma, Squamous Cell/classification/epidemiology/*pathology/*virology Cohort Studies DNA, Viral Female Human papillomavirus 16/genetics/pathogenicity Humans Male Middle Aged Oropharyngeal Neoplasms/classification/epidemiology/*pathology/*virology Papillomavirus Infections/*complications Polymerase Chain Reaction Prevalence Prognosis Survival Analysis Viral Load},
	number = {5},
	pages = {736-47},
	title = {Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16401683},
	volume = {24},
	year = {2006},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/16401683},
	bdsk-url-2 = {https://doi.org/10.1200/JCO.2004.00.3335}}

@article{RN56,
	abstract = {PURPOSE: We sought to determine the prevalence of biologically relevant human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (OSCC). Retinoblastoma (Rb) downregulation by HPV E7 results in p16 upregulation. We hypothesized that p16 overexpression in OSCC defines HPV-induced tumors with favorable prognosis. METHODS: Using real-time polymerase chain reaction for HPV16, we determined HPV16 viral load in a cohort of 79 OSCCs annotated with long-term patient follow-up. A tissue microarray including these cases was also analyzed for p53, p16, and Rb utilizing in situ quantitative protein expression analysis. Seventy-seven tumors were classified into a three-class model on the basis of p16 expression and HPV-DNA presence: class I, HPV-, p16 low; class II, HPV+, p16 low; and class III, HPV+, p16 high. RESULTS: Sixty-one percent of OSCCs were HPV16+; HPV status alone was of no prognostic value for local recurrence and was barely significant for survival times. Overall survival was improved in class III (79%) compared with the other two classes (20% and 18%; P = .0095). Disease-free survival for the same class was 75% versus 15% and 13% (P = .0025). The 5-year local recurrence was 14% in class III versus 45% and 74% (P = .03). Only patients in class III had significantly lower p53 and Rb expression (P = .017 and .001, respectively). Multivariable survival analysis confirmed the prognostic value of the three-class model. CONCLUSION: Using this system for classification, we define the molecular profile of HPV+ OSCC with favorable prognosis, namely HPV+/p16 high (class III). This study defines a novel classification scheme that may have value for patient stratification for clinical trials testing HPV-targeted therapies.},
	author = {Weinberger, P. M. and Yu, Z. and Haffty, B. G. and Kowalski, D. and Harigopal, M. and Brandsma, J. and Sasaki, C. and Joe, J. and Camp, R. L. and Rimm, D. L. and Psyrri, A.},
	doi = {10.1200/JCO.2004.00.3335},
	issn = {1527-7755 (Electronic) 0732-183X (Linking)},
	journal = {J Clin Oncol},
	keywords = {Adult Aged Carcinoma, Squamous Cell/classification/epidemiology/*pathology/*virology Cohort Studies DNA, Viral Female Human papillomavirus 16/genetics/pathogenicity Humans Male Middle Aged Oropharyngeal Neoplasms/classification/epidemiology/*pathology/*virology Papillomavirus Infections/*complications Polymerase Chain Reaction Prevalence Prognosis Survival Analysis Viral Load},
	note = {Weinberger, Paul M Yu, Ziwei Haffty, Bruce G Kowalski, Diane Harigopal, Malini Brandsma, Janet Sasaki, Clarence Joe, John Camp, Robert L Rimm, David L Psyrri, Amanda eng Research Support, Non-U.S. Gov't 2006/01/13 J Clin Oncol. 2006 Feb 10;24(5):736-47. doi: 10.1200/JCO.2004.00.3335. Epub 2006 Jan 9.},
	number = {5},
	pages = {736-47},
	title = {Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16401683},
	volume = {24},
	year = {2006},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/16401683},
	bdsk-url-2 = {https://doi.org/10.1200/JCO.2004.00.3335}}

@article{RN104,
	abstract = {PURPOSE: We sought to determine the prevalence of biologically relevant human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (OSCC). Retinoblastoma (Rb) downregulation by HPV E7 results in p16 upregulation. We hypothesized that p16 overexpression in OSCC defines HPV-induced tumors with favorable prognosis. METHODS: Using real-time polymerase chain reaction for HPV16, we determined HPV16 viral load in a cohort of 79 OSCCs annotated with long-term patient follow-up. A tissue microarray including these cases was also analyzed for p53, p16, and Rb utilizing in situ quantitative protein expression analysis. Seventy-seven tumors were classified into a three-class model on the basis of p16 expression and HPV-DNA presence: class I, HPV-, p16 low; class II, HPV+, p16 low; and class III, HPV+, p16 high. RESULTS: Sixty-one percent of OSCCs were HPV16+; HPV status alone was of no prognostic value for local recurrence and was barely significant for survival times. Overall survival was improved in class III (79%) compared with the other two classes (20% and 18%; P = .0095). Disease-free survival for the same class was 75% versus 15% and 13% (P = .0025). The 5-year local recurrence was 14% in class III versus 45% and 74% (P = .03). Only patients in class III had significantly lower p53 and Rb expression (P = .017 and .001, respectively). Multivariable survival analysis confirmed the prognostic value of the three-class model. CONCLUSION: Using this system for classification, we define the molecular profile of HPV+ OSCC with favorable prognosis, namely HPV+/p16 high (class III). This study defines a novel classification scheme that may have value for patient stratification for clinical trials testing HPV-targeted therapies.},
	author = {Weinberger, P. M. and Yu, Z. and Haffty, B. G. and Kowalski, D. and Harigopal, M. and Brandsma, J. and Sasaki, C. and Joe, J. and Camp, R. L. and Rimm, D. L. and Psyrri, A.},
	doi = {10.1200/jco.2004.00.3335},
	issn = {0732-183x},
	journal = {J Clin Oncol},
	keywords = {Adult Aged Carcinoma, Squamous Cell/classification/epidemiology/*pathology/*virology Cohort Studies DNA, Viral Female Human papillomavirus 16/genetics/pathogenicity Humans Male Middle Aged Oropharyngeal Neoplasms/classification/epidemiology/*pathology/*virology Papillomavirus Infections/*complications Polymerase Chain Reaction Prevalence Prognosis Survival Analysis Viral Load},
	note = {1527-7755 Weinberger, Paul M Yu, Ziwei Haffty, Bruce G Kowalski, Diane Harigopal, Malini Brandsma, Janet Sasaki, Clarence Joe, John Camp, Robert L Rimm, David L Psyrri, Amanda Journal Article Research Support, Non-U.S. Gov't United States 2006/01/13 J Clin Oncol. 2006 Feb 10;24(5):736-47. doi: 10.1200/JCO.2004.00.3335. Epub 2006 Jan 9.},
	number = {5},
	pages = {736-47},
	title = {Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis},
	type = {Journal Article},
	volume = {24},
	year = {2006},
	bdsk-url-1 = {https://doi.org/10.1200/jco.2004.00.3335}}

@book{RN174,
	author = {Werner, J.A.},
	isbn = {9783642559235},
	publisher = {Springer Berlin Heidelberg},
	title = {Lymphknotenerkrankungen im Kopf-Hals-Bereich: Onkologie und Differenzialdiagnostik},
	type = {Book},
	url = {https://books.google.de/books?id=dx0fBgAAQBAJ},
	year = {2013},
	bdsk-url-1 = {https://books.google.de/books?id=dx0fBgAAQBAJ}}

@article{RN417,
	author = {Wicha, M. S. and Liu, S. and Dontu, G.},
	doi = {10.1158/0008-5472.CAN-05-3153},
	issn = {0008-5472 (Print) 0008-5472 (Linking)},
	journal = {Cancer Res},
	keywords = {Animals Embryonal Carcinoma Stem Cells Humans Neoplasms/*etiology/pathology/prevention & control Neoplastic Stem Cells/*pathology Risk Factors},
	number = {4},
	pages = {1883-90; discussion 1895-6},
	title = {Cancer stem cells: an old idea--a paradigm shift},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16488983},
	volume = {66},
	year = {2006},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/16488983},
	bdsk-url-2 = {https://doi.org/10.1158/0008-5472.CAN-05-3153}}

@article{RN70,
	abstract = {Although the concept that cancers arise from "stem cells" or "germ cells" was first proposed about 150 years ago, it is only recently that advances in stem cell biology have given new impetus to the "cancer stem cell hypothesis." Two important related concepts of this hypothesis are that (a) tumors originate in either tissue stem cells or their immediate progeny through dysregulation of the normally tightly regulated process of self-renewal. As a result of this, (b) tumors contain a cellular subcomponent that retains key stem cell properties. These properties include self-renewal, which drives tumorigenesis, and differentiation albeit aberrant that contributes to cellular heterogeneity. Recent experimental evidence in a variety of tumors has lent strong support to the cancer stem cell hypothesis that represents a paradigm shift in our understanding of carcinogenesis and tumor cell biology. This hypothesis has fundamental implications for cancer risk assessment, early detection, prognostication, and prevention. Furthermore, the current development of cancer therapeutics based on tumor regression may have produced agents that kill differentiated tumor cells while sparing the rare cancer stem cell population. The development of more effective cancer therapies may thus require targeting this important cell population.},
	author = {Wicha, M. S. and Liu, S. and Dontu, G.},
	doi = {10.1158/0008-5472.CAN-05-3153},
	issn = {0008-5472 (Print) 0008-5472 (Linking)},
	journal = {Cancer Res},
	keywords = {Animals Embryonal Carcinoma Stem Cells Humans Neoplasms/*etiology/pathology/prevention & control Neoplastic Stem Cells/*pathology Risk Factors},
	note = {Wicha, Max S Liu, Suling Dontu, Gabriela eng P30CA46592/CA/NCI NIH HHS/ R01-CA101860/CA/NCI NIH HHS/ Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. 2006/02/21 Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6. doi: 10.1158/0008-5472.CAN-05-3153.},
	number = {4},
	pages = {1883-90; discussion 1895-6},
	title = {Cancer stem cells: an old idea--a paradigm shift},
	type = {Journal Article},
	url = {https://cancerres.aacrjournals.org/content/canres/66/4/1883.full.pdf},
	volume = {66},
	year = {2006},
	bdsk-url-1 = {https://cancerres.aacrjournals.org/content/canres/66/4/1883.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/0008-5472.CAN-05-3153}}

@article{RN304,
	abstract = {Although the concept that cancers arise from "stem cells" or "germ cells" was first proposed about 150 years ago, it is only recently that advances in stem cell biology have given new impetus to the "cancer stem cell hypothesis." Two important related concepts of this hypothesis are that (a) tumors originate in either tissue stem cells or their immediate progeny through dysregulation of the normally tightly regulated process of self-renewal. As a result of this, (b) tumors contain a cellular subcomponent that retains key stem cell properties. These properties include self-renewal, which drives tumorigenesis, and differentiation albeit aberrant that contributes to cellular heterogeneity. Recent experimental evidence in a variety of tumors has lent strong support to the cancer stem cell hypothesis that represents a paradigm shift in our understanding of carcinogenesis and tumor cell biology. This hypothesis has fundamental implications for cancer risk assessment, early detection, prognostication, and prevention. Furthermore, the current development of cancer therapeutics based on tumor regression may have produced agents that kill differentiated tumor cells while sparing the rare cancer stem cell population. The development of more effective cancer therapies may thus require targeting this important cell population.},
	author = {Wicha, M. S. and Liu, S. and Dontu, G.},
	doi = {10.1158/0008-5472.Can-05-3153},
	issn = {0008-5472 (Print) 0008-5472},
	journal = {Cancer Res},
	keywords = {Animals Embryonal Carcinoma Stem Cells Humans Neoplasms/*etiology/pathology/prevention & control Neoplastic Stem Cells/*pathology Risk Factors},
	note = {Wicha, Max S Liu, Suling Dontu, Gabriela P30CA46592/CA/NCI NIH HHS/United States R01-CA101860/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. United States 2006/02/21 Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6. doi: 10.1158/0008-5472.CAN-05-3153.},
	number = {4},
	pages = {1883-90; discussion 1895-6},
	title = {Cancer stem cells: an old idea--a paradigm shift},
	type = {Journal Article},
	url = {https://cancerres.aacrjournals.org/content/canres/66/4/1883.full.pdf},
	volume = {66},
	year = {2006},
	bdsk-url-1 = {https://cancerres.aacrjournals.org/content/canres/66/4/1883.full.pdf},
	bdsk-url-2 = {https://doi.org/10.1158/0008-5472.Can-05-3153}}

@article{RN224,
	abstract = {The 10 year follow-up of a clinical trial involving the comparison of 3F/wk versus 5F/wk in radiotherapy of squamous cell carcinoma of the larynx and hypopharynx has now been completed. The trial involved an intake of 734 patients between 1966 and 1975. The classification of all patients has been revised to conform with the latest TNM publication. A reduction in total dose was made for 3F/wk compared with 5F/wk. This varied between 13% and 11% in centres treating over 3 weeks and 6 weeks, respectively. No statistically significant differences have been found between the two arms (3F/wk versus 5F/wk) of the trial in any of the main group analyses. A number of sub-group analyses relating to survival, tumour-free and laryngectomy-free rates and to the comparison of acute or late normal-tissue radiation damage have also been performed. No differences have been found that could be considered to be statistically significant in relation to the particular sub-group. Previous interim reports suggested minor differences in sub-group analyses between the 3F/wk and 5F/wk regimes in this trial; these have diminished now that the full follow-up data are available. This trial has provided evidence on which clinicians may base their choice between either a 3F/wk fractionation regime or a conventional 5F/wk treatment protocol in the treatment of carcinoma of the laryngo-pharynx.},
	author = {Wiernik, G. and Bates, T. D. and Bleehen, N. M. and Brindle, J. M. and Bullimore, J. and Fowler, J. F. and Haybittle, J. L. and Howard, N. and Laing, A. H. and Lindup, R. and et al.},
	doi = {10.1259/0007-1285-63-747-169},
	issn = {0007-1285 (Print) 0007-1285},
	journal = {Br J Radiol},
	keywords = {Carcinoma, Squamous Cell/mortality/*radiotherapy Follow-Up Studies Humans Hypopharyngeal Neoplasms/mortality/*radiotherapy Laryngeal Neoplasms/mortality/*radiotherapy/surgery Laryngectomy Neoplasm Recurrence, Local Pharyngeal Neoplasms/*radiotherapy Radiotherapy/adverse effects Radiotherapy Dosage Randomized Controlled Trials as Topic Survival Rate Time Factors United Kingdom/epidemiology},
	note = {Wiernik, G Bates, T D Bleehen, N M Brindle, J M Bullimore, J Fowler, J F Haybittle, J L Howard, N Laing, A H Lindup, R Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't England 1990/03/01 Br J Radiol. 1990 Mar;63(747):169-80. doi: 10.1259/0007-1285-63-747-169.},
	number = {747},
	pages = {169-80},
	title = {Final report of the general clinical results of the British Institute of Radiology fractionation study of 3F/wk versus 5F/wk in radiotherapy of carcinoma of the laryngo-pharynx},
	type = {Journal Article},
	volume = {63},
	year = {1990},
	bdsk-url-1 = {https://doi.org/10.1259/0007-1285-63-747-169}}

@article{RN257,
	abstract = {BACKGROUND: The treatment of oral cancer has a strong impact on the quality of life. In recent years different therapeutic concepts have been developed, these include preoperative simultaneous "neoadjuvant" radiochemotherapy (RCT) and one-stage surgery with tumor ablation and reconstruction. When considering long-term survival, there is substantial evidence that evidenced modality treatment including neoadjuvant RCT is superior to the primary surgical approach with postoperative radiation. PATIENTS AND METHODS: This longitudinal study prospectively evaluates quality of life in two groups consisting of 53 neoadjuvant and primarily surgically treated patients with oral cancer, using the quality-of-life core questionnaire (QLQ-C30) and the head and neck cancer module (H and N 35) of the European Organization for Research and Treatment of Cancer (EORTC). RESULTS: Postoperatively both groups showed a marked reduction in quality of life. 1 year later quality of life had equalized between the two groups to such an extent that the quality of life scores had almost reached the preoperative level. Both groups showed specific impairments in the symptom scales. In the neoadjuvant therapy group however, global health and the emotional status were reduced to a greater degree than in the other group. CONCLUSION: Temporary limitations in quality of life can be expected after tumor treatment of oral cancer as presented here. Neoadjuvant therapy concept is more aggressive and might result in a longer disease-free survival, but the restriction in quality of life is more severe. Primary goal is the eradication of the tumor. Nevertheless preservation or reconstruction of a maximum of function is essential for a high level of quality of life.},
	author = {Wiltfang, J. and Grabenbauer, G. and Bloch-Birkholz, A. and Leher, A. and Neukam, F. W. and Kessler, P.},
	doi = {10.1007/s00066-003-1143-8},
	issn = {0179-7158 (Print) 0179-7158},
	journal = {Strahlenther Onkol},
	keywords = {Adult Aged Antimetabolites, Antineoplastic/administration & dosage/therapeutic use Antineoplastic Agents/administration & dosage/therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carcinoma, Squamous Cell/drug therapy/radiotherapy/surgery/*therapy Cisplatin/administration & dosage/therapeutic use Female Fluorouracil/administration & dosage/therapeutic use Follow-Up Studies Humans Longitudinal Studies Male Middle Aged Mouth Neoplasms/drug therapy/radiotherapy/surgery/*therapy Neoadjuvant Therapy Prospective Studies *Quality of Life Radiotherapy Dosage Surveys and Questionnaires Time Factors Tongue Neoplasms/drug therapy/radiotherapy/therapy},
	note = {Wiltfang, J{\"o}rg Grabenbauer, Gerhard Bloch-Birkholz, Alexandra Leher, Anna Neukam, Friedrich Wilhelm Kessler, Peter Comparative Study English Abstract Journal Article Germany 2003/10/21 Strahlenther Onkol. 2003 Oct;179(10):682-9. doi: 10.1007/s00066-003-1143-8.},
	number = {10},
	pages = {682-9},
	title = {[Evaluation of quality of life of patients with oral squamous cell carcinoma. Comparison of two treatment protocols in a prospective study-first results]},
	type = {Journal Article},
	url = {https://link.springer.com/content/pdf/10.1007/s00066-003-1143-8.pdf},
	volume = {179},
	year = {2003},
	bdsk-url-1 = {https://link.springer.com/content/pdf/10.1007/s00066-003-1143-8.pdf},
	bdsk-url-2 = {https://doi.org/10.1007/s00066-003-1143-8}}

@book{RN128,
	author = {Wittekind, C.},
	isbn = {9783527335084},
	publisher = {Wiley-VCH},
	title = {TNM-Supplement: Erlauterungen Zur Einheitlichen Anwendung},
	type = {Book},
	url = {https://books.google.de/books?id=8MGpBAAAQBAJ},
	year = {2013},
	bdsk-url-1 = {https://books.google.de/books?id=8MGpBAAAQBAJ}}

@book{RN333,
	author = {Wittekind, C.},
	isbn = {9783527335084},
	publisher = {Wiley-VCH},
	title = {TNM-Supplement: Erlauterungen Zur Einheitlichen Anwendung},
	type = {Book},
	url = {https://books.google.de/books?id=8MGpBAAAQBAJ},
	year = {2013},
	bdsk-url-1 = {https://books.google.de/books?id=8MGpBAAAQBAJ}}

@book{RN155,
	author = {Wittekind, C.},
	isbn = {9783527347728},
	publisher = {Wiley-VCH Verlag GmbH},
	title = {TNM Klassifikation Maligner Tumoren: Korrigierter Nachdruck 2020 Mit Allen Erg{\"a}nzungen der UICC Aus Den Jahren 2017 Bis 2019},
	type = {Book},
	url = {https://books.google.de/books?id=H9VHywEACAAJ},
	year = {2020},
	bdsk-url-1 = {https://books.google.de/books?id=H9VHywEACAAJ}}

@article{RN199,
	abstract = {Our recent analysis of papillomavirus (HPV) DNA in different malignant head and neck tumors revealed that HPV infections occurred most frequently in tonsillar carcinomas (58%) and that 84% of positive cases contained the highly oncogenic HPV type 16. We could also present data in favor of the hypothesis that in view of their clinical behavior and the involved risk factors HPV-positive and HPV-negative tonsillar carcinomas may represent two separate tumor entities. Looking for a surrogate marker, which in further epidemiological studies could replace the laborious and expensive HPV detection/typing we analyzed p16 protein expression in 34 tonsillar carcinomas for their correlation with HPV status. p16 is an inhibitor of cyclin-dependent kinases 4 and 6 which activate the negative cell cycle regulator protein pRB which in turn downregulates p16 expression. It could be shown that in neoplastic cells of the cervix uteri E7 protein of the high-risk HPVs can interfere with this regulatory circuit by its virtue to inactivate pRB and thus lead to the overexpession of p16. We found 53% of the tested tonsillar carcinomas to be HPV positive. 56% of all tumors tested were immunohistochemically positive for the p16 protein. In 16 of 18 of the HPV-positive carcinomas diffuse p16 expression was observed. In contrast, only 1 of the HPV-negative carcinomas showed focal p16 staining (p < 0.001). Clinical outcome analysis revealed a significant correlation of p16 expression with increased disease-free survival (p = 0.02). These data indicate that p16 is a technically simple immunohistological marker, applicable for routine pathological histology, and its prognostic value for survival is fully equivalent to HPV DNA detection.},
	author = {Wittekindt, C. and G{\"u}ltekin, E. and Weissenborn, S. J. and Dienes, H. P. and Pfister, H. J. and Klussmann, J. P.},
	doi = {10.1159/000082474},
	issn = {0065-3071 (Print) 0065-3071},
	journal = {Adv Otorhinolaryngol},
	keywords = {Biomarkers, Tumor/analysis Biopsy, Needle Carcinoma, Squamous Cell/genetics/mortality/pathology/*virology Case-Control Studies Cell Transformation, Neoplastic/*pathology Cyclin-Dependent Kinase Inhibitor p16/genetics/*metabolism DNA, Viral/analysis Disease-Free Survival Female Gene Expression Regulation, Neoplastic Humans Immunohistochemistry Male Papillomaviridae/*genetics/isolation & purification Papillomavirus Infections/*genetics/mortality Probability Prognosis Reference Values Sampling Studies Sensitivity and Specificity Survival Analysis Tonsillar Neoplasms/genetics/mortality/*virology},
	note = {Wittekindt, Claus G{\"u}ltekin, Elif Weissenborn, Soenke J Dienes, Hans P Pfister, Herbert J Klussmann, Jens P Comparative Study Journal Article Research Support, Non-U.S. Gov't Switzerland 2004/12/21 Adv Otorhinolaryngol. 2005;62:72-80. doi: 10.1159/000082474.},
	pages = {72-80},
	title = {Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival},
	type = {Journal Article},
	url = {https://www.karger.com/Article/Pdf/82474},
	volume = {62},
	year = {2005},
	bdsk-url-1 = {https://www.karger.com/Article/Pdf/82474},
	bdsk-url-2 = {https://doi.org/10.1159/000082474}}

@article{RN179,
	author = {Wolff, Klaus-Dietrich and Rau, Andrea and Weitz, Jochen and Langer, Thomas and Zidane, Miriam},
	issn = {1865-9667},
	journal = {Der MKG-Chirurg},
	number = {3},
	pages = {177-183},
	title = {Aktualisierung der S3-Leitlinie Diagnostik und Therapie des Mundh{\"o}hlenkarzinoms ``: Was ist neu?},
	type = {Journal Article},
	volume = {14},
	year = {2021}}

@article{RN216,
	abstract = {Human papillomavirus (HPV) has been implicated in the pathogenesis of a subset of oropharyngeal squamous cell carcinoma. As a result, traditional paradigms in relation to the management of head and neck squamous cell carcinoma have been changing. Research into HPV-related oropharyngeal squamous cell carcinoma is rapidly expanding, however many molecular pathological and clinical aspects of the role of HPV remain uncertain and are the subject of ongoing investigation. A detailed search of the literature pertaining to HPV-related oropharyngeal squamous cell carcinoma was performed and information on the topic was gathered. In this article, we present an extensive review of the current literature on the role of HPV in oropharyngeal squamous cell carcinoma, particularly in relation to epidemiology, risk factors, carcinogenesis, biomarkers and clinical implications. HPV has been established as a causative agent in oropharyngeal squamous cell carcinoma and biologically active HPV can act as a prognosticator with better overall survival than HPV-negative tumours. A distinct group of younger patients with limited tobacco and alcohol exposure have emerged as characteristic of this HPV-related subset of squamous cell carcinoma of the head and neck. However, the exact molecular mechanisms of carcinogenesis are not completely understood and further studies are needed to assist development of optimal prevention and treatment modalities.},
	author = {Woods, R., Sr. and O'Regan, E. M. and Kennedy, S. and Martin, C. and O'Leary, J. J. and Timon, C.},
	doi = {10.12998/wjcc.v2.i6.172},
	issn = {2307-8960 (Print) 2307-8960},
	journal = {World J Clin Cases},
	keywords = {Head and neck Human papillomavirus Oncology Oropharyngeal Oropharynx Squamous cell carcinoma},
	note = {2307-8960 Woods, Robbie Sr O'Regan, Esther M Kennedy, Susan Martin, Cara O'Leary, John J Timon, Conrad Journal Article Review 2014/06/20 World J Clin Cases. 2014 Jun 16;2(6):172-93. doi: 10.12998/wjcc.v2.i6.172.},
	number = {6},
	pages = {172-93},
	title = {Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061306/pdf/WJCC-2-172.pdf},
	volume = {2},
	year = {2014},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061306/pdf/WJCC-2-172.pdf},
	bdsk-url-2 = {https://doi.org/10.12998/wjcc.v2.i6.172}}

@article{RN217,
	abstract = {Human papillomavirus (HPV) has been implicated in the pathogenesis of a subset of oropharyngeal squamous cell carcinoma. As a result, traditional paradigms in relation to the management of head and neck squamous cell carcinoma have been changing. Research into HPV-related oropharyngeal squamous cell carcinoma is rapidly expanding, however many molecular pathological and clinical aspects of the role of HPV remain uncertain and are the subject of ongoing investigation. A detailed search of the literature pertaining to HPV-related oropharyngeal squamous cell carcinoma was performed and information on the topic was gathered. In this article, we present an extensive review of the current literature on the role of HPV in oropharyngeal squamous cell carcinoma, particularly in relation to epidemiology, risk factors, carcinogenesis, biomarkers and clinical implications. HPV has been established as a causative agent in oropharyngeal squamous cell carcinoma and biologically active HPV can act as a prognosticator with better overall survival than HPV-negative tumours. A distinct group of younger patients with limited tobacco and alcohol exposure have emerged as characteristic of this HPV-related subset of squamous cell carcinoma of the head and neck. However, the exact molecular mechanisms of carcinogenesis are not completely understood and further studies are needed to assist development of optimal prevention and treatment modalities.},
	author = {Woods, R., Sr. and O'Regan, E. M. and Kennedy, S. and Martin, C. and O'Leary, J. J. and Timon, C.},
	doi = {10.12998/wjcc.v2.i6.172},
	issn = {2307-8960 (Print) 2307-8960},
	journal = {World J Clin Cases},
	keywords = {Head and neck Human papillomavirus Oncology Oropharyngeal Oropharynx Squamous cell carcinoma},
	note = {2307-8960 Woods, Robbie Sr O'Regan, Esther M Kennedy, Susan Martin, Cara O'Leary, John J Timon, Conrad Journal Article Review 2014/06/20 World J Clin Cases. 2014 Jun 16;2(6):172-93. doi: 10.12998/wjcc.v2.i6.172.},
	number = {6},
	pages = {172-93},
	title = {Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review},
	type = {Journal Article},
	volume = {2},
	year = {2014},
	bdsk-url-1 = {https://doi.org/10.12998/wjcc.v2.i6.172}}

@article{RN269,
	abstract = {Histopathological assessment of the surgical resection specimen continues to provide information that is central to determining the post-operative treatment needs and prognosis for an individual patient with oral/oropharyngeal squamous cell carcinoma. This review describes the prognostic value of histopathological features related to the primary tumour and the cervical lymph nodes, and considers their relative merits. In addition, a brief overview of more general patient factors is included. Throughout the review, guidance is offered on practical aspects of the histopathological assessment together with brief mention of potential inaccuracies. Emphasis is given also to the importance of the partnership between the surgeon and the pathologist, the need for standardisation during all stages of the histopathological assessment, and the value of accurate documentation of the findings.},
	author = {Woolgar, J. A.},
	doi = {10.1016/j.oraloncology.2005.05.008},
	issn = {1368-8375 (Print) 1368-8375},
	journal = {Oral Oncol},
	keywords = {Carcinoma, Squamous Cell/*pathology/secondary Humans Mouth Neoplasms/*pathology Oropharyngeal Neoplasms/*pathology Prognosis},
	note = {Woolgar, Julia A Journal Article Review England 2005/09/10 Oral Oncol. 2006 Mar;42(3):229-39. doi: 10.1016/j.oraloncology.2005.05.008. Epub 2005 Sep 16.},
	number = {3},
	pages = {229-39},
	title = {Histopathological prognosticators in oral and oropharyngeal squamous cell carcinoma},
	type = {Journal Article},
	url = {https://www.sciencedirect.com/science/article/abs/pii/S1368837505001521?via%3Dihub},
	volume = {42},
	year = {2006},
	bdsk-url-1 = {https://www.sciencedirect.com/science/article/abs/pii/S1368837505001521?via%3Dihub},
	bdsk-url-2 = {https://doi.org/10.1016/j.oraloncology.2005.05.008}}

@article{RN164,
	abstract = {The prognostic significance of extracapsular spread of cervical metastases in oral cancer is still controversial. To investigate the importance of extent of extracapsular spread; the relationship between extracapsular spread and both traditional measures of metastatic disease and clinical/histological features of the primary tumour, and to determine their relative prognostic significance. The survival of 173 patients undergoing radical surgery and simultaneous neck dissection for oral/oropharyngeal squamous cell carcinoma with histologically confirmed nodal metastasis and followed for 2.2-12.3 years is reported and related to pathological features. The most predictive clinical/histopathological features were determined by Cox regression modelling. The 3-year survival probability was similar for patients with macroscopic and only microscopic extracapsular spread (33 and 36%, respectively, compared with 72% for patients with intranodal metastasis). The Cox model showed the most predictive factor was extracapsular spread followed by status of resection margins. Extracapsular spread should be incorporated into pathological staging systems. Even microscopic extracapsular spread is of critical importance and must be sought especially in small-volume metastatic disease.},
	author = {Woolgar, J. A. and Rogers, S. N. and Lowe, D. and Brown, J. S. and Vaughan, E. D.},
	doi = {10.1016/s1368-8375(02)00030-1},
	issn = {1368-8375 (Print) 1368-8375},
	journal = {Oral Oncol},
	keywords = {Adult Aged Aged, 80 and over Carcinoma, Squamous Cell/pathology/*secondary/surgery Female Follow-Up Studies Humans Lymphatic Metastasis Male Middle Aged Mouth Neoplasms/*pathology/surgery Neck Neck Dissection Neoplasm Invasiveness Neoplasm Staging Oropharyngeal Neoplasms/pathology/surgery Prognosis Proportional Hazards Models Survival Rate Treatment Outcome},
	note = {Woolgar, J A Rogers, S N Lowe, D Brown, J S Vaughan, E D Journal Article England 2003/01/03 Oral Oncol. 2003 Feb;39(2):130-7. doi: 10.1016/s1368-8375(02)00030-1.},
	number = {2},
	pages = {130-7},
	title = {Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread},
	type = {Journal Article},
	url = {https://www.sciencedirect.com/science/article/abs/pii/S1368837502000301?via%3Dihub},
	volume = {39},
	year = {2003},
	bdsk-url-1 = {https://www.sciencedirect.com/science/article/abs/pii/S1368837502000301?via%3Dihub},
	bdsk-url-2 = {https://doi.org/10.1016/s1368-8375(02)00030-1}}

@article{RN246,
	author = {Zelefsky, Michael J and Harrison, Louis B and Armstrong, John G},
	issn = {0008-543X},
	journal = {Cancer},
	number = {10},
	pages = {2388-2395},
	title = {Longterm treatment results of postoperative radiation therapy for advanced stage oropharyngeal carcinoma},
	type = {Journal Article},
	volume = {70},
	year = {1992}}

@article{RN429,
	author = {Zhang, Q. and Shi, S. and Yen, Y. and Brown, J. and Ta, J. Q. and Le, A. D.},
	doi = {10.1016/j.canlet.2009.08.010},
	issn = {1872-7980 (Electronic) 0304-3835 (Linking)},
	journal = {Cancer Lett},
	keywords = {AC133 Antigen Animals Antigens, CD/*metabolism Antineoplastic Agents/*adverse effects Carcinoma, Squamous Cell/drug therapy/*pathology Colony-Forming Units Assay *Drug Resistance, Neoplasm Female Flow Cytometry Glycoproteins/*metabolism Humans Immunoenzyme Techniques Mice Mice, Nude Mouth Neoplasms/drug therapy/*pathology Neoplastic Stem Cells/metabolism/*pathology Peptides/*metabolism RNA, Messenger/genetics/metabolism Reverse Transcriptase Polymerase Chain Reaction},
	number = {2},
	pages = {151-60},
	title = {A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy},
	type = {Journal Article},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/19748175},
	volume = {289},
	year = {2010},
	bdsk-url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/19748175},
	bdsk-url-2 = {https://doi.org/10.1016/j.canlet.2009.08.010}}

@article{RN79,
	abstract = {The potential role of cancer stem-like cells (CSCs) in chemoresistance of human oral squamous cell carcinoma (OSCC) was examined. A small subpopulation (1-2%) of CD133(+) CSCs was identified in OSCC cell lines and tissues. These CD133(+) CSCs possess higher clonogenicity, invasiveness, and increased in vivo tumorigenicity as compared to CD133(-) counterparts. Meanwhile, CD133(+) CSCs were substantially resistant to standard chemotherapy, wherein both in vitro and in vivo treatment with paclitaxel resulted in a marked enrichment for CD133(+) CSCs. Our data suggest that CD133(+) cells represent a small subpopulation of CSCs that may contribute to chemoresistance in human OSCC.},
	author = {Zhang, Q. and Shi, S. and Yen, Y. and Brown, J. and Ta, J. Q. and Le, A. D.},
	doi = {10.1016/j.canlet.2009.08.010},
	issn = {1872-7980 (Electronic) 0304-3835 (Linking)},
	journal = {Cancer Lett},
	keywords = {AC133 Antigen Animals Antigens, CD/*metabolism Antineoplastic Agents/*adverse effects Carcinoma, Squamous Cell/drug therapy/*pathology Colony-Forming Units Assay *Drug Resistance, Neoplasm Female Flow Cytometry Glycoproteins/*metabolism Humans Immunoenzyme Techniques Mice Mice, Nude Mouth Neoplasms/drug therapy/*pathology Neoplastic Stem Cells/metabolism/*pathology Peptides/*metabolism RNA, Messenger/genetics/metabolism Reverse Transcriptase Polymerase Chain Reaction},
	note = {Zhang, Qunzhou Shi, Shihong Yen, Yun Brown, Jimmy Ta, Joseph Quoc Le, Anh D eng AR47359/AR/NIAMS NIH HHS/ Research Support, N.I.H., Extramural Ireland 2009/09/15 Cancer Lett. 2010 Mar 28;289(2):151-60. doi: 10.1016/j.canlet.2009.08.010. Epub 2009 Sep 11.},
	number = {2},
	pages = {151-60},
	title = {A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy},
	type = {Journal Article},
	url = {https://www.sciencedirect.com/science/article/abs/pii/S0304383509005266?via%3Dihub},
	volume = {289},
	year = {2010},
	bdsk-url-1 = {https://www.sciencedirect.com/science/article/abs/pii/S0304383509005266?via%3Dihub},
	bdsk-url-2 = {https://doi.org/10.1016/j.canlet.2009.08.010}}

@article{RN315,
	abstract = {The potential role of cancer stem-like cells (CSCs) in chemoresistance of human oral squamous cell carcinoma (OSCC) was examined. A small subpopulation (1-2%) of CD133(+) CSCs was identified in OSCC cell lines and tissues. These CD133(+) CSCs possess higher clonogenicity, invasiveness, and increased in vivo tumorigenicity as compared to CD133(-) counterparts. Meanwhile, CD133(+) CSCs were substantially resistant to standard chemotherapy, wherein both in vitro and in vivo treatment with paclitaxel resulted in a marked enrichment for CD133(+) CSCs. Our data suggest that CD133(+) cells represent a small subpopulation of CSCs that may contribute to chemoresistance in human OSCC.},
	author = {Zhang, Q. and Shi, S. and Yen, Y. and Brown, J. and Ta, J. Q. and Le, A. D.},
	doi = {10.1016/j.canlet.2009.08.010},
	issn = {0304-3835},
	journal = {Cancer Lett},
	keywords = {AC133 Antigen Animals Antigens, CD/*metabolism Antineoplastic Agents/*adverse effects Carcinoma, Squamous Cell/drug therapy/*pathology Colony-Forming Units Assay *Drug Resistance, Neoplasm Female Flow Cytometry Glycoproteins/*metabolism Humans Immunoenzyme Techniques Mice Mice, Nude Mouth Neoplasms/drug therapy/*pathology Neoplastic Stem Cells/metabolism/*pathology Peptides/*metabolism RNA, Messenger/genetics/metabolism Reverse Transcriptase Polymerase Chain Reaction},
	note = {1872-7980 Zhang, Qunzhou Shi, Shihong Yen, Yun Brown, Jimmy Ta, Joseph Quoc Le, Anh D AR47359/AR/NIAMS NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Ireland 2009/09/15 Cancer Lett. 2010 Mar 28;289(2):151-60. doi: 10.1016/j.canlet.2009.08.010. Epub 2009 Sep 11.},
	number = {2},
	pages = {151-60},
	title = {A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy},
	type = {Journal Article},
	volume = {289},
	year = {2010},
	bdsk-url-1 = {https://doi.org/10.1016/j.canlet.2009.08.010}}

@article{RN133,
	abstract = {Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) has been known to have oncogenic properties during latent infection in nasopharyngeal carcinoma (NPC). Our studies focused on the role of LMP1 in NPC, and showed that LMP1 triggers the NF-kappaB, AP-1 and STAT signaling pathways. Strikingly, LMP1 was found to mediate the formation of a new heterodimer between c-Jun and JunB. Also, we have identified JAK/STAT and PI-PLC-PKC activation triggered by LMP1 through upregulating the expression of JAK3 and enhancing the phosphorylation of STAT. The constitutive activation of these signaling cascades explains LMP1's ability to induce such a diverse array of morphological and phenotypic effects in cells and provides insight into how LMP1 may induce cell transformation, in which multihit targeted genes in the downstream play an essential role. All signaling cascades triggered by LMP1 ultimately lead to the disruption of the cell cycle: the acceleration of G1/S phase and the arrest of G2/M phase. We also found that LMP1 induced the expression of hTERT and promoted cell immortalization. Importantly, by intervening physical intracellular signal transduction pathways and disturbing the progression of the cell cycle, LMP1, an important oncoprotein encoded by EBV, is thought to be a key modulator in the pathogenesis of NPC. Interfering LMP1 signaling could be a promising strategy to target the malignant phenotype of NPC.},
	author = {Zheng, H. and Li, L. L. and Hu, D. S. and Deng, X. Y. and Cao, Y.},
	issn = {1672-7681 (Print) 1672-7681},
	journal = {Cell Mol Immunol},
	keywords = {Carcinoma/*metabolism/pathology/*virology Cell Transformation, Viral Herpesvirus 4, Human/*physiology Humans Nasopharyngeal Neoplasms/*metabolism/pathology/*virology Viral Matrix Proteins/*physiology},
	note = {Zheng, Hui Li, Li Li Hu, Duo Sha Deng, Xi Yun Cao, Ya Journal Article Research Support, Non-U.S. Gov't Review China 2007/07/03 Cell Mol Immunol. 2007 Jun;4(3):185-96.},
	number = {3},
	pages = {185-96},
	title = {Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma},
	type = {Journal Article},
	volume = {4},
	year = {2007}}

@article{RN295,
	author = {zur Tumorentstehung, Neues Konzept},
	title = {Ist Krebs eine Stammzellerkrankung?},
	type = {Journal Article}}
